{
  "category": "Clinical Pathology",
  "subject": {
    "name": "Hematology, Hemostasis, and Thrombosis",
    "url": "https://app.pathprimer.com/curriculum/aa24ba7b-b30d-4eaf-865f-6d0151d0f9e8",
    "lessons": {
      "Methods": {
        "name": "Methods",
        "url": "https://app.pathprimer.com/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
        "topics": {
          "Measurement of Hemoglobin": {
            "name": "Measurement of Hemoglobin",
            "url": "https://app.pathprimer.com/document/35316ab5-d675-4d1d-a4ff-70beaa7db2f0/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "In Hb-cyanide method, absorbance of solution at 540 nm is compared with that of standard cyanmethemoglobin solution"
                  },
                  {
                    "text": "Advantage of hemoglobin-cyanide method is that it detects most forms of Hb (oxyhemoglobin, methemoglobin, carboxyhemoglobin)"
                  },
                  {
                    "text": "This method does not detect SHbSulfhemoglobinemia is typically due to medications (sulfonamides and sulfasalazine)Sulfhemoglobinemia causes cyanosis, and blood, skin, and mucous membranes turn green-black",
                    "sub_points": [
                      "Sulfhemoglobinemia is typically due to medications (sulfonamides and sulfasalazine)",
                      "Sulfhemoglobinemia causes cyanosis, and blood, skin, and mucous membranes turn green-black"
                    ]
                  },
                  {
                    "text": "Hb is used to calculate other RBC indicesMCHC = Hb/Hct x 100MCH = Hb/RBC x 10",
                    "sub_points": [
                      "MCHC = Hb/Hct x 100",
                      "MCH = Hb/RBC x 10"
                    ]
                  }
                ],
                "Limitations": [
                  {
                    "text": "Conditions that cause turbidity in sample can lead to falsely high absorbance and overestimation of Hb concentrationCauses of falsely elevated Hb include lipemia, hypergammaglobulinemia, cryoglobulinemia, and leukocytosis",
                    "sub_points": [
                      "Causes of falsely elevated Hb include lipemia, hypergammaglobulinemia, cryoglobulinemia, and leukocytosis"
                    ]
                  },
                  {
                    "text": "Hemoconcentration during phlebotomy can be caused by tourniquet that is too tight or left on too long; can result in falsely elevated hemoglobin measurements"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Hemoglobin Measurements": [
                  {
                    "text": "Hemoglobin (Hb) measurements typically performed in channel of automated cell counter"
                  }
                ],
                "Hemoglobin-Cyanide Method": [
                  {
                    "text": "Red blood cells (RBCs) are broken down with lysing agent to release Hb into solution"
                  },
                  {
                    "text": "Sample is diluted with cyanmethemoglobin reagentReagent contains potassium cyanide and potassium ferricyanide",
                    "sub_points": [
                      "Reagent contains potassium cyanide and potassium ferricyanide"
                    ]
                  },
                  {
                    "text": "Potassium ferricyanide in reagent converts Hb iron from ferrous state (Fe++) → ferric state (Fe+++) to form methemoglobin"
                  },
                  {
                    "text": "Methemoglobin combines with potassium cyanide to form stable cyanmethemoglobin"
                  },
                  {
                    "text": "Spectrophotometer measures absorbance of solution at 540 nmThis is compared with absorbance of standard cyanmethemoglobin solution",
                    "sub_points": [
                      "This is compared with absorbance of standard cyanmethemoglobin solution"
                    ]
                  },
                  {
                    "text": "Advantage of Hb-cyanide method is that it detects most forms of HbOxyhemoglobin, methemoglobin, carboxyhemoglobin",
                    "sub_points": [
                      "Oxyhemoglobin, methemoglobin, carboxyhemoglobin"
                    ]
                  },
                  {
                    "text": "This method does not detect sulfhemoglobin (SHb)SHb occurs when sulfur is incorporated into HbSHb is incapable of carrying O₂ and cannot convert back to normal HbSulfhemoglobinemia causes cyanosisBlood, skin, and mucous membranes turn green-blackSulfhemoglobinemia is typically due to medicationsSulfonamides and sulfasalazineSHb can be quantitated by spectrophotometry",
                    "sub_points": [
                      "SHb occurs when sulfur is incorporated into Hb",
                      "SHb is incapable of carrying O₂ and cannot convert back to normal Hb",
                      "Sulfhemoglobinemia causes cyanosisBlood, skin, and mucous membranes turn green-black",
                      "Blood, skin, and mucous membranes turn green-black",
                      "Sulfhemoglobinemia is typically due to medicationsSulfonamides and sulfasalazine",
                      "Sulfonamides and sulfasalazine",
                      "SHb can be quantitated by spectrophotometry"
                    ]
                  },
                  {
                    "text": "Many manufacturers have replaced Hb-cyanide method with similar methods that do not use cyanide-based reagents"
                  }
                ],
                "Other Methods to Measure Hemoglobin": [
                  {
                    "text": "Conductometry can be used to determine Hb levels"
                  },
                  {
                    "text": "In this method, alternating current is applied between 2 electrodes in contact with specimen"
                  },
                  {
                    "text": "Resulting voltage difference is measured"
                  },
                  {
                    "text": "Measured conductivity, after correction for electrolyte concentration, is inversely related to hematocrit"
                  },
                  {
                    "text": "Method is frequently used in point of care devices"
                  },
                  {
                    "text": "Major limitation of method is that patients who have electrolyte imbalances or who are receiving electrolytes can have incorrect Hb results"
                  }
                ],
                "Red Blood Cell Indices": [
                  {
                    "text": "Hb is typically measured as part of complete blood count (CBC)"
                  },
                  {
                    "text": "Hb is typically reported in g/dL"
                  },
                  {
                    "text": "Hb is used to calculate other RBC indicesMean corpuscular Hb concentration (MCHC) = Hb/Hct x 100Mean corpuscular Hb (MCH) = Hb/RBC x 10",
                    "sub_points": [
                      "Mean corpuscular Hb concentration (MCHC) = Hb/Hct x 100",
                      "Mean corpuscular Hb (MCH) = Hb/RBC x 10"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hemoglobin": [
                  {
                    "text": "Hb is iron-containing protein that carries oxygen in RBCs"
                  },
                  {
                    "text": "Low hemoglobin = anemiaSigns and symptomsFatigueWeaknessPallorCommon causesBlood lossNutritional deficienciesChronic kidney diseaseChronic inflammatory disordersBone marrow disordersThalassemiaHemoglobinopathies",
                    "sub_points": [
                      "Signs and symptomsFatigueWeaknessPallor",
                      "Fatigue",
                      "Weakness",
                      "Pallor",
                      "Common causesBlood lossNutritional deficienciesChronic kidney diseaseChronic inflammatory disordersBone marrow disordersThalassemiaHemoglobinopathies",
                      "Blood loss",
                      "Nutritional deficiencies",
                      "Chronic kidney disease",
                      "Chronic inflammatory disorders",
                      "Bone marrow disorders",
                      "Thalassemia",
                      "Hemoglobinopathies"
                    ]
                  },
                  {
                    "text": "High hemoglobin = polycythemiaSigns and symptomsVisual disturbancesHeadacheDizzinessFlushingSplenomegalyCommon causesLiving at high altitudeDehydrationLung diseaseCongenital heart diseaseSmoking",
                    "sub_points": [
                      "Signs and symptomsVisual disturbancesHeadacheDizzinessFlushingSplenomegaly",
                      "Visual disturbances",
                      "Headache",
                      "Dizziness",
                      "Flushing",
                      "Splenomegaly",
                      "Common causesLiving at high altitudeDehydrationLung diseaseCongenital heart diseaseSmoking",
                      "Living at high altitude",
                      "Dehydration",
                      "Lung disease",
                      "Congenital heart disease",
                      "Smoking"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Interference": [
                  {
                    "text": "Conditions that cause turbidity in sample can lead to falsely high absorbanceLeads to overestimation of Hb concentrationCauses of falsely elevated HbLipemiaHypergammaglobulinemiaCryoglobulinemiaLeukocytosis",
                    "sub_points": [
                      "Leads to overestimation of Hb concentration",
                      "Causes of falsely elevated HbLipemiaHypergammaglobulinemiaCryoglobulinemiaLeukocytosis",
                      "Lipemia",
                      "Hypergammaglobulinemia",
                      "Cryoglobulinemia",
                      "Leukocytosis"
                    ]
                  }
                ],
                "Technical Issues": [
                  {
                    "text": "Cyanmethemoglobin reagent is unstable when exposed to lightReagent should be protected from light",
                    "sub_points": [
                      "Reagent should be protected from light"
                    ]
                  }
                ],
                "Phlebotomy": [
                  {
                    "text": "Hemoconcentration during phlebotomy can be caused by tourniquet that is too tight or left on too longCauses blood to become concentrated below constrictionCan result in falsely elevated Hb measurements",
                    "sub_points": [
                      "Causes blood to become concentrated below constriction",
                      "Can result in falsely elevated Hb measurements"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Manual Measurement of Red Cells": {
            "name": "Manual Measurement of Red Cells",
            "url": "https://app.pathprimer.com/document/9a0cda87-dbe8-4420-8e4c-41059ba10f1c/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Manual counting of RBCs in blood samples with hemocytometer is no longer routinely performed in clinical laboratories"
                  },
                  {
                    "text": "Automated cell counters are faster and give more accurate results than manual methods, with little or no additional labor involved"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Many new automated cell counters perform automated RBC counts on body fluids (e.g., CSF)"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Too few RBCs = anemia; signs and symptoms include fatigue, weakness, pallor"
                  },
                  {
                    "text": "Too many RBCs = polycythemia; signs and symptoms include visual disturbances, headache, dizziness, flushing, splenomegaly"
                  }
                ]
              },
              "OVERVIEW": {
                "Manual Method": [
                  {
                    "text": "Counting of RBCs with hemocytometer is a manual procedure that takes a considerable amount of timeNo longer routinely performed in clinical laboratories",
                    "sub_points": [
                      "No longer routinely performed in clinical laboratories"
                    ]
                  },
                  {
                    "text": "Manual counting has been replaced by use of automated cell counters"
                  },
                  {
                    "text": "Automated cell counters are faster and give more accurate results on blood samples than manual methods with little or no additional labor involved"
                  },
                  {
                    "text": "Manual counting of RBCs is still routinely performed on some body fluids"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Cerebrospinal fluid (CSF)"
                  },
                  {
                    "text": "Complete blood count (CBC)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Procedure of Manual Counting of Red Cells": [
                  {
                    "text": "Sample is diluted"
                  },
                  {
                    "text": "Diluted sample is placed into counting chamber (hemocytometer)"
                  },
                  {
                    "text": "RBCs in counting chamber are counted"
                  },
                  {
                    "text": "Concentration of RBCs is reported"
                  }
                ],
                "Workflow": [
                  {
                    "text": "Manual RBC counts are performed only rarely on blood samples"
                  },
                  {
                    "text": "Many new automated cell counters perform automated RBC counts on body fluids (e.g., CSF)"
                  },
                  {
                    "text": "Automated methods are often accurate only at cell counts > 500"
                  },
                  {
                    "text": "Many laboratories first attempt a cell count on body fluids with automated cell counter"
                  },
                  {
                    "text": "If automated cell counter gives result within linearity of instrument, results are reported"
                  },
                  {
                    "text": "If automated cell counter gives a cell count outside linearity of instrument, manual cell count is performed"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Red Blood Cell Counts": [
                  {
                    "text": "RBC count is typically ordered as part of CBC"
                  },
                  {
                    "text": "Change in RBC count does not identify underlying cause"
                  },
                  {
                    "text": "Used to screen for various conditionsToo few RBCs = anemiaSigns and symptoms include fatigue, weakness, pallorIn pregnancy, RBC counts are decreased in relation to fluid volume, which is increasedToo many RBCs = polycythemiaSigns and symptoms of polycythemia include visual disturbances, headache, dizziness, flushing, splenomegalyLiving at high altitudes increases RBC count in response to decreased oxygen available",
                    "sub_points": [
                      "Too few RBCs = anemiaSigns and symptoms include fatigue, weakness, pallorIn pregnancy, RBC counts are decreased in relation to fluid volume, which is increased",
                      "Signs and symptoms include fatigue, weakness, pallor",
                      "In pregnancy, RBC counts are decreased in relation to fluid volume, which is increased",
                      "Too many RBCs = polycythemiaSigns and symptoms of polycythemia include visual disturbances, headache, dizziness, flushing, splenomegalyLiving at high altitudes increases RBC count in response to decreased oxygen available",
                      "Signs and symptoms of polycythemia include visual disturbances, headache, dizziness, flushing, splenomegaly",
                      "Living at high altitudes increases RBC count in response to decreased oxygen available"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Automated Analyzer Measurement of Red Blood Cells and Platelets": {
            "name": "Automated Analyzer Measurement of Red Blood Cells and Platelets",
            "url": "https://app.pathprimer.com/document/0df41b9c-72b7-4863-b423-26a73bc04d94/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Advantages of automated cell counters over manual methods include faster, more reliable, and less costly testing, with large number of additional new parameters that are available only with automated methods"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "In impedance method (a.k.a. Coulter principle), cell counting and sizing are based on detection and measurement of changes in electrical impedance (resistance) produced by particles (e.g., RBCs, platelets) as they pass through small aperture"
                  },
                  {
                    "text": "Forward and side scatter are optical methods in which diluted blood specimen passes in steady stream through which beam of laser light is focusedAs each cell passes through sensing zone of analyzer, cell scatters focused light; scattered light is detected by photodetector and converted to electrical impulseNumber of impulses generated is directly proportional to number of cells passing through sensing zone in specific period of time, and height of pulse can be used to determine size of cell",
                    "sub_points": [
                      "As each cell passes through sensing zone of analyzer, cell scatters focused light; scattered light is detected by photodetector and converted to electrical impulse",
                      "Number of impulses generated is directly proportional to number of cells passing through sensing zone in specific period of time, and height of pulse can be used to determine size of cell"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Summary": [
                  {
                    "text": "Advantages of automated cell counters over manual methodsFaster, more reliable, and less costly testingLarge number of additional new parameters that are available only with automated methods",
                    "sub_points": [
                      "Faster, more reliable, and less costly testing",
                      "Large number of additional new parameters that are available only with automated methods"
                    ]
                  },
                  {
                    "text": "In most laboratories, automated cell counters have almost entirely replaced manual methods to count RBCs and platelets"
                  },
                  {
                    "text": "Methods used in automated cell countersElectrical impedanceRadiofrequency conductivityForward and side light scatterCytochemistrySelective lysis of certain cell populations",
                    "sub_points": [
                      "Electrical impedance",
                      "Radiofrequency conductivity",
                      "Forward and side light scatter",
                      "Cytochemistry",
                      "Selective lysis of certain cell populations"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cells (RBCs)"
                  },
                  {
                    "text": "Hemoglobin (Hb)"
                  },
                  {
                    "text": "Mean corpuscular volume (MCV)"
                  },
                  {
                    "text": "Red cell distribution width (RDW)"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC)"
                  },
                  {
                    "text": "Hematocrit (HCT)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Electrical Impedance": [
                  {
                    "text": "a.k.a. Coulter principle"
                  },
                  {
                    "text": "Blood cells are nonconductiveFor analysis, they are suspended in electrically conductive diluent",
                    "sub_points": [
                      "For analysis, they are suspended in electrically conductive diluent"
                    ]
                  },
                  {
                    "text": "Cell counting and sizing based on detection and measurement of changes in electrical impedance (resistance)Changes in electrical impedance produced by particles (e.g., RBCs, platelets) as they pass through small aperture",
                    "sub_points": [
                      "Changes in electrical impedance produced by particles (e.g., RBCs, platelets) as they pass through small aperture"
                    ]
                  },
                  {
                    "text": "As dilute suspension of blood is drawn through aperture, passage of each individual cell momentarily increases impedance of electrical path between 2 electrodes located on each side of aperture"
                  },
                  {
                    "text": "Increase in impedance is used to count RBCs or platelets"
                  },
                  {
                    "text": "Histogram (size vs. number) of cells is plottedRed cell indices are measured from plot",
                    "sub_points": [
                      "Red cell indices are measured from plot"
                    ]
                  }
                ],
                "Forward and Side Light Scatter": [
                  {
                    "text": "Optical method used to some extent in most modern cell counters"
                  },
                  {
                    "text": "Diluted blood specimen passes in steady stream through which beam of laser light is focused"
                  },
                  {
                    "text": "As each cell passes through sensing zone of analyzer, cell scatters focused light"
                  },
                  {
                    "text": "Scattered light is detected by photodetector and converted to electrical impulse"
                  },
                  {
                    "text": "Number of impulses generated directly proportional to number of cells passing through sensing zone in specific period of time"
                  },
                  {
                    "text": "As single cell passes through laser beam, light is reflected and scattered"
                  },
                  {
                    "text": "Patterns of scatter are measured at different angles"
                  },
                  {
                    "text": "Scattered light provides information about cell structure, shape, and reflectivityCharacteristics used to differentiate various types of blood cells and and to produce scatterplots",
                    "sub_points": [
                      "Characteristics used to differentiate various types of blood cells and and to produce scatterplots"
                    ]
                  }
                ],
                "Radiofrequency Conductivity": [
                  {
                    "text": "Determined by high-frequency electromagnetic probe"
                  },
                  {
                    "text": "Provides information about cell nucleus and granules"
                  }
                ],
                "Selective Lysis": [
                  {
                    "text": "Lysis of selected cell groups used on most automated cell counterse.g., before counting white cells, red cells are lysed",
                    "sub_points": [
                      "e.g., before counting white cells, red cells are lysed"
                    ]
                  }
                ],
                "Cytochemistry": [
                  {
                    "text": "Some instruments use fluorescent dyes to separate platelets from RBCs"
                  }
                ],
                "Red Cell Indices": [
                  {
                    "text": "Several methods available to measure red cell indices"
                  },
                  {
                    "text": "Different methods result in differences in which parameters are measured and which parameters are calculated"
                  },
                  {
                    "text": "ExampleHb is typically measured using spectrophotometric methodsMean of red cell histogram is measured as MCVArea under red cell histogram curve is RBC countRDW can be measured as distance between points 20% above intersection with x-axis on lower side and 20% below intersection with x-axis on upper side of distributionIn this method, remaining red cell indices are calculatedMCH is average amount of Hb per cellMCH = Hb/RBCMCHC is average concentration of Hb per cellMCHC = MCH/MCV = (Hb/RBC)/MCV = Hb x MCV/RBCHCT is percentage of volume occupied by RBCs in whole bloodHCT = RBC x MCV",
                    "sub_points": [
                      "Hb is typically measured using spectrophotometric methods",
                      "Mean of red cell histogram is measured as MCV",
                      "Area under red cell histogram curve is RBC count",
                      "RDW can be measured as distance between points 20% above intersection with x-axis on lower side and 20% below intersection with x-axis on upper side of distribution",
                      "In this method, remaining red cell indices are calculatedMCH is average amount of Hb per cellMCH = Hb/RBCMCHC is average concentration of Hb per cellMCHC = MCH/MCV = (Hb/RBC)/MCV = Hb x MCV/RBCHCT is percentage of volume occupied by RBCs in whole bloodHCT = RBC x MCV",
                      "MCH is average amount of Hb per cellMCH = Hb/RBC",
                      "MCH = Hb/RBC",
                      "MCHC is average concentration of Hb per cellMCHC = MCH/MCV = (Hb/RBC)/MCV = Hb x MCV/RBC",
                      "MCHC = MCH/MCV = (Hb/RBC)/MCV = Hb x MCV/RBC",
                      "HCT is percentage of volume occupied by RBCs in whole bloodHCT = RBC x MCV",
                      "HCT = RBC x MCV"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Automated Analyzer Measurement of Platelets (Artifacts of Platelet Window)": {
            "name": "Automated Analyzer Measurement of Platelets (Artifacts of Platelet Window)",
            "url": "https://app.pathprimer.com/document/5ce31b88-275e-4fe6-aea0-a91be0fc2d79/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Automated cell counters use impedance (Coulter principle) or optical methods to count platelets"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "In impedance-based instruments, platelet counts are based on detection and measurement of these changes in electrical impedance (resistance) produced by platelets as they pass through aperture"
                  },
                  {
                    "text": "In instruments based on optical methods, number of impulses generated is proportional to number of cells passing through sensing zone in specific period of time"
                  },
                  {
                    "text": "Some cell counters use fluorescent dyes to improve accuracy of platelet counts and to provide novel parameters"
                  },
                  {
                    "text": "One approach is to perform impedance-based count first; if impedance count is not flagged by automated cell counter, result is reported, but if impedance count is flagged, aliquot of sample will be stained and analyzed in optical channel"
                  }
                ]
              },
              "OVERVIEW": {
                "History": [
                  {
                    "text": "Until 1980, platelets were counted manually with Neubauer hemocytometers"
                  },
                  {
                    "text": "Hemocytometers have been replaced by automated cell counters in most laboratories"
                  },
                  {
                    "text": "Automated cell counters use impedance (Coulter principle) or optical methods to count platelets"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Immature platelet fraction (IPF)"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Impedance-Based Platelet Counts (Conductivity-Based Systems)": [
                  {
                    "text": "Platelets are suspended in electrically conductive diluent"
                  },
                  {
                    "text": "Platelets are nonconductive"
                  },
                  {
                    "text": "Dilute suspension of cells is drawn through aperture"
                  },
                  {
                    "text": "Passage of each individual platelet momentarily increases impedance of electrical path between 2 electrodes located on each side of aperture"
                  },
                  {
                    "text": "In impedance-based instruments, platelet counts are based on detection and measurement of changes in electrical impedance (resistance) produced by platelets as they pass through apertureEach platelet will deflect voltage; these events can be counted by volumeArea under deflection is proportional to size of platelet",
                    "sub_points": [
                      "Each platelet will deflect voltage; these events can be counted by volume",
                      "Area under deflection is proportional to size of platelet"
                    ]
                  },
                  {
                    "text": "Disadvantage of impedance-based approach is that platelets are only identified by sizeBecause platelets are only distinguished from erythrocytes by size, multiple conditions can lead to overcounts or undercounts of plateletsPlatelet clumps can be miss-counted as erythrocytes, leading to falsely low platelet countsSmall erythrocytes can be miss-counted as platelets, leading to falsely elevated platelet countsCan be major problem in diseases like TTPPatients can have schistocytes miscounted as platelets, masking critically low platelet countFungus, bacterial, and cytoplasmic fragments of blasts can also be erroneously counted as platelets",
                    "sub_points": [
                      "Because platelets are only distinguished from erythrocytes by size, multiple conditions can lead to overcounts or undercounts of plateletsPlatelet clumps can be miss-counted as erythrocytes, leading to falsely low platelet countsSmall erythrocytes can be miss-counted as platelets, leading to falsely elevated platelet countsCan be major problem in diseases like TTPPatients can have schistocytes miscounted as platelets, masking critically low platelet countFungus, bacterial, and cytoplasmic fragments of blasts can also be erroneously counted as platelets",
                      "Platelet clumps can be miss-counted as erythrocytes, leading to falsely low platelet counts",
                      "Small erythrocytes can be miss-counted as platelets, leading to falsely elevated platelet counts",
                      "Can be major problem in diseases like TTPPatients can have schistocytes miscounted as platelets, masking critically low platelet count",
                      "Patients can have schistocytes miscounted as platelets, masking critically low platelet count",
                      "Fungus, bacterial, and cytoplasmic fragments of blasts can also be erroneously counted as platelets"
                    ]
                  }
                ],
                "Optical Methods": [
                  {
                    "text": "Diluted specimen containing platelets passes in steady stream before laser light"
                  },
                  {
                    "text": "As each platelet passes through sensing zone of flow cell, it scatters focused laser light"
                  },
                  {
                    "text": "Scattered light is detected by photodetector and converted to electrical impulse"
                  },
                  {
                    "text": "In instruments based on optical methods, number of impulses generated is proportional to number of cells passing through sensing zone in specific period of time"
                  },
                  {
                    "text": "Scattered light provides information about cell structure, shape, and reflectivity"
                  },
                  {
                    "text": "Can be used to determine platelet parametersPlatelet countMean platelet volumePlatelet distribution width",
                    "sub_points": [
                      "Platelet count",
                      "Mean platelet volume",
                      "Platelet distribution width"
                    ]
                  }
                ],
                "Novel Methods": [
                  {
                    "text": "Some cell counters use fluorescent dyes to improve accuracy of platelet counts and to provide novel parameters"
                  },
                  {
                    "text": "One approach is to perform impedance-based count firstIf impedance count is not flagged by automated cell counter, impedance result is reportedIf impedance count is flagged, aliquot of sample will be stained and analyzed in optical channel",
                    "sub_points": [
                      "If impedance count is not flagged by automated cell counter, impedance result is reported",
                      "If impedance count is flagged, aliquot of sample will be stained and analyzed in optical channel"
                    ]
                  },
                  {
                    "text": "Use of specific fluorescent dyes also allows measurement of IPFPercentage of platelets recently released from bone marrowLow IPF indicates that the reason for patient's low platelet counts is that marrow is not making enough plateletsNormal or high IPF indicates that the reason for patient's low platelet count is destruction of platelets in periphery",
                    "sub_points": [
                      "Percentage of platelets recently released from bone marrow",
                      "Low IPF indicates that the reason for patient's low platelet counts is that marrow is not making enough platelets",
                      "Normal or high IPF indicates that the reason for patient's low platelet count is destruction of platelets in periphery"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Automated Analyzer Measurement of Red Blood Cells (Artifacts of Red Cell Window)": {
            "name": "Automated Analyzer Measurement of Red Blood Cells (Artifacts of Red Cell Window)",
            "url": "https://app.pathprimer.com/document/1f553364-1a36-443a-a3cd-6e4dcfd1c93f/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Automated cell counters use impedance (original \"Coulter principle\") or optical methods to count RBCs"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "In impedance-based methods, passage of each RBC through small aperture increases resistance through apertureMethod determines number of RBCs (how often has resistance been increased?) and size of RBCs (how long did each RBC increase resistance in aperture?)",
                    "sub_points": [
                      "Method determines number of RBCs (how often has resistance been increased?) and size of RBCs (how long did each RBC increase resistance in aperture?)"
                    ]
                  },
                  {
                    "text": "In optical methods, each RBC passes through sensing zone of instrument and scatters focused laser lightScattered light provides information about RBC structure and shapeMethod allows determination of RBC parameters, including RBC count, RBC size, RDW, hemoglobin, and MCH",
                    "sub_points": [
                      "Scattered light provides information about RBC structure and shape",
                      "Method allows determination of RBC parameters, including RBC count, RBC size, RDW, hemoglobin, and MCH"
                    ]
                  },
                  {
                    "text": "Spurious increases in RBC counts can be due to giant platelets being miscounted as RBCs"
                  },
                  {
                    "text": "Spurious decreases in RBC counts can be due to microcytosis (small RBCs being miscounted as platelets), agglutinins, cryoglobulins"
                  }
                ]
              },
              "OVERVIEW": {
                "Analyzers": [
                  {
                    "text": "Automated cell counters use impedance (\"Coulter principle\") or optical methods to count RBCs"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Red cell distribution width (RDW)"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin (MCH)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Impedance-Based Instruments": [
                  {
                    "text": "RBCs are suspended in electrically conductive diluent"
                  },
                  {
                    "text": "In impedance-based methods, passage of each RBC through small aperture increases resistance through aperture"
                  },
                  {
                    "text": "The larger the RBC, the more resistance increases as it passes through aperture"
                  },
                  {
                    "text": "Impedance method determines number and size of RBCsNumber of RBCsHow often has resistance been increased?Size of RBCsHow long did each RBC increase resistance in aperture?",
                    "sub_points": [
                      "Number of RBCsHow often has resistance been increased?",
                      "How often has resistance been increased?",
                      "Size of RBCsHow long did each RBC increase resistance in aperture?",
                      "How long did each RBC increase resistance in aperture?"
                    ]
                  },
                  {
                    "text": "Impedance method uses only size to distinguish RBCs from plateletsSmall RBCs can be miscounted as plateletsLarge platelets can be miscounted as RBCs",
                    "sub_points": [
                      "Small RBCs can be miscounted as platelets",
                      "Large platelets can be miscounted as RBCs"
                    ]
                  }
                ],
                "Optical Methods": [
                  {
                    "text": "Diluted specimen containing RBCs passes in steady stream before a laser light"
                  },
                  {
                    "text": "In optical methods, each RBC passes through sensing zone of instrument and scatters focused laser light"
                  },
                  {
                    "text": "Scattered light is detected by photodetector and converted to electric impulse"
                  },
                  {
                    "text": "Scattered light provides information about RBC structure and shape"
                  },
                  {
                    "text": "Optical method allows determination of RBC parametersRBC countRBC sizeRDWHemoglobin content of RBCsMCH",
                    "sub_points": [
                      "RBC count",
                      "RBC size",
                      "RDW",
                      "Hemoglobin content of RBCs",
                      "MCH"
                    ]
                  }
                ],
                "Situations That Can Lead to Incorrect Automated Red Cell Counts": [
                  {
                    "text": "Spurious increases in RBC countsGiant platelets being miscounted as RBCsVery high white cell counts",
                    "sub_points": [
                      "Giant platelets being miscounted as RBCs",
                      "Very high white cell counts"
                    ]
                  },
                  {
                    "text": "Spurious decreases in RBC countsAgglutininsMicrocytosis (small RBCs being miscounted as platelets)CryoglobulinsIn vitro hemolysisClotted sample",
                    "sub_points": [
                      "Agglutinins",
                      "Microcytosis (small RBCs being miscounted as platelets)",
                      "Cryoglobulins",
                      "In vitro hemolysis",
                      "Clotted sample"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Measurement of Reticulocytes and Calculation of Reticulocyte Production Index": {
            "name": "Measurement of Reticulocytes and Calculation of Reticulocyte Production Index",
            "url": "https://app.pathprimer.com/document/f79c37ce-576f-4a9c-9bb8-89e86221afe9/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Majority of reticulocyte counts are now performed using automated cell countersAutomated counts are based on uptake of ribonucleic acid (RNA) dyeImmature red blood cells (RBCs), which contain RNA, take up dye and absorb more light than mature red cells, which do not contain RNA; they can then be counted separately",
                    "sub_points": [
                      "Automated counts are based on uptake of ribonucleic acid (RNA) dyeImmature red blood cells (RBCs), which contain RNA, take up dye and absorb more light than mature red cells, which do not contain RNA; they can then be counted separately",
                      "Immature red blood cells (RBCs), which contain RNA, take up dye and absorb more light than mature red cells, which do not contain RNA; they can then be counted separately"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Low reticulocyte count: Suggests decreased production of RBCs from bone marrowSeen in iron deficiency anemiaSeen in vitamin B12 and folate deficiency",
                    "sub_points": [
                      "Seen in iron deficiency anemia",
                      "Seen in vitamin B12 and folate deficiency"
                    ]
                  },
                  {
                    "text": "Elevated reticulocyte count: Suggests increased production of red cells from bone marrowSeen in hemolytic anemiaSeen in bleeding",
                    "sub_points": [
                      "Seen in hemolytic anemia",
                      "Seen in bleeding"
                    ]
                  },
                  {
                    "text": "Reticulocyte production index (RPI) adjusts for degree of anemia present to determine if bone marrow is responding appropriately for degree of anemiaRPI calculated as → [(percent observed reticulocytes x patient's hematocrit) ÷ 45] x [1 ÷ correction factor]",
                    "sub_points": [
                      "RPI calculated as → [(percent observed reticulocytes x patient's hematocrit) ÷ 45] x [1 ÷ correction factor]"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Manual Reticulocyte Counts": [
                  {
                    "text": "Very low precision and accuracyDiscontinued in most clinical laboratories",
                    "sub_points": [
                      "Discontinued in most clinical laboratories"
                    ]
                  },
                  {
                    "text": "Majority of reticulocyte counts are now performed using automated cell counters"
                  }
                ],
                "Automated Reticulocyte Counts": [
                  {
                    "text": "Based on uptake of ribonucleic acid (RNA) dyeImmature RBCs, which contain RNA, take up dye and absorb more light than mature red cells, which do not contain RNA; they can then be counted separately",
                    "sub_points": [
                      "Immature RBCs, which contain RNA, take up dye and absorb more light than mature red cells, which do not contain RNA; they can then be counted separately"
                    ]
                  },
                  {
                    "text": "Method also allows for determination of size and hemoglobin content of reticulocytes, which allows reporting of many novel parameterse.g., CHr (mean hemoglobin content of reticulocytes) (Siemens ADVIA) and RET-Y (Sysmex)These are generally accepted as good measures of present iron stores in bone marrow and can be useful in several waysDiagnose iron deficiency in childrenGuide iron and erythropoietin therapy in hemodialysis patientsDiagnose iron deficiency in patients with inflammation or chronic disease",
                    "sub_points": [
                      "e.g., CHr (mean hemoglobin content of reticulocytes) (Siemens ADVIA) and RET-Y (Sysmex)These are generally accepted as good measures of present iron stores in bone marrow and can be useful in several waysDiagnose iron deficiency in childrenGuide iron and erythropoietin therapy in hemodialysis patientsDiagnose iron deficiency in patients with inflammation or chronic disease",
                      "These are generally accepted as good measures of present iron stores in bone marrow and can be useful in several waysDiagnose iron deficiency in childrenGuide iron and erythropoietin therapy in hemodialysis patientsDiagnose iron deficiency in patients with inflammation or chronic disease",
                      "Diagnose iron deficiency in children",
                      "Guide iron and erythropoietin therapy in hemodialysis patients",
                      "Diagnose iron deficiency in patients with inflammation or chronic disease"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Anemia Evaluation": [
                  {
                    "text": "Reticulocyte count is useful in evaluation of anemiaReticulocytes are newly produced, relatively immature RBCs",
                    "sub_points": [
                      "Reticulocytes are newly produced, relatively immature RBCs"
                    ]
                  },
                  {
                    "text": "Low reticulocyte count: Suggests decreased production of RBCs from bone marrow and can be seen inIron deficiency anemiaVitamin B12 and folate deficiencyPernicious anemiaAplastic anemiaChemotherapy &/or radiation therapyAlcoholismEndocrine disease, severe kidney disease",
                    "sub_points": [
                      "Iron deficiency anemia",
                      "Vitamin B12 and folate deficiency",
                      "Pernicious anemia",
                      "Aplastic anemia",
                      "Chemotherapy &/or radiation therapy",
                      "Alcoholism",
                      "Endocrine disease, severe kidney disease"
                    ]
                  },
                  {
                    "text": "Elevated reticulocyte count: Suggests increased production of red cells from bone marrow and can be seen inHemolytic anemiaBleedingIncreases several days after acute blood loss to replace RBCsIn chronic bleeding, reticulocyte count increases to compensate for RBC loss; however, if iron deficiency develops, reticulocyte count may not increasePregnancyNeonatal periodPolycythemia veraErythropoietin-producing tumors",
                    "sub_points": [
                      "Hemolytic anemia",
                      "BleedingIncreases several days after acute blood loss to replace RBCsIn chronic bleeding, reticulocyte count increases to compensate for RBC loss; however, if iron deficiency develops, reticulocyte count may not increase",
                      "Increases several days after acute blood loss to replace RBCs",
                      "In chronic bleeding, reticulocyte count increases to compensate for RBC loss; however, if iron deficiency develops, reticulocyte count may not increase",
                      "Pregnancy",
                      "Neonatal period",
                      "Polycythemia vera",
                      "Erythropoietin-producing tumors"
                    ]
                  }
                ],
                "Corrected Reticulocyte Count (CRC)": [
                  {
                    "text": "CRC calculated as → (percent observed reticulocytes x patient's hematocrit) ÷ 45"
                  }
                ],
                "Reticulocyte Production Index (RPI)": [
                  {
                    "text": "Adjusts for degree of anemia present to determine if bone marrow is responding appropriately for degree of anemia (e.g., severe anemia should have more reticulocytes produced than mild anemia)"
                  },
                  {
                    "text": "RPI calculated as → [(percent observed reticulocytes x patient's hematocrit) ÷ 45] x [1 ÷ correction factor]Correction factor (maturation index) should be selected from hematocrit range belowHct 40-45: Correction factor 1.0Hct 35-39: Correction factor 1.5Hct 25-34: Correction factor 2.0Hct 15-24: Correction factor 2.5Hct < 15: Correction factor 3.0",
                    "sub_points": [
                      "Correction factor (maturation index) should be selected from hematocrit range belowHct 40-45: Correction factor 1.0Hct 35-39: Correction factor 1.5Hct 25-34: Correction factor 2.0Hct 15-24: Correction factor 2.5Hct < 15: Correction factor 3.0",
                      "Hct 40-45: Correction factor 1.0",
                      "Hct 35-39: Correction factor 1.5",
                      "Hct 25-34: Correction factor 2.0",
                      "Hct 15-24: Correction factor 2.5",
                      "Hct < 15: Correction factor 3.0"
                    ]
                  },
                  {
                    "text": "CRC and RPI are rarely used in clinical practice"
                  }
                ],
                "Novel Reticulocyte Parameters": [
                  {
                    "text": "Some automated cell counters offer new parameters, such as immature reticulocyte fraction (IRF)IRF quantifies younger fraction of reticulocytesPreviously referred to as reticulocyte maturity index",
                    "sub_points": [
                      "IRF quantifies younger fraction of reticulocytes",
                      "Previously referred to as reticulocyte maturity index"
                    ]
                  },
                  {
                    "text": "Increased IRF indicates adequate erythroid response to anemia"
                  },
                  {
                    "text": "Decreased IRF indicates inadequate erythroid response to anemia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Osmotic Fragility Test Interpretation": {
            "name": "Osmotic Fragility Test Interpretation",
            "url": "https://app.pathprimer.com/document/f51ca6e7-3860-4e7c-b4d7-fba021f59ac1/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Osmotic fragility test measures in vitro hemolysis of RBCs incubated in solutions of decreasing concentrations (osmolarity) of NaCl"
                  },
                  {
                    "text": "Normal RBC membrane is freely permeable to water allowing RBC to increase its volume in hypotonic solutions"
                  },
                  {
                    "text": "“Critical hemolytic volume” is volume at which RBC membrane ruptures, releasing hemoglobin into supernatant solution"
                  },
                  {
                    "text": "Spherocytes, owing to membrane loss, have decreased surface area and lower critical hemolytic volume than normal RBCs"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Increased osmotic fragility is seen in conditions with spherocytosis; it is not specific for hereditary spherocytosis"
                  },
                  {
                    "text": "Osmotic fragility can be increased in hemolytic anemias associated with RBC enzyme deficiencies, RBC membrane disorders other than hereditary spherocytosis, and severe burns"
                  },
                  {
                    "text": "Osmotic fragility can be decreased in thalassemia, iron deficiency, polycythemia vera, sickle cell disease, liver disease, reticulocytosis, and any disorder in which target cells are found"
                  }
                ]
              },
              "OVERVIEW": {
                "Physiology": [
                  {
                    "text": "Osmotic fragility test measures in vitro hemolysis of RBCs incubated in solutions of decreasing concentrations (osmolarity) of NaCl"
                  },
                  {
                    "text": "Normal RBC membrane is freely permeable to water allowing RBC to increase its volume in hypotonic solutions"
                  },
                  {
                    "text": "“Critical hemolytic volume” is volume at which RBC membrane ruptures, releasing hemoglobin into supernatant solution"
                  },
                  {
                    "text": "Spherocytes, owing to membrane loss, have decreased surface area and lower critical hemolytic volume than normal RBCs"
                  },
                  {
                    "text": "Spherocytes hemolyze more easily than normal RBCs when suspended in hypotonic NaCl solutions and have increased osmotic fragility"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cells (RBCs)"
                  },
                  {
                    "text": "Sodium chloride (NaCl)"
                  },
                  {
                    "text": "Ethylenediaminetetraacetic acid (EDTA)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Osmotic Fragility Test": [
                  {
                    "text": "Several dilutions of NaCl (0.9%-0%) are prepared"
                  },
                  {
                    "text": "Patient RBCs are added to each tube of NaCl and incubated at room temperature for 30 min"
                  },
                  {
                    "text": "After incubation, samples are centrifuged at 2500g"
                  },
                  {
                    "text": "Supernatant is collected from each tubeAbsorbance at 540 nm is read by spectrophotometry to measure released hemoglobin",
                    "sub_points": [
                      "Absorbance at 540 nm is read by spectrophotometry to measure released hemoglobin"
                    ]
                  },
                  {
                    "text": "Percent of hemolysis is calculated for each NaCl concentration from absorbance"
                  },
                  {
                    "text": "InterpretationIn normal RBCs, hemolysis should not be detected in NaCl concentrations > 0.45%Complete hemolysis should be seen at NaCl concentrations < 0.3%Hemolysis in patient sample is compared with reference range and simultaneously run normal controlResults are reported as normal, increased, or decreased osmotic fragility",
                    "sub_points": [
                      "In normal RBCs, hemolysis should not be detected in NaCl concentrations > 0.45%",
                      "Complete hemolysis should be seen at NaCl concentrations < 0.3%",
                      "Hemolysis in patient sample is compared with reference range and simultaneously run normal control",
                      "Results are reported as normal, increased, or decreased osmotic fragility"
                    ]
                  },
                  {
                    "text": "Incubated osmotic fragility testOsmotic fragility test can be performed with incubation at 37°C for 24 hoursIncubated test is more sensitive and helps in diagnosing cases of spherocytosis with only slight defect",
                    "sub_points": [
                      "Osmotic fragility test can be performed with incubation at 37°C for 24 hours",
                      "Incubated test is more sensitive and helps in diagnosing cases of spherocytosis with only slight defect"
                    ]
                  },
                  {
                    "text": "Increased osmotic fragility is seen in conditions with spherocytosisNot specific for hereditary spherocytosisImmune-mediated hemolytic anemia can show increased osmotic fragility",
                    "sub_points": [
                      "Not specific for hereditary spherocytosis",
                      "Immune-mediated hemolytic anemia can show increased osmotic fragility"
                    ]
                  },
                  {
                    "text": "Osmotic fragility increasedHemolytic anemias associated with RBC enzyme deficienciesRBC membrane disorders other than hereditary spherocytosisSevere burns",
                    "sub_points": [
                      "Hemolytic anemias associated with RBC enzyme deficiencies",
                      "RBC membrane disorders other than hereditary spherocytosis",
                      "Severe burns"
                    ]
                  },
                  {
                    "text": "Osmotic fragility decreasedThalassemiaIron deficiencyPolycythemia veraSickle cell diseaseLiver diseaseReticulocytosisAny disorder in which target cells are found",
                    "sub_points": [
                      "Thalassemia",
                      "Iron deficiency",
                      "Polycythemia vera",
                      "Sickle cell disease",
                      "Liver disease",
                      "Reticulocytosis",
                      "Any disorder in which target cells are found"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Diagnostic Indications": [
                  {
                    "text": "Osmotic fragility test used to diagnose conditions in which physical properties of RBC membrane are altered"
                  },
                  {
                    "text": "Fragility of RBCs increasedIn conditions in which surface area-to-volume ratio is decreased as in spherocytes",
                    "sub_points": [
                      "In conditions in which surface area-to-volume ratio is decreased as in spherocytes"
                    ]
                  },
                  {
                    "text": "Fragility of RBCs decreasedIn conditions in which RBCs are partially empty, thin, sickled shaped or surface area-to-volume ratio is increased as in target cells",
                    "sub_points": [
                      "In conditions in which RBCs are partially empty, thin, sickled shaped or surface area-to-volume ratio is increased as in target cells"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection and Storage": [
                  {
                    "text": "Whole blood collected in EDTA or heparin"
                  },
                  {
                    "text": "Samples should be tested within 72 hours of collection if kept refrigerated"
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Normal control should be run with each patient sample"
                  }
                ],
                "Proficiency Testing": [
                  {
                    "text": "Split sample testing performed with another laboratory that offers test and results compared"
                  },
                  {
                    "text": "Proficiency testing program not commercially available"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sucrose Lysis and Ham Test Interpretation for Diagnosis of PNH": {
            "name": "Sucrose Lysis and Ham Test Interpretation for Diagnosis of PNH",
            "url": "https://app.pathprimer.com/document/a736a25c-c72d-49db-8818-72e4dd8d602a/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "PNH is clonal disorder of bone marrow caused by somatic mutation inPIG-Agene"
                  },
                  {
                    "text": "Mutation causes partial or total deficiency of all proteins anchored to cell membrane by GPI anchorAbsence of these proteins results in increased sensitivity of red cells to complement-mediated lysis",
                    "sub_points": [
                      "Absence of these proteins results in increased sensitivity of red cells to complement-mediated lysis"
                    ]
                  },
                  {
                    "text": "CD59 (membrane inhibitor of reactive lysis) and CD55 (decay accelerating factor) are reduced or absent in patients with PNH, compared with normal controls﻿"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Acidified serum test (Ham test) is confirmatory test for PNHSerum is acidified, which activates complement, binds RBCs, and lyses PNH erythrocytesPositive test if both of 2 specific outcomesHemolysis occurs with patient's own cells and not with control cellsHemolysis is enhanced by acidified serum and does not occur with heat-inactivated serumAcidification activates complement, and heat inactivates complement",
                    "sub_points": [
                      "Serum is acidified, which activates complement, binds RBCs, and lyses PNH erythrocytes",
                      "Positive test if both of 2 specific outcomesHemolysis occurs with patient's own cells and not with control cellsHemolysis is enhanced by acidified serum and does not occur with heat-inactivated serumAcidification activates complement, and heat inactivates complement",
                      "Hemolysis occurs with patient's own cells and not with control cells",
                      "Hemolysis is enhanced by acidified serum and does not occur with heat-inactivated serumAcidification activates complement, and heat inactivates complement",
                      "Acidification activates complement, and heat inactivates complement"
                    ]
                  },
                  {
                    "text": "Flow cytometry for GPI-anchored proteins CD16, CD48, CD55, or CD59 is currently primary method used for diagnosis of PNH"
                  }
                ]
              },
              "OVERVIEW": {
                "Paroxysmal Nocturnal Hemoglobinuria": [
                  {
                    "text": "PNH is clonal disorder of bone marrow caused by somatic mutation inPIG-Agene"
                  },
                  {
                    "text": "Mutation causes partial or total deficiency of all proteins anchored to cell membrane by GPI anchor"
                  },
                  {
                    "text": "CD59 (membrane inhibitor of reactive lysis) and CD55 (decay accelerating factor) are reduced or absent in patients with PNH, compared with normal controls﻿"
                  },
                  {
                    "text": "Absence of these proteins results in increased sensitivity of red cells to complement-mediated lysis"
                  },
                  {
                    "text": "Laboratory tests for PNHSucrose lysis testAcidified serum test (Ham test)Flow cytometry for GPI-anchored proteins (CD16, CD48, CD55, and CD59)",
                    "sub_points": [
                      "Sucrose lysis test",
                      "Acidified serum test (Ham test)",
                      "Flow cytometry for GPI-anchored proteins (CD16, CD48, CD55, and CD59)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Congenital dyserythropoietic anemia type II (CDA-II)"
                  },
                  {
                    "text": "Glycophosphatidylinositol (GPI)"
                  },
                  {
                    "text": "Hereditary erythroblastic multinuclearity with positive acidified serum (HEMPAS)"
                  },
                  {
                    "text": "Paroxysmal nocturnal hemoglobinuria (PNH)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Sucrose Lysis Test (Sucrose Hemolysis Test)": [
                  {
                    "text": "Screening test for PNHNot specific for PNH; positive in other hemolytic anemias",
                    "sub_points": [
                      "Not specific for PNH; positive in other hemolytic anemias"
                    ]
                  },
                  {
                    "text": "Sucrose is added to sample and promotes binding of complement to RBCs"
                  },
                  {
                    "text": "Complement-sensitive PNH erythrocytes are lysed, while normal red cells are not lysed"
                  }
                ],
                "Acidified Serum Test (Ham Test)": [
                  {
                    "text": "Acidified serum test is confirmatory test for PNHPositive in PNHAlso positive in CDA-II, also known as HEMPAS",
                    "sub_points": [
                      "Positive in PNHAlso positive in CDA-II, also known as HEMPAS",
                      "Also positive in CDA-II, also known as HEMPAS"
                    ]
                  },
                  {
                    "text": "Serum is acidified, which activates complement, binds RBCs, and lyses PNH erythrocytes"
                  },
                  {
                    "text": "Positive test if both of 2 specific outcomes:Hemolysis occurs with patient's own cells and not with control cellsHemolysis is enhanced by acidified serum and does not occur with heat-inactivated serumAcidification activates complement, and heat inactivates complement",
                    "sub_points": [
                      "Hemolysis occurs with patient's own cells and not with control cells",
                      "Hemolysis is enhanced by acidified serum and does not occur with heat-inactivated serumAcidification activates complement, and heat inactivates complement",
                      "Acidification activates complement, and heat inactivates complement"
                    ]
                  },
                  {
                    "text": "Seven tubes are set upNormal serum and patient cells: Slight hemolysis occurs if patient has PNHAcidified normal serum and patient cells: Very significant hemolysis occurs if patient has PNHAcidified patient serum and patient cells: Significant hemolysis occurs if patient has PNHAcidified heat-inactivated normal serum and patient cells: No hemolysis occurs, whether patient has PNH or notThis is control tube for heat-inactivation of acidified serumNormal serum plus normal cells: No hemolysis occurs; this is control tubeAcidified normal serum and normal cells: No hemolysis occurs; this is control tubeAcidified heat-inactivated normal serum and normal cells: No hemolysis occursThis is control tube for heat-inactivation of acidified serum",
                    "sub_points": [
                      "Normal serum and patient cells: Slight hemolysis occurs if patient has PNH",
                      "Acidified normal serum and patient cells: Very significant hemolysis occurs if patient has PNH",
                      "Acidified patient serum and patient cells: Significant hemolysis occurs if patient has PNH",
                      "Acidified heat-inactivated normal serum and patient cells: No hemolysis occurs, whether patient has PNH or notThis is control tube for heat-inactivation of acidified serum",
                      "This is control tube for heat-inactivation of acidified serum",
                      "Normal serum plus normal cells: No hemolysis occurs; this is control tube",
                      "Acidified normal serum and normal cells: No hemolysis occurs; this is control tube",
                      "Acidified heat-inactivated normal serum and normal cells: No hemolysis occursThis is control tube for heat-inactivation of acidified serum",
                      "This is control tube for heat-inactivation of acidified serum"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Flow cytometry for GPI-anchored proteins CD16, CD48, CD55, or CD59 is currently primary method used for diagnosis of PNH"
                  },
                  {
                    "text": "Sucrose lysis test and Ham test are rarely used for clinical diagnosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "G6PD Tests: Qualitative and Quantitative": {
            "name": "G6PD Tests: Qualitative and Quantitative",
            "url": "https://app.pathprimer.com/document/b6c53222-77d0-4d81-a369-2450a95eb870/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Assays of G6PD activity either directly or indirectly assess production of NADPH"
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "NADPH fluoresces when exposed to UV light, while NADP+ does not fluoresce"
                  },
                  {
                    "text": "NADPH can be detected by spectrophotometry at wavelength of 340 nm"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "﻿Heterozygous females due to random X-inactivation may not have sufficiently low activity to be detected as G6PD-deficient by this test"
                  },
                  {
                    "text": "Test may give normal result (false-negative) in G6PD-deficient individual who is recovering from acute hemolytic event and has reticulocytosis"
                  }
                ],
                "Specimens": [
                  {
                    "text": "Samples should not be frozen because G6PD is not stable in hemolysates"
                  }
                ]
              },
              "OVERVIEW": {
                "Physiology": [
                  {
                    "text": "Glucose-6-phosphate dehydrogenase (G6PD) catalyzes first step of hexose-monophosphate (HMP) shunt converting glucose-6-phosphate (G6P) to 6-phosphogluconate (6PG)This reaction is accompanied by reduction of nicotinamide adenine dinucleotide phosphate (NADP+) to its reduced form NADPH",
                    "sub_points": [
                      "This reaction is accompanied by reduction of nicotinamide adenine dinucleotide phosphate (NADP+) to its reduced form NADPH"
                    ]
                  },
                  {
                    "text": "Assays of G6PD activity either directly or indirectly assess production of NADPH"
                  },
                  {
                    "text": "Qualitative and semiquantitative assays indirectly measure NADPH production"
                  },
                  {
                    "text": "Quantitative enzyme assays directly measure rate of NADPH production"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "NADPH": [
                  {
                    "text": "NADPH fluoresces when exposed to UV light, while NADP+ does not fluoresce"
                  },
                  {
                    "text": "NADPH can be detected by spectrophotometry at wavelength of 340 nmAs NADPH is produced, absorbance at 340 nm increases",
                    "sub_points": [
                      "As NADPH is produced, absorbance at 340 nm increases"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "G6PD Qualitative Assay": [
                  {
                    "text": "Fluorescence spot testPatient RBCs are incubated with G6P and NADP+ at 37ºCAfter 5 and 10 minutes of incubation, mixture of patient blood, G6P, and NADP+ is added to filter paperAfter allowing blood spot to dry, filter paper is visually inspected with long-wave UV lightSamples from G6PD-normal patients should fluoresce brightly when checked at 5 and 10 minutesEnzyme-deficient samples will not fluoresce or will show very dull fluorescenceInterpretationNormal sample shows moderate to strong fluorescence after 5 minutes and strong fluorescence after 10 minutesIntermediate-level sample demonstrates weak fluorescence at 5 minutes and moderate fluorescence after 10 minutesGrossly deficient sample shows only faint or no fluorescence after 10 minutesLimitationsIndividuals with mild deficiency may be missed by this test (false-negative)﻿Heterozygous females due to random X-inactivation may not have sufficiently low activity to be detected as G6PD-deficient by this testTest may give normal result (false-negative) in G6PD-deficient individual who is recovering from acute hemolytic event and has reticulocytosisG6PD activity, even in deficient individuals with mutation that causes decreased stability of this protein, is highest in young RBCs (reticulocytes) and decreases as cells ageTherefore, in patient with reticulocytosis, measured G6PD activity may be higher than when patient is at baseline and has normal reticulocyte countElevated leukocyte and platelet counts can also lead to falsely normal results since they both contain G6PDRecommended that samples determined to be intermediate or deficient should be followed up with quantitative assay",
                    "sub_points": [
                      "Patient RBCs are incubated with G6P and NADP+ at 37ºC",
                      "After 5 and 10 minutes of incubation, mixture of patient blood, G6P, and NADP+ is added to filter paper",
                      "After allowing blood spot to dry, filter paper is visually inspected with long-wave UV light",
                      "Samples from G6PD-normal patients should fluoresce brightly when checked at 5 and 10 minutes",
                      "Enzyme-deficient samples will not fluoresce or will show very dull fluorescence",
                      "InterpretationNormal sample shows moderate to strong fluorescence after 5 minutes and strong fluorescence after 10 minutesIntermediate-level sample demonstrates weak fluorescence at 5 minutes and moderate fluorescence after 10 minutesGrossly deficient sample shows only faint or no fluorescence after 10 minutes",
                      "Normal sample shows moderate to strong fluorescence after 5 minutes and strong fluorescence after 10 minutes",
                      "Intermediate-level sample demonstrates weak fluorescence at 5 minutes and moderate fluorescence after 10 minutes",
                      "Grossly deficient sample shows only faint or no fluorescence after 10 minutes",
                      "LimitationsIndividuals with mild deficiency may be missed by this test (false-negative)﻿Heterozygous females due to random X-inactivation may not have sufficiently low activity to be detected as G6PD-deficient by this testTest may give normal result (false-negative) in G6PD-deficient individual who is recovering from acute hemolytic event and has reticulocytosisG6PD activity, even in deficient individuals with mutation that causes decreased stability of this protein, is highest in young RBCs (reticulocytes) and decreases as cells ageTherefore, in patient with reticulocytosis, measured G6PD activity may be higher than when patient is at baseline and has normal reticulocyte countElevated leukocyte and platelet counts can also lead to falsely normal results since they both contain G6PDRecommended that samples determined to be intermediate or deficient should be followed up with quantitative assay",
                      "Individuals with mild deficiency may be missed by this test (false-negative)",
                      "﻿Heterozygous females due to random X-inactivation may not have sufficiently low activity to be detected as G6PD-deficient by this test",
                      "Test may give normal result (false-negative) in G6PD-deficient individual who is recovering from acute hemolytic event and has reticulocytosisG6PD activity, even in deficient individuals with mutation that causes decreased stability of this protein, is highest in young RBCs (reticulocytes) and decreases as cells ageTherefore, in patient with reticulocytosis, measured G6PD activity may be higher than when patient is at baseline and has normal reticulocyte count",
                      "G6PD activity, even in deficient individuals with mutation that causes decreased stability of this protein, is highest in young RBCs (reticulocytes) and decreases as cells age",
                      "Therefore, in patient with reticulocytosis, measured G6PD activity may be higher than when patient is at baseline and has normal reticulocyte count",
                      "Elevated leukocyte and platelet counts can also lead to falsely normal results since they both contain G6PD",
                      "Recommended that samples determined to be intermediate or deficient should be followed up with quantitative assay"
                    ]
                  }
                ],
                "G6PD Quantitative Assay": [
                  {
                    "text": "Patient RBCs (containing G6PD) are lysed and added to mixture of G6P and NADP+ at 37ºC"
                  },
                  {
                    "text": "Spectrophotometric measurement is performed at time 0 and after 5 minutes of incubation to determine rate of NADPH production (absorbance at 340 nm increases with NADPH production)From this measurement, G6PD activity is calculated and normalized to hemoglobin concentrationResults reported in units of activity per hemoglobin concentration or units of activity per RBC countReference range should be determined by laboratory performing test",
                    "sub_points": [
                      "From this measurement, G6PD activity is calculated and normalized to hemoglobin concentration",
                      "Results reported in units of activity per hemoglobin concentration or units of activity per RBC count",
                      "Reference range should be determined by laboratory performing test"
                    ]
                  },
                  {
                    "text": "LimitationsTest may give normal result (false-negative) in G6PD-deficient individual who is recovering from acute hemolytic event and has reticulocytosis﻿Heterozygous females due to random X-inactivation may not have sufficiently low activity to be detected as G6PD-deficient by this test",
                    "sub_points": [
                      "Test may give normal result (false-negative) in G6PD-deficient individual who is recovering from acute hemolytic event and has reticulocytosis",
                      "﻿Heterozygous females due to random X-inactivation may not have sufficiently low activity to be detected as G6PD-deficient by this test"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Diagnosing G6PD Deficiency": [
                  {
                    "text": "G6PD deficiency is X-linked enzyme deficiency characterized by destruction of RBCs following exposure to oxidative stress"
                  },
                  {
                    "text": "Qualitative and quantitative G6PD assays are used to identify individuals who are deficient in this enzyme and who may be at risk of experiencing hemolysis in response to oxidative stress"
                  },
                  {
                    "text": "Several medications and other exposures should be avoided by G6PD-deficient individuals﻿Dapsone﻿Primaquine﻿Methylene blue﻿Nitrofurantoin﻿Fava beansPhenazopyridineRasburicaseToluidine blueNaphthalene",
                    "sub_points": [
                      "﻿Dapsone",
                      "﻿Primaquine",
                      "﻿Methylene blue",
                      "﻿Nitrofurantoin",
                      "﻿Fava beans",
                      "Phenazopyridine",
                      "Rasburicase",
                      "Toluidine blue",
                      "Naphthalene"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection and Storage": [
                  {
                    "text": "Whole blood collected in EDTA, heparin, or acid citrate dextrose (ACD)"
                  },
                  {
                    "text": "RBC G6PD is stable in whole blood for 1 week refrigerated"
                  },
                  {
                    "text": "Samples should not be frozen because G6PD is not stable in hemolysates"
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Normal and deficient G6PD controls should be included in every assay run"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sickle Solubility": {
            "name": "Sickle Solubility",
            "url": "https://app.pathprimer.com/document/634e4492-3ac3-4317-b651-d95a3cb2356b/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Solubility test for Hb SSodium hydrosulfite is added to reduce HbIf Hb S is present, it precipitates and causes turbid/cloudy solutionSolution is observed for turbidity by reading black lines behind test tubesLines behind test tube cannot be seen in positive samples",
                    "sub_points": [
                      "Sodium hydrosulfite is added to reduce Hb",
                      "If Hb S is present, it precipitates and causes turbid/cloudy solution",
                      "Solution is observed for turbidity by reading black lines behind test tubes",
                      "Lines behind test tube cannot be seen in positive samples"
                    ]
                  },
                  {
                    "text": "Test cannot differentiate between patients with sickle trait (Hb S), sickle cell disease (Hb SS), or Hb S and another Hb variant (Hb SC)"
                  },
                  {
                    "text": "Hb electrophoresis or HPLC is required for definite diagnosis of Hb S (sickle cell trait), definite diagnosis of Hb SS (sickle cell disease), or detection of presence of variant Hb/Hb S"
                  }
                ]
              },
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "Sickle test and sickle solubility test are used to determine if hemoglobin (Hb) S is present"
                  },
                  {
                    "text": "Hb S (sickle cell trait) results from mutation in 1 β-globin chain at position 6, with replacement of glutamic acid by valine"
                  },
                  {
                    "text": "Hb SS (sickle cell disease) results from mutation in both β-globin chains at position 6 with replacement of glutamic acid by valine"
                  },
                  {
                    "text": "Other forms of sickle cell disease include Hb SC, Hb SE, Hb S/β-thalassemia, and Hb S/other variant Hb"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Sickle Cell Test": [
                  {
                    "text": "Red blood cells (RBCs) are deoxygenated by adding reducing agent (sodium hydrosulfite)"
                  },
                  {
                    "text": "Deoxygenation causes crystallization of Hb S, if present"
                  },
                  {
                    "text": "Crystallized Hb S causes affected RBCs to assume characteristic sickle shape"
                  },
                  {
                    "text": "Test is positive only if > 25% Hb S is presentNegative test cannot be used to exclude Hb S trait in newbornsMost of Hb may still be Hb FIf the test is negative and the clinical suspicion is still high, hemoglobin fractionation can be performed to rule out a false negative sickle solubility",
                    "sub_points": [
                      "Negative test cannot be used to exclude Hb S trait in newbornsMost of Hb may still be Hb F",
                      "Most of Hb may still be Hb F",
                      "If the test is negative and the clinical suspicion is still high, hemoglobin fractionation can be performed to rule out a false negative sickle solubility"
                    ]
                  },
                  {
                    "text": "Test cannot differentiate between patients withSickle trait (Hb S)Sickle cell disease (Hb SS)Hb S and another Hb variant (Hb SC)These disorders all have positive test results",
                    "sub_points": [
                      "Sickle trait (Hb S)",
                      "Sickle cell disease (Hb SS)",
                      "Hb S and another Hb variant (Hb SC)",
                      "These disorders all have positive test results"
                    ]
                  }
                ],
                "Solubility Test for Hemoglobin S": [
                  {
                    "text": "Lysate of RBCs is placed in high phosphate buffer solution"
                  },
                  {
                    "text": "Sodium hydrosulfite is added to reduce Hb"
                  },
                  {
                    "text": "If Hb S is present, it precipitates and causes turbid/cloudy solution"
                  },
                  {
                    "text": "Solution is observed for turbidity by reading black lines behind test tubes"
                  },
                  {
                    "text": "Lines behind test tube cannot be seen in positive samples"
                  },
                  {
                    "text": "Test cannot differentiate between patients withSickle trait (Hb S)Sickle cell disease (Hb SS)Hb S and another Hb variant (Hb SC)These disorders all have positive test results",
                    "sub_points": [
                      "Sickle trait (Hb S)",
                      "Sickle cell disease (Hb SS)",
                      "Hb S and another Hb variant (Hb SC)",
                      "These disorders all have positive test results"
                    ]
                  },
                  {
                    "text": "Other Hb variants can cause positive testsHb C-HarlemHb S-TravisHb Georgetown",
                    "sub_points": [
                      "Hb C-Harlem",
                      "Hb S-Travis",
                      "Hb Georgetown"
                    ]
                  },
                  {
                    "text": "Hb electrophoresis or high-performance liquid chromatography (HPLC) is requiredFor definite diagnosis of Hb S (sickle cell trait)For definite diagnosis of Hb SS (sickle cell disease)For detection of presence of variant Hb/Hb S",
                    "sub_points": [
                      "For definite diagnosis of Hb S (sickle cell trait)",
                      "For definite diagnosis of Hb SS (sickle cell disease)",
                      "For detection of presence of variant Hb/Hb S"
                    ]
                  }
                ],
                "Interference": [
                  {
                    "text": "False-negative results can occurIn patient who has received large number of RBC transfusionsIn infants because most of their Hb may still be Hb FIf percentage of Hb S is < 15%-20%",
                    "sub_points": [
                      "In patient who has received large number of RBC transfusions",
                      "In infants because most of their Hb may still be Hb F",
                      "If percentage of Hb S is < 15%-20%"
                    ]
                  },
                  {
                    "text": "False positive results can occurIn lipemic samplesIf patient has hypergammaglobulinemiaIf nucleated RBCs are present",
                    "sub_points": [
                      "In lipemic samples",
                      "If patient has hypergammaglobulinemia",
                      "If nucleated RBCs are present"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Whole blood anticoagulated with ethylenediaminetetraacetic acid (EDTA)"
                  },
                  {
                    "text": "Stable for 1 week refrigerated"
                  },
                  {
                    "text": "Rejection criteriaLipemiaClotted samples",
                    "sub_points": [
                      "Lipemia",
                      "Clotted samples"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Measurement of Plasma-Free Hemoglobin": {
            "name": "Measurement of Plasma-Free Hemoglobin",
            "url": "https://app.pathprimer.com/document/2d99aa40-05c2-4f62-8fcc-b8a348e58e93/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "In absence of preanalytic issues, increase of free hemoglobin in plasma indicates intravascular hemolysis"
                  },
                  {
                    "text": "When red cells undergo intravascular lysis, hemoglobin is released into plasma"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Used to confirm presence of free hemoglobin due to intravascular lysisMany hematologic and nonhematologic disorders can lead to release of free hemoglobin from red cellsIncompatible blood transfusions (ABO or other blood groups)Hemoglobin-derived blood substituteHemolytic transfusion reactionSickle cell anemiaG6PD deficiencyThalassemiaHereditary spherocytosisMechanical circulatory support (e.g., cardiopulmonary bypass, extracorporeal membrane oxygenation, left ventricular assist device)Free hemoglobin in plasma can lead to downstream adverse effects and poor clinical outcomes",
                    "sub_points": [
                      "Many hematologic and nonhematologic disorders can lead to release of free hemoglobin from red cellsIncompatible blood transfusions (ABO or other blood groups)Hemoglobin-derived blood substituteHemolytic transfusion reactionSickle cell anemiaG6PD deficiencyThalassemiaHereditary spherocytosisMechanical circulatory support (e.g., cardiopulmonary bypass, extracorporeal membrane oxygenation, left ventricular assist device)",
                      "Incompatible blood transfusions (ABO or other blood groups)",
                      "Hemoglobin-derived blood substitute",
                      "Hemolytic transfusion reaction",
                      "Sickle cell anemia",
                      "G6PD deficiency",
                      "Thalassemia",
                      "Hereditary spherocytosis",
                      "Mechanical circulatory support (e.g., cardiopulmonary bypass, extracorporeal membrane oxygenation, left ventricular assist device)",
                      "Free hemoglobin in plasma can lead to downstream adverse effects and poor clinical outcomes"
                    ]
                  }
                ],
                "Specimens": [
                  {
                    "text": "Preanalytic interferenceAvoiding hemolysis during sample collection is key to valid resultsPlace tourniquet lightly around around upper armMinimize trauma during venipuncture, and do not use small bore needlesMix specimen gently",
                    "sub_points": [
                      "Avoiding hemolysis during sample collection is key to valid resultsPlace tourniquet lightly around around upper armMinimize trauma during venipuncture, and do not use small bore needlesMix specimen gently",
                      "Place tourniquet lightly around around upper arm",
                      "Minimize trauma during venipuncture, and do not use small bore needles",
                      "Mix specimen gently"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "When red cells undergo intravascular lysis, hemoglobin is released into plasma, but it is usually rapidly cleared by protective mechanisms (e.g., haptoglobin, hemopexin, heme oxygenase)"
                  },
                  {
                    "text": "When protective mechanisms are overwhelmed, free hemoglobin accumulates in plasma"
                  },
                  {
                    "text": "Many hematologic and nonhematologic disorders can lead to hemolysis and free plasma hemoglobinParoxysmal nocturnal hemoglobinuria (PNH)Cold hemagglutininsIncompatible blood transfusions (ABO or other blood groups)MalariaMarch hemoglobinuriaBurnsHemoglobinopathies and thalassemiasMechanical circulatory supportCardiopulmonary bypassExtracorporeal membrane oxygenationLeft ventricular assist deviceHemoglobin-derived blood substitute",
                    "sub_points": [
                      "Paroxysmal nocturnal hemoglobinuria (PNH)",
                      "Cold hemagglutinins",
                      "Incompatible blood transfusions (ABO or other blood groups)",
                      "Malaria",
                      "March hemoglobinuria",
                      "Burns",
                      "Hemoglobinopathies and thalassemias",
                      "Mechanical circulatory supportCardiopulmonary bypassExtracorporeal membrane oxygenationLeft ventricular assist device",
                      "Cardiopulmonary bypass",
                      "Extracorporeal membrane oxygenation",
                      "Left ventricular assist device",
                      "Hemoglobin-derived blood substitute"
                    ]
                  },
                  {
                    "text": "Adverse effects of free hemoglobinOxidative stress (ferric iron)Nitrosylation of nitric oxide (NO scavenging)HypertensionVasoocclusionAltered iron metabolismRenal failureExtramedullary hematopoiesisAltered immune regulationChronic endothelial injuryAtherosclerosis",
                    "sub_points": [
                      "Oxidative stress (ferric iron)",
                      "Nitrosylation of nitric oxide (NO scavenging)",
                      "Hypertension",
                      "Vasoocclusion",
                      "Altered iron metabolism",
                      "Renal failure",
                      "Extramedullary hematopoiesis",
                      "Altered immune regulation",
                      "Chronic endothelial injury",
                      "Atherosclerosis"
                    ]
                  },
                  {
                    "text": "Protective mechanismsHaptoglobin sequesters hemoglobin in intravascular spaceHemopexin blocks interactions with cell surface receptors",
                    "sub_points": [
                      "Haptoglobin sequesters hemoglobin in intravascular space",
                      "Hemopexin blocks interactions with cell surface receptors"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Analytic Methods": [
                  {
                    "text": "Visual inspection of plasma for pink or red colorNot sensitive or specific",
                    "sub_points": [
                      "Not sensitive or specific"
                    ]
                  },
                  {
                    "text": "Spectrophotometric methodsBenzidine reactionOxidation of colorless benzidine dye to violet-blue in presence of hemoglobin and hydrogen peroxideColor is measured spectrophotometrically at 515 nmMeasurement of absorbance of oxyhemoglobin at 578 nmCyanomethemoglobin methodReagent contains ferricyanide and potassium cyanideMechanismHemoglobin ferrous ions (Fe²⁺) are oxidized to ferric iron (Fe³⁺) by ferricyanide to form methemoglobinMethemoglobin then reacts with potassium cyanide to form cyanmethemoglobinCyanmethemoglobin is stable and can be measured reliably by absorption of 540 nm lightHemoglobin standards are tested using this method, and absorbance at 540 nm is measuredStandard calibration curve is createdPatient sample is tested and absorbance is used to determine amount of hemoglobin present from calibration curveAdvantagesSingle reagentAll forms of hemoglobin are converted to (hemiglobincyanide; methemoglobincyanide) HiCN except for sulfhemoglobinDisadvantagesReaction solution is unstable and must be protected from lightReagent components must have consistent ratiosToxicity of reaction solution requires special handling measures (use of mechanical pipettes, careful discarding of solution in sink)",
                    "sub_points": [
                      "Benzidine reactionOxidation of colorless benzidine dye to violet-blue in presence of hemoglobin and hydrogen peroxideColor is measured spectrophotometrically at 515 nm",
                      "Oxidation of colorless benzidine dye to violet-blue in presence of hemoglobin and hydrogen peroxide",
                      "Color is measured spectrophotometrically at 515 nm",
                      "Measurement of absorbance of oxyhemoglobin at 578 nm",
                      "Cyanomethemoglobin methodReagent contains ferricyanide and potassium cyanideMechanismHemoglobin ferrous ions (Fe²⁺) are oxidized to ferric iron (Fe³⁺) by ferricyanide to form methemoglobinMethemoglobin then reacts with potassium cyanide to form cyanmethemoglobinCyanmethemoglobin is stable and can be measured reliably by absorption of 540 nm lightHemoglobin standards are tested using this method, and absorbance at 540 nm is measuredStandard calibration curve is createdPatient sample is tested and absorbance is used to determine amount of hemoglobin present from calibration curveAdvantagesSingle reagentAll forms of hemoglobin are converted to (hemiglobincyanide; methemoglobincyanide) HiCN except for sulfhemoglobinDisadvantagesReaction solution is unstable and must be protected from lightReagent components must have consistent ratiosToxicity of reaction solution requires special handling measures (use of mechanical pipettes, careful discarding of solution in sink)",
                      "Reagent contains ferricyanide and potassium cyanide",
                      "MechanismHemoglobin ferrous ions (Fe²⁺) are oxidized to ferric iron (Fe³⁺) by ferricyanide to form methemoglobinMethemoglobin then reacts with potassium cyanide to form cyanmethemoglobinCyanmethemoglobin is stable and can be measured reliably by absorption of 540 nm light",
                      "Hemoglobin ferrous ions (Fe²⁺) are oxidized to ferric iron (Fe³⁺) by ferricyanide to form methemoglobin",
                      "Methemoglobin then reacts with potassium cyanide to form cyanmethemoglobin",
                      "Cyanmethemoglobin is stable and can be measured reliably by absorption of 540 nm light",
                      "Hemoglobin standards are tested using this method, and absorbance at 540 nm is measuredStandard calibration curve is created",
                      "Standard calibration curve is created",
                      "Patient sample is tested and absorbance is used to determine amount of hemoglobin present from calibration curve",
                      "AdvantagesSingle reagentAll forms of hemoglobin are converted to (hemiglobincyanide; methemoglobincyanide) HiCN except for sulfhemoglobin",
                      "Single reagent",
                      "All forms of hemoglobin are converted to (hemiglobincyanide; methemoglobincyanide) HiCN except for sulfhemoglobin",
                      "DisadvantagesReaction solution is unstable and must be protected from lightReagent components must have consistent ratiosToxicity of reaction solution requires special handling measures (use of mechanical pipettes, careful discarding of solution in sink)",
                      "Reaction solution is unstable and must be protected from light",
                      "Reagent components must have consistent ratios",
                      "Toxicity of reaction solution requires special handling measures (use of mechanical pipettes, careful discarding of solution in sink)"
                    ]
                  },
                  {
                    "text": "Determination of oxygen or carbon monoxide capacity"
                  },
                  {
                    "text": "Refractometry; methods measuring enzymatic reactions, such as pseudoperoxidase activity of hemoglobin; measurement of iron content"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Determination of Presence or Absence of Hemolysis": [
                  {
                    "text": "Used to confirm presence of free hemoglobin due to intravascular lysis"
                  },
                  {
                    "text": "Hematologic causesHemolytic transfusion reactionSickle cell anemiaG6PD deficiencyThalassemiaHereditary spherocytosis",
                    "sub_points": [
                      "Hemolytic transfusion reaction",
                      "Sickle cell anemia",
                      "G6PD deficiency",
                      "Thalassemia",
                      "Hereditary spherocytosis"
                    ]
                  },
                  {
                    "text": "Nonhematologic causeMechanical circulatory support",
                    "sub_points": [
                      "Mechanical circulatory support"
                    ]
                  }
                ],
                "Mechanical Circulatory Support": [
                  {
                    "text": "Spikes of free hemoglobin can represent problems with mechanical circuit or with patient"
                  },
                  {
                    "text": "Hemolysis during extracorporeal membrane oxygenation (ECMO)Plasma hemoglobin levels > 50 mg/dL should be investigated for problems with mechanical circuit or other cause of hemolysisIf plasma hemoglobin is normal, then continue to monitor for plasma-free hemoglobin spikesIncrease in plasma-free hemoglobin is associated with increased mortality",
                    "sub_points": [
                      "Plasma hemoglobin levels > 50 mg/dL should be investigated for problems with mechanical circuit or other cause of hemolysis",
                      "If plasma hemoglobin is normal, then continue to monitor for plasma-free hemoglobin spikes",
                      "Increase in plasma-free hemoglobin is associated with increased mortality"
                    ]
                  }
                ],
                "Use in Quality Control": [
                  {
                    "text": "Packed red blood cell manufacturing → cell free hemoglobin can be sign of older red cells or damage during processing or storage"
                  },
                  {
                    "text": "Hemolysis index → automated chemistry analyzers include measurement of samples for interference by hemolysis"
                  }
                ]
              },
              "LIMITATIONS": {
                "Preanalytic Interference": [
                  {
                    "text": "Hemolysis from traumatic blood draw or from mechanical lysis during collection, transport, and storage can falsely elevate free hemoglobin"
                  },
                  {
                    "text": "Icteric plasma or lipemia can interfere with spectrophotometric measurement at 540 nm"
                  },
                  {
                    "text": "Collection in serum separators or clotting tubes are more susceptible to preanalytic hemolysis"
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Avoiding hemolysis during sample collection is key to valid resultsPlace tourniquet lightly around upper armMinimize trauma during venipuncture, and do not use small-bore needlesMix specimen gently",
                    "sub_points": [
                      "Place tourniquet lightly around upper arm",
                      "Minimize trauma during venipuncture, and do not use small-bore needles",
                      "Mix specimen gently"
                    ]
                  },
                  {
                    "text": "Depending on specific assay, heparin, citrate, EDTA, or clotted samples may be acceptable"
                  }
                ],
                "Sample Handling": [
                  {
                    "text": "If analysis cannot be performed immediately, plasma should be separated and frozen"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Principles and Interpretation of Hemoglobin Electrophoresis": {
            "name": "Principles and Interpretation of Hemoglobin Electrophoresis",
            "url": "https://app.pathprimer.com/document/046fb318-9c2c-4799-b37b-100c521d5358/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Hb types are initially separated by charge on cellulose acetate gels under alkaline conditions"
                  },
                  {
                    "text": "Hb types that cannot be identified by electrophoresis under alkaline conditions are reanalyzed on citrate agar under acidic conditions"
                  },
                  {
                    "text": "Hb electrophoresis is common technique to evaluate for presence of abnormal Hb"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "pH is 8.2-8.6 for alkaline electrophoresisAt this pH, Hb is negatively charged and moves toward anode (positive terminal)Hb S, Hb G, Hb D, and Hb Lepore migrate in same location and cannot be separated with alkaline electrophoresis alone; they need to be identified by electrophoresis under acid conditionsHb C, Hb E, and Hb O-Arab all migrate to A₂ position and cannot be separated with alkaline electrophoresis alone",
                    "sub_points": [
                      "At this pH, Hb is negatively charged and moves toward anode (positive terminal)",
                      "Hb S, Hb G, Hb D, and Hb Lepore migrate in same location and cannot be separated with alkaline electrophoresis alone; they need to be identified by electrophoresis under acid conditions",
                      "Hb C, Hb E, and Hb O-Arab all migrate to A₂ position and cannot be separated with alkaline electrophoresis alone"
                    ]
                  },
                  {
                    "text": "pH ~ 6.2 for acid electrophoresisSome Hb variants bind agaropectin in agarHb-agaropectin migrates toward anode (positive terminal)",
                    "sub_points": [
                      "Some Hb variants bind agaropectin in agar",
                      "Hb-agaropectin migrates toward anode (positive terminal)"
                    ]
                  },
                  {
                    "text": "Acid electrophoresis allows separation of Hb C, Hb E, and Hb O-Arab and allows differentiation of Hb S from Hb D and Hb G, but does not distinguish between Hb D and Hb G"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Hemoglobin Electrophoresis": [
                  {
                    "text": "Hemoglobin (Hb) electrophoresis is common technique to evaluate for presence of abnormal Hb"
                  },
                  {
                    "text": "Hb types are initially separated by charge on cellulose acetate gels under alkaline conditions"
                  },
                  {
                    "text": "Hb types that cannot be identified by electrophoresis under alkaline conditions are reanalyzed on citrate agar under acidic conditionsHb C, Hb E, Hb O, Hb A2 migrate to same position on alkaline electrophoresisHb S, Hb G, Hb D migrate to same position on alkaline electrophoresis",
                    "sub_points": [
                      "Hb C, Hb E, Hb O, Hb A2 migrate to same position on alkaline electrophoresis",
                      "Hb S, Hb G, Hb D migrate to same position on alkaline electrophoresis"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Principle and Procedure of Hemoglobin Electrophoresis": [
                  {
                    "text": "Red cell lysates are applied to membrane (cellulose acetate or agar)"
                  },
                  {
                    "text": "Electric current is applied"
                  },
                  {
                    "text": "Samples usually are first analyzed by electrophoresis on cellulose acetate at alkaline pHHb types are separated by charge on alkaline electrophoresisSamples travel to their isoelectric point (point where they carry net zero charge) and migration stopsDifferences in isoelectric points of various Hb types allow separation of Hb variants",
                    "sub_points": [
                      "Hb types are separated by charge on alkaline electrophoresisSamples travel to their isoelectric point (point where they carry net zero charge) and migration stopsDifferences in isoelectric points of various Hb types allow separation of Hb variants",
                      "Samples travel to their isoelectric point (point where they carry net zero charge) and migration stops",
                      "Differences in isoelectric points of various Hb types allow separation of Hb variants"
                    ]
                  },
                  {
                    "text": "If variant Hb is detected by electrophoresis at alkaline pH, electrophoresis at acidic pH is performedHb types are separated by charge and their ability to bind citrate agar on acid electrophoresis",
                    "sub_points": [
                      "Hb types are separated by charge and their ability to bind citrate agar on acid electrophoresis"
                    ]
                  },
                  {
                    "text": "Control samples containing Hb A, Hb F, Hb S, and Hb C should be included with every run"
                  },
                  {
                    "text": "Relative percentage of each Hb can be determined by scanning densitometry"
                  }
                ],
                "Electrophoresis on Cellulose Acetate at Alkaline pH": [
                  {
                    "text": "pH is 8.2-8.6 for alkaline electrophoresisAt this pH, Hb is negatively charged and moves toward anode (positive terminal)",
                    "sub_points": [
                      "At this pH, Hb is negatively charged and moves toward anode (positive terminal)"
                    ]
                  },
                  {
                    "text": "Identifies Hb A, Hb F, Hb H, and various other Hb types"
                  },
                  {
                    "text": "Hb S (mutation β6Glu->Val) has 1 more positive charge than Hb A and migrates more slowly than Hb A on alkaline electrophoresis"
                  },
                  {
                    "text": "Hb C (mutation β6Glu->Lys) has 2 more positive charges than Hb A and migrates more slowly than Hb A and Hb S on alkaline electrophoresis"
                  },
                  {
                    "text": "Hb variants such as Hb J, Hb Bart's, and Hb H can also run faster than Hb A"
                  },
                  {
                    "text": "Not all Hb types can be separated on alkaline electrophoresisHb S, Hb G, Hb D, and Hb Lepore migrate in same location and cannot be separated with alkaline electrophoresis aloneThese Hb variants need to be identified by electrophoresis under acid conditionsHb C, Hb E, and Hb O-Arab all migrate to A₂ position and cannot be separated with alkaline electrophoresis alone",
                    "sub_points": [
                      "Hb S, Hb G, Hb D, and Hb Lepore migrate in same location and cannot be separated with alkaline electrophoresis aloneThese Hb variants need to be identified by electrophoresis under acid conditions",
                      "These Hb variants need to be identified by electrophoresis under acid conditions",
                      "Hb C, Hb E, and Hb O-Arab all migrate to A₂ position and cannot be separated with alkaline electrophoresis alone"
                    ]
                  }
                ],
                "Electrophoresis on Citrate Agar at Acid pH": [
                  {
                    "text": "pH ~ 6.2 for acid electrophoresisSome Hb variants bind agaropectin in agarHb-agaropectin migrates toward anode (positive terminal)Noncomplexed Hb migrates toward cathode (negative terminal)",
                    "sub_points": [
                      "Some Hb variants bind agaropectin in agarHb-agaropectin migrates toward anode (positive terminal)Noncomplexed Hb migrates toward cathode (negative terminal)",
                      "Hb-agaropectin migrates toward anode (positive terminal)",
                      "Noncomplexed Hb migrates toward cathode (negative terminal)"
                    ]
                  },
                  {
                    "text": "Allows differentiation of Hb S from Hb D and Hb GDoes not distinguish between Hb D and Hb G",
                    "sub_points": [
                      "Does not distinguish between Hb D and Hb G"
                    ]
                  },
                  {
                    "text": "Allows separation of Hb C, Hb E, and Hb O-Arab"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Principles and Interpretation of Hemoglobin HPLC": {
            "name": "Principles and Interpretation of Hemoglobin HPLC",
            "url": "https://app.pathprimer.com/document/7a0bc206-8f79-4d93-aab5-170221ee1e89/lesson/093f2723-ffda-49ed-bbe2-ee0cde0a60eb",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "HPLC allows mixture of normal and variant hemoglobins to be separated by their adsorption onto negatively charged stationary phase in chromatography columnAmino acid substitutions present in variant hemoglobin alter retention time and allow identification of variant hemoglobinPercentage of each hemoglobin fraction is determined by quantifying area of each peak relative to total areaHPLC allows identification and quantification of larger number of hemoglobins than electrophoresis",
                    "sub_points": [
                      "Amino acid substitutions present in variant hemoglobin alter retention time and allow identification of variant hemoglobin",
                      "Percentage of each hemoglobin fraction is determined by quantifying area of each peak relative to total area",
                      "HPLC allows identification and quantification of larger number of hemoglobins than electrophoresis"
                    ]
                  },
                  {
                    "text": "Post-translationally modified hemoglobin variants may be presentThere are normally post-translationally modified hemoglobins; for example, hemoglobin A1c is glycated form of hemoglobin A that is used to monitor glucose control",
                    "sub_points": [
                      "There are normally post-translationally modified hemoglobins; for example, hemoglobin A1c is glycated form of hemoglobin A that is used to monitor glucose control"
                    ]
                  }
                ],
                "Laboratory Finances": [
                  {
                    "text": "Generally no difference in total cost to laboratory between using HPLC and electrophoresis for hemoglobin analysis"
                  }
                ]
              },
              "OVERVIEW": {
                "High Performance Liquid Chromatography": [
                  {
                    "text": "Used to quantify normal hemoglobins and quantify/determine if variant hemoglobins are present in single test"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "High performance liquid chromatography (HPLC)"
                  },
                  {
                    "text": "Retention time (RT)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "HPLC": [
                  {
                    "text": "HPLC allows mixture of normal and variant hemoglobins to be separated by their adsorption onto negatively charged stationary phase in chromatography column"
                  },
                  {
                    "text": "Followed by their elution in mobile phase"
                  },
                  {
                    "text": "Every HPLC system has specific period of time (\"retention time\" or RT) before specific hemoglobin is seen in eluate"
                  },
                  {
                    "text": "Amino acid substitutions present in variant hemoglobins alter RT and allow identification of variant hemoglobin"
                  },
                  {
                    "text": "Percentage of each hemoglobin fraction is determined by quantifying area of each peak relative to total area"
                  },
                  {
                    "text": "HPLC allows identification and quantification of larger number of hemoglobin than electrophoresis"
                  }
                ],
                "HPLC Interpretation (Hemoglobins)": [
                  {
                    "text": "HPLC is generally divided according to RT relative to window where variant elutesRT is very reproducible from run to run and individual to individual",
                    "sub_points": [
                      "RT is very reproducible from run to run and individual to individual"
                    ]
                  },
                  {
                    "text": "RT specific for common hemoglobins is labeledF windowA2 windowA windowS windowD windowC window",
                    "sub_points": [
                      "F window",
                      "A2 window",
                      "A window",
                      "S window",
                      "D window",
                      "C window"
                    ]
                  },
                  {
                    "text": "Elution of hemoglobin variant in RT window is very reproducible"
                  },
                  {
                    "text": "Interpretation begins with identifying major hemoglobin peaks"
                  },
                  {
                    "text": "Percentage of hemoglobin should be taken into considerationIn sickle cell trait, hemoglobin A is greater than hemoglobin SIn sickle cell/beta plus thalassemia, hemoglobin S is greater than hemoglobin A",
                    "sub_points": [
                      "In sickle cell trait, hemoglobin A is greater than hemoglobin S",
                      "In sickle cell/beta plus thalassemia, hemoglobin S is greater than hemoglobin A"
                    ]
                  },
                  {
                    "text": "Minor hemoglobin fractions should be taken into considerationHemoglobin A2 is most common δ chain variantHemoglobin A2 elutes at S window on HPLCIt represents very small fraction of total hemoglobin and can be easily missed",
                    "sub_points": [
                      "Hemoglobin A2 is most common δ chain variant",
                      "Hemoglobin A2 elutes at S window on HPLCIt represents very small fraction of total hemoglobin and can be easily missed",
                      "It represents very small fraction of total hemoglobin and can be easily missed"
                    ]
                  },
                  {
                    "text": "Post-translationally modified hemoglobin variants may be presentThere are normally post-translationally modified hemoglobinsFor example, hemoglobin A1c is glycated form of hemoglobin A that is used to monitor glucose controlPost-translationally modified hemoglobin C elute very closely to hemoglobin CAcetylated and glycated hemoglobin C elute as minor peaks",
                    "sub_points": [
                      "There are normally post-translationally modified hemoglobinsFor example, hemoglobin A1c is glycated form of hemoglobin A that is used to monitor glucose control",
                      "For example, hemoglobin A1c is glycated form of hemoglobin A that is used to monitor glucose control",
                      "Post-translationally modified hemoglobin C elute very closely to hemoglobin CAcetylated and glycated hemoglobin C elute as minor peaks",
                      "Acetylated and glycated hemoglobin C elute as minor peaks"
                    ]
                  },
                  {
                    "text": "Transfusion should always be consideredIn sickle cell/beta plus thalassemia, hemoglobin S is greater than hemoglobin ADiagnosis of sickle/beta thalassemia should not be confused with patient with hemoglobin SS who has been transfused normal red cells",
                    "sub_points": [
                      "In sickle cell/beta plus thalassemia, hemoglobin S is greater than hemoglobin ADiagnosis of sickle/beta thalassemia should not be confused with patient with hemoglobin SS who has been transfused normal red cells",
                      "Diagnosis of sickle/beta thalassemia should not be confused with patient with hemoglobin SS who has been transfused normal red cells"
                    ]
                  }
                ],
                "Advantages of HPLC Over Electrophoresis": [
                  {
                    "text": "Less labor-intensive than electrophoresis"
                  },
                  {
                    "text": "Allows quantification of hemoglobin A2Not possible with electrophoresis",
                    "sub_points": [
                      "Not possible with electrophoresis"
                    ]
                  },
                  {
                    "text": "Larger number of hemoglobin variants that can be identified"
                  }
                ],
                "Disadvantages of HPLC Over Electrophoresis": [
                  {
                    "text": "HPLC requires highly skilled personnel to operate equipment, troubleshoot, and interpret results"
                  },
                  {
                    "text": "HPLC equipment is more expensive than electrophoresis instrumentation"
                  }
                ]
              },
              "LABORATORY FINANCES": {
                "Financial Impact of Using HPLC": [
                  {
                    "text": "Generally no difference in total cost to laboratory between using HPLC and electrophoresis for hemoglobin analysisElectrophoresis is more labor intensive than HPLCHPLC requires more expensive equipment than electrophoresis",
                    "sub_points": [
                      "Electrophoresis is more labor intensive than HPLC",
                      "HPLC requires more expensive equipment than electrophoresis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Peripheral Blood Smear Interpretation": {
        "name": "Peripheral Blood Smear Interpretation",
        "url": "https://app.pathprimer.com/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
        "topics": {
          "Basophilic Stippling": {
            "name": "Basophilic Stippling",
            "url": "https://app.pathprimer.com/document/f406b2d3-909c-4d7f-ac4d-a4579d1c2525/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Coarse stippling reflects aggregated ribosomes due to incomplete RNA degradation"
                  },
                  {
                    "text": "Fine stippling reflects clumping of ribosomes +/- degenerated mitochondria/siderosomes due to drying artifacts"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Microscopy shows small, coarse and deep blue to blue-gray granules (< 0.5 µm) dispersed throughout RBC"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Associated with impaired hemoglobin synthesisLead poisoning, hemoglobinopathies, pyrimidine 5’ nucleotidase deficiency, MDS",
                    "sub_points": [
                      "Lead poisoning, hemoglobinopathies, pyrimidine 5’ nucleotidase deficiency, MDS"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "Red blood cells (RBCs) have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lacks nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Life Span and Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hemoglobin (Hb) is composed of heme + globinHeme: Iron + protoporphyrinFour globin chains (2 pairs)Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)",
                    "sub_points": [
                      "Heme: Iron + protoporphyrin",
                      "Four globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Punctate basophilia"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Coarse stipplingAggregated ﻿ribosomes ﻿(&/or polyribosomes) due to incomplete RNA degradation reflecting impaired hemoglobin synthesis",
                    "sub_points": [
                      "Aggregated ﻿ribosomes ﻿(&/or polyribosomes) due to incomplete RNA degradation reflecting impaired hemoglobin synthesis"
                    ]
                  },
                  {
                    "text": "Fine stipplingClumping of ribosomes +/- degenerated mitochondria/siderosomes due to drying artifacts",
                    "sub_points": [
                      "Clumping of ribosomes +/- degenerated mitochondria/siderosomes due to drying artifacts"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Normal Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories; the following ranges may differ slightly"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10⁶/μL"
                  },
                  {
                    "text": "HemoglobinMale: 13.6-17.2 g/dLFemale: 12-15 g/dL",
                    "sub_points": [
                      "Male: 13.6-17.2 g/dL",
                      "Female: 12-15 g/dL"
                    ]
                  },
                  {
                    "text": "Mean corpuscular volume (MCV): 80-100 fL"
                  },
                  {
                    "text": "Hematocrit (Hct)Male: 39-49%Female: 33-43%",
                    "sub_points": [
                      "Male: 39-49%",
                      "Female: 33-43%"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC): 33-37 g/dL"
                  },
                  {
                    "text": "Red cell distribution width (RDW): 11.5-14.5%"
                  }
                ],
                "Microscopy": [
                  {
                    "text": "Multiple small, coarse, deep blue to blue-gray granules (< 0.5 µm), regularly dispersed within red cells"
                  },
                  {
                    "text": "Stippled red blood cells are often polychromatophilic"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "﻿Lead poisoning (coarse basophilic stippling)﻿"
                  },
                  {
                    "text": "Pyrimidine 5’ nucleotidase deficiency"
                  },
                  {
                    "text": "Hemoglobinopathies (e.g., thalassemia)﻿"
                  },
                  {
                    "text": "Sideroblastic anemia"
                  },
                  {
                    "text": "Megaloblastic anemia"
                  },
                  {
                    "text": "Sickle cell anemia"
                  },
                  {
                    "text": "Myelodysplastic syndrome (MDS)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Spherocytes": {
            "name": "Spherocytes",
            "url": "https://app.pathprimer.com/document/f7f4b84d-23d4-4a7e-b5cf-ea231239b687/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Membrane loss without volume loss leads to loss of biconcave shape and of central pallor"
                  },
                  {
                    "text": "CausesImmune-mediated hemolysis and phagocytosis via Fc receptor on macrophages (extravascular hemolysis)Intrinsic defects in red cell cytoskeletal proteins (ankyrin, spectrin, or band 3) in hereditary spherocytosisMechanical damage/hemolysis by fibrin strands",
                    "sub_points": [
                      "Immune-mediated hemolysis and phagocytosis via Fc receptor on macrophages (extravascular hemolysis)",
                      "Intrinsic defects in red cell cytoskeletal proteins (ankyrin, spectrin, or band 3) in hereditary spherocytosis",
                      "Mechanical damage/hemolysis by fibrin strands"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "RBC indices: Normal to mildly decreased MCV, increased MCHC"
                  },
                  {
                    "text": "Microscopy: Smaller, hyperchromic RBCs without central pallor"
                  },
                  {
                    "text": "Increased osmotic fragility testing is seen in patients with hereditary spherocytosis"
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "Red blood cells (RBCs) have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lack nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Life Span and Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hemoglobin (Hb) is composed of heme + globin chainsHeme: Iron + protoporphyrinFour globin chains (2 pairs)Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)",
                    "sub_points": [
                      "Heme: Iron + protoporphyrin",
                      "Four globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Membrane loss without volume loss results in loss of biconcave shape and of central pallor"
                  },
                  {
                    "text": "CausesImmune-mediated hemolysis and phagocytosis via Fc receptor on macrophages (extravascular hemolysis)Intrinsic defects in red cells cytoskeletal proteins (ankyrin, spectrin, or band 3) in hereditary spherocytosisMechanical damage/hemolysis by fibrin strands",
                    "sub_points": [
                      "Immune-mediated hemolysis and phagocytosis via Fc receptor on macrophages (extravascular hemolysis)",
                      "Intrinsic defects in red cells cytoskeletal proteins (ankyrin, spectrin, or band 3) in hereditary spherocytosis",
                      "Mechanical damage/hemolysis by fibrin strands"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Normal Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories; the following values are approximate"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10⁶/μL"
                  },
                  {
                    "text": "HemoglobinMale: 13.6-17.2 g/dLFemale: 12-15 g/dL",
                    "sub_points": [
                      "Male: 13.6-17.2 g/dL",
                      "Female: 12-15 g/dL"
                    ]
                  },
                  {
                    "text": "Mean corpuscular volume (MCV): 80-100 fL"
                  },
                  {
                    "text": "Hematocrit (Hct)Male: 39-49%Female: 33-43%",
                    "sub_points": [
                      "Male: 39-49%",
                      "Female: 33-43%"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC): 33-37 g/dL"
                  },
                  {
                    "text": "Red cell distribution width (RDW): 11.5-14.5%"
                  }
                ],
                "AbnormalRed Blood Cell Indices in Spherocytes": [
                  {
                    "text": "Normal to mildly decreased MCV"
                  },
                  {
                    "text": "Increased MCHC (36-40 g/dL)"
                  }
                ],
                "Microscopy": [
                  {
                    "text": "No central pallor"
                  },
                  {
                    "text": "Hyperchromic (spherocytes are darker than adjacent normal RBCs )"
                  },
                  {
                    "text": "Smaller than normal red cells: < 6.5 µm"
                  },
                  {
                    "text": "In cases of artifactual spherocytes, red cells are broader and paler than true spherocytes"
                  }
                ],
                "Osmotic Fragility": [
                  {
                    "text": "Spherocytes are more vulnerable to hemolysis when exposed to varying dilutions of saline (also see CP PATHPrimer topic Osmotic Fragility Test Interpretation)"
                  },
                  {
                    "text": "Increased osmotic fragility testing is seen in hereditary spherocytosis; however, test is nonspecific and requires clinical correlation to exclude other causes of spherocytes"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "Hereditary spherocytosis (HS)"
                  },
                  {
                    "text": "Microangiopathic hemolytic anemia (MAHA)"
                  },
                  {
                    "text": "Autoimmune hemolytic anemia (AIHA)"
                  },
                  {
                    "text": "Severe burns or other thermal injury"
                  },
                  {
                    "text": "Venoms"
                  },
                  {
                    "text": "Artifact (e.g., recent transfusion)"
                  }
                ],
                "Epidemiology ofHereditary Spherocytosis": [
                  {
                    "text": "Most prevalent in northern Europe (1 per 5,000) with autosomal dominant inheritance in most affected individuals"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemoglobin Crystals": {
            "name": "Hemoglobin Crystals",
            "url": "https://app.pathprimer.com/document/c940977f-3669-472b-9b64-5f68a992ee8f/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Hemoglobin C results from substitution of glutamic acid residue with lysine residue at position 6 mutation in β-globin chain, which leads to unstable hemoglobin"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Crystals are seen in homozygous Hb C disease, but are not seen in Hb C traitCigar shaped﻿Octahedral (may resemble Washington Monument) enveloped by clear membrane﻿",
                    "sub_points": [
                      "Cigar shaped﻿",
                      "Octahedral (may resemble Washington Monument) enveloped by clear membrane﻿"
                    ]
                  },
                  {
                    "text": "Increased MCHC due to RBC dehydration"
                  },
                  {
                    "text": "Multiple target cells are also seen in hemoglobin C disease (CC)"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Seen in hemoglobin C disease (CC), hemoglobin SC disease, and hemoglobin C/β-thalassemia"
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "Red blood cells (RBCs) have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lacks nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Life Span and Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hemoglobin (Hb) composed of heme + globinHeme: Iron + protoporphyrinFour globin chains (2 pairs)Dominant hemoglobin in adults is Hb A, (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)",
                    "sub_points": [
                      "Heme: Iron + protoporphyrin",
                      "Four globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is Hb A, (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Hemoglobin C (Hb C) results from substitution of glutamic acid residue with lysine residue at position 6 mutation in β-globin chain, which leads to unstable hemoglobin"
                  },
                  {
                    "text": "Precipitation and crystallization of Hb C occurs as red cells pass through splenic microvascular environment"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Normal Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories; the following ranges may differ slightly"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10⁶/μL"
                  },
                  {
                    "text": "HemoglobinMale: 13.6-17.2 g/dLFemale: 12-15 g/dL",
                    "sub_points": [
                      "Male: 13.6-17.2 g/dL",
                      "Female: 12-15 g/dL"
                    ]
                  },
                  {
                    "text": "Mean corpuscular volume (MCV): 80-100 fL"
                  },
                  {
                    "text": "Hematocrit (Hct)Male: 39-49%Female: 33-43%",
                    "sub_points": [
                      "Male: 39-49%",
                      "Female: 33-43%"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC): 33-37 g/dL"
                  },
                  {
                    "text": "Red cell distribution width (RDW): 11.5-14.5%"
                  }
                ],
                "Abnormal RBC Indices in Hemoglobin Crystals": [
                  {
                    "text": "Increased MCHC due to induction of red cell dehydration"
                  }
                ],
                "﻿Microscopy﻿": [
                  {
                    "text": "Crystals are seen in homozygous Hb C disease, but are not seen in Hb C traitCigar shaped﻿Rod shapedOctahedral (may resemble Washington Monument) enveloped by clear membrane﻿RhomboidHexagonal",
                    "sub_points": [
                      "Cigar shaped﻿",
                      "Rod shaped",
                      "Octahedral (may resemble Washington Monument) enveloped by clear membrane﻿",
                      "Rhomboid",
                      "Hexagonal"
                    ]
                  },
                  {
                    "text": "Crystals may cause distortion of red cells"
                  },
                  {
                    "text": "Multiple target cells also present in hemoglobin C disease (homozygous Hb CC)"
                  }
                ],
                "﻿Analytic Techniques﻿": [
                  {
                    "text": "Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "Hemoglobin C disease (homozygous hemoglobin CC)"
                  },
                  {
                    "text": "Hemoglobin SC disease"
                  },
                  {
                    "text": "Hemoglobin C/β-thalassemia"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Prevalence in United StatesHomozygous Hb CC: ~ 0.02%Heterozygous (Hb C trait): ~ 2.4%",
                    "sub_points": [
                      "Homozygous Hb CC: ~ 0.02%",
                      "Heterozygous (Hb C trait): ~ 2.4%"
                    ]
                  },
                  {
                    "text": "More prevalent on west coast of Africa, in southern Europe, and in South and Central AmericaHb C is thought to confer protection against malaria",
                    "sub_points": [
                      "Hb C is thought to confer protection against malaria"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Ring Forms": {
            "name": "Ring Forms",
            "url": "https://app.pathprimer.com/document/b48af17e-d0fe-4c96-aa9b-3bd2f6b29893/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Ring forms of malaria and babesiosis are trophozoites, whereas Cabot rings are microtubule remnants of mitotic spindle"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Malarial infection: Malarial ring forms are usually < 2 µmExact size and features vary by species",
                    "sub_points": [
                      "Exact size and features vary by species"
                    ]
                  },
                  {
                    "text": "B. microti: Compact ring forms with possible tetradsCan be seen inside or outside RBCs",
                    "sub_points": [
                      "Can be seen inside or outside RBCs"
                    ]
                  },
                  {
                    "text": "Cabot rings: Ring shape or \"figure 8\""
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Malarial rings and babesiosis rings representPlasmodiumandBabesiainfection, respectively"
                  },
                  {
                    "text": "Cabot rings are associated with dyserythropoiesis"
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "RBCs have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lacks nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Lifespan/Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hb is composed of heme + globinHeme: iron + protoporphyrin4 globin chains (2 pairs)Dominant hemoglobin in adults is HbA (~ 96% of Hb)Composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adults are HbA₂ (~ 3%; α₂δ₂), and HbF (~ 1%; α₂γ₂)",
                    "sub_points": [
                      "Heme: iron + protoporphyrin",
                      "4 globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is HbA (~ 96% of Hb)Composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adults are HbA₂ (~ 3%; α₂δ₂), and HbF (~ 1%; α₂γ₂)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hematocrit (Hct)"
                  },
                  {
                    "text": "Hemoglobin (Hb)"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC)"
                  },
                  {
                    "text": "Mean corpuscular volume (MCV)"
                  },
                  {
                    "text": "Red blood cells (RBC)"
                  },
                  {
                    "text": "Red cell distribution width (RDW)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Ring forms of malaria and babesiosis: Trophozoite stage of respective causative organisms"
                  },
                  {
                    "text": "Cabot rings: Microtubule remnants of mitotic spindle due to dyserythropoiesis"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Normal Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories; following values are approximate"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10^6/μL"
                  },
                  {
                    "text": "Hemoglobin13.6-17.2 g/dL (male)12-15 g/dL (female)",
                    "sub_points": [
                      "13.6-17.2 g/dL (male)",
                      "12-15 g/dL (female)"
                    ]
                  },
                  {
                    "text": "MCV: 80-100 fL"
                  },
                  {
                    "text": "Hct39-49% (male)33-43% (female)",
                    "sub_points": [
                      "39-49% (male)",
                      "33-43% (female)"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "MCHC: 33-37 g/dL"
                  },
                  {
                    "text": "RDW: 11.5-14.5"
                  }
                ],
                "﻿Microscopy﻿": [
                  {
                    "text": "Malarial infection: Malarial ring forms (usually < 2 µm) represent trophozoite stage; always in RBCsPlasmodium falciparumRing forms < 1/3 of red cell diameter and often at red cell peripheryRed cells contain characteristic banana gametocytesPlasmodium vivaxRing forms > 1/3 of red cell diameter and single chromatin dotsMacrocytic red cells with coarse red granulesPlasmodium ovaleRing forms > 1/3 of red cell diameter and single chromatin dotsMacrocytic and oval red cells with coarse red granules and fibrillated edgePlasmodium malariaeRing forms > 1/3 of red cell diameter and single inverted chromatin dotsRed cells are normocytic",
                    "sub_points": [
                      "Plasmodium falciparumRing forms < 1/3 of red cell diameter and often at red cell peripheryRed cells contain characteristic banana gametocytes",
                      "Ring forms < 1/3 of red cell diameter and often at red cell periphery",
                      "Red cells contain characteristic banana gametocytes",
                      "Plasmodium vivaxRing forms > 1/3 of red cell diameter and single chromatin dotsMacrocytic red cells with coarse red granules",
                      "Ring forms > 1/3 of red cell diameter and single chromatin dots",
                      "Macrocytic red cells with coarse red granules",
                      "Plasmodium ovaleRing forms > 1/3 of red cell diameter and single chromatin dotsMacrocytic and oval red cells with coarse red granules and fibrillated edge",
                      "Ring forms > 1/3 of red cell diameter and single chromatin dots",
                      "Macrocytic and oval red cells with coarse red granules and fibrillated edge",
                      "Plasmodium malariaeRing forms > 1/3 of red cell diameter and single inverted chromatin dotsRed cells are normocytic",
                      "Ring forms > 1/3 of red cell diameter and single inverted chromatin dots",
                      "Red cells are normocytic"
                    ]
                  },
                  {
                    "text": "BabesiosisBabesia microtiCompact ring forms; tetrads may be presentCan be seen inside or outside RBCs",
                    "sub_points": [
                      "Babesia microtiCompact ring forms; tetrads may be presentCan be seen inside or outside RBCs",
                      "Compact ring forms; tetrads may be present",
                      "Can be seen inside or outside RBCs"
                    ]
                  },
                  {
                    "text": "Cabot ringBlue-purple to red-purple intracytoplasmic inclusion with shape of ring, loop, or \"figure 8\"May have associated basophilic stippling",
                    "sub_points": [
                      "Blue-purple to red-purple intracytoplasmic inclusion with shape of ring, loop, or \"figure 8\"",
                      "May have associated basophilic stippling"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "Malarial rings:Plasmodiuminfection"
                  },
                  {
                    "text": "Babesiosis rings:B. microtiorBabesiadivergensinfection"
                  },
                  {
                    "text": "Cabot ringsMegaloblastic anemiaLead poisoningDyserythropoietic anemiaMyelodysplastic syndrome",
                    "sub_points": [
                      "Megaloblastic anemia",
                      "Lead poisoning",
                      "Dyserythropoietic anemia",
                      "Myelodysplastic syndrome"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Malaria (Plasmodiuminfection)Mosquito-borne disease most common in Africa, followed by Southeast Asia and Eastern Mediterranean region",
                    "sub_points": [
                      "Mosquito-borne disease most common in Africa, followed by Southeast Asia and Eastern Mediterranean region"
                    ]
                  },
                  {
                    "text": "B.microtiTick-borne disease endemic in North America (e.g., Massachusetts, Connecticut, New Jersey)",
                    "sub_points": [
                      "Tick-borne disease endemic in North America (e.g., Massachusetts, Connecticut, New Jersey)"
                    ]
                  },
                  {
                    "text": "B.divergensTick-borne disease endemic in Europe",
                    "sub_points": [
                      "Tick-borne disease endemic in Europe"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Schistocytes": {
            "name": "Schistocytes",
            "url": "https://app.pathprimer.com/document/0edb11ad-7f5e-4fff-a7f9-96eace4c002b/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "RBC fragmentation due to increased intravascular hemolysis (microangiopathy) or mechanical damage"
                  },
                  {
                    "text": "MechanismsFibrin strands in microcirculationIncreased sheer force due to high blood pressure or dialysisProsthetic valveOxidative stress",
                    "sub_points": [
                      "Fibrin strands in microcirculation",
                      "Increased sheer force due to high blood pressure or dialysis",
                      "Prosthetic valve",
                      "Oxidative stress"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Variable size (usually microcytic) and shape, with at least 2 points and no central pallor"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Clinical associationsMicroangiopathic hemolytic anemia (DIC, TTP, or HUS)Artificial heart valvesSevere burnsMalignant hypertension",
                    "sub_points": [
                      "Microangiopathic hemolytic anemia (DIC, TTP, or HUS)",
                      "Artificial heart valves",
                      "Severe burns",
                      "Malignant hypertension"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "Red blood cells (RBCs) have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lack nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Life Span and Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hemoglobin (Hb) is composed of heme + globinHeme: Iron + protoporphyrinFour globin chains (2 pairs)Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)",
                    "sub_points": [
                      "Heme: Iron + protoporphyrin",
                      "Four globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Fragmented cells"
                  },
                  {
                    "text": "Cell fragments"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Fragmentation of red cells due to increased microangiopathic or macroangiopathic destruction"
                  },
                  {
                    "text": "MechanismsFibrin strands in microcirculationIncreased sheer force due to high blood pressure or dialysisProsthetic valveOxidative stressHeatIntrinsic defects of red cells",
                    "sub_points": [
                      "Fibrin strands in microcirculation",
                      "Increased sheer force due to high blood pressure or dialysis",
                      "Prosthetic valve",
                      "Oxidative stress",
                      "Heat",
                      "Intrinsic defects of red cells"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Normal Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories; the following values are approximate"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10⁶/μL"
                  },
                  {
                    "text": "HemoglobinMale: 13.6-17.2 g/dLFemale: 12-15 g/dL",
                    "sub_points": [
                      "Male: 13.6-17.2 g/dL",
                      "Female: 12-15 g/dL"
                    ]
                  },
                  {
                    "text": "Mean corpuscular volume (MCV): 80-100 fL"
                  },
                  {
                    "text": "Hematocrit (Hct)Male: 39-49%Female: 33-43%",
                    "sub_points": [
                      "Male: 39-49%",
                      "Female: 33-43%"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC): 33-37 g/dL"
                  },
                  {
                    "text": "Red cell distribution width (RDW): 11.5-14.5%"
                  }
                ],
                "Microscopy": [
                  {
                    "text": "Variable size (usually microcytic)"
                  },
                  {
                    "text": "Variable shapes with at least 2 pointsHelmet cells, bite cells, horn cells/keratocytes, triangulocytes, microspherocytes",
                    "sub_points": [
                      "Helmet cells, bite cells, horn cells/keratocytes, triangulocytes, microspherocytes"
                    ]
                  },
                  {
                    "text": "No central pallorVs. nonspecific poikilocytes with central pallor",
                    "sub_points": [
                      "Vs. nonspecific poikilocytes with central pallor"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "Microangiopathic hemolytic anemia (MAHA)Disseminated intravascular coagulopathy (DIC)Thrombotic thrombocytopenic purpura (TTP)Hemolytic uremic syndrome (HUS)",
                    "sub_points": [
                      "Disseminated intravascular coagulopathy (DIC)",
                      "Thrombotic thrombocytopenic purpura (TTP)",
                      "Hemolytic uremic syndrome (HUS)"
                    ]
                  },
                  {
                    "text": "Artificial heart valves"
                  },
                  {
                    "text": "Severe burns"
                  },
                  {
                    "text": "Malignant hypertension"
                  },
                  {
                    "text": "Snake bites"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Pseudothrombocytopenia": {
            "name": "Pseudothrombocytopenia",
            "url": "https://app.pathprimer.com/document/b53e2a35-4622-4c15-8e36-a74afb222780/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "EDTA can induce agglutinating antibodies against GPIIb/IIIa on platelets and FCγ receptor on neutrophils, resulting in artificial low platelet count due to platelet clumping and platelet satellitism"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "MicroscopyAggregates of plateletsPlatelet satellitism: Adherence of ≥ 4 platelets to surface of granulocytes (e.g., neutrophils)",
                    "sub_points": [
                      "Aggregates of platelets",
                      "Platelet satellitism: Adherence of ≥ 4 platelets to surface of granulocytes (e.g., neutrophils)"
                    ]
                  },
                  {
                    "text": "Alternate MethodsMaintaining blood at 37°C before maintaining platelet count often reduces pseudothrombocytopeniaCollection in non-EDTA tube; sodium citrate tubes are often used (with blue top) to reduce pseudothrombocytopenia",
                    "sub_points": [
                      "Maintaining blood at 37°C before maintaining platelet count often reduces pseudothrombocytopenia",
                      "Collection in non-EDTA tube; sodium citrate tubes are often used (with blue top) to reduce pseudothrombocytopenia"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Often seen in EDTA-anticoagulated blood sample"
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "Platelets are small, with discoid shape"
                  },
                  {
                    "text": "Size (2-4 µm in diameter)"
                  },
                  {
                    "text": "Anucleate with organelles (e.g., have mitochondria)"
                  }
                ],
                "Normal Platelet Lifespan/Maturation": [
                  {
                    "text": "Origin: Hematopoietic stem cells and megakaryocytes in bone marrow"
                  },
                  {
                    "text": "Maturation time: 4-5 days"
                  },
                  {
                    "text": "Lifespan: 7-10 days"
                  },
                  {
                    "text": "Functions: Hemostasis and wound healing"
                  }
                ],
                "Cytoplasmic Granules and Composition": [
                  {
                    "text": "Dense granules (smallest) contain pro-aggregating factorse.g., ADP, serotonin, histamine, bivalent cations",
                    "sub_points": [
                      "e.g., ADP, serotonin, histamine, bivalent cations"
                    ]
                  },
                  {
                    "text": "α-granules contain adhesion and repairing factorsFibrinogenvWFTSPFactor VPlatelet-derived growth factorTGF-β",
                    "sub_points": [
                      "Fibrinogen",
                      "vWF",
                      "TSP",
                      "Factor V",
                      "Platelet-derived growth factor",
                      "TGF-β"
                    ]
                  },
                  {
                    "text": "Lysosomes contain clearing factorse.g., acid proteases (cathepsins) and glycohydrolases (heparinase)",
                    "sub_points": [
                      "e.g., acid proteases (cathepsins) and glycohydrolases (heparinase)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Ethylenediaminetetraacetic acid (EDTA)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "Thrombospondin (TSP)"
                  },
                  {
                    "text": "Transforming growth factor-β (TGF-β)"
                  },
                  {
                    "text": "Von Willebrand factor (vWF)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Often induced by EDTA, heavy metal chelator, present in collection tubesLeads to agglutinating antibodies (plasma factor) that recognize GPIIb/IIIa complex on platelets and FCγ receptor on neutrophilsAntibodies result in in vitro platelet clumping, artificial low platelet count, and platelet satellitism",
                    "sub_points": [
                      "Leads to agglutinating antibodies (plasma factor) that recognize GPIIb/IIIa complex on platelets and FCγ receptor on neutrophils",
                      "Antibodies result in in vitro platelet clumping, artificial low platelet count, and platelet satellitism"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Laboratory Testing": [
                  {
                    "text": "Normal platelet count is 150,000-450,000/µL"
                  },
                  {
                    "text": "In pseudothrombocytopenia, platelet count is artifactually lower on analyzer count"
                  }
                ],
                "﻿Microscopy﻿": [
                  {
                    "text": "Aggregates of platelets"
                  },
                  {
                    "text": "Platelet satellitism: Adherence of ≥ 4 platelets to surface of granulocytes (e.g., neutrophils)"
                  }
                ],
                "Alternate Methods": [
                  {
                    "text": "Maintaining blood at 37°C before maintaining platelet count often reduces pseudothrombocytopenia"
                  },
                  {
                    "text": "Collection in non-EDTA tube; sodium citrate tubes are often used (with blue top) to reduce pseudothrombocytopenia"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "EDTA-anticoagulated blood sample"
                  },
                  {
                    "text": "Can be seen with platelet cold agglutinins"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acanthocytes": {
            "name": "Acanthocytes",
            "url": "https://app.pathprimer.com/document/4dbcf6d1-b68a-4940-bc89-e41f6092fcba/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Lipid accumulation in outer RBC membrane leads to evagination of RBC membrane and irreversible spicule formation"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "﻿Microscopy﻿﻿Irregularly distributed spiny projections (3-20) on red cell surface﻿Projections are fewer, are often longer, and have narrower base compared to those seen on echinocytes﻿Compared to normal RBC: Smaller, more hyperchromic, and lacking central pallor",
                    "sub_points": [
                      "﻿Irregularly distributed spiny projections (3-20) on red cell surface﻿Projections are fewer, are often longer, and have narrower base compared to those seen on echinocytes﻿",
                      "Projections are fewer, are often longer, and have narrower base compared to those seen on echinocytes﻿",
                      "Compared to normal RBC: Smaller, more hyperchromic, and lacking central pallor"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Associated with liver disease, abetalipoproteinemia, hypothyroidism, and McLeod and Lu blood groups"
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "Red blood cells (RBCs) have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lacks nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Life Span and Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hemoglobin (Hb) is composed of heme + globinHeme: Iron + protoporphyrinFour globin chains (2 pairs)Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                    "sub_points": [
                      "Heme: Iron + protoporphyrin",
                      "Four globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "﻿Spur cells﻿"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Deranged accumulation of lipid content (sphingomyelin or cholesterol) in outer red cell membraneEvagination of RBC membrane leads to irreversible spicule formation",
                    "sub_points": [
                      "Evagination of RBC membrane leads to irreversible spicule formation"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories; the following are approximate values"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10⁶/μL"
                  },
                  {
                    "text": "HemoglobinMale: 13.6-17.2 g/dLFemale: 12-15 g/dL",
                    "sub_points": [
                      "Male: 13.6-17.2 g/dL",
                      "Female: 12-15 g/dL"
                    ]
                  },
                  {
                    "text": "Mean corpuscular volume (MCV): 80-100 fL"
                  },
                  {
                    "text": "Hematocrit (Hct)Male: 39-49%Female: 33-43%",
                    "sub_points": [
                      "Male: 39-49%",
                      "Female: 33-43%"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC): 33-37 g/dL"
                  },
                  {
                    "text": "Red cell distribution width (RDW): 11.5-14.5"
                  }
                ],
                "Microscopy": [
                  {
                    "text": "Irregularly distributed spiny projections (3-20) on red cell surfaceProjections are fewer, are often longer, and have narrower base compared to those seen on echinocytes﻿",
                    "sub_points": [
                      "Projections are fewer, are often longer, and have narrower base compared to those seen on echinocytes﻿"
                    ]
                  },
                  {
                    "text": "Smaller than normal red cells"
                  },
                  {
                    "text": "No central pallor (unlike echinocytes/burr cells)"
                  },
                  {
                    "text": "Hyperchromic (stains like spherocytes)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical associations": [
                  {
                    "text": "> 10% acanthocytes﻿Liver disease﻿Neonatal hepatitis, Wilson disease, cirrhosis, metastatic cancer﻿Abetalipoproteinemia (Bassen-Kornzweig syndrome)﻿Hypobetalipoproteinemia﻿McLeod blood group﻿Lutheran (Lu) blood group",
                    "sub_points": [
                      "﻿Liver disease﻿Neonatal hepatitis, Wilson disease, cirrhosis, metastatic cancer",
                      "Neonatal hepatitis, Wilson disease, cirrhosis, metastatic cancer",
                      "﻿Abetalipoproteinemia (Bassen-Kornzweig syndrome)﻿",
                      "Hypobetalipoproteinemia",
                      "﻿McLeod blood group﻿",
                      "Lutheran (Lu) blood group"
                    ]
                  },
                  {
                    "text": "< 10% acanthocytesEndocrineHypothyroidism, myxedema, panhypopituitarismAnemiaMicroangiopathic hemolytic anemia, autoimmune hemolytic anemia, thalassemia majorPostsplenectomyMyeloproliferative disordersPsoriatic skin disordersVitamin E deficiency",
                    "sub_points": [
                      "EndocrineHypothyroidism, myxedema, panhypopituitarism",
                      "Hypothyroidism, myxedema, panhypopituitarism",
                      "AnemiaMicroangiopathic hemolytic anemia, autoimmune hemolytic anemia, thalassemia major",
                      "Microangiopathic hemolytic anemia, autoimmune hemolytic anemia, thalassemia major",
                      "Postsplenectomy",
                      "Myeloproliferative disorders",
                      "Psoriatic skin disorders",
                      "Vitamin E deficiency"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Echinocytes": {
            "name": "Echinocytes",
            "url": "https://app.pathprimer.com/document/47f84556-4312-48e3-913d-9e8f12d29604/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Reversible expansion of outer leaflet of RBC membrane"
                  },
                  {
                    "text": "Reversible (vs. irreversible process in acanthocytes)"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Multiple regularly distributed, short, blunt projections over RBC surface"
                  },
                  {
                    "text": "RBC has intact central pallor"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Associated conditions﻿Renal failure﻿﻿Pyruvate kinase deficiency﻿Smearing artifact due to increased pH in reaction to glass slide (most common), decreased albumin, etc﻿",
                    "sub_points": [
                      "﻿Renal failure﻿",
                      "﻿Pyruvate kinase deficiency﻿",
                      "Smearing artifact due to increased pH in reaction to glass slide (most common), decreased albumin, etc﻿"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "RBCs have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lacks nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Lifespan/Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hb is composed of heme + globinHeme: iron + protoporphyrin4 globin chains (2 pairs)Dominant hemoglobin in adults is Hb A (~ 96% of Hb)Composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)",
                    "sub_points": [
                      "Heme: iron + protoporphyrin",
                      "4 globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is Hb A (~ 96% of Hb)Composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hematocrit (Hct)"
                  },
                  {
                    "text": "Hemoglobin (Hb)"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC)"
                  },
                  {
                    "text": "Mean corpuscular volume (MCV)"
                  },
                  {
                    "text": "Red blood cells (RBCs)"
                  },
                  {
                    "text": "Red cell distribution width (RDW)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Burr cells"
                  },
                  {
                    "text": "Crenated cells"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Preferentially expanded outer leaflet of red cell membrane due to artifacts or physiologic changesE.g. Increased pH, reduced albumin, increased osmolarityReversible (vs. irreversible process in acanthocytes)",
                    "sub_points": [
                      "E.g. Increased pH, reduced albumin, increased osmolarity",
                      "Reversible (vs. irreversible process in acanthocytes)"
                    ]
                  },
                  {
                    "text": "Depletion of intracytoplasmic adenosine triphosphate (ATP) or accumulation of surface lipid in burn patients"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "﻿Normal Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories; following values are approximate"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10^6/μL"
                  },
                  {
                    "text": "Hemoglobin13.6-17.2 g/dL (male)12-15 g/dL (female)",
                    "sub_points": [
                      "13.6-17.2 g/dL (male)",
                      "12-15 g/dL (female)"
                    ]
                  },
                  {
                    "text": "MCV: 80-100 fL"
                  },
                  {
                    "text": "Hct39-49% (male)33-43% (female)",
                    "sub_points": [
                      "39-49% (male)",
                      "33-43% (female)"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "MCHC: 33-37 g/dL"
                  },
                  {
                    "text": "RDW: 11.5-14.5"
                  }
                ],
                "﻿Microscopy": [
                  {
                    "text": "Multiple (10-30), regularly distributed, short, blunt projections over red cell surfaceCompared with irregularly distributed, longer spicules in acanthocytes",
                    "sub_points": [
                      "Compared with irregularly distributed, longer spicules in acanthocytes"
                    ]
                  },
                  {
                    "text": "Normocytic or microcytic"
                  },
                  {
                    "text": "Intact central pallorCompared with absent central pallor in acanthocytes",
                    "sub_points": [
                      "Compared with absent central pallor in acanthocytes"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "Renal failure"
                  },
                  {
                    "text": "Liver disease"
                  },
                  {
                    "text": "﻿Pyruvate kinase deficiency﻿"
                  },
                  {
                    "text": "Burns"
                  },
                  {
                    "text": "Heparin anticoagulation"
                  },
                  {
                    "text": "Myeloproliferative disorders"
                  },
                  {
                    "text": "Gastrointestinal diseasese.g., peptic ulcer disease, Crohn disease, carcinoma",
                    "sub_points": [
                      "e.g., peptic ulcer disease, Crohn disease, carcinoma"
                    ]
                  },
                  {
                    "text": "Smearing artifact due to increased pH in reaction to glass slide (most common), decreased albumin, etc﻿."
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Pappenheimer Bodies": {
            "name": "Pappenheimer Bodies",
            "url": "https://app.pathprimer.com/document/28acce08-e9e0-4475-a3fd-c445acc08c76/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Pappenheimer bodies are iron deposits in red blood cells"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Pappenheimer bodies are small gray-blue inclusions (< 1 µm) with irregular borders; often at periphery of red blood cell"
                  },
                  {
                    "text": "Prussian blue iron stain positive"
                  },
                  {
                    "text": "Pappenheimer bodies can lead to false elevation in platelet count"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Associated with asplenia/postsplenectomy and iron overload conditions"
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "Red blood cells (RBCs) have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lacks nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Life Span and Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hemoglobin (Hb) is composed of heme + globinHeme: Iron + protoporphyrinFour globin chains (2 pairs)Dominant hemoglobin in adults is Hb A (~ 96% of Hb) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)",
                    "sub_points": [
                      "Heme: Iron + protoporphyrin",
                      "Four globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is Hb A (~ 96% of Hb) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Pappenheimer bodies are iron deposits in red blood cellsMechanism of formation unknownCan be aggregated iron or mitochondria/phagosomes containing ironSeen in normal reticulocytes or in association with various pathological conditions",
                    "sub_points": [
                      "Mechanism of formation unknown",
                      "Can be aggregated iron or mitochondria/phagosomes containing iron",
                      "Seen in normal reticulocytes or in association with various pathological conditions"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Normal Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10⁶/μL"
                  },
                  {
                    "text": "HemoglobinMale: 13.6-17.2 g/dLFemale: 12-15 g/dL",
                    "sub_points": [
                      "Male: 13.6-17.2 g/dL",
                      "Female: 12-15 g/dL"
                    ]
                  },
                  {
                    "text": "Mean corpuscular volume (MCV): 80-100 fL"
                  },
                  {
                    "text": "Hematocrit (Hct)Male: 39-49%Female: 33-43%",
                    "sub_points": [
                      "Male: 39-49%",
                      "Female: 33-43%"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC): 33-37 g/dL"
                  },
                  {
                    "text": "Red cell distribution width (RDW): 11.5-14.5%"
                  }
                ],
                "﻿Microscopy﻿": [
                  {
                    "text": "One to two irregularly small gray-blue inclusions (< 1 µm)Irregular bordersOften at periphery of red blood cell",
                    "sub_points": [
                      "Irregular borders",
                      "Often at periphery of red blood cell"
                    ]
                  }
                ],
                "﻿Cytochemical Stains﻿": [
                  {
                    "text": "Prussian blue iron stain positive"
                  }
                ],
                "Platelet Counts": [
                  {
                    "text": "Normal Platelet count 150,000-450,000/μL"
                  },
                  {
                    "text": "Pappenheimer bodies can lead to false elevation in platelet count (erroneously counted by some instruments as platelets)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "Asplenia/postsplenectomy"
                  },
                  {
                    "text": "Iron overload"
                  },
                  {
                    "text": "Sideroblastic anemia"
                  },
                  {
                    "text": "Thalassemia"
                  },
                  {
                    "text": "Megaloblastic anemia"
                  },
                  {
                    "text": "Hemolytic anemia"
                  },
                  {
                    "text": "Congenital dyserythropoietic anemia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Heinz Bodies": {
            "name": "Heinz Bodies",
            "url": "https://app.pathprimer.com/document/b868eaed-204f-4bb1-b9fe-32adf7b3a107/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Heinz bodies: Inclusions formed of insoluble, ﻿denatured/precipitated hemoglobin"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Not visible with stains typically used to prepare peripheral blood smears (Wright or Wright-Giemsa)"
                  },
                  {
                    "text": "Staining with supravital dye is required for visualization"
                  },
                  {
                    "text": "Multiple blue to purple inclusions (1-5 µm) predominantly at periphery of red blood cells"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Clinical Associations﻿G6PD deficiency (X-linked recessive disease)﻿﻿Congenital Heinz body anemia (amino acid substitution in hemoglobin)﻿Hemolytic anemia due to oxidizing agents (eg dapsone)",
                    "sub_points": [
                      "﻿G6PD deficiency (X-linked recessive disease)﻿",
                      "﻿Congenital Heinz body anemia (amino acid substitution in hemoglobin)﻿",
                      "Hemolytic anemia due to oxidizing agents (eg dapsone)"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "Red blood cells (RBCs) have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lacks nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Life Span and Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hemoglobin (Hb) is composed of heme + globinHeme: Iron + protoporphyrinFour globin chains (2 pairs)Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)",
                    "sub_points": [
                      "Heme: Iron + protoporphyrin",
                      "Four globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Heinz bodies: Inclusions formed of insoluble,﻿ denatured/precipitated hemoglobin"
                  },
                  {
                    "text": "When damaged, hemoglobin transfers electron to oxygen molecule, creating a reactive oxygen species (ROS)"
                  },
                  {
                    "text": "ROS causes severe cell damage, leading to cell death"
                  },
                  {
                    "text": "Normally, spleen removes Heinz bodies and damaged membrane from RBCsBite cells and teardrop cells can be by-products",
                    "sub_points": [
                      "Bite cells and teardrop cells can be by-products"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories; the following values are approximate"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10⁶/μL"
                  },
                  {
                    "text": "HemoglobinMale: 13.6-17.2 g/dLFemale: 12-15 g/dL",
                    "sub_points": [
                      "Male: 13.6-17.2 g/dL",
                      "Female: 12-15 g/dL"
                    ]
                  },
                  {
                    "text": "Mean corpuscular volume (MCV): 80-100 fL"
                  },
                  {
                    "text": "Hematocrit (Hct)Male: 39-49%Female: 33-43%",
                    "sub_points": [
                      "Male: 39-49%",
                      "Female: 33-43%"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC): 33-37 g/dL"
                  },
                  {
                    "text": "Red cell distribution width (RDW): 11.5-14.5%"
                  }
                ],
                "Microscopy": [
                  {
                    "text": "Multiple blue to purple inclusions (1-5 µm) predominantly at periphery of RBCs"
                  },
                  {
                    "text": "Not visible with stains typically used to prepare peripheral blood smears (Wright or Wright-Giemsa﻿)"
                  },
                  {
                    "text": "Staining with supravital dye (e.g., crystal violet, brilliant cresyl blue, new methylene blue) is required for visualization"
                  },
                  {
                    "text": "Bite cells or teardrop cells can be seen concurrently as result of splenic clearance"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "﻿G6PD deficiency (X-linked recessive disease)﻿"
                  },
                  {
                    "text": "Thalassemia major or intermedia"
                  },
                  {
                    "text": "﻿Congenital Heinz body anemia (amino acid substitution in hemoglobin)﻿"
                  },
                  {
                    "text": "﻿Hemolytic anemia due to oxidizing agents﻿Drugs: Dapsone, phenylhydrazineChemical poisons: Phenazopyridine, naphthalene",
                    "sub_points": [
                      "Drugs: Dapsone, phenylhydrazine",
                      "Chemical poisons: Phenazopyridine, naphthalene"
                    ]
                  },
                  {
                    "text": "Hemolytic anemia due to alcoholic or severe liver disease"
                  },
                  {
                    "text": "Postsplenectomy"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Howell-Jolly Bodies": {
            "name": "Howell-Jolly Bodies",
            "url": "https://app.pathprimer.com/document/aae10260-638e-424a-956d-21d46481ab70/lesson/19fb6510-2cac-4bc9-a4ed-233c8d729894",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Derived from karyorrhexis or chromosome fragments separated from mitotic spindle during abnormal cell division"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Compared to Pappenheimer bodies, Howell-Jolly bodies are more oftenLargerSingle inclusionEccentrically centrally placed (as opposed to periphery of cell membrane)Prussian-blue iron stain negative (Pappenheimer bodies are positive)",
                    "sub_points": [
                      "Larger",
                      "Single inclusion",
                      "Eccentrically centrally placed (as opposed to periphery of cell membrane)",
                      "Prussian-blue iron stain negative (Pappenheimer bodies are positive)"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Associated with asplenia/hyposplenia, megaloblastic anemia, or MDS"
                  }
                ]
              },
              "OVERVIEW": {
                "Normal Morphology": [
                  {
                    "text": "Red blood cells (RBCs) have round, biconcave shape"
                  },
                  {
                    "text": "Size (6-8 µm in diameter)"
                  },
                  {
                    "text": "Central pallor ~ 1/3 red cell diameter"
                  },
                  {
                    "text": "Lack nuclei, organelles (e.g., mitochondria), and inclusions"
                  }
                ],
                "Normal Erythroid Life Span and Maturation": [
                  {
                    "text": "Pronormoblast and normoblast: 5-7 days in marrow"
                  },
                  {
                    "text": "Reticulocyte: 3 days in marrow; 1 day in peripheral blood"
                  },
                  {
                    "text": "Mature RBC: ~ 120 days in circulation"
                  }
                ],
                "Normal Composition": [
                  {
                    "text": "Hemoglobin (Hb) is composed of heme + globinHeme: Iron + protoporphyrinFour globin chains (2 pairs)Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)",
                    "sub_points": [
                      "Heme: Iron + protoporphyrin",
                      "Four globin chains (2 pairs)",
                      "Dominant hemoglobin in adults is Hb A (~ 96% of Hb); composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adults are Hb A₂ (~ 3%; α₂δ₂) and Hb F (~ 1%; α₂γ₂)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Nuclear fragments"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Small nuclear fragments derived fromKaryorrhexisChromosomal material separated from mitotic spindle during abnormal cell division",
                    "sub_points": [
                      "Karyorrhexis",
                      "Chromosomal material separated from mitotic spindle during abnormal cell division"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Normal Red Blood Cell Indices": [
                  {
                    "text": "Red cell indices vary slightly between laboratories"
                  },
                  {
                    "text": "RBC count: 3.5-5.9 x 10⁶/μL"
                  },
                  {
                    "text": "HemoglobinMale: 13.6-17.2 g/dLFemale: 12-15 g/dL",
                    "sub_points": [
                      "Male: 13.6-17.2 g/dL",
                      "Female: 12-15 g/dL"
                    ]
                  },
                  {
                    "text": "Mean corpuscular volume (MCV): 80-100 fL"
                  },
                  {
                    "text": "Hematocrit (Hct)Male: 39-49%Female: 33-43%",
                    "sub_points": [
                      "Male: 39-49%",
                      "Female: 33-43%"
                    ]
                  },
                  {
                    "text": "Mean corpuscular hemoglobin: 27-33 pg/cell"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC): 33-37 g/dL"
                  },
                  {
                    "text": "Red cell distribution width (RDW): 11.5-14.5%"
                  }
                ],
                "﻿Microscopy﻿": [
                  {
                    "text": "Spherical to ovoid, purple to blue, with variable size (0.5-5 µm)"
                  },
                  {
                    "text": "Compared to Pappenheimer bodies, Howell-Jolly bodies are more oftenLargerSmoothSingle inclusionEccentrically centrally placed (as opposed to periphery of cell membrane)",
                    "sub_points": [
                      "Larger",
                      "Smooth",
                      "Single inclusion",
                      "Eccentrically centrally placed (as opposed to periphery of cell membrane)"
                    ]
                  }
                ],
                "Cytochemical Stains": [
                  {
                    "text": "Prussian-blue iron stain negative (Pappenheimer bodies are positive)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Associations": [
                  {
                    "text": "Asplenia or hyposplenia; often due to sickle cell anemia"
                  },
                  {
                    "text": "Postsplenectomy"
                  },
                  {
                    "text": "Severe hemolytic anemia"
                  },
                  {
                    "text": "Megaloblastic anemia"
                  },
                  {
                    "text": "Myelodysplasia (MDS)"
                  },
                  {
                    "text": "Leukemia"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Red Blood Cell Disorders": {
        "name": "Red Blood Cell Disorders",
        "url": "https://app.pathprimer.com/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
        "topics": {
          "Hereditary Spherocytosis": {
            "name": "Hereditary Spherocytosis",
            "url": "https://app.pathprimer.com/document/c51900f0-782c-412a-8b14-b27e46aa24c3/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Destabilization of lipid membrane leads to released lipids, surface area deficiency, and formation of poorly deformable spherocytes that are retained and damaged in spleen"
                  },
                  {
                    "text": "Almost all patients have favorable response to splenectomy"
                  },
                  {
                    "text": "2 important factors drive HS pathophysiologyIntrinsic RBC defectIntact spleen that selectively retains and damages HS RBCs",
                    "sub_points": [
                      "Intrinsic RBC defect",
                      "Intact spleen that selectively retains and damages HS RBCs"
                    ]
                  },
                  {
                    "text": "Molecular basis of HS is heterogeneous and can be divided into subsetsIsolated deficiency of spectrinCombined deficiencies of spectrin and ankyrin",
                    "sub_points": [
                      "Isolated deficiency of spectrin",
                      "Combined deficiencies of spectrin and ankyrin"
                    ]
                  },
                  {
                    "text": "Complications of HSPigmented gallstones (due to chronic hemolysis) found in 50% of patientsAplastic crises in setting of parvovirus B19 infection",
                    "sub_points": [
                      "Pigmented gallstones (due to chronic hemolysis) found in 50% of patients",
                      "Aplastic crises in setting of parvovirus B19 infection"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Spherocytes on peripheral blood smear"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC) is increased"
                  },
                  {
                    "text": "Increased osmotic fragility; spherocytes hemolyze more rapidly than normal RBCs when suspended in hypotonic NaCl solution"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology of Red Blood Cell Membrane Disorders": [
                  {
                    "text": "Red blood cell (RBC) membrane and its attachment to underlying cytoskeleton are important for maintaining shape, deformability, and structural integrity of RBCs"
                  },
                  {
                    "text": "RBC membrane proteins are integral part of these processesDefects in these proteins lead to membrane-associated disorders and hereditary hemolytic disease",
                    "sub_points": [
                      "Defects in these proteins lead to membrane-associated disorders and hereditary hemolytic disease"
                    ]
                  },
                  {
                    "text": "Abnormalities in RBC shape reflect underlying pathophysiology of RBC membrane protein disorders"
                  },
                  {
                    "text": "RBC membrane disorders categorized based on morphological and clinical phenotypesHereditary spherocytosis (HS)Hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), and related disordersSoutheast Asian ovalocytosis (SAO)Acanthocytosis (hereditary and acquired)Stomatocytosis (hereditary and acquired)",
                    "sub_points": [
                      "Hereditary spherocytosis (HS)",
                      "Hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), and related disorders",
                      "Southeast Asian ovalocytosis (SAO)",
                      "Acanthocytosis (hereditary and acquired)",
                      "Stomatocytosis (hereditary and acquired)"
                    ]
                  },
                  {
                    "text": "Mutations in RBC membrane proteins are associated with RBC membrane disordersα-spectrinβ-spectrinAnkyrinBand 3Protein 4.2Protein 4.1RGlycophorin CRh multiprotein complex",
                    "sub_points": [
                      "α-spectrin",
                      "β-spectrin",
                      "Ankyrin",
                      "Band 3",
                      "Protein 4.2",
                      "Protein 4.1R",
                      "Glycophorin C",
                      "Rh multiprotein complex"
                    ]
                  },
                  {
                    "text": "RBC membrane protein-protein and protein-lipid interactions can be classified as vertical or horizontalVertical interactionsPerpendicular to plane of membrane and serve to stabilize lipid bilayerSpectrin-ankyrin-band 3 interactionsSpectrin-protein 4.1R-junctional complex proteins linkageSpectrin-ankyrin-Rh multiprotein complex linkageSkeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)Disorders of vertical interactionsHSHorizontal interactionsParallel to plane of membrane and support structural integrity of RBCs upon exposure to shear stressSpectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) is important for membrane skeletonDistal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactionsDisorders of horizontal interactionsHEHPP",
                    "sub_points": [
                      "Vertical interactionsPerpendicular to plane of membrane and serve to stabilize lipid bilayerSpectrin-ankyrin-band 3 interactionsSpectrin-protein 4.1R-junctional complex proteins linkageSpectrin-ankyrin-Rh multiprotein complex linkageSkeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)Disorders of vertical interactionsHS",
                      "Perpendicular to plane of membrane and serve to stabilize lipid bilayerSpectrin-ankyrin-band 3 interactionsSpectrin-protein 4.1R-junctional complex proteins linkageSpectrin-ankyrin-Rh multiprotein complex linkageSkeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)",
                      "Spectrin-ankyrin-band 3 interactions",
                      "Spectrin-protein 4.1R-junctional complex proteins linkage",
                      "Spectrin-ankyrin-Rh multiprotein complex linkage",
                      "Skeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)",
                      "Disorders of vertical interactionsHS",
                      "HS",
                      "Horizontal interactionsParallel to plane of membrane and support structural integrity of RBCs upon exposure to shear stressSpectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) is important for membrane skeletonDistal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactionsDisorders of horizontal interactionsHEHPP",
                      "Parallel to plane of membrane and support structural integrity of RBCs upon exposure to shear stressSpectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) is important for membrane skeletonDistal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactions",
                      "Spectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) is important for membrane skeleton",
                      "Distal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactions",
                      "Disorders of horizontal interactionsHEHPP",
                      "HE",
                      "HPP"
                    ]
                  },
                  {
                    "text": "Asymmetric distribution of membrane lipids between outer and inner leaflets of RBC membranes can cause shape abnormalities (bilayer couple hypothesis)Acanthocytosis and echinocytosis result from expansion of outer membrane leafletStomatocytosis results from expansion of inner membrane leaflet",
                    "sub_points": [
                      "Acanthocytosis and echinocytosis result from expansion of outer membrane leaflet",
                      "Stomatocytosis results from expansion of inner membrane leaflet"
                    ]
                  }
                ],
                "Pathophysiology, Clinical Findings, and Treatment of Hereditary Spherocytosis": [
                  {
                    "text": "Two important factors drive HS pathophysiologyIntrinsic RBC defectIntact spleen that selectively retains and damages HS RBCs",
                    "sub_points": [
                      "Intrinsic RBC defect",
                      "Intact spleen that selectively retains and damages HS RBCs"
                    ]
                  },
                  {
                    "text": "Destabilization of RBC membrane leads to released lipids, reduced surface area, and formation of poorly deformable spherocytesAbnormal spherocytes are retained and destroyed in spleen",
                    "sub_points": [
                      "Abnormal spherocytes are retained and destroyed in spleen"
                    ]
                  },
                  {
                    "text": "Incidence of HS: 1 per 5,000 personsPredominantly those of Northern European ancestryIncreased in Japanese and African populations",
                    "sub_points": [
                      "Predominantly those of Northern European ancestry",
                      "Increased in Japanese and African populations"
                    ]
                  },
                  {
                    "text": "Autosomal inheritanceDominant in 2/3 of patientsNondominant in 1/3 of patients",
                    "sub_points": [
                      "Dominant in 2/3 of patients",
                      "Nondominant in 1/3 of patients"
                    ]
                  },
                  {
                    "text": "Molecular basis of HS is heterogeneous and can be divided into subsetsIsolated deficiency of spectrinDefects can be in α-spectrin or β-spectrinDominantly inherited HS associated with β-spectrin mutationNondominantly inherited HS associated with α-spectrin mutationCombined deficiencies of spectrin and ankyrinMost common abnormality found in RBCs of HS patientsDriven by mutations in ankyrin leading to ankyrin deficiencyProportional decrease exists in spectrin because ankyrin is principal binding site for spectrin on RBC membraneDeficiency of band 3 proteinFound in subset of HS patients with dominantly inherited, mild to moderate HSMost patients have concomitant decrease in protein 4.2 (protein 4.2 binds to band 3 normally)Deficiency of protein 4.2Associated with recessively inherited HS in JapanAlmost total loss of protein 4.2 from membrane of homozygous individualsRBCs deficient in protein 4.2 can also have decreased levels of ankyrin and band 3No abnormality identified",
                    "sub_points": [
                      "Isolated deficiency of spectrinDefects can be in α-spectrin or β-spectrinDominantly inherited HS associated with β-spectrin mutationNondominantly inherited HS associated with α-spectrin mutation",
                      "Defects can be in α-spectrin or β-spectrinDominantly inherited HS associated with β-spectrin mutationNondominantly inherited HS associated with α-spectrin mutation",
                      "Dominantly inherited HS associated with β-spectrin mutation",
                      "Nondominantly inherited HS associated with α-spectrin mutation",
                      "Combined deficiencies of spectrin and ankyrinMost common abnormality found in RBCs of HS patientsDriven by mutations in ankyrin leading to ankyrin deficiencyProportional decrease exists in spectrin because ankyrin is principal binding site for spectrin on RBC membrane",
                      "Most common abnormality found in RBCs of HS patients",
                      "Driven by mutations in ankyrin leading to ankyrin deficiency",
                      "Proportional decrease exists in spectrin because ankyrin is principal binding site for spectrin on RBC membrane",
                      "Deficiency of band 3 proteinFound in subset of HS patients with dominantly inherited, mild to moderate HSMost patients have concomitant decrease in protein 4.2 (protein 4.2 binds to band 3 normally)",
                      "Found in subset of HS patients with dominantly inherited, mild to moderate HS",
                      "Most patients have concomitant decrease in protein 4.2 (protein 4.2 binds to band 3 normally)",
                      "Deficiency of protein 4.2Associated with recessively inherited HS in JapanAlmost total loss of protein 4.2 from membrane of homozygous individualsRBCs deficient in protein 4.2 can also have decreased levels of ankyrin and band 3",
                      "Associated with recessively inherited HS in Japan",
                      "Almost total loss of protein 4.2 from membrane of homozygous individuals",
                      "RBCs deficient in protein 4.2 can also have decreased levels of ankyrin and band 3",
                      "No abnormality identified"
                    ]
                  },
                  {
                    "text": "Clinical spectrum is broad, ranging from asymptomatic to severe forms that appear in infancyTypical patient is relatively asymptomaticMild jaundice may be only symptomSplenomegaly develops gradually in most patientsAnemia may be mild to moderate, or absent (compensatory bone marrow hyperplasia)",
                    "sub_points": [
                      "Typical patient is relatively asymptomatic",
                      "Mild jaundice may be only symptom",
                      "Splenomegaly develops gradually in most patients",
                      "Anemia may be mild to moderate, or absent (compensatory bone marrow hyperplasia)"
                    ]
                  },
                  {
                    "text": "Mild HSComplete blood count and reticulocyte count are usually normalChanges in RBC shape may be subtle and not noticed on peripheral smearMay be detected by osmotic fragility testing",
                    "sub_points": [
                      "Complete blood count and reticulocyte count are usually normal",
                      "Changes in RBC shape may be subtle and not noticed on peripheral smearMay be detected by osmotic fragility testing",
                      "May be detected by osmotic fragility testing"
                    ]
                  },
                  {
                    "text": "Severe and atypical HSNondominant inheritanceMay have severely life-threatening hemolysis early in lifeUnderlying molecular defect is usually severe spectrin or band 3 deficiency",
                    "sub_points": [
                      "Nondominant inheritance",
                      "May have severely life-threatening hemolysis early in life",
                      "Underlying molecular defect is usually severe spectrin or band 3 deficiency"
                    ]
                  },
                  {
                    "text": "Complications of HSSplenomegalyPigmented gallstones (due to chronic hemolysis) found in 50% of patientsAplastic crises in setting of parvovirus B19 infectionComplications associated with severe HSLeg ulcersGoutChronic dermatitisMasses resulting from extramedullary hematopoiesis",
                    "sub_points": [
                      "Splenomegaly",
                      "Pigmented gallstones (due to chronic hemolysis) found in 50% of patients",
                      "Aplastic crises in setting of parvovirus B19 infection",
                      "Complications associated with severe HSLeg ulcersGoutChronic dermatitisMasses resulting from extramedullary hematopoiesis",
                      "Leg ulcers",
                      "Gout",
                      "Chronic dermatitis",
                      "Masses resulting from extramedullary hematopoiesis"
                    ]
                  },
                  {
                    "text": "TreatmentSplenectomyAlmost all patients have favorable response to splenectomyRBC survival normalizedCorrects anemiaCorrects hyperbilirubinemiaSpherocytosis and increased osmotic fragility persistPatients should be vaccinated against pneumococcus,Haemophilus influenzaetype b, and meningococcus prior to splenectomyPost-splenectomy failure is usually due to presence of accessory spleen missed during surgery or presence of concomitant RBC disorder, such as enzyme deficiency",
                    "sub_points": [
                      "SplenectomyAlmost all patients have favorable response to splenectomyRBC survival normalizedCorrects anemiaCorrects hyperbilirubinemiaSpherocytosis and increased osmotic fragility persistPatients should be vaccinated against pneumococcus,Haemophilus influenzaetype b, and meningococcus prior to splenectomy",
                      "Almost all patients have favorable response to splenectomyRBC survival normalizedCorrects anemiaCorrects hyperbilirubinemiaSpherocytosis and increased osmotic fragility persistPatients should be vaccinated against pneumococcus,Haemophilus influenzaetype b, and meningococcus prior to splenectomy",
                      "RBC survival normalized",
                      "Corrects anemia",
                      "Corrects hyperbilirubinemia",
                      "Spherocytosis and increased osmotic fragility persist",
                      "Patients should be vaccinated against pneumococcus,Haemophilus influenzaetype b, and meningococcus prior to splenectomy",
                      "Post-splenectomy failure is usually due to presence of accessory spleen missed during surgery or presence of concomitant RBC disorder, such as enzyme deficiency"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Variable anemia; mild to severe in nondominant HS"
                  },
                  {
                    "text": "Spherocytes on peripheral blood smear"
                  },
                  {
                    "text": "Mean corpuscular volume (MCV) is low-normal or slightly decreased"
                  },
                  {
                    "text": "Mean corpuscular hemoglobin concentration (MCHC) is increased"
                  },
                  {
                    "text": "Evidence of increased RBC clearance/destruction (may be absent in mild disease)Elevated lactate dehydrogenase (LDH)Increased indirect bilirubinDecreased haptoglobinReticulocytosis",
                    "sub_points": [
                      "Elevated lactate dehydrogenase (LDH)",
                      "Increased indirect bilirubin",
                      "Decreased haptoglobin",
                      "Reticulocytosis"
                    ]
                  }
                ],
                "Specialized Assays": [
                  {
                    "text": "Increased osmotic fragilityLoss of RBC membrane leads to surface area deficiencyCritical hemolytic volume of spherocytes is lower than that of normal cellsSpherocytes hemolyze more rapidly than normal RBCs when suspended in hypotonic NaCl solutionIncreased osmotic fragility may be present in other conditions associated with spherocytes, such as immune hemolytic anemiaDirect antiglobulin test (DAT) should be performed to rule out immune hemolysis as cause of spherocytosisIn HS, DAT is negative",
                    "sub_points": [
                      "Loss of RBC membrane leads to surface area deficiency",
                      "Critical hemolytic volume of spherocytes is lower than that of normal cells",
                      "Spherocytes hemolyze more rapidly than normal RBCs when suspended in hypotonic NaCl solution",
                      "Increased osmotic fragility may be present in other conditions associated with spherocytes, such as immune hemolytic anemiaDirect antiglobulin test (DAT) should be performed to rule out immune hemolysis as cause of spherocytosisIn HS, DAT is negative",
                      "Direct antiglobulin test (DAT) should be performed to rule out immune hemolysis as cause of spherocytosis",
                      "In HS, DAT is negative"
                    ]
                  },
                  {
                    "text": "Decreased intensity of eosin-5’-maleimide (EMA) staining in RBCsFluorescently labeled EMA can bind to band 3 and Rh-related proteins 1:1Intensity of binding of EMA to band 3 is reduced in HS RBCs",
                    "sub_points": [
                      "Fluorescently labeled EMA can bind to band 3 and Rh-related proteins 1:1",
                      "Intensity of binding of EMA to band 3 is reduced in HS RBCs"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "G6PD Deficiency": {
            "name": "G6PD Deficiency",
            "url": "https://app.pathprimer.com/document/4726c8e0-d65a-4ee1-8c88-72d6e4f5423d/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Most prevalent enzyme deficiency in the world"
                  },
                  {
                    "text": "X-linked inheritance"
                  },
                  {
                    "text": "Geographic distribution coincides with endemic malaria"
                  },
                  {
                    "text": "G6PD catalyzes first step of HMP converting G6P to 6PG and producing NADPHG6PD activity is only source of NADPH in RBCsG6PD is critically important in protecting RBCs from oxidative damage",
                    "sub_points": [
                      "G6PD activity is only source of NADPH in RBCs",
                      "G6PD is critically important in protecting RBCs from oxidative damage"
                    ]
                  },
                  {
                    "text": "Diagnosis is usually made when acute hemolysis is triggered by infection or oxidant exposure including dapsone, methylene blue, primaquine, nitrofurantoin, fava beans, naphthalene (found in mothballs)"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Peripheral blood smear may show “bite cells” or \"blister cells\" (RBCs with hemoglobin sequestered to 1 side of cell)"
                  },
                  {
                    "text": "Heinz bodies may be seen after staining of RBCs with supravital stains such as crystal violet or new methylene blue"
                  },
                  {
                    "text": "Assessment of G6PD activity in immediate period after hemolytic event can be confounded by reticulocytosis, as younger RBCs have higher G6PD activityTesting G6PD activity after hemolysis should be delayed until patient has returned to steady state",
                    "sub_points": [
                      "Testing G6PD activity after hemolysis should be delayed until patient has returned to steady state"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Glucose-6-phosphate dehydrogenase (G6PD) catalyzes 1st step of hexose-monophosphate pathway (HMP)Converts glucose-6-phosphate (G6P) to 6-phosphogluconate (6PG)Produces reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)",
                    "sub_points": [
                      "Converts glucose-6-phosphate (G6P) to 6-phosphogluconate (6PG)",
                      "Produces reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)"
                    ]
                  },
                  {
                    "text": "NADPH generated from this reaction is used by glutathione reductase to reduce oxidized glutathione (GSSG) to reduced glutathione (GSH)"
                  },
                  {
                    "text": "GSH is used by glutathione peroxidase to reduce harmful reactive oxygen species hydrogen peroxide (H₂O₂) to water (H₂O)"
                  },
                  {
                    "text": "G6PD activity is only source of NADPH in red blood cells (RBCs)"
                  },
                  {
                    "text": "G6PD is critical in protecting RBCs from oxidative damage"
                  },
                  {
                    "text": "In G6PD deficiency, oxidative stress leads to oxidation of hemoglobin, membrane proteins, lipidsOxidized hemoglobin has decreased solubility and precipitatesOxidized hemoglobin that precipitates can be visualized as Heinz bodies with special stains",
                    "sub_points": [
                      "Oxidized hemoglobin has decreased solubility and precipitatesOxidized hemoglobin that precipitates can be visualized as Heinz bodies with special stains",
                      "Oxidized hemoglobin that precipitates can be visualized as Heinz bodies with special stains"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Most prevalent enzyme deficiency worldwideAffects ~ 400 million people",
                    "sub_points": [
                      "Affects ~ 400 million people"
                    ]
                  },
                  {
                    "text": "﻿X-linked inheritance"
                  },
                  {
                    "text": "Geographic distribution coincides with endemic malaria"
                  },
                  {
                    "text": "Highest prevalence is in sub-Saharan Africa, followed by Middle East, Mediterranean Europe, Southeast Asia"
                  },
                  {
                    "text": "Overall prevalence in United States is 0.5-0.7%Prevalence among African American men ~ 10%",
                    "sub_points": [
                      "Prevalence among African American men ~ 10%"
                    ]
                  },
                  {
                    "text": "> 400 biochemical and 200 genetic variants of G6PDMost common G6PD variants are G6PD A- and G6PD Mediterranean",
                    "sub_points": [
                      "Most common G6PD variants are G6PD A- and G6PD Mediterranean"
                    ]
                  },
                  {
                    "text": "World Health Organization (WHO) classifies G6PD variants based on enzyme activity and degree of associated hemolysisClass I: Severely deficient enzyme activity with chronic hemolysisClass II: Severely deficient (< 10% residual) activity with acute, episodic (exposure-related) hemolysisClass III: Moderately to mildly deficient (10-60% residual) activity with acute, episodic (exposure-related) hemolysisClass IV: Mildly deficient to normal (60-100%) activity without hemolysisClass V: Increased activity (> 150%)",
                    "sub_points": [
                      "Class I: Severely deficient enzyme activity with chronic hemolysis",
                      "Class II: Severely deficient (< 10% residual) activity with acute, episodic (exposure-related) hemolysis",
                      "Class III: Moderately to mildly deficient (10-60% residual) activity with acute, episodic (exposure-related) hemolysis",
                      "Class IV: Mildly deficient to normal (60-100%) activity without hemolysis",
                      "Class V: Increased activity (> 150%)"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Most G6PD-deficient individuals have no clinical symptoms and are not anemic"
                  },
                  {
                    "text": "Diagnosis is usually made when acute hemolysis is triggered by infection or oxidant exposure"
                  },
                  {
                    "text": "Several medications and other exposures should be avoided by G6PD-deficient individuals﻿Dapsone﻿Methylene blue﻿Primaquine﻿Nitrofurantoin﻿Fava beans﻿Naphthalene (found in mothballs)PhenazopyridineRasburicaseToluidine blue",
                    "sub_points": [
                      "﻿Dapsone",
                      "﻿Methylene blue",
                      "﻿Primaquine",
                      "﻿Nitrofurantoin",
                      "﻿Fava beans",
                      "﻿Naphthalene (found in mothballs)",
                      "Phenazopyridine",
                      "Rasburicase",
                      "Toluidine blue"
                    ]
                  },
                  {
                    "text": "Signs and symptoms characteristic of acute hemolytic episodeFatigueJaundicePallorDark urineAbdominal &/or low back pain",
                    "sub_points": [
                      "Fatigue",
                      "Jaundice",
                      "Pallor",
                      "Dark urine",
                      "Abdominal &/or low back pain"
                    ]
                  },
                  {
                    "text": "In oxidant medication-induced hemolysis, symptoms occur ~ 2-4 hr after exposure and can be associated with 3-4 g/dL decrease in hemoglobin followed by reticulocytosis"
                  },
                  {
                    "text": "Degree of hemolysis after oxidative stress exposure is associated with G6PD variant that is presentHemolysis is often self-limited in mild class III A- variantHemolysis is more severe in class II Mediterranean variantDifference in hemolysis is due to differences in half-life of G6PD enzyme caused by particular mutationWild-type G6PD B half-life is 62 daysG6PD A- half-life is 13 daysG6PD Mediterranean half-life is on order of hoursAlthough only older G6PD A- RBCs are susceptible to hemolysis, virtually all G6PD Mediterranean RBCs are susceptible to hemolysis",
                    "sub_points": [
                      "Hemolysis is often self-limited in mild class III A- variant",
                      "Hemolysis is more severe in class II Mediterranean variant",
                      "Difference in hemolysis is due to differences in half-life of G6PD enzyme caused by particular mutationWild-type G6PD B half-life is 62 daysG6PD A- half-life is 13 daysG6PD Mediterranean half-life is on order of hoursAlthough only older G6PD A- RBCs are susceptible to hemolysis, virtually all G6PD Mediterranean RBCs are susceptible to hemolysis",
                      "Wild-type G6PD B half-life is 62 days",
                      "G6PD A- half-life is 13 days",
                      "G6PD Mediterranean half-life is on order of hours",
                      "Although only older G6PD A- RBCs are susceptible to hemolysis, virtually all G6PD Mediterranean RBCs are susceptible to hemolysis"
                    ]
                  },
                  {
                    "text": "Favism refers to acute hemolysis that is provoked by consumption of fava beans2 substances in fava beans are believed to cause hemolysisDivicineIsouramilHemolysis in response to fava beans can develop within 5-24 hr after ingestion",
                    "sub_points": [
                      "2 substances in fava beans are believed to cause hemolysisDivicineIsouramil",
                      "Divicine",
                      "Isouramil",
                      "Hemolysis in response to fava beans can develop within 5-24 hr after ingestion"
                    ]
                  },
                  {
                    "text": "﻿Neonatal jaundice may be associated with G6PD deficiencyHyperbilirubinemia in G6PD-deficient neonates is caused by imbalance between production and conjugation of bilirubinRelationship is not well understood> 30% of kernicterus cases associated with G6PD deficiency",
                    "sub_points": [
                      "Hyperbilirubinemia in G6PD-deficient neonates is caused by imbalance between production and conjugation of bilirubin",
                      "Relationship is not well understood> 30% of kernicterus cases associated with G6PD deficiency",
                      "> 30% of kernicterus cases associated with G6PD deficiency"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Mainstay of treatment is to avoid exposure to oxidative medications and other substances that can cause oxidative stress"
                  },
                  {
                    "text": "In event of acute hemolysis secondary to exposure to oxidative stress, exposure to inciting agent should be stopped"
                  },
                  {
                    "text": "If severe symptomatic anemia results from acute hemolysis, RBC transfusion can be given"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "At steady state, most G6PD-deficient individuals have no laboratory evidence of hemolysis"
                  },
                  {
                    "text": "Laboratory findings indicative of acute hemolysis may be seen after exposure to oxidative stressAnemiaReticulocytosisElevated indirect bilirubinIncreased lactate dehydrogenase (LDH)Decreased haptoglobin﻿Hemoglobinuria (presence of hemoglobin, but not RBCs, in urine)Peripheral blood smear may show “bite cells” or \"blister cells\" (RBCs with hemoglobin sequestered to 1 side of cell)Heinz bodies may be seen after staining of RBCs with supravital stainsCrystal violetNew methylene blue",
                    "sub_points": [
                      "Anemia",
                      "Reticulocytosis",
                      "Elevated indirect bilirubin",
                      "Increased lactate dehydrogenase (LDH)",
                      "Decreased haptoglobin",
                      "﻿Hemoglobinuria (presence of hemoglobin, but not RBCs, in urine)",
                      "Peripheral blood smear may show “bite cells” or \"blister cells\" (RBCs with hemoglobin sequestered to 1 side of cell)",
                      "Heinz bodies may be seen after staining of RBCs with supravital stainsCrystal violetNew methylene blue",
                      "Crystal violet",
                      "New methylene blue"
                    ]
                  }
                ],
                "G6PD Assays": [
                  {
                    "text": "Fluorescence spot testScreening assay for G6PD deficiencyPatient blood (contains G6PD) is mixed with NADP⁺ and G6P followed by application to filter paperBlood spot on filter paper is examined for fluorescence under long-wave ultraviolet (UV) lightNADPH fluoresces under UV light, whereas NADP⁺ does notFluorescence indicates that G6PD activity is presentLack of fluorescence or dim fluorescence suggests G6PD deficiency",
                    "sub_points": [
                      "Screening assay for G6PD deficiency",
                      "Patient blood (contains G6PD) is mixed with NADP⁺ and G6P followed by application to filter paper",
                      "Blood spot on filter paper is examined for fluorescence under long-wave ultraviolet (UV) light",
                      "NADPH fluoresces under UV light, whereas NADP⁺ does notFluorescence indicates that G6PD activity is presentLack of fluorescence or dim fluorescence suggests G6PD deficiency",
                      "Fluorescence indicates that G6PD activity is present",
                      "Lack of fluorescence or dim fluorescence suggests G6PD deficiency"
                    ]
                  },
                  {
                    "text": "Semiquantitative assays indirectly measure generation of NADPH by G6PDAssay couples NADPH production to colorimetric reactionConsidered screening assay",
                    "sub_points": [
                      "Assay couples NADPH production to colorimetric reaction",
                      "Considered screening assay"
                    ]
                  },
                  {
                    "text": "Quantitative G6PD assays directly measure enzyme activityAssay measures rate of generation of NADPH using spectrophotometryLow G6PD activity below reference range consistent with G6PD deficiency",
                    "sub_points": [
                      "Assay measures rate of generation of NADPH using spectrophotometry",
                      "Low G6PD activity below reference range consistent with G6PD deficiency"
                    ]
                  },
                  {
                    "text": "Assessment of G6PD activity in immediate period after hemolytic event can be confounded by reticulocytosisYounger RBCs have higher G6PD activityTesting G6PD activity after hemolysis should be delayed until patient has returned to steady stateIf diagnosis must be confirmed before this time, molecular studies can be performed",
                    "sub_points": [
                      "Younger RBCs have higher G6PD activity",
                      "Testing G6PD activity after hemolysis should be delayed until patient has returned to steady state",
                      "If diagnosis must be confirmed before this time, molecular studies can be performed"
                    ]
                  },
                  {
                    "text": "Enzyme activity assays may not correctly diagnose heterozygous femalesHeterozygous females have 2 populations of RBCs (normal and deficient) due to random X-inactivationWidely used clinical assays for G6PD activity are performed using hemolysates (combining normal and deficient cells)Combined activity may not be detected as deficientMolecular testing may be best approach for definitive diagnosis in this setting",
                    "sub_points": [
                      "Heterozygous females have 2 populations of RBCs (normal and deficient) due to random X-inactivation",
                      "Widely used clinical assays for G6PD activity are performed using hemolysates (combining normal and deficient cells)Combined activity may not be detected as deficient",
                      "Combined activity may not be detected as deficient",
                      "Molecular testing may be best approach for definitive diagnosis in this setting"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "G6PDgeneLocated on X chromosome18 kb long13 exons and 12 introns",
                    "sub_points": [
                      "Located on X chromosome",
                      "18 kb long",
                      "13 exons and 12 introns"
                    ]
                  },
                  {
                    "text": "GenotypingUseful in definitively diagnosing deficiencyUseful in diagnosing heterozygous females",
                    "sub_points": [
                      "Useful in definitively diagnosing deficiency",
                      "Useful in diagnosing heterozygous females"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Microangiopathic Hemolytic Anemia": {
            "name": "Microangiopathic Hemolytic Anemia",
            "url": "https://app.pathprimer.com/document/958c17e6-ddde-40b9-aba3-1d8b9bfb3918/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Microangiopathic hemolytic anemia (MAHA): Group of nonimmune hemolytic anemias caused by red blood cell (RBC) fragmentation in circulationDisseminated intravascular coagulation (DIC)Thrombotic thrombocytopenia purpura (TTP)Hemolytic uremic syndrome (HUS)Pregnancy-related conditions (preeclampsia, eclampsia, hemolysis plus elevated liver enzymes and low platelets [HELLP syndrome])",
                    "sub_points": [
                      "Disseminated intravascular coagulation (DIC)",
                      "Thrombotic thrombocytopenia purpura (TTP)",
                      "Hemolytic uremic syndrome (HUS)",
                      "Pregnancy-related conditions (preeclampsia, eclampsia, hemolysis plus elevated liver enzymes and low platelets [HELLP syndrome])"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Evidence of RBC fragmentation (schistocytes and helmet cells) will be visible on peripheral blood smear"
                  },
                  {
                    "text": "Platelet countCan help with differential; will be decreased in TMA-associated MAHA",
                    "sub_points": [
                      "Can help with differential; will be decreased in TMA-associated MAHA"
                    ]
                  },
                  {
                    "text": "ADAMSTS13Low levels of ADAMTS13 are classic for TTP; helpful in differentiating TTP from other types of MAHA",
                    "sub_points": [
                      "Low levels of ADAMTS13 are classic for TTP; helpful in differentiating TTP from other types of MAHA"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Microangiopathic hemolytic anemia (MAHA): Group of nonimmune hemolytic anemias caused by RBC fragmentation in circulation"
                  },
                  {
                    "text": "Can be separated into 3 broad categories(1) Thrombotic microangiopathy (TMA)–associated MAHAPhysical destruction of RBCs as they pass across fibrin strands or microthrombi in small vesselsMAHA is seen in most TMAs in which microthrombi form in capillaries and arterioles, and result in end-organ damageTMAs associated with MAHA includeDisseminated intravascular coagulation (DIC)Thrombotic thrombocytopenia purpura (TTP)Hemolytic uremic syndrome (HUS)Pregnancy-related conditions (preeclampsia, eclampsia, hemolysis plus elevated liver enzymes and low platelets [HELLP syndrome])TMA can also be caused by metastatic tumor, infection, or medications(2) RBC fragmentation due to mechanical damageExamples: Mechanical heart valves, extracorporeal membrane oxygenation (ECMO), arteriovenous malformations (AVM)(3) Other causes of MAHA that do not result in TMA",
                    "sub_points": [
                      "(1) Thrombotic microangiopathy (TMA)–associated MAHAPhysical destruction of RBCs as they pass across fibrin strands or microthrombi in small vesselsMAHA is seen in most TMAs in which microthrombi form in capillaries and arterioles, and result in end-organ damageTMAs associated with MAHA includeDisseminated intravascular coagulation (DIC)Thrombotic thrombocytopenia purpura (TTP)Hemolytic uremic syndrome (HUS)Pregnancy-related conditions (preeclampsia, eclampsia, hemolysis plus elevated liver enzymes and low platelets [HELLP syndrome])TMA can also be caused by metastatic tumor, infection, or medications",
                      "Physical destruction of RBCs as they pass across fibrin strands or microthrombi in small vessels",
                      "MAHA is seen in most TMAs in which microthrombi form in capillaries and arterioles, and result in end-organ damage",
                      "TMAs associated with MAHA includeDisseminated intravascular coagulation (DIC)Thrombotic thrombocytopenia purpura (TTP)Hemolytic uremic syndrome (HUS)Pregnancy-related conditions (preeclampsia, eclampsia, hemolysis plus elevated liver enzymes and low platelets [HELLP syndrome])TMA can also be caused by metastatic tumor, infection, or medications",
                      "Disseminated intravascular coagulation (DIC)",
                      "Thrombotic thrombocytopenia purpura (TTP)",
                      "Hemolytic uremic syndrome (HUS)",
                      "Pregnancy-related conditions (preeclampsia, eclampsia, hemolysis plus elevated liver enzymes and low platelets [HELLP syndrome])",
                      "TMA can also be caused by metastatic tumor, infection, or medications",
                      "(2) RBC fragmentation due to mechanical damageExamples: Mechanical heart valves, extracorporeal membrane oxygenation (ECMO), arteriovenous malformations (AVM)",
                      "Examples: Mechanical heart valves, extracorporeal membrane oxygenation (ECMO), arteriovenous malformations (AVM)",
                      "(3) Other causes of MAHA that do not result in TMA"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Symptoms vary based on underlying disease mechanismTMAs typically have hemolytic anemia and low platelets with or without evidence of end-organ damageThrombotic thrombocytopenia purpura-hemolytic uremic syndrome (TTP-HUS) has classic pentad: Fever, microangiopathic hemolytic anemia, thrombocytopenia, renal dysfunction, and neurological impairmentHUS may have bloody diarrhea",
                    "sub_points": [
                      "TMAs typically have hemolytic anemia and low platelets with or without evidence of end-organ damageThrombotic thrombocytopenia purpura-hemolytic uremic syndrome (TTP-HUS) has classic pentad: Fever, microangiopathic hemolytic anemia, thrombocytopenia, renal dysfunction, and neurological impairmentHUS may have bloody diarrhea",
                      "Thrombotic thrombocytopenia purpura-hemolytic uremic syndrome (TTP-HUS) has classic pentad: Fever, microangiopathic hemolytic anemia, thrombocytopenia, renal dysfunction, and neurological impairment",
                      "HUS may have bloody diarrhea"
                    ]
                  },
                  {
                    "text": "Symptoms of anemia: Fatigue, weakness, shortness of breath, pallor"
                  },
                  {
                    "text": "Signs: Hemoglobinuria and hemosiderinuria (dark urine), hemoglobinemia"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Varies based on underlying mechanism"
                  },
                  {
                    "text": "Patient's ability to replace RBC loss should be optimized with iron or folic acid supplementation"
                  },
                  {
                    "text": "Plasma exchange is standard treatment for TTP"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Identification of etiology for MAHA is crucial; differential is broad and includes the followingSystemic malignancySystemic autoimmune diseaseSystemic lupus erythematosus, scleroderma, catastrophic antiphospholipid syndromeSystemic infectionSepsis, bacterial endocarditis, rickettsial diseases, brucellosis, cytomegalovirus, HIV, ehrlichiosis, intraerythrocytic parasites (Plasmodium falciparum, Babesia)Pregnancy relatedMedications: Quinine, cyclosporine, mitomycin, tacrolimus, cocaineClopidrogel-associated TTP: Presents within 2 weeks of exposure; associated with mild thrombocytopenia, MAHA, and slightly increased LDH, but has severe renal insufficiency and near-normal ADAMTS13Ticlodipine-associated TTP: Occurs 2-12 weeks after exposure; presents with severe thrombocytopenia, MAHA, markedly elevated LDH, and normal renal function with severely low ADAMTS13 levelTotal body irradiation and bone marrow transplantationVasculitisWegener granulomatosis, polyarteritis, acute glomerulonephritisRenal allograft rejectionToxinsHemolysis has been reported following bee and wasp stings, spider bites (black widow, brown recluse), snake bites (rattlesnake, cottonmouth, copperhead, water moccasin, and coral snake), and lead intoxicationAortic stenosis, coarctation of aorta, atrioventricular shuntsCardiac valve grafts or prosthesesAVM, hemangioendotheliomasMalignant hypertensionMarch hemoglobinuriaMechanical trauma to red cells passing through microvasculature in feet (e.g., soldier after long march, runner after long run on hard pavement, conga drummer after long practice)Cardiopulmonary bypassComplement is thought to be activated as blood is passed through oxygenator, resulting in RBC lysis",
                    "sub_points": [
                      "Systemic malignancy",
                      "Systemic autoimmune diseaseSystemic lupus erythematosus, scleroderma, catastrophic antiphospholipid syndrome",
                      "Systemic lupus erythematosus, scleroderma, catastrophic antiphospholipid syndrome",
                      "Systemic infectionSepsis, bacterial endocarditis, rickettsial diseases, brucellosis, cytomegalovirus, HIV, ehrlichiosis, intraerythrocytic parasites (Plasmodium falciparum, Babesia)",
                      "Sepsis, bacterial endocarditis, rickettsial diseases, brucellosis, cytomegalovirus, HIV, ehrlichiosis, intraerythrocytic parasites (Plasmodium falciparum, Babesia)",
                      "Pregnancy related",
                      "Medications: Quinine, cyclosporine, mitomycin, tacrolimus, cocaineClopidrogel-associated TTP: Presents within 2 weeks of exposure; associated with mild thrombocytopenia, MAHA, and slightly increased LDH, but has severe renal insufficiency and near-normal ADAMTS13Ticlodipine-associated TTP: Occurs 2-12 weeks after exposure; presents with severe thrombocytopenia, MAHA, markedly elevated LDH, and normal renal function with severely low ADAMTS13 level",
                      "Clopidrogel-associated TTP: Presents within 2 weeks of exposure; associated with mild thrombocytopenia, MAHA, and slightly increased LDH, but has severe renal insufficiency and near-normal ADAMTS13",
                      "Ticlodipine-associated TTP: Occurs 2-12 weeks after exposure; presents with severe thrombocytopenia, MAHA, markedly elevated LDH, and normal renal function with severely low ADAMTS13 level",
                      "Total body irradiation and bone marrow transplantation",
                      "VasculitisWegener granulomatosis, polyarteritis, acute glomerulonephritis",
                      "Wegener granulomatosis, polyarteritis, acute glomerulonephritis",
                      "Renal allograft rejection",
                      "ToxinsHemolysis has been reported following bee and wasp stings, spider bites (black widow, brown recluse), snake bites (rattlesnake, cottonmouth, copperhead, water moccasin, and coral snake), and lead intoxication",
                      "Hemolysis has been reported following bee and wasp stings, spider bites (black widow, brown recluse), snake bites (rattlesnake, cottonmouth, copperhead, water moccasin, and coral snake), and lead intoxication",
                      "Aortic stenosis, coarctation of aorta, atrioventricular shunts",
                      "Cardiac valve grafts or prostheses",
                      "AVM, hemangioendotheliomas",
                      "Malignant hypertension",
                      "March hemoglobinuriaMechanical trauma to red cells passing through microvasculature in feet (e.g., soldier after long march, runner after long run on hard pavement, conga drummer after long practice)",
                      "Mechanical trauma to red cells passing through microvasculature in feet (e.g., soldier after long march, runner after long run on hard pavement, conga drummer after long practice)",
                      "Cardiopulmonary bypassComplement is thought to be activated as blood is passed through oxygenator, resulting in RBC lysis",
                      "Complement is thought to be activated as blood is passed through oxygenator, resulting in RBC lysis"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Hemoglobin is decreasedDegree of anemia is based on underlying disorder",
                    "sub_points": [
                      "Degree of anemia is based on underlying disorder"
                    ]
                  },
                  {
                    "text": "Serum potassium is elevatedIntracellular potassium is released during cell lysis, resulting in elevated potassium levels",
                    "sub_points": [
                      "Intracellular potassium is released during cell lysis, resulting in elevated potassium levels"
                    ]
                  },
                  {
                    "text": "Platelet countCan help with differential; decreased in TMA-associated MAHA",
                    "sub_points": [
                      "Can help with differential; decreased in TMA-associated MAHA"
                    ]
                  },
                  {
                    "text": "HaptoglobinScavenges free hemoglobin, thus will be very low in hemolytic anemia",
                    "sub_points": [
                      "Scavenges free hemoglobin, thus will be very low in hemolytic anemia"
                    ]
                  },
                  {
                    "text": "Lactate dehydrogenase (LDH) is elevatedIsoenzyme LD1 is increased due to high levels present in RBCs",
                    "sub_points": [
                      "Isoenzyme LD1 is increased due to high levels present in RBCs"
                    ]
                  },
                  {
                    "text": "Indirect bilirubin is modestly increasedTypically 2-2.5 times normal levels",
                    "sub_points": [
                      "Typically 2-2.5 times normal levels"
                    ]
                  },
                  {
                    "text": "Reticulocyte count is elevated"
                  },
                  {
                    "text": "ADAMSTS13Low levels of ADAMTS13 are classic for TTP; helpful in differentiating TTP from other types of MAHA",
                    "sub_points": [
                      "Low levels of ADAMTS13 are classic for TTP; helpful in differentiating TTP from other types of MAHA"
                    ]
                  }
                ],
                "Microscopy": [
                  {
                    "text": "Peripheral blood smear shows evidence of RBC fragmentation (schistocytes and helmet cells)"
                  },
                  {
                    "text": "Nucleated RBCs indicate increased compensatory red cell production"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Iron Deficiency Anemia": {
            "name": "Iron Deficiency Anemia",
            "url": "https://app.pathprimer.com/document/68b4f52a-b161-4c36-8794-e84e51326d86/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Iron deficiency occurs when there is prolonged increase in red cell production (e.g., pregnancy) or excessive loss without adequate dietary replacement (e.g., hemorrhage, heavy menstruation, multiple pregnancies, frequent blood donation)"
                  },
                  {
                    "text": "Symptoms of anemia: Fatigue, pallor, shortness of breath, weakness, dizziness, increased cold sensitivity"
                  },
                  {
                    "text": "When iron stores are depleted, hemoglobin synthesis is impaired and following sequence occursIron deficiency: Body iron stores are utilized, iron absorption increases, plasma ferritin decreases, and iron-binding capacity (transferrin) increasesIron depletion: Body iron stores are empty, plasma iron levels drop, transferrin decreases to below 15%, percent of sideroblasts in bone marrow decreases, and red cell protoporphyrin increasesIron deficiency anemia: Red cell morphology progresses from normochromic, normocytic to normochromic, microcytic, and finally to hypochromic, microcytic anemia",
                    "sub_points": [
                      "Iron deficiency: Body iron stores are utilized, iron absorption increases, plasma ferritin decreases, and iron-binding capacity (transferrin) increases",
                      "Iron depletion: Body iron stores are empty, plasma iron levels drop, transferrin decreases to below 15%, percent of sideroblasts in bone marrow decreases, and red cell protoporphyrin increases",
                      "Iron deficiency anemia: Red cell morphology progresses from normochromic, normocytic to normochromic, microcytic, and finally to hypochromic, microcytic anemia"
                    ]
                  },
                  {
                    "text": "Hepcidin is main regulator of iron in body; ferroportin is its receptor"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Iron studies are essential"
                  },
                  {
                    "text": "Platelets are typically slightly elevated in iron deficiency; thrombocytosis is frequently seen in association with iron deficiency anemia"
                  },
                  {
                    "text": "Absolute reticulocyte count will be decreased, unless recent iron therapy has been administered"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Iron deficiency occurs when there is prolonged increase in red cell production (e.g., pregnancy) or excessive loss without adequate dietary replacement (e.g., hemorrhage, heavy menstruation, multiple pregnancies, frequent blood donation)"
                  },
                  {
                    "text": "When iron stores are depleted, hemoglobin synthesis is impaired and following sequence occursIron deficiencyBody iron stores are utilizedIron absorption increasesPlasma ferritin decreasesIron-binding capacity (transferrin) increasesIron depletionBody iron stores are emptyPlasma iron levels dropTransferrin decreases to below 15%Percent of sideroblasts in bone marrow decreasesRed cell protoporphyrin increasesIron deficiency anemiaRed cell morphology progresses from normochromic, normocytic to normochromic, microcytic, and finally to hypochromic, microcytic anemia",
                    "sub_points": [
                      "Iron deficiencyBody iron stores are utilizedIron absorption increasesPlasma ferritin decreasesIron-binding capacity (transferrin) increases",
                      "Body iron stores are utilized",
                      "Iron absorption increases",
                      "Plasma ferritin decreases",
                      "Iron-binding capacity (transferrin) increases",
                      "Iron depletionBody iron stores are emptyPlasma iron levels dropTransferrin decreases to below 15%Percent of sideroblasts in bone marrow decreasesRed cell protoporphyrin increases",
                      "Body iron stores are empty",
                      "Plasma iron levels drop",
                      "Transferrin decreases to below 15%",
                      "Percent of sideroblasts in bone marrow decreases",
                      "Red cell protoporphyrin increases",
                      "Iron deficiency anemiaRed cell morphology progresses from normochromic, normocytic to normochromic, microcytic, and finally to hypochromic, microcytic anemia",
                      "Red cell morphology progresses from normochromic, normocytic to normochromic, microcytic, and finally to hypochromic, microcytic anemia"
                    ]
                  },
                  {
                    "text": "Iron deficiency occurs before effects of anemia become noticeable, thus some patients may be iron-depleted without anemia"
                  },
                  {
                    "text": "Hepcidin is main regulator of iron in body; ferroportin is its receptorHepcidin is hormone produced by liver that is controlled by iron stores and inflammationWhen hepcidin concentration is high, there is decreased absorption of iron via enterocytes into plasmaFerroportin is internalized, which prevents iron from exiting enterocytes, macrophage, and hepatocytesEffect is decreased serum iron and increased iron storesWhen hepcidin concentration is lowIncreased iron absorptionIncreased release of iron from iron storesIn iron deficiency anemia, hepcidin concentration should be low to increase iron availability for erythropoiesisIn anemia of chronic disease, inflammation increases hepcidin and decreases iron availability for erythropoiesisIron is trapped in enterocytes, macrophage, and hepatocytes",
                    "sub_points": [
                      "Hepcidin is hormone produced by liver that is controlled by iron stores and inflammation",
                      "When hepcidin concentration is high, there is decreased absorption of iron via enterocytes into plasmaFerroportin is internalized, which prevents iron from exiting enterocytes, macrophage, and hepatocytesEffect is decreased serum iron and increased iron stores",
                      "Ferroportin is internalized, which prevents iron from exiting enterocytes, macrophage, and hepatocytes",
                      "Effect is decreased serum iron and increased iron stores",
                      "When hepcidin concentration is lowIncreased iron absorptionIncreased release of iron from iron stores",
                      "Increased iron absorption",
                      "Increased release of iron from iron stores",
                      "In iron deficiency anemia, hepcidin concentration should be low to increase iron availability for erythropoiesis",
                      "In anemia of chronic disease, inflammation increases hepcidin and decreases iron availability for erythropoiesisIron is trapped in enterocytes, macrophage, and hepatocytes",
                      "Iron is trapped in enterocytes, macrophage, and hepatocytes"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Iron deficiency is one of most common nutritional deficiencies worldwideChildren and women of childbearing age are particularly susceptible",
                    "sub_points": [
                      "Children and women of childbearing age are particularly susceptible"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Symptoms of anemiaFatiguePallorShortness of breathWeaknessDizzinessIncreased cold sensitivity",
                    "sub_points": [
                      "Fatigue",
                      "Pallor",
                      "Shortness of breath",
                      "Weakness",
                      "Dizziness",
                      "Increased cold sensitivity"
                    ]
                  },
                  {
                    "text": "Symptoms of iron deficiency in other tissuesParesthesiasAtrophy of epithelium of tongue, with burning or sorenessFissures at corners of mouth (angular stomatitis)Spoon-shaped nails (koilonychia)",
                    "sub_points": [
                      "Paresthesias",
                      "Atrophy of epithelium of tongue, with burning or soreness",
                      "Fissures at corners of mouth (angular stomatitis)",
                      "Spoon-shaped nails (koilonychia)"
                    ]
                  },
                  {
                    "text": "Pica (craving non-food items) is symptom of iron deficiency and may develop prior to anemiaChewing ice chips is common but under-recognized sign",
                    "sub_points": [
                      "Chewing ice chips is common but under-recognized sign"
                    ]
                  },
                  {
                    "text": "Restless leg syndrome has been linked to iron deficiency and often improves with iron therapy"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Underlying cause should be identified and treated (e.g., heavy menstruation, gastrointestinal bleeding)"
                  },
                  {
                    "text": "Oral ferrous iron can be given in divided doses up to 200 mg/dayOral iron is poorly tolerated, and compliance tends to be challenging",
                    "sub_points": [
                      "Oral iron is poorly tolerated, and compliance tends to be challenging"
                    ]
                  },
                  {
                    "text": "Intravenous iron can be given for rapid repletion or for those who fail oral therapy"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "It is important to differentiate iron deficiency from other causes of microcytic anemiaThalassemias are hereditary; will have normal iron studies and increased RBC countAnemia of chronic disease will have low serum iron but low or normal total iron-binding capacity (TIBC)Sideroblastic anemias will have increased iron and percent saturation, with ring forms on peripheral blood smear",
                    "sub_points": [
                      "Thalassemias are hereditary; will have normal iron studies and increased RBC count",
                      "Anemia of chronic disease will have low serum iron but low or normal total iron-binding capacity (TIBC)",
                      "Sideroblastic anemias will have increased iron and percent saturation, with ring forms on peripheral blood smear"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Hemoglobin and hematocrit levels will be decreasedHemoglobin will be relatively lower than erythrocyte count",
                    "sub_points": [
                      "Hemoglobin will be relatively lower than erythrocyte count"
                    ]
                  },
                  {
                    "text": "Absolute reticulocyte count will be decreased unless recent iron therapy has been administered"
                  },
                  {
                    "text": "Mean corpuscular volume (MCV) will be low"
                  },
                  {
                    "text": "Platelets are typically slightly elevated in iron deficiency, and thrombocytosis is frequently seen in association with iron deficiency anemiaPlatelets will decrease when anemia becomes severe",
                    "sub_points": [
                      "Platelets will decrease when anemia becomes severe"
                    ]
                  },
                  {
                    "text": "Osmotic fragility will be decreased due to thinner red cell membranes"
                  },
                  {
                    "text": "Slight decrease in leukocyte count may be present"
                  },
                  {
                    "text": "Rare hypersegmented neutrophils may be presentIf there are more than 5%, consider concomitant vitamin B12 or folate deficiency",
                    "sub_points": [
                      "If there are more than 5%, consider concomitant vitamin B12 or folate deficiency"
                    ]
                  },
                  {
                    "text": "Iron studies are essentialSerum iron will be low (normal 50-160 µg/dL)Diurnal variation in serum iron occurs and can vary by as much as 30%Early morning specimens are preferred for diagnosisTIBC will be increased (normal 400 µg/dL)Percent saturation of TIBC will decrease (normal 20-55%)Serum ferritin is good measure of iron stores (normal 12-300 µg/L)Ferritin is acute phase reactant, thus may mask iron deficiency during inflammatory states, malignancy, etc",
                    "sub_points": [
                      "Serum iron will be low (normal 50-160 µg/dL)Diurnal variation in serum iron occurs and can vary by as much as 30%Early morning specimens are preferred for diagnosis",
                      "Diurnal variation in serum iron occurs and can vary by as much as 30%",
                      "Early morning specimens are preferred for diagnosis",
                      "TIBC will be increased (normal 400 µg/dL)Percent saturation of TIBC will decrease (normal 20-55%)",
                      "Percent saturation of TIBC will decrease (normal 20-55%)",
                      "Serum ferritin is good measure of iron stores (normal 12-300 µg/L)Ferritin is acute phase reactant, thus may mask iron deficiency during inflammatory states, malignancy, etc",
                      "Ferritin is acute phase reactant, thus may mask iron deficiency during inflammatory states, malignancy, etc"
                    ]
                  }
                ],
                "Microscopy": [
                  {
                    "text": "Peripheral blood smear shows microcytic, hypochromic anemia"
                  },
                  {
                    "text": "Anisopoikilocytosis eventually develops"
                  },
                  {
                    "text": "Pencil cells develop from less pliable RBC membranes"
                  },
                  {
                    "text": "Platelets may be increased"
                  },
                  {
                    "text": "Rare hypersegmented neutrophils may be present"
                  },
                  {
                    "text": "Bone marrow shows normoblastic hyperplasia in early stages; this gradually declines"
                  },
                  {
                    "text": "Normoblasts are small, with irregular shape and frayed margins"
                  },
                  {
                    "text": "Iron stains will show absent storage iron"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Anemia of Chronic Disease": {
            "name": "Anemia of Chronic Disease",
            "url": "https://app.pathprimer.com/document/16b7c463-c1b1-442a-bdd2-d4dbb2b859b8/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "ACD is anemic state that occurs in patients with prolonged states of inflammation or malignancy"
                  },
                  {
                    "text": "ACD is characterized by reduced reticulocyte response to anemia and low serum iron, despite adequate storage iron"
                  },
                  {
                    "text": "Hypoproliferative state is multifactorial"
                  },
                  {
                    "text": "Altered iron metabolism mediated by hepcidinHepcidin is increased in ACD: It interferes with release of intracellular iron from macrophages (\"iron trapping\") and reduces absorption in gastrointestinal tract",
                    "sub_points": [
                      "Hepcidin is increased in ACD: It interferes with release of intracellular iron from macrophages (\"iron trapping\") and reduces absorption in gastrointestinal tract"
                    ]
                  },
                  {
                    "text": "TNFα is elevated in inflammation, malignancy, infection, rheumatoid arthritis, and HIVTNFα dampens bone marrow's response to EPO",
                    "sub_points": [
                      "TNFα dampens bone marrow's response to EPO"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Hemoglobin and hematocrit are decreasedAnemia is usually mild, with hemoglobin > 10 g/dLTypically normochromic, normocytic anemia",
                    "sub_points": [
                      "Anemia is usually mild, with hemoglobin > 10 g/dL",
                      "Typically normochromic, normocytic anemia"
                    ]
                  },
                  {
                    "text": "Reticulocyte count is low for degree of anemia"
                  },
                  {
                    "text": "Serum iron is decreased"
                  },
                  {
                    "text": "Serum ferritin is elevated"
                  },
                  {
                    "text": "TIBC is normal or decreased"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Anemia of chronic disease (ACD) is anemic state that occurs in patients with prolonged states of inflammation or malignancy"
                  },
                  {
                    "text": "ACD is characterized by reduced reticulocyte response to anemia and low serum iron, despite adequate storage iron"
                  },
                  {
                    "text": "Hypoproliferative state is multifactorial with these componentsAltered iron metabolism mediated by hepcidinHepcidin is increased in ACD: It interferes with release of intracellular iron from macrophages (\"iron trapping\") and reduces absorption in gastrointestinal tractHepcidin response in inflammatory states is mediated by IL-6Erythropoietin (EPO) is relatively decreased compared with other causes of anemiaInability to increase erythropoiesisTumor necrosis factor-α (TNFα) is elevated in certain conditionsInflammationMalignancyInfectionRheumatoid arthritisHIVTNFα dampens bone marrow's response to EPOAll of these effects individually are generally mild, but combination results in anemic state",
                    "sub_points": [
                      "Altered iron metabolism mediated by hepcidinHepcidin is increased in ACD: It interferes with release of intracellular iron from macrophages (\"iron trapping\") and reduces absorption in gastrointestinal tractHepcidin response in inflammatory states is mediated by IL-6",
                      "Hepcidin is increased in ACD: It interferes with release of intracellular iron from macrophages (\"iron trapping\") and reduces absorption in gastrointestinal tract",
                      "Hepcidin response in inflammatory states is mediated by IL-6",
                      "Erythropoietin (EPO) is relatively decreased compared with other causes of anemia",
                      "Inability to increase erythropoiesis",
                      "Tumor necrosis factor-α (TNFα) is elevated in certain conditionsInflammationMalignancyInfectionRheumatoid arthritisHIV",
                      "Inflammation",
                      "Malignancy",
                      "Infection",
                      "Rheumatoid arthritis",
                      "HIV",
                      "TNFα dampens bone marrow's response to EPO",
                      "All of these effects individually are generally mild, but combination results in anemic state"
                    ]
                  },
                  {
                    "text": "Shortened red cell lifespan is minor contributor to anemia"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "ACD is multifactorial and seen in variety of clinical conditionsIt is diagnosis of exclusionOther concomitant causes of anemia are commonIronFolateVitamin B12 deficiency",
                    "sub_points": [
                      "It is diagnosis of exclusion",
                      "Other concomitant causes of anemia are commonIronFolateVitamin B12 deficiency",
                      "Iron",
                      "Folate",
                      "Vitamin B12 deficiency"
                    ]
                  },
                  {
                    "text": "Very commonSecond most common cause of anemia worldwide (iron deficiency is first)ACD occurs in up to 50% of hospitalized patients and has increased incidence in elderly",
                    "sub_points": [
                      "Second most common cause of anemia worldwide (iron deficiency is first)",
                      "ACD occurs in up to 50% of hospitalized patients and has increased incidence in elderly"
                    ]
                  },
                  {
                    "text": "Anemia is usually mild, with hemoglobin > 10 g/dLTypically normochromic, normocyticIn 30% of patients, anemia can be severe, with microcytosis",
                    "sub_points": [
                      "Typically normochromic, normocytic",
                      "In 30% of patients, anemia can be severe, with microcytosis"
                    ]
                  },
                  {
                    "text": "Symptoms of anemiaFatigueWeaknessCold sensitivityPallorDizziness",
                    "sub_points": [
                      "Fatigue",
                      "Weakness",
                      "Cold sensitivity",
                      "Pallor",
                      "Dizziness"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment of ACD is usually unnecessary unless patient is symptomaticRisk/benefit of treatments for anemia such as EPO and iron therapy should be consideredEPO has been shown to be effective; high doses are typically needed to have adequate responseInitial dose of 20,000 units given subcutaneously on weekly basisGoal: Hemoglobin ~ 10-11 g/dLMay be more cost-effective than transfusion",
                    "sub_points": [
                      "Risk/benefit of treatments for anemia such as EPO and iron therapy should be consideredEPO has been shown to be effective; high doses are typically needed to have adequate responseInitial dose of 20,000 units given subcutaneously on weekly basisGoal: Hemoglobin ~ 10-11 g/dLMay be more cost-effective than transfusion",
                      "EPO has been shown to be effective; high doses are typically needed to have adequate responseInitial dose of 20,000 units given subcutaneously on weekly basisGoal: Hemoglobin ~ 10-11 g/dL",
                      "Initial dose of 20,000 units given subcutaneously on weekly basis",
                      "Goal: Hemoglobin ~ 10-11 g/dL",
                      "May be more cost-effective than transfusion"
                    ]
                  },
                  {
                    "text": "Underlying cause should be treated"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Hemoglobin and hematocrit are decreased"
                  },
                  {
                    "text": "Reticulocyte count is low for degree of anemia"
                  },
                  {
                    "text": "Serum iron is decreased"
                  },
                  {
                    "text": "Serum ferritin is elevatedFerritin is acute phase reactant, making interpretation challenging in setting of inflammation",
                    "sub_points": [
                      "Ferritin is acute phase reactant, making interpretation challenging in setting of inflammation"
                    ]
                  },
                  {
                    "text": "Total iron-binding capacity (TIBC) is normal or decreasedIn iron deficiency anemia, TIBC will be elevated",
                    "sub_points": [
                      "In iron deficiency anemia, TIBC will be elevated"
                    ]
                  },
                  {
                    "text": "Elevated erythrocyte sedimentation rate (ESR)"
                  }
                ],
                "Microscopy": [
                  {
                    "text": "Peripheral blood smearNormochromic normocytic anemia (unless severe, then can be microcytic)Mild nonspecific anisopoikilocytosis",
                    "sub_points": [
                      "Normochromic normocytic anemia (unless severe, then can be microcytic)",
                      "Mild nonspecific anisopoikilocytosis"
                    ]
                  },
                  {
                    "text": "Bone marrowNo features specific for diagnosis of ACDIron storesNormal to increased in macrophagesReflects iron trapping due to actions of hepcidinDecreased/absent in erythroid precursorsReflects reduced iron for RBC productionUseful to exclude malignancy or other causes of decreased erythropoiesis",
                    "sub_points": [
                      "No features specific for diagnosis of ACD",
                      "Iron storesNormal to increased in macrophagesReflects iron trapping due to actions of hepcidinDecreased/absent in erythroid precursorsReflects reduced iron for RBC production",
                      "Normal to increased in macrophagesReflects iron trapping due to actions of hepcidin",
                      "Reflects iron trapping due to actions of hepcidin",
                      "Decreased/absent in erythroid precursorsReflects reduced iron for RBC production",
                      "Reflects reduced iron for RBC production",
                      "Useful to exclude malignancy or other causes of decreased erythropoiesis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Megaloblastic Anemia": {
            "name": "Megaloblastic Anemia",
            "url": "https://app.pathprimer.com/document/a2f7e198-c17a-4579-ab86-faeb5a8a2eda/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Deficiency of vitamin B12 (cobalamin) or folate results in decrease in synthesis of intracellular 5,10-methylene tetrahydrofolate, which is essential for maintaining normal rate of DNA synthesisMost common causes of megaloblastic anemia are folate deficiency and vitamin B12 deficiencyOther causes of megaloblastic anemia include direct interference with DNA synthesis by medications, myelodysplastic syndrome, and HIV infection",
                    "sub_points": [
                      "Most common causes of megaloblastic anemia are folate deficiency and vitamin B12 deficiency",
                      "Other causes of megaloblastic anemia include direct interference with DNA synthesis by medications, myelodysplastic syndrome, and HIV infection"
                    ]
                  },
                  {
                    "text": "Neurological symptoms often occur before hematological ones develop, which can lead to misdiagnosis"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "B12 and folate deficiency are morphologically indistinguishable in peripheral blood and bone marrow"
                  },
                  {
                    "text": "Peripheral blood smearAnisopoikilocytosis including macro-ovalocytesNeutrophils with hypersegmented nuclei (1 with 6 lobes or ≥ 5% with 5 lobes)",
                    "sub_points": [
                      "Anisopoikilocytosis including macro-ovalocytes",
                      "Neutrophils with hypersegmented nuclei (1 with 6 lobes or ≥ 5% with 5 lobes)"
                    ]
                  },
                  {
                    "text": "Bone marrow aspirate exhibitsGiant metamyelocytes and band formsErythroid dysplasia: Megaloblastic maturation, frequent karyorrhexis, nuclear irregularities",
                    "sub_points": [
                      "Giant metamyelocytes and band forms",
                      "Erythroid dysplasia: Megaloblastic maturation, frequent karyorrhexis, nuclear irregularities"
                    ]
                  },
                  {
                    "text": "Earliest hematological manifestation is increased mean corpuscular volume (MCV)"
                  },
                  {
                    "text": "Pancytopenia is frequently seen"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Deficiency of vitamin B12 (cobalamin) or folate results in decrease in synthesis of intracellular 5,10-methylene tetrahydrofolate, which is essential for maintaining normal rate of DNA synthesis"
                  },
                  {
                    "text": "Defective DNA synthesis results in unbalanced cell growth of immature nuclei with mature cytoplasmGlobal DNA synthesis defect has more profound affect on rapidly proliferating cellsLuminal epithelial mucosal cells of gastrointestinal (GI) tract, cervix, vagina, and uterusAtrophy of GI luminal cells results in worsening symptoms, as it further blunts vitamin B12 and folate absorptionErythropoiesis is both increased and ineffectiveAs damaged cells divide, disparity between nuclear and cytoplasmic worsensDaughter cells become arrested in various stages of development",
                    "sub_points": [
                      "Global DNA synthesis defect has more profound affect on rapidly proliferating cellsLuminal epithelial mucosal cells of gastrointestinal (GI) tract, cervix, vagina, and uterusAtrophy of GI luminal cells results in worsening symptoms, as it further blunts vitamin B12 and folate absorptionErythropoiesis is both increased and ineffectiveAs damaged cells divide, disparity between nuclear and cytoplasmic worsensDaughter cells become arrested in various stages of development",
                      "Luminal epithelial mucosal cells of gastrointestinal (GI) tract, cervix, vagina, and uterusAtrophy of GI luminal cells results in worsening symptoms, as it further blunts vitamin B12 and folate absorption",
                      "Atrophy of GI luminal cells results in worsening symptoms, as it further blunts vitamin B12 and folate absorption",
                      "Erythropoiesis is both increased and ineffectiveAs damaged cells divide, disparity between nuclear and cytoplasmic worsensDaughter cells become arrested in various stages of development",
                      "As damaged cells divide, disparity between nuclear and cytoplasmic worsens",
                      "Daughter cells become arrested in various stages of development"
                    ]
                  },
                  {
                    "text": "Most common causes are folate deficiency and vitamin B12 (cobalamin) deficiencyVitamin B12 is found only in dietary sourcesPossible causes of deficiency include gastritis, celiac disease, medications such as proton-pump inhibitors, gastrectomy, Zollinger-Ellison syndrome,Diphyllobothrium latumparasitic infection, disorders of ileal mucosa, and metabolic disordersPoor diet can be a cause, but it is rare in developed countries unless extreme veganism is practicedPernicious anemia can lead to vitamin B12 deficiencyCaused by failure of gastric mucosa to secrete intrinsic factor, which is necessary for absorption of cobalaminBody is extremely efficient in absorbing, storing, and recycling B12, so that it may take 3-4 years of malabsorption before deficiency developsFolate found in dietary sources is ~ 50% bioavailable, and is highly susceptible to oxidative stressMost common cause of folate deficiency is lack of folate in dietOther causes of deficiency includeIncreased physiologic need (pregnancy)Chronic alcohol usePsoriasisMalabsorptionMedications (methotrexate, trimethoprim-sulfamethoxazole, barbiturates)",
                    "sub_points": [
                      "Vitamin B12 is found only in dietary sourcesPossible causes of deficiency include gastritis, celiac disease, medications such as proton-pump inhibitors, gastrectomy, Zollinger-Ellison syndrome,Diphyllobothrium latumparasitic infection, disorders of ileal mucosa, and metabolic disordersPoor diet can be a cause, but it is rare in developed countries unless extreme veganism is practicedPernicious anemia can lead to vitamin B12 deficiencyCaused by failure of gastric mucosa to secrete intrinsic factor, which is necessary for absorption of cobalaminBody is extremely efficient in absorbing, storing, and recycling B12, so that it may take 3-4 years of malabsorption before deficiency develops",
                      "Possible causes of deficiency include gastritis, celiac disease, medications such as proton-pump inhibitors, gastrectomy, Zollinger-Ellison syndrome,Diphyllobothrium latumparasitic infection, disorders of ileal mucosa, and metabolic disorders",
                      "Poor diet can be a cause, but it is rare in developed countries unless extreme veganism is practiced",
                      "Pernicious anemia can lead to vitamin B12 deficiencyCaused by failure of gastric mucosa to secrete intrinsic factor, which is necessary for absorption of cobalamin",
                      "Caused by failure of gastric mucosa to secrete intrinsic factor, which is necessary for absorption of cobalamin",
                      "Body is extremely efficient in absorbing, storing, and recycling B12, so that it may take 3-4 years of malabsorption before deficiency develops",
                      "Folate found in dietary sources is ~ 50% bioavailable, and is highly susceptible to oxidative stressMost common cause of folate deficiency is lack of folate in dietOther causes of deficiency includeIncreased physiologic need (pregnancy)Chronic alcohol usePsoriasisMalabsorptionMedications (methotrexate, trimethoprim-sulfamethoxazole, barbiturates)",
                      "Most common cause of folate deficiency is lack of folate in diet",
                      "Other causes of deficiency includeIncreased physiologic need (pregnancy)Chronic alcohol usePsoriasisMalabsorptionMedications (methotrexate, trimethoprim-sulfamethoxazole, barbiturates)",
                      "Increased physiologic need (pregnancy)",
                      "Chronic alcohol use",
                      "Psoriasis",
                      "Malabsorption",
                      "Medications (methotrexate, trimethoprim-sulfamethoxazole, barbiturates)"
                    ]
                  },
                  {
                    "text": "Other causes of megaloblastic anemia include direct interference with DNA synthesis by medications, myelodysplastic syndrome, and HIV infectionMedications include purine analogs (6-mercaptopurine, 6-thioguanine, acyclovir), pyrimidine analogs (5-fluorouracil, 5-azacytidine, zidovudine), and ribonucleotide reductase inhibitors (hydroxyurea, cytarabine arabinoside)",
                    "sub_points": [
                      "Medications include purine analogs (6-mercaptopurine, 6-thioguanine, acyclovir), pyrimidine analogs (5-fluorouracil, 5-azacytidine, zidovudine), and ribonucleotide reductase inhibitors (hydroxyurea, cytarabine arabinoside)"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Vitamin B12 deficiency leads to patchy demyelination, resulting in cerebral abnormalities and degeneration of spinal cordNeurological manifestations are variedPeripheral neuropathy (pins and needles sensation in distal extremities, and reduced vibrational sense are common)Paresthesias and decreased proprioception are also commonEarliest symptoms are often purely neurologicalNeurological symptoms often occur before hematological ones develop, which can lead to misdiagnosisOther symptoms include pallor, jaundice, glossitis, episodic abdominal pain, diarrhea, and constipation",
                    "sub_points": [
                      "Neurological manifestations are variedPeripheral neuropathy (pins and needles sensation in distal extremities, and reduced vibrational sense are common)Paresthesias and decreased proprioception are also commonEarliest symptoms are often purely neurologicalNeurological symptoms often occur before hematological ones develop, which can lead to misdiagnosis",
                      "Peripheral neuropathy (pins and needles sensation in distal extremities, and reduced vibrational sense are common)",
                      "Paresthesias and decreased proprioception are also common",
                      "Earliest symptoms are often purely neurologicalNeurological symptoms often occur before hematological ones develop, which can lead to misdiagnosis",
                      "Neurological symptoms often occur before hematological ones develop, which can lead to misdiagnosis",
                      "Other symptoms include pallor, jaundice, glossitis, episodic abdominal pain, diarrhea, and constipation"
                    ]
                  },
                  {
                    "text": "Folate deficiencySymptoms of anemia: Pallor, fatigue, headacheSmooth and tender tongueIncreased skin pigmentationGI symptoms: Nausea, vomiting, abdominal pain, and diarrheaFolate deficiency during pregnancy is associated with development of neural tube defects in fetus",
                    "sub_points": [
                      "Symptoms of anemia: Pallor, fatigue, headache",
                      "Smooth and tender tongue",
                      "Increased skin pigmentation",
                      "GI symptoms: Nausea, vomiting, abdominal pain, and diarrhea",
                      "Folate deficiency during pregnancy is associated with development of neural tube defects in fetus"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Replacement of deficient vitamin, if applicablePrompt recognition and treatment has best prognosis for improvement of neurological symptoms",
                    "sub_points": [
                      "Prompt recognition and treatment has best prognosis for improvement of neurological symptoms"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Challenging to differentiate vitamin B12 from folate deficiencyFolate deficiency is typically more acuteCause can typically be determined on patient history and physical examinationVitamin B12 deficiency is more insidious, with specific testing needed to identify it as cause",
                    "sub_points": [
                      "Folate deficiency is typically more acuteCause can typically be determined on patient history and physical examination",
                      "Cause can typically be determined on patient history and physical examination",
                      "Vitamin B12 deficiency is more insidious, with specific testing needed to identify it as cause"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Earliest hematological manifestation is increased MCV"
                  },
                  {
                    "text": "Pancytopenia is frequently seen"
                  },
                  {
                    "text": "Percent transferrin saturation will be increased due to ineffective use of ironConcomitant iron deficiency may result in normal MCV and mask megaloblastic signs in peripheral blood",
                    "sub_points": [
                      "Concomitant iron deficiency may result in normal MCV and mask megaloblastic signs in peripheral blood"
                    ]
                  },
                  {
                    "text": "Serum iron will be increased"
                  },
                  {
                    "text": "Lowered absolute reticulocyte count"
                  },
                  {
                    "text": "Increased bilirubin (up to 2 mg/dL)"
                  },
                  {
                    "text": "Decreased haptoglobin"
                  },
                  {
                    "text": "Increased lactate dehydrogenase (LDH) (> 1000 u/mL)"
                  },
                  {
                    "text": "Serum B12 and folate levels should be correlated with symptomsSerum folate is highly sensitive to folate intake and can correct after healthy meal, even in presence of folate deficiencyRed cell folate is more specific for true deficiencyRed cell folate may be low in vitamin B12 deficiency even if adequate folate is present; thus, vitamin B12 deficiency must be ruled out before folate deficiency is diagnosedThree folate/vitamin B12 levels taken on separate occasions is recommended to accurately correlate results",
                    "sub_points": [
                      "Serum folate is highly sensitive to folate intake and can correct after healthy meal, even in presence of folate deficiency",
                      "Red cell folate is more specific for true deficiencyRed cell folate may be low in vitamin B12 deficiency even if adequate folate is present; thus, vitamin B12 deficiency must be ruled out before folate deficiency is diagnosedThree folate/vitamin B12 levels taken on separate occasions is recommended to accurately correlate results",
                      "Red cell folate may be low in vitamin B12 deficiency even if adequate folate is present; thus, vitamin B12 deficiency must be ruled out before folate deficiency is diagnosed",
                      "Three folate/vitamin B12 levels taken on separate occasions is recommended to accurately correlate results"
                    ]
                  }
                ],
                "Microscopy": [
                  {
                    "text": "B12 and folate deficiency are morphologically indistinguishable in peripheral blood and bone marrow"
                  },
                  {
                    "text": "Peripheral blood smearMacrocytosisAnisopoikilocytosis including macro-ovalocytesNeutrophils with hypersegmented nuclei (1 with 6 lobes or ≥ 5% with 5 lobes)Mild to moderate thrombocytopeniaLeukoerythroblastosis (immature granulocytes and nucleated red blood cells)Howell-Jolly bodies and Cabot rings may be present",
                    "sub_points": [
                      "Macrocytosis",
                      "Anisopoikilocytosis including macro-ovalocytes",
                      "Neutrophils with hypersegmented nuclei (1 with 6 lobes or ≥ 5% with 5 lobes)",
                      "Mild to moderate thrombocytopenia",
                      "Leukoerythroblastosis (immature granulocytes and nucleated red blood cells)",
                      "Howell-Jolly bodies and Cabot rings may be present"
                    ]
                  },
                  {
                    "text": "Bone marrow aspirate exhibitsTrilineage hyperplasia with erythroid predominance; erythroid-to-myeloid ratio ~ 1:1Giant metamyelocytes and band formsErythroid dysplasia: Megaloblastic maturation, frequent karyorrhexis, nuclear irregularities",
                    "sub_points": [
                      "Trilineage hyperplasia with erythroid predominance; erythroid-to-myeloid ratio ~ 1:1",
                      "Giant metamyelocytes and band forms",
                      "Erythroid dysplasia: Megaloblastic maturation, frequent karyorrhexis, nuclear irregularities"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Hemochromatosis": {
            "name": "Hereditary Hemochromatosis",
            "url": "https://app.pathprimer.com/document/0d733ba1-a591-4b51-a1ed-ba16c3da8de5/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Iron is absorbed by enterocytes and released by macrophages after engulfing red blood cells﻿These processes are regulated by hepcidinHepcidin: Peptide hormone produced in liver; acts to inhibit dietary adsorption of iron in gut and release of iron from macrophages﻿",
                    "sub_points": [
                      "﻿These processes are regulated by hepcidinHepcidin: Peptide hormone produced in liver; acts to inhibit dietary adsorption of iron in gut and release of iron from macrophages﻿",
                      "Hepcidin: Peptide hormone produced in liver; acts to inhibit dietary adsorption of iron in gut and release of iron from macrophages﻿"
                    ]
                  },
                  {
                    "text": "Hereditary hemochromatosis: Inherited disorder that leads to increased iron absorption and iron overloadCaused by single nucleotide mutation inHFEgene90-95% of people with hereditary hemochromatosis are homozygous for Cys282Tyr (C282Y) mutation﻿",
                    "sub_points": [
                      "Caused by single nucleotide mutation inHFEgene",
                      "90-95% of people with hereditary hemochromatosis are homozygous for Cys282Tyr (C282Y) mutation﻿"
                    ]
                  },
                  {
                    "text": "HFE protein regulates hepcidin; ﻿thus, ﻿mutations inHFEgene interfere with hepcidin function﻿Mutated HFE allows absorption of iron by enterocytes and release of iron by macrophages, regardless of iron overload﻿",
                    "sub_points": [
                      "﻿Mutated HFE allows absorption of iron by enterocytes and release of iron by macrophages, regardless of iron overload﻿"
                    ]
                  },
                  {
                    "text": "Classic triad: Cirrhosis of liver, diabetes mellitus, bronzing of skin"
                  },
                  {
                    "text": "Treatment: Therapeutic phlebotomy"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "﻿Transferrin-iron saturation of 45% or greater﻿"
                  },
                  {
                    "text": "Serum﻿ferritin above upper limit of normal (> 300 ng/mL in males, > 200 ng/mL in females)"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Genetics and Epidemiology": [
                  {
                    "text": "Mutations inHFEgene lead to hereditary hemochromatosis90-95% of people with hereditary hemochromatosis are homozygous for Cys282Tyr (C282Y) mutation﻿11% carrier rate for Cys282Tyr in white North AmericansC282Y mutation has allelic frequency of 0.05-0.1 (this is high) in white populationsRare in nonwhites1-10% penetrance of C282Y homozygous mutationRemaining individuals are compound heterozygotes for Cys282Tyr and His63Asp (H63D) mutations33% carrier rate for His63Asp in white North AmericansIndividuals homozygous for His63Asp do not always have clinical signs of hemochromatosis, unless other cause for iron overload is present",
                    "sub_points": [
                      "90-95% of people with hereditary hemochromatosis are homozygous for Cys282Tyr (C282Y) mutation﻿11% carrier rate for Cys282Tyr in white North AmericansC282Y mutation has allelic frequency of 0.05-0.1 (this is high) in white populationsRare in nonwhites1-10% penetrance of C282Y homozygous mutation",
                      "11% carrier rate for Cys282Tyr in white North Americans",
                      "C282Y mutation has allelic frequency of 0.05-0.1 (this is high) in white populationsRare in nonwhites",
                      "Rare in nonwhites",
                      "1-10% penetrance of C282Y homozygous mutation",
                      "Remaining individuals are compound heterozygotes for Cys282Tyr and His63Asp (H63D) mutations33% carrier rate for His63Asp in white North Americans",
                      "33% carrier rate for His63Asp in white North Americans",
                      "Individuals homozygous for His63Asp do not always have clinical signs of hemochromatosis, unless other cause for iron overload is present"
                    ]
                  },
                  {
                    "text": "Other genes where mutation leads to hereditary hemochromatosisHAMP,HJV,TFR2,SLC40A1Phenotype expressed in hemochromatosis is dependent on interaction between mutated gene and hepcidin",
                    "sub_points": [
                      "HAMP,HJV,TFR2,SLC40A1",
                      "Phenotype expressed in hemochromatosis is dependent on interaction between mutated gene and hepcidin"
                    ]
                  },
                  {
                    "text": "HFEgene is linked to HLA locus on chromosome 6HFE protein is similar to class 1 major histocompatibility complex (MHC) proteins",
                    "sub_points": [
                      "HFE protein is similar to class 1 major histocompatibility complex (MHC) proteins"
                    ]
                  }
                ],
                "Normal Iron Body Stores": [
                  {
                    "text": "Iron is absorbed by enterocytes and released by macrophages after engulfing red blood cells"
                  },
                  {
                    "text": "These processes are regulated by hepcidinPeptide hormone that circulates in blood﻿Produced in liver﻿Inhibits dietary adsorption of iron in gut and release of iron from macrophages﻿",
                    "sub_points": [
                      "Peptide hormone that circulates in blood﻿",
                      "Produced in liver﻿",
                      "Inhibits dietary adsorption of iron in gut and release of iron from macrophages﻿"
                    ]
                  },
                  {
                    "text": "Types of iron depositionHemosiderin: InsolubleDeposited in hepatocytes and biliary epithelium and not in reticuloendothelial cellsFerritin: Soluble",
                    "sub_points": [
                      "Hemosiderin: InsolubleDeposited in hepatocytes and biliary epithelium and not in reticuloendothelial cells",
                      "Deposited in hepatocytes and biliary epithelium and not in reticuloendothelial cells",
                      "Ferritin: Soluble"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Hereditary hemochromatosis: Inherited disorder that leads to increased iron absorption and iron overload"
                  },
                  {
                    "text": "HFE protein regulates hepcidin; ﻿thus, ﻿mutations inHFEgene interfere with hepcidin function﻿Mutated HFE allows absorption of iron by enterocytes and release of iron by macrophages, regardless of iron overload﻿If no treatment, iron overload in blood leads to end organ damage, particularly within liver, pancreas, heart, gonadsHeart and endocrine organs are very sensitive to iron overload due to increased mitochondria and relatively fewer antioxidants",
                    "sub_points": [
                      "﻿Mutated HFE allows absorption of iron by enterocytes and release of iron by macrophages, regardless of iron overload﻿",
                      "If no treatment, iron overload in blood leads to end organ damage, particularly within liver, pancreas, heart, gonads",
                      "Heart and endocrine organs are very sensitive to iron overload due to increased mitochondria and relatively fewer antioxidants"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Classic triad﻿Cirrhosis﻿﻿Diabetes mellitus﻿Bronzing of skin﻿",
                    "sub_points": [
                      "﻿Cirrhosis﻿",
                      "﻿Diabetes mellitus﻿",
                      "Bronzing of skin﻿"
                    ]
                  },
                  {
                    "text": "Early in diseaseArthralgias, fatigue, decreased libido, abdominal painRoutine screen: Increased transferrin iron saturation or ferritin",
                    "sub_points": [
                      "Arthralgias, fatigue, decreased libido, abdominal pain",
                      "Routine screen: Increased transferrin iron saturation or ferritin"
                    ]
                  },
                  {
                    "text": "Late in disease: Hepatomegaly, cirrhosis, hepatocellular carcinoma, increased skin pigmentation, cardiomyopathy, hypothyroidism, arthritis, hypogonadism"
                  },
                  {
                    "text": "﻿Men: Clinically develop disease at 40-60 years of age﻿"
                  },
                  {
                    "text": "﻿Women: Clinically develop disease after menopause﻿"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Therapeutic phlebotomy"
                  },
                  {
                    "text": "Chelation therapyDeferoxamine",
                    "sub_points": [
                      "Deferoxamine"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Good prognosis if diagnosed and treated prior to development of cirrhosis"
                  },
                  {
                    "text": "10-30% risk of hepatocellular carcinoma, even with treatment"
                  },
                  {
                    "text": "Poor prognosis indicated if failure to achieve normal ferritin levels within 3 months of phlebotomy treatments"
                  }
                ],
                "Types of Hemochromatosis": [
                  {
                    "text": "Classic hemochromatosisHFEgene mutationLate onset of symptoms",
                    "sub_points": [
                      "HFEgene mutation",
                      "Late onset of symptoms"
                    ]
                  },
                  {
                    "text": "Juvenile hemochromatosis (hemochromatosis type 2:HFE2)﻿﻿Autosomal recessive﻿Two forms﻿HFE2A﻿HJVgene mutation chromosome 1a21Before age 30, patients present with cardiac iron deposition resulting in heart failurePatients often have hypogonadism at presentation﻿HFE2B﻿HAMPgene mutationMutation in hepcidin gene at 19q13Presents similarly to HFE2A",
                    "sub_points": [
                      "﻿Autosomal recessive﻿",
                      "Two forms﻿HFE2A﻿HJVgene mutation chromosome 1a21Before age 30, patients present with cardiac iron deposition resulting in heart failurePatients often have hypogonadism at presentation﻿HFE2B﻿HAMPgene mutationMutation in hepcidin gene at 19q13Presents similarly to HFE2A",
                      "﻿HFE2A﻿HJVgene mutation chromosome 1a21Before age 30, patients present with cardiac iron deposition resulting in heart failurePatients often have hypogonadism at presentation",
                      "HJVgene mutation chromosome 1a21",
                      "Before age 30, patients present with cardiac iron deposition resulting in heart failure",
                      "Patients often have hypogonadism at presentation",
                      "﻿HFE2B﻿HAMPgene mutationMutation in hepcidin gene at 19q13Presents similarly to HFE2A",
                      "HAMPgene mutation",
                      "Mutation in hepcidin gene at 19q13",
                      "Presents similarly to HFE2A"
                    ]
                  },
                  {
                    "text": "Hemochromatosis type 3TFR2gene mutationAutosomal recessive",
                    "sub_points": [
                      "TFR2gene mutation",
                      "Autosomal recessive"
                    ]
                  },
                  {
                    "text": "Hemochromatosis type 4SLC40A1mutationAutosomal dominant",
                    "sub_points": [
                      "SLC40A1mutation",
                      "Autosomal dominant"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Alcoholic liver diseaseIron stores may be elevated on liver biopsy; however, iron stores in patients with alcoholic liver disease are less than (< 4 g) those with hereditary hemochromatosis",
                    "sub_points": [
                      "Iron stores may be elevated on liver biopsy; however, iron stores in patients with alcoholic liver disease are less than (< 4 g) those with hereditary hemochromatosis"
                    ]
                  },
                  {
                    "text": "Iron overload secondary to multiple RBC transfusionsPatients requiring multiple transfusions (e.g., sickle cell disease, thalassemias) may have increased iron stores",
                    "sub_points": [
                      "Patients requiring multiple transfusions (e.g., sickle cell disease, thalassemias) may have increased iron stores"
                    ]
                  },
                  {
                    "text": "Neonatal hemochromatosisNot hereditary; pathogenesis unknownLiver failure &/or multiorgan failure is seen in first weeks of lifeCan result in fetal loss in 2nd or 3rd trimester of pregnancy",
                    "sub_points": [
                      "Not hereditary; pathogenesis unknown",
                      "Liver failure &/or multiorgan failure is seen in first weeks of life",
                      "Can result in fetal loss in 2nd or 3rd trimester of pregnancy"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Biochemical Tests": [
                  {
                    "text": "﻿Transferrin-iron saturation of 45% or greater﻿"
                  },
                  {
                    "text": "Serum ferritin above upper limit of normal (> 300 ng/mL in males; > 200 ng/mL in females)"
                  }
                ],
                "Molecular and Cytogenetic Tests": [
                  {
                    "text": "Various methods to test for C282Y and H63D mutationsPCR, real-time PCR, microarrays, microplate, or various sequencing methods",
                    "sub_points": [
                      "PCR, real-time PCR, microarrays, microplate, or various sequencing methods"
                    ]
                  },
                  {
                    "text": "Testing for non-HFEgenes (HAMP,HJV,TFR2,SLC40A1) is costlyLiver biopsy or MRI required before testing",
                    "sub_points": [
                      "Liver biopsy or MRI required before testing"
                    ]
                  }
                ],
                "Tissue Biopsy": [
                  {
                    "text": "Liver biopsy can be used to diagnosis hemochromatosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Relative Polycythemia": {
            "name": "Relative Polycythemia",
            "url": "https://app.pathprimer.com/document/9209493b-24c8-4120-a744-f457d326bcef/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Polycythemia is defined as elevated Hct"
                  },
                  {
                    "text": "Upper limit of normal for Hct is 52% in men and 48% in women"
                  },
                  {
                    "text": "Absolute polycythemia refers to increase in total red cell mass"
                  },
                  {
                    "text": "Relative polycythemia refers to increase in red cell volume as a result of decreased volume (total red cell mass is not increased) and may be due to a variety of causes"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Overfilling of blood collection tubes can result in pseudopolycythemia due to inadequate mixing"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Polycythemia is defined as elevated hematocrit (Hct)"
                  },
                  {
                    "text": "Upper limit of normal for Hct is 52% in men and 48% in women"
                  },
                  {
                    "text": "Absolute polycythemia refers to increase in total red cell massResults from increased erythropoietin levels due toChronic hypoxiaStructurally abnormal hemoglobinUnderlying malignancyRenal disordersFamilial polycythemiaPolycythemia vera",
                    "sub_points": [
                      "Results from increased erythropoietin levels due toChronic hypoxiaStructurally abnormal hemoglobinUnderlying malignancyRenal disordersFamilial polycythemiaPolycythemia vera",
                      "Chronic hypoxia",
                      "Structurally abnormal hemoglobin",
                      "Underlying malignancy",
                      "Renal disorders",
                      "Familial polycythemia",
                      "Polycythemia vera"
                    ]
                  },
                  {
                    "text": "Relative polycythemia refers to increase in red cell volume as a result of decreased volumeTotal red cell mass is not increasedMay be due to various causesProtracted diarrhea or vomitingProlonged exerciseSudden cold exposurePlasma loss from burnsSepsisInsensible lossAlcohol intoxicationDiabetic ketoacidosisDiuretic use or abuse",
                    "sub_points": [
                      "Total red cell mass is not increased",
                      "May be due to various causesProtracted diarrhea or vomitingProlonged exerciseSudden cold exposurePlasma loss from burnsSepsisInsensible lossAlcohol intoxicationDiabetic ketoacidosisDiuretic use or abuse",
                      "Protracted diarrhea or vomiting",
                      "Prolonged exercise",
                      "Sudden cold exposure",
                      "Plasma loss from burns",
                      "Sepsis",
                      "Insensible loss",
                      "Alcohol intoxication",
                      "Diabetic ketoacidosis",
                      "Diuretic use or abuse"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Polycythemia is asymptomaticSuspicion for relative polycythemia should be high in clinical situations that promote excessive fluid loss",
                    "sub_points": [
                      "Suspicion for relative polycythemia should be high in clinical situations that promote excessive fluid loss"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Transient polycythemia is easily corrected with appropriate fluid administration"
                  },
                  {
                    "text": "Underlying cause should be addressed"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Absolute polycythemia should be differentiated from transient stateRed cell mass is increased",
                    "sub_points": [
                      "Red cell mass is increased"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Overfilling of blood collection tubes can result in pseudopolycythemia due to inadequate mixing"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Paroxysmal Nocturnal Hemoglobinuria": {
            "name": "Paroxysmal Nocturnal Hemoglobinuria",
            "url": "https://app.pathprimer.com/document/ec2efe4b-f27b-45c5-8080-6b66b73c570c/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "PNH is manifestation of complement-mediated autoimmune hemolysisAffected cells display global deficiency in group of proteins fixed to cell surface by GPI anchorsPNH-affected RBCs are susceptible to complement-mediated hemolysis due to loss of these membrane inhibitors, which are protective against active lysisMembrane inhibitors include membrane inhibitor of reactive lysis (MIRL; CD59) and decay accelerating factor (DAF; CD55); CD14, CD58, CD16a and CD24 are also deficient in PNH",
                    "sub_points": [
                      "Affected cells display global deficiency in group of proteins fixed to cell surface by GPI anchors",
                      "PNH-affected RBCs are susceptible to complement-mediated hemolysis due to loss of these membrane inhibitors, which are protective against active lysis",
                      "Membrane inhibitors include membrane inhibitor of reactive lysis (MIRL; CD59) and decay accelerating factor (DAF; CD55); CD14, CD58, CD16a and CD24 are also deficient in PNH"
                    ]
                  },
                  {
                    "text": "PNH is attributed to mutations inPIGAgene, the product of which is part of first step in GPI anchor biosynthesisPIGAis present on X chromosome; however, due to gene lyonization, both males and females can be affected",
                    "sub_points": [
                      "PIGAis present on X chromosome; however, due to gene lyonization, both males and females can be affected"
                    ]
                  },
                  {
                    "text": "Most patients have intermittent episodes of hemoglobinuria at random times of day or no hemoglobinuria at all"
                  },
                  {
                    "text": "Thrombosis is most dangerous complication of PNH and is experienced by 40% of patients with PNHHepatic vein is common site of thrombosis in PNH; hepatic vein thrombosis (Budd-Chiari syndrome) may be fatal",
                    "sub_points": [
                      "Hepatic vein is common site of thrombosis in PNH; hepatic vein thrombosis (Budd-Chiari syndrome) may be fatal"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Ham acid test was first assay used in evaluation of PNH"
                  },
                  {
                    "text": "Anti-CD59 and anti-CD55 can be used to identify PNH clonal populations with flow cytometry; this is more sensitive and specific than Ham test"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Paroxysmal nocturnal hemoglobinuria (PNH) is a manifestation of complement-mediated autoimmune hemolysisAffected cells display global deficiency in group of proteins fixed to cell surface by glycosylphosphatidylinositol (GPI) anchorsPNH-affected red blood cells (RBCs) are susceptible to complement-mediated hemolysis due to loss of these membrane inhibitorsMembrane inhibitors are protective against active lysisMembrane inhibitor of reactive lysis (MIRL; CD59)Decay accelerating factor (DAF; CD55)CD59 is glycoprotein that interacts with membrane attack complex (MAC) to prevent lytic pores from being formed by blocking aggregation of C9CD59 reduces amount of MAC formedCD55 is glycoprotein that accelerates destruction of membrane bound C3 convertaseCD55 blocks cleavage of C3CD14, CD58, CD16a, and CD24 are also deficient in PNH",
                    "sub_points": [
                      "Affected cells display global deficiency in group of proteins fixed to cell surface by glycosylphosphatidylinositol (GPI) anchors",
                      "PNH-affected red blood cells (RBCs) are susceptible to complement-mediated hemolysis due to loss of these membrane inhibitorsMembrane inhibitors are protective against active lysisMembrane inhibitor of reactive lysis (MIRL; CD59)Decay accelerating factor (DAF; CD55)CD59 is glycoprotein that interacts with membrane attack complex (MAC) to prevent lytic pores from being formed by blocking aggregation of C9CD59 reduces amount of MAC formedCD55 is glycoprotein that accelerates destruction of membrane bound C3 convertaseCD55 blocks cleavage of C3CD14, CD58, CD16a, and CD24 are also deficient in PNH",
                      "Membrane inhibitors are protective against active lysisMembrane inhibitor of reactive lysis (MIRL; CD59)Decay accelerating factor (DAF; CD55)",
                      "Membrane inhibitor of reactive lysis (MIRL; CD59)",
                      "Decay accelerating factor (DAF; CD55)",
                      "CD59 is glycoprotein that interacts with membrane attack complex (MAC) to prevent lytic pores from being formed by blocking aggregation of C9CD59 reduces amount of MAC formed",
                      "CD59 reduces amount of MAC formed",
                      "CD55 is glycoprotein that accelerates destruction of membrane bound C3 convertaseCD55 blocks cleavage of C3",
                      "CD55 blocks cleavage of C3",
                      "CD14, CD58, CD16a, and CD24 are also deficient in PNH"
                    ]
                  },
                  {
                    "text": "PNH arises from clonal multipotent stem cell lineErythroid, myeloid, and lymphoid lineages affected3 types identified based on sensitivity of RBC to complement-mediated destructionType I—normalType II—moderately sensitiveType III—extremely sensitive",
                    "sub_points": [
                      "Erythroid, myeloid, and lymphoid lineages affected",
                      "3 types identified based on sensitivity of RBC to complement-mediated destructionType I—normalType II—moderately sensitiveType III—extremely sensitive",
                      "Type I—normal",
                      "Type II—moderately sensitive",
                      "Type III—extremely sensitive"
                    ]
                  }
                ],
                "Genetics": [
                  {
                    "text": "PNH is attributed to mutations inPIGAgene, the product of which is part of first step in GPI anchor biosynthesisPIGAis present on X chromosomeBecause of gene lyonization, males and females can be affectedMales and females equally affected",
                    "sub_points": [
                      "PIGAis present on X chromosomeBecause of gene lyonization, males and females can be affectedMales and females equally affected",
                      "Because of gene lyonization, males and females can be affected",
                      "Males and females equally affected"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Although paroxysmal bouts of hemoglobinuria occur overnight, this is a less common presentationMost patients have intermittent episodes of hemoglobinuria at random times of day or no hemoglobinuria at all",
                    "sub_points": [
                      "Most patients have intermittent episodes of hemoglobinuria at random times of day or no hemoglobinuria at all"
                    ]
                  },
                  {
                    "text": "Plasma turns red during attacks, consistent with intravascular hemolysisHemolysis occurs because PNH RBCs are more sensitive to complement-mediated lysis",
                    "sub_points": [
                      "Hemolysis occurs because PNH RBCs are more sensitive to complement-mediated lysis"
                    ]
                  },
                  {
                    "text": "Hemolysis is commonMay vary from mild to markedReticulocyte count typically elevatedNot to extent expected for level of anemiaPeripheral smear shows morphologically normal RBCsSome mild anisopoikilocytosis may be presentLow haptoglobinElevated LDHMay be markedly increased (> 3,000 IU/L) depending on extent of hemolysis",
                    "sub_points": [
                      "May vary from mild to marked",
                      "Reticulocyte count typically elevatedNot to extent expected for level of anemia",
                      "Not to extent expected for level of anemia",
                      "Peripheral smear shows morphologically normal RBCsSome mild anisopoikilocytosis may be present",
                      "Some mild anisopoikilocytosis may be present",
                      "Low haptoglobin",
                      "Elevated LDHMay be markedly increased (> 3,000 IU/L) depending on extent of hemolysis",
                      "May be markedly increased (> 3,000 IU/L) depending on extent of hemolysis"
                    ]
                  },
                  {
                    "text": "Hemolysis exacerbated by factors that increase complement activationInfectionsSurgeryStrenuous exerciseExcessive alcohol intakeBlood transfusions",
                    "sub_points": [
                      "Infections",
                      "Surgery",
                      "Strenuous exercise",
                      "Excessive alcohol intake",
                      "Blood transfusions"
                    ]
                  },
                  {
                    "text": "Typical symptoms of anemiaFatiguePallorShortness of breath with exertionWeakness",
                    "sub_points": [
                      "Fatigue",
                      "Pallor",
                      "Shortness of breath with exertion",
                      "Weakness"
                    ]
                  },
                  {
                    "text": "Symptoms of smooth muscle dystoniaCaused by increased consumption of free nitric oxide secondary to hemolysisAbdominal painEsophageal spasmThrombosisErectile dysfunction",
                    "sub_points": [
                      "Caused by increased consumption of free nitric oxide secondary to hemolysisAbdominal painEsophageal spasmThrombosisErectile dysfunction",
                      "Abdominal pain",
                      "Esophageal spasm",
                      "Thrombosis",
                      "Erectile dysfunction"
                    ]
                  },
                  {
                    "text": "Renal function may be affectedReduced creatinine clearanceEnlarged kidneysCortical thinningCortical infarctsPapillary necrosisAcute renal failure uncommon",
                    "sub_points": [
                      "Reduced creatinine clearance",
                      "Enlarged kidneys",
                      "Cortical thinning",
                      "Cortical infarcts",
                      "Papillary necrosis",
                      "Acute renal failure uncommon"
                    ]
                  },
                  {
                    "text": "Thrombosis most dangerous complication of PNHExperienced by 40% of patients with PNHMore commonly venous sitesArterial thrombosis can occurHigher risk of thrombosisPatients with classical symptomsPatients with high levels of PNH clone cellsMechanism incompletely understoodLikely due to proinflammatory complement activation with increased platelet aggregation and adhesion",
                    "sub_points": [
                      "Experienced by 40% of patients with PNH",
                      "More commonly venous sitesArterial thrombosis can occur",
                      "Arterial thrombosis can occur",
                      "Higher risk of thrombosisPatients with classical symptomsPatients with high levels of PNH clone cells",
                      "Patients with classical symptoms",
                      "Patients with high levels of PNH clone cells",
                      "Mechanism incompletely understoodLikely due to proinflammatory complement activation with increased platelet aggregation and adhesion",
                      "Likely due to proinflammatory complement activation with increased platelet aggregation and adhesion"
                    ]
                  },
                  {
                    "text": "Hepatic vein common site of thrombosis in PNHHepatic vein thrombosis (Budd-Chiari syndrome)May be fatal",
                    "sub_points": [
                      "Hepatic vein thrombosis (Budd-Chiari syndrome)",
                      "May be fatal"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "TransfusionGive type-specific RBCs and ABO-compatible plasma",
                    "sub_points": [
                      "Give type-specific RBCs and ABO-compatible plasma"
                    ]
                  },
                  {
                    "text": "Eculizumab is monoclonal antibody that inhibits terminal complementReduces incidence of fatal thrombosisHas dramatically affected outcome of PNHMost effective for classical PNH",
                    "sub_points": [
                      "Reduces incidence of fatal thrombosis",
                      "Has dramatically affected outcome of PNH",
                      "Most effective for classical PNH"
                    ]
                  },
                  {
                    "text": "Immunosuppressive therapy often effective for hypoplastic PNH"
                  },
                  {
                    "text": "Bone marrow transplantation curativeHas significant morbidity and mortalityNot recommended as initial therapy",
                    "sub_points": [
                      "Has significant morbidity and mortality",
                      "Not recommended as initial therapy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Prognostic associationsVenous thrombosisBone marrow failureDevelopment of myelodysplastic syndromes",
                    "sub_points": [
                      "Venous thrombosis",
                      "Bone marrow failure",
                      "Development of myelodysplastic syndromes"
                    ]
                  },
                  {
                    "text": "Patients with aplastic anemia have 20%-30% risk of developing PNH"
                  },
                  {
                    "text": "Larger PNH clonal populations increase risk of thrombosis and lead to poorer prognosis"
                  },
                  {
                    "text": "Acute leukemia develops in 3%-5% of patients with PNH"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Blood and Bone Marrow": [
                  {
                    "text": "Peripheral blood count result can vary widely from normal to severe pancytopenia"
                  },
                  {
                    "text": "Most patients have anemia, often with mild macrocytosis"
                  },
                  {
                    "text": "Bone marrow can vary from hypocellular to hypercellularIn PNH not related to aplastic anemia, bone marrow is usually normal to hypercellular with increased erythroid precursors and dyserythropoiesis",
                    "sub_points": [
                      "In PNH not related to aplastic anemia, bone marrow is usually normal to hypercellular with increased erythroid precursors and dyserythropoiesis"
                    ]
                  }
                ],
                "Ham Acid Test": [
                  {
                    "text": "First assay used in evaluation of PNHComplement activated by acidification of serumResults in lysis of PNH RBCs but not normal RBCsSpecific for PNHPoor sensitivitySucrose lysis test similar to Ham testComplement activatedMore sensitive PNH RBCs have increased lysisLess specific than Ham test",
                    "sub_points": [
                      "Complement activated by acidification of serumResults in lysis of PNH RBCs but not normal RBCsSpecific for PNHPoor sensitivity",
                      "Results in lysis of PNH RBCs but not normal RBCs",
                      "Specific for PNH",
                      "Poor sensitivity",
                      "Sucrose lysis test similar to Ham testComplement activatedMore sensitive PNH RBCs have increased lysisLess specific than Ham test",
                      "Complement activatedMore sensitive PNH RBCs have increased lysis",
                      "More sensitive PNH RBCs have increased lysis",
                      "Less specific than Ham test"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Anti-CD59 and anti-CD55 can be used to identify PNH clonal populations with flow cytometryAllows measurement of size of PNH clonal population for prognostic purposesMore sensitive and specific than Ham testAt least 2 different monoclonal antibodies should be used to identify PNHRecent hemolysis or blood transfusion may mask positive resultSize of clonal stem cell pool best reflected in percentage of affected granulocytes and monocytes",
                    "sub_points": [
                      "Allows measurement of size of PNH clonal population for prognostic purposes",
                      "More sensitive and specific than Ham test",
                      "At least 2 different monoclonal antibodies should be used to identify PNHRecent hemolysis or blood transfusion may mask positive result",
                      "Recent hemolysis or blood transfusion may mask positive result",
                      "Size of clonal stem cell pool best reflected in percentage of affected granulocytes and monocytes"
                    ]
                  }
                ],
                "Fluorescein-Labeled Proaerolysin Variant (FLAER)": [
                  {
                    "text": "Aerolysin is virulence factor of bacteriumAeromonas hydrophila"
                  },
                  {
                    "text": "A. hydrophilasecretes inert protoxin that binds selectively and with high affinity to GPI anchor"
                  },
                  {
                    "text": "After binding, protoxin is cleaved by cell proteases, which activates toxin and kills cell"
                  },
                  {
                    "text": "PNH cells are immune to aerolysin because they lack GPI anchors"
                  },
                  {
                    "text": "Using FLAER to bind to GPI anchors allows more accurate assessment of PNH clones than anti-CD59All cells express GPI anchors except PNH cells",
                    "sub_points": [
                      "All cells express GPI anchors except PNH cells"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Elliptocytosis, Pyropoikilocytosis, Ovalocytosis": {
            "name": "Hereditary Elliptocytosis, Pyropoikilocytosis, Ovalocytosis",
            "url": "https://app.pathprimer.com/document/4736057c-382e-4cf0-882d-7d4e049fa26f/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "HE: Group of inherited disorders that have elliptical RBCs on peripheral blood smearCan be categorized into 3 major groups based on RBC morphologyCommon HESpherocytic HE (also called hemolytic ovalocytosis)SAO",
                    "sub_points": [
                      "Can be categorized into 3 major groups based on RBC morphologyCommon HESpherocytic HE (also called hemolytic ovalocytosis)SAO",
                      "Common HE",
                      "Spherocytic HE (also called hemolytic ovalocytosis)",
                      "SAO"
                    ]
                  },
                  {
                    "text": "Molecular basis of HE is heterogeneous with ﻿defects found in several proteinsα-spectrin and β-spectrin, protein 4.1R, GPC, band 3",
                    "sub_points": [
                      "α-spectrin and β-spectrin, protein 4.1R, GPC, band 3"
                    ]
                  },
                  {
                    "text": "﻿Common HEPeripheral blood smear shows > 30% biconcave ﻿elliptocytes and, in some patients, rod-shaped cells﻿Includes hemolytic HE and hereditary pyropoikilocytosis (HPP)Peripheral blood smear shows marked anisopoikilocytosis with RBC fragments, microspherocytes, and poikilocytesSimilar changes in patients are also seen secondary to severe thermal injury/burns",
                    "sub_points": [
                      "Peripheral blood smear shows > 30% biconcave ﻿elliptocytes and, in some patients, rod-shaped cells",
                      "﻿Includes hemolytic HE and hereditary pyropoikilocytosis (HPP)Peripheral blood smear shows marked anisopoikilocytosis with RBC fragments, microspherocytes, and poikilocytesSimilar changes in patients are also seen secondary to severe thermal injury/burns",
                      "Peripheral blood smear shows marked anisopoikilocytosis with RBC fragments, microspherocytes, and poikilocytes",
                      "Similar changes in patients are also seen secondary to severe thermal injury/burns"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology of Red Blood Cell Membrane Disorders": [
                  {
                    "text": "Red blood cell (RBC) membrane and its attachment to underlying cytoskeleton are important for maintaining shape, deformability, and structural integrity of RBCs"
                  },
                  {
                    "text": "RBC membrane proteins are integral part of these processesDefects in these proteins lead to membrane-associated disorders and hereditary hemolytic disease",
                    "sub_points": [
                      "Defects in these proteins lead to membrane-associated disorders and hereditary hemolytic disease"
                    ]
                  },
                  {
                    "text": "Abnormalities in RBC shape reflect underlying pathophysiology of RBC membrane protein disorders"
                  },
                  {
                    "text": "RBC membrane disorders are categorized based on morphological and clinical phenotypesHereditary spherocytosis (HS)Hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), and related disordersSoutheast Asian ovalocytosis (SAO)Acanthocytosis (hereditary and acquired)Stomatocytosis (hereditary and acquired)",
                    "sub_points": [
                      "Hereditary spherocytosis (HS)",
                      "Hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), and related disorders",
                      "Southeast Asian ovalocytosis (SAO)",
                      "Acanthocytosis (hereditary and acquired)",
                      "Stomatocytosis (hereditary and acquired)"
                    ]
                  },
                  {
                    "text": "Mutations in RBC membrane proteins are associated with RBC membrane disordersα-spectrinβ-spectrinAnkyrinBand 3Protein 4.2Protein 4.1RGlycophorin C (GPC)Rh multiprotein complex",
                    "sub_points": [
                      "α-spectrin",
                      "β-spectrin",
                      "Ankyrin",
                      "Band 3",
                      "Protein 4.2",
                      "Protein 4.1R",
                      "Glycophorin C (GPC)",
                      "Rh multiprotein complex"
                    ]
                  },
                  {
                    "text": "RBC membrane protein-protein and protein-lipid interactions can be classified as vertical or horizontalVertical interactionsThese are perpendicular to plane of membrane and serve to stabilize lipid bilayerSpectrin-ankyrin-band 3 interactionsSpectrin-protein 4.1R-junctional complex proteins linkageSpectrin-ankyrin-Rh multiprotein complex linkageSkeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)Disorders of vertical interactionsHSHorizontal interactionsThese are parallel to plane of membrane and support structural integrity of RBCs upon exposure to shear stressSpectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) important for membrane skeletonDistal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactionsDisorders of horizontal interactionsHEHPP",
                    "sub_points": [
                      "Vertical interactionsThese are perpendicular to plane of membrane and serve to stabilize lipid bilayerSpectrin-ankyrin-band 3 interactionsSpectrin-protein 4.1R-junctional complex proteins linkageSpectrin-ankyrin-Rh multiprotein complex linkageSkeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)Disorders of vertical interactionsHS",
                      "These are perpendicular to plane of membrane and serve to stabilize lipid bilayerSpectrin-ankyrin-band 3 interactionsSpectrin-protein 4.1R-junctional complex proteins linkageSpectrin-ankyrin-Rh multiprotein complex linkageSkeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)",
                      "Spectrin-ankyrin-band 3 interactions",
                      "Spectrin-protein 4.1R-junctional complex proteins linkage",
                      "Spectrin-ankyrin-Rh multiprotein complex linkage",
                      "Skeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)",
                      "Disorders of vertical interactionsHS",
                      "HS",
                      "Horizontal interactionsThese are parallel to plane of membrane and support structural integrity of RBCs upon exposure to shear stressSpectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) important for membrane skeletonDistal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactionsDisorders of horizontal interactionsHEHPP",
                      "These are parallel to plane of membrane and support structural integrity of RBCs upon exposure to shear stressSpectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) important for membrane skeletonDistal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactions",
                      "Spectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) important for membrane skeleton",
                      "Distal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactions",
                      "Disorders of horizontal interactionsHEHPP",
                      "HE",
                      "HPP"
                    ]
                  },
                  {
                    "text": "Asymmetric distribution of membrane lipids between outer and inner leaflets of RBC membranes can cause shape abnormalities (bilayer couple hypothesis)Acanthocytosis and echinocytosis result from expansion of outer membrane leafletStomatocytosis results from expansion of inner membrane leaflet",
                    "sub_points": [
                      "Acanthocytosis and echinocytosis result from expansion of outer membrane leaflet",
                      "Stomatocytosis results from expansion of inner membrane leaflet"
                    ]
                  }
                ],
                "Pathophysiology, Clinical/Laboratory Findings, and Treatment of Hereditary Elliptocytosis Disorders": [
                  {
                    "text": "HE: Group of inherited disorders that have increased elliptical RBCs on peripheral blood smearAutosomal inheritancePrevalenceIn US: 3-5 per 10,000 personsCommon in people of African and Mediterranean descent﻿More frequent in areas of endemic malariaIn equatorial Africa: 0.6-1.6%",
                    "sub_points": [
                      "Autosomal inheritance",
                      "PrevalenceIn US: 3-5 per 10,000 personsCommon in people of African and Mediterranean descent﻿More frequent in areas of endemic malariaIn equatorial Africa: 0.6-1.6%",
                      "In US: 3-5 per 10,000 persons",
                      "Common in people of African and Mediterranean descent",
                      "﻿More frequent in areas of endemic malaria",
                      "In equatorial Africa: 0.6-1.6%"
                    ]
                  },
                  {
                    "text": "Molecular basis of HE is heterogeneous with﻿defects found in several proteins﻿α-spectrin and β-spectrinMutations found in 65-75% of HE patients﻿Protein 4.1RPartial deficiency associated with mild, dominantly inherited HEComplete (homozygous) deficiency leads to severe, hemolytic HE﻿GPCHeterozygous carriers are asymptomaticHomozygous individuals have only mild elliptocytosis and are not anemic﻿Band 3",
                    "sub_points": [
                      "α-spectrin and β-spectrinMutations found in 65-75% of HE patients",
                      "Mutations found in 65-75% of HE patients",
                      "﻿Protein 4.1RPartial deficiency associated with mild, dominantly inherited HEComplete (homozygous) deficiency leads to severe, hemolytic HE",
                      "Partial deficiency associated with mild, dominantly inherited HE",
                      "Complete (homozygous) deficiency leads to severe, hemolytic HE",
                      "﻿GPCHeterozygous carriers are asymptomaticHomozygous individuals have only mild elliptocytosis and are not anemic",
                      "Heterozygous carriers are asymptomatic",
                      "Homozygous individuals have only mild elliptocytosis and are not anemic",
                      "﻿Band 3"
                    ]
                  },
                  {
                    "text": "HE categorized into 3 major groups based on RBC morphology﻿Common HE﻿Autosomal dominant inheritancePeripheral blood smear shows > 30% biconcave ﻿elliptocytes and, in some patients, rod-shaped cellsClinical severity is highly variable, ranging from asymptomatic condition to severe recessively inherited hemolytic anemiaIncludes hemolytic HE and hereditary pyropoikilocytosis (HPP)Peripheral blood smear shows marked anisopoikilocytosis with RBC fragments, microspherocytes, and poikilocytesSimilar changes in patients are also seen secondary to severe thermal injury/burns﻿HPP﻿Recessively inherited form of HEIndividuals are double heterozygous for mutations in spectrin with RBCs that have ﻿both mutant α-spectrin (disrupts heterodimer self-association) and partial deficiency of normal spectrinLaboratory diagnosisPatients with only elliptocytosis on peripheral blood smear tend to have mild or no hemolysisPoikilocytosis usually found in individuals with hemolytic forms of common HEHomozygous forms of HE also show cell fragments on peripheral blood smearAppearance of RBC fragments along with severe microspherocytosis, and only occasional elliptocytes, suggests HPPOsmotic fragility is increased in HPP, and HE with poikilocytosisOsmotic fragility is normal in common HE without poikilocytosisTreatmentHeterozygous patients with autosomal dominant HE ﻿usually do not require splenectomyPatients with ﻿symptomatic hemolysis benefit from splenectomySpherocytic HE (a.k.a. hemolytic ovalocytosis)Peripheral blood smear shows round “fat” ovalocytes and spherocytesPoikilocytes, rod-shaped cells, and RBC fragments are not found on peripheral blood smearOsmotic fragility is increasedHemolysis is present despite relatively mild alteration in RBC morphologyMolecular basis is unknownSoutheast Asian ovalocytosis (SAO)Highly prevalent in malaria-endemic areas of Southeast Asia and PacificPeripheral blood smear shows rigid, spoon-shaped cells that have longitudinal slit or transverse ridge (≥ 30% of ovalocytes)No clinical or laboratory evidence of hemolysisDecreased osmotic fragilityIncreased RBC rigidityReduced expression of RBC antigensAll SAO individuals are heterozygous for 2 mutations in band 3 gene (AE1) incisDeletion of 9 codons encoding amino acids 400-40856 Lys to Glu substitution",
                    "sub_points": [
                      "﻿Common HE﻿Autosomal dominant inheritancePeripheral blood smear shows > 30% biconcave ﻿elliptocytes and, in some patients, rod-shaped cellsClinical severity is highly variable, ranging from asymptomatic condition to severe recessively inherited hemolytic anemiaIncludes hemolytic HE and hereditary pyropoikilocytosis (HPP)Peripheral blood smear shows marked anisopoikilocytosis with RBC fragments, microspherocytes, and poikilocytesSimilar changes in patients are also seen secondary to severe thermal injury/burns﻿HPP﻿Recessively inherited form of HEIndividuals are double heterozygous for mutations in spectrin with RBCs that have ﻿both mutant α-spectrin (disrupts heterodimer self-association) and partial deficiency of normal spectrinLaboratory diagnosisPatients with only elliptocytosis on peripheral blood smear tend to have mild or no hemolysisPoikilocytosis usually found in individuals with hemolytic forms of common HEHomozygous forms of HE also show cell fragments on peripheral blood smearAppearance of RBC fragments along with severe microspherocytosis, and only occasional elliptocytes, suggests HPPOsmotic fragility is increased in HPP, and HE with poikilocytosisOsmotic fragility is normal in common HE without poikilocytosisTreatmentHeterozygous patients with autosomal dominant HE ﻿usually do not require splenectomyPatients with ﻿symptomatic hemolysis benefit from splenectomy",
                      "﻿Autosomal dominant inheritance",
                      "Peripheral blood smear shows > 30% biconcave ﻿elliptocytes and, in some patients, rod-shaped cells",
                      "Clinical severity is highly variable, ranging from asymptomatic condition to severe recessively inherited hemolytic anemia",
                      "Includes hemolytic HE and hereditary pyropoikilocytosis (HPP)Peripheral blood smear shows marked anisopoikilocytosis with RBC fragments, microspherocytes, and poikilocytesSimilar changes in patients are also seen secondary to severe thermal injury/burns",
                      "Peripheral blood smear shows marked anisopoikilocytosis with RBC fragments, microspherocytes, and poikilocytes",
                      "Similar changes in patients are also seen secondary to severe thermal injury/burns",
                      "﻿HPP﻿Recessively inherited form of HEIndividuals are double heterozygous for mutations in spectrin with RBCs that have ﻿both mutant α-spectrin (disrupts heterodimer self-association) and partial deficiency of normal spectrin",
                      "﻿Recessively inherited form of HE",
                      "Individuals are double heterozygous for mutations in spectrin with RBCs that have ﻿both mutant α-spectrin (disrupts heterodimer self-association) and partial deficiency of normal spectrin",
                      "Laboratory diagnosisPatients with only elliptocytosis on peripheral blood smear tend to have mild or no hemolysisPoikilocytosis usually found in individuals with hemolytic forms of common HEHomozygous forms of HE also show cell fragments on peripheral blood smearAppearance of RBC fragments along with severe microspherocytosis, and only occasional elliptocytes, suggests HPPOsmotic fragility is increased in HPP, and HE with poikilocytosisOsmotic fragility is normal in common HE without poikilocytosis",
                      "Patients with only elliptocytosis on peripheral blood smear tend to have mild or no hemolysis",
                      "Poikilocytosis usually found in individuals with hemolytic forms of common HE",
                      "Homozygous forms of HE also show cell fragments on peripheral blood smear",
                      "Appearance of RBC fragments along with severe microspherocytosis, and only occasional elliptocytes, suggests HPP",
                      "Osmotic fragility is increased in HPP, and HE with poikilocytosis",
                      "Osmotic fragility is normal in common HE without poikilocytosis",
                      "TreatmentHeterozygous patients with autosomal dominant HE ﻿usually do not require splenectomyPatients with ﻿symptomatic hemolysis benefit from splenectomy",
                      "Heterozygous patients with autosomal dominant HE ﻿usually do not require splenectomy",
                      "Patients with ﻿symptomatic hemolysis benefit from splenectomy",
                      "Spherocytic HE (a.k.a. hemolytic ovalocytosis)Peripheral blood smear shows round “fat” ovalocytes and spherocytesPoikilocytes, rod-shaped cells, and RBC fragments are not found on peripheral blood smearOsmotic fragility is increasedHemolysis is present despite relatively mild alteration in RBC morphologyMolecular basis is unknown",
                      "Peripheral blood smear shows round “fat” ovalocytes and spherocytes",
                      "Poikilocytes, rod-shaped cells, and RBC fragments are not found on peripheral blood smear",
                      "Osmotic fragility is increased",
                      "Hemolysis is present despite relatively mild alteration in RBC morphology",
                      "Molecular basis is unknown",
                      "Southeast Asian ovalocytosis (SAO)Highly prevalent in malaria-endemic areas of Southeast Asia and PacificPeripheral blood smear shows rigid, spoon-shaped cells that have longitudinal slit or transverse ridge (≥ 30% of ovalocytes)No clinical or laboratory evidence of hemolysisDecreased osmotic fragilityIncreased RBC rigidityReduced expression of RBC antigensAll SAO individuals are heterozygous for 2 mutations in band 3 gene (AE1) incisDeletion of 9 codons encoding amino acids 400-40856 Lys to Glu substitution",
                      "Highly prevalent in malaria-endemic areas of Southeast Asia and Pacific",
                      "Peripheral blood smear shows rigid, spoon-shaped cells that have longitudinal slit or transverse ridge (≥ 30% of ovalocytes)",
                      "No clinical or laboratory evidence of hemolysis",
                      "Decreased osmotic fragility",
                      "Increased RBC rigidity",
                      "Reduced expression of RBC antigens",
                      "All SAO individuals are heterozygous for 2 mutations in band 3 gene (AE1) incisDeletion of 9 codons encoding amino acids 400-40856 Lys to Glu substitution",
                      "Deletion of 9 codons encoding amino acids 400-408",
                      "56 Lys to Glu substitution"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Stomatocytosis": {
            "name": "Hereditary Stomatocytosis",
            "url": "https://app.pathprimer.com/document/09ad2ada-8e81-49bc-8b78-fb0f3181d661/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Two main types of hereditary stomatocytosis1) Hereditary hydrocytosisIncreased RBC volume leads to hydrocytosis or overhydrated stomatocytosisSodium influx into RBC leads to marked increase in intracellular sodium and water content, with mild decrease in intracellular potassium﻿2) Hereditary xerocytosisDecreased RBC volume; dessicocytosis or xerocytosisCellular dehydration is caused by net loss of potassium (and water) from cell, without proportional gain of sodium",
                    "sub_points": [
                      "1) Hereditary hydrocytosisIncreased RBC volume leads to hydrocytosis or overhydrated stomatocytosisSodium influx into RBC leads to marked increase in intracellular sodium and water content, with mild decrease in intracellular potassium",
                      "Increased RBC volume leads to hydrocytosis or overhydrated stomatocytosis",
                      "Sodium influx into RBC leads to marked increase in intracellular sodium and water content, with mild decrease in intracellular potassium",
                      "﻿2) Hereditary xerocytosisDecreased RBC volume; dessicocytosis or xerocytosisCellular dehydration is caused by net loss of potassium (and water) from cell, without proportional gain of sodium",
                      "Decreased RBC volume; dessicocytosis or xerocytosis",
                      "Cellular dehydration is caused by net loss of potassium (and water) from cell, without proportional gain of sodium"
                    ]
                  },
                  {
                    "text": "TreatmentSplenectomy improves but does not fully correct the hemolysisSome patients with stomatocytosis (hydrocytosis and xerocytosis) have ﻿developed hypercoagulability following splenectomy, with catastrophic thrombotic episodes or chronic pulmonary hypertension",
                    "sub_points": [
                      "Splenectomy improves but does not fully correct the hemolysis",
                      "Some patients with stomatocytosis (hydrocytosis and xerocytosis) have ﻿developed hypercoagulability following splenectomy, with catastrophic thrombotic episodes or chronic pulmonary hypertension"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology of Red Blood Cell Membrane Disorders": [
                  {
                    "text": "Red blood cell (RBC) membrane and its attachment to underlying cytoskeleton are important for maintaining shape, deformability, and structural integrity of RBC"
                  },
                  {
                    "text": "RBC membrane proteins are integral part of these processes, and defects in these proteins lead to membrane-associated disorders and hereditary hemolytic disease"
                  },
                  {
                    "text": "Abnormalities in RBC shape reflect underlying pathophysiology of RBC membrane protein disorders"
                  },
                  {
                    "text": "RBC membrane disorders are categorized based on morphological and clinical phenotypesHereditary spherocytosis (HS)Hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), and related disordersSoutheast Asian ovalocytosis (SAO)Acanthocytosis (hereditary and acquired)Stomatocytosis (hereditary and acquired)",
                    "sub_points": [
                      "Hereditary spherocytosis (HS)",
                      "Hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), and related disorders",
                      "Southeast Asian ovalocytosis (SAO)",
                      "Acanthocytosis (hereditary and acquired)",
                      "Stomatocytosis (hereditary and acquired)"
                    ]
                  },
                  {
                    "text": "Mutations in RBC membrane proteins are associated with RBC membrane disordersα-Spectrinβ-SpectrinAnkyrinBand 3Protein 4.2Protein 4.1RGlycophorin CRh multiprotein complex",
                    "sub_points": [
                      "α-Spectrin",
                      "β-Spectrin",
                      "Ankyrin",
                      "Band 3",
                      "Protein 4.2",
                      "Protein 4.1R",
                      "Glycophorin C",
                      "Rh multiprotein complex"
                    ]
                  },
                  {
                    "text": "RBC membrane protein-protein and protein-lipid interactions can be classified as vertical or horizontalVertical interactionsPerpendicular to plane of membrane, and serve to stabilize lipid bilayerSpectrin-ankyrin-band 3 interactionsSpectrin-protein 4.1R-junctional complex proteins linkageSpectrin-ankyrin-Rh multiprotein complex linkageSkeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)Disorders of vertical interactionsHSHorizontal interactionsParallel to plane of membrane, and support structural integrity of RBCs upon exposure to shear stressSpectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) is important for membrane skeletonDistal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactionsDisorders of horizontal interactionsHEHPP",
                    "sub_points": [
                      "Vertical interactionsPerpendicular to plane of membrane, and serve to stabilize lipid bilayerSpectrin-ankyrin-band 3 interactionsSpectrin-protein 4.1R-junctional complex proteins linkageSpectrin-ankyrin-Rh multiprotein complex linkageSkeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)Disorders of vertical interactionsHS",
                      "Perpendicular to plane of membrane, and serve to stabilize lipid bilayerSpectrin-ankyrin-band 3 interactionsSpectrin-protein 4.1R-junctional complex proteins linkageSpectrin-ankyrin-Rh multiprotein complex linkageSkeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)",
                      "Spectrin-ankyrin-band 3 interactions",
                      "Spectrin-protein 4.1R-junctional complex proteins linkage",
                      "Spectrin-ankyrin-Rh multiprotein complex linkage",
                      "Skeletal proteins-negatively charged phospholipids of membrane inner leaflet (weak interactions)",
                      "Disorders of vertical interactionsHS",
                      "HS",
                      "Horizontal interactionsParallel to plane of membrane, and support structural integrity of RBCs upon exposure to shear stressSpectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) is important for membrane skeletonDistal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactionsDisorders of horizontal interactionsHEHPP",
                      "Parallel to plane of membrane, and support structural integrity of RBCs upon exposure to shear stress",
                      "Spectrin heterodimer association site (site of spectrin heterodimer assembly into tetramers) is important for membrane skeleton",
                      "Distal ends of spectrin heterodimers-actin-protein 4.1R-junctional complex interactions",
                      "Disorders of horizontal interactionsHEHPP",
                      "HE",
                      "HPP"
                    ]
                  },
                  {
                    "text": "Asymmetric distribution of membrane lipids between outer and inner leaflets of RBC membranes can cause shape abnormalities (bilayer couple hypothesis)Acanthocytosis and echinocytosis result from expansion of outer membrane leafletStomatocytosis results from expansion of inner membrane leaflet",
                    "sub_points": [
                      "Acanthocytosis and echinocytosis result from expansion of outer membrane leaflet",
                      "Stomatocytosis results from expansion of inner membrane leaflet"
                    ]
                  }
                ],
                "Pathophysiology, Clinical/Laboratory Findings, and Treatment of Hereditary Stomatocytosis": [
                  {
                    "text": "Stomatocytes are present in both inherited and acquired disorders"
                  },
                  {
                    "text": "Hereditary disorders (2 main types): Usually associated with abnormal RBC cation permeability that results in changes in RBC volume1) ﻿Hereditary hydrocytosisIncreased RBC volume leads to hydrocytosis or overhydrated stomatocytosisSodium influx into RBC leads to marked increase in intracellular sodium and water content, with mild decrease in intracellular potassiumMissense mutations in RhAG have been found in patients with hereditary hydrocytosis﻿Autosomal dominant inheritanceModerate to severe hemolytic anemia10-30% stomatocytes on peripheral blood smearElevated mean corpuscular volume (MCV)Decreased mean corpuscular hemoglobin concentration (MCHC)﻿Increased osmotic fragilityDecreased RBC deformability2) Hereditary xerocytosisDecreased RBC volume; dessicocytosis or xerocytosisCellular dehydration is caused by net loss of potassium (and water) from cell, without proportional gain of sodiumMutations inPIEZO1have been associated with hereditary xerocytosis﻿Autosomal dominant inheritanceModerate to severe hemolytic anemia﻿Peripheral blood smear may show stomatocytes, target cells, spiculated cells﻿Increased MCHCMildly increased MCV﻿Decreased osmotic fragilityFetal hydrops, with fetal anemia or fetal ascites, has been reported in some families",
                    "sub_points": [
                      "1) ﻿Hereditary hydrocytosisIncreased RBC volume leads to hydrocytosis or overhydrated stomatocytosisSodium influx into RBC leads to marked increase in intracellular sodium and water content, with mild decrease in intracellular potassiumMissense mutations in RhAG have been found in patients with hereditary hydrocytosis﻿Autosomal dominant inheritanceModerate to severe hemolytic anemia10-30% stomatocytes on peripheral blood smearElevated mean corpuscular volume (MCV)Decreased mean corpuscular hemoglobin concentration (MCHC)﻿Increased osmotic fragilityDecreased RBC deformability",
                      "Increased RBC volume leads to hydrocytosis or overhydrated stomatocytosis",
                      "Sodium influx into RBC leads to marked increase in intracellular sodium and water content, with mild decrease in intracellular potassium",
                      "Missense mutations in RhAG have been found in patients with hereditary hydrocytosis",
                      "﻿Autosomal dominant inheritance",
                      "Moderate to severe hemolytic anemia10-30% stomatocytes on peripheral blood smearElevated mean corpuscular volume (MCV)Decreased mean corpuscular hemoglobin concentration (MCHC)﻿Increased osmotic fragilityDecreased RBC deformability",
                      "10-30% stomatocytes on peripheral blood smear",
                      "Elevated mean corpuscular volume (MCV)",
                      "Decreased mean corpuscular hemoglobin concentration (MCHC)",
                      "﻿Increased osmotic fragility",
                      "Decreased RBC deformability",
                      "2) Hereditary xerocytosisDecreased RBC volume; dessicocytosis or xerocytosisCellular dehydration is caused by net loss of potassium (and water) from cell, without proportional gain of sodiumMutations inPIEZO1have been associated with hereditary xerocytosis﻿Autosomal dominant inheritanceModerate to severe hemolytic anemia﻿Peripheral blood smear may show stomatocytes, target cells, spiculated cells﻿Increased MCHCMildly increased MCV﻿Decreased osmotic fragilityFetal hydrops, with fetal anemia or fetal ascites, has been reported in some families",
                      "Decreased RBC volume; dessicocytosis or xerocytosis",
                      "Cellular dehydration is caused by net loss of potassium (and water) from cell, without proportional gain of sodium",
                      "Mutations inPIEZO1have been associated with hereditary xerocytosis",
                      "﻿Autosomal dominant inheritance",
                      "Moderate to severe hemolytic anemia﻿Peripheral blood smear may show stomatocytes, target cells, spiculated cells﻿Increased MCHCMildly increased MCV﻿Decreased osmotic fragility",
                      "﻿Peripheral blood smear may show stomatocytes, target cells, spiculated cells",
                      "﻿Increased MCHC",
                      "Mildly increased MCV",
                      "﻿Decreased osmotic fragility",
                      "Fetal hydrops, with fetal anemia or fetal ascites, has been reported in some families"
                    ]
                  },
                  {
                    "text": "TreatmentSplenectomy improves but does not fully correct the hemolysisSome patients with stomatocytosis (hydrocytosis and xerocytosis) have ﻿developed hypercoagulability following splenectomy, with catastrophic thrombotic episodes or chronic pulmonary hypertensionMajority of patients with hereditary stomatocytosis are able to maintain their hemoglobin and do not need splenectomy",
                    "sub_points": [
                      "Splenectomy improves but does not fully correct the hemolysis",
                      "Some patients with stomatocytosis (hydrocytosis and xerocytosis) have ﻿developed hypercoagulability following splenectomy, with catastrophic thrombotic episodes or chronic pulmonary hypertension",
                      "Majority of patients with hereditary stomatocytosis are able to maintain their hemoglobin and do not need splenectomy"
                    ]
                  },
                  {
                    "text": "Rh deficiency syndromeAssociated with absence (Rhnull) or severe deficiency (Rhmod) of Rh antigenRh-RHAG complex interacts with ankyrin to link membrane cytoskeleton to lipid bilayerMild to moderate hemolytic anemia﻿Peripheral blood smear shows stomatocytes and occasional spherocytes﻿Increased osmotic fragilityTreatmentHemolytic anemia is improved by splenectomy",
                    "sub_points": [
                      "Associated with absence (Rhnull) or severe deficiency (Rhmod) of Rh antigen",
                      "Rh-RHAG complex interacts with ankyrin to link membrane cytoskeleton to lipid bilayer",
                      "Mild to moderate hemolytic anemia﻿Peripheral blood smear shows stomatocytes and occasional spherocytes﻿Increased osmotic fragility",
                      "﻿Peripheral blood smear shows stomatocytes and occasional spherocytes",
                      "﻿Increased osmotic fragility",
                      "TreatmentHemolytic anemia is improved by splenectomy",
                      "Hemolytic anemia is improved by splenectomy"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Porphyria": {
            "name": "Porphyria",
            "url": "https://app.pathprimer.com/document/ffd23249-e970-42c9-83bc-e09d2c31eec3/lesson/5ba2eb4f-5ad9-4085-987a-921192d2afd1",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Porphyria is caused by reduction in activity or deficiency of specific enzyme in heme biosynthesis that results in impaired production of final heme product and buildup of heme precursors"
                  },
                  {
                    "text": "Clinical manifestations of acute porphyrias affect central, peripheral, and autonomic nervous systems"
                  },
                  {
                    "text": "Alcohol, fasting or dieting, hormones, stress, and smoking are common triggers; medications including sulfonamides, erythromycin, antidepressants, and contraceptives are known to precipitate attacks"
                  },
                  {
                    "text": "Acute intermittent porphyriaMost severe form of porphyrias with female predominance (4:1); usually occurs in young adults and rare in childrenAbdominal symptoms occur in 95% of cases and include colicky central abdominal pain, tenderness with minimal rigidity, vomiting, and constipationNeurologic symptoms, general muscle aches, and limb pain may occurHyponatremia occurs in severe attacks",
                    "sub_points": [
                      "Most severe form of porphyrias with female predominance (4:1); usually occurs in young adults and rare in children",
                      "Abdominal symptoms occur in 95% of cases and include colicky central abdominal pain, tenderness with minimal rigidity, vomiting, and constipation",
                      "Neurologic symptoms, general muscle aches, and limb pain may occur",
                      "Hyponatremia occurs in severe attacks"
                    ]
                  },
                  {
                    "text": "Hereditary coproporphyriaSymptoms of acute porphyria with photosensitive skin manifestations",
                    "sub_points": [
                      "Symptoms of acute porphyria with photosensitive skin manifestations"
                    ]
                  },
                  {
                    "text": "Porphyria cutanea tardaClinical evidence of liver disease is common, especially hepatic siderosisHallmark feature is bullous dermatosis on light-exposed areas",
                    "sub_points": [
                      "Clinical evidence of liver disease is common, especially hepatic siderosis",
                      "Hallmark feature is bullous dermatosis on light-exposed areas"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Porphyria is caused by reduction in activity or deficiency of specific enzyme in heme biosynthesisHeme biosynthesis occurs in all biologically active cells that contain mitochondriaIt is essential for hemoglobin synthesis and metabolic pathways such as cytochrome P-450Normal heme synthesisGlycine and succinyl coenzyme A are condensed to form aminolevulinic acid (ALA) via aminolevulinic acid synthase (ALAS) with cofactor pyridoxal phosphateSeries of enzymes converts ALA first to porphobilinogen (PBG), then to various porphyrinsNext, iron is inserted into protoporphyrin by ferrochelatase, forming heme",
                    "sub_points": [
                      "Heme biosynthesis occurs in all biologically active cells that contain mitochondriaIt is essential for hemoglobin synthesis and metabolic pathways such as cytochrome P-450",
                      "It is essential for hemoglobin synthesis and metabolic pathways such as cytochrome P-450",
                      "Normal heme synthesisGlycine and succinyl coenzyme A are condensed to form aminolevulinic acid (ALA) via aminolevulinic acid synthase (ALAS) with cofactor pyridoxal phosphateSeries of enzymes converts ALA first to porphobilinogen (PBG), then to various porphyrinsNext, iron is inserted into protoporphyrin by ferrochelatase, forming heme",
                      "Glycine and succinyl coenzyme A are condensed to form aminolevulinic acid (ALA) via aminolevulinic acid synthase (ALAS) with cofactor pyridoxal phosphate",
                      "Series of enzymes converts ALA first to porphobilinogen (PBG), then to various porphyrins",
                      "Next, iron is inserted into protoporphyrin by ferrochelatase, forming heme"
                    ]
                  },
                  {
                    "text": "Porphyrias result in impaired production of final heme product and buildup of heme precursorsEach porphyria is characterized by different excretion patternPorphyrins leak from capillaries into skinResult is characteristic photosensitivity",
                    "sub_points": [
                      "Each porphyria is characterized by different excretion pattern",
                      "Porphyrins leak from capillaries into skinResult is characteristic photosensitivity",
                      "Result is characteristic photosensitivity"
                    ]
                  },
                  {
                    "text": "Acute porphyriasLiver is main source of overproduction of porphyrins and precursorsExcessive excretion is caused by reduction in porphobilinogen deaminase (PBGD)",
                    "sub_points": [
                      "Liver is main source of overproduction of porphyrins and precursors",
                      "Excessive excretion is caused by reduction in porphobilinogen deaminase (PBGD)"
                    ]
                  },
                  {
                    "text": "Nonacute porphyriasBone marrow is primary source of overproduction of porphyrins onlyNo buildup of precursorsCompensatory increase in PBGD, ALAS, and site-specific heme synthesis may account for lack of precursor overproduction",
                    "sub_points": [
                      "Bone marrow is primary source of overproduction of porphyrins only",
                      "No buildup of precursors",
                      "Compensatory increase in PBGD, ALAS, and site-specific heme synthesis may account for lack of precursor overproduction"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Clinical manifestations of acute porphyrias affect central, peripheral, and autonomic nervous systemsAcute intermittent porphyriaMost severe porphyriaFemale predominance (4:1)Usually occurs in young adultsRare in childrenAbdominal symptoms occur in 95% of casesColicky central abdominal painTenderness with minimal rigidityVomitingConstipationGeneral muscle aches and limb pain may occurHyponatremia occurs in severe attacksNeurologic symptomsMotor neuropathy occurs in two-thirds of attacks and may be the presenting featureParalysis manifests peripherally and spreads proximallyShoulder girdle may be first area involvedParesthesias occur but are less commonPermanent weakness of wrists, hands, and ankles can occurMain psychiatric manifestationsAnxietyDepressionFrank psychosisCardiovascular system often affectedSinus tachycardia and hypertension most commonHereditary coproporphyriaSymptoms of acute porphyria with photosensitive skin manifestationsVariegate porphyriaAcute porphyria with severe skin manifestations, often with scarring",
                    "sub_points": [
                      "Acute intermittent porphyriaMost severe porphyriaFemale predominance (4:1)Usually occurs in young adultsRare in childrenAbdominal symptoms occur in 95% of casesColicky central abdominal painTenderness with minimal rigidityVomitingConstipationGeneral muscle aches and limb pain may occurHyponatremia occurs in severe attacksNeurologic symptomsMotor neuropathy occurs in two-thirds of attacks and may be the presenting featureParalysis manifests peripherally and spreads proximallyShoulder girdle may be first area involvedParesthesias occur but are less commonPermanent weakness of wrists, hands, and ankles can occurMain psychiatric manifestationsAnxietyDepressionFrank psychosisCardiovascular system often affectedSinus tachycardia and hypertension most common",
                      "Most severe porphyriaFemale predominance (4:1)Usually occurs in young adultsRare in children",
                      "Female predominance (4:1)",
                      "Usually occurs in young adults",
                      "Rare in children",
                      "Abdominal symptoms occur in 95% of casesColicky central abdominal painTenderness with minimal rigidityVomitingConstipation",
                      "Colicky central abdominal pain",
                      "Tenderness with minimal rigidity",
                      "Vomiting",
                      "Constipation",
                      "General muscle aches and limb pain may occur",
                      "Hyponatremia occurs in severe attacks",
                      "Neurologic symptomsMotor neuropathy occurs in two-thirds of attacks and may be the presenting featureParalysis manifests peripherally and spreads proximallyShoulder girdle may be first area involvedParesthesias occur but are less commonPermanent weakness of wrists, hands, and ankles can occur",
                      "Motor neuropathy occurs in two-thirds of attacks and may be the presenting feature",
                      "Paralysis manifests peripherally and spreads proximally",
                      "Shoulder girdle may be first area involved",
                      "Paresthesias occur but are less common",
                      "Permanent weakness of wrists, hands, and ankles can occur",
                      "Main psychiatric manifestationsAnxietyDepressionFrank psychosis",
                      "Anxiety",
                      "Depression",
                      "Frank psychosis",
                      "Cardiovascular system often affectedSinus tachycardia and hypertension most common",
                      "Sinus tachycardia and hypertension most common",
                      "Hereditary coproporphyriaSymptoms of acute porphyria with photosensitive skin manifestations",
                      "Symptoms of acute porphyria with photosensitive skin manifestations",
                      "Variegate porphyriaAcute porphyria with severe skin manifestations, often with scarring",
                      "Acute porphyria with severe skin manifestations, often with scarring"
                    ]
                  },
                  {
                    "text": "Nonacute porphyrias (cutaneous)Porphyria cutanea tardaInherited and acquired forms occurClinical evidence of liver disease common, especially hepatic siderosisAssociated with hereditary hemochromatosisHallmark feature is bullous dermatosis on light-exposed areasBegins as erythema → forms vesicles → coalesce in bullaeBullae may hemorrhage and leave scarsPruritus common symptomThickening and scarring of skin with calcification mimics sclerodermaMilia are commonMay precede or follow vesicle formationFacial hypertrichosis commonFemale patients may complain of hirsutismImportant to differentiate from pseudoporphyriaPseudoporphyria is usually photosensitivity brought on by drugs such as tetracyclinesNo abnormality in heme metabolism is present in pseudoporphyriaBiochemical features of porphyria also common in patients with renal failure before dialysisErythropoietic protoporphyriaFerrochelatase activity reduced in peripheral blood, bone marrow, liver, and skin, resulting in protoporphyrin excessSymptoms are pruritic urticarial swelling and redness of skin on exposure to sunlightUnbearable burning sensation is most challenging symptomMild microcytic anemia is commonMitochondrial iron accumulation and ringed sideroblasts may be observedLiver failure may occur later in life due to buildup of excess hepatotoxic protoporphyrin leading to chronic hepatitisCongenital porphyria (Günther disease)Extremely rareInherited in autosomal recessive patternReduced activity of uroporphyrinogen III synthaseOnset typically noted at birthLate-onset cases occurSkin manifestationsSevere skin reaction with blistering of light-exposed areas and fragile epidermisExtensive scarring and hypertrichosisScarring can be so severe that hands develop claw-like deformity, loss of digits may occur, and dystrophic nails curl up and drop offTeeth become brownish pink from high-porphyrin contentLenticular scarring may lead to blindnessHemolytic anemia often occurs secondary to erythrocyte fragility and splenomegaly",
                    "sub_points": [
                      "Porphyria cutanea tardaInherited and acquired forms occurClinical evidence of liver disease common, especially hepatic siderosisAssociated with hereditary hemochromatosisHallmark feature is bullous dermatosis on light-exposed areasBegins as erythema → forms vesicles → coalesce in bullaeBullae may hemorrhage and leave scarsPruritus common symptomThickening and scarring of skin with calcification mimics sclerodermaMilia are commonMay precede or follow vesicle formationFacial hypertrichosis commonFemale patients may complain of hirsutismImportant to differentiate from pseudoporphyriaPseudoporphyria is usually photosensitivity brought on by drugs such as tetracyclinesNo abnormality in heme metabolism is present in pseudoporphyriaBiochemical features of porphyria also common in patients with renal failure before dialysis",
                      "Inherited and acquired forms occur",
                      "Clinical evidence of liver disease common, especially hepatic siderosis",
                      "Associated with hereditary hemochromatosis",
                      "Hallmark feature is bullous dermatosis on light-exposed areasBegins as erythema → forms vesicles → coalesce in bullaeBullae may hemorrhage and leave scarsPruritus common symptomThickening and scarring of skin with calcification mimics scleroderma",
                      "Begins as erythema → forms vesicles → coalesce in bullae",
                      "Bullae may hemorrhage and leave scars",
                      "Pruritus common symptom",
                      "Thickening and scarring of skin with calcification mimics scleroderma",
                      "Milia are commonMay precede or follow vesicle formation",
                      "May precede or follow vesicle formation",
                      "Facial hypertrichosis commonFemale patients may complain of hirsutism",
                      "Female patients may complain of hirsutism",
                      "Important to differentiate from pseudoporphyriaPseudoporphyria is usually photosensitivity brought on by drugs such as tetracyclinesNo abnormality in heme metabolism is present in pseudoporphyriaBiochemical features of porphyria also common in patients with renal failure before dialysis",
                      "Pseudoporphyria is usually photosensitivity brought on by drugs such as tetracyclines",
                      "No abnormality in heme metabolism is present in pseudoporphyria",
                      "Biochemical features of porphyria also common in patients with renal failure before dialysis",
                      "Erythropoietic protoporphyriaFerrochelatase activity reduced in peripheral blood, bone marrow, liver, and skin, resulting in protoporphyrin excessSymptoms are pruritic urticarial swelling and redness of skin on exposure to sunlightUnbearable burning sensation is most challenging symptomMild microcytic anemia is commonMitochondrial iron accumulation and ringed sideroblasts may be observedLiver failure may occur later in life due to buildup of excess hepatotoxic protoporphyrin leading to chronic hepatitis",
                      "Ferrochelatase activity reduced in peripheral blood, bone marrow, liver, and skin, resulting in protoporphyrin excess",
                      "Symptoms are pruritic urticarial swelling and redness of skin on exposure to sunlightUnbearable burning sensation is most challenging symptom",
                      "Unbearable burning sensation is most challenging symptom",
                      "Mild microcytic anemia is commonMitochondrial iron accumulation and ringed sideroblasts may be observed",
                      "Mitochondrial iron accumulation and ringed sideroblasts may be observed",
                      "Liver failure may occur later in life due to buildup of excess hepatotoxic protoporphyrin leading to chronic hepatitis",
                      "Congenital porphyria (Günther disease)Extremely rareInherited in autosomal recessive patternReduced activity of uroporphyrinogen III synthaseOnset typically noted at birthLate-onset cases occurSkin manifestationsSevere skin reaction with blistering of light-exposed areas and fragile epidermisExtensive scarring and hypertrichosisScarring can be so severe that hands develop claw-like deformity, loss of digits may occur, and dystrophic nails curl up and drop offTeeth become brownish pink from high-porphyrin contentLenticular scarring may lead to blindnessHemolytic anemia often occurs secondary to erythrocyte fragility and splenomegaly",
                      "Extremely rareInherited in autosomal recessive pattern",
                      "Inherited in autosomal recessive pattern",
                      "Reduced activity of uroporphyrinogen III synthase",
                      "Onset typically noted at birthLate-onset cases occur",
                      "Late-onset cases occur",
                      "Skin manifestationsSevere skin reaction with blistering of light-exposed areas and fragile epidermisExtensive scarring and hypertrichosisScarring can be so severe that hands develop claw-like deformity, loss of digits may occur, and dystrophic nails curl up and drop off",
                      "Severe skin reaction with blistering of light-exposed areas and fragile epidermis",
                      "Extensive scarring and hypertrichosis",
                      "Scarring can be so severe that hands develop claw-like deformity, loss of digits may occur, and dystrophic nails curl up and drop off",
                      "Teeth become brownish pink from high-porphyrin content",
                      "Lenticular scarring may lead to blindness",
                      "Hemolytic anemia often occurs secondary to erythrocyte fragility and splenomegaly"
                    ]
                  }
                ],
                "Genetics": [
                  {
                    "text": "Nearly all nonacute porphyrias are inherited in autosomal dominant patternCongenital porphyria is an exception and is inherited in autosomal recessive pattern",
                    "sub_points": [
                      "Congenital porphyria is an exception and is inherited in autosomal recessive pattern"
                    ]
                  },
                  {
                    "text": "Erythropoietic protoporphyria is inherited in X-linked dominant pattern with incomplete penetrance"
                  }
                ],
                "Prevention and Treatment": [
                  {
                    "text": "Precipitating factors for acute porphyriasAlcoholFasting or dietingHormonesStressSmokingMedicationsSulfonamidesErythromycinAntidepressantsContraceptives",
                    "sub_points": [
                      "Alcohol",
                      "Fasting or dieting",
                      "Hormones",
                      "Stress",
                      "Smoking",
                      "MedicationsSulfonamidesErythromycinAntidepressantsContraceptives",
                      "Sulfonamides",
                      "Erythromycin",
                      "Antidepressants",
                      "Contraceptives"
                    ]
                  },
                  {
                    "text": "Precipitating factors for porphyria cutanea tardaAlcohol, halogenated hydrocarbons, hemodialysis, hepatitis C infection, medicationsRemoval of these factors is first step in treatmentRemoval of liver iron by therapeutic phlebotomy is mainstay of treatmentChloroquine in low doses increases urinary excretion of porphyrinCimetidine is alternative medicationIron chelation therapy is secondary choice",
                    "sub_points": [
                      "Alcohol, halogenated hydrocarbons, hemodialysis, hepatitis C infection, medicationsRemoval of these factors is first step in treatmentRemoval of liver iron by therapeutic phlebotomy is mainstay of treatmentChloroquine in low doses increases urinary excretion of porphyrinCimetidine is alternative medicationIron chelation therapy is secondary choice",
                      "Removal of these factors is first step in treatment",
                      "Removal of liver iron by therapeutic phlebotomy is mainstay of treatment",
                      "Chloroquine in low doses increases urinary excretion of porphyrinCimetidine is alternative medicationIron chelation therapy is secondary choice",
                      "Cimetidine is alternative medication",
                      "Iron chelation therapy is secondary choice"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Initial Screening": [
                  {
                    "text": "Fluorescence of urine under ultraviolet light is effective initial screening for acute porphyrias"
                  },
                  {
                    "text": "Plasma fluorescent spectroscopy is best initial screening method for cutaneous porphyrias"
                  }
                ],
                "Confirmatory Testing": [
                  {
                    "text": "Laboratory testing of urine, red blood cells, and feces for various porphyrins and heme pathway enzymes can be performedTesting laboratory should have algorithm for appropriate identification of type of porphyriaQuantitative evaluation for ALA and PBG in urinePorphyrins and PBGD in erythrocytesHigh-performance liquid chromatography (HPLC) and fluorometry are standard for analysis",
                    "sub_points": [
                      "Testing laboratory should have algorithm for appropriate identification of type of porphyriaQuantitative evaluation for ALA and PBG in urinePorphyrins and PBGD in erythrocytes",
                      "Quantitative evaluation for ALA and PBG in urine",
                      "Porphyrins and PBGD in erythrocytes",
                      "High-performance liquid chromatography (HPLC) and fluorometry are standard for analysis"
                    ]
                  },
                  {
                    "text": "Caution should be used when ordering genetic evaluationPorphyrias display variable penetrancePositive genetic analysis may not be representative of disease severity",
                    "sub_points": [
                      "Porphyrias display variable penetrance",
                      "Positive genetic analysis may not be representative of disease severity"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Hemoglobin Disorders": {
        "name": "Hemoglobin Disorders",
        "url": "https://app.pathprimer.com/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
        "topics": {
          "Sickle Cell Trait": {
            "name": "Sickle Cell Trait",
            "url": "https://app.pathprimer.com/document/9eca6dce-9494-4a97-8794-91c02d5c4033/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Patients are usually totally asymptomatic"
                  },
                  {
                    "text": "Heterozygous mutation in hemoglobin beta gene (Hb S)Mutation results in replacement of ﻿glutamic acid by valine in position 6",
                    "sub_points": [
                      "Mutation results in replacement of ﻿glutamic acid by valine in position 6"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)Decreased Hgb A (50-60%), and presence of Hb S (35-45%)Recent red cell transfusion (within 3 months) in patient with sickle cell disease (Hb SS) can look identical to sickle cell trait on HPLC or hemoglobin electrophoresisReview transfusion history and complete blood count prior to interpretation",
                    "sub_points": [
                      "Decreased Hgb A (50-60%), and presence of Hb S (35-45%)",
                      "Recent red cell transfusion (within 3 months) in patient with sickle cell disease (Hb SS) can look identical to sickle cell trait on HPLC or hemoglobin electrophoresisReview transfusion history and complete blood count prior to interpretation",
                      "Review transfusion history and complete blood count prior to interpretation"
                    ]
                  },
                  {
                    "text": "Sickledex test (solubility test for Hgb S)Turbidity of reduced Hb S solution observed in positive testsPositive in both sickle cell trait and sickle cell disease",
                    "sub_points": [
                      "Turbidity of reduced Hb S solution observed in positive tests",
                      "Positive in both sickle cell trait and sickle cell disease"
                    ]
                  },
                  {
                    "text": "Normal blood smear; ﻿sickle cells are not typically present"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Epidemiology": [
                  {
                    "text": "Most common hemoglobinopathy in United States"
                  },
                  {
                    "text": "Present in approximately 9% of African Americans"
                  },
                  {
                    "text": "Present in 25-45% of population in Western Africa"
                  },
                  {
                    "text": "Hemoglobin S thought to be protective againstPlasmodiuminfection"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Heterozygous mutation in hemoglobin beta gene (Hb S)Mutation results in replacement of ﻿glutamic acid by valine in position 6",
                    "sub_points": [
                      "Mutation results in replacement of ﻿glutamic acid by valine in position 6"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Patients are ﻿usually asymptomatic"
                  },
                  {
                    "text": "Rarely, symptoms can include vascular occlusion (infarcts) in hypoxic or acidotic conditions (e.g., chronic heart failure, plane travel, respiratory infections, anesthesia)"
                  },
                  {
                    "text": "Rarely, spontaneous sickling can occur in renal papillae, leading to papillary necrosis, hematuria, and impaired ability to concentrate urine"
                  },
                  {
                    "text": "Association with exercise-related sudden death and ﻿increased risk for renal medullary carcinoma"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)Decreased Hgb A (50-60%) and presence of Hb S (35-45%)If co-inherited with alpha-globin gene deletion(s), Hb S < 35%If co-inherited with β⁺ thalassemia, percentage of Hb S > percentage of Hb AIf co-inherited with β⁰ thalassemia, almost all hemoglobin is Hb S, same phenotype as sickle cell disease (~ Hb SS)Recent red cell transfusion (within 3 months) in patient with sickle cell disease (Hb SS) can look identical to sickle cell trait on HPLC or hemoglobin electrophoresisReview transfusion history and complete blood count prior to interpretation",
                    "sub_points": [
                      "Decreased Hgb A (50-60%) and presence of Hb S (35-45%)",
                      "If co-inherited with alpha-globin gene deletion(s), Hb S < 35%",
                      "If co-inherited with β⁺ thalassemia, percentage of Hb S > percentage of Hb A",
                      "If co-inherited with β⁰ thalassemia, almost all hemoglobin is Hb S, same phenotype as sickle cell disease (~ Hb SS)",
                      "Recent red cell transfusion (within 3 months) in patient with sickle cell disease (Hb SS) can look identical to sickle cell trait on HPLC or hemoglobin electrophoresisReview transfusion history and complete blood count prior to interpretation",
                      "Review transfusion history and complete blood count prior to interpretation"
                    ]
                  },
                  {
                    "text": "Sickle cell testMixes patient blood and sodium metabisulfiteDeoxygenated red blood cells will sickle and be observed under microscopePositive in both sickle cell trait and sickle cell disease",
                    "sub_points": [
                      "Mixes patient blood and sodium metabisulfite",
                      "Deoxygenated red blood cells will sickle and be observed under microscope",
                      "Positive in both sickle cell trait and sickle cell disease"
                    ]
                  },
                  {
                    "text": "Sickledex test (solubility test for Hgb S)Lyses RBCs, then adds reducing agentReduced Hb S is insolubleTurbidity of reduced Hb S solution observed in positive testsPositive in both sickle cell trait and sickle cell disease",
                    "sub_points": [
                      "Lyses RBCs, then adds reducing agent",
                      "Reduced Hb S is insoluble",
                      "Turbidity of reduced Hb S solution observed in positive tests",
                      "Positive in both sickle cell trait and sickle cell disease"
                    ]
                  },
                  {
                    "text": "Complete blood countNormal; mild anemia may be present",
                    "sub_points": [
                      "Normal; mild anemia may be present"
                    ]
                  }
                ],
                "Microscopy": [
                  {
                    "text": "Normal blood smear; ﻿sickle cells are not typically present"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sickle Cell Disease": {
            "name": "Sickle Cell Disease",
            "url": "https://app.pathprimer.com/document/ac425e21-4ea8-4f10-8b5a-5761b3ca7cfb/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Hb SS (a.k.a. sickle cell disease) caused by homozygous mutations in hemoglobin beta geneMutation results in replacement of ﻿glutamic acid by valine in position 6",
                    "sub_points": [
                      "Mutation results in replacement of ﻿glutamic acid by valine in position 6"
                    ]
                  },
                  {
                    "text": "Increased susceptibility to Salmonella and pneumococci"
                  },
                  {
                    "text": "Patients at ﻿increased risk for renal medullary carcinoma"
                  },
                  {
                    "text": "Elevated Hgb F associated with better prognosis"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Hemoglobin Electrophoresis or HPLC﻿No Hb A; 80% or more Hb S",
                    "sub_points": [
                      "﻿No Hb A; 80% or more Hb S"
                    ]
                  },
                  {
                    "text": "Blood smearSickle cells, target cells, increased polychromasiaHowell-Jolly bodies due to hyposplenism",
                    "sub_points": [
                      "Sickle cells, target cells, increased polychromasia",
                      "Howell-Jolly bodies due to hyposplenism"
                    ]
                  },
                  {
                    "text": "Sickledex test (solubility test for Hgb S)Positive in both sickle cell trait and sickle cell disease",
                    "sub_points": [
                      "Positive in both sickle cell trait and sickle cell disease"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Epidemiology": [
                  {
                    "text": "United StatesSickle cell disease is most common hemoglobinopathyIncidence: 0.1-0.2 % of African Americans",
                    "sub_points": [
                      "Sickle cell disease is most common hemoglobinopathy",
                      "Incidence: 0.1-0.2 % of African Americans"
                    ]
                  },
                  {
                    "text": "WorldwideMore than 125,000 people born with sickle cell disease every year",
                    "sub_points": [
                      "More than 125,000 people born with sickle cell disease every year"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Hb SS (a.k.a. sickle cell disease) caused by homozygous mutations in hemoglobin beta geneMutation results in replacement of ﻿glutamic acid by valine in position 6Hb S is produced instead of Hb A",
                    "sub_points": [
                      "Mutation results in replacement of ﻿glutamic acid by valine in position 6",
                      "Hb S is produced instead of Hb A"
                    ]
                  },
                  {
                    "text": "Hb S is unstable, and deoxygenated Hb S aggregates into polymersAggregation of Hb S causes red cells to sickle and lose deformabilitySickle cells are more susceptible to hemolysis and survive only 10-20 days (normal RBCs survive 90-120 days)",
                    "sub_points": [
                      "Aggregation of Hb S causes red cells to sickle and lose deformability",
                      "Sickle cells are more susceptible to hemolysis and survive only 10-20 days (normal RBCs survive 90-120 days)"
                    ]
                  },
                  {
                    "text": "Sickled cells lead to vascular obstruction, ischemia, and infarction of tissue"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Increased susceptibility toSalmonellaand pneumococci"
                  },
                  {
                    "text": "Vasoocclusive crisis"
                  },
                  {
                    "text": "Aplastic crisis"
                  },
                  {
                    "text": "Acute chest syndrome"
                  },
                  {
                    "text": "Hemolytic crisis, causing pigment gallstones"
                  },
                  {
                    "text": "Splenic sequestration (results in ﻿functional asplenia)"
                  },
                  {
                    "text": "Priapism"
                  },
                  {
                    "text": "Impaired urinary concentration"
                  },
                  {
                    "text": "Patients at ﻿increased risk for renal medullary carcinoma"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Elevated Hgb F associated with better prognosis"
                  },
                  {
                    "text": "Low Hgb F levels and high WBC counts associated with worse prognosis"
                  },
                  {
                    "text": "Patients with ﻿concurrent a-thalassemia trait have longer RBC survival and less severe anemiaHowever, also an increase in frequency of osteonecrosis and retinopathy",
                    "sub_points": [
                      "However, also an increase in frequency of osteonecrosis and retinopathy"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Complete blood count (CBC)AnemiaReticulocytosisIndications of hemolysisIncrease in unconjugated bilirubinElevated lactate dehydrogenase (LDH)Decrease in haptoglobin",
                    "sub_points": [
                      "Anemia",
                      "Reticulocytosis",
                      "Indications of hemolysisIncrease in unconjugated bilirubinElevated lactate dehydrogenase (LDH)Decrease in haptoglobin",
                      "Increase in unconjugated bilirubin",
                      "Elevated lactate dehydrogenase (LDH)",
                      "Decrease in haptoglobin"
                    ]
                  },
                  {
                    "text": "Blood smearSickle cells, target cells, increased polychromasiaHowell-Jolly bodies due to hyposplenism",
                    "sub_points": [
                      "Sickle cells, target cells, increased polychromasia",
                      "Howell-Jolly bodies due to hyposplenism"
                    ]
                  },
                  {
                    "text": "Bone marrowErythroid hyperplasiaExpansion of marrow spaceIncreased storage iron",
                    "sub_points": [
                      "Erythroid hyperplasia",
                      "Expansion of marrow space",
                      "Increased storage iron"
                    ]
                  },
                  {
                    "text": "Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)﻿No Hb A﻿80% or more Hb SRemainder of hemoglobin is Hb F and Hb A2Recent red cell transfusion (within 3 months) in patient with Hb SS can look identical to sickle cell trait on HPLC or hemoglobin electrophoresisTransfusion history and CBC should be reviewed prior to interpretation",
                    "sub_points": [
                      "﻿No Hb A",
                      "﻿80% or more Hb S",
                      "Remainder of hemoglobin is Hb F and Hb A2",
                      "Recent red cell transfusion (within 3 months) in patient with Hb SS can look identical to sickle cell trait on HPLC or hemoglobin electrophoresisTransfusion history and CBC should be reviewed prior to interpretation",
                      "Transfusion history and CBC should be reviewed prior to interpretation"
                    ]
                  },
                  {
                    "text": "Sickle cell testTest mixes patient blood and sodium metabisulfiteDeoxygenated red blood cells will sickle and be observed under microscopePositive in both sickle cell trait and sickle cell disease",
                    "sub_points": [
                      "Test mixes patient blood and sodium metabisulfite",
                      "Deoxygenated red blood cells will sickle and be observed under microscope",
                      "Positive in both sickle cell trait and sickle cell disease"
                    ]
                  },
                  {
                    "text": "Sickledex test (solubility test for Hgb S)Lyses RBCs, then adds reducing agentReduced Hb S is insolubleTurbidity of reduced Hb S solution is observed in positive testsPositive in both sickle cell trait and sickle cell disease",
                    "sub_points": [
                      "Lyses RBCs, then adds reducing agent",
                      "Reduced Hb S is insoluble",
                      "Turbidity of reduced Hb S solution is observed in positive tests",
                      "Positive in both sickle cell trait and sickle cell disease"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemoglobin C Trait/Disease": {
            "name": "Hemoglobin C Trait/Disease",
            "url": "https://app.pathprimer.com/document/62e2343b-6a08-46d2-ac4a-1b80e46dd12f/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Mutation in 1 (“trait”) or both (“disease”) copies of β-globin gene results in substitution of glutamic acid → lysine in sixth amino acid"
                  },
                  {
                    "text": "Hb C is less soluble than Hb A and crystallizes within RBC"
                  },
                  {
                    "text": "Hb C crystallizes in oxygenated state as opposed to Hb S, which polymerizes in deoxygenated state"
                  },
                  {
                    "text": "RBC life span is decreased to 30-35 days"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Hb electrophoresis or HPLCHb C trait: 50% Hb A, 45% Hb CHb C disease: 0% Hb A, 95% Hb C",
                    "sub_points": [
                      "Hb C trait: 50% Hb A, 45% Hb C",
                      "Hb C disease: 0% Hb A, 95% Hb C"
                    ]
                  },
                  {
                    "text": "Peripheral smear with target cells and in Hb CC polyhedral or rod-shaped \"cigar-shaped\" crystals (Hb C crystals)"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Normal Hemoglobin": [
                  {
                    "text": "Oxygen carrying capacity of red blood cells (RBCs) relies on hemoglobin (Hb)Composed of 4 major types of globins: alpha (α), beta (β), gamma (γ), delta (δ)",
                    "sub_points": [
                      "Composed of 4 major types of globins: alpha (α), beta (β), gamma (γ), delta (δ)"
                    ]
                  },
                  {
                    "text": "Dominant Hb in adultsHb A (approximately 96%) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                    "sub_points": [
                      "Hb A (approximately 96%) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)"
                    ]
                  },
                  {
                    "text": "Minor forms of Hb in adultsHb A₂ (approximately 3%; α₂δ₂)Hb F (approximately 1%; α₂γ₂)",
                    "sub_points": [
                      "Hb A₂ (approximately 3%; α₂δ₂)",
                      "Hb F (approximately 1%; α₂γ₂)"
                    ]
                  },
                  {
                    "text": "One copy of β-globin gene is located on each chromosome 11"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Mutation in 1 (“trait”) or both (“disease”) copies of β-globin gene results in substitution of glutamic acid → lysine in sixth amino acid"
                  },
                  {
                    "text": "Hb C has protective effect against malaria"
                  },
                  {
                    "text": "Hb C is less soluble than Hb A and crystallizes within RBC"
                  },
                  {
                    "text": "Hb C crystallizes in oxygenated stateHb S polymerizes in deoxygenated state",
                    "sub_points": [
                      "Hb S polymerizes in deoxygenated state"
                    ]
                  },
                  {
                    "text": "RBC life span is decreased to 30-35 days"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Hb C trait2%-3% incidence in African AmericansUp to 50% incidence in West Africa",
                    "sub_points": [
                      "2%-3% incidence in African Americans",
                      "Up to 50% incidence in West Africa"
                    ]
                  },
                  {
                    "text": "Hb C disease0.02% of African Americans",
                    "sub_points": [
                      "0.02% of African Americans"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Hb C traitClinically benign disorderPatients are asymptomatic",
                    "sub_points": [
                      "Clinically benign disorderPatients are asymptomatic",
                      "Patients are asymptomatic"
                    ]
                  },
                  {
                    "text": "Hb C diseaseMild to moderate hemolytic anemiaCan have splenomegaly, gallstones",
                    "sub_points": [
                      "Mild to moderate hemolytic anemia",
                      "Can have splenomegaly, gallstones"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment not usually necessary"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Hb C trait and diseaseNo clinical significance except for genetic counselingPossibility of Hb SC disease and of Hb C/β-thalassemia in offspring",
                    "sub_points": [
                      "No clinical significance except for genetic counselingPossibility of Hb SC disease and of Hb C/β-thalassemia in offspring",
                      "Possibility of Hb SC disease and of Hb C/β-thalassemia in offspring"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Complete blood count (CBC) and peripheral smearHb C traitMild microcytosisIncreased RBC distribution width (RDW)Target cellsHb C diseaseSignificant microcytosisReticulocyte count increasedTarget cells, spherocytes, microcytesNucleated RBCsPeripheral smear with polyhedral or rod-shaped \"cigar-shaped\" crystals (Hb C crystals)",
                    "sub_points": [
                      "Hb C traitMild microcytosisIncreased RBC distribution width (RDW)Target cells",
                      "Mild microcytosis",
                      "Increased RBC distribution width (RDW)",
                      "Target cells",
                      "Hb C diseaseSignificant microcytosisReticulocyte count increasedTarget cells, spherocytes, microcytesNucleated RBCsPeripheral smear with polyhedral or rod-shaped \"cigar-shaped\" crystals (Hb C crystals)",
                      "Significant microcytosis",
                      "Reticulocyte count increased",
                      "Target cells, spherocytes, microcytes",
                      "Nucleated RBCs",
                      "Peripheral smear with polyhedral or rod-shaped \"cigar-shaped\" crystals (Hb C crystals)"
                    ]
                  },
                  {
                    "text": "Bone marrowHb C traitNormalHb C diseaseNormal or erythroid hyperplasia",
                    "sub_points": [
                      "Hb C traitNormal",
                      "Normal",
                      "Hb C diseaseNormal or erythroid hyperplasia",
                      "Normal or erythroid hyperplasia"
                    ]
                  },
                  {
                    "text": "Hb electrophoresis or high-performance liquid chromatography (HPLC)Hb C trait50% Hb A, 45% Hb CHb C disease0% Hb A, 95% Hb CAppears identical to Hb EE on acid electrophoresis because Hb E migrates in same position",
                    "sub_points": [
                      "Hb C trait50% Hb A, 45% Hb C",
                      "50% Hb A, 45% Hb C",
                      "Hb C disease0% Hb A, 95% Hb CAppears identical to Hb EE on acid electrophoresis because Hb E migrates in same position",
                      "0% Hb A, 95% Hb C",
                      "Appears identical to Hb EE on acid electrophoresis because Hb E migrates in same position"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemoglobin SC Disease": {
            "name": "Hemoglobin SC Disease",
            "url": "https://app.pathprimer.com/document/c59e2d37-7e83-4e7c-b207-0f1cbd98f817/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "In African Americans, frequency is similar to Hb SS disease (0.1%-0.2%)"
                  },
                  {
                    "text": "Symptoms generally are milder than in patients with sickle cell disease"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Hb electrophoresis or HPLCHb S and Hb C are similar: approximately 50% each",
                    "sub_points": [
                      "Hb S and Hb C are similar: approximately 50% each"
                    ]
                  },
                  {
                    "text": "Blood smear﻿Sickle cells are not typically identified﻿Numerous target cellsSome RBCs may contain precipitated Hb, but hexagonal or rod-shaped crystals associated with Hb CC are not seen“Boat cells” (plump, angulated cells) are present",
                    "sub_points": [
                      "﻿Sickle cells are not typically identified﻿",
                      "Numerous target cells",
                      "Some RBCs may contain precipitated Hb, but hexagonal or rod-shaped crystals associated with Hb CC are not seen",
                      "“Boat cells” (plump, angulated cells) are present"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Double heterozygous mutations in β-globin genesOne β-globin gene has replacement of ﻿glutamic acid → valine at position 6Results in production of hemoglobin (Hb) SOther β-globin gene has replacement of ﻿glutamic acid → lysine at position 6Results in production of Hb C",
                    "sub_points": [
                      "One β-globin gene has replacement of ﻿glutamic acid → valine at position 6Results in production of hemoglobin (Hb) S",
                      "Results in production of hemoglobin (Hb) S",
                      "Other β-globin gene has replacement of ﻿glutamic acid → lysine at position 6Results in production of Hb C",
                      "Results in production of Hb C"
                    ]
                  },
                  {
                    "text": "Presence of Hb C causes increased potassium and chloride transport out of cellReduced potassium in red blood cells (RBCs) results in cell dehydration and concentration of Hb S that are thought to increase Hb polymerization",
                    "sub_points": [
                      "Reduced potassium in red blood cells (RBCs) results in cell dehydration and concentration of Hb S that are thought to increase Hb polymerization"
                    ]
                  },
                  {
                    "text": "SC cells have decreased life spanApproximately 27 days vs. 90-120 days for normal RBCs",
                    "sub_points": [
                      "Approximately 27 days vs. 90-120 days for normal RBCs"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Frequency similar to Hb SS disease (0.1%-0.2%) in African Americans"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Symptoms generally milder than in patients with sickle cell diseaseIncreased incidence of upper respiratory infectionsStreptococcus pneumoniaeHaemophilus influenzaeSplenic infarcts commonAsplenia occurs ﻿less frequently than in patients with Hb SSPainful vaso-occlusive crises occurLess frequent than in patients with Hb SSOsteonecrosis in 15% of patientsThromboembolic complications, renal papillary necrosis, and proliferative retinopathy more frequent than in patients with Hb SS﻿Increased risk of renal medullary carcinoma",
                    "sub_points": [
                      "Increased incidence of upper respiratory infectionsStreptococcus pneumoniaeHaemophilus influenzae",
                      "Streptococcus pneumoniae",
                      "Haemophilus influenzae",
                      "Splenic infarcts commonAsplenia occurs ﻿less frequently than in patients with Hb SS",
                      "Asplenia occurs ﻿less frequently than in patients with Hb SS",
                      "Painful vaso-occlusive crises occurLess frequent than in patients with Hb SS",
                      "Less frequent than in patients with Hb SS",
                      "Osteonecrosis in 15% of patients",
                      "Thromboembolic complications, renal papillary necrosis, and proliferative retinopathy more frequent than in patients with Hb SS",
                      "﻿Increased risk of renal medullary carcinoma"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Life expectancy slightly shortened"
                  },
                  {
                    "text": "Significantly longer life expectancy than for patients with Hb SS disease"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Complete blood countMild to moderate anemiaIncreased RBC distribution widthMean cell volume normal to decreasedReticulocytes approximately 3%-5%",
                    "sub_points": [
                      "Mild to moderate anemia",
                      "Increased RBC distribution width",
                      "Mean cell volume normal to decreased",
                      "Reticulocytes approximately 3%-5%"
                    ]
                  },
                  {
                    "text": "Blood smearNumerous target cellsSickle cells not typically identified﻿“Boat cells” or \"pita cells\" (plump, angulated cells) presentSome RBCs may contain precipitated HbHexagonal or rod-shaped crystals associated with Hb CC not seen",
                    "sub_points": [
                      "Numerous target cells",
                      "Sickle cells not typically identified﻿",
                      "“Boat cells” or \"pita cells\" (plump, angulated cells) present",
                      "Some RBCs may contain precipitated HbHexagonal or rod-shaped crystals associated with Hb CC not seen",
                      "Hexagonal or rod-shaped crystals associated with Hb CC not seen"
                    ]
                  },
                  {
                    "text": "Hb electrophoresis or high-performance liquid chromatography (HPLC)Hb S and Hb C are similarApproximately 50% each",
                    "sub_points": [
                      "Hb S and Hb C are similarApproximately 50% each",
                      "Approximately 50% each"
                    ]
                  },
                  {
                    "text": "Hb S solubility test (Sickledex)Positive",
                    "sub_points": [
                      "Positive"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hb C/β-Thalassemia": {
            "name": "Hb C/β-Thalassemia",
            "url": "https://app.pathprimer.com/document/570c3fb0-56c6-443d-b134-d1be0f21109c/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Hb C/β-thalassemia results from compound heterozygous mutation in β-globin geneOne beta chain gene has Hb C mutation: Replacement of glutamic acid by lysine at position 6One beta chain gene has β-thalassemia mutation: Primarily point mutations",
                    "sub_points": [
                      "One beta chain gene has Hb C mutation: Replacement of glutamic acid by lysine at position 6",
                      "One beta chain gene has β-thalassemia mutation: Primarily point mutations"
                    ]
                  },
                  {
                    "text": "Hb C/β⁺-thalassemia is predominantly found in Africa and in African-Americans"
                  },
                  {
                    "text": "Hb C/β⁰-thalassemia is predominantly found in people of Mediterranean descent"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Hb electrophoresis or HPLC"
                  },
                  {
                    "text": "Hb C/β⁺-thalassemia: Predominance of Hb C (65%-80%), Hb A (16%-30%), and Hb F (2%-5%)"
                  },
                  {
                    "text": "Hb C/β⁰-thalassemia: Predominance of Hb C with mildly elevated Hb A₂ (3%-8%) and Hb F (3%-10%); Hb A is absent"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Normal Hemoglobin": [
                  {
                    "text": "Oxygen carrying capacity of red blood cells relies on hemoglobin (Hb)Composed of 4 major types of globins: alpha (α), beta (β), gamma (γ), delta (δ)Dominant Hb in adultsHb A (approximately 96%) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)Minor forms of Hb in adultsHb A₂ (approximately 3%; α₂δ₂)Hb F (approximately 1%; α₂γ₂)",
                    "sub_points": [
                      "Composed of 4 major types of globins: alpha (α), beta (β), gamma (γ), delta (δ)",
                      "Dominant Hb in adultsHb A (approximately 96%) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Hb A (approximately 96%) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)",
                      "Minor forms of Hb in adultsHb A₂ (approximately 3%; α₂δ₂)Hb F (approximately 1%; α₂γ₂)",
                      "Hb A₂ (approximately 3%; α₂δ₂)",
                      "Hb F (approximately 1%; α₂γ₂)"
                    ]
                  },
                  {
                    "text": "One copy of β-globin gene is located on each chromosome 11"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Hb C/β-thalassemia results from compound heterozygous mutation in β-globin geneOne beta chain gene has Hb C mutationReplacement of glutamic acid by lysine at position 6One beta chain gene has β-thalassemia mutationPrimarily point mutationsCan result in β⁰ or β⁺",
                    "sub_points": [
                      "One beta chain gene has Hb C mutationReplacement of glutamic acid by lysine at position 6",
                      "Replacement of glutamic acid by lysine at position 6",
                      "One beta chain gene has β-thalassemia mutationPrimarily point mutationsCan result in β⁰ or β⁺",
                      "Primarily point mutations",
                      "Can result in β⁰ or β⁺"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Hb C/β⁺-thalassemiaPredominantly found in Africa and in African AmericansMild hemolytic anemiaLow Hb levels during pregnancy",
                    "sub_points": [
                      "Predominantly found in Africa and in African Americans",
                      "Mild hemolytic anemia",
                      "Low Hb levels during pregnancy"
                    ]
                  },
                  {
                    "text": "Hb C/β⁰-thalassemiaIn people of Mediterranean descentModerate to severe hemolytic anemiaSplenomegaly",
                    "sub_points": [
                      "In people of Mediterranean descent",
                      "Moderate to severe hemolytic anemia",
                      "Splenomegaly"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Hb C/β⁺-thalassemiaMicrocytic anemiaIncreased reticulocyte countPeripheral smear shows increased target cellsCrystals not typically present",
                    "sub_points": [
                      "Microcytic anemia",
                      "Increased reticulocyte count",
                      "Peripheral smear shows increased target cellsCrystals not typically present",
                      "Crystals not typically present"
                    ]
                  },
                  {
                    "text": "Hb C/β⁰-thalassemiaMicrocytic anemiaIncreased reticulocyte countPeripheral smear demonstrates predominance of target cellsGreater degree of anisopoikilocytosis than Hb CC diseaseHb C crystals not typically present but can be seen",
                    "sub_points": [
                      "Microcytic anemia",
                      "Increased reticulocyte count",
                      "Peripheral smear demonstrates predominance of target cellsGreater degree of anisopoikilocytosis than Hb CC disease",
                      "Greater degree of anisopoikilocytosis than Hb CC disease",
                      "Hb C crystals not typically present but can be seen"
                    ]
                  },
                  {
                    "text": "Hb electrophoresis or high-performance liquid chromatography (HPLC)Hb C/β⁺-thalassemiaPredominance of Hb C (65%-80%), Hb A (16%-30%), and Hb F (2%-5%)Hb C/β⁰-thalassemiaPredominance of Hb C with mildly elevated Hb A₂ (3%-8%) and Hb F (3%-10%)Hb A is absent",
                    "sub_points": [
                      "Hb C/β⁺-thalassemiaPredominance of Hb C (65%-80%), Hb A (16%-30%), and Hb F (2%-5%)",
                      "Predominance of Hb C (65%-80%), Hb A (16%-30%), and Hb F (2%-5%)",
                      "Hb C/β⁰-thalassemiaPredominance of Hb C with mildly elevated Hb A₂ (3%-8%) and Hb F (3%-10%)Hb A is absent",
                      "Predominance of Hb C with mildly elevated Hb A₂ (3%-8%) and Hb F (3%-10%)",
                      "Hb A is absent"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemoglobin E": {
            "name": "Hemoglobin E",
            "url": "https://app.pathprimer.com/document/c8308806-3e0b-4621-b529-7bf4f259ec9f/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Hgb E mutation causes replacement of glutamic acid by lysine at position 26 in β-globin gene"
                  },
                  {
                    "text": "Hgb E is 2nd most common Hgb mutation globallyVery frequent in Southeast Asia (Malaysia: Incidence up to 40%, Thailand: Incidence up to 70%)",
                    "sub_points": [
                      "Very frequent in Southeast Asia (Malaysia: Incidence up to 40%, Thailand: Incidence up to 70%)"
                    ]
                  },
                  {
                    "text": "Heterozygotes are asymptomatic, and homozygotes are often asymptomatic, except for mild anemia"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Blood smearHeterozygotes: NormalHomozygotes: Increased target cells",
                    "sub_points": [
                      "Heterozygotes: Normal",
                      "Homozygotes: Increased target cells"
                    ]
                  },
                  {
                    "text": "Hemoglobin electrophoresisHeterozygotes: Hgb A ~ 70%, Hgb E ~ 30%Homozygotes: Hgb E over 90%, remaining hemoglobin is Hgb A₂ and Hgb F; Hgb A is negligible",
                    "sub_points": [
                      "Heterozygotes: Hgb A ~ 70%, Hgb E ~ 30%",
                      "Homozygotes: Hgb E over 90%, remaining hemoglobin is Hgb A₂ and Hgb F; Hgb A is negligible"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Normal Hemoglobin": [
                  {
                    "text": "Oxygen-carrying capacity of red blood cells relies on hemoglobin (Hgb), which is composed of 4 major types of globinsAlpha (α)Beta (β)Gamma (γ)Delta (δ)",
                    "sub_points": [
                      "Alpha (α)",
                      "Beta (β)",
                      "Gamma (γ)",
                      "Delta (δ)"
                    ]
                  },
                  {
                    "text": "Dominant hemoglobin in adults, Hgb A, (~ 96%) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)"
                  },
                  {
                    "text": "Minor forms of Hgb in adults are Hgb A₂ (~ 3%; α₂δ₂), and Hgb F (~ 1%; α₂γ₂)"
                  },
                  {
                    "text": "One copy of β-globin gene is located on each chromosome 11"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Hgb E mutation causes replacement of glutamic acid by lysine at position 26 in β-globin geneMutations can be heterozygous (Hgb E) or homozygous (Hgb EE)",
                    "sub_points": [
                      "Mutations can be heterozygous (Hgb E) or homozygous (Hgb EE)"
                    ]
                  },
                  {
                    "text": "Hgb E mutation also activates cryptic mRNA splice site, which results in reduced synthesis of mutated β-chains"
                  },
                  {
                    "text": "Hgb E has weakened interface between α and β chains, which leads to instability during conditions of increased oxidant stress"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Hgb E is 2nd most common Hgb mutation globallyThird most common in United States",
                    "sub_points": [
                      "Third most common in United States"
                    ]
                  },
                  {
                    "text": "Very frequent in Southeast AsiaMalaysia incidence up to 40%Thailand incidence up to 70%",
                    "sub_points": [
                      "Malaysia incidence up to 40%",
                      "Thailand incidence up to 70%"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Heterozygotes (Hgb E)AsymptomaticMutation is only significant for genetic counseling",
                    "sub_points": [
                      "Asymptomatic",
                      "Mutation is only significant for genetic counseling"
                    ]
                  },
                  {
                    "text": "HomozygotesOften asymptomatic, except for mild anemiaTherefore, expression “Hgb E homozygosity” may be more appropriate than \"Hgb E disease”",
                    "sub_points": [
                      "Often asymptomatic, except for mild anemia",
                      "Therefore, expression “Hgb E homozygosity” may be more appropriate than \"Hgb E disease”"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "CBCMean corpuscular volume (MCV) decreasedBorderline decrease in heterozygotes, more significant decrease in heterozygotesReticulocyte count normalIncreased red blood cell count in homozygotes",
                    "sub_points": [
                      "Mean corpuscular volume (MCV) decreasedBorderline decrease in heterozygotes, more significant decrease in heterozygotes",
                      "Borderline decrease in heterozygotes, more significant decrease in heterozygotes",
                      "Reticulocyte count normal",
                      "Increased red blood cell count in homozygotes"
                    ]
                  },
                  {
                    "text": "Blood smearHeterozygotesNormalHomozygotesNumerous target cells",
                    "sub_points": [
                      "HeterozygotesNormal",
                      "Normal",
                      "HomozygotesNumerous target cells",
                      "Numerous target cells"
                    ]
                  },
                  {
                    "text": "Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)HeterozygotesHgb A ~ 70%Hgb E ~ 30%HomozygotesHgb E over 90%, remaining hemoglobin is Hgb A₂ and Hgb FHgb A is negligibleHgb E and Hgb A₂ co-elute on HPLC and cannot be accurately quantifiedThey can be easily separated and quantified on capillary electrophoresis",
                    "sub_points": [
                      "HeterozygotesHgb A ~ 70%Hgb E ~ 30%",
                      "Hgb A ~ 70%",
                      "Hgb E ~ 30%",
                      "HomozygotesHgb E over 90%, remaining hemoglobin is Hgb A₂ and Hgb FHgb A is negligible",
                      "Hgb E over 90%, remaining hemoglobin is Hgb A₂ and Hgb F",
                      "Hgb A is negligible",
                      "Hgb E and Hgb A₂ co-elute on HPLC and cannot be accurately quantifiedThey can be easily separated and quantified on capillary electrophoresis",
                      "They can be easily separated and quantified on capillary electrophoresis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hb E/β-Thalassemia": {
            "name": "Hb E/β-Thalassemia",
            "url": "https://app.pathprimer.com/document/0c9733d2-a9c5-4ec8-97f8-9cc002346f72/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "In Hgb E/β-thalassemiaOne β gene carries Hgb E mutation: Replacement of glutamic acid by lysine at position 26 on β-globin geneOther β gene carries β-thalassemia mutation (β⁰ or β⁺), resulting in reduced-to-absent production of normal beta chains",
                    "sub_points": [
                      "One β gene carries Hgb E mutation: Replacement of glutamic acid by lysine at position 26 on β-globin gene",
                      "Other β gene carries β-thalassemia mutation (β⁰ or β⁺), resulting in reduced-to-absent production of normal beta chains"
                    ]
                  },
                  {
                    "text": "Combined presence of Hgb E and β-thalassemia mutations leads to thalassemia with highly variable severity"
                  },
                  {
                    "text": "Hgb F level is strongest predictor of morbidity (higher Hgb F is protective)"
                  },
                  {
                    "text": "Hgb E/ β-thalassemia is common in Thailand and other parts of Southeast Asia"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Hgb E comigrates with Hgb C, Hgb O, and Hgb A₂ on alkaline electrophoresis"
                  },
                  {
                    "text": "Hgb E comigrates with Hgb A on citrate (acid) electrophoresis"
                  },
                  {
                    "text": "On HPLC, Hgb E and A₂ co-elute, and Hgb A₂ may not be quantifiable"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Normal Hemoglobin": [
                  {
                    "text": "Oxygen-carrying capacity of red blood cells relies on hemoglobin (Hgb), which is composed of 4 major types of globinsAlpha (α)Beta (β)Gamma (γ)Delta (δ)",
                    "sub_points": [
                      "Alpha (α)",
                      "Beta (β)",
                      "Gamma (γ)",
                      "Delta (δ)"
                    ]
                  },
                  {
                    "text": "Dominant Hgb in adults, Hgb A, (~ 96%) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)"
                  },
                  {
                    "text": "Minor forms of Hgb in adults are Hgb A₂ (~ 3%; α₂δ₂), and Hgb F (~ 1%; α₂γ₂)"
                  },
                  {
                    "text": "One copy of β-globin gene is located on each chromosome 11"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "In Hgb E/β-thalassemiaOne β gene carries Hgb E mutation: Replacement of glutamic acid by lysine at position 26 on β-globin geneHgb E mutation activates cryptic mRNA splice site, resulting in reduced synthesis of mutated β-chainHgb E mutation also weakens interaction between α and β chains, which can lead to instability during increased oxidant stressOther β gene carries β thalassemia mutation (β⁰ or β⁺), resulting in reduced-to-absent production of normal beta chains",
                    "sub_points": [
                      "One β gene carries Hgb E mutation: Replacement of glutamic acid by lysine at position 26 on β-globin geneHgb E mutation activates cryptic mRNA splice site, resulting in reduced synthesis of mutated β-chainHgb E mutation also weakens interaction between α and β chains, which can lead to instability during increased oxidant stress",
                      "Hgb E mutation activates cryptic mRNA splice site, resulting in reduced synthesis of mutated β-chain",
                      "Hgb E mutation also weakens interaction between α and β chains, which can lead to instability during increased oxidant stress",
                      "Other β gene carries β thalassemia mutation (β⁰ or β⁺), resulting in reduced-to-absent production of normal beta chains"
                    ]
                  },
                  {
                    "text": "Combined presence of Hgb E and β-thalassemia mutations leads to thalassemia with highly variable severity"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Hgb E/β-thalassemia is common in Thailand and other parts of Southeast Asia"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Clinical severity of Hgb E/β-thalassemia depends on β-globin chain imbalance (slight reduced production, significantly reduced production, or absent production of β chains)Resultant phenotype can be that of thalassemia minor, intermedia, or majorβ⁰-thalassemia mutations generally result in more severe phenotype than β⁺-thalassemia mutations",
                    "sub_points": [
                      "Resultant phenotype can be that of thalassemia minor, intermedia, or major",
                      "β⁰-thalassemia mutations generally result in more severe phenotype than β⁺-thalassemia mutations"
                    ]
                  },
                  {
                    "text": "Patients with very low β chain production may have hepatosplenomegaly, jaundice, and growth retardation, and are transfusion-dependent"
                  }
                ],
                "Prevention": [
                  {
                    "text": "Genetic counseling"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Hgb F level is strongest predictor of morbidity (higher Hgb F is protective)Patients benefit from treatment to increase Hgb F (hydroxyurea)",
                    "sub_points": [
                      "Patients benefit from treatment to increase Hgb F (hydroxyurea)"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Hemoglobin Electrophoresis or HPLC": [
                  {
                    "text": "Patients with β+-thalassemic traitPresence of Hgb E, Hgb A, Hgb A₂, and Hgb F; Hgb E > AElevated Hgb A₂",
                    "sub_points": [
                      "Presence of Hgb E, Hgb A, Hgb A₂, and Hgb F; Hgb E > A",
                      "Elevated Hgb A₂"
                    ]
                  },
                  {
                    "text": "Patients with β⁰-thalassemic traitPresence of Hgb E, Hgb A₂, and Hgb FNo Hgb AElevated Hgb A₂",
                    "sub_points": [
                      "Presence of Hgb E, Hgb A₂, and Hgb F",
                      "No Hgb A",
                      "Elevated Hgb A₂"
                    ]
                  },
                  {
                    "text": "Patients on hydroxyurea have elevated Hgb F"
                  },
                  {
                    "text": "Hgb E comigrates with Hgb C, Hgb O, and Hgb A₂ on alkaline electrophoresis"
                  },
                  {
                    "text": "Hgb E comigrates with Hgb A on citrate (acid) electrophoresis"
                  },
                  {
                    "text": "On high-performance liquid chromatography (HPLC), Hgb E and Hgb A₂ co-elute, and Hgb A₂ may not be quantifiable"
                  },
                  {
                    "text": "On capillary zone electrophoresis, Hgb E migrates to different location than Hgb A₂ and can be quantified"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hb Constant Spring": {
            "name": "Hb Constant Spring",
            "url": "https://app.pathprimer.com/document/42e66685-2b32-4615-878b-53b43aba4ee9/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Hgb Constant Spring is α-globin variantResults from mutation that eliminates mRNA stop codon in α₂ gene, which results in addition of 31 amino acids to protein chainElongated mRNA is unstable, and only very small amounts (1% of normal) of Constant Spring alpha chains are produced",
                    "sub_points": [
                      "Results from mutation that eliminates mRNA stop codon in α₂ gene, which results in addition of 31 amino acids to protein chain",
                      "Elongated mRNA is unstable, and only very small amounts (1% of normal) of Constant Spring alpha chains are produced"
                    ]
                  },
                  {
                    "text": "Most frequent in Southeast Asia; prevalence 3-4%"
                  },
                  {
                    "text": "αCSα/-- (2 deleted α genes [alpha thalassemia trait; --/αα] and Hgb CS with 1 normal α gene)Equivalent to 3 α-gene deletion (~ Hgb H disease)",
                    "sub_points": [
                      "Equivalent to 3 α-gene deletion (~ Hgb H disease)"
                    ]
                  },
                  {
                    "text": "αCSα/αCSα (2 copies of Hgb Constant Spring α gene, 2 normal α genes)Presence of 2 αCS genes may cause perturbations of red cell membrane, making 2 copies of αCS gene more pathogenetic than 2 deleted α genes",
                    "sub_points": [
                      "Presence of 2 αCS genes may cause perturbations of red cell membrane, making 2 copies of αCS gene more pathogenetic than 2 deleted α genes"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Normal Hemoglobin": [
                  {
                    "text": "Oxygen-carrying capacity of red blood cells relies on hemoglobin (Hgb), which is composed of 4 major types of globin subunitsAlpha (α)Beta (β)Gamma (γ)Delta (δ)",
                    "sub_points": [
                      "Alpha (α)",
                      "Beta (β)",
                      "Gamma (γ)",
                      "Delta (δ)"
                    ]
                  },
                  {
                    "text": "Dominant hemoglobin in adults, Hgb A, (~ 96%) is composed of 2 alpha subunits and 2 beta subunits (α₂β₂)"
                  },
                  {
                    "text": "Minor forms of Hgb in adults are Hgb A₂ (~ 3%; α₂δ₂) and Hgb F (~ 1%; α₂γ₂)"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Hgb Constant Spring is α-globin variantResults from mutation that eliminates mRNA stop codon in α₂ gene, which results in addition of 31 amino acids to protein chainElongated mRNA is unstable, and only very small amounts (1% of normal) of Constant Spring alpha chains are produced",
                    "sub_points": [
                      "Results from mutation that eliminates mRNA stop codon in α₂ gene, which results in addition of 31 amino acids to protein chain",
                      "Elongated mRNA is unstable, and only very small amounts (1% of normal) of Constant Spring alpha chains are produced"
                    ]
                  },
                  {
                    "text": "αCS essentially functions as α chain deletion"
                  },
                  {
                    "text": "Presence of 2 αCS genes may cause perturbations of red cell membrane, making 2 copies of αCS gene more pathogenetic than 2 deleted α genes"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Hgb Constant Spring is most common non-deletional α-thalassemia"
                  },
                  {
                    "text": "Most frequent in Southeast Asia; prevalence 3-4%"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "αCSα/αα (One copy of Hgb Constant Spring α gene, 3 normal α genes)Clinically asymptomatic",
                    "sub_points": [
                      "Clinically asymptomatic"
                    ]
                  },
                  {
                    "text": "αCSα/αCSα (2 copies of Hgb Constant Spring α gene, 2 normal α genes)HemolysisMild anemiaJaundiceSplenomegaly",
                    "sub_points": [
                      "Hemolysis",
                      "Mild anemia",
                      "Jaundice",
                      "Splenomegaly"
                    ]
                  },
                  {
                    "text": "αCSα/-α (1 copy of Hgb Constant Spring α gene, 1 deleted α gene, 2 normal α genes)Variant of Hgb H disease: Severe anemia, normal red cell size",
                    "sub_points": [
                      "Variant of Hgb H disease: Severe anemia, normal red cell size"
                    ]
                  },
                  {
                    "text": "αCSα/-- (2 deleted α genes [alpha thalassemia trait; --/αα] and Hgb CS with 1 normal α gene)Equivalent to 3 α gene deletion (~ Hgb H disease)HemolysisSevere anemiaJaundiceSplenomegalyGallstones",
                    "sub_points": [
                      "Equivalent to 3 α gene deletion (~ Hgb H disease)",
                      "Hemolysis",
                      "Severe anemia",
                      "Jaundice",
                      "Splenomegaly",
                      "Gallstones"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Complete blood count (CBC) and hemoglobin electrophoresisαCSα/αα (1 copy of Hgb Constant Spring α gene, 3 normal α genes)Normal CBCSlight microcytosis possibleElectrophoresis: Normal or with trace Hgb CSαCSα/-α (1 copy of Hgb Constant Spring α gene, 1 deleted α gene, 2 normal α genes)MicrocytosisElectrophoresis: Normal or with trace Hgb CSαCSα/αCSα (2 copies of Hgb Constant Spring α gene, 2 normal α genes)Low Hgb (9-11 g/dL), low RBCNormal mean corpuscular volumeElectrophoresis: Trace Hgb Bart's, Hgb CS, Hgb A₂ normal, Hgb AαCSα/-- (2 deleted α genes [alpha thalassemia trait; --/αα] and Hgb CS with 1 normal α gene)Low Hgb (8-10 g/dL)MicrocytosisElectrophoresis is similar to Hgb H disease with minute (often undetectable) amounts of Hgb CSHgb Bart's, Hgb H, Hgb A₂ decreased, Hgb A, trace Hgb CS",
                    "sub_points": [
                      "αCSα/αα (1 copy of Hgb Constant Spring α gene, 3 normal α genes)Normal CBCSlight microcytosis possibleElectrophoresis: Normal or with trace Hgb CS",
                      "Normal CBC",
                      "Slight microcytosis possible",
                      "Electrophoresis: Normal or with trace Hgb CS",
                      "αCSα/-α (1 copy of Hgb Constant Spring α gene, 1 deleted α gene, 2 normal α genes)MicrocytosisElectrophoresis: Normal or with trace Hgb CS",
                      "Microcytosis",
                      "Electrophoresis: Normal or with trace Hgb CS",
                      "αCSα/αCSα (2 copies of Hgb Constant Spring α gene, 2 normal α genes)Low Hgb (9-11 g/dL), low RBCNormal mean corpuscular volumeElectrophoresis: Trace Hgb Bart's, Hgb CS, Hgb A₂ normal, Hgb A",
                      "Low Hgb (9-11 g/dL), low RBC",
                      "Normal mean corpuscular volume",
                      "Electrophoresis: Trace Hgb Bart's, Hgb CS, Hgb A₂ normal, Hgb A",
                      "αCSα/-- (2 deleted α genes [alpha thalassemia trait; --/αα] and Hgb CS with 1 normal α gene)Low Hgb (8-10 g/dL)MicrocytosisElectrophoresis is similar to Hgb H disease with minute (often undetectable) amounts of Hgb CSHgb Bart's, Hgb H, Hgb A₂ decreased, Hgb A, trace Hgb CS",
                      "Low Hgb (8-10 g/dL)",
                      "Microcytosis",
                      "Electrophoresis is similar to Hgb H disease with minute (often undetectable) amounts of Hgb CSHgb Bart's, Hgb H, Hgb A₂ decreased, Hgb A, trace Hgb CS",
                      "Hgb Bart's, Hgb H, Hgb A₂ decreased, Hgb A, trace Hgb CS"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "α-Thalassemia": {
            "name": "α-Thalassemia",
            "url": "https://app.pathprimer.com/document/eb1e9058-f54d-4e59-be06-075c588569fd/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Dominant Hb in adults, Hb A (approximately 96%), is composed of 2 α subunits and 2 β subunits (α₂β₂)"
                  },
                  {
                    "text": "α-Thalassemia is caused mainly by inherited deletions of ≥ 1 of 4 copies of α-globin gene, resulting in decreased or absent synthesis of α-globin"
                  },
                  {
                    "text": "α⁰ trait with both loci missing on same chromosome (in cis) is frequent in Asian and Mediterranean populations"
                  },
                  {
                    "text": "In African American populations, there is a significant incidence of 2 deletions but usually on different chromosomes (in trans)"
                  },
                  {
                    "text": "Deletion of 3 α genes (₋₋/₋α): Hb H diseaseReduction in α-chain synthesis leads to formation of β-tetramers (Hb H)",
                    "sub_points": [
                      "Reduction in α-chain synthesis leads to formation of β-tetramers (Hb H)"
                    ]
                  },
                  {
                    "text": "Deletion of 4 α genes (₋₋/₋₋): Hb Bart's hydrops fetalisExcess γ-chains from Hb F (fetal) form γ-tetramers",
                    "sub_points": [
                      "Excess γ-chains from Hb F (fetal) form γ-tetramers"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Oxygen carrying capacity of red blood cells relies on hemoglobin (Hb), which is composed of 4 major types of globins: α, β, γ, δ"
                  },
                  {
                    "text": "Dominant Hb in adults, Hb A (approximately 96%), is composed of 2 α subunits and 2 β subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (approximately 3%; α₂δ₂) and Hb F (approximately 1%; α₂γ₂)",
                    "sub_points": [
                      "Minor forms of Hb in adults are Hb A₂ (approximately 3%; α₂δ₂) and Hb F (approximately 1%; α₂γ₂)"
                    ]
                  },
                  {
                    "text": "Two copies of α-globin gene are located on each chromosome 16Results in 4 α-chain gene loci in normal Hb (αα/αα)",
                    "sub_points": [
                      "Results in 4 α-chain gene loci in normal Hb (αα/αα)"
                    ]
                  },
                  {
                    "text": "α-Thalassemia is caused mainly by inherited deletions of ≥ 1 of 4 copies of α-globin geneResults in decreased or absent synthesis of α-globin",
                    "sub_points": [
                      "Results in decreased or absent synthesis of α-globin"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "Deletion of 1 α gene (₋α/αα): Silent carriers or α+ trait"
                  },
                  {
                    "text": "Deletion of 2 α genes: Can be cis (₋₋/αα) or trans (₋α/₋α): α⁰ trait"
                  },
                  {
                    "text": "Deletion of 3 α genes (₋₋/₋α): Hb H diseaseReduction in α-chain synthesis leads to formation of β-tetramers (Hb H)Hb H has high affinity to oxygen and leads to tissue hypoxia",
                    "sub_points": [
                      "Reduction in α-chain synthesis leads to formation of β-tetramers (Hb H)",
                      "Hb H has high affinity to oxygen and leads to tissue hypoxia"
                    ]
                  },
                  {
                    "text": "Deletion of 4 α genes (₋₋/₋₋): Hb Bart's hydrops fetalisExcess γ-chains from Hb F (fetal) form γ-tetramersResults in severe tissue hypoxia",
                    "sub_points": [
                      "Excess γ-chains from Hb F (fetal) form γ-tetramers",
                      "Results in severe tissue hypoxia"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "α⁰ trait with both loci missing on same chromosome (in cis) is frequent in Asian and Mediterranean populationsThese populations are at risk for hydrops fetalis",
                    "sub_points": [
                      "These populations are at risk for hydrops fetalis"
                    ]
                  },
                  {
                    "text": "In African American populations, there is a significant incidence of 2 deletions but usually on different chromosomes (in trans)"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "(₋α/αα): Silent carriers or α⁺ traitClinically asymptomatic",
                    "sub_points": [
                      "Clinically asymptomatic"
                    ]
                  },
                  {
                    "text": "(₋₋/αα) or (₋α/₋α): α⁰ traitClinically asymptomatic",
                    "sub_points": [
                      "Clinically asymptomatic"
                    ]
                  },
                  {
                    "text": "(₋₋/₋α): Hb H diseaseChronic hemolytic anemiaOnly rarely need transfusion",
                    "sub_points": [
                      "Chronic hemolytic anemia",
                      "Only rarely need transfusion"
                    ]
                  },
                  {
                    "text": "(₋₋/₋₋): Hb Bart's hydrops fetalisFetus has severe pallor, generalized edema, massive hepatosplenomegalyDeath in utero results without intrauterine transfusion",
                    "sub_points": [
                      "Fetus has severe pallor, generalized edema, massive hepatosplenomegaly",
                      "Death in utero results without intrauterine transfusion"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Complete blood counts and blood smears(₋α/αα): Silent carriers or α⁺ traitUsually normalMay have slight microcytosis(₋₋/αα) or (₋α/₋α): α⁰ traitAnemiaLow mean corpuscular volume (MCV); microcytosisDiagnosis of exclusionExclude β-thalassemia, iron deficiency, other causes of microcytosis(₋₋/₋α): Hb H diseaseLow MCV and mean corpuscular hemoglobin (MCH)Red blood cells (RBCs) increasedHypochromasia, basophilic stippling, target cellsHb H inclusions seen supravital staining (brilliant cresyl blue, new methylene blue, or bromocresol green)",
                    "sub_points": [
                      "(₋α/αα): Silent carriers or α⁺ traitUsually normalMay have slight microcytosis",
                      "Usually normal",
                      "May have slight microcytosis",
                      "(₋₋/αα) or (₋α/₋α): α⁰ traitAnemiaLow mean corpuscular volume (MCV); microcytosisDiagnosis of exclusionExclude β-thalassemia, iron deficiency, other causes of microcytosis",
                      "Anemia",
                      "Low mean corpuscular volume (MCV); microcytosis",
                      "Diagnosis of exclusionExclude β-thalassemia, iron deficiency, other causes of microcytosis",
                      "Exclude β-thalassemia, iron deficiency, other causes of microcytosis",
                      "(₋₋/₋α): Hb H diseaseLow MCV and mean corpuscular hemoglobin (MCH)Red blood cells (RBCs) increasedHypochromasia, basophilic stippling, target cellsHb H inclusions seen supravital staining (brilliant cresyl blue, new methylene blue, or bromocresol green)",
                      "Low MCV and mean corpuscular hemoglobin (MCH)",
                      "Red blood cells (RBCs) increased",
                      "Hypochromasia, basophilic stippling, target cells",
                      "Hb H inclusions seen supravital staining (brilliant cresyl blue, new methylene blue, or bromocresol green)"
                    ]
                  },
                  {
                    "text": "Electrophoresis or high-performance liquid chromatography (HPLC)(₋α/αα): Silent carriers or α⁺ traitPresence of Hb Bart's in very low concentrations between birth and 6 months; after 6 months, diagnosis requires molecular methods(₋₋/αα) or (₋α/₋α): α⁰ traitNewborns: Hb Bart's present up to 10%After newborn period: Hb F, Hb A₂, and Hb A are normal(₋₋/₋α): Hb H diseaseHb H up to 40%Hb A₂ decreased(₋₋/₋₋): Hb Bart'sHb Bart's is fast migrating (alkaline electrophoresis) and fast eluting (HPLC) hemoglobinComposed of gamma chain tetramers.Is unstable and unable to delver Hemoglobin to the tissues.",
                    "sub_points": [
                      "(₋α/αα): Silent carriers or α⁺ traitPresence of Hb Bart's in very low concentrations between birth and 6 months; after 6 months, diagnosis requires molecular methods",
                      "Presence of Hb Bart's in very low concentrations between birth and 6 months; after 6 months, diagnosis requires molecular methods",
                      "(₋₋/αα) or (₋α/₋α): α⁰ traitNewborns: Hb Bart's present up to 10%After newborn period: Hb F, Hb A₂, and Hb A are normal",
                      "Newborns: Hb Bart's present up to 10%",
                      "After newborn period: Hb F, Hb A₂, and Hb A are normal",
                      "(₋₋/₋α): Hb H diseaseHb H up to 40%Hb A₂ decreased",
                      "Hb H up to 40%",
                      "Hb A₂ decreased",
                      "(₋₋/₋₋): Hb Bart'sHb Bart's is fast migrating (alkaline electrophoresis) and fast eluting (HPLC) hemoglobinComposed of gamma chain tetramers.Is unstable and unable to delver Hemoglobin to the tissues.",
                      "Hb Bart's is fast migrating (alkaline electrophoresis) and fast eluting (HPLC) hemoglobin",
                      "Composed of gamma chain tetramers.",
                      "Is unstable and unable to delver Hemoglobin to the tissues."
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemoglobin H Disease": {
            "name": "Hemoglobin H Disease",
            "url": "https://app.pathprimer.com/document/0cc350cf-53e2-4c45-866a-04968bc4102c/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Clinical findings include splenomegaly, jaundice, and symptoms of anemia"
                  },
                  {
                    "text": "α-Globin genes are located on chromosome 16"
                  },
                  {
                    "text": "Dominant hemoglobin in adults, Hb A (approximately 96%) is composed of 2 α subunits and 2 β subunits (α₂β₂)Hb H disease results in deletion of 3 of the 4 α genes (--/-α)This leads to reduced production of α chains and excess production of β chains because β chains do not have α chains to polymerize and form Hb AExcess β chain production leads to formation of β-tetramers, which cause membrane damage and hemolysis",
                    "sub_points": [
                      "Hb H disease results in deletion of 3 of the 4 α genes (--/-α)",
                      "This leads to reduced production of α chains and excess production of β chains because β chains do not have α chains to polymerize and form Hb A",
                      "Excess β chain production leads to formation of β-tetramers, which cause membrane damage and hemolysis"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "MCV and MCH are low, and RBCs are increased"
                  },
                  {
                    "text": "On electrophoresis and HPLC, Hb A₂ is decreased and Hb H is increased in adults"
                  },
                  {
                    "text": "Hb Barts (tetrameric γ chains) is increased in neonates up to 40% at birth, then decreases to average of 5%"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Genetics": [
                  {
                    "text": "Thalassemia is ﻿quantitative abnormality of normal globin chain synthesis"
                  },
                  {
                    "text": "α-Globin genes are located on chromosome 16"
                  },
                  {
                    "text": "There are 2 genetic loci for α-globin on each chromosome"
                  },
                  {
                    "text": "Diploid cells have 4 α-globin genes (αα/αα)"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Common in South East AsiaAlso seen in Mediterranean and Middle East",
                    "sub_points": [
                      "Also seen in Mediterranean and Middle East"
                    ]
                  },
                  {
                    "text": "Uncommon in blacks, as blacks generally carry α- genes (not -- genes)"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Oxygen-carrying capacity of red blood cells (RBCs) relies on hemoglobin (Hb), which is composed of 4 major types of globins: α, β, γ, δ"
                  },
                  {
                    "text": "Dominant hemoglobin in adults, Hb A (approximately 96%) is composed of 2 α subunits and 2 β subunits (α₂β₂)Fetal Hb (Hb F) is increased in neonates and is composed of 2 α subunits and 2 γ subunits (α₂γ₂)",
                    "sub_points": [
                      "Fetal Hb (Hb F) is increased in neonates and is composed of 2 α subunits and 2 γ subunits (α₂γ₂)"
                    ]
                  },
                  {
                    "text": "Hb H disease results in deletion of 3 of the 4 α genes (--/-α)"
                  },
                  {
                    "text": "This leads to reduced production of α chains and excess production of β chains because β chains do not have α chains to polymerize and form Hb AExcess β chain production leads to the formation of β-tetramersβ-Tetramers cause membrane damage and hemolysis",
                    "sub_points": [
                      "Excess β chain production leads to the formation of β-tetramers",
                      "β-Tetramers cause membrane damage and hemolysis"
                    ]
                  },
                  {
                    "text": "Results in microcytic anemia and increased number of RBCs as bone marrow tries to compensate"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Jaundice"
                  },
                  {
                    "text": "Symptoms of anemia"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Complete blood counts and blood smearsTotal Hb is lower than appropriate for age and sexMean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) are lowRBCs are increased﻿Target cells, basophilic stippling, hypochromasiaIncreased reticulocyte count and percentage",
                    "sub_points": [
                      "Total Hb is lower than appropriate for age and sex",
                      "Mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) are lowRBCs are increased",
                      "RBCs are increased",
                      "﻿Target cells, basophilic stippling, hypochromasia",
                      "Increased reticulocyte count and percentage"
                    ]
                  },
                  {
                    "text": "Hb electrophoresis and high-performance liquid chromatography (HPLC)Hb A₂ decreasedHb H (4 β chains) up to 40% in adultsHb Barts (tetrameric γ chains) increased in neonates up to 40% at birth, then decreases to average of 5%Hb Barts forms from unpaired γ chains due to increased Hb F (α₂γ₂) in neonatal period",
                    "sub_points": [
                      "Hb A₂ decreased",
                      "Hb H (4 β chains) up to 40% in adults",
                      "Hb Barts (tetrameric γ chains) increased in neonates up to 40% at birth, then decreases to average of 5%Hb Barts forms from unpaired γ chains due to increased Hb F (α₂γ₂) in neonatal period",
                      "Hb Barts forms from unpaired γ chains due to increased Hb F (α₂γ₂) in neonatal period"
                    ]
                  },
                  {
                    "text": "Hb H preparation:Can be performed when Hb H disease is suspected or when a band with motility similar to Hb H is seen on electrophoresisVital staining of blood samples from patients with Hgb H disease with brilliant cresyl blue causes induction of inclusion bodies in RBCsInclusions resemble golf balls",
                    "sub_points": [
                      "Can be performed when Hb H disease is suspected or when a band with motility similar to Hb H is seen on electrophoresis",
                      "Vital staining of blood samples from patients with Hgb H disease with brilliant cresyl blue causes induction of inclusion bodies in RBCs",
                      "Inclusions resemble golf balls"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "β-Thalassemia Trait": {
            "name": "β-Thalassemia Trait",
            "url": "https://app.pathprimer.com/document/c251050a-78e9-4459-ad8e-d1fb6b19c482/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Thalassemias are defined as quantitative abnormality in normal globin chain synthesis"
                  },
                  {
                    "text": "β-Thalassemia mutations are primarily point mutations"
                  },
                  {
                    "text": "Classification of mutationsβ⁺ mutations: ﻿Reduced production of β-globinβ⁰ mutations: ﻿No production of β-globin",
                    "sub_points": [
                      "β⁺ mutations: ﻿Reduced production of β-globin",
                      "β⁰ mutations: ﻿No production of β-globin"
                    ]
                  },
                  {
                    "text": "Iron deficiency can decrease Hb A₂ and mask diagnosis of β-thalassemia minor"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Hb A₂ elevated; 4%-8% (normal 2.5%-3%)"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Thalassemias are defined as quantitative abnormality in normal globin chain synthesis"
                  },
                  {
                    "text": "Oxygen carrying capacity of red blood cells (RBCs) relies on hemoglobin (Hb), which is composed of 4 major types of globins: α, β, γ, δDominant hemoglobin in adults, Hb A (approximately 96%), is composed of 2 α subunits and 2 β subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (approximately 3%; α₂δ₂) and Hb F (approximately 1%; α₂γ₂)",
                    "sub_points": [
                      "Dominant hemoglobin in adults, Hb A (approximately 96%), is composed of 2 α subunits and 2 β subunits (α₂β₂)",
                      "Minor forms of Hb in adults are Hb A₂ (approximately 3%; α₂δ₂) and Hb F (approximately 1%; α₂γ₂)"
                    ]
                  },
                  {
                    "text": "One copy of β-globin gene is located on each chromosome 11"
                  },
                  {
                    "text": "β-Thalassemia is caused by inherited mutations in β-globin gene, which results in decreased or absent synthesis of β-globin chains"
                  },
                  {
                    "text": "β-Thalassemia mutations are primarily point mutationsClassification of mutationsβ⁺ mutations: ﻿Reduced production of β-globinβ⁰ mutations: ﻿No production of β-globin",
                    "sub_points": [
                      "Classification of mutationsβ⁺ mutations: ﻿Reduced production of β-globinβ⁰ mutations: ﻿No production of β-globin",
                      "β⁺ mutations: ﻿Reduced production of β-globin",
                      "β⁰ mutations: ﻿No production of β-globin"
                    ]
                  },
                  {
                    "text": "Reduced β-globin chains result inReduced Hb ALow Hb content of RBCs and microcytosisSurplus of α-chainsFree α-chains precipitatePrecipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysis",
                    "sub_points": [
                      "Reduced Hb ALow Hb content of RBCs and microcytosis",
                      "Low Hb content of RBCs and microcytosis",
                      "Surplus of α-chainsFree α-chains precipitatePrecipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysis",
                      "Free α-chains precipitate",
                      "Precipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysis"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Most common in Mediterranean countries, parts of Africa, Southeast Asia"
                  }
                ],
                "Clinical Classification of β-Thalassemia Trait": [
                  {
                    "text": "β-Thalassemia minorUsually asymptomatic but can have mild hematologic abnormalitiesHeterozygous β-thalassemia mutations with either β⁺ or β⁰ and 1 normal β-globin gene (β⁰/β, β⁺/β)Mild erythroid hyperplasia in bone marrowImportant to recognize for genetic counseling",
                    "sub_points": [
                      "Usually asymptomatic but can have mild hematologic abnormalities",
                      "Heterozygous β-thalassemia mutations with either β⁺ or β⁰ and 1 normal β-globin gene (β⁰/β, β⁺/β)",
                      "Mild erythroid hyperplasia in bone marrow",
                      "Important to recognize for genetic counseling"
                    ]
                  },
                  {
                    "text": "β-Thalassemia intermediaVariable genotypeCan be heterozygous or homozygous (β⁰/β⁺, β⁺/β⁺, β⁰/β, β⁺/β)Clinical symptoms determine classification as β-thalassemia intermedia in heterozygotes (vs. β-thalassemia minor)Significant anemia but usually no need for regular blood transfusionsOverall, β-Thalassemia intermedia is worse than β-Thalassemia minor.",
                    "sub_points": [
                      "Variable genotypeCan be heterozygous or homozygous (β⁰/β⁺, β⁺/β⁺, β⁰/β, β⁺/β)",
                      "Can be heterozygous or homozygous (β⁰/β⁺, β⁺/β⁺, β⁰/β, β⁺/β)",
                      "Clinical symptoms determine classification as β-thalassemia intermedia in heterozygotes (vs. β-thalassemia minor)",
                      "Significant anemia but usually no need for regular blood transfusions",
                      "Overall, β-Thalassemia intermedia is worse than β-Thalassemia minor."
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Other causes of elevated Hb A₂Antiretroviral therapyVitamin B12 and folate deficiencyHyperthyroidism",
                    "sub_points": [
                      "Antiretroviral therapy",
                      "Vitamin B12 and folate deficiency",
                      "Hyperthyroidism"
                    ]
                  },
                  {
                    "text": "Iron deficiency can decrease Hb A₂ and mask diagnosis of β-thalassemia minor"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Complete blood count (CBC)Elevated RBC countAnemia (if present) is mild in β-thalassemia minorDecreased mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH)",
                    "sub_points": [
                      "Elevated RBC count",
                      "Anemia (if present) is mild in β-thalassemia minor",
                      "Decreased mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH)"
                    ]
                  },
                  {
                    "text": "Blood smearMicrocytosisHypochromasiaTarget cellsBasophilic stippling",
                    "sub_points": [
                      "Microcytosis",
                      "Hypochromasia",
                      "Target cells",
                      "Basophilic stippling"
                    ]
                  },
                  {
                    "text": "Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)Hb A₂ elevated4%-8% (normal 2.5%-3%)",
                    "sub_points": [
                      "Hb A₂ elevated4%-8% (normal 2.5%-3%)",
                      "4%-8% (normal 2.5%-3%)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "β-Thalassemia Major": {
            "name": "β-Thalassemia Major",
            "url": "https://app.pathprimer.com/document/fb4f4a97-6c10-4105-ae18-8022a433dffe/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Dominant hemoglobin in adults, Hb A (approximately 96%), is composed of 2 α subunits and 2 β subunits (α₂β₂)"
                  },
                  {
                    "text": "β-Thalassemia is caused by inherited mutations in β-globin gene, which results in decreased or absent synthesis of β-globin chainsReduced β-globin chains result in reduced Hb A tetramers and accumulation of free α-chainsFree α-chains precipitate; precipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysis",
                    "sub_points": [
                      "Reduced β-globin chains result in reduced Hb A tetramers and accumulation of free α-chainsFree α-chains precipitate; precipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysis",
                      "Free α-chains precipitate; precipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysis"
                    ]
                  },
                  {
                    "text": "﻿Transfusion dependent"
                  },
                  {
                    "text": "Severe anemia and tissue hypoxia result in erythropoietin increase and marrow expansion"
                  },
                  {
                    "text": "Marrow expansion results in bony deformities including prominent frontal bones, cheekbones, and jaws"
                  },
                  {
                    "text": "Untreated disease leads to growth retardation and early death from complications of anemiaTreatment with transfusions and iron chelation extends survival",
                    "sub_points": [
                      "Treatment with transfusions and iron chelation extends survival"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Hemoglobin electrophoresis or HPLCβ⁺-Thalassemia: Some Hb A and Hb F markedly elevatedβ⁰-Thalassemia: No Hb A and Hb F markedly elevated",
                    "sub_points": [
                      "β⁺-Thalassemia: Some Hb A and Hb F markedly elevated",
                      "β⁰-Thalassemia: No Hb A and Hb F markedly elevated"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Thalassemias are defined as quantitative abnormality in normal globin chain synthesis"
                  },
                  {
                    "text": "Oxygen carrying capacity of red blood cells (RBCs) relies on hemoglobin (Hb), which is composed of 4 major types of globins: α, β, γ, δ"
                  },
                  {
                    "text": "Dominant hemoglobin in adults, Hb A (approximately 96%), is composed of 2 α subunits and 2 β subunits (α₂β₂)Minor forms of Hb in adults are Hb A₂ (approximately 3%; α₂δ₂) and Hb F (approximately 1%; α₂γ₂)",
                    "sub_points": [
                      "Minor forms of Hb in adults are Hb A₂ (approximately 3%; α₂δ₂) and Hb F (approximately 1%; α₂γ₂)"
                    ]
                  },
                  {
                    "text": "One copy of β-globin gene is located on each chromosome 11"
                  },
                  {
                    "text": "β-Thalassemia is caused by inherited mutations in β-globin gene, which results in decreased or absent synthesis of β-globin chainsMutations are primarily point mutationsReduced β-globin chains result inReduced Hb A tetramersLow hemoglobin in RBCs and microcytosisAccumulation of free α-chainsFree α-chains precipitatePrecipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysisIneffective erythropoiesis and shortened RBC life span",
                    "sub_points": [
                      "Mutations are primarily point mutations",
                      "Reduced β-globin chains result inReduced Hb A tetramersLow hemoglobin in RBCs and microcytosisAccumulation of free α-chainsFree α-chains precipitatePrecipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysisIneffective erythropoiesis and shortened RBC life span",
                      "Reduced Hb A tetramersLow hemoglobin in RBCs and microcytosis",
                      "Low hemoglobin in RBCs and microcytosis",
                      "Accumulation of free α-chainsFree α-chains precipitatePrecipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysis",
                      "Free α-chains precipitate",
                      "Precipitates cause RBC membrane damage, leading to apoptosis of RBCs and hemolysis",
                      "Ineffective erythropoiesis and shortened RBC life span"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "Thalassemia majorTransfusion dependentUsually homozygous for β-thalassemia mutations ( β⁺/β⁺, β⁰/β⁰, β⁰/β⁺)",
                    "sub_points": [
                      "Transfusion dependent",
                      "Usually homozygous for β-thalassemia mutations ( β⁺/β⁺, β⁰/β⁰, β⁰/β⁺)"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Most frequent in areas and populations with present or historic high incidence of malariaPresence of thalassemia provides a survival advantage against malaria",
                    "sub_points": [
                      "Presence of thalassemia provides a survival advantage against malaria"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Patients present in 1st year of life"
                  },
                  {
                    "text": "Severe anemia and tissue hypoxia result in erythropoietin increase and marrow expansion"
                  },
                  {
                    "text": "Marrow expansion results in bony deformitiesProminent frontal bonesProminent cheekbonesProminent jaws",
                    "sub_points": [
                      "Prominent frontal bones",
                      "Prominent cheekbones",
                      "Prominent jaws"
                    ]
                  },
                  {
                    "text": "Hepatosplenomegaly (secondary to extramedullary hematopoiesis)"
                  },
                  {
                    "text": "Jaundice and gallstones (bilirubin stones)"
                  },
                  {
                    "text": "Asplenia"
                  }
                ],
                "Prenatal Diagnosis": [
                  {
                    "text": "Can be made by amniocentesis and chorionic villus sampling"
                  },
                  {
                    "text": "Analysis usually by polymerase chain reaction (PCR)"
                  },
                  {
                    "text": "Prenatal diagnosis programs can significantly reduce incidence of β-thalassemia major"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Transfusion therapyGoal is to maintain Hb > 9-10.5 g/dLUsually requires RBC transfusion every 2-5 weeksFrequent transfusions frequently lead to iron overload and severe cardiac disease",
                    "sub_points": [
                      "Goal is to maintain Hb > 9-10.5 g/dL",
                      "Usually requires RBC transfusion every 2-5 weeks",
                      "Frequent transfusions frequently lead to iron overload and severe cardiac disease"
                    ]
                  },
                  {
                    "text": "Chelation therapy is used to reduce iron overload"
                  },
                  {
                    "text": "Hematopoietic stem cell transplantationBone marrow transplantOnly curative treatmentRequires human leukocyte antigen (HLA)-matched donorRisks include graft-vs.-host diseaseAlternative to bone marrow transplant is cord blood stem cell transplantationThis modality has lower success rate",
                    "sub_points": [
                      "Bone marrow transplantOnly curative treatmentRequires human leukocyte antigen (HLA)-matched donorRisks include graft-vs.-host disease",
                      "Only curative treatment",
                      "Requires human leukocyte antigen (HLA)-matched donor",
                      "Risks include graft-vs.-host disease",
                      "Alternative to bone marrow transplant is cord blood stem cell transplantationThis modality has lower success rate",
                      "This modality has lower success rate"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Untreated disease leads to growth retardation and early death from complications of anemia"
                  },
                  {
                    "text": "Treatment with transfusions and iron chelation extends survival"
                  },
                  {
                    "text": "Patients with β-thalassemia major live an average of 17 years"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Complete blood count (CBC)Hypochromic, severe microcytic anemia (Hb 3-6 g/dL)",
                    "sub_points": [
                      "Hypochromic, severe microcytic anemia (Hb 3-6 g/dL)"
                    ]
                  },
                  {
                    "text": "Blood smearSevere poikilocytosisTarget cellsHypochromasiaBasophilic stipplingPappenheimer bodies",
                    "sub_points": [
                      "Severe poikilocytosis",
                      "Target cells",
                      "Hypochromasia",
                      "Basophilic stippling",
                      "Pappenheimer bodies"
                    ]
                  },
                  {
                    "text": "Bone marrowErythroid hyperplasiaIncreased iron stores",
                    "sub_points": [
                      "Erythroid hyperplasia",
                      "Increased iron stores"
                    ]
                  },
                  {
                    "text": "Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC)β⁺-ThalassemiaSome Hb AHb F markedly elevatedβ⁰-ThalassemiaNo Hb AHb F markedly elevated",
                    "sub_points": [
                      "β⁺-ThalassemiaSome Hb AHb F markedly elevated",
                      "Some Hb A",
                      "Hb F markedly elevated",
                      "β⁰-ThalassemiaNo Hb AHb F markedly elevated",
                      "No Hb A",
                      "Hb F markedly elevated"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "δβ-Thalassemia/Hereditary Persistence of Fetal Hemoglobin": {
            "name": "δβ-Thalassemia/Hereditary Persistence of Fetal Hemoglobin",
            "url": "https://app.pathprimer.com/document/8518e631-991a-4111-a312-2361764703f6/lesson/fe006d90-e32f-4360-89b0-7730c12cc6c5",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "δβ-Thalassemia and HPFH are part of a continuum"
                  },
                  {
                    "text": "δβ-Thalassemia is due to long deletion involving β and δ genes"
                  },
                  {
                    "text": "HPFH is defined by persistence of HbF beyond childhood"
                  },
                  {
                    "text": "HbF is variably increased in δβ-thalassemia and HPFH"
                  },
                  {
                    "text": "Increased HbF is protective in patients with HbS-HPFH"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Definition": [
                  {
                    "text": "Thalassemias are defined as quantitative abnormality in normal globin chain synthesis"
                  },
                  {
                    "text": "δβ-Thalassemia and hereditary persistence of fetal hemoglobin (HPFH) are part of a continuum"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Dominant hemoglobin (Hb) in adults, HbA (approximately 96%), is composed of 2 α subunits and 2 β subunits (α₂β₂)Minor forms of Hb in adults are HbA₂ (approximately 3%; α₂δ₂) and HbF (approximately 1%; α₂γ₂)",
                    "sub_points": [
                      "Minor forms of Hb in adults are HbA₂ (approximately 3%; α₂δ₂) and HbF (approximately 1%; α₂γ₂)"
                    ]
                  },
                  {
                    "text": "δβ-Thalassemia is due to long deletion involving β and δ genesPersistence of γ chain production after childhoodCan be heterozygous or homozygous",
                    "sub_points": [
                      "Persistence of γ chain production after childhood",
                      "Can be heterozygous or homozygous"
                    ]
                  },
                  {
                    "text": "HPFH is a group of rare disorders in which HbF persists into adulthoodNo significant hematologic abnormalities",
                    "sub_points": [
                      "No significant hematologic abnormalities"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Most frequent in patients of Mediterranean descent (Greece, Italy)"
                  },
                  {
                    "text": "Increased HbF protective in patients with HbS-HPFH"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Heterozygotes for δβ-thalassemiaSimilar to β-thalassemia traitMild anemia",
                    "sub_points": [
                      "Similar to β-thalassemia trait",
                      "Mild anemia"
                    ]
                  },
                  {
                    "text": "Homozygotes for δβ-thalassemiaSimilar to β-thalassemia intermedia",
                    "sub_points": [
                      "Similar to β-thalassemia intermedia"
                    ]
                  },
                  {
                    "text": "HPFHAsymptomaticHbF produced into adulthoodPercentage of HbF variable2 typesPancellular HPFHUniform distribution of HbF in cellsHeterocellular HPFHUneven distribution of HbF in cells",
                    "sub_points": [
                      "Asymptomatic",
                      "HbF produced into adulthoodPercentage of HbF variable",
                      "Percentage of HbF variable",
                      "2 typesPancellular HPFHUniform distribution of HbF in cellsHeterocellular HPFHUneven distribution of HbF in cells",
                      "Pancellular HPFHUniform distribution of HbF in cells",
                      "Uniform distribution of HbF in cells",
                      "Heterocellular HPFHUneven distribution of HbF in cells",
                      "Uneven distribution of HbF in cells"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Hemoglobin Electrophoresis and High-Performance Liquid Chromatography": [
                  {
                    "text": "Heterozygotes for δβ thalassemiaHbF elevations up to 20%HbA₂ is normal to low",
                    "sub_points": [
                      "HbF elevations up to 20%",
                      "HbA₂ is normal to low"
                    ]
                  },
                  {
                    "text": "Homozygotes or δβ-thalassemia100% of Hb is HbF",
                    "sub_points": [
                      "100% of Hb is HbF"
                    ]
                  },
                  {
                    "text": "HPFHElevation in HbFDecrease in HbA₂",
                    "sub_points": [
                      "Elevation in HbF",
                      "Decrease in HbA₂"
                    ]
                  }
                ],
                "Complete Blood Count": [
                  {
                    "text": "Heterozygosity for δβ-thalassemiaMild anemia (if present)Mean cell volume (MCV), mean cell hemoglobin (MCH) reduced",
                    "sub_points": [
                      "Mild anemia (if present)",
                      "Mean cell volume (MCV), mean cell hemoglobin (MCH) reduced"
                    ]
                  },
                  {
                    "text": "Homozygosity for δβ-thalassemiaModerate anemia (Hb 10-13 g/dL)Red blood cells (RBCs) increasedMCV, MCH reduced",
                    "sub_points": [
                      "Moderate anemia (Hb 10-13 g/dL)",
                      "Red blood cells (RBCs) increased",
                      "MCV, MCH reduced"
                    ]
                  },
                  {
                    "text": "HPFHNormal complete blood count (CBC)May have slight microcytosis and mild anemia in homozygotes",
                    "sub_points": [
                      "Normal complete blood count (CBC)May have slight microcytosis and mild anemia in homozygotes",
                      "May have slight microcytosis and mild anemia in homozygotes"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Normal Hemostasis": {
        "name": "Normal Hemostasis",
        "url": "https://app.pathprimer.com/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
        "topics": {
          "Endothelial Regulation of Hemostasis": {
            "name": "Endothelial Regulation of Hemostasis",
            "url": "https://app.pathprimer.com/document/89edd57d-9662-4595-a67d-b9b8f33b68db/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Endothelium has several functions"
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "Normal, undamaged endothelium is a nonthrombogenic surface that inhibits platelet aggregation, prevents activation and propagation of coagulation, and enhances fibrinolysis"
                  },
                  {
                    "text": "The endothelium has antiplatelet, anticoagulant, and procoagulant functions"
                  }
                ]
              },
              "OVERVIEW": {
                "Physiology": [
                  {
                    "text": "Endothelium has multiple functionsControl of vasomotor toneBarrier functionHemostatic balanceLeukocyte traffickingAngiogenesisCell survival/apoptosisAntigen presentationInnate immunity",
                    "sub_points": [
                      "Control of vasomotor tone",
                      "Barrier function",
                      "Hemostatic balance",
                      "Leukocyte trafficking",
                      "Angiogenesis",
                      "Cell survival/apoptosis",
                      "Antigen presentation",
                      "Innate immunity"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Prostaglandin I₂ (PGI₂; prostacyclin)"
                  },
                  {
                    "text": "Nitric oxide (NO)"
                  },
                  {
                    "text": "Ecto-adenosine phosphatase (ADPase)"
                  },
                  {
                    "text": "Nucleoside triphosphate diphosphohydrolase (NTPDase-1)"
                  },
                  {
                    "text": "Tissue factor (TF)"
                  },
                  {
                    "text": "Tissue factor pathway inhibitor (TFPI)"
                  },
                  {
                    "text": "Tissue plasminogen activator (tPA)"
                  },
                  {
                    "text": "Plasminogen activator inhibitor 1 (PAI-1)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Endothelium in Hemostasis": [
                  {
                    "text": "Normal, undamaged endothelium is nonthrombogenic surfaceInhibits platelet aggregationPrevents activation and propagation of coagulationEnhances fibrinolysis",
                    "sub_points": [
                      "Inhibits platelet aggregation",
                      "Prevents activation and propagation of coagulation",
                      "Enhances fibrinolysis"
                    ]
                  },
                  {
                    "text": "Antiplatelet endothelial functionsSecretion of prostacyclin (PGI₂)Inhibits platelet activation, secretion, aggregationSecretion of NOInhibits platelet adhesion, activation, aggregationSurface expression of ADPase/CD39/NTPDase-1Inactivates ADP leading to decreased platelet recruitment and return to platelet resting state",
                    "sub_points": [
                      "Secretion of prostacyclin (PGI₂)Inhibits platelet activation, secretion, aggregation",
                      "Inhibits platelet activation, secretion, aggregation",
                      "Secretion of NOInhibits platelet adhesion, activation, aggregation",
                      "Inhibits platelet adhesion, activation, aggregation",
                      "Surface expression of ADPase/CD39/NTPDase-1Inactivates ADP leading to decreased platelet recruitment and return to platelet resting state",
                      "Inactivates ADP leading to decreased platelet recruitment and return to platelet resting state"
                    ]
                  },
                  {
                    "text": "Anticoagulant endothelial functionsBlood flow that removes activated clotting factors and maintains protective flow at endotheliumMaintenance of vascular integrity to separate blood elements (i.e., platelets and coagulation factors) from TF and collagen-rich subendotheliumProduction of endogenous heparin that enhances function of antithrombin III to inactivate activated clotting cascade factors (i.e., IIa, Xa, XIa, IXa, XIIa)Thrombomodulin-endothelial protein C receptor expressed on endothelial cells modulates function of activated factor II (thrombin) enhancing activation of protein C, which along with protein S inactivates activated factors V (Va) and VIII (VIIIa)TFPI produced by endothelial cells inhibits extrinsic pathway by forming ternary complex with TF, factors VIIa/Xa, and plasmintPA produced by endothelial cells activates plasminogen to plasmin (degrades fibrinogen)",
                    "sub_points": [
                      "Blood flow that removes activated clotting factors and maintains protective flow at endothelium",
                      "Maintenance of vascular integrity to separate blood elements (i.e., platelets and coagulation factors) from TF and collagen-rich subendothelium",
                      "Production of endogenous heparin that enhances function of antithrombin III to inactivate activated clotting cascade factors (i.e., IIa, Xa, XIa, IXa, XIIa)",
                      "Thrombomodulin-endothelial protein C receptor expressed on endothelial cells modulates function of activated factor II (thrombin) enhancing activation of protein C, which along with protein S inactivates activated factors V (Va) and VIII (VIIIa)",
                      "TFPI produced by endothelial cells inhibits extrinsic pathway by forming ternary complex with TF, factors VIIa/Xa, and plasmin",
                      "tPA produced by endothelial cells activates plasminogen to plasmin (degrades fibrinogen)"
                    ]
                  },
                  {
                    "text": "Procoagulant endothelial functionsEndothelial cells produce several procoagulant substancesPAI-1vWFProtease activated receptorsTF",
                    "sub_points": [
                      "Endothelial cells produce several procoagulant substancesPAI-1vWFProtease activated receptorsTF",
                      "PAI-1",
                      "vWF",
                      "Protease activated receptors",
                      "TF"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Platelet Adhesion": {
            "name": "Platelet Adhesion",
            "url": "https://app.pathprimer.com/document/fa07a4cd-36ae-4548-883c-330984b99d2f/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Platelet receptors bind to adhesive proteinsGPIa-IIa, GPVI bind to collagenGPIIb-IIIa, vitronectin receptor bind to fibrinogenGPIc-IIa, GP IIb-IIIa bind to fibronectinGPIb-V-IX, GPIIb-IIIa bind to vWF",
                    "sub_points": [
                      "GPIa-IIa, GPVI bind to collagen",
                      "GPIIb-IIIa, vitronectin receptor bind to fibrinogen",
                      "GPIc-IIa, GP IIb-IIIa bind to fibronectin",
                      "GPIb-V-IX, GPIIb-IIIa bind to vWF"
                    ]
                  },
                  {
                    "text": "Following endothelial damage, collagen and microfibrils are exposed"
                  },
                  {
                    "text": "vWF mediates rapid, reversible platelet adhesion (via matrix constituents and platelet GPIb-V-IX receptors) that leads to platelet rolling along damaged vascular surfaceFunction of vWF is most important under high shear conditions",
                    "sub_points": [
                      "Function of vWF is most important under high shear conditions"
                    ]
                  },
                  {
                    "text": "Binding of vWF to GPIb-V-IX receptor complex induces intracellular signaling events that eventually lead to activation of GPIIb-IIIa and platelet aggregation"
                  }
                ]
              },
              "OVERVIEW": {
                "Physiology": [
                  {
                    "text": "In the resting state, platelets normally circulate in blood as single cells that do not interact with each other or with other cell types"
                  },
                  {
                    "text": "After exposure to stimulatory agonists, whether in laboratory testing or following blood vessel damage, platelets transition from being nonadhesive to adhesive"
                  },
                  {
                    "text": "Damage to endothelial lining of blood vessels exposes constituents of subendothelial matrix that promote platelet attachment"
                  },
                  {
                    "text": "After initial attachment, platelets spread enabling formation of multiple tight contacts between platelet cell surface and subendothelial matrix"
                  },
                  {
                    "text": "Binding of platelet receptors to ligands within subendothelial matrix leads to platelet signaling and activation"
                  },
                  {
                    "text": "Attached platelets encounter agonists in microenvironment that lead to secretion of platelet granules"
                  },
                  {
                    "text": "Substances from released granules (i.e., ADP) can stimulate and activate circulating platelets causing them to become adhesive"
                  },
                  {
                    "text": "Stimulated platelets interact with each other during platelet aggregation to form a platelet plug to seal damaged blood vessel wall"
                  },
                  {
                    "text": "Summary of platelet responses after vessel injuryAdhesion/attachmentSpreadingActivationSecretionAggregation",
                    "sub_points": [
                      "Adhesion/attachment",
                      "Spreading",
                      "Activation",
                      "Secretion",
                      "Aggregation"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Subendothelial Interactions": [
                  {
                    "text": "Subendothelial matrix factors that support platelet adhesionvWFSupports platelet attachment and spreadingCollagen (types I, III, VI)Supports platelet attachment, spreading, and secretory responseFibronectinSupports platelet attachment and spreadingThrombospondin-1LamininsMicrofibrils",
                    "sub_points": [
                      "vWFSupports platelet attachment and spreading",
                      "Supports platelet attachment and spreading",
                      "Collagen (types I, III, VI)Supports platelet attachment, spreading, and secretory response",
                      "Supports platelet attachment, spreading, and secretory response",
                      "FibronectinSupports platelet attachment and spreading",
                      "Supports platelet attachment and spreading",
                      "Thrombospondin-1",
                      "Laminins",
                      "Microfibrils"
                    ]
                  },
                  {
                    "text": "Platelet receptors bind to adhesive proteinsGPIa-IIa, GPVI bind to collagenGPIIb-IIIa, vitronectin receptor bind to fibrinogenGPIc-IIa, GP IIb-IIIa bind to fibronectinVitronectin receptor, GP IV bind to thrombospondin-1Vitronectin receptor, GPIIb-IIIa bind to vitronectinGPIb-V-IX, GPIIb-IIIa bind to vWFGPIc-IIa bind to laminin",
                    "sub_points": [
                      "GPIa-IIa, GPVI bind to collagen",
                      "GPIIb-IIIa, vitronectin receptor bind to fibrinogen",
                      "GPIc-IIa, GP IIb-IIIa bind to fibronectin",
                      "Vitronectin receptor, GP IV bind to thrombospondin-1",
                      "Vitronectin receptor, GPIIb-IIIa bind to vitronectin",
                      "GPIb-V-IX, GPIIb-IIIa bind to vWF",
                      "GPIc-IIa bind to laminin"
                    ]
                  }
                ],
                "Platelet Adhesion": [
                  {
                    "text": "Following endothelial damage, collagen and microfibrils are exposedExposed collagen and microfibrils bind to vWFvWF also binds to the GPIb-V-IX receptor on plateletsvWF mediates rapid, reversible platelet adhesion (via matrix constituents and platelet GPIb-V-IX receptors) that leads to platelet rolling along damaged vascular surfaceFunction of vWF is most important under high shear conditionsRolling transiently bridges platelets to subendothelial matrix until more stable adhesive integrin-mediated bonds can be formedBinding of vWF to GPIb-V-IX receptor complex induces intracellular signaling events that eventually lead to activation of GPIIb-IIIa and platelet aggregation",
                    "sub_points": [
                      "Exposed collagen and microfibrils bind to vWF",
                      "vWF also binds to the GPIb-V-IX receptor on platelets",
                      "vWF mediates rapid, reversible platelet adhesion (via matrix constituents and platelet GPIb-V-IX receptors) that leads to platelet rolling along damaged vascular surfaceFunction of vWF is most important under high shear conditions",
                      "Function of vWF is most important under high shear conditions",
                      "Rolling transiently bridges platelets to subendothelial matrix until more stable adhesive integrin-mediated bonds can be formed",
                      "Binding of vWF to GPIb-V-IX receptor complex induces intracellular signaling events that eventually lead to activation of GPIIb-IIIa and platelet aggregation"
                    ]
                  },
                  {
                    "text": "Exposed collagen binds directly to platelet receptors to stabilize platelet-subendothelial matrix attachmentGPVI serves as collagen receptor under low shear conditionsCollagen binding to GPVI induces intracellular platelet signaling leading to activation of GPIa-IIa receptorGPIa-IIa binds collagen with high affinity to from stable interaction between platelet and subendothelial matrix",
                    "sub_points": [
                      "GPVI serves as collagen receptor under low shear conditionsCollagen binding to GPVI induces intracellular platelet signaling leading to activation of GPIa-IIa receptor",
                      "Collagen binding to GPVI induces intracellular platelet signaling leading to activation of GPIa-IIa receptor",
                      "GPIa-IIa binds collagen with high affinity to from stable interaction between platelet and subendothelial matrix"
                    ]
                  },
                  {
                    "text": "Additional interaction between other subendothelial matrix factors and their receptors further strengthen and stabilize platelet adhesion"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Platelet Activation, Release Reaction": {
            "name": "Platelet Activation, Release Reaction",
            "url": "https://app.pathprimer.com/document/5ee5dfc5-8cf1-4a54-b166-7d9ff4e07c4a/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Reorganization of cytoskeleton allows platelet change in shape from discoid to irregular morphology with multiple filipodial projections"
                  },
                  {
                    "text": "As platelets adhere at site of blood vessel damage and become activated, they release substances that act as platelet agonists, adhesive proteins, coagulation factors, growth modulators"
                  },
                  {
                    "text": "Within platelets, substances are packaged into storage granules that are released on activation"
                  },
                  {
                    "text": "Platelets have 3 types of granulesDense granules contain platelet agonists and signaling molecules that amplify platelet activation (~ 3-8 dense granules per platelet)Alpha granules contain proteins that enhance adhesion, growth factors, and coagulation factors (~ 80 alpha granules per platelet)Lysosomal granules contain glycosidases and proteases",
                    "sub_points": [
                      "Dense granules contain platelet agonists and signaling molecules that amplify platelet activation (~ 3-8 dense granules per platelet)",
                      "Alpha granules contain proteins that enhance adhesion, growth factors, and coagulation factors (~ 80 alpha granules per platelet)",
                      "Lysosomal granules contain glycosidases and proteases"
                    ]
                  },
                  {
                    "text": "Factors located in platelet cytoplasm are factor XIII and PD-ECGF"
                  },
                  {
                    "text": "Platelet activation amplified through generation and passive release of TXA₂"
                  }
                ]
              },
              "OVERVIEW": {
                "Physiology": [
                  {
                    "text": "In resting state, platelets normally circulate in blood as single cells that do not interact with each other or with other cell types"
                  },
                  {
                    "text": "After exposure to stimulatory agonists, whether in laboratory testing or following blood vessel damage, platelets transition from being nonadhesive to adhesive"
                  },
                  {
                    "text": "Damage to endothelial lining of blood vessels exposes constituents of subendothelial matrix that promote platelet attachment"
                  },
                  {
                    "text": "After initial attachment, platelets spread, enabling formation of multiple tight contacts between platelet cell surface and subendothelial matrix"
                  },
                  {
                    "text": "Binding of platelet receptors to ligands within subendothelial matrix leads to platelet signaling and activation"
                  },
                  {
                    "text": "Attached platelets encounter agonists in microenvironment that lead to secretion of platelet granules"
                  },
                  {
                    "text": "Substances from released granules (i.e., ADP) can stimulate and activate circulating platelets, causing them to become adhesive"
                  },
                  {
                    "text": "Stimulated platelets interact with each other during platelet aggregation to form platelet plug to seal damaged blood vessel wall"
                  },
                  {
                    "text": "Summary of platelet responses after vessel injuryAdhesion/attachmentSpreadingActivationSecretionAggregation",
                    "sub_points": [
                      "Adhesion/attachment",
                      "Spreading",
                      "Activation",
                      "Secretion",
                      "Aggregation"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Adenosine triphosphate (ATP)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Platelet-derived growth factor (PDGF)"
                  },
                  {
                    "text": "Connective tissue activating peptide (CTAP)"
                  },
                  {
                    "text": "Transforming growth factor-β (TGF-β)"
                  },
                  {
                    "text": "Platelet factor 4 (PF4)"
                  },
                  {
                    "text": "High-molecular-weight kininogen (HMWK)"
                  },
                  {
                    "text": "Plasminogen activator inhibitor-1 (PAI-1)"
                  },
                  {
                    "text": "Platelet-derived endothelial cell growth factor (PD-ECGF)"
                  },
                  {
                    "text": "Thromboxane A₂ (TXA₂)"
                  },
                  {
                    "text": "Cyclooxygenase-1 (COX-1)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Platelet Cytoskeleton": [
                  {
                    "text": "Platelet cytoskeleton is arranged into 3 major structuresCytoplasmic actin networkRim of membrane-associated cytoskeletonMarginal band composed of microtubule coil",
                    "sub_points": [
                      "Cytoplasmic actin network",
                      "Rim of membrane-associated cytoskeleton",
                      "Marginal band composed of microtubule coil"
                    ]
                  },
                  {
                    "text": "Reorganization of cytoskeleton allows platelet change in shape from discoid to irregular morphology with multiple filipodial projections"
                  },
                  {
                    "text": "Shape change occurs when platelets adhere and spread on collagen fibrils or become activated in circulation"
                  },
                  {
                    "text": "In resting platelets, actin cytoskeleton has to be disassembled before platelet secretion (release of granules)"
                  }
                ],
                "Platelet Granules": [
                  {
                    "text": "As platelets adhere at site of blood vessel damage and become activated, they release substances that act as platelet agonists, adhesive proteins, coagulation factors, growth modulators"
                  },
                  {
                    "text": "Within platelets, substances are packaged into storage granules that are released on activation"
                  },
                  {
                    "text": "Platelets have 3 types of granulesDense granules contain platelet agonists and signaling molecules that amplify platelet activation (~ 3-8 dense granules per platelet)AgonistsADPATPSerotoninCalciumAlpha granules contain proteins that enhance adhesion, growth factors, and coagulation factors (~ 80 alpha granules per platelet)Adhesive proteinsFibrinogenFibronectinvWFThrombospondinVitronectinGrowth modulatorsPDGFCTAP IIITGF-βPF4ThrombospondinCoagulation factorsFactor VHMWKC1 inhibitorFibrinogenFactor XIProtein SPAI-1Membranes of platelet alpha granules contain P-selectinLysosomal granules contain glycosidases and proteases",
                    "sub_points": [
                      "Dense granules contain platelet agonists and signaling molecules that amplify platelet activation (~ 3-8 dense granules per platelet)AgonistsADPATPSerotoninCalcium",
                      "AgonistsADPATP",
                      "ADP",
                      "ATP",
                      "Serotonin",
                      "Calcium",
                      "Alpha granules contain proteins that enhance adhesion, growth factors, and coagulation factors (~ 80 alpha granules per platelet)Adhesive proteinsFibrinogenFibronectinvWFThrombospondinVitronectinGrowth modulatorsPDGFCTAP IIITGF-βPF4ThrombospondinCoagulation factorsFactor VHMWKC1 inhibitorFibrinogenFactor XIProtein SPAI-1Membranes of platelet alpha granules contain P-selectin",
                      "Adhesive proteinsFibrinogenFibronectinvWFThrombospondinVitronectin",
                      "Fibrinogen",
                      "Fibronectin",
                      "vWF",
                      "Thrombospondin",
                      "Vitronectin",
                      "Growth modulatorsPDGFCTAP IIITGF-βPF4Thrombospondin",
                      "PDGF",
                      "CTAP III",
                      "TGF-β",
                      "PF4",
                      "Thrombospondin",
                      "Coagulation factorsFactor VHMWKC1 inhibitorFibrinogenFactor XIProtein SPAI-1",
                      "Factor V",
                      "HMWK",
                      "C1 inhibitor",
                      "Fibrinogen",
                      "Factor XI",
                      "Protein S",
                      "PAI-1",
                      "Membranes of platelet alpha granules contain P-selectin",
                      "Lysosomal granules contain glycosidases and proteases"
                    ]
                  },
                  {
                    "text": "Factors located in platelet cytoplasmFactor XIIIPD-ECGF",
                    "sub_points": [
                      "Factor XIII",
                      "PD-ECGF"
                    ]
                  }
                ],
                "Secretion of Platelet Granules": [
                  {
                    "text": "Mechanism of secretion of platelet granules is similar to secretion in mast cells and neurons"
                  },
                  {
                    "text": "Secretion involves exocytosis in which actin cytoskeleton is disassembled, allowing granules to move outward toward cell surface, followed by fusion of granule membranes with plasma membrane to release granule contents"
                  },
                  {
                    "text": "Secretion triggered directly by strong agonists such as thrombin and high doses of collagen"
                  },
                  {
                    "text": "Secretion is indirectly triggered (requires generation of TXA₂) by weak agonists such as ADP, epinephrine, and lower doses of collagen"
                  }
                ],
                "Generation and Release of Thromboxane A₂": [
                  {
                    "text": "Platelet activation amplified through generation and passive release of TXA₂Arachidonic acid released from membrane phospholipids by action of phospholipase A₂ (stimulated by increase in cytosolic Ca²⁺) during platelet activationCOX-1 metabolizes arachidonic acid to prostaglandin intermediates (PGG₂/PGH₂) that are made into TXA₂ by thromboxane synthaseTXA₂ diffuses across platelet plasma membrane and activates other platelets through signaling pathways",
                    "sub_points": [
                      "Arachidonic acid released from membrane phospholipids by action of phospholipase A₂ (stimulated by increase in cytosolic Ca²⁺) during platelet activation",
                      "COX-1 metabolizes arachidonic acid to prostaglandin intermediates (PGG₂/PGH₂) that are made into TXA₂ by thromboxane synthase",
                      "TXA₂ diffuses across platelet plasma membrane and activates other platelets through signaling pathways"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Platelet Activation Receptors": {
            "name": "Platelet Activation Receptors",
            "url": "https://app.pathprimer.com/document/ab22d88a-8c2a-4ab7-a903-d7a3109cb210/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Responses of platelets to agonists leading to shape change, granule secretion, aggregation, and TXA₂ generation are part of platelet activation"
                  },
                  {
                    "text": "Binding and activation of thrombin, TXA₂, and ADP receptors leads to production and release of intracellular messenger moleculesIntracellular messenger molecules induce or modulate platelet responses of Ca²⁺ mobilization, protein phosphorylation, aggregation, secretion, and TXA₂ generation",
                    "sub_points": [
                      "Intracellular messenger molecules induce or modulate platelet responses of Ca²⁺ mobilization, protein phosphorylation, aggregation, secretion, and TXA₂ generation"
                    ]
                  },
                  {
                    "text": "Platelet activation results in increase in cytoplasmic Ca²⁺ that mediates other eventsMediators released are able to interact with receptors on other platelets to amplify activation and aggregation",
                    "sub_points": [
                      "Mediators released are able to interact with receptors on other platelets to amplify activation and aggregation"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Physiology": [
                  {
                    "text": "In the resting state, platelets normally circulate in blood as single cells that do not interact with each other or with other cell types"
                  },
                  {
                    "text": "After exposure to stimulatory agonists, whether in laboratory testing or after blood vessel damage, platelets transition from being nonadhesive to adhesive"
                  },
                  {
                    "text": "Damage to endothelial lining of blood vessels exposes constituents of subendothelial matrix that promote platelet attachment"
                  },
                  {
                    "text": "After initial attachment, platelets spread, enabling formation of multiple tight contacts between platelet surfaces and subendothelial matrix"
                  },
                  {
                    "text": "Binding of platelet receptors to ligands within subendothelial matrix leads to platelet signaling and activation"
                  },
                  {
                    "text": "Attached platelets encounter agonists in microenvironment that lead to secretion of platelet granules"
                  },
                  {
                    "text": "Substances from released granules (i.e., ADP) can stimulate and activate circulating platelets causing them to become adhesive"
                  },
                  {
                    "text": "Stimulated platelets interact with each other during platelet aggregation to form platelet plug to seal damaged blood vessel wall"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Thromboxane A₂ (TXA₂)"
                  },
                  {
                    "text": "Cyclic adenosine monophosphate (cAMP)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "Protease activated receptor (PAR)"
                  },
                  {
                    "text": "Protein kinase C (PKC)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Inositol 1,4,5-triphosphate (IP₃)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Platelet Activation": [
                  {
                    "text": "Responses of platelets to agonists leading to shape change, granule secretion, aggregation, and TXA₂ generation are part of platelet activation"
                  },
                  {
                    "text": "These processes are mediated by agonists signaling through various receptors"
                  },
                  {
                    "text": "Several platelet agonists induce signaling eventsADPADP receptorsP2Y1 receptor mediates increase in cytoplasmic Ca²⁺P2X1 receptor has attributes of ion channel and may mediate increase in cytoplasmic Ca²⁺P2Y12 receptor mediates inhibition of adenylyl cyclase activity to reduce cAMP levels to promote platelet activation and granule releaseCollagenSignaling collagen receptorGPVI is member of immunoglobulin receptor superfamily, and activation of this receptor leads to activation of GPIa-IIaThrombinThrombin interacts with PARsPAR1 and PAR4Activation of these receptors results in activation of phospholipase C pathways and inhibition of adenylyl cyclaseTXA₂Binds to TXA₂ receptor",
                    "sub_points": [
                      "ADPADP receptorsP2Y1 receptor mediates increase in cytoplasmic Ca²⁺P2X1 receptor has attributes of ion channel and may mediate increase in cytoplasmic Ca²⁺P2Y12 receptor mediates inhibition of adenylyl cyclase activity to reduce cAMP levels to promote platelet activation and granule release",
                      "ADP receptorsP2Y1 receptor mediates increase in cytoplasmic Ca²⁺P2X1 receptor has attributes of ion channel and may mediate increase in cytoplasmic Ca²⁺P2Y12 receptor mediates inhibition of adenylyl cyclase activity to reduce cAMP levels to promote platelet activation and granule release",
                      "P2Y1 receptor mediates increase in cytoplasmic Ca²⁺",
                      "P2X1 receptor has attributes of ion channel and may mediate increase in cytoplasmic Ca²⁺",
                      "P2Y12 receptor mediates inhibition of adenylyl cyclase activity to reduce cAMP levels to promote platelet activation and granule release",
                      "CollagenSignaling collagen receptorGPVI is member of immunoglobulin receptor superfamily, and activation of this receptor leads to activation of GPIa-IIa",
                      "Signaling collagen receptorGPVI is member of immunoglobulin receptor superfamily, and activation of this receptor leads to activation of GPIa-IIa",
                      "GPVI is member of immunoglobulin receptor superfamily, and activation of this receptor leads to activation of GPIa-IIa",
                      "ThrombinThrombin interacts with PARsPAR1 and PAR4Activation of these receptors results in activation of phospholipase C pathways and inhibition of adenylyl cyclase",
                      "Thrombin interacts with PARsPAR1 and PAR4Activation of these receptors results in activation of phospholipase C pathways and inhibition of adenylyl cyclase",
                      "PAR1 and PAR4",
                      "Activation of these receptors results in activation of phospholipase C pathways and inhibition of adenylyl cyclase",
                      "TXA₂Binds to TXA₂ receptor",
                      "Binds to TXA₂ receptor"
                    ]
                  },
                  {
                    "text": "Binding and activation of thrombin, TXA₂, and ADP receptors leads to production and release of intracellular messenger moleculesProducts of hydrolysis of phosphoinositides by phospholipase CDiacylglycerol activates PKC family of enzymes that phosphorylates several proteins including pleckstrinPKC activation promotes activation of GPIIb-IIIa receptors (“inside-out signaling”)Activation of GPIIb-IIIa receptors allows them to bind fibrinogen and vWF to promote aggregationBinding of fibrinogen and vWF to GPIIb-IIIa causes activation of tyrosine kinases and additional signaling events known as “outside-in signaling”IP₃Promotes release of Ca²⁺ from intracellular stores",
                    "sub_points": [
                      "Products of hydrolysis of phosphoinositides by phospholipase CDiacylglycerol activates PKC family of enzymes that phosphorylates several proteins including pleckstrinPKC activation promotes activation of GPIIb-IIIa receptors (“inside-out signaling”)Activation of GPIIb-IIIa receptors allows them to bind fibrinogen and vWF to promote aggregationBinding of fibrinogen and vWF to GPIIb-IIIa causes activation of tyrosine kinases and additional signaling events known as “outside-in signaling”IP₃Promotes release of Ca²⁺ from intracellular stores",
                      "Diacylglycerol activates PKC family of enzymes that phosphorylates several proteins including pleckstrinPKC activation promotes activation of GPIIb-IIIa receptors (“inside-out signaling”)Activation of GPIIb-IIIa receptors allows them to bind fibrinogen and vWF to promote aggregationBinding of fibrinogen and vWF to GPIIb-IIIa causes activation of tyrosine kinases and additional signaling events known as “outside-in signaling”",
                      "PKC activation promotes activation of GPIIb-IIIa receptors (“inside-out signaling”)",
                      "Activation of GPIIb-IIIa receptors allows them to bind fibrinogen and vWF to promote aggregation",
                      "Binding of fibrinogen and vWF to GPIIb-IIIa causes activation of tyrosine kinases and additional signaling events known as “outside-in signaling”",
                      "IP₃Promotes release of Ca²⁺ from intracellular stores",
                      "Promotes release of Ca²⁺ from intracellular stores"
                    ]
                  },
                  {
                    "text": "Intracellular messenger molecules induce or modulate platelet responsesCa²⁺ mobilizationProtein phosphorylationAggregationSecretionTXA₂ generation",
                    "sub_points": [
                      "Ca²⁺ mobilization",
                      "Protein phosphorylation",
                      "Aggregation",
                      "Secretion",
                      "TXA₂ generation"
                    ]
                  },
                  {
                    "text": "G proteins mediate interaction between platelet surface receptors and intracellular enzymesPhospholipase A₂ (release of arachidonic acid from membrane phospholipids)Adenylyl cyclase (cAMP production)",
                    "sub_points": [
                      "Phospholipase A₂ (release of arachidonic acid from membrane phospholipids)",
                      "Adenylyl cyclase (cAMP production)"
                    ]
                  },
                  {
                    "text": "Platelet activation results in increase in cytoplasmic Ca²⁺ that mediates other eventsActivation of phospholipase A₂ leading to TXA₂ productionPhosphorylation of myosin light chains by myosin light chain kinase to promote shape change and secretionMediators released are able to interact with receptors on other platelets to amplify activation and aggregation",
                    "sub_points": [
                      "Activation of phospholipase A₂ leading to TXA₂ production",
                      "Phosphorylation of myosin light chains by myosin light chain kinase to promote shape change and secretion",
                      "Mediators released are able to interact with receptors on other platelets to amplify activation and aggregation"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Platelet Aggregation": {
            "name": "Platelet Aggregation",
            "url": "https://app.pathprimer.com/document/d71c8490-7688-4978-a5f3-6b6914a4a4e4/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "GPIIb-IIIa receptor on platelets binds to fibrinogen and vWF to mediate platelet-platelet interactions"
                  },
                  {
                    "text": "GPIIb-IIIa must become activated and undergo conformational change before it is able to bind to fibrinogen and vWF"
                  },
                  {
                    "text": "Platelet adhesion and agonist-induced signaling lead to activation of GPIIb-IIIa allowing the receptors to bind fibrinogen and vWF to promote platelet-platelet interactions"
                  }
                ]
              },
              "OVERVIEW": {
                "Physiology": [
                  {
                    "text": "In the resting state, platelets normally circulate in blood as single cells that do not interact with each other or with other cell types"
                  },
                  {
                    "text": "After exposure to stimulatory agonists, whether in laboratory testing or following blood vessel damage, platelets transition from being nonadhesive to adhesive"
                  },
                  {
                    "text": "Damage to endothelial lining of blood vessels exposes constituents of subendothelial matrix that promote platelet attachment"
                  },
                  {
                    "text": "After initial attachment, platelets spread enabling formation of multiple tight contacts between platelet cell surface and subendothelial matrix"
                  },
                  {
                    "text": "Binding of platelet receptors to ligands within subendothelial matrix leads to platelet signaling and activation"
                  },
                  {
                    "text": "Attached platelets encounter agonists in microenvironment that lead to secretion of platelet granules"
                  },
                  {
                    "text": "Substances from released granules (i.e., ADP) can stimulate and activate circulating platelets causing them to become adhesive"
                  },
                  {
                    "text": "Stimulated platelets interact with each other during platelet aggregation to form a platelet plug to seal damaged blood vessel wall"
                  },
                  {
                    "text": "Summary of platelet responses following vessel injuryAdhesion/attachmentSpreadingActivationSecretionAggregation",
                    "sub_points": [
                      "Adhesion/attachment",
                      "Spreading",
                      "Activation",
                      "Secretion",
                      "Aggregation"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Ligands and Receptors in Platelet Aggregation": [
                  {
                    "text": "Platelet aggregation occurs through platelets binding to each other"
                  },
                  {
                    "text": "Platelet aggregation is energy-dependent process"
                  },
                  {
                    "text": "GPIIb-IIIa receptor on platelets binds to fibrinogen and vWF to mediate platelet-platelet interactionsResting platelet has 40,000-80,000 copies of GPIIb-IIIa on its surfacePlatelet activation can cause 10% increase in surface GPIIb-IIIa by mobilization of internal receptor poolsGPIIb-IIIa must become activated and undergo conformational change before it is able to bind to fibrinogen and vWFSignaling process responsible for activation of GPIIb-IIIa is referred to as “inside-out” signalingSignaling that is initiated by binding of GPIb-V-IX complex to vWF leads to activation of GPIIb-IIIaSeveral agonists are able to cause activation of GPIIb-IIIaADPThrombinCollagenEpinephrineArachidonic acid and its metabolites (i.e., thromboxane A₂)SerotoninPlatelet-activating factor",
                    "sub_points": [
                      "Resting platelet has 40,000-80,000 copies of GPIIb-IIIa on its surface",
                      "Platelet activation can cause 10% increase in surface GPIIb-IIIa by mobilization of internal receptor pools",
                      "GPIIb-IIIa must become activated and undergo conformational change before it is able to bind to fibrinogen and vWF",
                      "Signaling process responsible for activation of GPIIb-IIIa is referred to as “inside-out” signalingSignaling that is initiated by binding of GPIb-V-IX complex to vWF leads to activation of GPIIb-IIIaSeveral agonists are able to cause activation of GPIIb-IIIaADPThrombinCollagenEpinephrineArachidonic acid and its metabolites (i.e., thromboxane A₂)SerotoninPlatelet-activating factor",
                      "Signaling that is initiated by binding of GPIb-V-IX complex to vWF leads to activation of GPIIb-IIIa",
                      "Several agonists are able to cause activation of GPIIb-IIIaADPThrombinCollagenEpinephrineArachidonic acid and its metabolites (i.e., thromboxane A₂)SerotoninPlatelet-activating factor",
                      "ADP",
                      "Thrombin",
                      "Collagen",
                      "Epinephrine",
                      "Arachidonic acid and its metabolites (i.e., thromboxane A₂)",
                      "Serotonin",
                      "Platelet-activating factor"
                    ]
                  }
                ],
                "Platelet Aggregation": [
                  {
                    "text": "Platelet adhesion and agonist-induced signaling lead to activation of GPIIb-IIIa allowing receptors to bind fibrinogen and vWF to promote platelet-platelet interactions"
                  },
                  {
                    "text": "Following occupancy of GPIIb-IIIa receptors by ligand, a series of intracellular signaling events is initiated and propagatedTyrosine and serine/threonine kinase activationPhosphatase activation (“outside-in signaling”)",
                    "sub_points": [
                      "Tyrosine and serine/threonine kinase activation",
                      "Phosphatase activation (“outside-in signaling”)"
                    ]
                  },
                  {
                    "text": "Effects of “outside-in signaling” on platelet aggregation are not clearly understood"
                  },
                  {
                    "text": "As platelets aggregate and are brought into close proximity to one another, platelet activation and granule secretion leads to additional activation of plateletsFurther propagates aggregation",
                    "sub_points": [
                      "Further propagates aggregation"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Coagulation Cascade (Intrinsic)": {
            "name": "Coagulation Cascade (Intrinsic)",
            "url": "https://app.pathprimer.com/document/7f27922f-349c-488d-a1c8-0cced4862e3e/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Intrinsic (contact) pathway requires coagulation factors XII, XI, IX, X"
                  },
                  {
                    "text": "Intrinsic pathway leads to formation of tenase complex (FIXa:FVIIIa:FX:PL:Ca²⁺﻿), where key event is factor X being cleaved to factor Xa"
                  },
                  {
                    "text": "Formation of prothrombinase complex: Factor Xa combines with factor Va, factor II (prothrombin), and Ca²⁺ on PL surface (platelet membrane phosphatidylserine in vivo)"
                  },
                  {
                    "text": "Assembled in this complex, factor II (prothrombin) is cleaved to factor IIa (thrombin)"
                  },
                  {
                    "text": "Factor XIIIa is required to convert fibrin polymers to cross-linked fibrin polymers"
                  }
                ]
              },
              "OVERVIEW": {
                "Experiment to Consider": [
                  {
                    "text": "Fill glass container as atraumatically as possible from vein"
                  },
                  {
                    "text": "Blood eventually clots"
                  },
                  {
                    "text": "If glass rod is used to stir blood in container, clot formation is much faster"
                  },
                  {
                    "text": "Conclusion: There must be factor intrinsic to blood that becomes activated when it contacts surface, in this case, glass"
                  },
                  {
                    "text": "Called \"cascade\" because activation leads to activation of additional factors downstream, with positive feedback to amplify pathway"
                  }
                ],
                "Coagulation Factors and Cofactors": [
                  {
                    "text": "Intrinsic (contact) pathway requires coagulation factors XII, XI, IX, X"
                  },
                  {
                    "text": "These coagulation factors are zymogens that do not have activity until cleaved by activated coagulation factor specific for that zymogen"
                  },
                  {
                    "text": "Factor X is also part of extrinsic pathway"
                  },
                  {
                    "text": "Proteins HMWK and PK are also required"
                  }
                ],
                "Contact Pathway (Intrinsic Pathway)": [
                  {
                    "text": "Contact requires negatively charged surface and contact activation componentsFactor XIIFactor XIPKHMWK",
                    "sub_points": [
                      "Factor XII",
                      "Factor XI",
                      "PK",
                      "HMWK"
                    ]
                  },
                  {
                    "text": "Initiation of intrinsic pathway begins with factor XII coming into contact with negatively charged surface﻿In vivo, contact can occur on lipoproteins, bacterial cell walls, homocysteine",
                    "sub_points": [
                      "In vivo, contact can occur on lipoproteins, bacterial cell walls, homocysteine"
                    ]
                  },
                  {
                    "text": "Factor XII is activated to factor XIIaFactor XIIa “autoactivates” by conversion of additional factor XII to factor XIIaFactor XIIa cleaves PK to kallikreinFactor XIIa cleaves factor XI to factor XIa",
                    "sub_points": [
                      "Factor XIIa “autoactivates” by conversion of additional factor XII to factor XIIa",
                      "Factor XIIa cleaves PK to kallikrein",
                      "Factor XIIa cleaves factor XI to factor XIa"
                    ]
                  },
                  {
                    "text": "Kallikrein cleaves HMWK and cleaves factor XII to factor XIIa, amplifying cascade"
                  },
                  {
                    "text": "Factor XIa cleaves factor IX to factor IXa in presence of Ca²⁺"
                  }
                ],
                "Common Pathway": [
                  {
                    "text": "Intrinsic pathway leads to formation of tenase complexKey event is factor X being cleaved to factor Xa",
                    "sub_points": [
                      "Key event is factor X being cleaved to factor Xa"
                    ]
                  },
                  {
                    "text": "Formation of tenase complex from products of intrinsic pathwayFactor IXa combines with factor VIIIa, factor X, and Ca²⁺ on PL surface (platelet membrane phosphatidylserine in vivo)Factor VIIIa acts as cofactor in this complexSmall amounts of circulating thrombin cleave factor VIII to factor VIIIaTenase complex consists of FIXa:FVIIIa:FX:PL:Ca²⁺﻿Once assembled in this complex, factor IXa cleaves factor X to factor Xa",
                    "sub_points": [
                      "Factor IXa combines with factor VIIIa, factor X, and Ca²⁺ on PL surface (platelet membrane phosphatidylserine in vivo)",
                      "Factor VIIIa acts as cofactor in this complexSmall amounts of circulating thrombin cleave factor VIII to factor VIIIa",
                      "Small amounts of circulating thrombin cleave factor VIII to factor VIIIa",
                      "Tenase complex consists of FIXa:FVIIIa:FX:PL:Ca²⁺﻿",
                      "Once assembled in this complex, factor IXa cleaves factor X to factor Xa"
                    ]
                  },
                  {
                    "text": "Formation of prothrombinase complexFactor Xa combines with factor Va, factor II (prothrombin), and Ca²⁺ on PL surface (platelet membrane phosphatidylserine in vivo)Factor Va acts as cofactor in this complexSmall amounts of circulating thrombin cleave factor V to factor VaProthrombinase complex consists of FXa:FVa:FII:PL:Ca²⁺﻿Once assembled in this complex, factor II (prothrombin) is cleaved to factor IIa (thrombin)Formation of thrombin is required to cleave fibrinogen (factor I) to fibrinFactor XIIIa is required to convert fibrin polymers to cross-linked fibrin polymers",
                    "sub_points": [
                      "Factor Xa combines with factor Va, factor II (prothrombin), and Ca²⁺ on PL surface (platelet membrane phosphatidylserine in vivo)",
                      "Factor Va acts as cofactor in this complexSmall amounts of circulating thrombin cleave factor V to factor Va",
                      "Small amounts of circulating thrombin cleave factor V to factor Va",
                      "Prothrombinase complex consists of FXa:FVa:FII:PL:Ca²⁺﻿",
                      "Once assembled in this complex, factor II (prothrombin) is cleaved to factor IIa (thrombin)",
                      "Formation of thrombin is required to cleave fibrinogen (factor I) to fibrin",
                      "Factor XIIIa is required to convert fibrin polymers to cross-linked fibrin polymers"
                    ]
                  }
                ],
                "Problems With This Model": [
                  {
                    "text": "Intrinsic pathway is good model to know when explaining hemostasis testing"
                  },
                  {
                    "text": "It does not explain how intrinsic factors affect hemostasis in vivo"
                  },
                  {
                    "text": "Factor XII, prekallikrein, and HMWK are required to initiate intrinsic pathway but are not associated with bleeding disordersThere is evidence that factor XII deficiency may be associated with thrombosis",
                    "sub_points": [
                      "There is evidence that factor XII deficiency may be associated with thrombosis"
                    ]
                  },
                  {
                    "text": "If intrinsic pathway cannot be initiated, why do factor VIII and factor IX deficiency result in severe bleeding disordersNewer models of coagulation are needed, such as in vivo model of coagulation and 2-cell model of coagulation",
                    "sub_points": [
                      "Newer models of coagulation are needed, such as in vivo model of coagulation and 2-cell model of coagulation"
                    ]
                  }
                ],
                "In Vivo Model of Coagulation": [
                  {
                    "text": "Intrinsic pathway proteins PK, HMWK, and factor XII do not contribute significantly to this model because they are not associated with bleeding disorders"
                  },
                  {
                    "text": "Factor IX and factor VIII are central in this model because they are associated with severe bleeding disorders"
                  },
                  {
                    "text": "In extrinsic pathway, which was deduced from in vitro testing (PT), TF and factor VIIa cleave factor X to factor XaThrough study of TFPI, we know that TF:FVIIa does not cleave factor X to factor Xa efficiently ﻿in vivo﻿This occurs only at high concentrations of TF, such as concentrations of TF in thromboplastins (PT)",
                    "sub_points": [
                      "Through study of TFPI, we know that TF:FVIIa does not cleave factor X to factor Xa efficiently ﻿in vivo﻿This occurs only at high concentrations of TF, such as concentrations of TF in thromboplastins (PT)",
                      "This occurs only at high concentrations of TF, such as concentrations of TF in thromboplastins (PT)"
                    ]
                  },
                  {
                    "text": "In vivo, TF:FVIIa cleaves factor IX to factor IXa, which then combines with factor VIIIa and factor X as well as Ca²⁺ and PL to form tenase complex"
                  }
                ],
                "Intrinsic Pathway and Activated Partial Thromboplastin Time": [
                  {
                    "text": "PT is insensitive to intrinsic factor deficiencies"
                  },
                  {
                    "text": "aPTT is more sensitive to intrinsic factor deficiencies"
                  },
                  {
                    "text": "Prolonged aPTT with normal PT reflects certain deficiencies﻿Factor VIII﻿﻿Factor IX﻿﻿Factor XI﻿Factor XIIPKHMWK",
                    "sub_points": [
                      "﻿Factor VIII﻿",
                      "﻿Factor IX﻿",
                      "﻿Factor XI﻿",
                      "Factor XII",
                      "PK",
                      "HMWK"
                    ]
                  }
                ],
                "Easy Way to Remember Intrinsic and Common Pathways": [
                  {
                    "text": "Intrinsic pathway and common pathway are written in arabic numerals from left to rightWrite 12 - 11 - 9 (\"You made a mistake\") - 10 (\"Go back and correct it\") - 2 - 2a (thrombin) - 1 (fibrinogen) - fibrinFactor 8a and factor 5a are required cofactors",
                    "sub_points": [
                      "Write 12 - 11 - 9 (\"You made a mistake\") - 10 (\"Go back and correct it\") - 2 - 2a (thrombin) - 1 (fibrinogen) - fibrin",
                      "Factor 8a and factor 5a are required cofactors"
                    ]
                  },
                  {
                    "text": "\"T-shirt\" represents vitamin K-dependent coagulation factors II, VII, IX, XNatural anticoagulants protein C and protein S are also vitamin K-dependent factors and inactivate factor 8a and factor 5aFactors form tenase and prothrombinase complexes that form on PL surfaces in presence of calcium ions",
                    "sub_points": [
                      "Natural anticoagulants protein C and protein S are also vitamin K-dependent factors and inactivate factor 8a and factor 5a",
                      "Factors form tenase and prothrombinase complexes that form on PL surfaces in presence of calcium ions"
                    ]
                  },
                  {
                    "text": "Prothrombinase complex cleaves prothrombin (2) to thrombin (2a)"
                  },
                  {
                    "text": "Thrombin (2a) cleaves fibrinogen (1) to fibrin"
                  },
                  {
                    "text": "Factor 13 acts on fibrin polymers to form cross-linked fibrin"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "High-molecular-weight-kininogen (HMWK)"
                  },
                  {
                    "text": "Prekallikrein (PK)"
                  },
                  {
                    "text": "Phospholipid (PL)"
                  },
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "Tissue factor (TF)"
                  },
                  {
                    "text": "Tissue factor pathway inhibitor (TFPI)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Activated Partial Thromboplastin Time": [
                  {
                    "text": "PT is insensitive to intrinsic factor deficiencies"
                  },
                  {
                    "text": "aPTT is more sensitive to intrinsic factor deficiencies"
                  },
                  {
                    "text": "aPTT is performed on PPP obtained from anticoagulated whole blood3.2% sodium citrate in 1:9 anticoagulant-to-whole blood ratio is neededNo other anticoagulant is acceptable",
                    "sub_points": [
                      "3.2% sodium citrate in 1:9 anticoagulant-to-whole blood ratio is needed",
                      "No other anticoagulant is acceptable"
                    ]
                  },
                  {
                    "text": "Aliquot of PPP is incubated to 37°C with aPTT reagent"
                  },
                  {
                    "text": "aPTT reagent contains source of phospholipid (e.g., cephalin) and contact activator (e.g., silica, kaolin)"
                  },
                  {
                    "text": "Clotting is initiated by recalcifying plasma using calcium chloride"
                  },
                  {
                    "text": "Time from initiation to clot detection is measured in seconds"
                  },
                  {
                    "text": "Clots can be detected using optical (e.g., spectrophotometry), impedance, mechanical, and original tilt tube method (visual observation in test tube)"
                  },
                  {
                    "text": "Prolonged aPTT with normal PT reflects certain deficiencies﻿Factor VIII﻿﻿Factor IX﻿﻿Factor XII﻿Factor XIPKHMWK",
                    "sub_points": [
                      "﻿Factor VIII﻿",
                      "﻿Factor IX﻿",
                      "﻿Factor XII﻿",
                      "Factor XI",
                      "PK",
                      "HMWK"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Transport": [
                  {
                    "text": "aPTT transport and storageCentrifuge and store at refrigerated or room temperatureTest within 4 hr of specimen collectionIf longer storage is required, centrifuge and freeze plasma at -20°C",
                    "sub_points": [
                      "Centrifuge and store at refrigerated or room temperature",
                      "Test within 4 hr of specimen collection",
                      "If longer storage is required, centrifuge and freeze plasma at -20°C"
                    ]
                  }
                ],
                "Reference Range": [
                  {
                    "text": "Reference range should be determined for each lot of aPTT reagent"
                  },
                  {
                    "text": "Heparin therapeutic range should be determined for each lot of aPTT reagent"
                  },
                  {
                    "text": "aPTT range is approximately 24-36 sec"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Coagulation Cascade (Extrinsic)": {
            "name": "Coagulation Cascade (Extrinsic)",
            "url": "https://app.pathprimer.com/document/35d1f969-3b9d-4d17-aacc-b53bb3cc046a/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Extrinsic pathway has same endpoint as intrinsic pathway, which is conversion of factor X to factor Xa"
                  },
                  {
                    "text": "Tissue injury leads to exposure of blood to TF"
                  },
                  {
                    "text": "TF:FVIIa then cleaves factor X to factor Xa"
                  },
                  {
                    "text": "After factor Xa is generated, prothrombinase complex is formed"
                  },
                  {
                    "text": "Factor Xa combines with factor Va, factor II (prothrombin), and Ca²⁺ on PL surface (platelet membrane phosphatidylserine in vivo)"
                  },
                  {
                    "text": "Assembled in this complex, factor II (prothrombin) is cleaved to factor IIa (thrombin)"
                  },
                  {
                    "text": "Formation of thrombin is required to cleave fibrinogen (factor I) to fibrin"
                  },
                  {
                    "text": "Factor XIIIa is required to convert fibrin polymers to crosslinked fibrin polymers"
                  },
                  {
                    "text": "Elevated PT and normal aPTT most often reflect congenital or acquired deficiency of extrinsic pathway, mainly factor VII"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "PT is performed on PPP obtained from anticoagulated whole blood"
                  },
                  {
                    "text": "Test is initiated by adding thromboplastin (tissue factor + phospholipid) and calcium chloride"
                  },
                  {
                    "text": "For patients on warfarin, monitoring can be performed independently of PT testing system by calculating INR"
                  }
                ]
              },
              "OVERVIEW": {
                "Experiment to Consider": [
                  {
                    "text": "Person’s skin is cut with knife, and blood vessels and tissue are damaged; wound starts to bleed"
                  },
                  {
                    "text": "After some time, clot forms and bleeding stops"
                  },
                  {
                    "text": "Conclusion: There must be something extrinsic to blood that is released with tissue damage that initiates clotting"
                  },
                  {
                    "text": "We now know that extrinsic factor or tissue thromboplastin is tissue factor"
                  },
                  {
                    "text": "Therefore, this pathway is called “extrinsic” or tissue factor pathway"
                  }
                ],
                "Extrinsic (Tissue Factor) Pathway": [
                  {
                    "text": "Extrinsic pathway has same endpoint as intrinsic pathway, which is conversion of factor X to factor XaTissue injury leads to exposure of blood to TFTissue factor is present in subendothelium (e.g., smooth muscle, fibroblasts) and expressed by macrophage and endothelial cells in presence of inflammationTF:FVIIa then cleaves factor X to factor XaTissue factor acts as cofactor in this pathwaySmall amount of factor VII is cleaved to FVIIa by thrombinThis small amount circulates in blood and is available when there is tissue injury",
                    "sub_points": [
                      "Tissue injury leads to exposure of blood to TFTissue factor is present in subendothelium (e.g., smooth muscle, fibroblasts) and expressed by macrophage and endothelial cells in presence of inflammation",
                      "Tissue factor is present in subendothelium (e.g., smooth muscle, fibroblasts) and expressed by macrophage and endothelial cells in presence of inflammation",
                      "TF:FVIIa then cleaves factor X to factor XaTissue factor acts as cofactor in this pathwaySmall amount of factor VII is cleaved to FVIIa by thrombinThis small amount circulates in blood and is available when there is tissue injury",
                      "Tissue factor acts as cofactor in this pathway",
                      "Small amount of factor VII is cleaved to FVIIa by thrombinThis small amount circulates in blood and is available when there is tissue injury",
                      "This small amount circulates in blood and is available when there is tissue injury"
                    ]
                  }
                ],
                "Common Pathway": [
                  {
                    "text": "Extrinsic pathway and intrinsic pathway lead to shared event of factor X being cleaved to factor Xa"
                  },
                  {
                    "text": "In extrinsic pathway, factor Xa is formed when TF:FVIIa cleaves factor X to factor Xa in presence of Ca²⁺"
                  },
                  {
                    "text": "In intrinsic pathway, FIXa:FVIIIa:Ca²⁺:PL cleaves factor X to factor Xa"
                  },
                  {
                    "text": "After factor Xa is generated, prothrombinase complex﻿ is formedFactor Xa combines with factor Va, factor II (prothrombin), and Ca²⁺ on PL surface (platelet membrane phosphatidylserine in vivo)Factor Va acts as cofactor in this complexSmall amounts of circulating thrombin cleave factor V to factor VaProthrombinase complex consists of FXa:FVa:FII:PL:Ca²⁺﻿Assembled in this complex, factor II (prothrombin) is cleaved to factor IIa (thrombin)Formation of thrombin is required to cleave fibrinogen (factor I) to fibrinFactor XIIIa is required to convert fibrin polymers to crosslinked fibrin polymers",
                    "sub_points": [
                      "Factor Xa combines with factor Va, factor II (prothrombin), and Ca²⁺ on PL surface (platelet membrane phosphatidylserine in vivo)",
                      "Factor Va acts as cofactor in this complexSmall amounts of circulating thrombin cleave factor V to factor Va",
                      "Small amounts of circulating thrombin cleave factor V to factor Va",
                      "Prothrombinase complex consists of FXa:FVa:FII:PL:Ca²⁺﻿",
                      "Assembled in this complex, factor II (prothrombin) is cleaved to factor IIa (thrombin)",
                      "Formation of thrombin is required to cleave fibrinogen (factor I) to fibrin",
                      "Factor XIIIa is required to convert fibrin polymers to crosslinked fibrin polymers"
                    ]
                  }
                ],
                "In Vivo Coagulation Cascade": [
                  {
                    "text": "This model is good for explaining coagulation testing, but it is somewhat limited in explaining clinical hemostasis"
                  },
                  {
                    "text": "In vivo, TF:FVIIa cleaves factor IX to factor IXaThrough study of TFPI, we now know that TF:FVIIa does not cleave factor X to factor Xa efficiently in vivoTissue factor mediated conversion of factor X to factor Xa only occurs at high concentrations of tissue factor, such as concentrations of tissue factor in thromboplastin (prothrombin time)",
                    "sub_points": [
                      "Through study of TFPI, we now know that TF:FVIIa does not cleave factor X to factor Xa efficiently in vivo",
                      "Tissue factor mediated conversion of factor X to factor Xa only occurs at high concentrations of tissue factor, such as concentrations of tissue factor in thromboplastin (prothrombin time)"
                    ]
                  },
                  {
                    "text": "TF:FVIIa cleaves factor X to factor Xa only under testing conditions in which high concentrations of tissue factor are added"
                  },
                  {
                    "text": "Factor IXa then assembles into tenase complex, leading to formation of thrombin"
                  },
                  {
                    "text": "Intrinsic pathway proteins PK, HMWK, and factor XII do not contribute significantly to this model, because they are not associated with bleeding disorders"
                  },
                  {
                    "text": "Factor IX and factor VIII are central in this model, because they are associated with severe bleeding disorders"
                  }
                ],
                "Simpler Coagulation Cascade": [
                  {
                    "text": "Intrinsic pathway and common pathway are written in arabic numerals from left to right"
                  },
                  {
                    "text": "Write 12 - 11 - 9 (\"You made a mistake\") - 10 (\"Go back and correct it\") - 2 - 2a (thrombin) - 1 (fibrinogen) - fibrinFactor 8a and factor 5a are required cofactors",
                    "sub_points": [
                      "Factor 8a and factor 5a are required cofactors"
                    ]
                  },
                  {
                    "text": "Extrinsic pathway shows TF and FVIIa at factor X at right angle"
                  },
                  {
                    "text": "\"T-shirt\" represents vitamin K-dependent coagulation factor II, factor VII, factor IX, and factor XNatural anticoagulants protein C and protein S are also vitamin K-dependent factors and inactivate factor 8a and factor 5aFactors form tenase and prothrombinase complexes that form on phospholipid surfaces in presence of calcium ions",
                    "sub_points": [
                      "Natural anticoagulants protein C and protein S are also vitamin K-dependent factors and inactivate factor 8a and factor 5a",
                      "Factors form tenase and prothrombinase complexes that form on phospholipid surfaces in presence of calcium ions"
                    ]
                  },
                  {
                    "text": "Prothrombinase complex cleaves prothrombin (2) to thrombin (2a)"
                  },
                  {
                    "text": "Thrombin (2a) cleaves fibrinogen (1) to fibrin"
                  },
                  {
                    "text": "Factor 13 acts on fibrin polymers to form crosslinked fibrin"
                  }
                ],
                "Extrinsic Pathway and Prothrombin Time": [
                  {
                    "text": "PT measures deficiencies in both extrinsic pathway (factor VII) and common pathway"
                  },
                  {
                    "text": "Elevated PT and normal aPTT most often reflect congenital or acquired deficiency of extrinsic pathway, mainly factor VII"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Factor VIIa (FVIIa)"
                  },
                  {
                    "text": "International normalized ratio (INR)"
                  },
                  {
                    "text": "International sensitivity index (ISI)"
                  },
                  {
                    "text": "Phospholipid (PL)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  },
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "Tissue factor (TF)"
                  },
                  {
                    "text": "Tissue factor pathway inhibitor (TFPI)"
                  },
                  {
                    "text": "World Health Organization (WHO)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Prothrombin Time": [
                  {
                    "text": "PT is performed on PPP obtained from anticoagulated whole blood3.2% sodium citrate in 1:9 anticoagulant to whole blood ratio is neededNo other anticoagulant is acceptableWaste tube should be drawn prior to collecting specimen",
                    "sub_points": [
                      "3.2% sodium citrate in 1:9 anticoagulant to whole blood ratio is needed",
                      "No other anticoagulant is acceptable",
                      "Waste tube should be drawn prior to collecting specimen"
                    ]
                  },
                  {
                    "text": "Aliquot of PPP is incubated to 37°C"
                  },
                  {
                    "text": "Test is initiated by adding thromboplastin (tissue factor + phospholipid) and calcium chlorideThromboplastin can be made from rabbit brain, which is good source of TF and PLThromboplastin can also be made from recombinant tissue factor",
                    "sub_points": [
                      "Thromboplastin can be made from rabbit brain, which is good source of TF and PL",
                      "Thromboplastin can also be made from recombinant tissue factor"
                    ]
                  },
                  {
                    "text": "Time from initiation to clot detection is then measured in seconds"
                  },
                  {
                    "text": "Clots can be detected using optical (e.g., spectrophotometry), impedance, mechanical, and original tilt tube method (visual observation in test tube)"
                  },
                  {
                    "text": "For patients on warfarin, monitoring can be performed independently of PT testing system by calculating INRINR = (Patient PT ÷ PT mean) ^ ISI or log INR = ISI x log (PT ratio)ISI is determined by comparing reagent against WHO reagent (international reference preparation) in normal donors and patients on stable warfarin therapyPT mean = geometric mean of PT performed on 120 normal donorsPT ratio = Patient PT ÷ PT mean",
                    "sub_points": [
                      "INR = (Patient PT ÷ PT mean) ^ ISI or log INR = ISI x log (PT ratio)",
                      "ISI is determined by comparing reagent against WHO reagent (international reference preparation) in normal donors and patients on stable warfarin therapy",
                      "PT mean = geometric mean of PT performed on 120 normal donors",
                      "PT ratio = Patient PT ÷ PT mean"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Coagulation Cascade (In Vivo)": {
            "name": "Coagulation Cascade (In Vivo)",
            "url": "https://app.pathprimer.com/document/aa3d7919-add8-451f-a2f6-2d6dd5c2647e/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Traditional cascade model of coagulation (intrinsic, extrinsic, common pathways) does not entirely describe coagulation in vivo but rather reflects﻿ in vitro﻿events"
                  },
                  {
                    "text": "In in vitro coagulation cascade model, extrinsic pathway is initiated when TF:factor VIIa cleaves factor X to Xa"
                  },
                  {
                    "text": "In vivo, TF:FVIIa has greater activity on factor IX to IXa conversion than factor X to Xa conversion"
                  },
                  {
                    "text": "In 2-cell model, 3 processes are needed for fibrin clot formation: initiation, amplification, propagation"
                  },
                  {
                    "text": "PT and aPTT are useful screening tests but are limited"
                  },
                  {
                    "text": "aPTT may be abnormal with deficiencies of intrinsic coagulation factors &/or proteins, but without bleeding"
                  }
                ]
              },
              "OVERVIEW": {
                "Model of Coagulation Cascade Inadequate": [
                  {
                    "text": "Teaching intrinsic, extrinsic, and common pathways is traditional approach to teaching secondary hemostasis (coagulation cascade)"
                  },
                  {
                    "text": "Cascade describes how activation of 1 coagulation factor leads to activation of subsequent factorsPositive feedback amplifies pathways",
                    "sub_points": [
                      "Positive feedback amplifies pathways"
                    ]
                  },
                  {
                    "text": "Cascade is useful, as it describes coagulation behavior in in vitro tests of coagulation (e.g., PT, aPTT, TT)PT and aPTT are useful screening tests but are limitedNormal PT and aPTT do not predict that patient will not bleed during surgeryAbnormal PT &/or aPTT does not reliably predict patient will bleed during surgery, with or without factor replacementPatient who bleeds during surgery may or may not have abnormal PT &/or aPTT",
                    "sub_points": [
                      "PT and aPTT are useful screening tests but are limitedNormal PT and aPTT do not predict that patient will not bleed during surgeryAbnormal PT &/or aPTT does not reliably predict patient will bleed during surgery, with or without factor replacementPatient who bleeds during surgery may or may not have abnormal PT &/or aPTT",
                      "Normal PT and aPTT do not predict that patient will not bleed during surgery",
                      "Abnormal PT &/or aPTT does not reliably predict patient will bleed during surgery, with or without factor replacement",
                      "Patient who bleeds during surgery may or may not have abnormal PT &/or aPTT"
                    ]
                  },
                  {
                    "text": "Traditional cascade model of coagulation (intrinsic, extrinsic, common pathways) does not entirely describe coagulation in vivo but rather reflects﻿ in vitro﻿eventsaPTT may be abnormal with deficiencies of intrinsic coagulation factors &/or proteins, but without bleedingHMWK, PK, and factor XII not associated with bleedingaPTT may be abnormal in factor XI deficiencyBleeding not predicted by factor XI activityOne could conclude that intrinsic pathway does not contribute significantly to hemostasisFactor VIII and IX deficiencies are associated with severe bleeding disorders",
                    "sub_points": [
                      "aPTT may be abnormal with deficiencies of intrinsic coagulation factors &/or proteins, but without bleedingHMWK, PK, and factor XII not associated with bleeding",
                      "HMWK, PK, and factor XII not associated with bleeding",
                      "aPTT may be abnormal in factor XI deficiencyBleeding not predicted by factor XI activity",
                      "Bleeding not predicted by factor XI activity",
                      "One could conclude that intrinsic pathway does not contribute significantly to hemostasis",
                      "Factor VIII and IX deficiencies are associated with severe bleeding disorders"
                    ]
                  }
                ],
                "In Vivo Coagulation Cascade": [
                  {
                    "text": "In in vitro coagulation cascade model, extrinsic pathway is initiated when TF:factor VIIa cleaves factor X to Xa"
                  },
                  {
                    "text": "Studies of TFPI provide evidence that TF:FVIIa does not cleave factor X to Xa efficiently ﻿in vivo﻿TF:FVIIa activation of factor X to Xa reflects what occurs when high concentrations of TF are present (i.e., PT reagent)",
                    "sub_points": [
                      "TF:FVIIa activation of factor X to Xa reflects what occurs when high concentrations of TF are present (i.e., PT reagent)"
                    ]
                  },
                  {
                    "text": "In vivo, TF:FVIIa has greater activity on factor IX to IXa conversion than factor X to Xa conversionThis places factor IX and VIII in a position of greater importance than their placement in intrinsic pathway",
                    "sub_points": [
                      "This places factor IX and VIII in a position of greater importance than their placement in intrinsic pathway"
                    ]
                  },
                  {
                    "text": "In vivo, factor XII and proteins HMWK and PK have little to no role in coagulation"
                  },
                  {
                    "text": "Factor XI in this model amplifies conversion of factor IX to IXaFactor XI activated to factor XIa by thrombin",
                    "sub_points": [
                      "Factor XI activated to factor XIa by thrombin"
                    ]
                  },
                  {
                    "text": "Remainder of pathway is common pathway with assembly of \"tenase\" and \"prothrombinase\" complexesThis leads to generation of thrombin and fibrin clot",
                    "sub_points": [
                      "This leads to generation of thrombin and fibrin clot"
                    ]
                  }
                ],
                "Two-Cell Model": [
                  {
                    "text": "Improvement in model of hemostasis incorporates knowledge that 2 cells are present during coagulationTF-bearing cell (e.g., endothelium)Platelets",
                    "sub_points": [
                      "TF-bearing cell (e.g., endothelium)",
                      "Platelets"
                    ]
                  },
                  {
                    "text": "In 2-cell model, 3 processes are needed for fibrin clot formationInitiationSmall amounts of activated coagulation factors produced on TF-bearing cellsSmall amounts of thrombin and factor IXa generated on TF-bearing cellsThrombin and factor IXa available to accelerate coagulation when there is vessel injuryWhen clotting not biologically necessary, thrombin and factor IXa are quickly inactivated or moved to extravascular spaceAmplificationPlatelets activated by thrombin generated on TF-bearing cellsFactor V released by platelets and activated by thrombin to factor VaFactor VIII activated to factor VIIIaFactor XI activated to factor XIaFactor XI provides supplemental pathway for generating factor IXa for propagation phaseAll components for generating thrombin in propagation phase now available and \"primed\" to fully respondPropagationActivated platelets provide phospholipid surface (phosphatidylserine exposure) for coagulation to take placeSurface needed for formation of \"tenase\" and \"prothrombinase\" complexes on activated platelets\"Thrombin burst\" generated during this phaseThrombin burst leads to large amounts of fibrinogen being converted to fibrinFactor XIIIa cross-links fibrin to form cross-linked fibrin polymer",
                    "sub_points": [
                      "InitiationSmall amounts of activated coagulation factors produced on TF-bearing cellsSmall amounts of thrombin and factor IXa generated on TF-bearing cellsThrombin and factor IXa available to accelerate coagulation when there is vessel injuryWhen clotting not biologically necessary, thrombin and factor IXa are quickly inactivated or moved to extravascular space",
                      "Small amounts of activated coagulation factors produced on TF-bearing cellsSmall amounts of thrombin and factor IXa generated on TF-bearing cellsThrombin and factor IXa available to accelerate coagulation when there is vessel injuryWhen clotting not biologically necessary, thrombin and factor IXa are quickly inactivated or moved to extravascular space",
                      "Small amounts of thrombin and factor IXa generated on TF-bearing cells",
                      "Thrombin and factor IXa available to accelerate coagulation when there is vessel injury",
                      "When clotting not biologically necessary, thrombin and factor IXa are quickly inactivated or moved to extravascular space",
                      "AmplificationPlatelets activated by thrombin generated on TF-bearing cellsFactor V released by platelets and activated by thrombin to factor VaFactor VIII activated to factor VIIIaFactor XI activated to factor XIaFactor XI provides supplemental pathway for generating factor IXa for propagation phaseAll components for generating thrombin in propagation phase now available and \"primed\" to fully respond",
                      "Platelets activated by thrombin generated on TF-bearing cells",
                      "Factor V released by platelets and activated by thrombin to factor Va",
                      "Factor VIII activated to factor VIIIa",
                      "Factor XI activated to factor XIaFactor XI provides supplemental pathway for generating factor IXa for propagation phase",
                      "Factor XI provides supplemental pathway for generating factor IXa for propagation phase",
                      "All components for generating thrombin in propagation phase now available and \"primed\" to fully respond",
                      "PropagationActivated platelets provide phospholipid surface (phosphatidylserine exposure) for coagulation to take placeSurface needed for formation of \"tenase\" and \"prothrombinase\" complexes on activated platelets\"Thrombin burst\" generated during this phaseThrombin burst leads to large amounts of fibrinogen being converted to fibrinFactor XIIIa cross-links fibrin to form cross-linked fibrin polymer",
                      "Activated platelets provide phospholipid surface (phosphatidylserine exposure) for coagulation to take place",
                      "Surface needed for formation of \"tenase\" and \"prothrombinase\" complexes on activated platelets",
                      "\"Thrombin burst\" generated during this phase",
                      "Thrombin burst leads to large amounts of fibrinogen being converted to fibrin",
                      "Factor XIIIa cross-links fibrin to form cross-linked fibrin polymer"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Thrombin time (TT)"
                  },
                  {
                    "text": "High-molecular-weight kininogen (HMWK)"
                  },
                  {
                    "text": "Prekallikrein (PK)"
                  },
                  {
                    "text": "Tissue factor (TF)"
                  },
                  {
                    "text": "Tissue factor pathway inhibitor (TFPI)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Natural Anticoagulants: Protein C and Protein S": {
            "name": "Natural Anticoagulants: Protein C and Protein S",
            "url": "https://app.pathprimer.com/document/2bc8458f-ac9d-4dff-b0fd-e433dd717db7/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Protein C and S are vitamin K dependent"
                  },
                  {
                    "text": "Protein C and S are synthesized primarily in liver"
                  },
                  {
                    "text": "Protein C has very short half-life (6-8 hours)"
                  },
                  {
                    "text": "Function under normal physiological conditionsThrombin (IIa) binds to thrombomodulin receptor located on endothelial cell surfaceThrombin binding causes activation of protein C, which is bound to endothelial surface protein C receptorAPC is released from receptor and binds with its cofactor, PSAPC:PS cleaves activated factor Va and factor VIIIa to inactive forms, Vi and VIIIiInactivation of Va and VIIIa dampens clotting cascade",
                    "sub_points": [
                      "Thrombin (IIa) binds to thrombomodulin receptor located on endothelial cell surface",
                      "Thrombin binding causes activation of protein C, which is bound to endothelial surface protein C receptor",
                      "APC is released from receptor and binds with its cofactor, PS",
                      "APC:PS cleaves activated factor Va and factor VIIIa to inactive forms, Vi and VIIIi",
                      "Inactivation of Va and VIIIa dampens clotting cascade"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Mechanism of Action": [
                  {
                    "text": "Protein CProtein C has very short half-life (6-8 hours)Vitamin K dependent zymogenSynthesized primarily in liverProtein C function under normal physiological conditionsThrombin (IIa) binds to thrombomodulin receptor located on endothelial cell surfaceBinding of thrombin to thrombomodulin prevents thrombin’s coagulant activities, such as fibrinogen clotting and activation of plateletsInflammatory cytokines such as TNFα downregulate thrombomodulinThrombin binding causes activation of protein C, which is bound to endothelial surface protein C receptorAPC is released from receptor and binds with its cofactor, PSAPC:PS cleaves activated factor Va and factor VIIIa to inactive forms, Vi and VIIIiInactivation of factor Va and factor VIIIa dampens clotting cascadeProtein C deficiency is associated with thromboembolic events (see section on Protein C deficiency for complete discussion)Autosomal-dominant inheritanceDefective allele on gene encoding protein C (PROC)Patients with heterozygous mutation have moderately increased risk for venous thrombosisPatients with homozygous mutation have severe thrombotic disorder that typically presents in neonatal periodInfants with severe protein C deficiency present with thrombotic purpura fulminans and/or DICDiagnosis is typically made using plasma protein C activity",
                    "sub_points": [
                      "Protein C has very short half-life (6-8 hours)",
                      "Vitamin K dependent zymogen",
                      "Synthesized primarily in liver",
                      "Protein C function under normal physiological conditionsThrombin (IIa) binds to thrombomodulin receptor located on endothelial cell surfaceBinding of thrombin to thrombomodulin prevents thrombin’s coagulant activities, such as fibrinogen clotting and activation of plateletsInflammatory cytokines such as TNFα downregulate thrombomodulinThrombin binding causes activation of protein C, which is bound to endothelial surface protein C receptorAPC is released from receptor and binds with its cofactor, PSAPC:PS cleaves activated factor Va and factor VIIIa to inactive forms, Vi and VIIIiInactivation of factor Va and factor VIIIa dampens clotting cascade",
                      "Thrombin (IIa) binds to thrombomodulin receptor located on endothelial cell surfaceBinding of thrombin to thrombomodulin prevents thrombin’s coagulant activities, such as fibrinogen clotting and activation of plateletsInflammatory cytokines such as TNFα downregulate thrombomodulin",
                      "Binding of thrombin to thrombomodulin prevents thrombin’s coagulant activities, such as fibrinogen clotting and activation of platelets",
                      "Inflammatory cytokines such as TNFα downregulate thrombomodulin",
                      "Thrombin binding causes activation of protein C, which is bound to endothelial surface protein C receptor",
                      "APC is released from receptor and binds with its cofactor, PS",
                      "APC:PS cleaves activated factor Va and factor VIIIa to inactive forms, Vi and VIIIi",
                      "Inactivation of factor Va and factor VIIIa dampens clotting cascade",
                      "Protein C deficiency is associated with thromboembolic events (see section on Protein C deficiency for complete discussion)Autosomal-dominant inheritanceDefective allele on gene encoding protein C (PROC)Patients with heterozygous mutation have moderately increased risk for venous thrombosisPatients with homozygous mutation have severe thrombotic disorder that typically presents in neonatal periodInfants with severe protein C deficiency present with thrombotic purpura fulminans and/or DICDiagnosis is typically made using plasma protein C activity",
                      "Autosomal-dominant inheritance",
                      "Defective allele on gene encoding protein C (PROC)",
                      "Patients with heterozygous mutation have moderately increased risk for venous thrombosis",
                      "Patients with homozygous mutation have severe thrombotic disorder that typically presents in neonatal periodInfants with severe protein C deficiency present with thrombotic purpura fulminans and/or DIC",
                      "Infants with severe protein C deficiency present with thrombotic purpura fulminans and/or DIC",
                      "Diagnosis is typically made using plasma protein C activity"
                    ]
                  },
                  {
                    "text": "Protein SVitamin K dependentSynthesized primarily in liverPS function under normal physiological conditionsPS acts as cofactor to protein C and accelerates inactivation of factor Va and factor VIIIa → inactive forms Vi and VIIIiPS may also directly bind and inactivate factor Va and factor XaApproximately 60% of PS is bound to C4b-binding protein and is essentially non-functionalRemaining 40% is free PS and is considered functional PSPS deficiency is associated with thromboembolic events (see section on PS deficiency for complete discussion)Autosomal-dominant inheritance with variable penetranceHeterozygous mutations cause moderate-strong increase in risk for venous thrombosisHomozygous PS deficiency is exceedingly rareWhen present, often causes catastrophic thrombotic purpura fulminans and DIC in neonatal periodDefective allele on gene encoding PS (PROS1)is present in type I deficiency (most common)DiagnosisScreening assays; PS activity or free fraction of PSConfirmatory assay; PS free antigen testing",
                    "sub_points": [
                      "Vitamin K dependent",
                      "Synthesized primarily in liver",
                      "PS function under normal physiological conditionsPS acts as cofactor to protein C and accelerates inactivation of factor Va and factor VIIIa → inactive forms Vi and VIIIiPS may also directly bind and inactivate factor Va and factor XaApproximately 60% of PS is bound to C4b-binding protein and is essentially non-functionalRemaining 40% is free PS and is considered functional PS",
                      "PS acts as cofactor to protein C and accelerates inactivation of factor Va and factor VIIIa → inactive forms Vi and VIIIi",
                      "PS may also directly bind and inactivate factor Va and factor Xa",
                      "Approximately 60% of PS is bound to C4b-binding protein and is essentially non-functional",
                      "Remaining 40% is free PS and is considered functional PS",
                      "PS deficiency is associated with thromboembolic events (see section on PS deficiency for complete discussion)Autosomal-dominant inheritance with variable penetranceHeterozygous mutations cause moderate-strong increase in risk for venous thrombosisHomozygous PS deficiency is exceedingly rareWhen present, often causes catastrophic thrombotic purpura fulminans and DIC in neonatal periodDefective allele on gene encoding PS (PROS1)is present in type I deficiency (most common)DiagnosisScreening assays; PS activity or free fraction of PSConfirmatory assay; PS free antigen testing",
                      "Autosomal-dominant inheritance with variable penetrance",
                      "Heterozygous mutations cause moderate-strong increase in risk for venous thrombosis",
                      "Homozygous PS deficiency is exceedingly rareWhen present, often causes catastrophic thrombotic purpura fulminans and DIC in neonatal period",
                      "When present, often causes catastrophic thrombotic purpura fulminans and DIC in neonatal period",
                      "Defective allele on gene encoding PS (PROS1)is present in type I deficiency (most common)",
                      "DiagnosisScreening assays; PS activity or free fraction of PSConfirmatory assay; PS free antigen testing",
                      "Screening assays; PS activity or free fraction of PS",
                      "Confirmatory assay; PS free antigen testing"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Activated protein C (APC)"
                  },
                  {
                    "text": "Activated protein C resistance (APCR)"
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)"
                  },
                  {
                    "text": "Protein S (PS)"
                  },
                  {
                    "text": "Tumor necrosis factor (TNF)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Protein C and Related Disease": [
                  {
                    "text": "Protein C deficiency is inherited disorder that increases risk of venous thromboembolism"
                  },
                  {
                    "text": "APCRFactor V Leiden mutation is most common cause of APCRAPCR is disorder of factor V that makes it resistant to inactivation by APC",
                    "sub_points": [
                      "Factor V Leiden mutation is most common cause of APCR",
                      "APCR is disorder of factor V that makes it resistant to inactivation by APC"
                    ]
                  },
                  {
                    "text": "Warfarin skin necrosis and limb gangreneSince half-life of protein C and PS are shorter than half-life of factor X and factor II (prothrombin), initiation of warfarin therapy results in prothrombotic state before therapeutic anticoagulation (due to decreased factor X and factor II activity) is achievedProthrombotic state is associated with skin necrosis, as well as limb gangrene",
                    "sub_points": [
                      "Since half-life of protein C and PS are shorter than half-life of factor X and factor II (prothrombin), initiation of warfarin therapy results in prothrombotic state before therapeutic anticoagulation (due to decreased factor X and factor II activity) is achieved",
                      "Prothrombotic state is associated with skin necrosis, as well as limb gangrene"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Natural Anticoagulants: Antithrombin": {
            "name": "Natural Anticoagulants: Antithrombin",
            "url": "https://app.pathprimer.com/document/193b78f2-98f2-4c71-b308-3bf7747abe9a/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "AT is most important inhibitor of thrombin"
                  },
                  {
                    "text": "AT forms complex with and inactivates thrombin and factor Xa, which are then cleared by liver; AT also inactivates factors IXa, XIa, XIIa"
                  },
                  {
                    "text": "Therapeutically AT plays a role in anticoagulation using heparinHeparin binds AT, which exposes active site; this action potentiates activity of AT by approximately 1000-fold",
                    "sub_points": [
                      "Heparin binds AT, which exposes active site; this action potentiates activity of AT by approximately 1000-fold"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "AT activity normal range in adults is 70%-130%"
                  },
                  {
                    "text": "Use of age-adjusted normal ranges is warranted in infants"
                  }
                ]
              },
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "AT is natural anticoagulant produced by liver432 amino acids with glycosylated sites and disulfide bondsHalf-life is 2-3 days",
                    "sub_points": [
                      "432 amino acids with glycosylated sites and disulfide bonds",
                      "Half-life is 2-3 days"
                    ]
                  },
                  {
                    "text": "Role of ATMost important inhibitor of thrombinForms complex with and inactivates thrombin and factor Xa, which are cleared by liverAT also inactivates factors IXa, XIa, XIIaTwo domains on AT: heparin binding domain and active siteAT functions in normal physiologic conditions with activation by heparan sulfate from vascular endotheliumAT plays a role therapeutically in anticoagulation with heparinHeparin binds AT, which exposes active siteThis action potentiates activity of AT by approximately 1000-fold",
                    "sub_points": [
                      "Most important inhibitor of thrombin",
                      "Forms complex with and inactivates thrombin and factor Xa, which are cleared by liverAT also inactivates factors IXa, XIa, XIIa",
                      "AT also inactivates factors IXa, XIa, XIIa",
                      "Two domains on AT: heparin binding domain and active site",
                      "AT functions in normal physiologic conditions with activation by heparan sulfate from vascular endothelium",
                      "AT plays a role therapeutically in anticoagulation with heparinHeparin binds AT, which exposes active siteThis action potentiates activity of AT by approximately 1000-fold",
                      "Heparin binds AT, which exposes active site",
                      "This action potentiates activity of AT by approximately 1000-fold"
                    ]
                  },
                  {
                    "text": "Gene for AT isSERPINC1(serine protease inhibitor family C1) located on long arm of chromosome 1"
                  },
                  {
                    "text": "AT deficiency can be inherited or acquiredInherited as type I or type II",
                    "sub_points": [
                      "Inherited as type I or type II"
                    ]
                  },
                  {
                    "text": "Hereditary causesType IAutosomal dominantGene deletions or point mutations lead to quantitative abnormalities of ATType IIAutosomal dominantSingle amino acid substitution leads to functional abnormalities of AT",
                    "sub_points": [
                      "Type IAutosomal dominantGene deletions or point mutations lead to quantitative abnormalities of AT",
                      "Autosomal dominant",
                      "Gene deletions or point mutations lead to quantitative abnormalities of AT",
                      "Type IIAutosomal dominantSingle amino acid substitution leads to functional abnormalities of AT",
                      "Autosomal dominant",
                      "Single amino acid substitution leads to functional abnormalities of AT"
                    ]
                  },
                  {
                    "text": "Physiologic changes in ATNewbornsHealthy neonates born with < 50% of normal adult AT levelsNewborns not predisposed to thrombotic complicationsAT activity remains unchanged during pregnancy",
                    "sub_points": [
                      "NewbornsHealthy neonates born with < 50% of normal adult AT levelsNewborns not predisposed to thrombotic complications",
                      "Healthy neonates born with < 50% of normal adult AT levels",
                      "Newborns not predisposed to thrombotic complications",
                      "AT activity remains unchanged during pregnancy"
                    ]
                  },
                  {
                    "text": "Acquired causesDecreased synthesisLiver diseaseIncreased consumptionSepsisIncreased clearanceKidney disease (i.e., nephrotic syndrome)Drug-induced (specifically heparin)Asparaginase therapy",
                    "sub_points": [
                      "Decreased synthesisLiver disease",
                      "Liver disease",
                      "Increased consumptionSepsis",
                      "Sepsis",
                      "Increased clearanceKidney disease (i.e., nephrotic syndrome)Drug-induced (specifically heparin)Asparaginase therapy",
                      "Kidney disease (i.e., nephrotic syndrome)",
                      "Drug-induced (specifically heparin)",
                      "Asparaginase therapy"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Antithrombin (AT)"
                  },
                  {
                    "text": "Extracorporeal membrane oxygenation (ECMO)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Evaluation of Antithrombin Activity": [
                  {
                    "text": "Chromogenic methods used to determine AT activityCan be used to diagnose inherited AT deficiencyCan be used to determine if AT replacement is necessary in patients undergoing heparin therapy for extended time periodsPatients on ECMO",
                    "sub_points": [
                      "Can be used to diagnose inherited AT deficiency",
                      "Can be used to determine if AT replacement is necessary in patients undergoing heparin therapy for extended time periodsPatients on ECMO",
                      "Patients on ECMO"
                    ]
                  },
                  {
                    "text": "AT activity normal range in adults is 70%-130%"
                  },
                  {
                    "text": "Use of age-adjusted normal ranges is warranted in infants"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fibrinolysis": {
            "name": "Fibrinolysis",
            "url": "https://app.pathprimer.com/document/dd550ac6-fa9b-416a-bb5f-3971400f3c4b/lesson/7fabcac6-1115-4967-8faf-4fc3511cbce9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Fibrinogen consists of 2 sets of 3 polypeptide chains (Aα, Bβ, γ) that are linked by disulfide bondsC-terminal ends of pairs of 3 polypeptide chains are on the outside (D-domains); this forms a triglobular structure with E-domain located centrally between 2 D-domains",
                    "sub_points": [
                      "C-terminal ends of pairs of 3 polypeptide chains are on the outside (D-domains); this forms a triglobular structure with E-domain located centrally between 2 D-domains"
                    ]
                  },
                  {
                    "text": "After coagulation is initiated, final common pathway is conversion of fibrinogen to fibrinThrombin cleaves FPA and FPB on fibrinogen to create soluble fibrin monomerFPA and FPB are released, and areas of E domain are exposedExposed areas on E domains bind D domains of other fibrin monomers to form insoluble fibrin polymers and then fibers",
                    "sub_points": [
                      "Thrombin cleaves FPA and FPB on fibrinogen to create soluble fibrin monomer",
                      "FPA and FPB are released, and areas of E domain are exposed",
                      "Exposed areas on E domains bind D domains of other fibrin monomers to form insoluble fibrin polymers and then fibers"
                    ]
                  },
                  {
                    "text": "Factor XIIIa stabilizes fibrin polymer by cross-linking D-domains; this cross-linked fibrin has greater strength and resistance to fibrinolysis"
                  },
                  {
                    "text": "Clot lysis is initiated by tPA"
                  },
                  {
                    "text": "tPA activates plasminogen to produce plasmin"
                  }
                ]
              },
              "OVERVIEW": {
                "Formation of Fibrin From Fibrinogen": [
                  {
                    "text": "Fibrinogen is soluble molecule present in plasmaPresent in plasma at concentration of 200-400 g/LFibrinogen is acute phase reactant and increases during stress, inflammation, pregnancyFibrinogen consists of 2 sets of 3 polypeptide chains (Aα, Bβ, γ) that are linked by disulfide bondsN-terminal ends of each of 2 sets of 3 polypeptide chains face each other to form globular structure called E-domainC-terminal ends of pairs of 3 polypeptide chains are on the outside (D-domains)This forms triglobular structure with E-domain located centrally between 2 D-domainsFPA and FPB are present on α and β chains on E-domainThrombin cleaves FPA and FPB, which initiates formation of fibrin polymersFibrinogen participates in aggregation phase of primary hemostasis by bridging activated plateletsFibrinogen has role in inflammation and wound repair",
                    "sub_points": [
                      "Present in plasma at concentration of 200-400 g/LFibrinogen is acute phase reactant and increases during stress, inflammation, pregnancy",
                      "Fibrinogen is acute phase reactant and increases during stress, inflammation, pregnancy",
                      "Fibrinogen consists of 2 sets of 3 polypeptide chains (Aα, Bβ, γ) that are linked by disulfide bondsN-terminal ends of each of 2 sets of 3 polypeptide chains face each other to form globular structure called E-domainC-terminal ends of pairs of 3 polypeptide chains are on the outside (D-domains)This forms triglobular structure with E-domain located centrally between 2 D-domainsFPA and FPB are present on α and β chains on E-domainThrombin cleaves FPA and FPB, which initiates formation of fibrin polymers",
                      "N-terminal ends of each of 2 sets of 3 polypeptide chains face each other to form globular structure called E-domain",
                      "C-terminal ends of pairs of 3 polypeptide chains are on the outside (D-domains)",
                      "This forms triglobular structure with E-domain located centrally between 2 D-domains",
                      "FPA and FPB are present on α and β chains on E-domainThrombin cleaves FPA and FPB, which initiates formation of fibrin polymers",
                      "Thrombin cleaves FPA and FPB, which initiates formation of fibrin polymers",
                      "Fibrinogen participates in aggregation phase of primary hemostasis by bridging activated platelets",
                      "Fibrinogen has role in inflammation and wound repair"
                    ]
                  },
                  {
                    "text": "Fibrin formationAfter coagulation is initiated, final common pathway is conversion of fibrinogen to fibrinThrombin is generated as product of prothrombinase complexFXa:FVa:FII:Ca²⁺:phospholipid converts factor II (prothrombin) to factor IIa (thrombin)Thrombin cleaves FPA and FPB on fibrinogen to to create soluble fibrin monomerFPA and FPB are releasedAreas of E-domain are exposedExposed areas on E-domains bind D-domains of other fibrin monomers to form insoluble fibrin polymers and fibersFactor XIIIa stabilizes fibrin polymer by cross-linking D-domainsCross-linked fibrin has greater strength and resistance to fibrinolysisThrombin acts on factor XIII to form factor XIIIaα₂-Antiplasmin is incorporated into fibrin network",
                    "sub_points": [
                      "After coagulation is initiated, final common pathway is conversion of fibrinogen to fibrin",
                      "Thrombin is generated as product of prothrombinase complexFXa:FVa:FII:Ca²⁺:phospholipid converts factor II (prothrombin) to factor IIa (thrombin)",
                      "FXa:FVa:FII:Ca²⁺:phospholipid converts factor II (prothrombin) to factor IIa (thrombin)",
                      "Thrombin cleaves FPA and FPB on fibrinogen to to create soluble fibrin monomer",
                      "FPA and FPB are releasedAreas of E-domain are exposedExposed areas on E-domains bind D-domains of other fibrin monomers to form insoluble fibrin polymers and fibers",
                      "Areas of E-domain are exposed",
                      "Exposed areas on E-domains bind D-domains of other fibrin monomers to form insoluble fibrin polymers and fibers",
                      "Factor XIIIa stabilizes fibrin polymer by cross-linking D-domainsCross-linked fibrin has greater strength and resistance to fibrinolysisThrombin acts on factor XIII to form factor XIIIaα₂-Antiplasmin is incorporated into fibrin network",
                      "Cross-linked fibrin has greater strength and resistance to fibrinolysis",
                      "Thrombin acts on factor XIII to form factor XIIIa",
                      "α₂-Antiplasmin is incorporated into fibrin network"
                    ]
                  }
                ],
                "Fibrinolysis": [
                  {
                    "text": "Clot lysis is initiated by tPA"
                  },
                  {
                    "text": "Clot lysis is mechanism to limit clot propagation and to dissolve clots when they are no longer needed"
                  },
                  {
                    "text": "tPA activates plasminogen to produce plasminPlasminogen and tPA bound to fibrin surfacetPA produced by endothelial cells and released after cell activation by fibrin",
                    "sub_points": [
                      "Plasminogen and tPA bound to fibrin surface",
                      "tPA produced by endothelial cells and released after cell activation by fibrin"
                    ]
                  },
                  {
                    "text": "uPA is another plasminogen activatorPresent in plasma and subendotheliumInitially isolated from urineProduced by urothelial cellsuPA has greater activity on soluble fibrin(ogen) than tPAtPA has predominantly surface activity",
                    "sub_points": [
                      "Present in plasma and subendothelium",
                      "Initially isolated from urineProduced by urothelial cells",
                      "Produced by urothelial cells",
                      "uPA has greater activity on soluble fibrin(ogen) than tPAtPA has predominantly surface activity",
                      "tPA has predominantly surface activity"
                    ]
                  },
                  {
                    "text": "Plasmin acts to lyse bonds in fibrin(ogen)Resulting products are FDPsFDPs can include any of the fragmentsDegradation of fibrinogen releases D, D-E, and E fragmentsFollowing fragments can also be released from cross-linked fibrin: D-E, E-D-E, D-D-E, D-D (D-dimer)Presence of specific FDP, D-dimer, is evidence of the followingThrombin acted on fibrinogen to form fibrinCross-linked fibrin was formed (linkage of D-domains by action of factor XIIIa)Plasmin was generated and clot lysis occurred",
                    "sub_points": [
                      "Resulting products are FDPsFDPs can include any of the fragmentsDegradation of fibrinogen releases D, D-E, and E fragmentsFollowing fragments can also be released from cross-linked fibrin: D-E, E-D-E, D-D-E, D-D (D-dimer)Presence of specific FDP, D-dimer, is evidence of the followingThrombin acted on fibrinogen to form fibrinCross-linked fibrin was formed (linkage of D-domains by action of factor XIIIa)Plasmin was generated and clot lysis occurred",
                      "FDPs can include any of the fragmentsDegradation of fibrinogen releases D, D-E, and E fragmentsFollowing fragments can also be released from cross-linked fibrin: D-E, E-D-E, D-D-E, D-D (D-dimer)",
                      "Degradation of fibrinogen releases D, D-E, and E fragments",
                      "Following fragments can also be released from cross-linked fibrin: D-E, E-D-E, D-D-E, D-D (D-dimer)",
                      "Presence of specific FDP, D-dimer, is evidence of the followingThrombin acted on fibrinogen to form fibrinCross-linked fibrin was formed (linkage of D-domains by action of factor XIIIa)Plasmin was generated and clot lysis occurred",
                      "Thrombin acted on fibrinogen to form fibrin",
                      "Cross-linked fibrin was formed (linkage of D-domains by action of factor XIIIa)",
                      "Plasmin was generated and clot lysis occurred"
                    ]
                  }
                ],
                "Natural Inhibitors of Fibrinolysis": [
                  {
                    "text": "Plasmin inactivated in 1:1 stoichiometry with PAI-1 and PAI-2"
                  },
                  {
                    "text": "Plasmin inactivated by α₂-antiplasmin, TAFI, α₂-macroglobulin"
                  }
                ],
                "Hyperfibrinolysis": [
                  {
                    "text": "Excess fibrinolytic activity associated with bleeding"
                  },
                  {
                    "text": "DIC most common cause of hyperfibrinolysis"
                  },
                  {
                    "text": "Deficiency of natural antifibrinolytics such as α₂-antiplasminDecreased synthesis of α₂-antiplasmin in chronic liver diseaseUrinary loss of α₂-antiplasmin in nephrotic syndrome",
                    "sub_points": [
                      "Decreased synthesis of α₂-antiplasmin in chronic liver disease",
                      "Urinary loss of α₂-antiplasmin in nephrotic syndrome"
                    ]
                  },
                  {
                    "text": "Primary fibrinolysis from production of urokinase in urothelial carcinoma and prostate cancer"
                  },
                  {
                    "text": "Trauma is associated with hyperfibrinolysistPA release from tissue damagePAI-1 release in shock",
                    "sub_points": [
                      "tPA release from tissue damage",
                      "PAI-1 release in shock"
                    ]
                  },
                  {
                    "text": "Cardiopulmonary bypass can lead to tPA release"
                  }
                ],
                "Hypofibrinolysis": [
                  {
                    "text": "Hypofibrinolysis can cause thrombosisAutoantibodies to tPA can lead to thrombosisAlcoholic liver disease or nephrotic syndrome leads to PAI-1 deficiency and increased thrombosisHypothyroidism associated with abnormal activity of tPA, PAI-1, TAFI, α₂-antiplasminMultiple myeloma hypofibrinolysis can start after induction chemotherapy",
                    "sub_points": [
                      "Autoantibodies to tPA can lead to thrombosis",
                      "Alcoholic liver disease or nephrotic syndrome leads to PAI-1 deficiency and increased thrombosis",
                      "Hypothyroidism associated with abnormal activity of tPA, PAI-1, TAFI, α₂-antiplasmin",
                      "Multiple myeloma hypofibrinolysis can start after induction chemotherapy"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fibrinopeptides A and B (FPA and FPB)"
                  },
                  {
                    "text": "Tissue plasminogen activator (tPA)"
                  },
                  {
                    "text": "Urokinase plasminogen activator (uPA)"
                  },
                  {
                    "text": "Fibrin(ogen) degradation products (FDPs)"
                  },
                  {
                    "text": "Plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2 (PAI-1 and PAI-2)"
                  },
                  {
                    "text": "Tissue activatable fibrinolysis inhibitor (TAFI)"
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)"
                  },
                  {
                    "text": "Thromboelastography (TEG)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Clot Lysis": [
                  {
                    "text": "Clot lysis time is global test of fibrinolysis"
                  },
                  {
                    "text": "Platelet-poor plasma is clottedExogenous tPA added to fibrin clot",
                    "sub_points": [
                      "Exogenous tPA added to fibrin clot"
                    ]
                  },
                  {
                    "text": "Amount of time it takes to lyse clot is reported as clot lysis time"
                  },
                  {
                    "text": "Increase in clot lysis time associated with hypofibrinolysis and risk of thrombosis"
                  },
                  {
                    "text": "Clot lysis time not as predictive for hyperfibrinolysis"
                  }
                ],
                "Thromboelastography": [
                  {
                    "text": "TEG measures viscoelastic properties of clot formation from whole blood"
                  },
                  {
                    "text": "Test measures amount of torque required to rotate pin or cup as clot forms in sample container"
                  },
                  {
                    "text": "Maximum strength of clot reflects platelet function and activity of fibrinogen"
                  },
                  {
                    "text": "Amount of time it takes for clot to lyse, as measured by decreasing clot strength after reaching maximum strength, reflects fibrinolysis"
                  },
                  {
                    "text": "Additional types of tests are available with these instrumentsSpecific inhibitor of platelets can be added so that maximum strength reflects only fibrinogen activity",
                    "sub_points": [
                      "Specific inhibitor of platelets can be added so that maximum strength reflects only fibrinogen activity"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Laboratory Evaluation of Hemostasis": {
        "name": "Laboratory Evaluation of Hemostasis",
        "url": "https://app.pathprimer.com/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
        "topics": {
          "Normal Light Transmission Platelet Aggregometry (LTA)": {
            "name": "Normal Light Transmission Platelet Aggregometry (LTA)",
            "url": "https://app.pathprimer.com/document/42ce9dc0-9a71-4588-9f67-a2b7e2d4e0f2/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Defective platelet function suspected when platelet count is normal in setting of bleeding that is characteristic of disorder of primary hemostasis"
                  },
                  {
                    "text": "Platelet function is evaluated by observing response of platelets to agonists that bind to platelets via their receptors leading to activation and aggregation"
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "Agonists known to bind to or activate platelet receptors are used to evaluate platelet function in LTA﻿ADP agonist binds P2Y1 and P2Y12 receptors﻿Epinephrine agonist binds to adrenergic receptors﻿Type I collagen binds to GPIa-IIa and GPVIAA agonist is metabolized to TXA₂, which binds to TX receptorsRistocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutination",
                    "sub_points": [
                      "﻿ADP agonist binds P2Y1 and P2Y12 receptors",
                      "﻿Epinephrine agonist binds to adrenergic receptors",
                      "﻿Type I collagen binds to GPIa-IIa and GPVI",
                      "AA agonist is metabolized to TXA₂, which binds to TX receptors",
                      "Ristocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutination"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Pattern of response to agonists can help in determining if there is platelet function defect and can help categorize type of defect"
                  }
                ],
                "Limitations": [
                  {
                    "text": "Extensive list of medications and dietary substances that can inhibit platelet function"
                  }
                ],
                "Specimens": [
                  {
                    "text": "Patients should not take medications known to affect platelet function for 10-14 days before specimen collection"
                  }
                ]
              },
              "OVERVIEW": {
                "Platelet Function Testing": [
                  {
                    "text": "Indicated to determine if bleeding is due to defective platelet functionAdhesionActivationGranule releaseAggregation",
                    "sub_points": [
                      "Adhesion",
                      "Activation",
                      "Granule release",
                      "Aggregation"
                    ]
                  },
                  {
                    "text": "Defective platelet function suspected when platelet count is normal in setting of bleeding that is characteristic of disorder of primary hemostasis"
                  },
                  {
                    "text": "LTA is considered gold standard for platelet function testing"
                  },
                  {
                    "text": "Platelet function is evaluated by observing response of platelets to agonists that bind to platelets via their receptors leading to activation and aggregation"
                  },
                  {
                    "text": "LTA uses PRP to assess response of patient platelets to panel of added (exogenous) agonists"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Light transmission aggregometry (LTA)"
                  },
                  {
                    "text": "Platelet-rich plasma (PRP)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Protease-activated receptor (PAR)"
                  },
                  {
                    "text": "Thromboxane A₂ (TXA₂)"
                  },
                  {
                    "text": "Thromboxane (TX)"
                  },
                  {
                    "text": "Arachidonic acid (AA)"
                  },
                  {
                    "text": "Thrombin receptor activating peptide (TRAP)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Platelet Receptors": [
                  {
                    "text": "Platelets have important signaling, adhesion, and aggregation receptors on their surface that interact with endogenous agonistsGPIb-V-IX binds to vWF﻿GPIa-IIa binds to collagen﻿GPVI binds to collagen﻿GPIIb-IIIa binds to fibrinogen and vWFAdrenergic receptors bind to epinephrineP2Y1 receptor binds to ADPP2Y12 receptor binds to ADPThrombin activates PARsPAR-1 and PAR-4TXA₂ binds to TX receptor",
                    "sub_points": [
                      "GPIb-V-IX binds to vWF",
                      "﻿GPIa-IIa binds to collagen",
                      "﻿GPVI binds to collagen",
                      "﻿GPIIb-IIIa binds to fibrinogen and vWF",
                      "Adrenergic receptors bind to epinephrine",
                      "P2Y1 receptor binds to ADP",
                      "P2Y12 receptor binds to ADP",
                      "Thrombin activates PARsPAR-1 and PAR-4",
                      "PAR-1 and PAR-4",
                      "TXA₂ binds to TX receptor"
                    ]
                  }
                ],
                "Platelet Agonists Used in Testing Platelet Function": [
                  {
                    "text": "Agonists known to bind to or activate platelet receptors are used to evaluate platelet function in LTA﻿ADP agonist binds P2Y1 and P2Y12 receptors﻿Epinephrine agonist binds to adrenergic receptorsAA agonist is metabolized to TXA₂, which binds to TX receptors﻿Type I collagen binds to GPIa-IIa and GPVIRistocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutinationGamma-thrombin activates PARsTRAP activates PAR-1 and PAR-4U-46619 binds to the TX receptor",
                    "sub_points": [
                      "﻿ADP agonist binds P2Y1 and P2Y12 receptors",
                      "﻿Epinephrine agonist binds to adrenergic receptors",
                      "AA agonist is metabolized to TXA₂, which binds to TX receptors",
                      "﻿Type I collagen binds to GPIa-IIa and GPVI",
                      "Ristocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutination",
                      "Gamma-thrombin activates PARs",
                      "TRAP activates PAR-1 and PAR-4",
                      "U-46619 binds to the TX receptor"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "LTA": [
                  {
                    "text": "PRP has high optical density and transmits light poorly because platelets prevent passage of light"
                  },
                  {
                    "text": "PPP has been depleted of platelets and is able to transmit light well (low optical density)"
                  },
                  {
                    "text": "When substance that promotes platelet activation and aggregation (agonist) is added to PRP, normal platelets are activated and aggregate"
                  },
                  {
                    "text": "Platelet aggregometer is instrument that measures change in optical density (or light transmittance) over time of stirred PRP in cuvettes at 37°C after addition of agonistsAggregometers calibrated for light transmission using autologous PPP and PRPPPP—100% light transmissionPRP—0% light transmission",
                    "sub_points": [
                      "Aggregometers calibrated for light transmission using autologous PPP and PRPPPP—100% light transmissionPRP—0% light transmission",
                      "PPP—100% light transmission",
                      "PRP—0% light transmission"
                    ]
                  },
                  {
                    "text": "Aggregation of platelets in PRP results in decrease in optical density (increased light transmittance) as aggregated platelets fall out of path of light"
                  },
                  {
                    "text": "LTA measures change in optical density (or light transmittance) of stirred PRP that occurs after addition of agonistsAggregation tracing presents change in light transmission (y-axis) against time in minutes (x-axis)After addition of agonist, light transmission response should be observed for at least 5 minBaseline panel of agonists generally used for LTAADP (0.5-20 µM)Epinephrine (0.5-10 µM)Collagen (1.0-5.0 µg/mL)Ristocetin (0.8-1.5 mg/mL)AA (0.5-1.64 mM)Additional agonists can be considered to further investigate abnormal responses noted with baseline panel",
                    "sub_points": [
                      "Aggregation tracing presents change in light transmission (y-axis) against time in minutes (x-axis)",
                      "After addition of agonist, light transmission response should be observed for at least 5 min",
                      "Baseline panel of agonists generally used for LTAADP (0.5-20 µM)Epinephrine (0.5-10 µM)Collagen (1.0-5.0 µg/mL)Ristocetin (0.8-1.5 mg/mL)AA (0.5-1.64 mM)",
                      "ADP (0.5-20 µM)",
                      "Epinephrine (0.5-10 µM)",
                      "Collagen (1.0-5.0 µg/mL)",
                      "Ristocetin (0.8-1.5 mg/mL)",
                      "AA (0.5-1.64 mM)",
                      "Additional agonists can be considered to further investigate abnormal responses noted with baseline panel"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Diagnosis of Bleeding Disorder": [
                  {
                    "text": "Pattern of response to agonists can help in determining if there is platelet function defect and can help categorize type of defect"
                  }
                ],
                "Monitoring Antiplatelet Therapy": [
                  {
                    "text": "Effects of antiplatelet medications can be seen with LTA"
                  },
                  {
                    "text": "LTA used for monitoring antiplatelet therapy typically in research setting"
                  },
                  {
                    "text": "Antiplatelet therapy monitoring typically performed using assays that are performed more quickly and are less labor-intensive"
                  }
                ]
              },
              "LIMITATIONS": {
                "Standardization": [
                  {
                    "text": "Wide variation in laboratory practice with performance of LTAConcentrations of agonists usedWhether or not to adjust platelet count of PRP with PPPWhether or not sample from normal control is analyzed on day of testing",
                    "sub_points": [
                      "Concentrations of agonists used",
                      "Whether or not to adjust platelet count of PRP with PPP",
                      "Whether or not sample from normal control is analyzed on day of testing"
                    ]
                  }
                ],
                "Influence of Medications and Dietary Components": [
                  {
                    "text": "Extensive list of medications and dietary substances that can inhibit platelet function"
                  },
                  {
                    "text": "Abnormal LTA result can be due to ingestion of medication or other dietary substance, rather than inherent platelet defect"
                  }
                ],
                "Thrombocytopenia": [
                  {
                    "text": "PRP that has low platelet count can give abnormal response to agonists independent of true platelet dysfunction"
                  },
                  {
                    "text": "If PRP with platelet count < 150 x 10⁹/L is used, abnormal results should be treated with caution"
                  },
                  {
                    "text": "Ideally, platelet count of normal control specimen is adjusted to platelet count of patientResponse to agonists is compared",
                    "sub_points": [
                      "Response to agonists is compared"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Patients should not take medications known to affect platelet function for 10-14 days before specimen collection"
                  },
                  {
                    "text": "Atraumatic venipuncture using minimum tourniquet pressure"
                  },
                  {
                    "text": "3.2% sodium citrate1:9 citrate-to-whole blood ratio",
                    "sub_points": [
                      "1:9 citrate-to-whole blood ratio"
                    ]
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ],
                "Transport": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature"
                  },
                  {
                    "text": "Tubes should not be subjected to vibration, shaking, vortexing, continuous mixing, or agitation"
                  },
                  {
                    "text": "Samples should not be transported via pneumatic tube system"
                  },
                  {
                    "text": "Samples should be tested between 30 min and no more than 4 hr from blood collection"
                  }
                ]
              },
              "PROCESSING": {
                "Centrifugation": [
                  {
                    "text": "Citrated blood samples are centrifuged to prepare PRP and PPPWhole-blood tubes centrifuged at 170gto 200gfor 10 min at room temperature to make PRPWhole-blood samples or PRP centrifuged at minimum of 1500gfor at least 15 min at room temperature to make PPPPRP or PPP transferred to polypropylene tubes, capped, and stored at room temperature",
                    "sub_points": [
                      "Whole-blood tubes centrifuged at 170gto 200gfor 10 min at room temperature to make PRP",
                      "Whole-blood samples or PRP centrifuged at minimum of 1500gfor at least 15 min at room temperature to make PPP",
                      "PRP or PPP transferred to polypropylene tubes, capped, and stored at room temperature"
                    ]
                  }
                ],
                "Platelet Count of PRP": [
                  {
                    "text": "Platelet count of PRP is performed and should be 200-300 x 10⁹/L"
                  },
                  {
                    "text": "If platelet count is > 300 x 10⁹/L, concentration can be adjusted with autologous PPP"
                  }
                ],
                "Addition of Agonist": [
                  {
                    "text": "PRP is added to cuvette along with stirring bar"
                  },
                  {
                    "text": "Agonist is added at maximum of one-tenth volume of agonist to PRP to initiate aggregation"
                  }
                ]
              },
              "LABORATORY STATISTICS": {
                "Interpretation of Results": [
                  {
                    "text": "Several parameters are evaluated for interpretation of these studiesLag phase (time between addition of agonist and start of aggregation)Platelet shape changePrimary aggregation slopeSecondary aggregationDisaggregationMaximum amplitudePercent aggregationStirred PRP set at 0% aggregationPPP set at 100% aggregationPercent aggregation after addition of agonist calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of sample) ÷ distance (along y-axis of aggregation tracing) from 0% to 100% aggregation (PPP) x 100",
                    "sub_points": [
                      "Lag phase (time between addition of agonist and start of aggregation)",
                      "Platelet shape change",
                      "Primary aggregation slope",
                      "Secondary aggregation",
                      "Disaggregation",
                      "Maximum amplitude",
                      "Percent aggregationStirred PRP set at 0% aggregationPPP set at 100% aggregationPercent aggregation after addition of agonist calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of sample) ÷ distance (along y-axis of aggregation tracing) from 0% to 100% aggregation (PPP) x 100",
                      "Stirred PRP set at 0% aggregation",
                      "PPP set at 100% aggregation",
                      "Percent aggregation after addition of agonist calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of sample) ÷ distance (along y-axis of aggregation tracing) from 0% to 100% aggregation (PPP) x 100"
                    ]
                  },
                  {
                    "text": "Based on parameters used to evaluate these studies, response to given agonist is designated as either normal or abnormal"
                  },
                  {
                    "text": "Pattern of normal and abnormal responses to agonists is used to identify possible defect in platelet function"
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Sample from healthy normal control volunteer who is known to have normal platelet function and who is not taking any medications known to inhibit platelet function should run on each day that patient samples are analyzed"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Interpretation of LTA: Adhesion Defects": {
            "name": "Interpretation of LTA: Adhesion Defects",
            "url": "https://app.pathprimer.com/document/f60f5f6b-84f9-4cda-b0c5-f8a069ded6ae/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Defective platelet function is suspected when platelet count is normal and there is bleeding characteristic of a disorder of primary hemostasis"
                  },
                  {
                    "text": "Platelet function is typically evaluated by observing response of platelets to agonists that bind to platelets via their receptors, leading to activation and aggregation"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Pattern of response to agonists can help in determining if there is a platelet function defect and can help categorize type of defect"
                  },
                  {
                    "text": "Abnormal agglutination response only to ristocetin agonist may be noted if there is defect in GPIb receptor as in BSS or decreased/abnormal vWF as in vWDExamination of peripheral blood smear can be helpful in distinguishing vWD and BSS, as BSS is usually accompanied by macrothrombocytopenia (giant platelets)Addition of cryoprecipitate (source of vWF) corrects abnormal response to ristocetin that may be seen in vWD, but not in BSS",
                    "sub_points": [
                      "Examination of peripheral blood smear can be helpful in distinguishing vWD and BSS, as BSS is usually accompanied by macrothrombocytopenia (giant platelets)",
                      "Addition of cryoprecipitate (source of vWF) corrects abnormal response to ristocetin that may be seen in vWD, but not in BSS"
                    ]
                  },
                  {
                    "text": "Abnormal aggregation response only to collagen agonist may be noted if there is defect in collagen receptors (GPIa-IIa or GPVI)"
                  }
                ]
              },
              "OVERVIEW": {
                "Platelet Function Testing": [
                  {
                    "text": "Indicated for bleeding due to disorders in primary hemostasis (inability to form platelet plug)May be caused by low platelet counts (thrombocytopenia) &/or defective platelet function (i.e., adhesion, activation, granule release, aggregation)",
                    "sub_points": [
                      "May be caused by low platelet counts (thrombocytopenia) &/or defective platelet function (i.e., adhesion, activation, granule release, aggregation)"
                    ]
                  },
                  {
                    "text": "Defective platelet function suspected when platelet count is normal and there is bleeding characteristic of a disorder of primary hemostasisPlatelet function is typically evaluated by observing response of platelets to agonists that bind to platelets via their receptors, leading to activation and aggregation",
                    "sub_points": [
                      "Platelet function is typically evaluated by observing response of platelets to agonists that bind to platelets via their receptors, leading to activation and aggregation"
                    ]
                  },
                  {
                    "text": "LTA is considered gold standard for platelet function testing"
                  },
                  {
                    "text": "LTA uses PRP to assess response of patient platelets to panel of added (exogenous) agonists"
                  },
                  {
                    "text": "LTA can detect defects in platelet adhesion"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Light transmission aggregometry (LTA)"
                  },
                  {
                    "text": "Platelet-rich plasma (PRP)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Arachidonic acid (AA)"
                  },
                  {
                    "text": "Bernard-Soulier syndrome (BSS)"
                  },
                  {
                    "text": "von Willebrand disease (vWD)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Platelet Receptors": [
                  {
                    "text": "Platelets have important adhesion receptors on their surface that interact with endogenous agonistsGPIb-V-IX binds to vWFGPIa-IIa binds to collagenGPVI binds to collagen",
                    "sub_points": [
                      "GPIb-V-IX binds to vWF",
                      "GPIa-IIa binds to collagen",
                      "GPVI binds to collagen"
                    ]
                  }
                ],
                "Platelet Agonists Used in Testing Platelet Function (Adhesion)": [
                  {
                    "text": "Response to various agonists that are known to be involved in platelet adhesion is used to evaluate platelet adhesion in LTA﻿Type I collagen binds to GPIa-IIa and GPVIRistocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutination",
                    "sub_points": [
                      "﻿Type I collagen binds to GPIa-IIa and GPVI",
                      "Ristocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutination"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "LTA": [
                  {
                    "text": "PRP has high optical density and transmits light poorly because platelets prevent passage of light"
                  },
                  {
                    "text": "PPP has been depleted of platelets and is able to transmit light well (low optical density)"
                  },
                  {
                    "text": "When substance that promotes platelet adhesion is added to PRP, normal platelets become activated or agglutinatePlatelets become activated when collagen agonist is addedPlatelets agglutinate when ristocetin is added",
                    "sub_points": [
                      "Platelets become activated when collagen agonist is added",
                      "Platelets agglutinate when ristocetin is added"
                    ]
                  },
                  {
                    "text": "Platelet aggregometer is instrument that measures change in optical density (or light transmittance) over time of stirred PRP in cuvettes at 37°C after addition of agonistsAggregometers are calibrated for light transmission using autologous PPP and PRPPPP—100% light transmissionPRP—0% light transmission",
                    "sub_points": [
                      "Aggregometers are calibrated for light transmission using autologous PPP and PRPPPP—100% light transmissionPRP—0% light transmission",
                      "PPP—100% light transmission",
                      "PRP—0% light transmission"
                    ]
                  },
                  {
                    "text": "Aggregation of platelets in PRP results in decrease in optical density (increased light transmittance) as aggregated platelets fall out of path of light"
                  },
                  {
                    "text": "LTA measures change in optical density (or light transmittance) of stirred PRP that occurs after addition of agonistsAggregation tracing presents change in light transmission (y-axis) against time in minutes (x-axis)After addition of agonist, light transmission response should be observed for at least 5 minBaseline panel of agonists is generally used for LTAADP (0.5-20 µM)Epinephrine (0.5-10 µM)Collagen (1.0-5.0 µg/mL)Ristocetin (0.8-1.5 mg/mL)AA (0.5-1.64 mM)",
                    "sub_points": [
                      "Aggregation tracing presents change in light transmission (y-axis) against time in minutes (x-axis)",
                      "After addition of agonist, light transmission response should be observed for at least 5 min",
                      "Baseline panel of agonists is generally used for LTAADP (0.5-20 µM)Epinephrine (0.5-10 µM)Collagen (1.0-5.0 µg/mL)Ristocetin (0.8-1.5 mg/mL)AA (0.5-1.64 mM)",
                      "ADP (0.5-20 µM)",
                      "Epinephrine (0.5-10 µM)",
                      "Collagen (1.0-5.0 µg/mL)",
                      "Ristocetin (0.8-1.5 mg/mL)",
                      "AA (0.5-1.64 mM)"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Diagnosis of Bleeding Disorder": [
                  {
                    "text": "Pattern of response to agonists can help in determining if there is platelet function defect and can help categorize type of defectAbnormal agglutination response only to ristocetin agonist may be noted if there is defect in GPIb receptor as in BSS or decreased/abnormal vWF as in vWDExamination of peripheral blood smear can be helpful in distinguishing vWD and BSSBSS is usually accompanied by macrothrombocytopenia (giant platelets)Addition of cryoprecipitate (source of vWF) corrects abnormal response to ristocetin that may be seen in vWD, but not in BSSvWF antigen and activity studies and factor VIII activity assay can be performed if vWD is suspectedAbnormal aggregation response only to collagen agonist may be noted if there is defect in collagen receptors (GPIa-IIa or GPVI)Flow cytometry can be used to evaluate for low levels of GPIa-IIa or GPVIAggregation studies with collagen-related protein (GPVI agonist) can be performed to test specifically for GPVI defect",
                    "sub_points": [
                      "Abnormal agglutination response only to ristocetin agonist may be noted if there is defect in GPIb receptor as in BSS or decreased/abnormal vWF as in vWDExamination of peripheral blood smear can be helpful in distinguishing vWD and BSSBSS is usually accompanied by macrothrombocytopenia (giant platelets)Addition of cryoprecipitate (source of vWF) corrects abnormal response to ristocetin that may be seen in vWD, but not in BSSvWF antigen and activity studies and factor VIII activity assay can be performed if vWD is suspected",
                      "Examination of peripheral blood smear can be helpful in distinguishing vWD and BSSBSS is usually accompanied by macrothrombocytopenia (giant platelets)",
                      "BSS is usually accompanied by macrothrombocytopenia (giant platelets)",
                      "Addition of cryoprecipitate (source of vWF) corrects abnormal response to ristocetin that may be seen in vWD, but not in BSS",
                      "vWF antigen and activity studies and factor VIII activity assay can be performed if vWD is suspected",
                      "Abnormal aggregation response only to collagen agonist may be noted if there is defect in collagen receptors (GPIa-IIa or GPVI)Flow cytometry can be used to evaluate for low levels of GPIa-IIa or GPVIAggregation studies with collagen-related protein (GPVI agonist) can be performed to test specifically for GPVI defect",
                      "Flow cytometry can be used to evaluate for low levels of GPIa-IIa or GPVI",
                      "Aggregation studies with collagen-related protein (GPVI agonist) can be performed to test specifically for GPVI defect"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Standardization": [
                  {
                    "text": "There is wide variation in laboratory practice with performance of LTAConcentrations of agonists usedWhether or not to adjust platelet count of PRP with PPPWhether or not a sample from normal control is analyzed on day of testing",
                    "sub_points": [
                      "Concentrations of agonists used",
                      "Whether or not to adjust platelet count of PRP with PPP",
                      "Whether or not a sample from normal control is analyzed on day of testing"
                    ]
                  }
                ],
                "Influence of Medications and Dietary Components": [
                  {
                    "text": "Extensive list of medications and dietary substances that can inhibit platelet function"
                  },
                  {
                    "text": "Risk exists that abnormal LTA result is due to ingestion of medication or other dietary substance, rather than inherent platelet defect"
                  },
                  {
                    "text": "Ingestion of aspirin can inhibit aggregation response to collagen agonist"
                  }
                ],
                "Thrombocytopenia": [
                  {
                    "text": "PRP that has low platelet count can give abnormal response to agonists in absence of true platelet dysfunction"
                  },
                  {
                    "text": "If PRP with platelet count < 150 x 10⁹/L is to be used, abnormal results should be treated with caution"
                  },
                  {
                    "text": "Platelet count of normal control specimen is adjusted to platelet count of patient before response to agonists is compared"
                  },
                  {
                    "text": "Patients with BSS are likely to have severe thrombocytopeniaIt is still useful to adjust patient and control platelet counts before performing LTA",
                    "sub_points": [
                      "It is still useful to adjust patient and control platelet counts before performing LTA"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Patients should not take medications known to affect platelet function for 10-14 days before specimen collection"
                  },
                  {
                    "text": "Atraumatic venipuncture using minimum tourniquet pressure"
                  },
                  {
                    "text": "3.2% sodium citrate1:9 citrate-to-whole blood ratio",
                    "sub_points": [
                      "1:9 citrate-to-whole blood ratio"
                    ]
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ],
                "Transport": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature"
                  },
                  {
                    "text": "Tubes should not be subjected to vibration, shaking, vortexing, continuous mixing, or agitation"
                  },
                  {
                    "text": "Samples should not be transported via pneumatic tube system"
                  },
                  {
                    "text": "Samples should be tested between 30 min and no more than 4 hr from blood collection"
                  }
                ]
              },
              "PROCESSING": {
                "Centrifugation": [
                  {
                    "text": "Citrated blood samples are centrifuged to prepare PRP and PPPWhole-blood tubes centrifuged at 170gto 200gfor 10 min at room temperature to make PRPWhole-blood samples or PRP centrifuged at minimum of 1500gfor at least 15 min at room temperature to make PPPPRP or PPP transferred to polypropylene tubes, capped, and stored at room temperature",
                    "sub_points": [
                      "Whole-blood tubes centrifuged at 170gto 200gfor 10 min at room temperature to make PRP",
                      "Whole-blood samples or PRP centrifuged at minimum of 1500gfor at least 15 min at room temperature to make PPP",
                      "PRP or PPP transferred to polypropylene tubes, capped, and stored at room temperature"
                    ]
                  }
                ],
                "Platelet Count of PRP": [
                  {
                    "text": "Platelet count of PRP is performed and should be 200-300 x 10⁹/L"
                  },
                  {
                    "text": "If platelet count is > 300 x 10⁹/L, concentration can be adjusted with autologous PPP"
                  }
                ],
                "Addition of Agonist": [
                  {
                    "text": "PRP is added to cuvette along with stirring bar"
                  },
                  {
                    "text": "Agonist is added at maximum of one-tenth volume of agonist to PRP to initiate aggregation"
                  }
                ]
              },
              "LABORATORY STATISTICS": {
                "Interpretation of Results": [
                  {
                    "text": "Several parameters evaluated for interpretation of studiesLag phase (time between addition of agonist and start of aggregation)Platelet shape changePrimary aggregation slopeSecondary aggregationDisaggregationMaximum amplitudePercent aggregationStirred PRP set at 0% aggregationPPP set at 100% aggregationPercent aggregation after addition of agonist is calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of the sample) ÷ distance (along y-axis of aggregation tracing) from 0 to 100% aggregation (PPP) x 100",
                    "sub_points": [
                      "Lag phase (time between addition of agonist and start of aggregation)",
                      "Platelet shape change",
                      "Primary aggregation slope",
                      "Secondary aggregation",
                      "Disaggregation",
                      "Maximum amplitude",
                      "Percent aggregationStirred PRP set at 0% aggregationPPP set at 100% aggregationPercent aggregation after addition of agonist is calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of the sample) ÷ distance (along y-axis of aggregation tracing) from 0 to 100% aggregation (PPP) x 100",
                      "Stirred PRP set at 0% aggregation",
                      "PPP set at 100% aggregation",
                      "Percent aggregation after addition of agonist is calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of the sample) ÷ distance (along y-axis of aggregation tracing) from 0 to 100% aggregation (PPP) x 100"
                    ]
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Sample from healthy normal control volunteer who is known to have normal platelet function and who is not taking any medications known to inhibit platelet function should run on each day that patient samples are analyzed"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Interpretation of LTA: Release Reaction Defects": {
            "name": "Interpretation of LTA: Release Reaction Defects",
            "url": "https://app.pathprimer.com/document/28271043-aa0f-40cd-8e85-23f514ef13e8/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Platelet function is typically evaluated by observing response of platelets to agonists that bind to platelets via their receptors, leading to activation and aggregation"
                  },
                  {
                    "text": "Defective platelet function is suspected when platelet count is normal and there is bleeding that is characteristic of disorder of primary hemostasis"
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "As platelets become activated, they release substances that act as platelet agonists, adhesive proteins, coagulation factors, and growth modulators"
                  },
                  {
                    "text": "Platelet-dense granules contain platelet agonists (ADP and ATP) and signaling molecules (serotonin and calcium) that amplify platelet activation"
                  },
                  {
                    "text": "Release of platelet-dense granules is necessary for secondary wave of irreversible aggregation that is seen on LTA in response to ADP, epinephrine, and collagen agonists"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Defect in platelet-dense granules is due to either contents of granules (storage pool disorder) or inability to release granules (release defect) and manifests as lack of secondary aggregation on LTA in response to ADP, epinephrine, collagen, and AA"
                  }
                ],
                "Limitations": [
                  {
                    "text": "Medications that inhibit synthesis of PGs (e.g., aspirin) and decrease production of TXA₂ show pattern on LTA that resembles release defect or storage pool disorder"
                  }
                ]
              },
              "OVERVIEW": {
                "Platelet Function Testing": [
                  {
                    "text": "Indicated for bleeding due to disorders in primary hemostasis (inability to form platelet plug)May be caused by thrombocytopenia &/or defective platelet function (i.e., adhesion, activation, granule release, aggregation)",
                    "sub_points": [
                      "May be caused by thrombocytopenia &/or defective platelet function (i.e., adhesion, activation, granule release, aggregation)"
                    ]
                  },
                  {
                    "text": "Defective platelet function is suspected when platelet count is normal and there is bleeding that is characteristic of disorder of primary hemostasis"
                  },
                  {
                    "text": "Platelet function is evaluated by observing response of platelets to agonists that bind to platelets via their receptorsLeads to activation and aggregation",
                    "sub_points": [
                      "Leads to activation and aggregation"
                    ]
                  },
                  {
                    "text": "LTA is considered gold standard for platelet function testing"
                  },
                  {
                    "text": "LTA uses PRP to assess response of patient platelets to panel of added (exogenous) agonists"
                  },
                  {
                    "text": "﻿Defects in platelet activation and release of granules can be detected using LTA"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Light transmission aggregometry (LTA)"
                  },
                  {
                    "text": "Platelet-rich plasma (PRP)"
                  },
                  {
                    "text": "Thromboxane A₂ (TXA₂)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Cyclic adenosine monophosphate (cAMP)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "Protease-activated receptor (PAR)"
                  },
                  {
                    "text": "Thromboxane (TX)"
                  },
                  {
                    "text": "Adenosine triphosphate (ATP)"
                  },
                  {
                    "text": "Arachidonic acid (AA)"
                  },
                  {
                    "text": "Cyclooxygenase-1 (COX-1)"
                  },
                  {
                    "text": "Prostaglandin (PG)"
                  },
                  {
                    "text": "Thrombin receptor activating peptide (TRAP)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Platelet Activation": [
                  {
                    "text": "Responses of platelets to agonists leading to shape change, granule secretion, aggregation, and TXA₂ generation all are considered part of platelet activation"
                  },
                  {
                    "text": "Processes are mediated by agonists signaling through various receptors"
                  },
                  {
                    "text": "Several platelet agonists induce signaling eventsADPADP receptorsP2Y1 receptor mediates the rise in cytoplasmic Ca²⁺P2Y12 receptor mediates inhibition of adenylyl cyclase activity to reduce cAMP levels to promote platelet activation and granule releaseCollagenSignaling collagen receptorGPVI is member of immunoglobulin receptor superfamily and activation of receptor leads to GPIa-IIa activationThrombinThrombin interacts with PARsPAR1 and PAR4Activation of PARs results in activation of phospholipase C pathways and inhibition of adenylyl cyclaseTXA₂Binds to TX receptor",
                    "sub_points": [
                      "ADPADP receptorsP2Y1 receptor mediates the rise in cytoplasmic Ca²⁺P2Y12 receptor mediates inhibition of adenylyl cyclase activity to reduce cAMP levels to promote platelet activation and granule release",
                      "ADP receptorsP2Y1 receptor mediates the rise in cytoplasmic Ca²⁺P2Y12 receptor mediates inhibition of adenylyl cyclase activity to reduce cAMP levels to promote platelet activation and granule release",
                      "P2Y1 receptor mediates the rise in cytoplasmic Ca²⁺",
                      "P2Y12 receptor mediates inhibition of adenylyl cyclase activity to reduce cAMP levels to promote platelet activation and granule release",
                      "CollagenSignaling collagen receptorGPVI is member of immunoglobulin receptor superfamily and activation of receptor leads to GPIa-IIa activation",
                      "Signaling collagen receptorGPVI is member of immunoglobulin receptor superfamily and activation of receptor leads to GPIa-IIa activation",
                      "GPVI is member of immunoglobulin receptor superfamily and activation of receptor leads to GPIa-IIa activation",
                      "ThrombinThrombin interacts with PARsPAR1 and PAR4Activation of PARs results in activation of phospholipase C pathways and inhibition of adenylyl cyclase",
                      "Thrombin interacts with PARsPAR1 and PAR4Activation of PARs results in activation of phospholipase C pathways and inhibition of adenylyl cyclase",
                      "PAR1 and PAR4",
                      "Activation of PARs results in activation of phospholipase C pathways and inhibition of adenylyl cyclase",
                      "TXA₂Binds to TX receptor",
                      "Binds to TX receptor"
                    ]
                  }
                ],
                "Platelet Granule Release": [
                  {
                    "text": "As platelets become activated, they release substances that act as platelet agonists, adhesive proteins, coagulation factors, and growth modulators"
                  },
                  {
                    "text": "Platelet-dense granules contain platelet agonists (ADP and ATP) and signaling molecules (serotonin and calcium) that amplify platelet activation"
                  },
                  {
                    "text": "Release of platelet-dense granules is necessary for secondary wave of irreversible aggregation that is seen on LTA in response to ADP, epinephrine, and collagen agonists"
                  }
                ],
                "Generation and Release of TXA₂": [
                  {
                    "text": "Platelet activation is amplified through generation and passive release of TXA₂AA is released from membrane phospholipids by action of phospholipase A₂COX-1 metabolizes AA to PG intermediates (PGG₂/PGH₂)PGG₂/PGH₂ made into TXA₂ by thromboxane synthaseTXA₂ diffuses across platelet plasma membraneActivates other platelets through signaling pathwaysTXA₂ signaling promotes dense granule release",
                    "sub_points": [
                      "AA is released from membrane phospholipids by action of phospholipase A₂",
                      "COX-1 metabolizes AA to PG intermediates (PGG₂/PGH₂)PGG₂/PGH₂ made into TXA₂ by thromboxane synthase",
                      "PGG₂/PGH₂ made into TXA₂ by thromboxane synthase",
                      "TXA₂ diffuses across platelet plasma membraneActivates other platelets through signaling pathways",
                      "Activates other platelets through signaling pathways",
                      "TXA₂ signaling promotes dense granule release"
                    ]
                  }
                ],
                "Platelet Agonists Used in Testing Platelet Function": [
                  {
                    "text": "Various agonists known to be involved in platelet activation and granule release used to evaluate platelet function in LTAADP agonist binds P2Y1 and P2Y12 receptorsEpinephrine agonist binds to adrenergic receptorsAA agonist metabolized to TXA₂, which binds to TX receptorsType I collagen binds to GPVIGamma-thrombin activates PARsTRAP activates PAR-1 and PAR-4U-46619 binds to TX receptor",
                    "sub_points": [
                      "ADP agonist binds P2Y1 and P2Y12 receptors",
                      "Epinephrine agonist binds to adrenergic receptors",
                      "AA agonist metabolized to TXA₂, which binds to TX receptors",
                      "Type I collagen binds to GPVI",
                      "Gamma-thrombin activates PARs",
                      "TRAP activates PAR-1 and PAR-4",
                      "U-46619 binds to TX receptor"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "LTA": [
                  {
                    "text": "PRP has high optical density and transmits light poorly because platelets prevent passage of light"
                  },
                  {
                    "text": "PPP has been depleted of platelets and is able to transmit light well (low optical density)"
                  },
                  {
                    "text": "When substance that promotes platelet activation and aggregation (agonist) is added to PRP, normal platelets are activated and aggregate"
                  },
                  {
                    "text": "Platelet aggregometer is instrument that measures change in optical density (or light transmittance) over time of stirred PRP in cuvettes at 37°C after addition of agonistsAggregometers calibrated for light transmission using autologous PPP and PRPPPP—100% light transmissionPRP—0% light transmission",
                    "sub_points": [
                      "Aggregometers calibrated for light transmission using autologous PPP and PRPPPP—100% light transmissionPRP—0% light transmission",
                      "PPP—100% light transmission",
                      "PRP—0% light transmission"
                    ]
                  },
                  {
                    "text": "Aggregation of platelets in PRP results in decrease in optical density (increased light transmittance) as aggregated platelets fall out of path of light"
                  },
                  {
                    "text": "LTA measures change in optical density (or light transmittance) of stirred PRP that occurs after addition of agonistsAggregation tracing presents change in light transmission (y-axis) against time in minutes (x-axis)After addition of agonist, light transmission response should be observed for at least 5 minBaseline panel of agonists generally used for LTAADP (0.5-20 µM)Epinephrine (0.5-10 µM)Collagen (1.0-5.0 µg/mL)Ristocetin (0.8-1.5 mg/mL)AA (0.5-1.64 mM)",
                    "sub_points": [
                      "Aggregation tracing presents change in light transmission (y-axis) against time in minutes (x-axis)",
                      "After addition of agonist, light transmission response should be observed for at least 5 min",
                      "Baseline panel of agonists generally used for LTAADP (0.5-20 µM)Epinephrine (0.5-10 µM)Collagen (1.0-5.0 µg/mL)Ristocetin (0.8-1.5 mg/mL)AA (0.5-1.64 mM)",
                      "ADP (0.5-20 µM)",
                      "Epinephrine (0.5-10 µM)",
                      "Collagen (1.0-5.0 µg/mL)",
                      "Ristocetin (0.8-1.5 mg/mL)",
                      "AA (0.5-1.64 mM)"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Diagnosis of Bleeding Disorder": [
                  {
                    "text": "Pattern of response to agonists can help determine if there is platelet function defect and can help categorize type of defectDefect in platelet-dense granules is due to either contents of granules (storage pool disorder) or inability to release granules (release defect)Manifests as lack of secondary aggregation on LTA in response to ADP, epinephrine, collagen, and AAAdditional studies can be performed to distinguish between storage pool disorder and release defectElectron microscopy can be used to examine contents of platelet-dense granules to investigate storage pool disorderMeasurement of total platelet content of ADP and ATP and release of ATP in response to agonists can help to distinguish between storage pool disorder and release defectStorage pool defects have decrease in amount of stored and released ADP with increased ratio of ATP to ADPRelease defects have normal ADP levels, normal ATP:ADP ratio, but decreased ADP release",
                    "sub_points": [
                      "Defect in platelet-dense granules is due to either contents of granules (storage pool disorder) or inability to release granules (release defect)Manifests as lack of secondary aggregation on LTA in response to ADP, epinephrine, collagen, and AA",
                      "Manifests as lack of secondary aggregation on LTA in response to ADP, epinephrine, collagen, and AA",
                      "Additional studies can be performed to distinguish between storage pool disorder and release defectElectron microscopy can be used to examine contents of platelet-dense granules to investigate storage pool disorderMeasurement of total platelet content of ADP and ATP and release of ATP in response to agonists can help to distinguish between storage pool disorder and release defectStorage pool defects have decrease in amount of stored and released ADP with increased ratio of ATP to ADPRelease defects have normal ADP levels, normal ATP:ADP ratio, but decreased ADP release",
                      "Electron microscopy can be used to examine contents of platelet-dense granules to investigate storage pool disorder",
                      "Measurement of total platelet content of ADP and ATP and release of ATP in response to agonists can help to distinguish between storage pool disorder and release defectStorage pool defects have decrease in amount of stored and released ADP with increased ratio of ATP to ADPRelease defects have normal ADP levels, normal ATP:ADP ratio, but decreased ADP release",
                      "Storage pool defects have decrease in amount of stored and released ADP with increased ratio of ATP to ADP",
                      "Release defects have normal ADP levels, normal ATP:ADP ratio, but decreased ADP release"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Standardization": [
                  {
                    "text": "Wide variation in laboratory practice with performance of LTAConcentrations of agonists usedWhether or not to adjust platelet count of PRP with PPPWhether or not sample from normal control is analyzed on day of testing",
                    "sub_points": [
                      "Concentrations of agonists used",
                      "Whether or not to adjust platelet count of PRP with PPP",
                      "Whether or not sample from normal control is analyzed on day of testing"
                    ]
                  }
                ],
                "Influence of Medications and Dietary Components": [
                  {
                    "text": "Extensive list of medications and dietary substances that can inhibit platelet function"
                  },
                  {
                    "text": "Abnormal LTA result can be due to ingestion of medication or other dietary substance, rather than inherent platelet defect"
                  },
                  {
                    "text": "Medications that inhibit synthesis of PGs (e.g., aspirin) and decrease production of TXA₂ show pattern on LTA that resembles release defect or storage pool disorder"
                  }
                ],
                "Thrombocytopenia": [
                  {
                    "text": "PRP that has low platelet count can give abnormal response to agonists independent of true platelet dysfunction"
                  },
                  {
                    "text": "If PRP with platelet count < 150 x 10⁹/L is to be used, abnormal results should be treated with caution"
                  },
                  {
                    "text": "Ideally platelet count of normal control specimen is adjusted to platelet count of patient before response to agonists is compared"
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Patients should not take medications known to affect platelet function for 10-14 days before specimen collection"
                  },
                  {
                    "text": "Atraumatic venipuncture using minimum tourniquet pressure"
                  },
                  {
                    "text": "3.2% sodium citrate1:9 citrate-to-whole blood ratio",
                    "sub_points": [
                      "1:9 citrate-to-whole blood ratio"
                    ]
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ],
                "Transport": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature"
                  },
                  {
                    "text": "Tubes should not be subjected to vibration, shaking, vortexing, continuous mixing, or agitation"
                  },
                  {
                    "text": "Samples should not be transported via pneumatic tube system"
                  },
                  {
                    "text": "Samples should be tested between 30 min and no more than 4 hr from blood collection"
                  }
                ]
              },
              "PROCESSING": {
                "Centrifugation": [
                  {
                    "text": "Citrated blood samples are centrifuged to prepare PRP and PPPWhole-blood tubes are centrifuged at 170gto 200gfor 10 min at room temperature to make PRPWhole-blood samples or PRP are centrifuged at a minimum of 1500gfor at least 15 min at room temperature to make PPPPRP or PPP transferred to polypropylene tubes, capped, and stored at room temperature",
                    "sub_points": [
                      "Whole-blood tubes are centrifuged at 170gto 200gfor 10 min at room temperature to make PRP",
                      "Whole-blood samples or PRP are centrifuged at a minimum of 1500gfor at least 15 min at room temperature to make PPP",
                      "PRP or PPP transferred to polypropylene tubes, capped, and stored at room temperature"
                    ]
                  }
                ],
                "Platelet Count of PRP": [
                  {
                    "text": "Platelet count of PRP should be 200-300 x 10⁹/L"
                  },
                  {
                    "text": "If platelet count is > 300 x 10⁹/L, concentration can be adjusted with autologous PPP"
                  }
                ],
                "Addition of Agonists": [
                  {
                    "text": "PRP is added to cuvette along with stirring bar"
                  },
                  {
                    "text": "Agonist is added at maximum of one-tenth volume of agonist to PRP to initiate aggregation"
                  }
                ]
              },
              "LABORATORY STATISTICS": {
                "Interpretation of Results": [
                  {
                    "text": "Parameters evaluated for interpretation of studiesLag phase (time between addition of agonist and start of aggregation)Platelet shape changePrimary aggregation slopeSecondary aggregationDisaggregationMaximum amplitudePercent aggregationStirred PRP is set at 0% aggregationPPP is set at 100% aggregationPercent aggregation after addition of agonist is calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of sample) ÷ distance (along y-axis of aggregation tracing) from 0 to 100% aggregation (PPP) x 100",
                    "sub_points": [
                      "Lag phase (time between addition of agonist and start of aggregation)",
                      "Platelet shape change",
                      "Primary aggregation slope",
                      "Secondary aggregation",
                      "Disaggregation",
                      "Maximum amplitude",
                      "Percent aggregationStirred PRP is set at 0% aggregationPPP is set at 100% aggregationPercent aggregation after addition of agonist is calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of sample) ÷ distance (along y-axis of aggregation tracing) from 0 to 100% aggregation (PPP) x 100",
                      "Stirred PRP is set at 0% aggregation",
                      "PPP is set at 100% aggregation",
                      "Percent aggregation after addition of agonist is calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of sample) ÷ distance (along y-axis of aggregation tracing) from 0 to 100% aggregation (PPP) x 100"
                    ]
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Sample from healthy normal control volunteer with normal platelet function who is not taking any medications known to inhibit platelet function should run on each day that patient samples are analyzed"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Interpretation of LTA: Aggregation Defects": {
            "name": "Interpretation of LTA: Aggregation Defects",
            "url": "https://app.pathprimer.com/document/4b9fe4c8-3bd1-41f8-8f70-c16189f9cdb3/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Defective platelet function suspected when platelet count is normal and there is bleeding characteristic of disorder of primary hemostasis"
                  },
                  {
                    "text": "Platelet function typically evaluated by observing response of platelets to agonists that bind to platelets via their receptors, leading to activation and aggregation"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Lack of platelet aggregation in response to all agonists except for ristocetin indicates defect in platelet aggregationAggregation pattern can be seen in patients with GT, who lack or have a defect of GPIIb-IIIa receptorSimilar aggregation pattern may be seen in severe hypofibrinogenemia or afibrinogenemiaDefects in aggregation can be remedied by addition of cryoprecipitate (source of fibrinogen) to PRP in case of hypofibrinogenemia or afibrinogenemiaGT diagnosis can be confirmed by performing flow cytometry to examine number of GPIIb-IIIa receptors on platelets",
                    "sub_points": [
                      "Aggregation pattern can be seen in patients with GT, who lack or have a defect of GPIIb-IIIa receptor",
                      "Similar aggregation pattern may be seen in severe hypofibrinogenemia or afibrinogenemia",
                      "Defects in aggregation can be remedied by addition of cryoprecipitate (source of fibrinogen) to PRP in case of hypofibrinogenemia or afibrinogenemia",
                      "GT diagnosis can be confirmed by performing flow cytometry to examine number of GPIIb-IIIa receptors on platelets"
                    ]
                  }
                ],
                "Limitations": [
                  {
                    "text": "Patients taking medications that act as GPIIb-IIIa receptor antagonists (e.g., abciximab, tirofiban, eptifibatide) show lack of aggregation in response to all agonists except for ristocetin"
                  }
                ]
              },
              "OVERVIEW": {
                "Platelet Function Testing": [
                  {
                    "text": "Indicated for bleeding due to disorders in primary hemostasis (inability to form platelet plug)May be caused by low platelet counts (thrombocytopenia) &/or defective platelet function (i.e., adhesion, activation, granule release, aggregation)",
                    "sub_points": [
                      "May be caused by low platelet counts (thrombocytopenia) &/or defective platelet function (i.e., adhesion, activation, granule release, aggregation)"
                    ]
                  },
                  {
                    "text": "Defective platelet function suspected when platelet count is normal and there is bleeding characteristic of disorder of primary hemostasis"
                  },
                  {
                    "text": "Platelet function typically evaluated by observing response of platelets to agonists that bind to platelets via their receptorsLeads to activation and aggregation",
                    "sub_points": [
                      "Leads to activation and aggregation"
                    ]
                  },
                  {
                    "text": "LTA is considered gold standard for platelet function testing"
                  },
                  {
                    "text": "LTA uses PRP to assess response of patient platelets to panel of added (exogenous) agonists"
                  },
                  {
                    "text": "LTA can detect defects in platelet aggregation"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Light transmission aggregometry (LTA)"
                  },
                  {
                    "text": "Platelet-rich plasma (PRP)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Protease-activated receptor (PAR)"
                  },
                  {
                    "text": "Thromboxane A₂ (TXA₂)"
                  },
                  {
                    "text": "Thromboxane (TX)"
                  },
                  {
                    "text": "Arachidonic acid (AA)"
                  },
                  {
                    "text": "Thrombin receptor activating peptide (TRAP)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  },
                  {
                    "text": "Glanzmann thrombasthenia (GT)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Platelet Aggregation": [
                  {
                    "text": "Platelet adhesion and agonist-induced signaling lead to activation of GPIIb-IIIaAllows receptors to bind fibrinogen and vWF to promote platelet-platelet interactions",
                    "sub_points": [
                      "Allows receptors to bind fibrinogen and vWF to promote platelet-platelet interactions"
                    ]
                  },
                  {
                    "text": "End result of platelet adhesion, activation, and granule release is aggregation (platelet-platelet binding)"
                  }
                ],
                "Platelet Receptors": [
                  {
                    "text": "Platelets have important signaling, adhesion, and aggregation receptors on their surface that interact with endogenous agonistsGPIb-V-IX binds to vWF﻿GPIa-IIa binds to collagen﻿GPVI binds to collagen﻿GPIIb-IIIa binds to fibrinogen and vWFAdrenergic receptors bind to epinephrineP2Y1 receptor binds to ADPP2Y12 receptor binds to ADPThrombin activates PAR-1 and PAR-4TXA₂ binds to TX receptor",
                    "sub_points": [
                      "GPIb-V-IX binds to vWF",
                      "﻿GPIa-IIa binds to collagen",
                      "﻿GPVI binds to collagen",
                      "﻿GPIIb-IIIa binds to fibrinogen and vWF",
                      "Adrenergic receptors bind to epinephrine",
                      "P2Y1 receptor binds to ADP",
                      "P2Y12 receptor binds to ADP",
                      "Thrombin activates PAR-1 and PAR-4",
                      "TXA₂ binds to TX receptor"
                    ]
                  }
                ],
                "Platelet Agonists Used in Testing Platelet Function": [
                  {
                    "text": "Response to various agonists known to be involved in platelet adhesion used to evaluate platelet adhesion in LTAADP agonist binds to P2Y1 and P2Y12 receptors﻿Epinephrine agonist binds to adrenergic receptorsAA agonist is metabolized to TXA₂, which binds to TX receptors﻿Type I collagen binds to GPIa-IIa and GPVIRistocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutinationGamma-thrombin activates PARsTRAP activates PAR-1 and PAR-4U-46619 binds to TX receptor",
                    "sub_points": [
                      "ADP agonist binds to P2Y1 and P2Y12 receptors",
                      "﻿Epinephrine agonist binds to adrenergic receptors",
                      "AA agonist is metabolized to TXA₂, which binds to TX receptors",
                      "﻿Type I collagen binds to GPIa-IIa and GPVI",
                      "Ristocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutination",
                      "Gamma-thrombin activates PARs",
                      "TRAP activates PAR-1 and PAR-4",
                      "U-46619 binds to TX receptor"
                    ]
                  },
                  {
                    "text": "Defects in ability of platelets to bind to each other (aggregate) manifested after treatment with all agonists except for ristocetinRistocetin promotes platelet agglutination and does not rely on function of GPIIb-IIIa to have its effect",
                    "sub_points": [
                      "Ristocetin promotes platelet agglutination and does not rely on function of GPIIb-IIIa to have its effect"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "LTA": [
                  {
                    "text": "PRP has high optical density and transmits light poorly because platelets prevent passage of light"
                  },
                  {
                    "text": "PPP has been depleted of platelets and is able to transmit light well (low optical density)"
                  },
                  {
                    "text": "When substance that promotes platelet activation and aggregation (agonist) is added to PRP, normal platelets are activated and aggregate"
                  },
                  {
                    "text": "Platelet aggregometer measures change in optical density (or light transmittance) over time of stirred PRP in cuvettes at 37°C after addition of agonistsAggregometers are calibrated for light transmission using autologous PPP and PRPPPP—100% light transmissionPRP—0% light transmission",
                    "sub_points": [
                      "Aggregometers are calibrated for light transmission using autologous PPP and PRPPPP—100% light transmissionPRP—0% light transmission",
                      "PPP—100% light transmission",
                      "PRP—0% light transmission"
                    ]
                  },
                  {
                    "text": "Aggregation of platelets in PRP results in decrease in optical density (increased light transmittance) as aggregated platelets fall out of path of light"
                  },
                  {
                    "text": "LTA measures change in optical density (or light transmittance) of stirred PRP that occurs after addition of agonistsAggregation tracing presents change in light transmission (y-axis) against time in minutes (x-axis)After addition of agonist, light transmission response should be observed for at least 5 minBaseline panel of agonists is generally used for LTAADP (0.5-20 µM)Epinephrine (0.5-10 µM)Collagen (1.0-5.0 µg/mL)Ristocetin (0.8-1.5 mg/mL)AA (0.5-1.64 mM)",
                    "sub_points": [
                      "Aggregation tracing presents change in light transmission (y-axis) against time in minutes (x-axis)",
                      "After addition of agonist, light transmission response should be observed for at least 5 min",
                      "Baseline panel of agonists is generally used for LTAADP (0.5-20 µM)Epinephrine (0.5-10 µM)Collagen (1.0-5.0 µg/mL)Ristocetin (0.8-1.5 mg/mL)AA (0.5-1.64 mM)",
                      "ADP (0.5-20 µM)",
                      "Epinephrine (0.5-10 µM)",
                      "Collagen (1.0-5.0 µg/mL)",
                      "Ristocetin (0.8-1.5 mg/mL)",
                      "AA (0.5-1.64 mM)"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Diagnosis of Bleeding Disorder": [
                  {
                    "text": "Pattern of response to agonists can help in determining if there is platelet function defect and can help categorize type of defectLack of platelet aggregation in response to all agonists except for ristocetin indicates defect in platelet aggregationAggregation pattern can be seen in GTPatients lack or have defect of GPIIb-IIIa receptorSimilar aggregation pattern may be seen in severe hypofibrinogenemia or afibrinogenemiaDefects in aggregation can be remedied by addition of cryoprecipitate (source of fibrinogen) to PRP in the case of hypofibrinogenemia or afibrinogenemiaGT diagnosis can be confirmed by performing flow cytometry to examine number of GPIIb-IIIa receptors on platelets",
                    "sub_points": [
                      "Lack of platelet aggregation in response to all agonists except for ristocetin indicates defect in platelet aggregationAggregation pattern can be seen in GTPatients lack or have defect of GPIIb-IIIa receptorSimilar aggregation pattern may be seen in severe hypofibrinogenemia or afibrinogenemiaDefects in aggregation can be remedied by addition of cryoprecipitate (source of fibrinogen) to PRP in the case of hypofibrinogenemia or afibrinogenemiaGT diagnosis can be confirmed by performing flow cytometry to examine number of GPIIb-IIIa receptors on platelets",
                      "Aggregation pattern can be seen in GTPatients lack or have defect of GPIIb-IIIa receptor",
                      "Patients lack or have defect of GPIIb-IIIa receptor",
                      "Similar aggregation pattern may be seen in severe hypofibrinogenemia or afibrinogenemiaDefects in aggregation can be remedied by addition of cryoprecipitate (source of fibrinogen) to PRP in the case of hypofibrinogenemia or afibrinogenemiaGT diagnosis can be confirmed by performing flow cytometry to examine number of GPIIb-IIIa receptors on platelets",
                      "Defects in aggregation can be remedied by addition of cryoprecipitate (source of fibrinogen) to PRP in the case of hypofibrinogenemia or afibrinogenemia",
                      "GT diagnosis can be confirmed by performing flow cytometry to examine number of GPIIb-IIIa receptors on platelets"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Standardization": [
                  {
                    "text": "There is wide variation in laboratory practice with performance of LTAConcentrations of agonists usedWhether or not to adjust platelet count of PRP with PPPWhether or not a sample from a normal control is analyzed on day of testing",
                    "sub_points": [
                      "Concentrations of agonists used",
                      "Whether or not to adjust platelet count of PRP with PPP",
                      "Whether or not a sample from a normal control is analyzed on day of testing"
                    ]
                  }
                ],
                "Influence of Medications and Dietary Components": [
                  {
                    "text": "Extensive list of medications and dietary substances that can inhibit platelet function"
                  },
                  {
                    "text": "Abnormal LTA result can be due to ingestion of medication or other dietary substance, rather than inherent platelet defect"
                  },
                  {
                    "text": "Patients taking medications that act as GPIIb-IIIa receptor antagonists show lack of aggregation in response to all agonists except for ristocetinAbciximabTirofibanEptifibatide",
                    "sub_points": [
                      "Abciximab",
                      "Tirofiban",
                      "Eptifibatide"
                    ]
                  }
                ],
                "Thrombocytopenia": [
                  {
                    "text": "PRP that has low platelet count can give abnormal response to agonists independent of true platelet dysfunction"
                  },
                  {
                    "text": "If PRP with platelet count of < 150 x 10⁹/L is to be used, abnormal results should be treated with caution"
                  },
                  {
                    "text": "Ideally, platelet count of normal control specimen is adjusted to platelet count of patient before response to agonists is compared"
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Patients should not take medications known to affect platelet function for 10-14 days before specimen collection"
                  },
                  {
                    "text": "Atraumatic venipuncture using minimum tourniquet pressure"
                  },
                  {
                    "text": "3.2% sodium citrate1:9 citrate-to-whole blood ratio",
                    "sub_points": [
                      "1:9 citrate-to-whole blood ratio"
                    ]
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ],
                "Transport": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature"
                  },
                  {
                    "text": "Tubes should not be subjected to vibration, shaking, vortexing, continuous mixing, or agitation"
                  },
                  {
                    "text": "Samples should not be transported via pneumatic tube system"
                  },
                  {
                    "text": "Samples should be tested between 30 min and no more than 4 hr from blood collection"
                  }
                ]
              },
              "PROCESSING": {
                "Centrifugation": [
                  {
                    "text": "Citrated blood samples are centrifuged to prepare PRP and PPPWhole-blood tubes centrifuged at 170gto 200gfor 10 min at room temperature to make PRPWhole-blood samples or PRP centrifuged at a minimum of 1500gfor at least 15 min at room temperature to make PPPPRP or PPP transferred to polypropylene tubes, capped, and stored at room temperature",
                    "sub_points": [
                      "Whole-blood tubes centrifuged at 170gto 200gfor 10 min at room temperature to make PRP",
                      "Whole-blood samples or PRP centrifuged at a minimum of 1500gfor at least 15 min at room temperature to make PPP",
                      "PRP or PPP transferred to polypropylene tubes, capped, and stored at room temperature"
                    ]
                  }
                ],
                "Platelet Count of PRP": [
                  {
                    "text": "Platelet count of PRP is performed and should be 200-300 x 10⁹/L"
                  },
                  {
                    "text": "If platelet count is > 300 x 10⁹/L, concentration can be adjusted with autologous PPP"
                  }
                ],
                "Addition of Agonist": [
                  {
                    "text": "PRP is added to cuvette along with stirring bar"
                  },
                  {
                    "text": "Agonist is added at maximum of one-tenth volume of agonist to PRP to initiate aggregation"
                  }
                ]
              },
              "LABORATORY STATISTICS": {
                "Interpretation of Results": [
                  {
                    "text": "Several parameters are evaluated for interpretation of these studiesLag phase (time between addition of agonist and start of aggregation)Platelet shape changePrimary aggregation slopeSecondary aggregationDisaggregationMaximum amplitudePercent aggregationStirred PRP is set at 0% aggregationPPP is set at 100% aggregationPercent aggregation after addition of agonist is calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of sample) ÷ distance (along y-axis of aggregation tracing) from 0 to 100% aggregation (PPP) x 100",
                    "sub_points": [
                      "Lag phase (time between addition of agonist and start of aggregation)",
                      "Platelet shape change",
                      "Primary aggregation slope",
                      "Secondary aggregation",
                      "Disaggregation",
                      "Maximum amplitude",
                      "Percent aggregationStirred PRP is set at 0% aggregationPPP is set at 100% aggregationPercent aggregation after addition of agonist is calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of sample) ÷ distance (along y-axis of aggregation tracing) from 0 to 100% aggregation (PPP) x 100",
                      "Stirred PRP is set at 0% aggregation",
                      "PPP is set at 100% aggregation",
                      "Percent aggregation after addition of agonist is calculated as distance (along y-axis of aggregation tracing) from 0 to maximum aggregation (of sample) ÷ distance (along y-axis of aggregation tracing) from 0 to 100% aggregation (PPP) x 100"
                    ]
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Sample from healthy normal control volunteer who is known to have normal platelet function and who is not taking any medications known to inhibit platelet function should run on each day that patient samples are analyzed"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Other Platelet Function Methods": {
            "name": "Other Platelet Function Methods",
            "url": "https://app.pathprimer.com/document/db5e5a54-7e2f-4d95-b8a1-ec14fa25932c/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Platelet function is typically evaluated by observing response of platelets to agonists that bind to platelets via their receptors leading to activation and aggregation"
                  },
                  {
                    "text": "Defective platelet function should be considered when platelet count is normal in setting of bleeding"
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "Platelets have important signaling, adhesion, and aggregation receptors on their surface that interact with endogenous agonistsGPIb-V-IX binds to vWF﻿GPIa-IIa binds to collagen﻿GPVI binds to collagen﻿GPIIb-IIIa binds to fibrinogen and vWF",
                    "sub_points": [
                      "GPIb-V-IX binds to vWF",
                      "﻿GPIa-IIa binds to collagen",
                      "﻿GPVI binds to collagen",
                      "﻿GPIIb-IIIa binds to fibrinogen and vWF"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Platelet aggregometry alone may not be sensitive enough to detect mild defects in granule releaseFlow cytometry shows lack of surface GPIIb-IIIa in Glanzmann thrombasthenia and lack of surface GPIb in Bernard-Soulier syndrome",
                    "sub_points": [
                      "Flow cytometry shows lack of surface GPIIb-IIIa in Glanzmann thrombasthenia and lack of surface GPIb in Bernard-Soulier syndrome"
                    ]
                  }
                ],
                "Specimens": [
                  {
                    "text": "Patients should not take medications known to affect platelet function for 10-14 days before specimen collection"
                  }
                ]
              },
              "OVERVIEW": {
                "Platelet Function Testing": [
                  {
                    "text": "Bleeding due to disorders in primary hemostasis (formation of platelet plug) may be caused by thrombocytopenia &/or defective platelet functionDefective platelet function includes adhesion, activation, granule release, aggregation",
                    "sub_points": [
                      "Defective platelet function includes adhesion, activation, granule release, aggregation"
                    ]
                  },
                  {
                    "text": "Defective platelet function should be considered when platelet count is normal in setting of bleeding"
                  },
                  {
                    "text": "Platelet function is typically evaluated by observing response of platelets to agonists that bind to platelets via their receptors leading to activation and aggregation"
                  },
                  {
                    "text": "Although LTA is considered gold standard for platelet function testing, several other methods are used to evaluate platelet function"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Light transmission aggregometry (LTA)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Protease-activated receptor (PAR)"
                  },
                  {
                    "text": "Thromboxane A₂ (TXA₂)"
                  },
                  {
                    "text": "Thromboxane (TX)"
                  },
                  {
                    "text": "Arachidonic acid (AA)"
                  },
                  {
                    "text": "Thrombin receptor activating peptide (TRAP)"
                  },
                  {
                    "text": "Whole-blood aggregometry (WBA)"
                  },
                  {
                    "text": "Platelet function analyzer (PFA-100)"
                  },
                  {
                    "text": "Adenosine triphosphate (ATP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Platelet Receptors": [
                  {
                    "text": "Platelets have important signaling, adhesion, and aggregation receptors on their surface that interact with endogenous agonistsGPIb-V-IX binds to vWF﻿GPIa-IIa binds to collagen﻿GPVI binds to collagen﻿GPIIb-IIIa binds to fibrinogen and vWFAdrenergic receptors bind to epinephrineP2Y1 receptor binds to ADPP2Y12 receptor binds to ADPThrombin activates PARsPAR-1 and PAR-4TXA₂ binds to TX receptor",
                    "sub_points": [
                      "GPIb-V-IX binds to vWF",
                      "﻿GPIa-IIa binds to collagen",
                      "﻿GPVI binds to collagen",
                      "﻿GPIIb-IIIa binds to fibrinogen and vWF",
                      "Adrenergic receptors bind to epinephrine",
                      "P2Y1 receptor binds to ADP",
                      "P2Y12 receptor binds to ADP",
                      "Thrombin activates PARsPAR-1 and PAR-4",
                      "PAR-1 and PAR-4",
                      "TXA₂ binds to TX receptor"
                    ]
                  }
                ],
                "Platelet Agonists Used in Testing Platelet Function": [
                  {
                    "text": "Agonists used to evaluate platelet function on different testing platformsADP agonist binds P2Y1 and P2Y12 receptorsEpinephrine agonist binds to adrenergic receptorsAA agonist is metabolized to TXA₂, which binds to TX receptorsType I collagen binds to GPIa-IIa and GPVIRistocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutinationGamma-thrombin activates PARsTRAP activates PAR-1 and PAR-4U-46619 binds to TX receptor",
                    "sub_points": [
                      "ADP agonist binds P2Y1 and P2Y12 receptors",
                      "Epinephrine agonist binds to adrenergic receptors",
                      "AA agonist is metabolized to TXA₂, which binds to TX receptors",
                      "Type I collagen binds to GPIa-IIa and GPVI",
                      "Ristocetin promotes binding of vWF to GPIb-V-IX receptor complex leading to platelet agglutination",
                      "Gamma-thrombin activates PARs",
                      "TRAP activates PAR-1 and PAR-4",
                      "U-46619 binds to TX receptor"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Whole-Blood (Impedance) Aggregometry": [
                  {
                    "text": "Uses electric impedance to evaluate platelet aggregation in whole blood"
                  },
                  {
                    "text": "Citrated whole blood sample is stirred at 37°C"
                  },
                  {
                    "text": "Electric current is passed between 2 electrodes immersed in sampleImpedance is measured between electrodes",
                    "sub_points": [
                      "Impedance is measured between electrodes"
                    ]
                  },
                  {
                    "text": "Platelet aggregation occurs on surface of electrodes and increases impedance"
                  },
                  {
                    "text": "Addition of agonist to sample increases aggregation of platelets on surface of electrodesThis is detected as increase in impedance measured in ohms",
                    "sub_points": [
                      "This is detected as increase in impedance measured in ohms"
                    ]
                  },
                  {
                    "text": "WBA uses same agonists as LTAADPEpinephrineCollagenRistocetinAA",
                    "sub_points": [
                      "ADP",
                      "Epinephrine",
                      "Collagen",
                      "Ristocetin",
                      "AA"
                    ]
                  },
                  {
                    "text": "WBA requires 1/4 of blood needed for LTA"
                  }
                ],
                "Platelet Function Analyzer": [
                  {
                    "text": "PFA-100 uses whole blood to measure platelet function under high shear flow conditions"
                  },
                  {
                    "text": "Sample collected in 3.2% sodium citrate"
                  },
                  {
                    "text": "Whole blood passes through opening cut into coated membraneMembrane coated with collagen and epinephrine or collagen and ADP as agonists",
                    "sub_points": [
                      "Membrane coated with collagen and epinephrine or collagen and ADP as agonists"
                    ]
                  },
                  {
                    "text": "These agonists promote platelet adhesion, activation, and aggregation leading to occlusion of aperture and cessation of blood flow"
                  },
                  {
                    "text": "Time to occlusion of opening by platelet plug is measuredProlonged occlusion or “closure” times suggest impaired platelet function",
                    "sub_points": [
                      "Prolonged occlusion or “closure” times suggest impaired platelet function"
                    ]
                  },
                  {
                    "text": "Results are reported as closure times"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Uses fluorescently labeled antibodies to detect antigens on platelet surface"
                  },
                  {
                    "text": "Mainly used clinically for quantification of surface GP receptor densityGlanzmann thrombastheniaFlow cytometry shows lack of surface GPIIb-IIIaBernard-Soulier syndromeFlow cytometry shows lack of surface GPIb",
                    "sub_points": [
                      "Glanzmann thrombastheniaFlow cytometry shows lack of surface GPIIb-IIIa",
                      "Flow cytometry shows lack of surface GPIIb-IIIa",
                      "Bernard-Soulier syndromeFlow cytometry shows lack of surface GPIb",
                      "Flow cytometry shows lack of surface GPIb"
                    ]
                  },
                  {
                    "text": "Flow cytometry can used to measure platelet activation in response to platelet agonistsThrough detection of P-selectin (CD62) and phosphatidylserine",
                    "sub_points": [
                      "Through detection of P-selectin (CD62) and phosphatidylserine"
                    ]
                  }
                ],
                "Measurement of Platelet Nucleotides": [
                  {
                    "text": "ATP and ADP are released from platelet granules after platelet activation"
                  },
                  {
                    "text": "Measurement of total &/or released nucleotides aids in evaluation of platelet release defects and storage pool disorders"
                  },
                  {
                    "text": "Platelet aggregometry alone may not be sensitive enough to detect mild defects in granule release"
                  },
                  {
                    "text": "Evaluation of released adenine nucleotides (ATP and ADP) can be used as independent measure of granule releaseRelease of ATP from dense granules is quantitated using luciferin/luciferase systemLumi-aggregometer (LTA or WBA) simultaneously measures ATP release and aggregationATP release occurs during secondary aggregation phase in LTAMeasurement of ATP release does not distinguish between storage pool and release defects",
                    "sub_points": [
                      "Release of ATP from dense granules is quantitated using luciferin/luciferase system",
                      "Lumi-aggregometer (LTA or WBA) simultaneously measures ATP release and aggregation",
                      "ATP release occurs during secondary aggregation phase in LTA",
                      "Measurement of ATP release does not distinguish between storage pool and release defects"
                    ]
                  },
                  {
                    "text": "Measurement of total platelet ADP and ATP in lysed platelet preparation can distinguish between storage pool disorders and release defectsAdenine nucleotides can be measured by high-performance liquid chromatography or luminometerMeasurement of total platelet content of ADP and ATP and release of ATP in response to agonists can help to distinguish between storage pool disorder and release defectStorage pool defects have decrease in amount of stored and released ADP with increased ATP:ADP ratioRelease defects have normal ADP levels, normal ATP:ADP ratio, but decreased ADP release",
                    "sub_points": [
                      "Adenine nucleotides can be measured by high-performance liquid chromatography or luminometer",
                      "Measurement of total platelet content of ADP and ATP and release of ATP in response to agonists can help to distinguish between storage pool disorder and release defectStorage pool defects have decrease in amount of stored and released ADP with increased ATP:ADP ratioRelease defects have normal ADP levels, normal ATP:ADP ratio, but decreased ADP release",
                      "Storage pool defects have decrease in amount of stored and released ADP with increased ATP:ADP ratio",
                      "Release defects have normal ADP levels, normal ATP:ADP ratio, but decreased ADP release"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Patients should not take medications known to affect platelet function for 10-14 days before specimen collection"
                  },
                  {
                    "text": "Atraumatic venipuncture using minimum tourniquet pressure"
                  },
                  {
                    "text": "3.2% sodium citrate1:9 citrate:whole blood ratio",
                    "sub_points": [
                      "1:9 citrate:whole blood ratio"
                    ]
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ],
                "Transport": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature"
                  },
                  {
                    "text": "Tubes should not be subjected to vibration, shaking, vortexing, continuous mixing, or agitation"
                  },
                  {
                    "text": "Samples should not be transported via pneumatic tube system"
                  },
                  {
                    "text": "Samples should be tested between 30 min and no more than 4 hr from blood collection"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Evaluation of an Isolated PT Elevation": {
            "name": "Evaluation of an Isolated PT Elevation",
            "url": "https://app.pathprimer.com/document/a8f1e82f-4347-426f-afdb-4f032e3bba76/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "PT is sensitive test used to screen for acquired or inherited abnormalities in extrinsic (factor VII) and common (factors X, V, and prothrombin (II)) coagulation pathways"
                  },
                  {
                    "text": "INR is standardized number used to calibrate variability of PT for purpose of warfarin (Coumadin) monitoring"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Healthy patient with excess bleeding during surgery or minor trauma or elevated PT with no other abnormalities likely has factor VII deficiency"
                  }
                ],
                "Limitations": [
                  {
                    "text": "INR was specifically designed to provide standardized way of monitoring of warfarin therapy; using this value for clinical decision making (e.g., estimating risk of bleeding) in other situations has not been proven to be useful"
                  }
                ]
              },
              "OVERVIEW": {
                "Clinical Uses": [
                  {
                    "text": "PT is sensitive test used to screen for acquired or inherited abnormalities in factors V, VII, X and prothrombin (II)"
                  },
                  {
                    "text": "Typical reference range for PT is 10-15 sec"
                  },
                  {
                    "text": "PT is used to monitor warfarin (Coumadin) for patients on oral anticoagulation therapy"
                  },
                  {
                    "text": "International normalized ratio (INR) is standardized value used to calibrate variability of PT between laboratories for the purpose of warfarin monitoring"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "International normalized ratio (INR)"
                  },
                  {
                    "text": "Tissue factor (TF)"
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "International sensitivity index (ISI)"
                  },
                  {
                    "text": "World Health Organization (WHO)"
                  },
                  {
                    "text": "International reference preparation (IRP)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Thromboplastin: Commercial preparation of TF, phospholipid, and calcium that binds factor VII in patient plasma sample to initiate coagulation"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Clot Formation in Prothrombin Time": [
                  {
                    "text": "Clotting is measured using plasma viscosity mechanically or plasma absorbance photo-optically"
                  },
                  {
                    "text": "Clotting is initiated in platelet-poor plasma by addition of phospholipid and TF, which binds factor VIIa"
                  },
                  {
                    "text": "TF:factor VIIa (activated) activates factor X"
                  },
                  {
                    "text": "Factor Xa converts prothrombin (II) to thrombin (IIa)"
                  },
                  {
                    "text": "thrombin coverts fibrinogen to form a fibrin clot"
                  },
                  {
                    "text": "Time to clot is recorded in seconds"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Prothrombin Time Is Used for Evaluation of Extrinsic Coagulation Pathway": [
                  {
                    "text": "Deficiency of factor VII, V, X, II can be estimated based on severity of prolongationPT does not differentiate from multiple simultaneous factor deficienciesDICVitamin K deficiencyPT is most sensitive in detecting decreases in circulating levels of factors VII and XIt is less affected by decreases in factor V, prothrombin (II), or fibrinogenDecrease in factor to < 40%-50% of normal levels is typically necessary to observe increase in PTProlongation correlates with degree of deficiency of relevant factor or degree of inhibitor presentSpecific factor inhibitors or nonspecific inhibitors (lupus anticoagulant, heparin, argatroban) can prolong PT",
                    "sub_points": [
                      "PT does not differentiate from multiple simultaneous factor deficienciesDICVitamin K deficiency",
                      "DIC",
                      "Vitamin K deficiency",
                      "PT is most sensitive in detecting decreases in circulating levels of factors VII and XIt is less affected by decreases in factor V, prothrombin (II), or fibrinogen",
                      "It is less affected by decreases in factor V, prothrombin (II), or fibrinogen",
                      "Decrease in factor to < 40%-50% of normal levels is typically necessary to observe increase in PT",
                      "Prolongation correlates with degree of deficiency of relevant factor or degree of inhibitor present",
                      "Specific factor inhibitors or nonspecific inhibitors (lupus anticoagulant, heparin, argatroban) can prolong PT"
                    ]
                  },
                  {
                    "text": "Clinical history is essential to interpret PT and determine next step for testing and treatmentHealthy patient with excess bleeding during surgery or minor trauma or elevated PT with no other abnormalitiesFactor VII deficiency likelyMedical conditions such as liver disease or DIC can cause isolated elevation of PTMore commonly aPTT also elevated",
                    "sub_points": [
                      "Healthy patient with excess bleeding during surgery or minor trauma or elevated PT with no other abnormalitiesFactor VII deficiency likely",
                      "Factor VII deficiency likely",
                      "Medical conditions such as liver disease or DIC can cause isolated elevation of PTMore commonly aPTT also elevated",
                      "More commonly aPTT also elevated"
                    ]
                  }
                ],
                "Differential Diagnosis for Isolated Prolonged Prothrombin Time": [
                  {
                    "text": "Congenital factor VII deficiency"
                  },
                  {
                    "text": "Factor VII inhibitor"
                  },
                  {
                    "text": "Mild vitamin K deficiency"
                  },
                  {
                    "text": "MedicationsWarfarin (Coumadin)Direct thrombin inhibitorsOral anti-Xa inhibitors",
                    "sub_points": [
                      "Warfarin (Coumadin)",
                      "Direct thrombin inhibitors",
                      "Oral anti-Xa inhibitors"
                    ]
                  },
                  {
                    "text": "Deficiencies of common pathway factor (II, V, or X)"
                  },
                  {
                    "text": "Liver diseaseTypically also has prolonged aPTT",
                    "sub_points": [
                      "Typically also has prolonged aPTT"
                    ]
                  },
                  {
                    "text": "DICTypically also has prolonged aPTT",
                    "sub_points": [
                      "Typically also has prolonged aPTT"
                    ]
                  },
                  {
                    "text": "Dysfibrinogenemia"
                  }
                ]
              },
              "LIMITATIONS": {
                "Prothrombin Time Reference Range Can Vary Widely Based on Type of Tissue Factor/Thromboplastin Used": [
                  {
                    "text": "INR was specifically designed to standardize monitoring of warfarin therapyUsing this value for estimating risk of bleeding in other situations has not been proven to be useful predictor",
                    "sub_points": [
                      "Using this value for estimating risk of bleeding in other situations has not been proven to be useful predictor"
                    ]
                  },
                  {
                    "text": "PT does not measure factors in intrinsic pathway (VIII, IX, XI, XII) or factor XIII activity"
                  },
                  {
                    "text": "PT is much less sensitive to heparin than aPTTUnfractionated heparin may prolong PT by 1-2 sec",
                    "sub_points": [
                      "Unfractionated heparin may prolong PT by 1-2 sec"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Prothrombin Time Can Be Affected by Reagent Type and Errors in Collection Method": [
                  {
                    "text": "Commercially available TF/thromboplastin and calcium used to initiate clotting process"
                  },
                  {
                    "text": "Various formulations have different levels of procoagulantPT results can vary widely between laboratories",
                    "sub_points": [
                      "PT results can vary widely between laboratories"
                    ]
                  },
                  {
                    "text": "INR minimizes differences with standard calculationINR is patient's PT divided by mean PT of pooled normal plasma, then raised to power of assigned ISI valueINR = (patient's PT/mean normal PT)^ISIISI is standard assigned to each formulation of thromboplastin by comparing its procoagulant ability with international standard (WHO; IRP)",
                    "sub_points": [
                      "INR is patient's PT divided by mean PT of pooled normal plasma, then raised to power of assigned ISI valueINR = (patient's PT/mean normal PT)^ISI",
                      "INR = (patient's PT/mean normal PT)^ISI",
                      "ISI is standard assigned to each formulation of thromboplastin by comparing its procoagulant ability with international standard (WHO; IRP)"
                    ]
                  }
                ],
                "Preanalytic Variables": [
                  {
                    "text": "Samples must be collected in 3.2% sodium citrate with final blood-to-citrate ratio of 9:1Patients with high hematocrit (> 55%) have decreased percentage of plasma in collection sampleResults in falsely prolonged PT due to excess citrateUnderfilled tubes can also result in abnormal plasma-to-citrate ratio",
                    "sub_points": [
                      "Patients with high hematocrit (> 55%) have decreased percentage of plasma in collection sampleResults in falsely prolonged PT due to excess citrate",
                      "Results in falsely prolonged PT due to excess citrate",
                      "Underfilled tubes can also result in abnormal plasma-to-citrate ratio"
                    ]
                  },
                  {
                    "text": "Prolonged storage can result in factor degradationResults in falsely prolonged PT",
                    "sub_points": [
                      "Results in falsely prolonged PT"
                    ]
                  },
                  {
                    "text": "Cold-temperature storage may result in in vitro activation of factor XII"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Evaluation of an Isolated PTT Elevation": {
            "name": "Evaluation of an Isolated PTT Elevation",
            "url": "https://app.pathprimer.com/document/1dbd82c3-9cff-4b91-9258-688e0905a041/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "aPTT: Sensitive screening test used to evaluate intrinsic (factors XII, XI, IX, and VIII) coagulation pathway"
                  },
                  {
                    "text": "Used for monitoring heparin therapy [unfractionated heparin → low-molecular-weight heparin (LMWH)]"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "aPTT may be prolonged by single or multiple factor deficiencies; additional testing is required to determine underlying cause"
                  },
                  {
                    "text": "aPTT reagents are generally designed so clotting factors must be < 40% activity to prolong aPTT"
                  },
                  {
                    "text": "Not all causes of prolonged aPTT lead to increased risk of bleedingDeficiency of factor XII, PK, and HMWK result in severe prolongation, but have no effect on clinical bleeding",
                    "sub_points": [
                      "Deficiency of factor XII, PK, and HMWK result in severe prolongation, but have no effect on clinical bleeding"
                    ]
                  },
                  {
                    "text": "If aPTT prolongation is associated with bleeding, consider deficiency or inhibitor of factor VIII, IX, or XI"
                  },
                  {
                    "text": "If aPTT prolongation is not associated with bleeding, consider lupus anticoagulant or deficiency of factor XII, PK, or HMWK"
                  }
                ]
              },
              "OVERVIEW": {
                "Evaluation of Isolated Prolongation of aPTT": [
                  {
                    "text": "Activated partial thromboplastin time (aPTT)Sensitive screening test used to evaluate intrinsic (factors VIII , IX, XI, and XII) coagulation pathwayAlso affected by contact factors prekallikrein (PK) and high-molecular-weight kininogen (HMWK)Defects in common pathway may affect aPTTSensitive screening test for lupus anticoagulantShould be used in combination with other screening tests to determine next step for diagnosis",
                    "sub_points": [
                      "Sensitive screening test used to evaluate intrinsic (factors VIII , IX, XI, and XII) coagulation pathwayAlso affected by contact factors prekallikrein (PK) and high-molecular-weight kininogen (HMWK)Defects in common pathway may affect aPTT",
                      "Also affected by contact factors prekallikrein (PK) and high-molecular-weight kininogen (HMWK)",
                      "Defects in common pathway may affect aPTT",
                      "Sensitive screening test for lupus anticoagulant",
                      "Should be used in combination with other screening tests to determine next step for diagnosis"
                    ]
                  },
                  {
                    "text": "Typical reference range: 25-36 seconds"
                  },
                  {
                    "text": "Not all causes of prolonged aPTT lead to increased risk of bleedingBleeding risk must be assessed based on underlying cause of prolongation",
                    "sub_points": [
                      "Bleeding risk must be assessed based on underlying cause of prolongation"
                    ]
                  },
                  {
                    "text": "Used for monitoring heparin therapy (unfractionated heparin → low molecular weight heparin [LMWH])"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Activated partial thromboplastin time (aPTT, or PTT)"
                  },
                  {
                    "text": "High-molecular-weight kininogen (HMWK)"
                  },
                  {
                    "text": "Low-molecular-weight heparin (LMWH)"
                  },
                  {
                    "text": "Prekallikrein (PK)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Activated Partial Thromboplastin Time": [
                  {
                    "text": "Platelet-poor plasma is incubated with addition of phospholipids, calcium, and surface activator (silica, kaolin), which activates clot formation"
                  },
                  {
                    "text": "Surface activator provides negatively charged surface for initiation of intrinsic cascade"
                  },
                  {
                    "text": "FXII and FXI activate in presence of PK and HMWK"
                  },
                  {
                    "text": "Activated FXI converts FIX → FIXa, which converts FX → FXa"
                  },
                  {
                    "text": "FXa cleaves prothrombin (II) → thrombin (IIa)"
                  },
                  {
                    "text": "Thrombin then accelerates process by activating FVIII → FVIIIa and FV → FVa, which in turn increase activity of FIXa and FXa"
                  },
                  {
                    "text": "This cascade results in increased activation of prothrombin (II) → thrombin (IIa), which converts fibrinogen → fibrin"
                  },
                  {
                    "text": "Fibrin polymerizes to form clot"
                  },
                  {
                    "text": "Clotting is measured using plasma viscosity mechanically or plasma absorbance photo-opticallyTime to clot is recorded in seconds",
                    "sub_points": [
                      "Time to clot is recorded in seconds"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "aPTT Used for Evaluation of Defects of Intrinsic Coagulation Pathway": [
                  {
                    "text": "Factor deficiencies occurring early in intrinsic pathway may significantly prolong aPTT, but have little bleeding risk; thus, length of prolongation of aPTT does not estimate severity of deficiency"
                  },
                  {
                    "text": "aPTT reagents are generally designed so clotting factors must be < 40% activity to prolong aPTTDeficiency of factor XII, PK, and HMWK result in severe prolongation, but have no effect on clinical bleeding",
                    "sub_points": [
                      "Deficiency of factor XII, PK, and HMWK result in severe prolongation, but have no effect on clinical bleeding"
                    ]
                  },
                  {
                    "text": "aPTT may be prolonged by single or multiple factor deficienciesAdditional testing is required to determine underlying cause",
                    "sub_points": [
                      "Additional testing is required to determine underlying cause"
                    ]
                  },
                  {
                    "text": "Clinical history is essential to interpretation of aPTT and determining next step for testing and treatmentIf aPTT prolongation is associated with bleeding, consider deficiency or inhibitor of factor VIII, IX, or XIIf aPTT prolongation is not associated with bleeding, consider lupus anticoagulant or deficiency of factor XII, PK, or HMWKHigh levels of FVIII (an acute phase reactant) may override other factor deficiencies and result in normal or near-normal aPTTaPTT may be prolonged by defects in common coagulation pathway",
                    "sub_points": [
                      "If aPTT prolongation is associated with bleeding, consider deficiency or inhibitor of factor VIII, IX, or XI",
                      "If aPTT prolongation is not associated with bleeding, consider lupus anticoagulant or deficiency of factor XII, PK, or HMWK",
                      "High levels of FVIII (an acute phase reactant) may override other factor deficiencies and result in normal or near-normal aPTT",
                      "aPTT may be prolonged by defects in common coagulation pathway"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Factor VIII deficiency (hemophilia A) or inhibitor"
                  },
                  {
                    "text": "Factor IX deficiency (hemophilia B)"
                  },
                  {
                    "text": "Factor XI deficiency (hemophilia C)"
                  },
                  {
                    "text": "Acquired factor deficiency"
                  },
                  {
                    "text": "Lupus anticoagulant"
                  },
                  {
                    "text": "MedicationsHeparin (unfractionated)Direct thrombin inhibitors (dabigatran)Long-term warfarin (Coumadin) therapy",
                    "sub_points": [
                      "Heparin (unfractionated)",
                      "Direct thrombin inhibitors (dabigatran)",
                      "Long-term warfarin (Coumadin) therapy"
                    ]
                  },
                  {
                    "text": "Hypofibrinogenemia (< 100 mg/dL) may prolong aPTT"
                  }
                ]
              },
              "LIMITATIONS": {
                "Sensitivity of aPTT Dependent on Reagent": [
                  {
                    "text": "Most commonly used aPTT reagents are less sensitive to factor IX than factors VIII, XI, and XII"
                  },
                  {
                    "text": "Choice of reagent affects ability to detect mild factor deficiency vs. lupus anticoagulant"
                  }
                ]
              },
              "SPECIMENS": {
                "Preanalytic Variables": [
                  {
                    "text": "Patient sample should be collected in 3.2% citrated plasma with 1:9 citrate to whole blood ratioPatients with high hematocrit (> 55%) have decreased percentage of plasma in collection sample, resulting in falsely prolonged aPTT due to excess citrateUnder-filled tubes can result in abnormal plasma to citrate ratio and falsely prolonged aPTT",
                    "sub_points": [
                      "Patients with high hematocrit (> 55%) have decreased percentage of plasma in collection sample, resulting in falsely prolonged aPTT due to excess citrate",
                      "Under-filled tubes can result in abnormal plasma to citrate ratio and falsely prolonged aPTT"
                    ]
                  },
                  {
                    "text": "Poor venipuncture technique may activate clotting cascade and provide incorrect result"
                  },
                  {
                    "text": "Heparin contamination from line draws will falsely elevate aPTTWaste tube should always be drawn prior to collection for coagulation testing",
                    "sub_points": [
                      "Waste tube should always be drawn prior to collection for coagulation testing"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Evaluation of Concurrent PT and PTT Elevation": {
            "name": "Evaluation of Concurrent PT and PTT Elevation",
            "url": "https://app.pathprimer.com/document/3e4fe9fc-c328-4bf4-875a-6aa6e799ca48/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Elevation of both PT and aPTT indicates defect in common pathway or multiple factor deficiencies"
                  },
                  {
                    "text": "When both tests are performed along with thrombin time, results encompass essentially all blood coagulation protein bleeding states"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Clinical history is important in determining likely underlying cause"
                  },
                  {
                    "text": "Differential diagnosis includesLiver diseaseDisseminated intravascular coagulation (DIC)Vitamin K deficiencyAnticoagulantsDeficiency or inhibitor of factors II (prothrombin), V, or XDysfibrinogenemiaSystemic amyloidosisPT and aPTT may be prolonged because amyloid protein absorbs factors X and IX",
                    "sub_points": [
                      "Liver disease",
                      "Disseminated intravascular coagulation (DIC)",
                      "Vitamin K deficiency",
                      "Anticoagulants",
                      "Deficiency or inhibitor of factors II (prothrombin), V, or X",
                      "Dysfibrinogenemia",
                      "Systemic amyloidosisPT and aPTT may be prolonged because amyloid protein absorbs factors X and IX",
                      "PT and aPTT may be prolonged because amyloid protein absorbs factors X and IX"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Prothrombin Time and Activated Partial Thromboplastin Time": [
                  {
                    "text": "PT: Screening test that evaluates extrinsic pathway (factor VII) and common pathway (factors II [prothrombin], V, and X)"
                  },
                  {
                    "text": "aPTT: Screening test that evaluates intrinsic (factors VIII, IX, XI, and XII) and common pathway (factors II [prothrombin], V, and X)"
                  },
                  {
                    "text": "Elevation of both PT and aPTT indicates defect in common pathway or multiple factor deficienciesWhen both tests are performed along with thrombin time, results encompass essentially all blood coagulation protein bleeding states",
                    "sub_points": [
                      "When both tests are performed along with thrombin time, results encompass essentially all blood coagulation protein bleeding states"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Activated partial thromboplastin time (PTT, or aPTT)"
                  },
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "Thrombin time (TT)"
                  },
                  {
                    "text": "Tissue factor (TF)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "PT and aPTT Assays": [
                  {
                    "text": "PT is activated by addition of excess TFPhospholipid, thromboplastin, and patient plasma are incubated together for at least 5 minutesCalcium chloride is added to reverse citrate anticoagulation, and time to clot is measured",
                    "sub_points": [
                      "Phospholipid, thromboplastin, and patient plasma are incubated together for at least 5 minutes",
                      "Calcium chloride is added to reverse citrate anticoagulation, and time to clot is measured"
                    ]
                  },
                  {
                    "text": "aPTT is activated by addition of surface activator (e.g., ground glass)Negatively charged surface and phospholipid mixture are combined in equal parts and incubated with patient plasma for at least 5 minutesCalcium chloride is added to reverse citrate anticoagulation, and time to clot is measured",
                    "sub_points": [
                      "Negatively charged surface and phospholipid mixture are combined in equal parts and incubated with patient plasma for at least 5 minutes",
                      "Calcium chloride is added to reverse citrate anticoagulation, and time to clot is measured"
                    ]
                  },
                  {
                    "text": "Both tests measure rate of clot formationIf factor is sufficiently deficient or nonfunctional, time to clot is prolonged",
                    "sub_points": [
                      "If factor is sufficiently deficient or nonfunctional, time to clot is prolonged"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "In Presence of Elevated PT and aPTT": [
                  {
                    "text": "Clinical history is important in determining underlying cause of prolongations in PT and aPTTPattern of bleeding should guide differentialComplementary laboratory testsCBCTTFibrinogen levelD dimerSpecific factor assays may be useful, but should not be initial test of choice",
                    "sub_points": [
                      "Pattern of bleeding should guide differential",
                      "Complementary laboratory testsCBCTTFibrinogen levelD dimer",
                      "CBC",
                      "TT",
                      "Fibrinogen level",
                      "D dimer",
                      "Specific factor assays may be useful, but should not be initial test of choice"
                    ]
                  },
                  {
                    "text": "Common medical conditions and medications (e.g., anticoagulation, liver disease) should be ruled out before rarer causes are sought"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Liver diseaseFactors V, VII, X, and fibrinogen are manufactured in liverFactors V, VII, and XI are first to decrease in liver diseaseLiver disease also results in abnormal fibrinogen",
                    "sub_points": [
                      "Factors V, VII, X, and fibrinogen are manufactured in liver",
                      "Factors V, VII, and XI are first to decrease in liver disease",
                      "Liver disease also results in abnormal fibrinogen"
                    ]
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)Clinical diagnosisUseful testsCBCPlatelet countFibrinogen levelTTD dimer",
                    "sub_points": [
                      "Clinical diagnosis",
                      "Useful testsCBCPlatelet countFibrinogen levelTTD dimer",
                      "CBC",
                      "Platelet count",
                      "Fibrinogen level",
                      "TT",
                      "D dimer"
                    ]
                  },
                  {
                    "text": "Vitamin K deficiencyWill prolong PT before aPTTPossible causesMalnutrition secondary to alcoholismIV nutrition without vitamin replacementBacterial overgrowth in gastrointestinal tract due to antibiotic therapyVitamin K absorption or transport defects (rare)",
                    "sub_points": [
                      "Will prolong PT before aPTT",
                      "Possible causesMalnutrition secondary to alcoholismIV nutrition without vitamin replacementBacterial overgrowth in gastrointestinal tract due to antibiotic therapyVitamin K absorption or transport defects (rare)",
                      "Malnutrition secondary to alcoholism",
                      "IV nutrition without vitamin replacement",
                      "Bacterial overgrowth in gastrointestinal tract due to antibiotic therapy",
                      "Vitamin K absorption or transport defects (rare)"
                    ]
                  },
                  {
                    "text": "AnticoagulantsWarfarin (Coumadin)Typically prolongs only PT; high levels may also cause aPTT prolongationAnti-Xa inhibitors (e.g., rivaroxaban, apixaban)Variably prolongs PT &/or aPTT; PT more than aPTTTT is not affectedDirect thrombin inhibitors (e.g., dabigatran)aPTT is affected more than PTTT is more sensitive than PT and aPTTHeparinUncommon to prolong both PT and aPTTIn this scenario, consider contamination from heparinized line",
                    "sub_points": [
                      "Warfarin (Coumadin)Typically prolongs only PT; high levels may also cause aPTT prolongation",
                      "Typically prolongs only PT; high levels may also cause aPTT prolongation",
                      "Anti-Xa inhibitors (e.g., rivaroxaban, apixaban)Variably prolongs PT &/or aPTT; PT more than aPTTTT is not affected",
                      "Variably prolongs PT &/or aPTT; PT more than aPTT",
                      "TT is not affected",
                      "Direct thrombin inhibitors (e.g., dabigatran)aPTT is affected more than PTTT is more sensitive than PT and aPTT",
                      "aPTT is affected more than PT",
                      "TT is more sensitive than PT and aPTT",
                      "HeparinUncommon to prolong both PT and aPTTIn this scenario, consider contamination from heparinized line",
                      "Uncommon to prolong both PT and aPTT",
                      "In this scenario, consider contamination from heparinized line"
                    ]
                  },
                  {
                    "text": "Massive transfusion (hemodilution)Dilution of coagulation factors can occur if RBC transfusions are not replete with sufficient plasma and plateletsClinical history guides this diagnosis",
                    "sub_points": [
                      "Dilution of coagulation factors can occur if RBC transfusions are not replete with sufficient plasma and plateletsClinical history guides this diagnosis",
                      "Clinical history guides this diagnosis"
                    ]
                  },
                  {
                    "text": "Deficiency or inhibitor of factors II (prothrombin), V, or X"
                  },
                  {
                    "text": "Dysfibrinogenemia"
                  },
                  {
                    "text": "Lupus anticoagulantTypically prolongs aPTT alone, but can prolong both PT and aPTT",
                    "sub_points": [
                      "Typically prolongs aPTT alone, but can prolong both PT and aPTT"
                    ]
                  },
                  {
                    "text": "Systemic amyloidosisPT and aPTT may be prolonged because amyloid protein absorbs factors X and IX",
                    "sub_points": [
                      "PT and aPTT may be prolonged because amyloid protein absorbs factors X and IX"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Evaluation of Fibrinogen and Thrombin Time": {
            "name": "Evaluation of Fibrinogen and Thrombin Time",
            "url": "https://app.pathprimer.com/document/8bfaf6ee-2a85-4256-82c5-12cd6c61ccc6/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Fibrinogen is a clotting factor that is converted to fibrin by thrombin and forms a meshwork to provide initial stabilization of newly formed clotLevels < 100 mg/dL may lead to loss of surgical hemostasisLevels < 40 mg/dL increase risk of spontaneous hemorrhage",
                    "sub_points": [
                      "Levels < 100 mg/dL may lead to loss of surgical hemostasis",
                      "Levels < 40 mg/dL increase risk of spontaneous hemorrhage"
                    ]
                  },
                  {
                    "text": "TT is direct measure of fibrinogen function; it is prolonged with hypofibrinogenemia, dysfibrinogenemia and direct thrombin inhibitors"
                  },
                  {
                    "text": "TT is very sensitive to heparin and can be used to screen for heparin contamination in patient sample"
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "Fibrinogen serves as meshwork on which platelets can aggregate; initial cross-linking provides initial hemostatic barrier for hemostatic injury"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "TT measures rate of conversion of fibrinogen → fibrin"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Clinical history is important in evaluation of elevated TT; the most common causes are liver disease, DIC, and trauma; congenital hypofibrinogenemias and dysfibrinogenemias are rare"
                  },
                  {
                    "text": "CBC, PT, and PTT should be used in conjunction with TT when evaluating for underlying causes"
                  }
                ]
              },
              "OVERVIEW": {
                "Fibrinogen": [
                  {
                    "text": "Fibrinogen is a clotting factor that is converted to fibrin by thrombin and forms a meshwork to provide initial stabilization of newly formed clot"
                  },
                  {
                    "text": "Normal range is 150-400 mg/dLLevels < 100 mg/dL may lead to loss of surgical hemostasisLevels < 40 mg/dL increase risk of spontaneous hemorrhage",
                    "sub_points": [
                      "Levels < 100 mg/dL may lead to loss of surgical hemostasis",
                      "Levels < 40 mg/dL increase risk of spontaneous hemorrhage"
                    ]
                  },
                  {
                    "text": "Fibrinogen is acute phase reactantIt can be elevated in inflammation and physiologic stress",
                    "sub_points": [
                      "It can be elevated in inflammation and physiologic stress"
                    ]
                  }
                ],
                "Thrombin Time": [
                  {
                    "text": "TT is direct measure of fibrinogen function"
                  },
                  {
                    "text": "TT is prolonged withHypofibrinogenemiaDysfibrinogenemiaDirect thrombin inhibitors",
                    "sub_points": [
                      "Hypofibrinogenemia",
                      "Dysfibrinogenemia",
                      "Direct thrombin inhibitors"
                    ]
                  },
                  {
                    "text": "TT is very sensitive to heparinTT can be used to screen for heparin contamination in patient sample",
                    "sub_points": [
                      "TT can be used to screen for heparin contamination in patient sample"
                    ]
                  },
                  {
                    "text": "Normal range is 11-25 sec"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Thrombin time (TT)"
                  },
                  {
                    "text": "Fibrin degradation products (FDP)"
                  },
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "Thromboelastography (TEG)"
                  },
                  {
                    "text": "Enzyme-linked immunosorbent assay (ELISA)"
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)"
                  },
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "Partial thromboplastin time (PTT)"
                  },
                  {
                    "text": "Tissue plasminogen activator (tPA)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiologic Role of Fibrinogen": [
                  {
                    "text": "Fibrinogen is plasma glycoprotein composed of 3 dimeric subunits: Aα, Bβ, and γ"
                  },
                  {
                    "text": "Fibrinogen serves as meshwork on which platelets can aggregateInitial cross-linking provides initial hemostatic barrier for hemostatic injury",
                    "sub_points": [
                      "Initial cross-linking provides initial hemostatic barrier for hemostatic injury"
                    ]
                  },
                  {
                    "text": "Thrombin converts fibrinogen → fibrin by cleaving peptides from Aα and Bβ chains and forming soluble fibrin monomers"
                  },
                  {
                    "text": "Fibrin monomers polymerize into mesh-like network that stabilizes platelet plug"
                  },
                  {
                    "text": "Factor XIIIa cross-links monomers, further stabilizing fibrin meshwork and providing longer term hemostasis"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Test Performance": [
                  {
                    "text": "TT measures rate of conversion of fibrinogen → fibrinKnown amount of purified exogenous thrombin is added to platelet-poor plasma, and time to clot is measuredHigh levels of FDP may cause falsely prolonged TT due to interferenceHigh fibrinogen (> 5 mg/dL) may result in prolonged TT due to interferenceLow fibrinogen concentrations should be compared with measurement of fibrinogen mass presentChemical or immunologic method is usedDiscrepancy of > 25%-30% indicates dysfibrinogenemia",
                    "sub_points": [
                      "Known amount of purified exogenous thrombin is added to platelet-poor plasma, and time to clot is measuredHigh levels of FDP may cause falsely prolonged TT due to interferenceHigh fibrinogen (> 5 mg/dL) may result in prolonged TT due to interference",
                      "High levels of FDP may cause falsely prolonged TT due to interference",
                      "High fibrinogen (> 5 mg/dL) may result in prolonged TT due to interference",
                      "Low fibrinogen concentrations should be compared with measurement of fibrinogen mass presentChemical or immunologic method is usedDiscrepancy of > 25%-30% indicates dysfibrinogenemia",
                      "Chemical or immunologic method is used",
                      "Discrepancy of > 25%-30% indicates dysfibrinogenemia"
                    ]
                  },
                  {
                    "text": "Functional fibrinogen is measured using Clauss method or PT-based testClauss fibrinogen testUses very high thrombin levelsThrombin added to diluted patient plasmaPT-based fibrinogen testMeasures rate of change in plasma turbidity in plasma sample stimulated by PT reagentRate of change is proportional to rate of fibrin polymerizationFormation of fibrin is rate-limiting stepTime to clot proportional to clottable fibrinogen concentrationCan be run as part of PT testHas higher risk of inaccuracy",
                    "sub_points": [
                      "Clauss fibrinogen testUses very high thrombin levelsThrombin added to diluted patient plasma",
                      "Uses very high thrombin levelsThrombin added to diluted patient plasma",
                      "Thrombin added to diluted patient plasma",
                      "PT-based fibrinogen testMeasures rate of change in plasma turbidity in plasma sample stimulated by PT reagentRate of change is proportional to rate of fibrin polymerizationFormation of fibrin is rate-limiting stepTime to clot proportional to clottable fibrinogen concentrationCan be run as part of PT testHas higher risk of inaccuracy",
                      "Measures rate of change in plasma turbidity in plasma sample stimulated by PT reagent",
                      "Rate of change is proportional to rate of fibrin polymerization",
                      "Formation of fibrin is rate-limiting stepTime to clot proportional to clottable fibrinogen concentration",
                      "Time to clot proportional to clottable fibrinogen concentration",
                      "Can be run as part of PT testHas higher risk of inaccuracy",
                      "Has higher risk of inaccuracy"
                    ]
                  },
                  {
                    "text": "TEGPoint of care test designed to provide real-time view of active hemostasis during trauma management or surgeryRotational force of pin turning in cup containing whole-blood sample is measuredTorque on pin increases proportionally to clot strengthMagnitude of shear force correlates platelet and fibrinogen activity combinedFibrinogen-specific modules available",
                    "sub_points": [
                      "Point of care test designed to provide real-time view of active hemostasis during trauma management or surgery",
                      "Rotational force of pin turning in cup containing whole-blood sample is measured",
                      "Torque on pin increases proportionally to clot strength",
                      "Magnitude of shear force correlates platelet and fibrinogen activity combined",
                      "Fibrinogen-specific modules available"
                    ]
                  },
                  {
                    "text": "Total fibrinogen measured via precipitation methods, ELISA, or immunodiffusionTotal fibrinogen is useful to evaluate dysfibrinogenemiasRatio of clottable to total fibrinogen of 0.8-1.7 suggests normal fibrinogen function",
                    "sub_points": [
                      "Total fibrinogen is useful to evaluate dysfibrinogenemias",
                      "Ratio of clottable to total fibrinogen of 0.8-1.7 suggests normal fibrinogen function"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Evaluation": [
                  {
                    "text": "Clinical history important in evaluation of elevated TTMost common causes are liver disease, DIC, and traumaCongenital afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia are rareCBC, PT, and PTT should be used in conjunction with TT when evaluating for underlying causes",
                    "sub_points": [
                      "Most common causes are liver disease, DIC, and trauma",
                      "Congenital afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia are rare",
                      "CBC, PT, and PTT should be used in conjunction with TT when evaluating for underlying causes"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Afibrinogenemia (rare)Lack of fibrinogen in bloodAutosomal recessive trait with homozygous inheritance that manifests with bleeding of variable severity, usually mucosal or umbilical stumpPoor wound healing is common",
                    "sub_points": [
                      "Lack of fibrinogen in blood",
                      "Autosomal recessive trait with homozygous inheritance that manifests with bleeding of variable severity, usually mucosal or umbilical stump",
                      "Poor wound healing is common"
                    ]
                  },
                  {
                    "text": "HypofibrinogenemiaPartial deficiency of fibrinogen due to heterozygous inheritance of mutated fibrinogen geneCan be dominant or autosomal recessive inheritance",
                    "sub_points": [
                      "Partial deficiency of fibrinogen due to heterozygous inheritance of mutated fibrinogen gene",
                      "Can be dominant or autosomal recessive inheritance"
                    ]
                  },
                  {
                    "text": "DysfibrinogenemiaQualitative fibrinogen deficiency due to production of dysfunctional fibrinogenCongenital inheritance is rare but does occurHeterozygous inheritance more commonThrombin and reptilase time studies should be used to assess dysfibrinogenemiasDysfibrinogenemias are most commonly acquired as a result of liver disease, especially hepatitis B and C",
                    "sub_points": [
                      "Qualitative fibrinogen deficiency due to production of dysfunctional fibrinogen",
                      "Congenital inheritance is rare but does occurHeterozygous inheritance more common",
                      "Heterozygous inheritance more common",
                      "Thrombin and reptilase time studies should be used to assess dysfibrinogenemiasDysfibrinogenemias are most commonly acquired as a result of liver disease, especially hepatitis B and C",
                      "Dysfibrinogenemias are most commonly acquired as a result of liver disease, especially hepatitis B and C"
                    ]
                  },
                  {
                    "text": "MedicationsHeparinDirect thrombin inhibitorsMore sensitive to use TT than PT or PTT for monitoring of these medicationsFibrinolytics (tPA, streptokinase)L-asparaginase (chemotherapeutic agent for leukemia) can reduce fibrinogen concentration",
                    "sub_points": [
                      "Heparin",
                      "Direct thrombin inhibitorsMore sensitive to use TT than PT or PTT for monitoring of these medications",
                      "More sensitive to use TT than PT or PTT for monitoring of these medications",
                      "Fibrinolytics (tPA, streptokinase)",
                      "L-asparaginase (chemotherapeutic agent for leukemia) can reduce fibrinogen concentration"
                    ]
                  },
                  {
                    "text": "Waldenström macroglobulinemia or other monoclonal gammopathies"
                  },
                  {
                    "text": "Acquired specific thrombin inhibitorsMost commonly develop in patients exposed to topical bovine thrombin (e.g., during cardiac or spinal surgery)",
                    "sub_points": [
                      "Most commonly develop in patients exposed to topical bovine thrombin (e.g., during cardiac or spinal surgery)"
                    ]
                  },
                  {
                    "text": "Liver diseaseFibrinogen is synthesized by liverHypofibrinogenemia and dysfibrinogenemia associated with liver disease are common",
                    "sub_points": [
                      "Fibrinogen is synthesized by liverHypofibrinogenemia and dysfibrinogenemia associated with liver disease are common",
                      "Hypofibrinogenemia and dysfibrinogenemia associated with liver disease are common"
                    ]
                  },
                  {
                    "text": "DICFibrinogen is consumed with other factors",
                    "sub_points": [
                      "Fibrinogen is consumed with other factors"
                    ]
                  },
                  {
                    "text": "Trauma and hemorrhageLow levels of fibrinogen in trauma setting is an independent predictor of poor survival",
                    "sub_points": [
                      "Low levels of fibrinogen in trauma setting is an independent predictor of poor survival"
                    ]
                  },
                  {
                    "text": "Kidney disease (nephrotic syndrome, renal cell carcinoma)"
                  }
                ]
              },
              "SPECIMENS": {
                "Preanalytic Variables": [
                  {
                    "text": "Samples must be collected in 3.2% sodium citrate with final blood-to-citrate ratio of 9:1Patients with high hematocrit (> 55%) have decreased percentage of plasma in collection sampleResults in falsely prolonged TT due to excess citrateUnderfilled tubes can result in abnormal plasma-to-citrate ratio",
                    "sub_points": [
                      "Patients with high hematocrit (> 55%) have decreased percentage of plasma in collection sampleResults in falsely prolonged TT due to excess citrate",
                      "Results in falsely prolonged TT due to excess citrate",
                      "Underfilled tubes can result in abnormal plasma-to-citrate ratio"
                    ]
                  },
                  {
                    "text": "Radiocontrast dye can falsely prolong TT by inhibiting fibrinopeptide A release﻿ in vitro﻿"
                  },
                  {
                    "text": "Hemolysis or sample discoloration can interfere with photo-optical methods of clot detection"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Interpretation of D-Dimer Test Result/Fibrin Degradation Products": {
            "name": "Interpretation of D-Dimer Test Result/Fibrin Degradation Products",
            "url": "https://app.pathprimer.com/document/6926c424-4e21-4744-ae0f-09b71d4e825f/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "D-Dimer is fragment of cross-linked fibrin that has been degraded by plasmin"
                  },
                  {
                    "text": "Presence of D-dimers indicates excessive thrombin activation"
                  },
                  {
                    "text": "Useful for discriminating between fibrinolysis and fibrinogenolysis"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "D-Dimer is screening test of choice for disease states that are typified by excessive thrombosis, including DIC, DVT, and PE"
                  },
                  {
                    "text": "D-Dimer is sensitive but not specific, and clinical history and other testing modalities should be used for confirmation"
                  },
                  {
                    "text": "Many hospitalized patients have elevation of D-dimers that are above normal reference range, but they do not have clinical evidence of DIC, DVT, or PE"
                  }
                ]
              },
              "OVERVIEW": {
                "D-Dimer": [
                  {
                    "text": "D-Dimer is fragment of cross-linked fibrin that has been degraded by plasmin"
                  },
                  {
                    "text": "Presence of D-dimers indicates excessive thrombin activation"
                  },
                  {
                    "text": "Useful for discriminating between fibrinolysis and fibrinogenolysis"
                  }
                ],
                "Fibrin Degradation Products": [
                  {
                    "text": "FDPs include fragments of soluble fibrin that have been cleaved before cross-linking by factor XIII"
                  },
                  {
                    "text": "Fragments include degradation products generated by action of thrombin on fibrinogen (fibrinogenolysis) and by action of plasmin on fibrin (fibrinolysis)"
                  },
                  {
                    "text": "FDPs do not distinguish between fibrinogenolysis and fibrinolysisTesting for FDPs has been largely replaced by D-dimers",
                    "sub_points": [
                      "Testing for FDPs has been largely replaced by D-dimers"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fibrin degradation products (FDPs)"
                  },
                  {
                    "text": "Tissue plasmin activator (tPA)"
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)"
                  },
                  {
                    "text": "Deep vein thrombosis (DVT)"
                  },
                  {
                    "text": "Pulmonary embolism (PE)"
                  },
                  {
                    "text": "Enzyme-linked immunosorbent assay (ELISA)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Fibrinogen Function": [
                  {
                    "text": "Fibrinogen is composed of 6 peptide chains (Aα, Bβ, Cγ) organized into structure that consists of central E domain and 2 terminal D domains"
                  },
                  {
                    "text": "Thrombin acts on fibrinogen by cleaving fibrinopeptides A and BResults in soluble fibrin monomer",
                    "sub_points": [
                      "Results in soluble fibrin monomer"
                    ]
                  },
                  {
                    "text": "Soluble fibrin monomers self-assemble to form non-covalently bonded chains with end-to-end and side-to-side formation"
                  },
                  {
                    "text": "Formation creates meshwork to stabilize newly formed clot"
                  },
                  {
                    "text": "Factor XIII cross-links fibrin monomers, forming covalent bonds that increase stability of clot"
                  }
                ],
                "Plasminogen": [
                  {
                    "text": "Plasminogen is activated to plasmin by endogenous tPA"
                  },
                  {
                    "text": "Plasmin is clot-lysing enzyme that degrades soluble fibrinogen into FDPsFibrinogen is cleaved at 2 sites by plasminFirst at α chain creating X fragmentThen diagonally across D-E linkages, creating Y fragmentFibrin is also degraded by plasmin (FDPs) and destroys cross-linked fibrin at D-D sitesD-D fragments, or D-dimers, are released",
                    "sub_points": [
                      "Fibrinogen is cleaved at 2 sites by plasminFirst at α chain creating X fragmentThen diagonally across D-E linkages, creating Y fragment",
                      "First at α chain creating X fragment",
                      "Then diagonally across D-E linkages, creating Y fragment",
                      "Fibrin is also degraded by plasmin (FDPs) and destroys cross-linked fibrin at D-D sitesD-D fragments, or D-dimers, are released",
                      "D-D fragments, or D-dimers, are released"
                    ]
                  },
                  {
                    "text": "Presence of D-dimers indicatesThrombin was formedClotting occurredFibrin was cross-linked by factor XIIIPlasmin was activatedPlasmin degraded cross-linked fibrin",
                    "sub_points": [
                      "Thrombin was formed",
                      "Clotting occurred",
                      "Fibrin was cross-linked by factor XIII",
                      "Plasmin was activated",
                      "Plasmin degraded cross-linked fibrin"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Identification of D-Dimers": [
                  {
                    "text": "Specific monoclonal antibodies are commercially available"
                  },
                  {
                    "text": "D-Dimer levels are not comparable between testing platforms"
                  },
                  {
                    "text": "Assay of specific reference ranges should be assigned to assist with interpretation of D-dimer that is above normal but below expected level for DIC, DVT, or PE"
                  }
                ],
                "Latex Agglutination": [
                  {
                    "text": "Less sensitive than ELISA in detection of D-dimers for critical situations such as PE"
                  }
                ],
                "Enzyme-Linked Immunosorbent Assay": [
                  {
                    "text": "Reference test of choiceProvides > 90% sensitivity for detection of D-dimersNegative results have > 90% negative predictive value for DVT",
                    "sub_points": [
                      "Provides > 90% sensitivity for detection of D-dimers",
                      "Negative results have > 90% negative predictive value for DVT"
                    ]
                  },
                  {
                    "text": "Automated method also available"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "D-Dimer Use in Clinical Diagnosis": [
                  {
                    "text": "D-Dimer is screening test of choice for disease states that are typified by excessive thrombosisDICDVTPE",
                    "sub_points": [
                      "DIC",
                      "DVT",
                      "PE"
                    ]
                  },
                  {
                    "text": "D-Dimer is sensitive but not specificClinical history and other testing modalities should be used for confirmation",
                    "sub_points": [
                      "Clinical history and other testing modalities should be used for confirmation"
                    ]
                  },
                  {
                    "text": "D-Dimers can be elevated in many clinical situations where inflammation and activation of coagulation are presentObstetric complications (HELLP syndrome)MalignancySickle cell crisisCirrhosisSubarachnoid hemorrhageAcute aortic dissection",
                    "sub_points": [
                      "Obstetric complications (HELLP syndrome)",
                      "Malignancy",
                      "Sickle cell crisis",
                      "Cirrhosis",
                      "Subarachnoid hemorrhage",
                      "Acute aortic dissection"
                    ]
                  },
                  {
                    "text": "Many hospitalized patients have elevation of D-dimers that are above normal reference range but do not have clinical evidence of DIC, DVT, or PE"
                  }
                ]
              },
              "SPECIMENS": {
                "Sample": [
                  {
                    "text": "Specimens should be collected in sodium citrate"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Interpretation of Mixing Studies": {
            "name": "Interpretation of Mixing Studies",
            "url": "https://app.pathprimer.com/document/1a2f2701-3e00-458d-ba93-dd43ca157cbf/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Mixing study: Used to distinguish between specific coagulation factor deficiency and inhibitorAppropriate for use when patient has prolonged PT &/or aPTT and appropriate clinical history",
                    "sub_points": [
                      "Appropriate for use when patient has prolonged PT &/or aPTT and appropriate clinical history"
                    ]
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "Typically, factor must be < 40-50% to prolong PT or aPTT"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "PT or aPTT is performed immediately on patient sample mixed in 1:1 ratio with pooled plasma from normal healthy donorsBecause individual factor must be < 50% to show prolongation in PT or aPTT, combining patient plasma (factor range 0-50%) with normal pooled plasma (100%) results in total of > 50% and should correct PT/aPTT to normal range",
                    "sub_points": [
                      "Because individual factor must be < 50% to show prolongation in PT or aPTT, combining patient plasma (factor range 0-50%) with normal pooled plasma (100%) results in total of > 50% and should correct PT/aPTT to normal range"
                    ]
                  },
                  {
                    "text": "Plasma mixture is then incubated for 1 hour at 37°C and PT or aPTT is performed againIf PT or aPTT corrects, factor deficiency is likelyIf PT or aPTT is prolonged, inhibitor or lupus anticoagulant is likely",
                    "sub_points": [
                      "If PT or aPTT corrects, factor deficiency is likely",
                      "If PT or aPTT is prolonged, inhibitor or lupus anticoagulant is likely"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "In Vitro Method to Assess Presence of Factors": [
                  {
                    "text": "Coagulation factors must be present in vivo in varying amounts to maintain normal homeostasisTypically, factor or its activity must be < 40-50% to prolong PT or aPTTSome factors (e.g., factor XI) can be as low as 20-25% before prolongation of aPTT is seenLevel of coagulation factor present does not necessarily correlate with bleeding severityPatients with deficiency or inhibitor of factor VIII typically have mild bleeding for levels 6-30%Patients with deficiencies of factor XI can have unpredictable bleeding, even with factor levels > 25%",
                    "sub_points": [
                      "Typically, factor or its activity must be < 40-50% to prolong PT or aPTT",
                      "Some factors (e.g., factor XI) can be as low as 20-25% before prolongation of aPTT is seen",
                      "Level of coagulation factor present does not necessarily correlate with bleeding severityPatients with deficiency or inhibitor of factor VIII typically have mild bleeding for levels 6-30%Patients with deficiencies of factor XI can have unpredictable bleeding, even with factor levels > 25%",
                      "Patients with deficiency or inhibitor of factor VIII typically have mild bleeding for levels 6-30%",
                      "Patients with deficiencies of factor XI can have unpredictable bleeding, even with factor levels > 25%"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Test Methods": [
                  {
                    "text": "PT or aPTT is performed immediately on patient sample mixed in 1:1 ratio with pooled plasma from normal healthy donorsFactor activity can be 0-150% in given person; pooling healthy donors provides average factor levels of 100%Because individual factor must be < 50% to show prolongation in PT or aPTT, combining patient plasma (factor range 0-50%) with normal pooled plasma (100%) results in total of > 50% and should correct PT/aPTT to normal rangeMultiple factor deficiencies may not correct fully",
                    "sub_points": [
                      "Factor activity can be 0-150% in given person; pooling healthy donors provides average factor levels of 100%",
                      "Because individual factor must be < 50% to show prolongation in PT or aPTT, combining patient plasma (factor range 0-50%) with normal pooled plasma (100%) results in total of > 50% and should correct PT/aPTT to normal rangeMultiple factor deficiencies may not correct fully",
                      "Multiple factor deficiencies may not correct fully"
                    ]
                  },
                  {
                    "text": "Next, plasma mixture is incubated for 1 hour at 37°C and PT or aPTT is performed againIf PT or aPTT corrects, a factor deficiency is likelyIf PT or aPTT is prolonged, an inhibitor or lupus anticoagulant is likelyInhibitor inactivates clotting factor provided by pooled plasma, and PT or aPTT is prolongedSome inhibitors are time dependent, so incubation period is used",
                    "sub_points": [
                      "If PT or aPTT corrects, a factor deficiency is likely",
                      "If PT or aPTT is prolonged, an inhibitor or lupus anticoagulant is likelyInhibitor inactivates clotting factor provided by pooled plasma, and PT or aPTT is prolongedSome inhibitors are time dependent, so incubation period is used",
                      "Inhibitor inactivates clotting factor provided by pooled plasma, and PT or aPTT is prolonged",
                      "Some inhibitors are time dependent, so incubation period is used"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Interpretation": [
                  {
                    "text": "Prolonged aPTT without significant bleeding history is suspicious for lupus anticoagulant or factor XII deficiencyRuling out heparin contamination is important in evaluating prolonged aPTT in this setting",
                    "sub_points": [
                      "Ruling out heparin contamination is important in evaluating prolonged aPTT in this setting"
                    ]
                  },
                  {
                    "text": "Prolonged PT is most often due to vitamin K deficiencyMay be due to warfarin therapy, liver disease, bacterial overgrowth due to antibiotic use, or malnutritionIn vitamin K deficiency, PT will often not correct fully due to multiple factor deficienciesIsolated factor VII deficiency is uncommon, but does occur",
                    "sub_points": [
                      "May be due to warfarin therapy, liver disease, bacterial overgrowth due to antibiotic use, or malnutrition",
                      "In vitamin K deficiency, PT will often not correct fully due to multiple factor deficiencies",
                      "Isolated factor VII deficiency is uncommon, but does occur"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Preanalytic Variables": [
                  {
                    "text": "Heparin contaminationIn hospitalized patients, high levels of heparin used in central line can contaminate sample and give falsely elevated aPTTSample can be treated with heparin-neutralizing agent (heparinase) to remove exogenous heparinMixing study should correct to normal if contamination is mild or heparin is at normal therapeutic levels",
                    "sub_points": [
                      "In hospitalized patients, high levels of heparin used in central line can contaminate sample and give falsely elevated aPTT",
                      "Sample can be treated with heparin-neutralizing agent (heparinase) to remove exogenous heparin",
                      "Mixing study should correct to normal if contamination is mild or heparin is at normal therapeutic levels"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Performance of Factor Assays": {
            "name": "Performance of Factor Assays",
            "url": "https://app.pathprimer.com/document/2ec4265f-aa7c-4ccc-bad3-6d774b7c8ee0/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Coagulation factors can be tested for quantity and ability to functionType I defects are quantitative, with reduced or absent amounts of factorType II defects are qualitative, with decreased activity of antigen despite normal or near-normal levelsAcquired defects can behave as either type I or type II",
                    "sub_points": [
                      "Type I defects are quantitative, with reduced or absent amounts of factor",
                      "Type II defects are qualitative, with decreased activity of antigen despite normal or near-normal levels",
                      "Acquired defects can behave as either type I or type II"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Activity assays assess functionality of factor being tested"
                  },
                  {
                    "text": "Antigen assays quantify factor being tested"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "When choosing PT or aPTT based assay vs. chromogenic assay, it is important to remember that levels of other proteins can affect resultsExample: Heterozygous factor V Leiden affects protein C results in coagulant assay, but activity in chromogenic assay is not affected",
                    "sub_points": [
                      "Example: Heterozygous factor V Leiden affects protein C results in coagulant assay, but activity in chromogenic assay is not affected"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Coagulation Factor Testing": [
                  {
                    "text": "Coagulation factors can be tested for quantity and ability to functionType I defects are quantitative, with reduced or absent amounts of factorDefects may be due to inadequate production or increased clearanceType II defects are qualitative, with decreased activity of antigen despite normal or near-normal levelsDefects may be due to gene mutation or post-translational alterationAcquired defects can behave as either type I or type IIAntibody commonly develops that reacts with factor and clears it from system or renders it nonfunctional",
                    "sub_points": [
                      "Type I defects are quantitative, with reduced or absent amounts of factorDefects may be due to inadequate production or increased clearance",
                      "Defects may be due to inadequate production or increased clearance",
                      "Type II defects are qualitative, with decreased activity of antigen despite normal or near-normal levelsDefects may be due to gene mutation or post-translational alteration",
                      "Defects may be due to gene mutation or post-translational alteration",
                      "Acquired defects can behave as either type I or type IIAntibody commonly develops that reacts with factor and clears it from system or renders it nonfunctional",
                      "Antibody commonly develops that reacts with factor and clears it from system or renders it nonfunctional"
                    ]
                  },
                  {
                    "text": "Inhibitors are alloantibodies or autoantibodies that can develop in patientsAlloantibodies should be considered when patient with known congenital deficiency fails to respond to therapy as expectedAutoantibodies are suspect when otherwise unaffected patient develops low factor levels",
                    "sub_points": [
                      "Alloantibodies should be considered when patient with known congenital deficiency fails to respond to therapy as expected",
                      "Autoantibodies are suspect when otherwise unaffected patient develops low factor levels"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Enzyme-linked immunosorbent assay (ELISA)"
                  },
                  {
                    "text": "Latex immunoassay (LIA)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Coagulation Factor Assays": [
                  {
                    "text": "Antigen assays quantify factor being tested"
                  },
                  {
                    "text": "Activity assays assess function of factor being testedAssays can be chromogenic or clot-basedChromogenic assays provide all components of cascade needed for clot except for factor being measuredEndpoint is cleavage of synthetic substrate through enzymatic reaction, detected colorimetricallyChromogenic assays precisely measure activity of protein being testedClot-based assays are modified PT or aPTT designed to make factor of interest the rate-limiting stepTest plasma is compared with control plasma and amount of correction is measuredClot-based assays give broader view of factor of interest functionExample of clot-based assayaPTT reagent, factor VIII-deficient plasma, and patient plasma are combinedAfter brief incubation, time to clot is measured, forcing patient factor VIII (or lack of) to be rate-limiting stepSpecific factor testingFactor VIIIActivity measured in 1-stage or 2-stage clot-based assay or chromogenic methodAntigen measured using human or monoclonal antibodiesAntigen not routinely measuredFactor IXActivity measured in 1-stage assay using aPTTAntigen tested for with monoclonal or heterologous antibodiesFactor XI measured in 1-stage assay using aPTTFactor XII measured in 1-stage assay using aPTTFactor X, V, II, VII measured via clot-based PT assayFactor Xa measured with chromogenic assayFactor XIIIActivity cannot be detected by clot-based methods5M urea or 1% monochloroacetic acid used to assess for clot stabilityTo determine activity, measurement of specific substrate cleavage must be performedAntigen for factor XIII A and B subunits can be measured immunologicallyThrombin, protein C, protein S measured with chromogenic assayImmunologic methods for testingELISALIA",
                    "sub_points": [
                      "Assays can be chromogenic or clot-basedChromogenic assays provide all components of cascade needed for clot except for factor being measuredEndpoint is cleavage of synthetic substrate through enzymatic reaction, detected colorimetricallyChromogenic assays precisely measure activity of protein being testedClot-based assays are modified PT or aPTT designed to make factor of interest the rate-limiting stepTest plasma is compared with control plasma and amount of correction is measuredClot-based assays give broader view of factor of interest functionExample of clot-based assayaPTT reagent, factor VIII-deficient plasma, and patient plasma are combinedAfter brief incubation, time to clot is measured, forcing patient factor VIII (or lack of) to be rate-limiting step",
                      "Chromogenic assays provide all components of cascade needed for clot except for factor being measuredEndpoint is cleavage of synthetic substrate through enzymatic reaction, detected colorimetricallyChromogenic assays precisely measure activity of protein being tested",
                      "Endpoint is cleavage of synthetic substrate through enzymatic reaction, detected colorimetrically",
                      "Chromogenic assays precisely measure activity of protein being tested",
                      "Clot-based assays are modified PT or aPTT designed to make factor of interest the rate-limiting stepTest plasma is compared with control plasma and amount of correction is measuredClot-based assays give broader view of factor of interest function",
                      "Test plasma is compared with control plasma and amount of correction is measured",
                      "Clot-based assays give broader view of factor of interest function",
                      "Example of clot-based assayaPTT reagent, factor VIII-deficient plasma, and patient plasma are combinedAfter brief incubation, time to clot is measured, forcing patient factor VIII (or lack of) to be rate-limiting step",
                      "aPTT reagent, factor VIII-deficient plasma, and patient plasma are combined",
                      "After brief incubation, time to clot is measured, forcing patient factor VIII (or lack of) to be rate-limiting step",
                      "Specific factor testingFactor VIIIActivity measured in 1-stage or 2-stage clot-based assay or chromogenic methodAntigen measured using human or monoclonal antibodiesAntigen not routinely measuredFactor IXActivity measured in 1-stage assay using aPTTAntigen tested for with monoclonal or heterologous antibodiesFactor XI measured in 1-stage assay using aPTTFactor XII measured in 1-stage assay using aPTTFactor X, V, II, VII measured via clot-based PT assayFactor Xa measured with chromogenic assayFactor XIIIActivity cannot be detected by clot-based methods5M urea or 1% monochloroacetic acid used to assess for clot stabilityTo determine activity, measurement of specific substrate cleavage must be performedAntigen for factor XIII A and B subunits can be measured immunologicallyThrombin, protein C, protein S measured with chromogenic assay",
                      "Factor VIIIActivity measured in 1-stage or 2-stage clot-based assay or chromogenic methodAntigen measured using human or monoclonal antibodiesAntigen not routinely measured",
                      "Activity measured in 1-stage or 2-stage clot-based assay or chromogenic method",
                      "Antigen measured using human or monoclonal antibodies",
                      "Antigen not routinely measured",
                      "Factor IXActivity measured in 1-stage assay using aPTTAntigen tested for with monoclonal or heterologous antibodies",
                      "Activity measured in 1-stage assay using aPTT",
                      "Antigen tested for with monoclonal or heterologous antibodies",
                      "Factor XI measured in 1-stage assay using aPTT",
                      "Factor XII measured in 1-stage assay using aPTT",
                      "Factor X, V, II, VII measured via clot-based PT assay",
                      "Factor Xa measured with chromogenic assay",
                      "Factor XIIIActivity cannot be detected by clot-based methods5M urea or 1% monochloroacetic acid used to assess for clot stabilityTo determine activity, measurement of specific substrate cleavage must be performedAntigen for factor XIII A and B subunits can be measured immunologically",
                      "Activity cannot be detected by clot-based methods",
                      "5M urea or 1% monochloroacetic acid used to assess for clot stability",
                      "To determine activity, measurement of specific substrate cleavage must be performed",
                      "Antigen for factor XIII A and B subunits can be measured immunologically",
                      "Thrombin, protein C, protein S measured with chromogenic assay",
                      "Immunologic methods for testingELISALIA",
                      "ELISA",
                      "LIA"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Indications": [
                  {
                    "text": "To determine if specific factor is cause of prolongation of PT or aPTT that is not explained by patient history or medication (e.g., anticoagulation)Family history may lead to screening for specific factor deficienciesFactor VIII, IXUnexpected bleeding in otherwise healthy individualFactor XIProlonged aPTT with no history of bleedingFactor XII",
                    "sub_points": [
                      "Family history may lead to screening for specific factor deficienciesFactor VIII, IX",
                      "Factor VIII, IX",
                      "Unexpected bleeding in otherwise healthy individualFactor XI",
                      "Factor XI",
                      "Prolonged aPTT with no history of bleedingFactor XII",
                      "Factor XII"
                    ]
                  },
                  {
                    "text": "To monitor known factor deficiencies in patient being monitored or treated with factor replacement (e.g., hemophilia)"
                  }
                ],
                "Choosing Test Method": [
                  {
                    "text": "When choosing PT or aPTT clot-based assay vs. chromogenic assayIt is important to remember that levels of other proteins can affect resultsExample: Heterozygous factor V Leiden affects protein C results in coagulant assay, but activity in chromogenic assay is not affected",
                    "sub_points": [
                      "It is important to remember that levels of other proteins can affect results",
                      "Example: Heterozygous factor V Leiden affects protein C results in coagulant assay, but activity in chromogenic assay is not affected"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Preanalytic Variables": [
                  {
                    "text": "Heparin contamination can interfere with assayHeparinase may be used to remove heparin",
                    "sub_points": [
                      "Heparinase may be used to remove heparin"
                    ]
                  },
                  {
                    "text": "Lupus anticoagulant can interfere with clot-based assaysAffects multiple factors",
                    "sub_points": [
                      "Affects multiple factors"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Interpretation of Nonparallelism in Factor Assays": {
            "name": "Interpretation of Nonparallelism in Factor Assays",
            "url": "https://app.pathprimer.com/document/3ffa679d-6217-43a5-9fa7-fb176373bfac/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Activity of coagulation factor is determined by creating calibration curveCalibrator (calibration plasma) that has been assayed for coagulation factor activity is diluted with varying amounts of specific factor-deficient plasmaPTT is measured for each of the dilutionsLog-linear graph is constructed and regression line is calculated: log (factor %) = x-axis, clot time = y-axisPatient sample is analyzed and clot time is determined and compared with calibration curve",
                    "sub_points": [
                      "Calibrator (calibration plasma) that has been assayed for coagulation factor activity is diluted with varying amounts of specific factor-deficient plasma",
                      "PTT is measured for each of the dilutions",
                      "Log-linear graph is constructed and regression line is calculated: log (factor %) = x-axis, clot time = y-axis",
                      "Patient sample is analyzed and clot time is determined and compared with calibration curve"
                    ]
                  },
                  {
                    "text": "Parallelism: When ≥ 2 dilutions of patient sample are analyzed against calibration curve, the recovery should be proportional to dilutionFor example, if an assay recovers 25% from a patient sample diluted 1:20, the sample diluted 1:40 should recover 12.5%",
                    "sub_points": [
                      "For example, if an assay recovers 25% from a patient sample diluted 1:20, the sample diluted 1:40 should recover 12.5%"
                    ]
                  },
                  {
                    "text": "Nonparallelism: If dilutions are not parallel within a preset coefficient of variation, nonparallelism is presentNonparallelism is commonly seen in presence of lupus anticoagulant",
                    "sub_points": [
                      "Nonparallelism is commonly seen in presence of lupus anticoagulant"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Partial thromboplastin time (PTT)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Determining Coagulation Factor Activity (One-Stage Assay)": [
                  {
                    "text": "Activity of coagulation factor is determined by creating calibration curveCalibrator (calibration plasma) that has been assayed for coagulation factor activity is diluted with varying amounts of specific factor-deficient plasmaFor example, calibrator assayed at 100% for factor VIII would be diluted to 1:2 (50%), 1:4 (25%), 1:8 (12.5%)PTT is measured for each of the dilutionsLog-linear graph is constructed and regression line is calculated: log (factor %) = x-axis, clot time = y-axisPatient sample is analyzed, and clot time is determinedUsually sample is analyzed at 2 dilutions and then averaged (e.g., plasma run neat and 1:20 dilution)This allows for patient sample to be compared at different areas on calibration curve",
                    "sub_points": [
                      "Calibrator (calibration plasma) that has been assayed for coagulation factor activity is diluted with varying amounts of specific factor-deficient plasmaFor example, calibrator assayed at 100% for factor VIII would be diluted to 1:2 (50%), 1:4 (25%), 1:8 (12.5%)PTT is measured for each of the dilutionsLog-linear graph is constructed and regression line is calculated: log (factor %) = x-axis, clot time = y-axis",
                      "For example, calibrator assayed at 100% for factor VIII would be diluted to 1:2 (50%), 1:4 (25%), 1:8 (12.5%)",
                      "PTT is measured for each of the dilutions",
                      "Log-linear graph is constructed and regression line is calculated: log (factor %) = x-axis, clot time = y-axis",
                      "Patient sample is analyzed, and clot time is determinedUsually sample is analyzed at 2 dilutions and then averaged (e.g., plasma run neat and 1:20 dilution)This allows for patient sample to be compared at different areas on calibration curve",
                      "Usually sample is analyzed at 2 dilutions and then averaged (e.g., plasma run neat and 1:20 dilution)This allows for patient sample to be compared at different areas on calibration curve",
                      "This allows for patient sample to be compared at different areas on calibration curve"
                    ]
                  }
                ],
                "Parallelism and Nonparallelism": [
                  {
                    "text": "LinearityConcept of parallelism is similar to concept of linearity in clinical chemistryIf sample is diluted 1:2, one-half of analyte should be recoveredSimilarly, if sample is diluted 1:4, one-fourth of analyte should be recovered",
                    "sub_points": [
                      "Concept of parallelism is similar to concept of linearity in clinical chemistry",
                      "If sample is diluted 1:2, one-half of analyte should be recoveredSimilarly, if sample is diluted 1:4, one-fourth of analyte should be recovered",
                      "Similarly, if sample is diluted 1:4, one-fourth of analyte should be recovered"
                    ]
                  },
                  {
                    "text": "ParallelismWhen ≥ 2 dilutions of patient sample are analyzed against calibration curve, recovery should be proportional to dilutionFor example, if an assay recovers 25% from patient sample diluted 1:20, the sample diluted 1:40 should recover 12.5%",
                    "sub_points": [
                      "When ≥ 2 dilutions of patient sample are analyzed against calibration curve, recovery should be proportional to dilution",
                      "For example, if an assay recovers 25% from patient sample diluted 1:20, the sample diluted 1:40 should recover 12.5%"
                    ]
                  },
                  {
                    "text": "NonparallelismIf dilutions are not parallel within preset coefficient of variation, nonparallelism is presentNonparallelism is commonly seen in presence of lupus anticoagulantAs higher dilutions of patient plasma are tested, lupus anticoagulant is diluted and more factor activity is recoveredIncrease in activity as sample is dilutedCauses of nonparallelism in coagulation assaysNonspecific inhibitors (e.g., lupus anticoagulant)Specific factor inhibitors (e.g., factor VIII inhibitor)Anticoagulant agents (e.g., heparin, direct thrombin inhibitor)Lupus insensitive aPTT reagent can be used to eliminate effect of lupus anticoagulantThrombin time can be performed to determine if heparin, direct thrombin inhibitor, or other anticoagulant agent is interfering",
                    "sub_points": [
                      "If dilutions are not parallel within preset coefficient of variation, nonparallelism is presentNonparallelism is commonly seen in presence of lupus anticoagulantAs higher dilutions of patient plasma are tested, lupus anticoagulant is diluted and more factor activity is recoveredIncrease in activity as sample is diluted",
                      "Nonparallelism is commonly seen in presence of lupus anticoagulant",
                      "As higher dilutions of patient plasma are tested, lupus anticoagulant is diluted and more factor activity is recoveredIncrease in activity as sample is diluted",
                      "Increase in activity as sample is diluted",
                      "Causes of nonparallelism in coagulation assaysNonspecific inhibitors (e.g., lupus anticoagulant)Specific factor inhibitors (e.g., factor VIII inhibitor)Anticoagulant agents (e.g., heparin, direct thrombin inhibitor)",
                      "Nonspecific inhibitors (e.g., lupus anticoagulant)",
                      "Specific factor inhibitors (e.g., factor VIII inhibitor)",
                      "Anticoagulant agents (e.g., heparin, direct thrombin inhibitor)",
                      "Lupus insensitive aPTT reagent can be used to eliminate effect of lupus anticoagulant",
                      "Thrombin time can be performed to determine if heparin, direct thrombin inhibitor, or other anticoagulant agent is interfering"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Performance and Interpretation of the Bethesda Assay": {
            "name": "Performance and Interpretation of the Bethesda Assay",
            "url": "https://app.pathprimer.com/document/cd76310d-d9cf-4f3f-9999-b6535e471909/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Terminology": [
                  {
                    "text": "Bethesda unit (BU) is amount of inhibitor that neutralizes 50% of factor in incubation mixture"
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "Inhibitors are alloantibodies in patients with ﻿congenital factor deficiency and autoantibodies in patients with acquired factor deficiency"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Each BU is a reduction by 50%: ﻿0 BU is 100% → 1 BU is 50% → 2 BU is 25% → 3 BU is 12.5% → 4 BU is 6.25%"
                  },
                  {
                    "text": "Most common type of acquired factor inhibitor is to factor VIII, most commonly seen in elderly patients, patients with connective tissue disorders, postpartum patients, and patients with B-cell malignancies"
                  }
                ],
                "Limitations": [
                  {
                    "text": "Lupus anticoagulant and nonspecific inhibitors may give false-positive results"
                  },
                  {
                    "text": "Heparin contamination can give false-positive results"
                  },
                  {
                    "text": "Circulating factor VIII, such as recently administered recombinant factor VIII in a hemophilia patient, may give false-negative or falsely low results"
                  }
                ]
              },
              "OVERVIEW": {
                "Testing for Factor Inhibitors": [
                  {
                    "text": "Bethesda assay was developed to quantify factor VIII inhibitorsDeveloped in 1973 in Bethesda, Maryland, when group of investigators devised standardized method of measurementBethesda unit (BU)Has been expanded for use to quantify other factor inhibitors",
                    "sub_points": [
                      "Developed in 1973 in Bethesda, Maryland, when group of investigators devised standardized method of measurementBethesda unit (BU)",
                      "Bethesda unit (BU)",
                      "Has been expanded for use to quantify other factor inhibitors"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Bethesda unit (BU)"
                  },
                  {
                    "text": "Normal pooled plasma (NPP)"
                  },
                  {
                    "text": "Residual activity (RA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Normal pooled plasma (NPP): Mixture of plasma donated by healthy donors to provide 100% of all factor levels"
                  },
                  {
                    "text": "Residual activity (RA): Percentage of factor activity remaining at completion of Bethesda assay"
                  },
                  {
                    "text": "Bethesda unit (BU): Amount of inhibitor that neutralizes 50% of factor in incubation mixture"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Inhibitors": [
                  {
                    "text": "Alloantibodies in patients with congenital factor deficiency"
                  },
                  {
                    "text": "Autoantibodies in patients with acquired factor deficiency"
                  },
                  {
                    "text": "Neutralize specific factor, affecting patient hemostasis"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Performance of Bethesda Assay": [
                  {
                    "text": "Typically, Bethesda assay is performed after 1:1 mix of normal plasma fails to correct immediately and at 2 hr incubation at 37°CProlongation is determined to be due to specific factor inhibitor (vs. a phospholipid inhibitor such as lupus anticoagulant)",
                    "sub_points": [
                      "Prolongation is determined to be due to specific factor inhibitor (vs. a phospholipid inhibitor such as lupus anticoagulant)"
                    ]
                  },
                  {
                    "text": "Bethesda assay is performed by mixing 1 part of patient's plasma with 1 part of NPP, incubated at 37°CRemaining factor activity is measured",
                    "sub_points": [
                      "Remaining factor activity is measured"
                    ]
                  },
                  {
                    "text": "Remaining activity is divided by activity present in control mixture of NPP and imidazole bufferThis number is multiplied by 100 to give the % RA% RA is plotted on graph that has logarithm of RA vs. BU to give total BUBU = (2-log)(RA) ÷ (0.301)",
                    "sub_points": [
                      "This number is multiplied by 100 to give the % RA",
                      "% RA is plotted on graph that has logarithm of RA vs. BU to give total BU",
                      "BU = (2-log)(RA) ÷ (0.301)"
                    ]
                  }
                ],
                "Nijmegen Modification": [
                  {
                    "text": "Improves specificity and reliability of Bethesda assay with 2 specific changesPatient and control plasma samples are buffered with imidazole at pH of 7.4 to prevent deactivation of factor VIII, which can occur at higher pHPlasma depleted of factor VIII is combined with control sample in 1:1 ratio to provide equivalent plasma protein ratio as patient sample",
                    "sub_points": [
                      "Patient and control plasma samples are buffered with imidazole at pH of 7.4 to prevent deactivation of factor VIII, which can occur at higher pH",
                      "Plasma depleted of factor VIII is combined with control sample in 1:1 ratio to provide equivalent plasma protein ratio as patient sample"
                    ]
                  },
                  {
                    "text": "These changes prevent inactivation of factor VIII at higher pH or low protein concentrations, which can result in false-positive Bethesda titers"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Interpretation": [
                  {
                    "text": "If RA = 100%, then BU = 0For RA in range of 25%-100%, BU of lowest dilution is reportedIf RA < 25%, BU of highest dilution that falls between 25% and 75% is reportedThis result must be multiplied by dilution factor",
                    "sub_points": [
                      "For RA in range of 25%-100%, BU of lowest dilution is reported",
                      "If RA < 25%, BU of highest dilution that falls between 25% and 75% is reportedThis result must be multiplied by dilution factor",
                      "This result must be multiplied by dilution factor"
                    ]
                  },
                  {
                    "text": "Each BU is a reduction by 50%0 BU is 100% → 1 BU is 50% → 2 BU is 25% → 3 BU is 12.5% → 4 BU is 6.25%",
                    "sub_points": [
                      "0 BU is 100% → 1 BU is 50% → 2 BU is 25% → 3 BU is 12.5% → 4 BU is 6.25%"
                    ]
                  },
                  {
                    "text": "Multiple dilutions help to identify type 1 vs. type 2 inhibitor kineticsType 1 kinetics are linear will serial dilutionsAs patient:NPP mix is diluted, RA increasesAssociated withAlloantibodiesCongenital factor deficienciesType 2 kinetics are nonlinear with serial dilutionsAs patient:NPP mix is diluted, RA may stay the sameAssociated withAutoantibodiesAcquired factor deficiencies",
                    "sub_points": [
                      "Type 1 kinetics are linear will serial dilutionsAs patient:NPP mix is diluted, RA increasesAssociated withAlloantibodiesCongenital factor deficiencies",
                      "As patient:NPP mix is diluted, RA increases",
                      "Associated withAlloantibodiesCongenital factor deficiencies",
                      "Alloantibodies",
                      "Congenital factor deficiencies",
                      "Type 2 kinetics are nonlinear with serial dilutionsAs patient:NPP mix is diluted, RA may stay the sameAssociated withAutoantibodiesAcquired factor deficiencies",
                      "As patient:NPP mix is diluted, RA may stay the same",
                      "Associated withAutoantibodiesAcquired factor deficiencies",
                      "Autoantibodies",
                      "Acquired factor deficiencies"
                    ]
                  }
                ],
                "Acquired Factor VIII Inhibitor": [
                  {
                    "text": "Most common type of acquired factor inhibitor is to factor VIII"
                  },
                  {
                    "text": "Most commonly seenElderly patientsPatients with connective tissue disordersPostpartum patientsPatients with B-cell malignancies",
                    "sub_points": [
                      "Elderly patients",
                      "Patients with connective tissue disorders",
                      "Postpartum patients",
                      "Patients with B-cell malignancies"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Possible Errors": [
                  {
                    "text": "Lupus anticoagulant and nonspecific inhibitors may give false-positive results"
                  },
                  {
                    "text": "Heparin contamination can give false-positive results"
                  },
                  {
                    "text": "Circulating factor VIII may give false-negative or falsely low resultsSuch as recently administered recombinant factor VIII in patient with hemophilia",
                    "sub_points": [
                      "Such as recently administered recombinant factor VIII in patient with hemophilia"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Measurement and Interpretation of Protein C and Protein S": {
            "name": "Measurement and Interpretation of Protein C and Protein S",
            "url": "https://app.pathprimer.com/document/3956e249-f74d-44ed-92df-f5c246a72112/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Protein CVitamin K-dependentVery short half-life (6-8 hours)Synthesized as zymogen in liver",
                    "sub_points": [
                      "Vitamin K-dependent",
                      "Very short half-life (6-8 hours)",
                      "Synthesized as zymogen in liver"
                    ]
                  },
                  {
                    "text": "APC is released from receptor, binds with its cofactor, PS, and cleaves activated factors Va and VIIIa to inactive forms, Vi and VIIIi"
                  },
                  {
                    "text": "Primary function of PS is to act as cofactor for APC and accelerate inactivation of factor Va and factor VIIIa"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "For measurement of protein C, functional assays should be performed first, and if low functional activity is detected, antigen assay should be performed to detect type 2 protein C deficiency"
                  }
                ]
              },
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "Protein CVery short half-life (6-8 hours)Vitamin K-dependentSynthesized as zymogen in liverFunctions under normal physiological conditionsThrombin (IIa) binds thrombomodulin receptor located on endothelial cell surfaceBinding causes activation of protein C, which is bound to endothelial surface protein C receptorAPC is released from receptor and binds with its cofactor, PSAPC:PS cleaves activated factor Va and factor VIIIa to inactive forms, Vi and VIIIi",
                    "sub_points": [
                      "Very short half-life (6-8 hours)",
                      "Vitamin K-dependent",
                      "Synthesized as zymogen in liver",
                      "Functions under normal physiological conditionsThrombin (IIa) binds thrombomodulin receptor located on endothelial cell surfaceBinding causes activation of protein C, which is bound to endothelial surface protein C receptorAPC is released from receptor and binds with its cofactor, PSAPC:PS cleaves activated factor Va and factor VIIIa to inactive forms, Vi and VIIIi",
                      "Thrombin (IIa) binds thrombomodulin receptor located on endothelial cell surface",
                      "Binding causes activation of protein C, which is bound to endothelial surface protein C receptor",
                      "APC is released from receptor and binds with its cofactor, PS",
                      "APC:PS cleaves activated factor Va and factor VIIIa to inactive forms, Vi and VIIIi"
                    ]
                  },
                  {
                    "text": "Protein SWhen bound to APC, PS acts to accelerate inactivation of factor Va and factor VIIIaPS may also directly bind and inactivate factor Va and factor XaVitamin K-dependent~ 60% of PS is bound to C4b-binding protein and is nonfunctionalRemaining 40% is free PS and is only functional PS",
                    "sub_points": [
                      "When bound to APC, PS acts to accelerate inactivation of factor Va and factor VIIIa",
                      "PS may also directly bind and inactivate factor Va and factor Xa",
                      "Vitamin K-dependent",
                      "~ 60% of PS is bound to C4b-binding protein and is nonfunctional",
                      "Remaining 40% is free PS and is only functional PS"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Activated protein C (APC)"
                  },
                  {
                    "text": "Protein S (PS)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Protein C Measurement": [
                  {
                    "text": "2 types of protein C assays are availableFunctional assaysAntigen assays",
                    "sub_points": [
                      "Functional assays",
                      "Antigen assays"
                    ]
                  },
                  {
                    "text": "Functional assays should be performed first, and if low functional activity is detected, antigen assay should be performed to detect type 2 protein C deficiency"
                  },
                  {
                    "text": "Functional assaysClot-basedPatient plasma is mixed with Protac (venom from southern copperhead snake), which activates protein CActivity of APC is measured by prolongation of aPTTVariety of preanalytical variables can affect resultsSubstances that interfere with clotting time may give false normal result (i.e., direct thrombin inhibitors, heparin, lupus anticoagulant)High levels of factor VIII &/or factor V Leiden mutation may result in falsely low levels of protein C activityChromogenic assayPatient plasma is mixed with synthetic substrate that resembles normal APC substrateActivity is measured by ability of APC to cleave synthetic substrate, which releases chromogenic signal, which is then detected by optical methodMost laboratories use chromogenic assays, due to fewer preanalytical interferences",
                    "sub_points": [
                      "Clot-basedPatient plasma is mixed with Protac (venom from southern copperhead snake), which activates protein CActivity of APC is measured by prolongation of aPTTVariety of preanalytical variables can affect resultsSubstances that interfere with clotting time may give false normal result (i.e., direct thrombin inhibitors, heparin, lupus anticoagulant)High levels of factor VIII &/or factor V Leiden mutation may result in falsely low levels of protein C activity",
                      "Patient plasma is mixed with Protac (venom from southern copperhead snake), which activates protein C",
                      "Activity of APC is measured by prolongation of aPTT",
                      "Variety of preanalytical variables can affect resultsSubstances that interfere with clotting time may give false normal result (i.e., direct thrombin inhibitors, heparin, lupus anticoagulant)High levels of factor VIII &/or factor V Leiden mutation may result in falsely low levels of protein C activity",
                      "Substances that interfere with clotting time may give false normal result (i.e., direct thrombin inhibitors, heparin, lupus anticoagulant)",
                      "High levels of factor VIII &/or factor V Leiden mutation may result in falsely low levels of protein C activity",
                      "Chromogenic assayPatient plasma is mixed with synthetic substrate that resembles normal APC substrateActivity is measured by ability of APC to cleave synthetic substrate, which releases chromogenic signal, which is then detected by optical methodMost laboratories use chromogenic assays, due to fewer preanalytical interferences",
                      "Patient plasma is mixed with synthetic substrate that resembles normal APC substrate",
                      "Activity is measured by ability of APC to cleave synthetic substrate, which releases chromogenic signal, which is then detected by optical method",
                      "Most laboratories use chromogenic assays, due to fewer preanalytical interferences"
                    ]
                  }
                ],
                "Protein S Measurement": [
                  {
                    "text": "Antigenic assaysMeasure free and bound PS by mixing patient plasma with monoclonal antibody that binds to protein S and causes agglutinationAgglutination causes change in absorption of lightIncrease in light absorption is directly proportional to concentration of PS present",
                    "sub_points": [
                      "Measure free and bound PS by mixing patient plasma with monoclonal antibody that binds to protein S and causes agglutination",
                      "Agglutination causes change in absorption of light",
                      "Increase in light absorption is directly proportional to concentration of PS present"
                    ]
                  },
                  {
                    "text": "Clot-based functional assaysActivity assayPatient plasma is mixed with PS-deficient plasma, APC, and factor VaCalcium is added to initiate clottingClotting time is measured using aPTT or PT based assayClotting time is compared to reference curve to determine PS levelsThis assay is subject to variety of preanalytical variablesHeparin and lupus anticoagulant may cause falsely high result when using aPTT assaysAPC resistance, factor V Leiden mutation, or high levels of factor VIII (as can be seen during acute illness) can give spuriously low resultDue to large number of potential interferences, activity assays should not be used as initial testing for PS deficiency",
                    "sub_points": [
                      "Activity assay",
                      "Patient plasma is mixed with PS-deficient plasma, APC, and factor Va",
                      "Calcium is added to initiate clotting",
                      "Clotting time is measured using aPTT or PT based assay",
                      "Clotting time is compared to reference curve to determine PS levels",
                      "This assay is subject to variety of preanalytical variablesHeparin and lupus anticoagulant may cause falsely high result when using aPTT assaysAPC resistance, factor V Leiden mutation, or high levels of factor VIII (as can be seen during acute illness) can give spuriously low resultDue to large number of potential interferences, activity assays should not be used as initial testing for PS deficiency",
                      "Heparin and lupus anticoagulant may cause falsely high result when using aPTT assays",
                      "APC resistance, factor V Leiden mutation, or high levels of factor VIII (as can be seen during acute illness) can give spuriously low result",
                      "Due to large number of potential interferences, activity assays should not be used as initial testing for PS deficiency"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Measurement and Interpretation of Antithrombin": {
            "name": "Measurement and Interpretation of Antithrombin",
            "url": "https://app.pathprimer.com/document/de3f2a4e-1322-46fb-85d5-149aa7ffe811/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Antithrombin is natural anticoagulant that inactivates thrombin and factor Xa, which are then cleared by liverAT also inactivates factor IXa, factor XIa, and factor XIIa",
                    "sub_points": [
                      "AT also inactivates factor IXa, factor XIa, and factor XIIa"
                    ]
                  },
                  {
                    "text": "Heparin binds AT, which exposes active site and potentiates activity of AT by approximately 1000-fold"
                  },
                  {
                    "text": "Decreased AT activity leads to increased risk of thrombosis and VTE"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "AT activity assays primarily use chromogenic methods"
                  },
                  {
                    "text": "AT deficiency can be inherited (as type I or type II) or acquired"
                  },
                  {
                    "text": "Physiological changes: Newborns (healthy neonates are born with less than 50% of normal adult AT levels, although they are not predisposed to thrombotic complications that adults are)"
                  },
                  {
                    "text": "Acquired causesDecreased synthesis: Liver diseaseIncreased consumption: Sepsis, disseminated intravascular coagulationIncreased clearance: Kidney disease (i.e., nephrotic syndrome); drug-induced (specifically heparin); asparaginase therapy",
                    "sub_points": [
                      "Decreased synthesis: Liver disease",
                      "Increased consumption: Sepsis, disseminated intravascular coagulation",
                      "Increased clearance: Kidney disease (i.e., nephrotic syndrome); drug-induced (specifically heparin); asparaginase therapy"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "Antithrombin is natural anticoagulant that inactivates thrombin and factor Xa, which are then cleared by liverAT also inactivates factor IXa, factor XIa, and factor XIIa",
                    "sub_points": [
                      "AT also inactivates factor IXa, factor XIa, and factor XIIa"
                    ]
                  },
                  {
                    "text": "Heparin binds AT, which exposes active site and potentiates activity of AT by approximately 1000-fold"
                  },
                  {
                    "text": "Decreased AT activity leads to increased risk of thrombosis and VTE"
                  },
                  {
                    "text": "Gene for AT isSERPINC1 (serine protease inhibitor family C1); located on long arm of chromosome 1"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Antithrombin (AT)"
                  },
                  {
                    "text": "Enzyme-linked immunosorbent assay (ELISA)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Antithrombin Activity Assays": [
                  {
                    "text": "AT activity assays primarily use chromogenic methods"
                  },
                  {
                    "text": "Reagent contains heparin, excess factor IIa (thrombin), and chromogenic substrate"
                  },
                  {
                    "text": "Patient platelet-poor plasma is incubated with reagent"
                  },
                  {
                    "text": "Patient AT forms heparin-thrombin-AT complexes, which inactivates thrombin in sample"
                  },
                  {
                    "text": "Residual thrombin not inactivated then cleaves reporter signal from chromogenic substrate"
                  },
                  {
                    "text": "Amount of residual thrombin is measured by amount of chromogenic peptide detected and is inversely proportional to amount of AT present"
                  },
                  {
                    "text": "Some assays use factor Xa instead of thrombin to avoid interference with heparin cofactor IIHeparin cofactor II is naturally occurring substance that inhibits thrombin but not factor XaHeparin cofactor II could cause overestimation of AT levels in thrombin-based assays",
                    "sub_points": [
                      "Heparin cofactor II is naturally occurring substance that inhibits thrombin but not factor Xa",
                      "Heparin cofactor II could cause overestimation of AT levels in thrombin-based assays"
                    ]
                  },
                  {
                    "text": "Other assays use bovine thrombin, which is not inhibited by heparin cofactor II"
                  }
                ],
                "Antithrombin Antigenic Assays": [
                  {
                    "text": "ELISAThere are several methods for measuring AT using direct, indirect, and sandwich methodsIn sandwich capture method, primary capture antibody binds AT in sampleSecondary antibody binds to different site from primary antibody on ATSecondary antibody also has reporter mechanism, such as antiglobulin linked to fluorescent signal or colorimetric signal",
                    "sub_points": [
                      "There are several methods for measuring AT using direct, indirect, and sandwich methods",
                      "In sandwich capture method, primary capture antibody binds AT in sampleSecondary antibody binds to different site from primary antibody on ATSecondary antibody also has reporter mechanism, such as antiglobulin linked to fluorescent signal or colorimetric signal",
                      "Secondary antibody binds to different site from primary antibody on AT",
                      "Secondary antibody also has reporter mechanism, such as antiglobulin linked to fluorescent signal or colorimetric signal"
                    ]
                  },
                  {
                    "text": "Immunoturbidimetric assayReagent containing latex beads coated with anti-AT antibodies is incubated with patient plasmaAT bound to latex beads reduces light transmission beamed across sampleAT antigen is inversely proportional to light transmission",
                    "sub_points": [
                      "Reagent containing latex beads coated with anti-AT antibodies is incubated with patient plasma",
                      "AT bound to latex beads reduces light transmission beamed across sample",
                      "AT antigen is inversely proportional to light transmission"
                    ]
                  },
                  {
                    "text": "Immunoelectrophoresis (Laurell rocket)anti-AT antibody is mixed into electrophoretic gelStandards containing known amount of AT (calibrators) are run with patient samplesAs AT migrates on gel, antibody slows migration; distance traveled is proportional to amount of AT present in sample",
                    "sub_points": [
                      "anti-AT antibody is mixed into electrophoretic gel",
                      "Standards containing known amount of AT (calibrators) are run with patient samples",
                      "As AT migrates on gel, antibody slows migration; distance traveled is proportional to amount of AT present in sample"
                    ]
                  }
                ],
                "Interpretation": [
                  {
                    "text": "AT reference range in adults: 70-130%"
                  },
                  {
                    "text": "AT deficiency can be inherited (as type I or type II) or acquiredType I: Autosomal-dominant; gene deletions or point mutations lead to decreased AT antigen and activity levelsType II: Autosomal-dominant; single amino acid substitution leads to functionally abnormal AT molecule",
                    "sub_points": [
                      "Type I: Autosomal-dominant; gene deletions or point mutations lead to decreased AT antigen and activity levels",
                      "Type II: Autosomal-dominant; single amino acid substitution leads to functionally abnormal AT molecule"
                    ]
                  },
                  {
                    "text": "Acquired causesDecreased synthesisLiver diseaseIncreased consumptionSepsisDisseminated intravascular coagulationIncreased clearanceKidney disease (i.e., nephrotic syndrome)Drug-induced (specifically heparin)Asparaginase therapy",
                    "sub_points": [
                      "Decreased synthesisLiver disease",
                      "Liver disease",
                      "Increased consumptionSepsisDisseminated intravascular coagulation",
                      "Sepsis",
                      "Disseminated intravascular coagulation",
                      "Increased clearanceKidney disease (i.e., nephrotic syndrome)Drug-induced (specifically heparin)Asparaginase therapy",
                      "Kidney disease (i.e., nephrotic syndrome)",
                      "Drug-induced (specifically heparin)",
                      "Asparaginase therapy"
                    ]
                  },
                  {
                    "text": "Physiological changesNewbornsHealthy neonates are born with less than 50% of normal adult AT levels, although they are not predisposed to thrombotic complications that adults are",
                    "sub_points": [
                      "NewbornsHealthy neonates are born with less than 50% of normal adult AT levels, although they are not predisposed to thrombotic complications that adults are",
                      "Healthy neonates are born with less than 50% of normal adult AT levels, although they are not predisposed to thrombotic complications that adults are"
                    ]
                  },
                  {
                    "text": "AT activity remains unchanged during pregnancy"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Evaluation of Quantitative Disorders of von Willebrand Factor": {
            "name": "Evaluation of Quantitative Disorders of von Willebrand Factor",
            "url": "https://app.pathprimer.com/document/6665141a-bf71-4a2a-8378-c748d715bfca/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Types 1 and 3 vWD are quantitative disorders of vWF"
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "vWF binds to collagen in subendothelium after blood vessel injury and causes adhesion of platelets through its binding to platelet GPIb/V/IX complex"
                  },
                  {
                    "text": "vWF binds to platelet GPIIb/IIIa and promotes platelet aggregation"
                  },
                  {
                    "text": "vWF binds to factor VIII and prolongs its circulation half-life"
                  },
                  {
                    "text": "vWF is made by endothelial cells and megakaryocytes and is stored in Weibel-Palade bodies of endothelial cells and α granules of platelets"
                  }
                ],
                "Specimens": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature to prevent cryoprecipitation of vWF and other proteins"
                  }
                ],
                "Laboratory Statistics": [
                  {
                    "text": "Assay results in type 1 vWDDecreased vWF activityDecreased vWF antigen in proportion to decrease in vWF activityvWF:RCo/vWF:Ag ratio > 0.5-0.7﻿﻿Normal multimeric distribution on vWF multimer analysis",
                    "sub_points": [
                      "Decreased vWF activity",
                      "Decreased vWF antigen in proportion to decrease in vWF activity",
                      "vWF:RCo/vWF:Ag ratio > 0.5-0.7",
                      "﻿﻿Normal multimeric distribution on vWF multimer analysis"
                    ]
                  },
                  {
                    "text": "Assay results in type 3 vWDSeverely decreased (or below limit of detection) vWF activitySeverely decreased (or below limit of detection) vWF antigenSeverely decreased factor VIII activity (approximately 2%-10%)﻿﻿Absence of all multimers on vWF multimer analysis",
                    "sub_points": [
                      "Severely decreased (or below limit of detection) vWF activity",
                      "Severely decreased (or below limit of detection) vWF antigen",
                      "Severely decreased factor VIII activity (approximately 2%-10%)",
                      "﻿﻿Absence of all multimers on vWF multimer analysis"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "vWF plays important roles in platelet adhesion/aggregationActs as carrier for factor VIII",
                    "sub_points": [
                      "Acts as carrier for factor VIII"
                    ]
                  },
                  {
                    "text": "Bleeding in vWD can be due to defects in primary &/or secondary hemostasis"
                  },
                  {
                    "text": "Classification subtypesType 1 vWDPartial quantitative deficiency of essentially normal vWFType 2 vWDQualitative defects of vWFType 3 vWDVirtually complete quantitative deficiency of vWF",
                    "sub_points": [
                      "Type 1 vWDPartial quantitative deficiency of essentially normal vWF",
                      "Partial quantitative deficiency of essentially normal vWF",
                      "Type 2 vWDQualitative defects of vWF",
                      "Qualitative defects of vWF",
                      "Type 3 vWDVirtually complete quantitative deficiency of vWF",
                      "Virtually complete quantitative deficiency of vWF"
                    ]
                  },
                  {
                    "text": "Types 1 and 3 vWD quantitative disorders of vWF"
                  },
                  {
                    "text": "Laboratory testing for diagnosing vWD evaluates quantitative and qualitative aspects of vWF"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "von Willebrand disease (vWD)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "vWF antigen (vWF:Ag)"
                  },
                  {
                    "text": "Enzyme-linked immunosorbent assay (ELISA)"
                  },
                  {
                    "text": "Latex immune assay (LIA)"
                  },
                  {
                    "text": "Ristocetin cofactor activity assay (vWF:RCo)"
                  },
                  {
                    "text": "Collagen-binding activity assay (vWF:CB)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Sodium dodecyl sulfate (SDS)"
                  },
                  {
                    "text": "High-molecular-weight multimer (HMWM)"
                  },
                  {
                    "text": "Intermediate-molecular-weight multimer (IMWM)"
                  },
                  {
                    "text": "Low-molecular-weight multimer (LMWM)"
                  },
                  {
                    "text": "Ristocetin-induced platelet aggregation (RIPA)"
                  },
                  {
                    "text": "vWF propeptide-to-antigen ratio (vWFpp/vWF:Ag)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Mendelian Inheritance": [
                  {
                    "text": "Autosomal inheritanceType 1 vWDAutosomal dominantType 3 vWDAutosomal recessive",
                    "sub_points": [
                      "Type 1 vWDAutosomal dominant",
                      "Autosomal dominant",
                      "Type 3 vWDAutosomal recessive",
                      "Autosomal recessive"
                    ]
                  }
                ],
                "Functions of von Willebrand Factor": [
                  {
                    "text": "vWF binds to collagen in subendothelium after blood vessel injuryCauses adhesion of platelets through its binding to platelet GPIb/V/IX complex",
                    "sub_points": [
                      "Causes adhesion of platelets through its binding to platelet GPIb/V/IX complex"
                    ]
                  },
                  {
                    "text": "vWF binds to platelet GPIIb/IIIa and promotes platelet aggregation"
                  },
                  {
                    "text": "vWF ﻿binds to factor VIII and prolongs its circulation half-life"
                  },
                  {
                    "text": "vWF is made by endothelial cells and megakaryocytesStored in Weibel-Palade bodies of endothelial cells and α granules of platelets",
                    "sub_points": [
                      "Stored in Weibel-Palade bodies of endothelial cells and α granules of platelets"
                    ]
                  }
                ],
                "Genetics": [
                  {
                    "text": "VWFgeneLocated on chromosome 12178 kB long52 exons",
                    "sub_points": [
                      "Located on chromosome 12",
                      "178 kB long",
                      "52 exons"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Diagnostic Assays for von Willebrand Disease": [
                  {
                    "text": "vWF:AgDetermines amount of vWF in plasmaMeasured using 2 types of assaysELISALIA",
                    "sub_points": [
                      "Determines amount of vWF in plasma",
                      "Measured using 2 types of assaysELISALIA",
                      "ELISA",
                      "LIA"
                    ]
                  },
                  {
                    "text": "vWF activityAssesses function of vWFMeasured using 2 types of assaysvWF:RCoGold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinvWF:CBMeasures ability of vWF to bind collagen-coated platelets",
                    "sub_points": [
                      "Assesses function of vWF",
                      "Measured using 2 types of assaysvWF:RCoGold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinvWF:CBMeasures ability of vWF to bind collagen-coated platelets",
                      "vWF:RCoGold standardMeasures ability of vWF to agglutinate platelets in response to ristocetin",
                      "Gold standard",
                      "Measures ability of vWF to agglutinate platelets in response to ristocetin",
                      "vWF:CBMeasures ability of vWF to bind collagen-coated platelets",
                      "Measures ability of vWF to bind collagen-coated platelets"
                    ]
                  },
                  {
                    "text": "Factor VIII activityMeasured using 2 types of assaysaPTT-based 1-stage clotting assayChromogenic factor activity assay",
                    "sub_points": [
                      "Measured using 2 types of assaysaPTT-based 1-stage clotting assayChromogenic factor activity assay",
                      "aPTT-based 1-stage clotting assay",
                      "Chromogenic factor activity assay"
                    ]
                  }
                ],
                "Assays for von Willebrand Disease Subtyping": [
                  {
                    "text": "vWF multimer analysisSDS-agarose electrophoresis followed by antibody detection used to assess vWF multimers in plasmaMultimers are classified asHMWMIMWMLMWM",
                    "sub_points": [
                      "SDS-agarose electrophoresis followed by antibody detection used to assess vWF multimers in plasma",
                      "Multimers are classified asHMWMIMWMLMWM",
                      "HMWM",
                      "IMWM",
                      "LMWM"
                    ]
                  },
                  {
                    "text": "RIPAMeasures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin",
                    "sub_points": [
                      "Measures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin"
                    ]
                  }
                ],
                "Additional Useful Assays": [
                  {
                    "text": "vWFpp/vWF:AgvWFpp cleaved from vWF during processing in Golgi apparatusCleaved vWFpp remains associated with vWF multimers in Weibel-Palade bodies of endothelial cellsSecreted in 1:1 ratio with mature vWFRatio of vWFpp/vWF:Ag can be used to estimate relative half-life of mature vWFElevated vWFpp/vWF:Ag indicates enhanced clearance",
                    "sub_points": [
                      "vWFpp cleaved from vWF during processing in Golgi apparatus",
                      "Cleaved vWFpp remains associated with vWF multimers in Weibel-Palade bodies of endothelial cellsSecreted in 1:1 ratio with mature vWF",
                      "Secreted in 1:1 ratio with mature vWF",
                      "Ratio of vWFpp/vWF:Ag can be used to estimate relative half-life of mature vWF",
                      "Elevated vWFpp/vWF:Ag indicates enhanced clearance"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Assay Results in Type 1 von Willebrand Disease": [
                  {
                    "text": "Decreased vWF antigen in proportion to decrease in vWF activity"
                  },
                  {
                    "text": "Decreased vWF activity"
                  },
                  {
                    "text": "vWF:RCo/vWF:Ag ratio > 0.5-0.7"
                  },
                  {
                    "text": "Normal or decreased factor VIII activity"
                  },
                  {
                    "text": "﻿﻿Normal multimeric distribution on vWF multimer analysis"
                  },
                  {
                    "text": "Mildly decreased to normal RIPA response"
                  },
                  {
                    "text": "May have increased vWFpp/vWF:Ag ratio"
                  }
                ],
                "Assay Results in Type 3 von Willebrand Disease": [
                  {
                    "text": "Severely decreased (or below limit of detection) vWF activity"
                  },
                  {
                    "text": "Severely decreased (or below limit of detection) vWF antigen"
                  },
                  {
                    "text": "Severely decreased factor VIII activity (approximately 2%-10%)"
                  },
                  {
                    "text": "﻿Absence of all multimers on vWF multimer analysis"
                  },
                  {
                    "text": "﻿Markedly decreased to absent RIPA response"
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "3.2% sodium citrate1:9 citrate-to-whole-blood ratio",
                    "sub_points": [
                      "1:9 citrate-to-whole-blood ratio"
                    ]
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ],
                "Transport": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature to prevent cryoprecipitation of vWF and other proteins"
                  }
                ]
              },
              "PROCESSING": {
                "Sample Preservation": [
                  {
                    "text": "Separate plasma from red blood cells promptly with centrifugation at room temperature to remove platelets"
                  },
                  {
                    "text": "If samples are assayed within 2 hr, keep plasma at room temperature"
                  },
                  {
                    "text": "If samples will not be assayed within 2 hr, they should be frozen and stored at or below -40°C"
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Normal and pathologic (low) controls used in every test run"
                  },
                  {
                    "text": "Quality control performed each 8 hr of testing"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Evaluation of Qualitative Disorders of von Willebrand Factor": {
            "name": "Evaluation of Qualitative Disorders of von Willebrand Factor",
            "url": "https://app.pathprimer.com/document/92eff470-a7e0-4d01-860e-61e3fcde2eed/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Subtypes of type 2 vWD are qualitative disorders of vWF"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Type 2 vWD suspected when vWF activity is decreased out of proportion to decrease in vWF:AgvWF:RCo/vWF:Ag ratio < 0.5-0.7 in types 2A, 2B, 2M",
                    "sub_points": [
                      "vWF:RCo/vWF:Ag ratio < 0.5-0.7 in types 2A, 2B, 2M"
                    ]
                  },
                  {
                    "text": "Type 2A vWDAbsence of HMWM and IMWM on vWF multimer analysisDecreased RIPA",
                    "sub_points": [
                      "Absence of HMWM and IMWM on vWF multimer analysis",
                      "Decreased RIPA"
                    ]
                  },
                  {
                    "text": "Type 2B vWDAbsence of HMWM on vWF multimer analysisNormal RIPA with increased low-dose RIPA",
                    "sub_points": [
                      "Absence of HMWM on vWF multimer analysis",
                      "Normal RIPA with increased low-dose RIPA"
                    ]
                  },
                  {
                    "text": "Type 2M vWD﻿Normal multimeric distribution on vWF multimer analysis",
                    "sub_points": [
                      "﻿Normal multimeric distribution on vWF multimer analysis"
                    ]
                  },
                  {
                    "text": "Type 2N vWDvWF:RCo/vWF:Ag ratio > 0.5-0.7Decreased factor VIII activity (5-15%)﻿Normal multimeric distribution on vWF multimer analysis",
                    "sub_points": [
                      "vWF:RCo/vWF:Ag ratio > 0.5-0.7",
                      "Decreased factor VIII activity (5-15%)",
                      "﻿Normal multimeric distribution on vWF multimer analysis"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "vWF plays important roles in platelet adhesion/aggregationActs as carrier for factor VIII",
                    "sub_points": [
                      "Acts as carrier for factor VIII"
                    ]
                  },
                  {
                    "text": "Bleeding in vWD can be due to defects in primary &/or secondary hemostasis"
                  },
                  {
                    "text": "Classification subtypesType 1 vWDPartial quantitative deficiency of essentially normal vWFType 2 vWDQualitative defects of vWFType 3 vWDVirtually complete quantitative deficiency of vWF",
                    "sub_points": [
                      "Type 1 vWDPartial quantitative deficiency of essentially normal vWF",
                      "Partial quantitative deficiency of essentially normal vWF",
                      "Type 2 vWDQualitative defects of vWF",
                      "Qualitative defects of vWF",
                      "Type 3 vWDVirtually complete quantitative deficiency of vWF",
                      "Virtually complete quantitative deficiency of vWF"
                    ]
                  },
                  {
                    "text": "Subtypes of type 2 vWD are qualitative disorders of vWF"
                  },
                  {
                    "text": "Laboratory testing for diagnosing vWD evaluates quantitative and qualitative aspects of vWF"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "von Willebrand disease (vWD)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "vWF antigen (vWF:Ag)"
                  },
                  {
                    "text": "Enzyme-linked immunosorbent assay (ELISA)"
                  },
                  {
                    "text": "Latex immune assay (LIA)"
                  },
                  {
                    "text": "Ristocetin cofactor activity assay (vWF:RCo)"
                  },
                  {
                    "text": "Collagen-binding activity assay (vWF:CB)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Sodium dodecyl sulfate (SDS)"
                  },
                  {
                    "text": "High-molecular-weight multimer (HMWM)"
                  },
                  {
                    "text": "Intermediate-molecular-weight multimer (IMWM)"
                  },
                  {
                    "text": "Low-molecular-weight multimer (LMWM)"
                  },
                  {
                    "text": "Ristocetin-induced platelet aggregation (RIPA)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Mendelian Inheritance": [
                  {
                    "text": "Autosomal inheritanceType 2A vWDUsually autosomal dominantSome variants are recessiveType 2B vWDAutosomal dominantType 2M vWDUsually autosomal dominantSome variants are recessiveType 2N vWDAutosomal recessive",
                    "sub_points": [
                      "Type 2A vWDUsually autosomal dominantSome variants are recessive",
                      "Usually autosomal dominant",
                      "Some variants are recessive",
                      "Type 2B vWDAutosomal dominant",
                      "Autosomal dominant",
                      "Type 2M vWDUsually autosomal dominantSome variants are recessive",
                      "Usually autosomal dominant",
                      "Some variants are recessive",
                      "Type 2N vWDAutosomal recessive",
                      "Autosomal recessive"
                    ]
                  }
                ],
                "Functions of von Willebrand Factor": [
                  {
                    "text": "vWF binds to collagen in subendothelium after blood vessel injuryCauses adhesion of platelets through binding to platelet GPIb/V/IX complex",
                    "sub_points": [
                      "Causes adhesion of platelets through binding to platelet GPIb/V/IX complex"
                    ]
                  },
                  {
                    "text": "vWF binds to platelet GPIIb/IIIa and promotes platelet aggregation"
                  },
                  {
                    "text": "vWF binds to factor VIII and prolongs its half-life"
                  },
                  {
                    "text": "vWF is made by endothelial cells and megakaryocytesStored in Weibel-Palade bodies of endothelial cells and α granules of platelets",
                    "sub_points": [
                      "Stored in Weibel-Palade bodies of endothelial cells and α granules of platelets"
                    ]
                  }
                ],
                "﻿Genetics": [
                  {
                    "text": "VWFgeneLocated on chromosome 12178 kB long52 exons",
                    "sub_points": [
                      "Located on chromosome 12",
                      "178 kB long",
                      "52 exons"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Diagnostic Assays for von Willebrand Disease": [
                  {
                    "text": "vWF:AgQuantifies amount of vWF presentMeasured using 2 types of assaysELISALIA",
                    "sub_points": [
                      "Quantifies amount of vWF present",
                      "Measured using 2 types of assaysELISALIA",
                      "ELISA",
                      "LIA"
                    ]
                  },
                  {
                    "text": "vWF activityAssesses function of vWFMeasured using 2 types of assaysvWF:RCoGold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinvWF:CBMeasures ability of vWF to bind collagen-coated plates",
                    "sub_points": [
                      "Assesses function of vWF",
                      "Measured using 2 types of assaysvWF:RCoGold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinvWF:CBMeasures ability of vWF to bind collagen-coated plates",
                      "vWF:RCoGold standardMeasures ability of vWF to agglutinate platelets in response to ristocetin",
                      "Gold standard",
                      "Measures ability of vWF to agglutinate platelets in response to ristocetin",
                      "vWF:CBMeasures ability of vWF to bind collagen-coated plates",
                      "Measures ability of vWF to bind collagen-coated plates"
                    ]
                  },
                  {
                    "text": "Factor VIII activityMeasured using 2 types of assaysaPTT-based 1-stage clotting assayChromogenic factor activity assay",
                    "sub_points": [
                      "Measured using 2 types of assaysaPTT-based 1-stage clotting assayChromogenic factor activity assay",
                      "aPTT-based 1-stage clotting assay",
                      "Chromogenic factor activity assay"
                    ]
                  }
                ],
                "﻿Assays for vWD Subtyping": [
                  {
                    "text": "vWF multimer analysisSDS-agarose electrophoresis followed by antibody detection used to assess vWF multimers in plasmaMultimers are classified asHMWMIMWMLMWM",
                    "sub_points": [
                      "SDS-agarose electrophoresis followed by antibody detection used to assess vWF multimers in plasma",
                      "Multimers are classified asHMWMIMWMLMWM",
                      "HMWM",
                      "IMWM",
                      "LMWM"
                    ]
                  },
                  {
                    "text": "RIPAMeasures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin",
                    "sub_points": [
                      "Measures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin"
                    ]
                  }
                ],
                "﻿Additional Useful Assays": [
                  {
                    "text": "vWF binding of factor VIIIMay be helpful if type 2N vWD is suspectedMeasures capacity of patient vWF to bind recombinant factor VIIIDecreased ability of patient vWF to bind factor VIII consistent with type 2N vWD",
                    "sub_points": [
                      "May be helpful if type 2N vWD is suspected",
                      "Measures capacity of patient vWF to bind recombinant factor VIII",
                      "Decreased ability of patient vWF to bind factor VIII consistent with type 2N vWD"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Assay Results in Type 2 von Willebrand Disease": [
                  {
                    "text": "Type 2 vWD suspected when vWF activity is decreased out of proportion to decrease in vWF:Ag"
                  },
                  {
                    "text": "Type 2A vWDDecreased vWF activity out of proportion to decrease in vWF:AgDecreased vWF antigenvWF:RCo/vWF:Ag ratio < 0.5-0.7Normal or decreased factor VIII activityAbsence of HMWM and IMWM on vWF multimer analysisDecreased RIPA",
                    "sub_points": [
                      "Decreased vWF activity out of proportion to decrease in vWF:Ag",
                      "Decreased vWF antigen",
                      "vWF:RCo/vWF:Ag ratio < 0.5-0.7",
                      "Normal or decreased factor VIII activity",
                      "Absence of HMWM and IMWM on vWF multimer analysis",
                      "Decreased RIPA"
                    ]
                  },
                  {
                    "text": "Type 2B vWDDecreased vWF activity out of proportion to decrease in vWF:AgDecreased vWF antigenvWF:RCo/vWF:Ag ratio < 0.5-0.7Normal or decreased factor VIII activityAbsence of HMWM on vWF multimer analysisNormal RIPA with increased low-dose RIPA",
                    "sub_points": [
                      "Decreased vWF activity out of proportion to decrease in vWF:Ag",
                      "Decreased vWF antigen",
                      "vWF:RCo/vWF:Ag ratio < 0.5-0.7",
                      "Normal or decreased factor VIII activity",
                      "Absence of HMWM on vWF multimer analysis",
                      "Normal RIPA with increased low-dose RIPA"
                    ]
                  },
                  {
                    "text": "Type 2M vWDDecreased vWF activity (vWFR:Co) out of proportion to decrease in vWF:AgDecreased vWF antigenvWF:RCo/vWF:Ag ratio < 0.5-0.7Normal or decreased factor VIII activity﻿Normal multimeric distribution on vWF multimer analysisDecreased RIPA",
                    "sub_points": [
                      "Decreased vWF activity (vWFR:Co) out of proportion to decrease in vWF:Ag",
                      "Decreased vWF antigen",
                      "vWF:RCo/vWF:Ag ratio < 0.5-0.7",
                      "Normal or decreased factor VIII activity",
                      "﻿Normal multimeric distribution on vWF multimer analysis",
                      "Decreased RIPA"
                    ]
                  },
                  {
                    "text": "Type 2N vWDNormal or decreased vWF activityNormal or decreased vWF antigenvWF:RCo/vWF:Ag ratio > 0.5-0.7Decreased factor VIII activity (5-15%)Decreased factor VIII binding by vWF﻿Normal multimeric distribution on vWF multimer analysisNormal RIPA",
                    "sub_points": [
                      "Normal or decreased vWF activity",
                      "Normal or decreased vWF antigen",
                      "vWF:RCo/vWF:Ag ratio > 0.5-0.7",
                      "Decreased factor VIII activity (5-15%)",
                      "Decreased factor VIII binding by vWF",
                      "﻿Normal multimeric distribution on vWF multimer analysis",
                      "Normal RIPA"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "3.2% sodium citrate1:9 citrate-to-whole-blood ratio",
                    "sub_points": [
                      "1:9 citrate-to-whole-blood ratio"
                    ]
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ],
                "Transport": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature to prevent cryoprecipitation of vWF and other proteins"
                  }
                ]
              },
              "PROCESSING": {
                "﻿Sample Preservation": [
                  {
                    "text": "Separate plasma from red blood cells promptly with centrifugation at room temperature to remove platelets"
                  },
                  {
                    "text": "If samples are assayed within 2 hours, keep plasma at room temperature"
                  },
                  {
                    "text": "If samples will not be assayed within 2 hours, they should be frozen and stored at or below -40°C"
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Normal and pathologic (low) controls included in every test run"
                  },
                  {
                    "text": "Quality control performed each 8 hours of testing"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Methods for Measuring Heparin Anticoagulation": {
            "name": "Methods for Measuring Heparin Anticoagulation",
            "url": "https://app.pathprimer.com/document/25f5f603-add1-4830-b92a-e3e6dd33eae8/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Diagnosis": [
                  {
                    "text": "Prolonged aPTT with normal PT can reflect deficiencies﻿ of factor VIII﻿﻿, factor IX﻿﻿, factor XII﻿, factor XI, prekallikrein, and HMWK; it can also be prolonged with heparin therapy, lupus anticoagulants, and coagulation factor inhibitors"
                  },
                  {
                    "text": "aPTT reagents are designed so that value is prolonged when factor levels are 40%, but specific value depends on reagent being used and specific coagulation factor being measured"
                  },
                  {
                    "text": "aPTT is not useful for monitoring heparin in situations where aPTT is elevated at baseline"
                  },
                  {
                    "text": "TT evaluates activity of fibrinogen in sample and presence of thrombin inhibitorsAbnormal TT can reflect anticoagulant therapy with heparin or direct thrombin inhibitors, hypofibrinogenemia or afibrinogenemia, and dysfibrinogenemiaProlonged TT and normal reptilase time suggest presence of heparinProlonged TT and prolonged reptilase time suggest afibrinogenemia, hypofibrinogenemia, or dysfibrinogenemia",
                    "sub_points": [
                      "Abnormal TT can reflect anticoagulant therapy with heparin or direct thrombin inhibitors, hypofibrinogenemia or afibrinogenemia, and dysfibrinogenemia",
                      "Prolonged TT and normal reptilase time suggest presence of heparin",
                      "Prolonged TT and prolonged reptilase time suggest afibrinogenemia, hypofibrinogenemia, or dysfibrinogenemia"
                    ]
                  },
                  {
                    "text": "Anti-Xa assay for UFH and LMWH is used in specific situations when aPTT and ACT are inaccurate or when tighter control is required, such as presence of lupus anticoagulant, renal failure, extremes of weight and age"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Heparin Anticoagulation": [
                  {
                    "text": "When immediate anticoagulation is required, unfractionated heparin (UFH) is typically anticoagulant of choice"
                  },
                  {
                    "text": "UFH size is 3000-30,000 Da with mean of 15 kDa and mean of 45 monosaccharides"
                  },
                  {
                    "text": "Low-molecular-weight heparins (LMWHs) weigh 2-10 kDa compared with 5-30 kDa for UFH"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Activated Partial Thromboplastin Time": [
                  {
                    "text": "Activated partial thromboplastin time (aPTT) reagent contains source of phospholipid (e.g., cephalin) and contact activator (e.g., silica, kaolin)"
                  },
                  {
                    "text": "Clotting is initiated by recalcifying plasma using calcium chloride"
                  },
                  {
                    "text": "Time from initiation to clot detection is measured in seconds"
                  },
                  {
                    "text": "Clots can be detected using optical (e.g., spectrophotometry), impedance, mechanical, or original tilt tube method (visual observation of clot formation in test tube)"
                  },
                  {
                    "text": "Prolonged aPTT with normal prothrombin time (PT) can reflect deficiencies﻿ of factor VIII﻿﻿, factor IX﻿﻿, factor XII﻿, factor XI, prekallikrein, and high-molecular-weight kininogen (HMWK)aPTT can also be prolonged with heparin therapy, lupus anticoagulants, and coagulation factor inhibitors",
                    "sub_points": [
                      "aPTT can also be prolonged with heparin therapy, lupus anticoagulants, and coagulation factor inhibitors"
                    ]
                  },
                  {
                    "text": "aPTT reagents are designed so that value is prolonged when factor levels are 40%Specific value depends on reagent being used and specific coagulation factor being measured",
                    "sub_points": [
                      "Specific value depends on reagent being used and specific coagulation factor being measured"
                    ]
                  },
                  {
                    "text": "aPTT reagents have differing concentrations of phospholipid making them variably sensitive to lupus anticoagulantsHigh phospholipid content is less sensitive to lupus anticoagulants",
                    "sub_points": [
                      "High phospholipid content is less sensitive to lupus anticoagulants"
                    ]
                  },
                  {
                    "text": "aPTT is measured 6 hr after initial bolus doseDepending on aPTT, rate of continuous heparin infusion is adjusted according to established weight-based nomograms",
                    "sub_points": [
                      "Depending on aPTT, rate of continuous heparin infusion is adjusted according to established weight-based nomograms"
                    ]
                  },
                  {
                    "text": "Heparin therapeutic range is determined by testing samples from patients on heparin and plotting against anti-Xa activity or heparin protamine titrationaPTT range is determined by range of aPTT corresponding to 0.3-0.7 anti-Xa activity or 0.2-0.4 by heparin titrationMore simply, some providers use 1.5x upper limit of reference range, but this method is not as reliable",
                    "sub_points": [
                      "aPTT range is determined by range of aPTT corresponding to 0.3-0.7 anti-Xa activity or 0.2-0.4 by heparin titration",
                      "More simply, some providers use 1.5x upper limit of reference range, but this method is not as reliable"
                    ]
                  },
                  {
                    "text": "aPTT is not useful for monitoring heparin in situations where aPTT is elevated at baselineInherited or acquired factor deficienciesLupus anticoagulant",
                    "sub_points": [
                      "Inherited or acquired factor deficiencies",
                      "Lupus anticoagulant"
                    ]
                  }
                ],
                "Thrombin Time": [
                  {
                    "text": "Thrombin time (TT) is performed by adding bovine or human thrombin to diluted platelet-poor plasma and measuring time to clot formation"
                  },
                  {
                    "text": "TT evaluates activity of fibrinogen in sample and presence of thrombin inhibitors"
                  },
                  {
                    "text": "TT is sensitive to heparin because heparin:antithrombin effectively inactivates thrombin reagent"
                  },
                  {
                    "text": "TT initiates clotting by cleaving fibrinopeptides A and B from fibrinogen, which leads to fibrin formationPresence of heparin inhibits thrombin and prevents release of fibrinopeptides A and B",
                    "sub_points": [
                      "Presence of heparin inhibits thrombin and prevents release of fibrinopeptides A and B"
                    ]
                  },
                  {
                    "text": "Reptilase time uses reptilase snake venom, which cleaves fibrinopeptide A and leads to fibrin formationReptilase cleaves fibrinopeptide A, which leads to fibrin formationReptilase is insensitive to heparin inactivation",
                    "sub_points": [
                      "Reptilase cleaves fibrinopeptide A, which leads to fibrin formation",
                      "Reptilase is insensitive to heparin inactivation"
                    ]
                  },
                  {
                    "text": "Causes of abnormal TTAnticoagulant therapy with heparin or direct thrombin inhibitorsHypofibrinogenemia or afibrinogenemiaDysfibrinogenemia",
                    "sub_points": [
                      "Anticoagulant therapy with heparin or direct thrombin inhibitors",
                      "Hypofibrinogenemia or afibrinogenemia",
                      "Dysfibrinogenemia"
                    ]
                  },
                  {
                    "text": "Prolonged TT and normal reptilase time suggest presence of heparin"
                  },
                  {
                    "text": "Prolonged TT and prolonged reptilase time suggest afibrinogenemia, hypofibrinogenemia, or dysfibrinogenemia"
                  }
                ],
                "Activated Clotting Time": [
                  {
                    "text": "Activated clotting time (ACT) is whole-blood assay most commonly performed at point of care"
                  },
                  {
                    "text": "Blood is added to test cartridge that measures time to clot formation after contact with activator (e.g., kaolin, Celite, glass balls)"
                  },
                  {
                    "text": "Test is usually performed at point of care when high concentration of heparin is used (e.g., cardiopulmonary bypass)aPTT is not useful for titrating heparin at high doses, when aPTT would be at maximum time",
                    "sub_points": [
                      "aPTT is not useful for titrating heparin at high doses, when aPTT would be at maximum time"
                    ]
                  },
                  {
                    "text": "Test result is highly dependent on activator that is used and other parameters are not standardized such as aPTTIn contrast to aPTT, ACT is not standardized for phospholipid or calciumACT relies on presence of platelets and calcium in whole-blood sampleCan vary from patient to patient",
                    "sub_points": [
                      "In contrast to aPTT, ACT is not standardized for phospholipid or calcium",
                      "ACT relies on presence of platelets and calcium in whole-blood sampleCan vary from patient to patient",
                      "Can vary from patient to patient"
                    ]
                  },
                  {
                    "text": "ACT is most reliable when heparin is only variableIt is less reliable when there are underlying reasons for abnormal hemostasisCoagulation factor deficienciesLupus anticoagulantsThrombocytopeniaAprotinin can prolong ACT when Celite activator is usedHypothermia and hemodilution can prolong ACT",
                    "sub_points": [
                      "It is less reliable when there are underlying reasons for abnormal hemostasisCoagulation factor deficienciesLupus anticoagulantsThrombocytopenia",
                      "Coagulation factor deficiencies",
                      "Lupus anticoagulants",
                      "Thrombocytopenia",
                      "Aprotinin can prolong ACT when Celite activator is used",
                      "Hypothermia and hemodilution can prolong ACT"
                    ]
                  }
                ],
                "Anti-Xa Assay": [
                  {
                    "text": "Anti-Xa assay for UFH and LMWH is used in specific situations when aPTT and ACT are inaccurate or when tighter control is requiredPresence of lupus anticoagulantRenal failureExtremes of weight and age",
                    "sub_points": [
                      "Presence of lupus anticoagulant",
                      "Renal failure",
                      "Extremes of weight and age"
                    ]
                  },
                  {
                    "text": "Anti-Xa assay is measured in U/mL of Xa inhibition"
                  },
                  {
                    "text": "Test is performed on patient platelet-poor plasmaExcess antithrombin and factor Xa are added to patient sampleHeparin in the sample binds to antithrombin and inactivates factor Xa added to sampleFactor Xa that is not inhibited by heparin:antithrombin is available to cleave a chromogenic signal on a substrateSubstrate is designed to mimic factor Xa cleavage site on prothrombinChromogenic signal is measured by spectrophotometry at specific wavelengthHeparin activity is inverse proportional to signal detectedHigh heparin activity → lower residual factor Xa → less chromogenic substrate cleavage → lower signalLipemia, hemolysis, and elevated total protein (e.g. in multiple myeloma) can interfere with this spectrophotometric assay",
                    "sub_points": [
                      "Excess antithrombin and factor Xa are added to patient sample",
                      "Heparin in the sample binds to antithrombin and inactivates factor Xa added to sample",
                      "Factor Xa that is not inhibited by heparin:antithrombin is available to cleave a chromogenic signal on a substrateSubstrate is designed to mimic factor Xa cleavage site on prothrombin",
                      "Substrate is designed to mimic factor Xa cleavage site on prothrombin",
                      "Chromogenic signal is measured by spectrophotometry at specific wavelength",
                      "Heparin activity is inverse proportional to signal detectedHigh heparin activity → lower residual factor Xa → less chromogenic substrate cleavage → lower signal",
                      "High heparin activity → lower residual factor Xa → less chromogenic substrate cleavage → lower signal",
                      "Lipemia, hemolysis, and elevated total protein (e.g. in multiple myeloma) can interfere with this spectrophotometric assay"
                    ]
                  },
                  {
                    "text": "Calibrators are available for UFH and LMWH"
                  },
                  {
                    "text": "Therapeutic ranges depend on type of heparin, indication, and periodicity of dosing (continuous infusion, once daily, twice daily)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Heparin Resistance": {
            "name": "Heparin Resistance",
            "url": "https://app.pathprimer.com/document/fd54a67c-055f-4d52-8378-0d553adb7a77/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Heparin is cofactor that accelerates activity of natural anticoagulant antithrombin III"
                  },
                  {
                    "text": "Unfractionated heparin is most common parenterally administered anticoagulation agent"
                  },
                  {
                    "text": "For indications where high doses of heparin are required (e.g., cardiopulmonary bypass, extracorporeal membrane oxygenation), ACT is used"
                  },
                  {
                    "text": "Heparin resistance is defined as administration of more than 35,000 units of heparin in 24 hours without aPTT reaching therapeutic range"
                  },
                  {
                    "text": "Mechanisms of heparin resistance include acute phase reaction, AT deficiency, and increased heparin binding"
                  },
                  {
                    "text": "AT deficiencyAT is natural anticoagulant that inactivates thrombin and factors Xa, IXa, and XIaAT deficiency can be inherited (rare) or acquired (due to liver disease, nephrotic syndrome, heparin treatment, disseminated intravascular coagulation, or mechanical circulation support)",
                    "sub_points": [
                      "AT is natural anticoagulant that inactivates thrombin and factors Xa, IXa, and XIa",
                      "AT deficiency can be inherited (rare) or acquired (due to liver disease, nephrotic syndrome, heparin treatment, disseminated intravascular coagulation, or mechanical circulation support)"
                    ]
                  },
                  {
                    "text": "AT concentrates: Provide AT with lower volume and lower risk of TRALI"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Heparin dose response is in vitro test of how individual responds to increasing concentrations of heparin"
                  },
                  {
                    "text": "Anti-Xa activity is chromogenic assay used to measure heparin levels"
                  }
                ]
              },
              "OVERVIEW": {
                "Heparin": [
                  {
                    "text": "Heparin is cofactor that accelerates activity of anticoagulant antithrombin IIIHeparin also accelerates anticoagulant activity of heparin cofactor II",
                    "sub_points": [
                      "Heparin also accelerates anticoagulant activity of heparin cofactor II"
                    ]
                  },
                  {
                    "text": "AT inactivates thrombin, factor Xa, factor IXa, factor XIa, and factor XIIa"
                  },
                  {
                    "text": "Heparin fractions at least 18 saccharides in length are required to inhibit thrombinEssential pentasaccharide sequence must be part of fraction",
                    "sub_points": [
                      "Essential pentasaccharide sequence must be part of fraction"
                    ]
                  },
                  {
                    "text": "Pentasaccharide sequence alone can inhibit factor Xa, but not thrombin"
                  },
                  {
                    "text": "Unfractionated heparin is most common parenterally administered anticoagulantAdministered as bolus followed by continuous infusionAfter 4-6 hours of initiating heparin, aPTT is measured and heparin infusion adjusted according to established nomograms",
                    "sub_points": [
                      "Administered as bolus followed by continuous infusion",
                      "After 4-6 hours of initiating heparin, aPTT is measured and heparin infusion adjusted according to established nomograms"
                    ]
                  },
                  {
                    "text": "Inter-individual bioavailability and anticoagulant response to heparin is highly variableDepends on degree of binding to proteins, endothelium, leukocytesHeparin is also cleared according to biphasic, concentration-dependent clearance",
                    "sub_points": [
                      "Depends on degree of binding to proteins, endothelium, leukocytes",
                      "Heparin is also cleared according to biphasic, concentration-dependent clearance"
                    ]
                  }
                ],
                "Anticoagulation Monitoring": [
                  {
                    "text": "For indications in which high doses of heparin are required (e.g., CPB, ECMO), ACT is usedaPTT cannot be used, because it would be at maximum throughout range of therapeutic doses",
                    "sub_points": [
                      "aPTT cannot be used, because it would be at maximum throughout range of therapeutic doses"
                    ]
                  },
                  {
                    "text": "When heparin is used to treat thromboembolism, aPTT or anti-Xa is monitored"
                  }
                ],
                "Heparin Resistance": [
                  {
                    "text": "Heparin resistance is defined as administration of greater than 35,000 units of heparin in 24 hours without aPTT achieving therapeutic targetHeparin resistance can also be defined by abnormally low slope in﻿ in vitro﻿test for heparin dose responseAlternatively, for cardiac bypass, ECMO, or other procedures requiring high heparin concentration, heparin resistance can be defined as failure to meet therapeutic target even after unusually high heparin doses or requiring AT to achieve therapeutic target",
                    "sub_points": [
                      "Heparin resistance can also be defined by abnormally low slope in﻿ in vitro﻿test for heparin dose response",
                      "Alternatively, for cardiac bypass, ECMO, or other procedures requiring high heparin concentration, heparin resistance can be defined as failure to meet therapeutic target even after unusually high heparin doses or requiring AT to achieve therapeutic target"
                    ]
                  },
                  {
                    "text": "Mechanisms of heparin resistance include acute phase reaction, AT deficiency, and increased heparin bindingFactor VIII and von Willebrand factor are acute phase reactantsElevated factor VIII can shorten aPTT so therapeutic target cannot be achievedAT deficiencyAT is natural anticoagulant that inactivates thrombin and factor Xa, factor IXa, factor XIaMechanism of action of heparin is to act as cofactor to accelerate activity of ATHeparin cannot achieve its anticoagulant effect without enzymatic activity of ATAT deficiency can be inherited (rare) or acquired (due to liver disease, nephrotic syndrome, heparin treatment, disseminated intravascular coagulation, or mechanical circulation support)Prior heparin treatment results in clearance of thrombin:AT complexes, leading to decline in ATIncreased heparin bindingIncreased heparin binding proteinsIncreased heparin binding by endothelium and leukocytes",
                    "sub_points": [
                      "Factor VIII and von Willebrand factor are acute phase reactantsElevated factor VIII can shorten aPTT so therapeutic target cannot be achieved",
                      "Elevated factor VIII can shorten aPTT so therapeutic target cannot be achieved",
                      "AT deficiencyAT is natural anticoagulant that inactivates thrombin and factor Xa, factor IXa, factor XIaMechanism of action of heparin is to act as cofactor to accelerate activity of ATHeparin cannot achieve its anticoagulant effect without enzymatic activity of ATAT deficiency can be inherited (rare) or acquired (due to liver disease, nephrotic syndrome, heparin treatment, disseminated intravascular coagulation, or mechanical circulation support)Prior heparin treatment results in clearance of thrombin:AT complexes, leading to decline in AT",
                      "AT is natural anticoagulant that inactivates thrombin and factor Xa, factor IXa, factor XIa",
                      "Mechanism of action of heparin is to act as cofactor to accelerate activity of AT",
                      "Heparin cannot achieve its anticoagulant effect without enzymatic activity of AT",
                      "AT deficiency can be inherited (rare) or acquired (due to liver disease, nephrotic syndrome, heparin treatment, disseminated intravascular coagulation, or mechanical circulation support)Prior heparin treatment results in clearance of thrombin:AT complexes, leading to decline in AT",
                      "Prior heparin treatment results in clearance of thrombin:AT complexes, leading to decline in AT",
                      "Increased heparin bindingIncreased heparin binding proteinsIncreased heparin binding by endothelium and leukocytes",
                      "Increased heparin binding proteins",
                      "Increased heparin binding by endothelium and leukocytes"
                    ]
                  }
                ],
                "Treatment of Heparin Resistance": [
                  {
                    "text": "Additional heparinIncreasing heparin dose may increase ACT into target range, but there is risk of heparin rebound with ↑ dosesIncreasing dose of heparin may not increase ACT into target range; many patients do not respond to ↑ heparin beyond certain dose",
                    "sub_points": [
                      "Increasing heparin dose may increase ACT into target range, but there is risk of heparin rebound with ↑ doses",
                      "Increasing dose of heparin may not increase ACT into target range; many patients do not respond to ↑ heparin beyond certain dose"
                    ]
                  },
                  {
                    "text": "PlasmaPlasma contains both coagulation factors and anticoagulants such as AT, protein C, and protein SAdministration of plasma provides source of ATTwo units of plasma contain about 500 international units of ATMore than 2 units of plasma may be required to improve heparin responsivenessImproved patient outcomes have not been clearly demonstratedThere are safety concerns about plasma infusions, such as TRALI and volume overload",
                    "sub_points": [
                      "Plasma contains both coagulation factors and anticoagulants such as AT, protein C, and protein S",
                      "Administration of plasma provides source of ATTwo units of plasma contain about 500 international units of ATMore than 2 units of plasma may be required to improve heparin responsiveness",
                      "Two units of plasma contain about 500 international units of AT",
                      "More than 2 units of plasma may be required to improve heparin responsiveness",
                      "Improved patient outcomes have not been clearly demonstrated",
                      "There are safety concerns about plasma infusions, such as TRALI and volume overload"
                    ]
                  },
                  {
                    "text": "AT concentrates: Provide AT with lower volume and lower risk of adverse eventsAvailable in plasma-derived (and recombinant outside United States)More expensive than plasma",
                    "sub_points": [
                      "Available in plasma-derived (and recombinant outside United States)",
                      "More expensive than plasma"
                    ]
                  },
                  {
                    "text": "AlgorithmUse heparin dose-response curve prior to heparin administration, if availableLow AT activityAdminister AT concentrates or plasma and then recheck aPTT or ACTNormal AT and low heparin anti-Xa activityIncrease dose of heparin and check aPTT or ACT",
                    "sub_points": [
                      "Use heparin dose-response curve prior to heparin administration, if available",
                      "Low AT activityAdminister AT concentrates or plasma and then recheck aPTT or ACT",
                      "Administer AT concentrates or plasma and then recheck aPTT or ACT",
                      "Normal AT and low heparin anti-Xa activityIncrease dose of heparin and check aPTT or ACT",
                      "Increase dose of heparin and check aPTT or ACT"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Activated clotting time (ACT)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Antithrombin (AT)"
                  },
                  {
                    "text": "Cardiopulmonary bypass (CPB)"
                  },
                  {
                    "text": "Extracorporeal membrane oxygenation (ECMO)"
                  },
                  {
                    "text": "Transfusion-related acute lung injury (TRALI)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Activated Clotting Time": [
                  {
                    "text": "Whole blood clotting assay usually performed at point of care"
                  },
                  {
                    "text": "Whole blood is added to test cartridge and is activated by contact with activator (e.g., kaolin, celite, glass balls) in test cartridge"
                  },
                  {
                    "text": "Clot is detected electronically by impedance method"
                  },
                  {
                    "text": "ACT reference range is generally 100-200 seconds"
                  },
                  {
                    "text": "Therapeutic ACT for CPB is in range of 300-400 seconds"
                  },
                  {
                    "text": "ACT is adequate for monitoring anticoagulation if heparin is only variableOther variables that change hemostasis will render test inaccurateLupus anticoagulantLow platelet countCoagulation factor deficienciesNon-heparin anticoagulation agentsHypothermia can decrease factor activity and increase ACTHemodilution can decrease factor activity and increase ACT",
                    "sub_points": [
                      "Other variables that change hemostasis will render test inaccurateLupus anticoagulantLow platelet countCoagulation factor deficienciesNon-heparin anticoagulation agents",
                      "Lupus anticoagulant",
                      "Low platelet count",
                      "Coagulation factor deficiencies",
                      "Non-heparin anticoagulation agents",
                      "Hypothermia can decrease factor activity and increase ACT",
                      "Hemodilution can decrease factor activity and increase ACT"
                    ]
                  }
                ],
                "Activated Partial Thromboplastin Time": [
                  {
                    "text": "Therapeutic range falls between 1.5-2.5 times that of normal reference value"
                  },
                  {
                    "text": "Different aPTT reagent preparations have different sensitivities to heparin"
                  },
                  {
                    "text": "aPTT therapeutic range should be established for each reagent lotCorresponds to heparin level of 0.2-0.4 units/mL using protamine titrationCorresponds to 0.3-0.7 units/mL using anti-Xa assay",
                    "sub_points": [
                      "Corresponds to heparin level of 0.2-0.4 units/mL using protamine titration",
                      "Corresponds to 0.3-0.7 units/mL using anti-Xa assay"
                    ]
                  },
                  {
                    "text": "Limitation is that it cannot be used to monitor high levels of heparin (e.g., CPB, ECMO, ventricular assist devices)"
                  }
                ],
                "Anti-Xa Assay": [
                  {
                    "text": "Anti-Xa activity is chromogenic assay used to measure heparin levels"
                  },
                  {
                    "text": "Usually aPTT is used to monitor heparin, but this may be necessary in limited situationsElevated aPTT prior to initiation of therapyLupus anticoagulantFactor deficiencyHepatic insufficiencyIncreased bleeding risk requiring tighter controlRecent surgeryStrokeSevere thrombocytopeniaExtremes of ageExtremes of weightRenal insufficiencyHeparin resistance",
                    "sub_points": [
                      "Elevated aPTT prior to initiation of therapyLupus anticoagulantFactor deficiencyHepatic insufficiency",
                      "Lupus anticoagulant",
                      "Factor deficiency",
                      "Hepatic insufficiency",
                      "Increased bleeding risk requiring tighter controlRecent surgeryStrokeSevere thrombocytopeniaExtremes of ageExtremes of weightRenal insufficiency",
                      "Recent surgery",
                      "Stroke",
                      "Severe thrombocytopenia",
                      "Extremes of age",
                      "Extremes of weight",
                      "Renal insufficiency",
                      "Heparin resistance"
                    ]
                  }
                ],
                "Heparin Dose-Response Curve": [
                  {
                    "text": "Heparin dose response is in vitro test of how individual responds to increasing concentrations of heparin"
                  },
                  {
                    "text": "ACT is measured on whole blood sample with addition of varying concentrations of heparin, usually in range of 0-5000 U/kg of heparin"
                  },
                  {
                    "text": "ACT is then plotted against heparin concentration, and linear regression line is graphed"
                  },
                  {
                    "text": "In patients with heparin resistance, ACT will increase with increasing concentrations of heparin except response will be flatter (i.e., lower slope)Even after high concentrations of heparin, ACT will still not prolong into therapeutic range in patients with heparin resistance",
                    "sub_points": [
                      "Even after high concentrations of heparin, ACT will still not prolong into therapeutic range in patients with heparin resistance"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Interpretation of the Euglobulin Lysis Test (Fibrinolysis)": {
            "name": "Interpretation of the Euglobulin Lysis Test (Fibrinolysis)",
            "url": "https://app.pathprimer.com/document/145b389e-80dd-4dc6-bb28-7f8412b787ec/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "Euglobulin lysis testMeasures time for clot to dissolve in absence of normal plasmin inhibitorsDistinguishes between primary fibrinolysis and disseminated intravascular coagulation (DIC)",
                    "sub_points": [
                      "Measures time for clot to dissolve in absence of normal plasmin inhibitors",
                      "Distinguishes between primary fibrinolysis and disseminated intravascular coagulation (DIC)"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Euglobulin Clot Lysis Time (ECLT)": [
                  {
                    "text": "Collect blood in 3.2% sodium citrate tube and immediately place on ice"
                  },
                  {
                    "text": "Centrifuge blood and then dilute with acetic acidThis causes precipitation of euglobulins, which include plasminogen, plasminogen activators (e.g., tissue plasminogen activator [t-PA]), and fibrinogen",
                    "sub_points": [
                      "This causes precipitation of euglobulins, which include plasminogen, plasminogen activators (e.g., tissue plasminogen activator [t-PA]), and fibrinogen"
                    ]
                  },
                  {
                    "text": "Supernatant contains inhibitors of fibrinolysis and is discarded"
                  },
                  {
                    "text": "Euglobulin pellet is then resuspended in buffer solution"
                  },
                  {
                    "text": "Thrombin or calcium is added to form clot"
                  },
                  {
                    "text": "Specimen is visually inspected every 15 minutes to determine time to clot lysis"
                  },
                  {
                    "text": "InterpretationIncreased fibrinolysis (decreased ECLT)Decreased clot lysis time: Exercise, venous occlusion, factor XIII deficiency, treatment with t-PA, streptokinase, or desmopressin (DDAVP)Decreased fibrinolysis (increased ECLT)Increased clot lysis time: Third trimester pregnancy, disseminated intravascular coagulation (DIC), liver disease, obesity",
                    "sub_points": [
                      "Increased fibrinolysis (decreased ECLT)Decreased clot lysis time: Exercise, venous occlusion, factor XIII deficiency, treatment with t-PA, streptokinase, or desmopressin (DDAVP)",
                      "Decreased clot lysis time: Exercise, venous occlusion, factor XIII deficiency, treatment with t-PA, streptokinase, or desmopressin (DDAVP)",
                      "Decreased fibrinolysis (increased ECLT)Increased clot lysis time: Third trimester pregnancy, disseminated intravascular coagulation (DIC), liver disease, obesity",
                      "Increased clot lysis time: Third trimester pregnancy, disseminated intravascular coagulation (DIC), liver disease, obesity"
                    ]
                  },
                  {
                    "text": "InterferencesFibrinolytic activity is increased when plasma comes into contact with glass; therefore, contact activation must be avoidedStorage of blood between 20°C and 30°C decreases fibrinolytic activityEDTA increases fibrinolysisHeparin reduces fibrinolysis",
                    "sub_points": [
                      "Fibrinolytic activity is increased when plasma comes into contact with glass; therefore, contact activation must be avoided",
                      "Storage of blood between 20°C and 30°C decreases fibrinolytic activity",
                      "EDTA increases fibrinolysis",
                      "Heparin reduces fibrinolysis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Interpretation of Thromboelastography": {
            "name": "Interpretation of Thromboelastography",
            "url": "https://app.pathprimer.com/document/c8f05ef5-9e2a-4009-b2e0-9bee21d06f15/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "TEG is global test of clot formation"
                  },
                  {
                    "text": "Traditionally assay is performed by adding sample of whole blood to sample well; as clot forms, strength of clot is measured over time"
                  }
                ],
                "Limitations": [
                  {
                    "text": "Insensitive to defects in von Willebrand factor"
                  },
                  {
                    "text": "Performed under nonphysiologic conditions (absence of shear forces)"
                  },
                  {
                    "text": "Correlation with coagulation testing may be unreliable (e.g., PT, aPTT)"
                  }
                ]
              },
              "OVERVIEW": {
                "Principle": [
                  {
                    "text": "TEG is global test of clot formation"
                  },
                  {
                    "text": "TEG is viscoelastic assay that reflects interaction among platelets, coagulation factors and natural anticoagulants, and fibrinogen and fibrinolytics"
                  },
                  {
                    "text": "There are 3 main proprietary versions of assayTEG, Rotem, SonoclotAll are based on same principle, but measurement of clot strength is slightly different",
                    "sub_points": [
                      "TEG, Rotem, Sonoclot",
                      "All are based on same principle, but measurement of clot strength is slightly different"
                    ]
                  },
                  {
                    "text": "Traditionally assay is performed by adding sample of whole blood to sample wellAs clot forms, strength of clot is measured over time",
                    "sub_points": [
                      "As clot forms, strength of clot is measured over time"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Thromboelastography (TEG)"
                  },
                  {
                    "text": "Kinetics (K)"
                  },
                  {
                    "text": "Maximum amplitude (MA)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Procedure": [
                  {
                    "text": "Whole blood or heparinized or citrated whole blood is added to sample well"
                  },
                  {
                    "text": "Most common methodPin suspended from wire is placed in sample well, and pin (or well) is rotatedPin movement/amount of torque required to maintain pin movement is measured over time",
                    "sub_points": [
                      "Pin suspended from wire is placed in sample well, and pin (or well) is rotated",
                      "Pin movement/amount of torque required to maintain pin movement is measured over time"
                    ]
                  },
                  {
                    "text": "Amount of torque required to rotate wire increases until maximum is reached"
                  },
                  {
                    "text": "After reaching maximum clot strength, fibrinolytic system lyses clotClot strength decreases",
                    "sub_points": [
                      "Clot strength decreases"
                    ]
                  },
                  {
                    "text": "Torque is graphed as clot firmness over time"
                  }
                ],
                "Examples of Quantitative Measurements": [
                  {
                    "text": "R-value = reaction time is time from starting test to initial clot formationMeasure of clot initiation",
                    "sub_points": [
                      "Measure of clot initiation"
                    ]
                  },
                  {
                    "text": "K = time to reach standard level of clot strengthMeasure of clot amplification",
                    "sub_points": [
                      "Measure of clot amplification"
                    ]
                  },
                  {
                    "text": "α angle = slope between R and K, which measures rate of clot formationMeasure of strength of thrombin \"burst\"",
                    "sub_points": [
                      "Measure of strength of thrombin \"burst\""
                    ]
                  },
                  {
                    "text": "MA = represents ultimate strength of fibrin clotMeasure of platelet function &/or fibrinogen activity",
                    "sub_points": [
                      "Measure of platelet function &/or fibrinogen activity"
                    ]
                  },
                  {
                    "text": "LY30 = percentage decrease in clot strength at 30 min after reaching MAMeasure of degree of fibrinolysis",
                    "sub_points": [
                      "Measure of degree of fibrinolysis"
                    ]
                  }
                ],
                "Interpretation and Treatment": [
                  {
                    "text": "Increased R = decreased coagulation factor activityAdminister plasma",
                    "sub_points": [
                      "Administer plasma"
                    ]
                  },
                  {
                    "text": "Decreased MA = impaired platelet function &/or fibrinogen activityAdminister platelets &/or cryoprecipitate (or fibrinogen concentrate)",
                    "sub_points": [
                      "Administer platelets &/or cryoprecipitate (or fibrinogen concentrate)"
                    ]
                  },
                  {
                    "text": "Increased LY30 = hyperfibrinolysisInfuse antifibrinolytic (e.g., aprotinin)",
                    "sub_points": [
                      "Infuse antifibrinolytic (e.g., aprotinin)"
                    ]
                  },
                  {
                    "text": "Decreased R or increased MA = hypercoagulabilityProvide anticoagulation or antiplatelet agent, according to clinical situation",
                    "sub_points": [
                      "Provide anticoagulation or antiplatelet agent, according to clinical situation"
                    ]
                  },
                  {
                    "text": "Decreased LY30 = hypofibrinolysis"
                  }
                ],
                "Performing Test With Additives": [
                  {
                    "text": "Test can be performed after adding different agentsThromboplastin → to assess extrinsic pathway of coagulation cascadeKaolin or Celite → to assess instrinsic pathway of coagulation cascadePlatelet inhibitor (prostacyclin, GPIIb/IIIa inhibitor, cytochalasin) → to measure contribution of fibrinogen aloneHeparin → to inhibit thrombin and measure effect of platelets aloneHeparinase → to observe TEG result without heparin effectFor cardiac bypass procedures",
                    "sub_points": [
                      "Thromboplastin → to assess extrinsic pathway of coagulation cascade",
                      "Kaolin or Celite → to assess instrinsic pathway of coagulation cascade",
                      "Platelet inhibitor (prostacyclin, GPIIb/IIIa inhibitor, cytochalasin) → to measure contribution of fibrinogen alone",
                      "Heparin → to inhibit thrombin and measure effect of platelets alone",
                      "Heparinase → to observe TEG result without heparin effectFor cardiac bypass procedures",
                      "For cardiac bypass procedures"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hemostasis Testing": [
                  {
                    "text": "See interpretation and treatment"
                  }
                ],
                "Platelet Mapping": [
                  {
                    "text": "Test can be performed with addition of heparin to inhibit thrombin generation"
                  },
                  {
                    "text": "Reptilase and factor XIIIa can be added to sample to ensure platelet aggregation (platelet to fibrin to platelet bridging)"
                  },
                  {
                    "text": "If agonist such as ADP is added and compared with test without adding ADP, effect of P2Y12 blockade by P2Y12-specific antiplatelet agents can be measured"
                  }
                ]
              },
              "LIMITATIONS": {
                "Test Limitations": [
                  {
                    "text": "Insensitive to defects in von Willebrand factor"
                  },
                  {
                    "text": "Performed under nonphysiologic conditions (absence of shear forces)"
                  },
                  {
                    "text": "Correlation with coagulation testing may be unreliablePT, aPTT",
                    "sub_points": [
                      "PT, aPTT"
                    ]
                  }
                ],
                "Technical Issues": [
                  {
                    "text": "Can be sensitive to mechanical vibration"
                  },
                  {
                    "text": "Operator dependent (e.g., manual pipetting)"
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Whole blood or citrated or heparinized whole blood"
                  },
                  {
                    "text": "Testing should be performed immediately after collection"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Evaluation of the Bleeding Patient": {
            "name": "Evaluation of the Bleeding Patient",
            "url": "https://app.pathprimer.com/document/bd3d1765-b17b-4731-9296-14b191e30112/lesson/0b2c1c88-3b53-4b24-bd36-8b45d1c68fa0",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Clinical history, physical examination, medication history, and laboratory studies should be explored with patient and considered in final diagnosis and treatment plan"
                  },
                  {
                    "text": "Platelet-type bleeding is considered \"immediate,\" whereas coagulation-type bleeding is \"delayed\"In secondary hemostatic disorders, primary hemostatic platelet plug is able to achieve short-term hemostasis, but without normal coagulation, clot is unstable and there is delayed bleeding",
                    "sub_points": [
                      "In secondary hemostatic disorders, primary hemostatic platelet plug is able to achieve short-term hemostasis, but without normal coagulation, clot is unstable and there is delayed bleeding"
                    ]
                  },
                  {
                    "text": "Findings in platelet-type (immediate) bleeding: petechiae, purpura, easy bruisability, mucosal bleeding (gum bleeding, epistaxis), menorrhagia"
                  },
                  {
                    "text": "Findings in coagulation-type (delayed) bleeding: soft tissue hematomas, hemarthrosis"
                  },
                  {
                    "text": "Over-the-counter, prescription, and herbal medications all should be considered as potential causes of bleeding"
                  },
                  {
                    "text": "Initial screening tests include complete blood count with platelet count, PT, and partial aPTT"
                  },
                  {
                    "text": "If initial screening tests are normal, bleeding disorders that do not affect screening tests should be considered: factor XIII deficiency, mild von Willebrand disease, qualitative platelet disorder, mild coagulation factor deficiency, disorder of fibrinolysis"
                  }
                ]
              },
              "OVERVIEW": {
                "General": [
                  {
                    "text": "Clinical history, physical examination, medication history, and laboratory studies are essential to determine underlying etiology and management of a patient's coagulopathy"
                  }
                ],
                "Clinical History": [
                  {
                    "text": "Clinical history is useful in determining whether bleeding disorder is present and severity of disorder"
                  },
                  {
                    "text": "Clinical history guides initial laboratory testing"
                  },
                  {
                    "text": "Bleeding historyAge at presentationInherited disorders more likely manifest at early ageUmbilical stump bleedingBleeding after circumcisionMild disease may not manifest until later in life or only after hemostatic challengeSexvon Willebrand disease is more common in womenType of bleedingEpistaxisGum bleedingBleeding during tooth extractionBleeding during major surgeryMenorrhagiaPostpartum hemorrhageHematomasHemarthrosisBruisingUpper or lower gastrointestinal bleeding (melena, hematochezia)Frequency and duration of bleedingTriggers of bleeding (spontaneous?)Mechanism needed to stop bleedingNone—spontaneous cessationTransfusionCoagulation factorsAntifibrinolyticsDesmopressinSurgicalVisits to emergency department or physician necessaryAnemia requiring iron therapy or red cell transfusionComorbiditiesLeukemia, uremia, portal hypertension, amyloidosis, liver disease",
                    "sub_points": [
                      "Age at presentationInherited disorders more likely manifest at early ageUmbilical stump bleedingBleeding after circumcisionMild disease may not manifest until later in life or only after hemostatic challenge",
                      "Inherited disorders more likely manifest at early ageUmbilical stump bleedingBleeding after circumcision",
                      "Umbilical stump bleeding",
                      "Bleeding after circumcision",
                      "Mild disease may not manifest until later in life or only after hemostatic challenge",
                      "Sexvon Willebrand disease is more common in women",
                      "von Willebrand disease is more common in women",
                      "Type of bleedingEpistaxisGum bleedingBleeding during tooth extractionBleeding during major surgeryMenorrhagiaPostpartum hemorrhageHematomasHemarthrosisBruisingUpper or lower gastrointestinal bleeding (melena, hematochezia)",
                      "Epistaxis",
                      "Gum bleeding",
                      "Bleeding during tooth extraction",
                      "Bleeding during major surgery",
                      "Menorrhagia",
                      "Postpartum hemorrhage",
                      "Hematomas",
                      "Hemarthrosis",
                      "Bruising",
                      "Upper or lower gastrointestinal bleeding (melena, hematochezia)",
                      "Frequency and duration of bleedingTriggers of bleeding (spontaneous?)Mechanism needed to stop bleedingNone—spontaneous cessationTransfusionCoagulation factorsAntifibrinolyticsDesmopressinSurgical",
                      "Triggers of bleeding (spontaneous?)",
                      "Mechanism needed to stop bleedingNone—spontaneous cessationTransfusionCoagulation factorsAntifibrinolyticsDesmopressinSurgical",
                      "None—spontaneous cessation",
                      "Transfusion",
                      "Coagulation factors",
                      "Antifibrinolytics",
                      "Desmopressin",
                      "Surgical",
                      "Visits to emergency department or physician necessary",
                      "Anemia requiring iron therapy or red cell transfusion",
                      "ComorbiditiesLeukemia, uremia, portal hypertension, amyloidosis, liver disease",
                      "Leukemia, uremia, portal hypertension, amyloidosis, liver disease"
                    ]
                  },
                  {
                    "text": "Family history of bleedingMode of inheritance, consanguinity, syndromic disorderUseful for distinguishing inherited from acquired bleeding disorders and for guiding differential diagnosis of inherited disordersAutosomal dominantvon Willebrand diseaseMYH9-related disordersDysfibrinogenemiaX-linkedHemophilia A (factor VIII deficiency)Hemophilia B (factor IX deficiency)Wiskott-Aldrich syndrome",
                    "sub_points": [
                      "Mode of inheritance, consanguinity, syndromic disorder",
                      "Useful for distinguishing inherited from acquired bleeding disorders and for guiding differential diagnosis of inherited disorders",
                      "Autosomal dominantvon Willebrand diseaseMYH9-related disordersDysfibrinogenemia",
                      "von Willebrand disease",
                      "MYH9-related disorders",
                      "Dysfibrinogenemia",
                      "X-linkedHemophilia A (factor VIII deficiency)Hemophilia B (factor IX deficiency)Wiskott-Aldrich syndrome",
                      "Hemophilia A (factor VIII deficiency)",
                      "Hemophilia B (factor IX deficiency)",
                      "Wiskott-Aldrich syndrome"
                    ]
                  }
                ],
                "Physical Examination": [
                  {
                    "text": "Platelet-type bleedingDisorders of primary hemostasis have physical findings distinct from coagulation abnormalitiesPlatelet-type bleeding considered \"immediate,\" whereas coagulation-type bleeding is \"delayed\"In secondary hemostatic disorders, primary hemostatic platelet plug is able to achieve short-term hemostasisWithout normal coagulation, clot is unstable and there is delayed bleedingFindings in platelet-type bleedingPetechiaePurpuraEasy bruisabilityMucosal bleeding (gum bleeding, epistaxis)Menorrhagia",
                    "sub_points": [
                      "Disorders of primary hemostasis have physical findings distinct from coagulation abnormalities",
                      "Platelet-type bleeding considered \"immediate,\" whereas coagulation-type bleeding is \"delayed\"In secondary hemostatic disorders, primary hemostatic platelet plug is able to achieve short-term hemostasisWithout normal coagulation, clot is unstable and there is delayed bleeding",
                      "In secondary hemostatic disorders, primary hemostatic platelet plug is able to achieve short-term hemostasis",
                      "Without normal coagulation, clot is unstable and there is delayed bleeding",
                      "Findings in platelet-type bleedingPetechiaePurpuraEasy bruisabilityMucosal bleeding (gum bleeding, epistaxis)Menorrhagia",
                      "Petechiae",
                      "Purpura",
                      "Easy bruisability",
                      "Mucosal bleeding (gum bleeding, epistaxis)",
                      "Menorrhagia"
                    ]
                  },
                  {
                    "text": "Coagulation-type bleedingFindings in coagulation-type bleedingSoft tissue hematomasHemarthrosis",
                    "sub_points": [
                      "Findings in coagulation-type bleedingSoft tissue hematomasHemarthrosis",
                      "Soft tissue hematomas",
                      "Hemarthrosis"
                    ]
                  },
                  {
                    "text": "Other useful physical findingsEczema → Wiskott-Aldrich syndromePerifollicular hemorrhage → ScurvyAlbinism → Hermansky-Pudlak disease",
                    "sub_points": [
                      "Eczema → Wiskott-Aldrich syndrome",
                      "Perifollicular hemorrhage → Scurvy",
                      "Albinism → Hermansky-Pudlak disease"
                    ]
                  }
                ],
                "Medications": [
                  {
                    "text": "Over-the-counter, prescription, and herbal medications all should be considered as potential causes of bleeding"
                  },
                  {
                    "text": "Antiplatelet agentsAspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-1 (COX-1) inhibitorsP2Y12 inhibitorsClopidogrel, prasugrelGPIIb/IIa inhibitorsAbciximab, eptifibatideSelective serotonin reuptake inhibitors (SSRIs), α/β-adrenergic receptor blockers, glucocorticoidsFish oils, herbal medications",
                    "sub_points": [
                      "Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-1 (COX-1) inhibitors",
                      "P2Y12 inhibitorsClopidogrel, prasugrel",
                      "Clopidogrel, prasugrel",
                      "GPIIb/IIa inhibitorsAbciximab, eptifibatide",
                      "Abciximab, eptifibatide",
                      "Selective serotonin reuptake inhibitors (SSRIs), α/β-adrenergic receptor blockers, glucocorticoids",
                      "Fish oils, herbal medications"
                    ]
                  },
                  {
                    "text": "AnticoagulantsOral anticoagulantsWarfarin, dabigatran (direct thrombin inhibitor), rivaroxaban or apixaban (factor Xa inhibitors)Parenteral anticoagulantsUnfractionated heparin and low-molecular-weight heparin, hirudin, bivalirudin, argatroban, fondaparinux",
                    "sub_points": [
                      "Oral anticoagulantsWarfarin, dabigatran (direct thrombin inhibitor), rivaroxaban or apixaban (factor Xa inhibitors)",
                      "Warfarin, dabigatran (direct thrombin inhibitor), rivaroxaban or apixaban (factor Xa inhibitors)",
                      "Parenteral anticoagulantsUnfractionated heparin and low-molecular-weight heparin, hirudin, bivalirudin, argatroban, fondaparinux",
                      "Unfractionated heparin and low-molecular-weight heparin, hirudin, bivalirudin, argatroban, fondaparinux"
                    ]
                  }
                ],
                "Laboratory Studies": [
                  {
                    "text": "Initial screening tests include complete blood count with platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "If initial screening tests are normal, bleeding disorders that do not affect screening tests should be consideredFactor XIII deficiencyMild von Willebrand diseaseQualitative platelet disorderMild coagulation factor deficiencyDisorder of fibrinolysis",
                    "sub_points": [
                      "Factor XIII deficiency",
                      "Mild von Willebrand disease",
                      "Qualitative platelet disorder",
                      "Mild coagulation factor deficiency",
                      "Disorder of fibrinolysis"
                    ]
                  },
                  {
                    "text": "Abnormal studies may lead to additional screening testsPFA-100Thrombin timeMixing study",
                    "sub_points": [
                      "PFA-100",
                      "Thrombin time",
                      "Mixing study"
                    ]
                  },
                  {
                    "text": "If second-level screening tests are abnormal, further testing is performed based on pattern of abnormal studiesNormal PT and prolonged aPTTTesting for factor VII activityLiver function testsProlonged aPTT and normal PTTesting for coagulation factor deficienciesAbnormal PFA-100Platelet function testingvon Willebrand disease work-upAbnormal thrombin timeEvaluation for heparin contamination or therapy or fibrin degradation products",
                    "sub_points": [
                      "Normal PT and prolonged aPTTTesting for factor VII activityLiver function tests",
                      "Testing for factor VII activity",
                      "Liver function tests",
                      "Prolonged aPTT and normal PTTesting for coagulation factor deficiencies",
                      "Testing for coagulation factor deficiencies",
                      "Abnormal PFA-100Platelet function testingvon Willebrand disease work-up",
                      "Platelet function testing",
                      "von Willebrand disease work-up",
                      "Abnormal thrombin timeEvaluation for heparin contamination or therapy or fibrin degradation products",
                      "Evaluation for heparin contamination or therapy or fibrin degradation products"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Coagulation Defects": {
        "name": "Coagulation Defects",
        "url": "https://app.pathprimer.com/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
        "topics": {
          "Hemophilia A (Factor VIII Deficiency)": {
            "name": "Hemophilia A (Factor VIII Deficiency)",
            "url": "https://app.pathprimer.com/document/2ad895b6-bcf8-4fe4-824c-3dfa7858a994/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Hemophilia A is X-linked recessive disorder almost exclusively affecting males; 30% of cases are spontaneous with no family history or carriers"
                  },
                  {
                    "text": "Females with symptomatic hemophilia A are rare; daughters and mothers are usually carriers"
                  },
                  {
                    "text": "Hemophilia A in a female can be due to Turner syndrome (XO), skewed lyonization, or homozygosity (carrier mother and affected father)"
                  },
                  {
                    "text": "ClassificationNormal (50%-150%)Mild (> 5%): Bleeding with surgery and traumaModerate (1%-5%): Bleeding with minor surgery and trauma; spontaneous bleeding episodes less common than severe hemophiliaSevere (< 1%): Bleeding after surgery and trauma; frequent spontaneous bleeding",
                    "sub_points": [
                      "Normal (50%-150%)",
                      "Mild (> 5%): Bleeding with surgery and trauma",
                      "Moderate (1%-5%): Bleeding with minor surgery and trauma; spontaneous bleeding episodes less common than severe hemophilia",
                      "Severe (< 1%): Bleeding after surgery and trauma; frequent spontaneous bleeding"
                    ]
                  },
                  {
                    "text": "In severe disease, most common initial bleeding manifestations are bleeding in association with circumcision and soft tissue trauma (ecchymoses, deep soft tissue and intramuscular hematomas)"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "﻿Elevated PTT with normal prothrombin time (PT) in absence of heparin"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Epidemiology": [
                  {
                    "text": "Congenital deficiency of coagulation factor VIII"
                  },
                  {
                    "text": "﻿X-linked recessive disorderAlmost exclusively affecting males",
                    "sub_points": [
                      "Almost exclusively affecting males"
                    ]
                  },
                  {
                    "text": "Present in 1 in 5000 male births"
                  },
                  {
                    "text": "30% of cases are spontaneous with no family history or carriers"
                  },
                  {
                    "text": "Equal incidence across ethnic and racial groups"
                  },
                  {
                    "text": "Factor VIII deficiency accounts for 80% of hemophilia cases"
                  },
                  {
                    "text": "Females with symptomatic hemophilia A are rareDaughters and mothers usually carriersHemophilia A in females can be due toTurner syndrome (XO)Skewed lyonizationHomozygosity (carrier mother and affected father)",
                    "sub_points": [
                      "Daughters and mothers usually carriers",
                      "Hemophilia A in females can be due toTurner syndrome (XO)Skewed lyonizationHomozygosity (carrier mother and affected father)",
                      "Turner syndrome (XO)",
                      "Skewed lyonization",
                      "Homozygosity (carrier mother and affected father)"
                    ]
                  }
                ],
                "Genetics": [
                  {
                    "text": "Inversion intron 22 on chromosome X accounts for 45% of casesInversion intron 1 accounts for 5% of casesPrevents transcription of normal, full-length factor VIIICoded protein usually has no functional and no immunologic activity",
                    "sub_points": [
                      "Inversion intron 1 accounts for 5% of cases",
                      "Prevents transcription of normal, full-length factor VIII",
                      "Coded protein usually has no functional and no immunologic activity"
                    ]
                  },
                  {
                    "text": "Other mutations include large deletions and point mutations (stop, insertion, deletion)Mild to moderate hemophilia mainly due to missense mutations, point mutations, deletions",
                    "sub_points": [
                      "Mild to moderate hemophilia mainly due to missense mutations, point mutations, deletions"
                    ]
                  },
                  {
                    "text": "Factor VIII gene is larger than factor IX geneMay account for greater prevalence of hemophilia A (5:1)",
                    "sub_points": [
                      "May account for greater prevalence of hemophilia A (5:1)"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "ClassificationNormal (50%-150% factor VIII)Mild (> 5%-40% factor VIII)Bleeding with surgery and traumaModerate (1%-5% factor VIII)Bleeding with minor surgery and traumaSpontaneous bleeding episodes less common than severe hemophiliaSevere (< 1% factor VIII)Bleeding after minor surgery and traumaFrequent spontaneous bleeding",
                    "sub_points": [
                      "Normal (50%-150% factor VIII)",
                      "Mild (> 5%-40% factor VIII)Bleeding with surgery and trauma",
                      "Bleeding with surgery and trauma",
                      "Moderate (1%-5% factor VIII)Bleeding with minor surgery and traumaSpontaneous bleeding episodes less common than severe hemophilia",
                      "Bleeding with minor surgery and trauma",
                      "Spontaneous bleeding episodes less common than severe hemophilia",
                      "Severe (< 1% factor VIII)Bleeding after minor surgery and traumaFrequent spontaneous bleeding",
                      "Bleeding after minor surgery and trauma",
                      "Frequent spontaneous bleeding"
                    ]
                  },
                  {
                    "text": "Early in lifeMost common initial bleeding manifestations in severe disease﻿Bleeding in association with circumcisionSoft tissue trauma—ecchymoses, deep soft tissue and intramuscular hematomasRecommendation of atraumatic vaginal deliveryNo forceps or vacuum3.5%-4% incidence of intracranial hemorrhage in newbornsHemarthrosis does not occur until after age 1 yrWith onset of walkingMild hemophilia may not be recognized until much later in life",
                    "sub_points": [
                      "Most common initial bleeding manifestations in severe disease﻿Bleeding in association with circumcisionSoft tissue trauma—ecchymoses, deep soft tissue and intramuscular hematomas",
                      "﻿Bleeding in association with circumcision",
                      "Soft tissue trauma—ecchymoses, deep soft tissue and intramuscular hematomas",
                      "Recommendation of atraumatic vaginal deliveryNo forceps or vacuum3.5%-4% incidence of intracranial hemorrhage in newborns",
                      "No forceps or vacuum",
                      "3.5%-4% incidence of intracranial hemorrhage in newborns",
                      "Hemarthrosis does not occur until after age 1 yrWith onset of walking",
                      "With onset of walking",
                      "Mild hemophilia may not be recognized until much later in life"
                    ]
                  },
                  {
                    "text": "Intraarticular bleedingMost common site of spontaneous bleedingKnees most common site of intraarticular hemorrhage (> 50%)Also affects ankles, shoulders, elbows, wristsBegins as swelling, “prickly” and “burning” sensationsProgresses to pain and limited joint mobilityArthropathy develops from repeated bleedingSynovial hypertrophy and friability lead to further bleedingHemosiderin deposition leads to inflammatory responseFibrosis and chronic synovitis lead to joint stiffness and erosive destruction of cartilage",
                    "sub_points": [
                      "Most common site of spontaneous bleeding",
                      "Knees most common site of intraarticular hemorrhage (> 50%)Also affects ankles, shoulders, elbows, wrists",
                      "Also affects ankles, shoulders, elbows, wrists",
                      "Begins as swelling, “prickly” and “burning” sensationsProgresses to pain and limited joint mobility",
                      "Progresses to pain and limited joint mobility",
                      "Arthropathy develops from repeated bleedingSynovial hypertrophy and friability lead to further bleedingHemosiderin deposition leads to inflammatory responseFibrosis and chronic synovitis lead to joint stiffness and erosive destruction of cartilage",
                      "Synovial hypertrophy and friability lead to further bleeding",
                      "Hemosiderin deposition leads to inflammatory response",
                      "Fibrosis and chronic synovitis lead to joint stiffness and erosive destruction of cartilage"
                    ]
                  },
                  {
                    "text": "Intramuscular bleedingSecond most common form of bleedingAccounts for 30% of bleeding eventsCompartment syndrome leads to neuropathy, ischemia, gangreneBleeding into large muscles can lead to loss of large amount of blood",
                    "sub_points": [
                      "Second most common form of bleeding",
                      "Accounts for 30% of bleeding events",
                      "Compartment syndrome leads to neuropathy, ischemia, gangrene",
                      "Bleeding into large muscles can lead to loss of large amount of blood"
                    ]
                  },
                  {
                    "text": "HematuriaSpontaneous gross hematuriaAssociated withNonsteroidal antiinflammatory drugs (NSAIDs)TraumaExertionTreated with hydration",
                    "sub_points": [
                      "Spontaneous gross hematuria",
                      "Associated withNonsteroidal antiinflammatory drugs (NSAIDs)TraumaExertion",
                      "Nonsteroidal antiinflammatory drugs (NSAIDs)",
                      "Trauma",
                      "Exertion",
                      "Treated with hydration"
                    ]
                  },
                  {
                    "text": "Intracranial/intracerebral hemorrhage (ICH)Most common cause of death from bleedingSpontaneous in 50% of casesAntiretroviral protease inhibitors may increase riskNeurologic sequelae develop in 50% of patients with ICH30% of events lead to death",
                    "sub_points": [
                      "Most common cause of death from bleeding",
                      "Spontaneous in 50% of cases",
                      "Antiretroviral protease inhibitors may increase risk",
                      "Neurologic sequelae develop in 50% of patients with ICH",
                      "30% of events lead to death"
                    ]
                  },
                  {
                    "text": "Gastrointestinal (GI) bleedingOccurs in 15% of adults with hemophiliaAnatomic lesions more common than spontaneous GI bleeds",
                    "sub_points": [
                      "Occurs in 15% of adults with hemophilia",
                      "Anatomic lesions more common than spontaneous GI bleeds"
                    ]
                  },
                  {
                    "text": "Pseudotumor formationRepetitive hematomas can encapsulateDue to inadequate treatment of bleeding events",
                    "sub_points": [
                      "Repetitive hematomas can encapsulate",
                      "Due to inadequate treatment of bleeding events"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Hemophilia treatment centersComprehensive medical and psychosocial support for patient and familySurvival advantage for patients treated at a centerMore cost-effective care",
                    "sub_points": [
                      "Comprehensive medical and psychosocial support for patient and family",
                      "Survival advantage for patients treated at a center",
                      "More cost-effective care"
                    ]
                  },
                  {
                    "text": "Clotting factor replacementProphylactic (primary) regular and frequent infusions before onset of bleedingSecondary prophylaxis after bleeding event is given to prevent further bleeding eventsGoals of treatment with factor replacement vary depending on eventMajor oral surgery—25%-50% factor VIIIHemarthrosis—30%-50% factor VIIIGI hemorrhage or hematuria—50% factor VIIIRetropharyngeal bleeding—80%-100% factor VIIIIntramuscular bleeding into psoas—80%-100% factor VIIIIntracranial hemorrhage/head trauma—100% factor VIIIPlasma derived and recombinantViral inactivation to reduce risk of transmission of virusesHuman immunodeficiency virus (HIV)Hepatitis B virus (HBV)Hepatitis C virus (HCV)Dosing based onPlasma volumeFactor half-lifeGoal of treatmentFactor VIII activity is increased 2% by 1 IU/kg body weight of factor VIIIFactor VIII circulating half-life is 8-12 hrLoading dose followed by maintenance dose",
                    "sub_points": [
                      "Prophylactic (primary) regular and frequent infusions before onset of bleeding",
                      "Secondary prophylaxis after bleeding event is given to prevent further bleeding events",
                      "Goals of treatment with factor replacement vary depending on eventMajor oral surgery—25%-50% factor VIIIHemarthrosis—30%-50% factor VIIIGI hemorrhage or hematuria—50% factor VIIIRetropharyngeal bleeding—80%-100% factor VIIIIntramuscular bleeding into psoas—80%-100% factor VIIIIntracranial hemorrhage/head trauma—100% factor VIII",
                      "Major oral surgery—25%-50% factor VIII",
                      "Hemarthrosis—30%-50% factor VIII",
                      "GI hemorrhage or hematuria—50% factor VIII",
                      "Retropharyngeal bleeding—80%-100% factor VIII",
                      "Intramuscular bleeding into psoas—80%-100% factor VIII",
                      "Intracranial hemorrhage/head trauma—100% factor VIII",
                      "Plasma derived and recombinantViral inactivation to reduce risk of transmission of virusesHuman immunodeficiency virus (HIV)Hepatitis B virus (HBV)Hepatitis C virus (HCV)Dosing based onPlasma volumeFactor half-lifeGoal of treatmentFactor VIII activity is increased 2% by 1 IU/kg body weight of factor VIIIFactor VIII circulating half-life is 8-12 hrLoading dose followed by maintenance dose",
                      "Viral inactivation to reduce risk of transmission of virusesHuman immunodeficiency virus (HIV)Hepatitis B virus (HBV)Hepatitis C virus (HCV)",
                      "Human immunodeficiency virus (HIV)",
                      "Hepatitis B virus (HBV)",
                      "Hepatitis C virus (HCV)",
                      "Dosing based onPlasma volumeFactor half-lifeGoal of treatment",
                      "Plasma volume",
                      "Factor half-life",
                      "Goal of treatment",
                      "Factor VIII activity is increased 2% by 1 IU/kg body weight of factor VIII",
                      "Factor VIII circulating half-life is 8-12 hr",
                      "Loading dose followed by maintenance dose"
                    ]
                  },
                  {
                    "text": "DesmopressinUsed in patients with mild hemophilia AIncreases factor VIII and von Willebrand factor release from endothelial cells and platelet α granulesPeak effect at 30-60 minCan be used for dental and minor procedures",
                    "sub_points": [
                      "Used in patients with mild hemophilia A",
                      "Increases factor VIII and von Willebrand factor release from endothelial cells and platelet α granules",
                      "Peak effect at 30-60 min",
                      "Can be used for dental and minor procedures"
                    ]
                  },
                  {
                    "text": "Ancillary treatmentsAntifibrinolytics (e.g., aminocaproic acid, tranexamic acid)Fibrin glue or sealant",
                    "sub_points": [
                      "Antifibrinolytics (e.g., aminocaproic acid, tranexamic acid)",
                      "Fibrin glue or sealant"
                    ]
                  }
                ],
                "Complications of Treatment": [
                  {
                    "text": "Alloimmunization﻿Development of alloantibodies to factor VIIISuspected when factor levels do not increase as expected after infusion of factor VIII (< 60% of expected)",
                    "sub_points": [
                      "﻿Development of alloantibodies to factor VIII",
                      "Suspected when factor levels do not increase as expected after infusion of factor VIII (< 60% of expected)"
                    ]
                  },
                  {
                    "text": "InfectionsHIVHBVHCV",
                    "sub_points": [
                      "HIV",
                      "HBV",
                      "HCV"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Women with low factor VIII activity should be tested for type 2N and type 3 von Willebrand disease (vWD)"
                  },
                  {
                    "text": "Factor VIII < 10%Severe type I vWDType 3 vWDType 2N vWDAcquired hemophilia AAcquired vWD",
                    "sub_points": [
                      "Severe type I vWD",
                      "Type 3 vWD",
                      "Type 2N vWD",
                      "Acquired hemophilia A",
                      "Acquired vWD"
                    ]
                  },
                  {
                    "text": "Factor VIII 10%-50%Mild hemophilia AType I vWDType 2N vWDCombined factor V and VIII deficiency",
                    "sub_points": [
                      "Mild hemophilia A",
                      "Type I vWD",
                      "Type 2N vWD",
                      "Combined factor V and VIII deficiency"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Clotting Assays": [
                  {
                    "text": "Elevated partial thromboplastin time (PTT) with normal prothrombin time (PT) in absence of heparin"
                  },
                  {
                    "text": "Factor VIII activity decreasedPTT-based 1-stage clotting assayChromogenic factor activity",
                    "sub_points": [
                      "PTT-based 1-stage clotting assay",
                      "Chromogenic factor activity"
                    ]
                  },
                  {
                    "text": "Factor IX, XI, XII activity normal"
                  },
                  {
                    "text": "Mixing study corrects immediately and at 2 hrLow likelihood of a factor inhibitor at presentation",
                    "sub_points": [
                      "Low likelihood of a factor inhibitor at presentation"
                    ]
                  },
                  {
                    "text": "Normal platelet counts and platelet function studies"
                  },
                  {
                    "text": "Women should be tested for vWD (type 2N and type 3)"
                  }
                ],
                "Specimen Collection": [
                  {
                    "text": "3.2% sodium citrate1:9 citrate-to-whole-blood ratio",
                    "sub_points": [
                      "1:9 citrate-to-whole-blood ratio"
                    ]
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Normal factor VIII activity 50%-150%"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Direct sequencing"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemophilia B (Factor IX Deficiency)": {
            "name": "Hemophilia B (Factor IX Deficiency)",
            "url": "https://app.pathprimer.com/document/827c703b-2f3f-4d3f-8cb6-c8f0807fbfa4/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Hemophilia B is X-linked recessive disorder that is frequently spontaneous with no family history or carriers"
                  },
                  {
                    "text": "Females with symptomatic hemophilia B are rare; females are usually carriers"
                  },
                  {
                    "text": "Hemophilia B in female can be due to Turner syndrome (XO), skewed lyonization, or homozygosity (carrier mother and father with hemophilia B)"
                  },
                  {
                    "text": "ClassificationMild (> 5%): Bleeding with injury, surgery, traumaModerate (1-5%): Bleeding with injury, surgery, trauma; spontaneous bleeding less common than severe hemophiliaSevere (< 1%): Bleeding with injury, surgery, trauma; frequent spontaneous bleeding",
                    "sub_points": [
                      "Mild (> 5%): Bleeding with injury, surgery, trauma",
                      "Moderate (1-5%): Bleeding with injury, surgery, trauma; spontaneous bleeding less common than severe hemophilia",
                      "Severe (< 1%): Bleeding with injury, surgery, trauma; frequent spontaneous bleeding"
                    ]
                  },
                  {
                    "text": "Most common initial bleeding in patients with severe disease is bleeding in association with circumcision and soft tissue trauma (ecchymoses, deep soft tissue and intramuscular hematomas)"
                  },
                  {
                    "text": "Intraarticular bleeding is most common site of spontaneous bleeding"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Epidemiology": [
                  {
                    "text": "Congenital deficiency of factor IX"
                  },
                  {
                    "text": "X-linked recessive disorder"
                  },
                  {
                    "text": "Occurs almost exclusively in malesOccurs in 1 in 30,000 male births",
                    "sub_points": [
                      "Occurs in 1 in 30,000 male births"
                    ]
                  },
                  {
                    "text": "Frequently spontaneous with no family history or carriers"
                  },
                  {
                    "text": "Equal incidence across ethnic and racial groups"
                  },
                  {
                    "text": "Symptomatic hemophilia B rare in femalesFemales are usually carriersHemophilia B in female can be due toTurner syndrome (XO)Skewed lyonizationHomozygosityCarrier mother and father with hemophilia B",
                    "sub_points": [
                      "Females are usually carriers",
                      "Hemophilia B in female can be due toTurner syndrome (XO)Skewed lyonizationHomozygosityCarrier mother and father with hemophilia B",
                      "Turner syndrome (XO)",
                      "Skewed lyonization",
                      "HomozygosityCarrier mother and father with hemophilia B",
                      "Carrier mother and father with hemophilia B"
                    ]
                  }
                ],
                "Genetics": [
                  {
                    "text": "Factor VIII gene larger than factor IX geneMay account for greater prevalence of hemophilia A (5:1)",
                    "sub_points": [
                      "May account for greater prevalence of hemophilia A (5:1)"
                    ]
                  },
                  {
                    "text": "Numerous (> 300) point mutations and deletions identifiedFrequently result in defective, nonfunctioning, but immunologically detectable protein",
                    "sub_points": [
                      "Frequently result in defective, nonfunctioning, but immunologically detectable protein"
                    ]
                  },
                  {
                    "text": "Individuals with large deletions do not have detectable proteinMore likely to develop alloantibodies",
                    "sub_points": [
                      "More likely to develop alloantibodies"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "ClassificationMild (> 5%)Bleeding with injury, surgery, traumaModerate (1-5%)Bleeding with injury, surgery, traumaSpontaneous bleeding less common than severe hemophiliaSevere (< 1%)Bleeding with injury, surgery, traumaFrequent spontaneous bleeding",
                    "sub_points": [
                      "Mild (> 5%)Bleeding with injury, surgery, trauma",
                      "Bleeding with injury, surgery, trauma",
                      "Moderate (1-5%)Bleeding with injury, surgery, traumaSpontaneous bleeding less common than severe hemophilia",
                      "Bleeding with injury, surgery, trauma",
                      "Spontaneous bleeding less common than severe hemophilia",
                      "Severe (< 1%)Bleeding with injury, surgery, traumaFrequent spontaneous bleeding",
                      "Bleeding with injury, surgery, trauma",
                      "Frequent spontaneous bleeding"
                    ]
                  },
                  {
                    "text": "Early in lifeMost common initial bleeding in patients with severe disease is bleeding in association withCircumcisionSoft tissue trauma (ecchymoses, deep soft tissue and intramuscular hematomas)EcchymosesDeep soft tissue and intramuscular hematomasIntracranial hemorrhageAtraumatic vaginal delivery most often recommendedCesarean section does not eliminate risk of bleedingHemarthrosis typically occurs after age 1 yearWith onset of walkingMild hemophilia may not be recognized until much later in life",
                    "sub_points": [
                      "Most common initial bleeding in patients with severe disease is bleeding in association withCircumcisionSoft tissue trauma (ecchymoses, deep soft tissue and intramuscular hematomas)EcchymosesDeep soft tissue and intramuscular hematomas",
                      "Circumcision",
                      "Soft tissue trauma (ecchymoses, deep soft tissue and intramuscular hematomas)EcchymosesDeep soft tissue and intramuscular hematomas",
                      "Ecchymoses",
                      "Deep soft tissue and intramuscular hematomas",
                      "Intracranial hemorrhageAtraumatic vaginal delivery most often recommendedCesarean section does not eliminate risk of bleeding",
                      "Atraumatic vaginal delivery most often recommended",
                      "Cesarean section does not eliminate risk of bleeding",
                      "Hemarthrosis typically occurs after age 1 yearWith onset of walking",
                      "With onset of walking",
                      "Mild hemophilia may not be recognized until much later in life"
                    ]
                  },
                  {
                    "text": "Intraarticular bleedingMost common site of spontaneous bleedingKnees most common intraarticular site (> 50%)Also affects ankles, shoulders, elbows, wristsInitially manifests with pain and swelling, “prickly” and “burning” sensationProgresses to decreased joint mobility and increased painArthropathy develops from repeated bleedingSynovial hypertrophy and friability lead to further bleedingHemosiderin deposition leads to inflammatory responseFibrosis and chronic synovitis leads to joint stiffness, erosive destruction of cartilage",
                    "sub_points": [
                      "Most common site of spontaneous bleeding",
                      "Knees most common intraarticular site (> 50%)Also affects ankles, shoulders, elbows, wrists",
                      "Also affects ankles, shoulders, elbows, wrists",
                      "Initially manifests with pain and swelling, “prickly” and “burning” sensationProgresses to decreased joint mobility and increased pain",
                      "Progresses to decreased joint mobility and increased pain",
                      "Arthropathy develops from repeated bleedingSynovial hypertrophy and friability lead to further bleedingHemosiderin deposition leads to inflammatory responseFibrosis and chronic synovitis leads to joint stiffness, erosive destruction of cartilage",
                      "Synovial hypertrophy and friability lead to further bleeding",
                      "Hemosiderin deposition leads to inflammatory response",
                      "Fibrosis and chronic synovitis leads to joint stiffness, erosive destruction of cartilage"
                    ]
                  },
                  {
                    "text": "Intramuscular bleedingSecond most common form of bleedingCompartment syndromeCompression of structuresLeads to neuropathy, ischemia, gangreneBleeding into large muscles can lead to loss of large amount of blood",
                    "sub_points": [
                      "Second most common form of bleeding",
                      "Compartment syndromeCompression of structuresLeads to neuropathy, ischemia, gangrene",
                      "Compression of structures",
                      "Leads to neuropathy, ischemia, gangrene",
                      "Bleeding into large muscles can lead to loss of large amount of blood"
                    ]
                  },
                  {
                    "text": "HematuriaSpontaneous gross hematuriaNonsteroidal antiinflammatory drugs (NSAIDs), trauma, exertionTreated with hydration",
                    "sub_points": [
                      "Spontaneous gross hematuria",
                      "Nonsteroidal antiinflammatory drugs (NSAIDs), trauma, exertion",
                      "Treated with hydration"
                    ]
                  },
                  {
                    "text": "Intracranial/intracerebral hemorrhage (ICH)Most common cause of death from bleedingPatient with ICH may develop neurologic sequelae30% of events may lead to death",
                    "sub_points": [
                      "Most common cause of death from bleeding",
                      "Patient with ICH may develop neurologic sequelae",
                      "30% of events may lead to death"
                    ]
                  },
                  {
                    "text": "Gastrointestinal (GI) bleedingOccurs in 15% of adults with hemophiliaBleeding associated with anatomic lesion more common than spontaneous bleeding",
                    "sub_points": [
                      "Occurs in 15% of adults with hemophilia",
                      "Bleeding associated with anatomic lesion more common than spontaneous bleeding"
                    ]
                  },
                  {
                    "text": "Pseudotumor formationIn 1-2% severe hemophilia, repetitive hematomas lead to encapsulationDue to inadequate treatment of bleeding events",
                    "sub_points": [
                      "In 1-2% severe hemophilia, repetitive hematomas lead to encapsulation",
                      "Due to inadequate treatment of bleeding events"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Hemophilia treatment centersComprehensive medical and psychosocial support for patient and familySurvival advantage for patients treated at centerMore cost-effective care",
                    "sub_points": [
                      "Comprehensive medical and psychosocial support for patient and family",
                      "Survival advantage for patients treated at center",
                      "More cost-effective care"
                    ]
                  },
                  {
                    "text": "Clotting factor replacementProphylactic (primary) infusion before onset of bleedingSecondary prophylaxis after bleeding event to prevent further bleedingGoals of treatment (factor IX activity)Major oral surgery: 25-50%Hemarthrosis: 30-50%GI hemorrhage and hematuria: 50%Retropharyngeal bleeding: 80-100%Intramuscular bleeding into psoas: 80-100%Intracranial hemorrhage/head trauma: 100%Plasma derived and recombinantViral inactivation to reduce risk of transmission of virusesHuman immunodeficiency virus (HIV)Hepatitis B virus (HBV)Hepatitis C virus (HCV)Dosing based onPlasma volumeFactor half-lifeGoal of treatmentFactor IX activity increased by 1% with 1 IU/kg body weight of factor IXFactor IX has larger extravascular distribution than factor VIIIRecombinant factor IX has 80% expected recovery at 15-30 minFactor IX circulating half-life ~ 18 hoursLoading dose followed by maintenance dose",
                    "sub_points": [
                      "Prophylactic (primary) infusion before onset of bleeding",
                      "Secondary prophylaxis after bleeding event to prevent further bleeding",
                      "Goals of treatment (factor IX activity)Major oral surgery: 25-50%Hemarthrosis: 30-50%GI hemorrhage and hematuria: 50%Retropharyngeal bleeding: 80-100%Intramuscular bleeding into psoas: 80-100%Intracranial hemorrhage/head trauma: 100%",
                      "Major oral surgery: 25-50%",
                      "Hemarthrosis: 30-50%",
                      "GI hemorrhage and hematuria: 50%",
                      "Retropharyngeal bleeding: 80-100%",
                      "Intramuscular bleeding into psoas: 80-100%",
                      "Intracranial hemorrhage/head trauma: 100%",
                      "Plasma derived and recombinant",
                      "Viral inactivation to reduce risk of transmission of virusesHuman immunodeficiency virus (HIV)Hepatitis B virus (HBV)Hepatitis C virus (HCV)",
                      "Human immunodeficiency virus (HIV)",
                      "Hepatitis B virus (HBV)",
                      "Hepatitis C virus (HCV)",
                      "Dosing based onPlasma volumeFactor half-lifeGoal of treatment",
                      "Plasma volume",
                      "Factor half-life",
                      "Goal of treatment",
                      "Factor IX activity increased by 1% with 1 IU/kg body weight of factor IXFactor IX has larger extravascular distribution than factor VIIIRecombinant factor IX has 80% expected recovery at 15-30 min",
                      "Factor IX has larger extravascular distribution than factor VIII",
                      "Recombinant factor IX has 80% expected recovery at 15-30 min",
                      "Factor IX circulating half-life ~ 18 hours",
                      "Loading dose followed by maintenance dose"
                    ]
                  },
                  {
                    "text": "Ancillary treatmentsAntifibrinolytics (e.g., aminocaproic acid, tranexamic acid)Fibrin glue or sealant",
                    "sub_points": [
                      "Antifibrinolytics (e.g., aminocaproic acid, tranexamic acid)",
                      "Fibrin glue or sealant"
                    ]
                  }
                ],
                "Complications of Treatment": [
                  {
                    "text": "Alloimmunization (development of alloantibodies to factor IX)Suspected when factor levels do not increase as expected after infusion of factor IX (< 60% of expected)",
                    "sub_points": [
                      "Suspected when factor levels do not increase as expected after infusion of factor IX (< 60% of expected)"
                    ]
                  },
                  {
                    "text": "InfectiousHIVHBVHCV",
                    "sub_points": [
                      "HIV",
                      "HBV",
                      "HCV"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Clotting Assays": [
                  {
                    "text": "Elevated partial thromboplastin time (PTT) with normal prothrombin time (PT) in absence of heparin"
                  },
                  {
                    "text": "Factor IX activity decreasedPTT-based 1-stage clotting assayChromogenic factor activity",
                    "sub_points": [
                      "PTT-based 1-stage clotting assay",
                      "Chromogenic factor activity"
                    ]
                  },
                  {
                    "text": "Factor VIII, XI, XII activity normal"
                  },
                  {
                    "text": "Normal platelet counts and platelet function studies"
                  },
                  {
                    "text": "Mixing study corrects immediately and at 2 hours (low likelihood of factor inhibitor at presentation)Factor inhibitor should be considered when factor recovery is < 60% predicted",
                    "sub_points": [
                      "Factor inhibitor should be considered when factor recovery is < 60% predicted"
                    ]
                  }
                ],
                "Specimen Collection": [
                  {
                    "text": "3.2% sodium citrate1:9 citrate-to-whole-blood ratio",
                    "sub_points": [
                      "1:9 citrate-to-whole-blood ratio"
                    ]
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Normal factor IX activity 50-150%"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Direct sequencing"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemophilia C (Factor XI Deficiency)": {
            "name": "Hemophilia C (Factor XI Deficiency)",
            "url": "https://app.pathprimer.com/document/5e0d6add-4190-486f-bf3a-b7c525b3c92b/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "﻿Autosomal dominant inheritance"
                  },
                  {
                    "text": "No sex predilection"
                  },
                  {
                    "text": "﻿Most prevalent among Ashkenazi Jews"
                  },
                  {
                    "text": "Bleeding manifestations highly variableFactor XI levels do not always correlate with bleeding tendency",
                    "sub_points": [
                      "Factor XI levels do not always correlate with bleeding tendency"
                    ]
                  },
                  {
                    "text": "Bleeding not as severe as in hemophilia A and B because ability to generate thrombin is intact; factor XI only provides boost to thrombin generation"
                  },
                  {
                    "text": "Treatment is with FFP"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology and Genetics": [
                  {
                    "text": "﻿Autosomal dominant inheritance"
                  },
                  {
                    "text": "No sex predilection"
                  },
                  {
                    "text": "F11gene is on long arm of ﻿chromosome at 4q34-35"
                  },
                  {
                    "text": "GenotypesType I mutations at intron-exon boundaries (splice junction mutations)Type II and III higher frequency in Ashkenazi Jewish populationType II—premature stop codonType III—missense mutations",
                    "sub_points": [
                      "Type I mutations at intron-exon boundaries (splice junction mutations)",
                      "Type II and III higher frequency in Ashkenazi Jewish populationType II—premature stop codonType III—missense mutations",
                      "Type II—premature stop codon",
                      "Type III—missense mutations"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "﻿Most prevalent among Ashkenazi JewsGene frequency 4.3%",
                    "sub_points": [
                      "Gene frequency 4.3%"
                    ]
                  },
                  {
                    "text": "Deficiency also occurs in non-Jewish populations"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Bleeding manifestations highly variable"
                  },
                  {
                    "text": "Factor XI levels do not always correlate with bleeding tendencyBleeding can occur in heterozygous, homozygous, or double heterozygous individualsFactor XI activity < 20% likely to occur in homozygous or double heterozygous individuals",
                    "sub_points": [
                      "Bleeding can occur in heterozygous, homozygous, or double heterozygous individualsFactor XI activity < 20% likely to occur in homozygous or double heterozygous individuals",
                      "Factor XI activity < 20% likely to occur in homozygous or double heterozygous individuals"
                    ]
                  },
                  {
                    "text": "Bleeding not as severe as in hemophilia A and B because ability to generate thrombin is intactFactor XI only provides boost to thrombin generation",
                    "sub_points": [
                      "Factor XI only provides boost to thrombin generation"
                    ]
                  },
                  {
                    "text": "Common manifestationsHematomaEpistaxisMenorrhagiaPostpartum bleedingHematuriaPerioperative and postoperative hemorrhage",
                    "sub_points": [
                      "Hematoma",
                      "Epistaxis",
                      "Menorrhagia",
                      "Postpartum bleeding",
                      "Hematuria",
                      "Perioperative and postoperative hemorrhage"
                    ]
                  },
                  {
                    "text": "Best predictor of excessive bleeding is presence or absence of history of excessive bleeding"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Ideal level of factor XI required to treat bleeding has not been establishedIn practice, for major surgery minimum level of 45% of normalFor minor surgery minimum level of 30% of normal",
                    "sub_points": [
                      "In practice, for major surgery minimum level of 45% of normal",
                      "For minor surgery minimum level of 30% of normal"
                    ]
                  },
                  {
                    "text": "Treatment is with fresh frozen plasma (FFP)Loading dose of 15-20 mL/kg and then 3-6 mL/kg every 12 hr",
                    "sub_points": [
                      "Loading dose of 15-20 mL/kg and then 3-6 mL/kg every 12 hr"
                    ]
                  },
                  {
                    "text": "Half-life of factor XI is 50 ± 22 hr"
                  },
                  {
                    "text": "Antifibrinolytics (e.g., aminocaproic acid, tranexamic acid) can be added to help control bleeding"
                  },
                  {
                    "text": "Recombinant factor VIIa also used to treat bleeding in factor XI deficiency"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Familial combined deficiency"
                  },
                  {
                    "text": "Acquired factor XI inhibitor due to autoimmune disorders (systemic lupus erythematosus)"
                  },
                  {
                    "text": "Platelet function defects"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Diagnostic Assays": [
                  {
                    "text": "Prolonged partial thromboplastin time (PTT) with normal prothrombin time (PT) in absence of heparin"
                  },
                  {
                    "text": "Mixing studies correct immediately and at 2 hr"
                  },
                  {
                    "text": "Decreased factor XI activity"
                  },
                  {
                    "text": "Normal factor VIII, IX, and XII activities"
                  },
                  {
                    "text": "Normal platelet count and platelet function"
                  },
                  {
                    "text": "Samples are best if processed as soon as possible with collection in plastic rather than glass to prevent autoactivation"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Factor XII Deficiency": {
            "name": "Factor XII Deficiency",
            "url": "https://app.pathprimer.com/document/025c1ec7-a79b-42b3-8920-d8c23a134752/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Factor XII (a.k.a. Hageman factor)Factor XII is converted to factor XIIa by contact with negatively charged surface in vitro (glass)Factor XIIa activates intrinsic pathway of coagulation cascade by activating factor XI in vitro",
                    "sub_points": [
                      "Factor XII is converted to factor XIIa by contact with negatively charged surface in vitro (glass)",
                      "Factor XIIa activates intrinsic pathway of coagulation cascade by activating factor XI in vitro"
                    ]
                  },
                  {
                    "text": "Autosomal recessive inheritance"
                  },
                  {
                    "text": "Factor XII deficiency is not associated with bleeding, even after trauma and major surgery"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Markedly Prolonged PTT with normal PT"
                  },
                  {
                    "text": "Factor XII activity decreased"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology and Genetics": [
                  {
                    "text": "Factor XII (a.k.a. Hageman factor)Factor XII is converted to factor XIIa by contact with negatively charged surface in vitro (glass)Factor XIIa activates intrinsic pathway of coagulation cascade by activating factor XI in vitro",
                    "sub_points": [
                      "Factor XII is converted to factor XIIa by contact with negatively charged surface in vitro (glass)",
                      "Factor XIIa activates intrinsic pathway of coagulation cascade by activating factor XI in vitro"
                    ]
                  },
                  {
                    "text": "Mutation in factor XII gene, located on chromosome 5, leads to deficiency of factor XII"
                  },
                  {
                    "text": "Autosomal recessive inheritanceHeterozygotes have 20-60% factor XIIHomozygous individuals typically have < 10% factor XII",
                    "sub_points": [
                      "Heterozygotes have 20-60% factor XII",
                      "Homozygous individuals typically have < 10% factor XII"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Heterozygosity for factor XII deficiency found in ~ 2% of healthy blood donors"
                  },
                  {
                    "text": "Asians have higher incidence of factor XII deficiency"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Factor XII deficiency is not associated with bleeding, even after trauma and major surgery"
                  }
                ],
                "Treatment": [
                  {
                    "text": "No treatment needed prior to surgery"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Very rarely, factor XII inhibitors are associated with autoimmune disease and in individuals treated with procainamide and chlorpromazine"
                  },
                  {
                    "text": "Factor XII deficiency can be found in association with factor IX deficiency and von Willebrand disease"
                  },
                  {
                    "text": "Factor XII deficiency can be seen in patients with liver disease"
                  },
                  {
                    "text": "Prekallikrein and high-molecular-weight kininogen deficiencies must be distinguished from factor XII deficiency by specific assays"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Coagulation Assays": [
                  {
                    "text": "Markedly prolonged PTT with normal PT"
                  },
                  {
                    "text": "Normal thrombin time"
                  },
                  {
                    "text": "No personal or family history of extended bleeding"
                  },
                  {
                    "text": "PTT mixing studies correct"
                  },
                  {
                    "text": "Normal factor VIII, IX, XI levels"
                  },
                  {
                    "text": "Factor XII activity decreased"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Congenital Factor VII Deficiency": {
            "name": "Congenital Factor VII Deficiency",
            "url": "https://app.pathprimer.com/document/a5dca6ef-1a27-4c0a-9aa3-80c9e2867115/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Deficiency or structural defect in coagulation protein factor VII"
                  },
                  {
                    "text": "Autosomal recessive inheritance"
                  },
                  {
                    "text": "Biologic half-life of factor VII is 3.5 hours, which is relatively short compared with other coagulation factors"
                  },
                  {
                    "text": "Treatment options include plasma, prothrombin complex concentrates, and recombinant factor VIIaShort half-life of factor VII makes plasma difficult to use because it can lead to transfusion-associated circulatory overload",
                    "sub_points": [
                      "Short half-life of factor VII makes plasma difficult to use because it can lead to transfusion-associated circulatory overload"
                    ]
                  },
                  {
                    "text": "Manifestations include easy bruising, epistaxis, soft tissue hematomas, menorrhagia, and postpartum bleedingLess than 1% activity may be associated with severe bleeding (similar to hemophilia A and B)",
                    "sub_points": [
                      "Less than 1% activity may be associated with severe bleeding (similar to hemophilia A and B)"
                    ]
                  },
                  {
                    "text": "Associated with Dubin-Johnson and Rotor syndromes"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Prolonged PT with normal APTT and thrombin time"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Genetics and Epidemiology": [
                  {
                    "text": "Deficiency or structural defect in coagulation protein factor VII"
                  },
                  {
                    "text": "Gene on chromosome 13q34"
                  },
                  {
                    "text": "Incidence of 1 per 500,000"
                  },
                  {
                    "text": "Autosomal recessive inheritance"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "1% of factor VII circulates in active form (factor VIIa) to initiate coagulation"
                  },
                  {
                    "text": "Biologic half-life of factor VII is 3.5 hours, which is relatively short compared with other coagulation factors"
                  },
                  {
                    "text": "Greater than 50% of patients have low functional activity and antigen (quantitative)"
                  },
                  {
                    "text": "Others have normal antigen levels and reduced activity (qualitative)"
                  },
                  {
                    "text": "Bleeding symptoms occur mostly in homozygotes and double heterozygotes"
                  },
                  {
                    "text": "Numerous genetic mutations have been identifiedVariable degree of expression",
                    "sub_points": [
                      "Variable degree of expression"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Bleeding severity varies widely from patient to patient"
                  },
                  {
                    "text": "Poor correlation between factor activity and severity of bleedingAssays using human tissue factor correlate bestPatients with factor VII activity < 8% are most likely to have hemorrhagic episodes",
                    "sub_points": [
                      "Assays using human tissue factor correlate best",
                      "Patients with factor VII activity < 8% are most likely to have hemorrhagic episodes"
                    ]
                  },
                  {
                    "text": "Manifestations include easy bruising, epistaxis, and soft tissue hematomas"
                  },
                  {
                    "text": "Women may experience menorrhagia, menometrorrhagia, and postpartum bleeding"
                  },
                  {
                    "text": "Less than 1% activity may be associated with severe bleeding (similar to hemophilia A and B)HemarthrosisRetroperitoneal bleedingMuscle hematomasFatal intracranial hemorrhageReported most often in infants after vaginal delivery (16% incidence)",
                    "sub_points": [
                      "Hemarthrosis",
                      "Retroperitoneal bleeding",
                      "Muscle hematomas",
                      "Fatal intracranial hemorrhage",
                      "Reported most often in infants after vaginal delivery (16% incidence)"
                    ]
                  },
                  {
                    "text": "Associated with Dubin-Johnson and Rotor syndromes"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Mild bleeding: Target goal 5-10% of normal factor VII activity"
                  },
                  {
                    "text": "Surgery or severe bleeding: Target goal 15-25% normal factor VII activity"
                  },
                  {
                    "text": "Treatment options include plasma, prothrombin complex concentrates, and recombinant factor VIIaFactor VII has short half-life, which makes plasma difficult to use because it can lead to transfusion-associated circulatory overloadRecombinant factor VIIa is efficacious and is treatment of choice20-30 micrograms per kilogram of body weightMild to moderate: One dose may be sufficientSevere: May require dose every 4-6 hours for several days",
                    "sub_points": [
                      "Factor VII has short half-life, which makes plasma difficult to use because it can lead to transfusion-associated circulatory overload",
                      "Recombinant factor VIIa is efficacious and is treatment of choice20-30 micrograms per kilogram of body weightMild to moderate: One dose may be sufficientSevere: May require dose every 4-6 hours for several days",
                      "20-30 micrograms per kilogram of body weight",
                      "Mild to moderate: One dose may be sufficient",
                      "Severe: May require dose every 4-6 hours for several days"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Inhibitory antibodies against administered factor VII have been reported in a few patients with severe congenital deficiency"
                  },
                  {
                    "text": "Warfarin use, vitamin K deficiency, and liver disease are main causes of acquired factor VII deficiency"
                  },
                  {
                    "text": "Familial combined factor deficiencies"
                  },
                  {
                    "text": "Acquired factor VII inhibitors"
                  },
                  {
                    "text": "Wilms tumor"
                  },
                  {
                    "text": "Aplastic anemia"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Coagulation Assays": [
                  {
                    "text": "Prolonged prothrombin time (PT) with normal activated partial thromboplastin time (APTT) and thrombin time"
                  },
                  {
                    "text": "On rare occasions, APTT can be also be prolonged"
                  },
                  {
                    "text": "PT mixing study corrects in 1:1 mix of patient and pooled normal plasma"
                  },
                  {
                    "text": "Factor VII activity is low (50-150% factor VII activity is normal)"
                  },
                  {
                    "text": "Factor VIIa assays are availableUseful for monitoring therapy",
                    "sub_points": [
                      "Useful for monitoring therapy"
                    ]
                  },
                  {
                    "text": "Prothrombin time is variable depending on source of thromboplastinHuman tissue factor should be used preferentially in all clotting assays for factor VII, especially for confirmation of original diagnosisOx brain thromboplastin gives very different results than human recombinantDifferent polymorphisms associated with varying response to thromboplastin sources",
                    "sub_points": [
                      "Human tissue factor should be used preferentially in all clotting assays for factor VII, especially for confirmation of original diagnosis",
                      "Ox brain thromboplastin gives very different results than human recombinant",
                      "Different polymorphisms associated with varying response to thromboplastin sources"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Factor V Deficiency": {
            "name": "Factor V Deficiency",
            "url": "https://app.pathprimer.com/document/baf6dee5-4dc8-448c-8f10-fdd8a81ce1eb/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Factor V is found in plasma and alpha granules of platelets"
                  },
                  {
                    "text": "Hepatocytes secrete majority of factor V"
                  },
                  {
                    "text": "Inheritance is autosomal recessive"
                  },
                  {
                    "text": "Consanguinity is common in affected patients"
                  },
                  {
                    "text": "Spontaneous development of inhibitors to factor V can be seen after surgery"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Prolonged PT and aPTT; normal thrombin time"
                  },
                  {
                    "text": "Factor V activity assay can be performed"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology, Genetics, and Epidemiology": [
                  {
                    "text": "Factor V is found in plasma and alpha granules of plateletsCirculates in plasma primarily in inactive formActivated by thrombin or factor XaHepatocytes secrete majority of factor VPlatelet factor V accounts for 20% of total body factor V",
                    "sub_points": [
                      "Circulates in plasma primarily in inactive formActivated by thrombin or factor Xa",
                      "Activated by thrombin or factor Xa",
                      "Hepatocytes secrete majority of factor V",
                      "Platelet factor V accounts for 20% of total body factor V"
                    ]
                  },
                  {
                    "text": "Uncommon disorder with incidence of 1 per 1,000,000"
                  },
                  {
                    "text": "Inheritance is autosomal recessive"
                  },
                  {
                    "text": "Decreased or absent factor V activity in plasma and platelets"
                  },
                  {
                    "text": "Consanguinity is common in affected patients"
                  },
                  {
                    "text": "Numerous genetic variants have been identified"
                  },
                  {
                    "text": "Variable correlation with factor activityUndetectable levels of factor V may have no bleeding or may have severe bleeding symptoms",
                    "sub_points": [
                      "Undetectable levels of factor V may have no bleeding or may have severe bleeding symptoms"
                    ]
                  },
                  {
                    "text": "Mutations in factor V can also cause resistance to activated protein C and thrombosis (e.g., factor V Leiden)"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Variable degree of bleedingMenorrhagiaPostpartum hemorrhageHemarthrosis after trauma",
                    "sub_points": [
                      "Menorrhagia",
                      "Postpartum hemorrhage",
                      "Hemarthrosis after trauma"
                    ]
                  },
                  {
                    "text": "Severely affected patient (< 1%)Present early in lifeUmbilical stump bleedingEasy bruisingEpistaxis< 1% activity can have spontaneous hemorrhage",
                    "sub_points": [
                      "Present early in life",
                      "Umbilical stump bleeding",
                      "Easy bruising",
                      "Epistaxis",
                      "< 1% activity can have spontaneous hemorrhage"
                    ]
                  },
                  {
                    "text": "Total lack of factor V is embryonic lethal in mice; therefore, patients with factor V deficiency are unlikely to completely lack factor V"
                  },
                  {
                    "text": "Bleeding risk is greater with platelet factor V deficiency"
                  },
                  {
                    "text": "Mild factor V deficiency: Asymptomatic if factor V activity > 30%"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Commercial factor V concentrates are not available"
                  },
                  {
                    "text": "Minor bleeds (e.g., epistaxis) can be treated with local application of antifibrinolytics"
                  },
                  {
                    "text": "Plasma infusion is treatment of choice for severe bleeding15-20 mL per kg of bodyweight loading dose; then 3-6 mL per kg of bodyweight every 24 hours for target activity of 25%Factor V half-life = 36 hoursMore severe bleeding may benefit from plasma exchange",
                    "sub_points": [
                      "15-20 mL per kg of bodyweight loading dose; then 3-6 mL per kg of bodyweight every 24 hours for target activity of 25%",
                      "Factor V half-life = 36 hours",
                      "More severe bleeding may benefit from plasma exchange"
                    ]
                  },
                  {
                    "text": "Platelet transfusion has also been reported to benefit bleeding"
                  },
                  {
                    "text": "Factor VIIa can be used, but is less effective if factor V activity is low"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Severe liver disease"
                  },
                  {
                    "text": "Disseminated intravascular coagulation"
                  },
                  {
                    "text": "Spontaneous development of inhibitors to factor V can rarely be seen after surgeryInhibitors after aminoglycoside, penicillin, and malignancies50% of inhibitors disappear after several weeksBovine thrombin, which contains factor V, can induce inhibitor formationBleeding can be severeTreatment: Corticosteroids and plasma exchange",
                    "sub_points": [
                      "Inhibitors after aminoglycoside, penicillin, and malignancies",
                      "50% of inhibitors disappear after several weeks",
                      "Bovine thrombin, which contains factor V, can induce inhibitor formation",
                      "Bleeding can be severe",
                      "Treatment: Corticosteroids and plasma exchange"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Coagulation Assays": [
                  {
                    "text": "Prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT); normal thrombin time"
                  },
                  {
                    "text": "Factor V activity assay can be performed"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acquired Factor VIII Inhibitor": {
            "name": "Acquired Factor VIII Inhibitor",
            "url": "https://app.pathprimer.com/document/d58233a2-8a3b-4838-b20f-31e8fd8429f4/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Acquired hemophilia A (AHA): Rare condition; incidence 1 per 1.5 million persons per year"
                  },
                  {
                    "text": "Occurs due to spontaneous production of IgG autoantibodies against native factor VIII﻿"
                  },
                  {
                    "text": "93% of patients have bleeding symptoms, typically severe"
                  },
                  {
                    "text": "Patients with AHA present withSkin hematomas (53%)Deep musculoskeletal or retroperitoneal bleeding (50%)Mucosal bleeding (32%)Hemarthrosis (5%)Compare to congenital hemophilia where 70-80% of patients have hemarthrosis",
                    "sub_points": [
                      "Skin hematomas (53%)",
                      "Deep musculoskeletal or retroperitoneal bleeding (50%)",
                      "Mucosal bleeding (32%)",
                      "Hemarthrosis (5%)Compare to congenital hemophilia where 70-80% of patients have hemarthrosis",
                      "Compare to congenital hemophilia where 70-80% of patients have hemarthrosis"
                    ]
                  },
                  {
                    "text": "Immunosuppression should be initiated as soon as possible to stop antibody production"
                  },
                  {
                    "text": "Very poor prognosis overall, with high mortality"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "BU: Amount of inhibitor that neutralizes 50% of factor VIII in pooled normal plasma"
                  },
                  {
                    "text": "Factor VIII inhibitor level and kinetics are second-order (Bethesda assay)Congenital hemophilia anti-factor VIII alloantibodies follow first-order kineticsAcquired hemophilia autoantibodies follow second-order kinetics﻿Rapid decrease in inhibitor activity with increasing inhibitor levels, but continued detectable factor VIII activity even at very high titer﻿",
                    "sub_points": [
                      "Congenital hemophilia anti-factor VIII alloantibodies follow first-order kinetics",
                      "Acquired hemophilia autoantibodies follow second-order kinetics﻿Rapid decrease in inhibitor activity with increasing inhibitor levels, but continued detectable factor VIII activity even at very high titer﻿",
                      "﻿Rapid decrease in inhibitor activity with increasing inhibitor levels, but continued detectable factor VIII activity even at very high titer﻿"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Epidemiology": [
                  {
                    "text": "Acquired hemophilia A (AHA): Rare condition; incidence 1 per 1.5 million persons per year"
                  },
                  {
                    "text": "Average age at presentation: 74 years (range: 13-104)"
                  },
                  {
                    "text": "Slight male predominance: 1.3:1Compare with congenital hemophilia, which has male predominance due to X-linked inheritance",
                    "sub_points": [
                      "Compare with congenital hemophilia, which has male predominance due to X-linked inheritance"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "AHA is due to spontaneous production of IgG autoantibodies that target endogenous factor VIII﻿"
                  },
                  {
                    "text": "Likely caused by dysregulation of immune system, which is affected by both genetic and environmental factorsHLA genotypes of DR1β*16 and DQβ1*0502 more frequently associated with AHA",
                    "sub_points": [
                      "HLA genotypes of DR1β*16 and DQβ1*0502 more frequently associated with AHA"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "AHA should be considered when patient presents as followsNo personal or family history of bleeding disorderBleeding typical for AHAAdvanced age or pregnancy",
                    "sub_points": [
                      "No personal or family history of bleeding disorder",
                      "Bleeding typical for AHA",
                      "Advanced age or pregnancy"
                    ]
                  },
                  {
                    "text": "~ 50% of cases are associated with underlying autoimmune disorder, malignancy, pregnancy, medications, infections, or dermatologic conditionsUnderlying cause can not be identified in remainder of cases",
                    "sub_points": [
                      "Underlying cause can not be identified in remainder of cases"
                    ]
                  },
                  {
                    "text": "93% of patients with AHA have bleeding symptoms, typically severeSeverity of bleeding is out of proportion to factor activity (e.g., severe spontaneous bleeding even with factor activity > 5%)﻿",
                    "sub_points": [
                      "Severity of bleeding is out of proportion to factor activity (e.g., severe spontaneous bleeding even with factor activity > 5%)﻿"
                    ]
                  },
                  {
                    "text": "Some AHA patients are diagnosed after evaluation for asymptomatic prolongation of activated partial thromboplastin time (APTT)"
                  },
                  {
                    "text": "Bleeding is most commonly spontaneous, but 1st episode may occur after trauma or surgery"
                  },
                  {
                    "text": "Bleeding seen in patients with AHA is different from congenital hemophilia A, where hemarthosis is commonPatient presentationSkin hematomas (53%)Deep musculoskeletal or retroperitoneal bleeding (50%)Mucosal bleeding (32%)Hemarthrosis (5%)Compare to congenital hemophilia where 70-80% of patients have hemarthrosisMajority of bleeds are severe (> 70%)Severity is independent of factor VIII or inhibitor level﻿",
                    "sub_points": [
                      "Patient presentationSkin hematomas (53%)Deep musculoskeletal or retroperitoneal bleeding (50%)Mucosal bleeding (32%)Hemarthrosis (5%)Compare to congenital hemophilia where 70-80% of patients have hemarthrosis",
                      "Skin hematomas (53%)",
                      "Deep musculoskeletal or retroperitoneal bleeding (50%)",
                      "Mucosal bleeding (32%)",
                      "Hemarthrosis (5%)Compare to congenital hemophilia where 70-80% of patients have hemarthrosis",
                      "Compare to congenital hemophilia where 70-80% of patients have hemarthrosis",
                      "Majority of bleeds are severe (> 70%)Severity is independent of factor VIII or inhibitor level﻿",
                      "Severity is independent of factor VIII or inhibitor level﻿"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment of acute bleedingTreatment with factor VIII concentrates is generally ineffective unless inhibitor is weakTreatment is dependent on level of inhibitorLow titer inhibitors (< 5 BU) can be overcome with larger than usual doses of factor VIII concentrateEffectiveness can be measured by factor VIII activityDesmopressin (DDAVP)Reserved for mild bleedingEffectiveness can be measured by factor VIII activityPorcine factor VIII concentrates15% cross-reactivity between porcine and human factor VIIIPlasma-derived porcine factor VIII shows to provide excellent hemostasis, but not readily available in United StatesRecombinant porcine factor VIII analogue (rpFVIII) can be used for treatment of bleeding in patients with AHAEffectiveness can be measured by factor VIII activityActivated prothrombin complex concentrates (e.g., factor VIII inhibitor bypassing activity (FEIBA), and recombinant activated factor VII (rFVIIa)Generally used when inhibitor level is > 5 BU76% of patients achieve hemostasis at median of 4 days after treatment",
                    "sub_points": [
                      "Treatment with factor VIII concentrates is generally ineffective unless inhibitor is weak",
                      "Treatment is dependent on level of inhibitorLow titer inhibitors (< 5 BU) can be overcome with larger than usual doses of factor VIII concentrateEffectiveness can be measured by factor VIII activity",
                      "Low titer inhibitors (< 5 BU) can be overcome with larger than usual doses of factor VIII concentrateEffectiveness can be measured by factor VIII activity",
                      "Effectiveness can be measured by factor VIII activity",
                      "Desmopressin (DDAVP)Reserved for mild bleedingEffectiveness can be measured by factor VIII activity",
                      "Reserved for mild bleeding",
                      "Effectiveness can be measured by factor VIII activity",
                      "Porcine factor VIII concentrates15% cross-reactivity between porcine and human factor VIIIPlasma-derived porcine factor VIII shows to provide excellent hemostasis, but not readily available in United StatesRecombinant porcine factor VIII analogue (rpFVIII) can be used for treatment of bleeding in patients with AHAEffectiveness can be measured by factor VIII activity",
                      "15% cross-reactivity between porcine and human factor VIII",
                      "Plasma-derived porcine factor VIII shows to provide excellent hemostasis, but not readily available in United States",
                      "Recombinant porcine factor VIII analogue (rpFVIII) can be used for treatment of bleeding in patients with AHA",
                      "Effectiveness can be measured by factor VIII activity",
                      "Activated prothrombin complex concentrates (e.g., factor VIII inhibitor bypassing activity (FEIBA), and recombinant activated factor VII (rFVIIa)Generally used when inhibitor level is > 5 BU76% of patients achieve hemostasis at median of 4 days after treatment",
                      "Generally used when inhibitor level is > 5 BU",
                      "76% of patients achieve hemostasis at median of 4 days after treatment"
                    ]
                  },
                  {
                    "text": "Long-term suppression of antibodyImmunosuppression should be initiated as soon as possible to stop antibody productionCorticosteroids +/- cyclophosphamideRituximab (anti-CD20 monoclonal antibody)Intravenous immunoglobulin (IVIG)",
                    "sub_points": [
                      "Immunosuppression should be initiated as soon as possible to stop antibody productionCorticosteroids +/- cyclophosphamideRituximab (anti-CD20 monoclonal antibody)Intravenous immunoglobulin (IVIG)",
                      "Corticosteroids +/- cyclophosphamide",
                      "Rituximab (anti-CD20 monoclonal antibody)",
                      "Intravenous immunoglobulin (IVIG)"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Very poor overall, with high mortality"
                  },
                  {
                    "text": "Risk of mortality greater with older age"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Work-up of Prolonged APTT and Normal Prothrombin": [
                  {
                    "text": "In patient presenting with bleeding and isolated elevation of APTT, testing (as follows) supports diagnosis of acquired factor VIII inhibitorRule out presence of heparinHeparinase treatment, thrombin time + reptilase time, anti-Xa assay, &/or medication administration history1:1 mixing study with pooled normal plasma does not correctDecreased factor VIII activityMean factor VIII activity level at diagnosis is 2% (range: 0-40%)Factor VIII inhibitor level and kinetics are second-order (Bethesda assay)Congenital hemophilia anti-factor VIII alloantibodies follow first-order kineticsLinear decrease in factor VIII activity as inhibitor titer increasesAcquired hemophilia autoantibodies follow second-order kinetics﻿Rapid decrease in inhibitor activity with increasing inhibitor levels, but continued detectable factor VIII activity even at very high titer﻿Mean Bethesda units: 12.8 BU (range: 0.2-2800)",
                    "sub_points": [
                      "Rule out presence of heparinHeparinase treatment, thrombin time + reptilase time, anti-Xa assay, &/or medication administration history",
                      "Heparinase treatment, thrombin time + reptilase time, anti-Xa assay, &/or medication administration history",
                      "1:1 mixing study with pooled normal plasma does not correct",
                      "Decreased factor VIII activityMean factor VIII activity level at diagnosis is 2% (range: 0-40%)",
                      "Mean factor VIII activity level at diagnosis is 2% (range: 0-40%)",
                      "Factor VIII inhibitor level and kinetics are second-order (Bethesda assay)Congenital hemophilia anti-factor VIII alloantibodies follow first-order kineticsLinear decrease in factor VIII activity as inhibitor titer increasesAcquired hemophilia autoantibodies follow second-order kinetics﻿Rapid decrease in inhibitor activity with increasing inhibitor levels, but continued detectable factor VIII activity even at very high titer﻿",
                      "Congenital hemophilia anti-factor VIII alloantibodies follow first-order kineticsLinear decrease in factor VIII activity as inhibitor titer increases",
                      "Linear decrease in factor VIII activity as inhibitor titer increases",
                      "Acquired hemophilia autoantibodies follow second-order kinetics﻿Rapid decrease in inhibitor activity with increasing inhibitor levels, but continued detectable factor VIII activity even at very high titer﻿",
                      "﻿Rapid decrease in inhibitor activity with increasing inhibitor levels, but continued detectable factor VIII activity even at very high titer﻿",
                      "Mean Bethesda units: 12.8 BU (range: 0.2-2800)"
                    ]
                  }
                ],
                "Bethesda Assay": [
                  {
                    "text": "Determine level of activity of factor VIII inhibitor"
                  },
                  {
                    "text": "Expressed in Bethesda units (BU)BU: Amount of inhibitor that neutralizes 50% of factor VIII in pooled normal plasma",
                    "sub_points": [
                      "BU: Amount of inhibitor that neutralizes 50% of factor VIII in pooled normal plasma"
                    ]
                  },
                  {
                    "text": "Method for determining BUDilutions of patient plasma are prepared and incubated with pooled normal plasma (PNP)With increasing dilutions, inhibitor is dilutedInhibitor activity decreases with greater dilutionsSubsequently, factor VIII activity in PNP is recovered",
                    "sub_points": [
                      "Dilutions of patient plasma are prepared and incubated with pooled normal plasma (PNP)",
                      "With increasing dilutions, inhibitor is dilutedInhibitor activity decreases with greater dilutions",
                      "Inhibitor activity decreases with greater dilutions",
                      "Subsequently, factor VIII activity in PNP is recovered"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemostatic Abnormalities in Liver Disease": {
            "name": "Hemostatic Abnormalities in Liver Disease",
            "url": "https://app.pathprimer.com/document/f7922e42-78d7-44eb-ba45-5736b48a1239/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Hepatocytes synthesize many coagulation factors, natural anticoagulants, and growth factors required for normal hemostasis and thrombosisCoagulation factors II, VII, IX, X, XIII﻿ and fibrinogenNatural anticoagulants protein C and protein S, antithrombinThrombopoietinADAMTS 13Factor VIII (produced by liver sinusoidal endothelial cells)",
                    "sub_points": [
                      "Coagulation factors II, VII, IX, X, XIII﻿ and fibrinogen",
                      "Natural anticoagulants protein C and protein S, antithrombin",
                      "Thrombopoietin",
                      "ADAMTS 13",
                      "Factor VIII (produced by liver sinusoidal endothelial cells)"
                    ]
                  },
                  {
                    "text": "Gastroesophageal varices are most significant bleeding complication and can be severe and life-threatening"
                  },
                  {
                    "text": "Plasma should not be routinely given before invasive procedures solely to correct abnormal PT/aPTT"
                  },
                  {
                    "text": "Because abnormal PT/aPTT is often seen in patients with liver disease, natural assumption has been that patient are \"naturally anticoagulated\"; this assumption is incorrectPatients with liver disease are not protected against venous thromboembolism",
                    "sub_points": [
                      "Patients with liver disease are not protected against venous thromboembolism"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Routine tests such as PT/aPTT are not good predictors of spontaneous bleeding or bleeding during invasive procedures (e.g., liver biopsy, liver transplantation)"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Overview": [
                  {
                    "text": "Hepatocytes synthesize many coagulation factors, natural anticoagulants, and growth factors required for normal hemostasis and thrombosisCoagulation factors II, VII, IX, X, XIII﻿, fibrinogenNatural anticoagulants protein C and protein S, antithrombinPlasminogen, α₂-antiplasmin, tissue activatable fibrinolysis inhibitor (TAFI)Thrombopoietin (megakaryocyte growth and development factor; c-Mpl ligand)ADAMTS 13 (von Willebrand factor [vWF] cleaving protease; a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13)Produced by liver stellate cellsFactor VIIIProduced by liver sinusoidal endothelial cells",
                    "sub_points": [
                      "Coagulation factors II, VII, IX, X, XIII﻿, fibrinogen",
                      "Natural anticoagulants protein C and protein S, antithrombin",
                      "Plasminogen, α₂-antiplasmin, tissue activatable fibrinolysis inhibitor (TAFI)",
                      "Thrombopoietin (megakaryocyte growth and development factor; c-Mpl ligand)",
                      "ADAMTS 13 (von Willebrand factor [vWF] cleaving protease; a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13)Produced by liver stellate cells",
                      "Produced by liver stellate cells",
                      "Factor VIIIProduced by liver sinusoidal endothelial cells",
                      "Produced by liver sinusoidal endothelial cells"
                    ]
                  },
                  {
                    "text": "Chronic liver disease, especially end-stage liver disease (ESLD), traditionally associated with bleedingElevation in prothrombin time (PT) led to 2 conclusionsPatients with ESLD were at higher risk of spontaneous bleedingCorrection of abnormal coagulation studies was necessary before invasive procedureNewer interpretations of evidence suggest that hemostatic system in patients with ESLD is rebalancedRoutine coagulation testing does not reflect in vivo hemostasisAdministration of plasma to correct abnormal coagulation studies does not change risk of bleeding in ESLD patients undergoing percutaneous liver biopsy",
                    "sub_points": [
                      "Elevation in prothrombin time (PT) led to 2 conclusionsPatients with ESLD were at higher risk of spontaneous bleedingCorrection of abnormal coagulation studies was necessary before invasive procedure",
                      "Patients with ESLD were at higher risk of spontaneous bleeding",
                      "Correction of abnormal coagulation studies was necessary before invasive procedure",
                      "Newer interpretations of evidence suggest that hemostatic system in patients with ESLD is rebalancedRoutine coagulation testing does not reflect in vivo hemostasisAdministration of plasma to correct abnormal coagulation studies does not change risk of bleeding in ESLD patients undergoing percutaneous liver biopsy",
                      "Routine coagulation testing does not reflect in vivo hemostasis",
                      "Administration of plasma to correct abnormal coagulation studies does not change risk of bleeding in ESLD patients undergoing percutaneous liver biopsy"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Accumulating evidence indicates that hemostatic pathway in ESLD is \"rebalanced\"Rebalancing describes changes in procoagulants, natural anticoagulants, fibrinolytics, growth factors, other proteinsChanges in procoagulants are balanced by similar changes in natural anticoagulants so that system is rebalancedRebalance is precariousAdditional comorbidities can tip balance toward bleeding or thrombosis",
                    "sub_points": [
                      "Rebalancing describes changes in procoagulants, natural anticoagulants, fibrinolytics, growth factors, other proteinsChanges in procoagulants are balanced by similar changes in natural anticoagulants so that system is rebalanced",
                      "Changes in procoagulants are balanced by similar changes in natural anticoagulants so that system is rebalanced",
                      "Rebalance is precariousAdditional comorbidities can tip balance toward bleeding or thrombosis",
                      "Additional comorbidities can tip balance toward bleeding or thrombosis"
                    ]
                  },
                  {
                    "text": "Rebalance of hemostatic systemChanges in primary hemostasis (platelet plug formation)Proplatelet plug formation due toIncreased vWFDecreased ADAMTS 13Antiplatelet plug formation due toDecreased thrombopoietin, thrombocytopenia, decreased platelet functionIncreased nitric oxide and prostacylin (inhibitors of platelets)Change in secondary hemostasis (coagulation factors and natural anticoagulants)Balance toward loss of procoagulantsProcoagulant factors II, VII, IX, V, X, and XI decreased in liver disease due to impaired protein synthesisDecreased fibrinogen activity due to decreased synthesis and presence of dysfibrinogenemiaBalance toward decrease in anticoagulants and increase in procoagulantsFactor VIII and vWF are increasedDecrease in natural anticoagulants protein C and S, antithrombin, α₂-macroglobulin, heparin cofactor IIFibrinolysisBalance toward fibrinolysis (antihemostatic) due toIncreased tissue plasminogen activatorDecreased α₂-antiplasmin, factor XIII, TAFIBalance toward hypofibrinolysis (prohemostatic) due toDecreased plasminogenIncreased plasminogen activator inhibitor (PAI-1, PAI-2)",
                    "sub_points": [
                      "Changes in primary hemostasis (platelet plug formation)Proplatelet plug formation due toIncreased vWFDecreased ADAMTS 13Antiplatelet plug formation due toDecreased thrombopoietin, thrombocytopenia, decreased platelet functionIncreased nitric oxide and prostacylin (inhibitors of platelets)",
                      "Proplatelet plug formation due toIncreased vWFDecreased ADAMTS 13",
                      "Increased vWF",
                      "Decreased ADAMTS 13",
                      "Antiplatelet plug formation due toDecreased thrombopoietin, thrombocytopenia, decreased platelet functionIncreased nitric oxide and prostacylin (inhibitors of platelets)",
                      "Decreased thrombopoietin, thrombocytopenia, decreased platelet function",
                      "Increased nitric oxide and prostacylin (inhibitors of platelets)",
                      "Change in secondary hemostasis (coagulation factors and natural anticoagulants)Balance toward loss of procoagulantsProcoagulant factors II, VII, IX, V, X, and XI decreased in liver disease due to impaired protein synthesisDecreased fibrinogen activity due to decreased synthesis and presence of dysfibrinogenemiaBalance toward decrease in anticoagulants and increase in procoagulantsFactor VIII and vWF are increasedDecrease in natural anticoagulants protein C and S, antithrombin, α₂-macroglobulin, heparin cofactor II",
                      "Balance toward loss of procoagulantsProcoagulant factors II, VII, IX, V, X, and XI decreased in liver disease due to impaired protein synthesisDecreased fibrinogen activity due to decreased synthesis and presence of dysfibrinogenemia",
                      "Procoagulant factors II, VII, IX, V, X, and XI decreased in liver disease due to impaired protein synthesis",
                      "Decreased fibrinogen activity due to decreased synthesis and presence of dysfibrinogenemia",
                      "Balance toward decrease in anticoagulants and increase in procoagulantsFactor VIII and vWF are increasedDecrease in natural anticoagulants protein C and S, antithrombin, α₂-macroglobulin, heparin cofactor II",
                      "Factor VIII and vWF are increased",
                      "Decrease in natural anticoagulants protein C and S, antithrombin, α₂-macroglobulin, heparin cofactor II",
                      "FibrinolysisBalance toward fibrinolysis (antihemostatic) due toIncreased tissue plasminogen activatorDecreased α₂-antiplasmin, factor XIII, TAFIBalance toward hypofibrinolysis (prohemostatic) due toDecreased plasminogenIncreased plasminogen activator inhibitor (PAI-1, PAI-2)",
                      "Balance toward fibrinolysis (antihemostatic) due toIncreased tissue plasminogen activatorDecreased α₂-antiplasmin, factor XIII, TAFI",
                      "Increased tissue plasminogen activator",
                      "Decreased α₂-antiplasmin, factor XIII, TAFI",
                      "Balance toward hypofibrinolysis (prohemostatic) due toDecreased plasminogenIncreased plasminogen activator inhibitor (PAI-1, PAI-2)",
                      "Decreased plasminogen",
                      "Increased plasminogen activator inhibitor (PAI-1, PAI-2)"
                    ]
                  }
                ],
                "Clinical Findings and Treatment": [
                  {
                    "text": "Gastroesophageal varices most significant bleeding complicationCan be severe and life-threateningAnatomic defectCoagulation system does not play critical role in cessation of bleedingAnatomic lesion must be repaired",
                    "sub_points": [
                      "Can be severe and life-threatening",
                      "Anatomic defectCoagulation system does not play critical role in cessation of bleedingAnatomic lesion must be repaired",
                      "Coagulation system does not play critical role in cessation of bleeding",
                      "Anatomic lesion must be repaired"
                    ]
                  },
                  {
                    "text": "Hemostatic bleedingBruising, petechiae, purpura, epistaxis, gum bleeding, menorrhagiaNot life-threateningInvasive proceduresRoutine coagulation tests not good predictors of bleedingPlasma should not be routinely given before invasive procedures solely to correct abnormal PT/activated partial thromboplastin time (aPTT)If bleeding occurs during invasive procedure, blood components, derivatives, or prohemostatic agents can be usedFactor prothrombin complex concentrates or recombinant activated factor VII commonly used blood derivatives",
                    "sub_points": [
                      "Bruising, petechiae, purpura, epistaxis, gum bleeding, menorrhagiaNot life-threatening",
                      "Not life-threatening",
                      "Invasive proceduresRoutine coagulation tests not good predictors of bleedingPlasma should not be routinely given before invasive procedures solely to correct abnormal PT/activated partial thromboplastin time (aPTT)If bleeding occurs during invasive procedure, blood components, derivatives, or prohemostatic agents can be usedFactor prothrombin complex concentrates or recombinant activated factor VII commonly used blood derivatives",
                      "Routine coagulation tests not good predictors of bleeding",
                      "Plasma should not be routinely given before invasive procedures solely to correct abnormal PT/activated partial thromboplastin time (aPTT)",
                      "If bleeding occurs during invasive procedure, blood components, derivatives, or prohemostatic agents can be usedFactor prothrombin complex concentrates or recombinant activated factor VII commonly used blood derivatives",
                      "Factor prothrombin complex concentrates or recombinant activated factor VII commonly used blood derivatives"
                    ]
                  },
                  {
                    "text": "Thrombosis and treatmentBecause abnormal PT/aPTT is often seen in patients with liver disease, natural assumption has been that patients are \"naturally anticoagulated\"This assumption is incorrectPatients with liver disease are not protected against venous thromboembolismThromboprophylaxis should be routinely providedLow-molecular-weight heparin is difficult to use because of low antithrombin activity in patients with liver diseaseAnti-Xa assay may not reflect true inhibition of thrombin generationTreatment of thrombosis with heparin is difficult because of low antithrombin activityTreatment with warfarin is challenging because vitamin K-dependent coagulation factors are already decreasedDirect thrombin inhibitors or direct factor Xa inhibitors are useful",
                    "sub_points": [
                      "Because abnormal PT/aPTT is often seen in patients with liver disease, natural assumption has been that patients are \"naturally anticoagulated\"This assumption is incorrect",
                      "This assumption is incorrect",
                      "Patients with liver disease are not protected against venous thromboembolism",
                      "Thromboprophylaxis should be routinely provided",
                      "Low-molecular-weight heparin is difficult to use because of low antithrombin activity in patients with liver diseaseAnti-Xa assay may not reflect true inhibition of thrombin generation",
                      "Anti-Xa assay may not reflect true inhibition of thrombin generation",
                      "Treatment of thrombosis with heparin is difficult because of low antithrombin activity",
                      "Treatment with warfarin is challenging because vitamin K-dependent coagulation factors are already decreased",
                      "Direct thrombin inhibitors or direct factor Xa inhibitors are useful"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Overview": [
                  {
                    "text": "Routine tests such as PT/aPTT are not good predictors of spontaneous bleeding or bleeding during invasive procedures (e.g., liver biopsy, liver transplantation)"
                  }
                ],
                "Prothrombin Time, International Normalized Ratio, Activated Partial Thromboplastin Time": [
                  {
                    "text": "PT and aPTT frequently prolonged in patients with ESLD"
                  },
                  {
                    "text": "Increased PT and aPTT reflect overall decrease in coagulation factor activityAre insensitive to rebalanced natural anticoagulants",
                    "sub_points": [
                      "Are insensitive to rebalanced natural anticoagulants"
                    ]
                  },
                  {
                    "text": "International normalized ratio (INR) originally created for patients on stable warfarin (Coumadin) therapyInternational sensitivity index (ISI) used to determine INR is based on experiments using patients on warfarin, not patients with ESLD",
                    "sub_points": [
                      "International sensitivity index (ISI) used to determine INR is based on experiments using patients on warfarin, not patients with ESLD"
                    ]
                  }
                ],
                "Thrombin Generation Assay": [
                  {
                    "text": "Thrombin generation activated by adding tissue factor, calcium chloride, and substrate conjugated to reporting structure (chromogenic or fluorescent) to platelet-poor plasma or whole blood"
                  },
                  {
                    "text": "As thrombin is generated, it cleaves chromogenic or fluorescent signal off substrateSignal is graphed over time",
                    "sub_points": [
                      "Signal is graphed over time"
                    ]
                  },
                  {
                    "text": "Thrombin generation assay (TGA) can be performed with addition of snake venom extract, Protac, which activates protein C in patient sampleTGA with Protac thought to be more representative of rebalanced hemostasis in patients with liver disease",
                    "sub_points": [
                      "TGA with Protac thought to be more representative of rebalanced hemostasis in patients with liver disease"
                    ]
                  }
                ],
                "Thromboelastography": [
                  {
                    "text": "Thromboelastography (TEG) measures global strength of clot formation in whole blood"
                  },
                  {
                    "text": "Time it takes for clot to start forming, rate at which clot develops its strength, maximum strength achieved, and time it takes for clot to lyse are measured"
                  },
                  {
                    "text": "Other tests can be performed with addition of activators of intrinsic and extrinsic pathway and inhibitors of platelets to determine fibrinogen activity"
                  },
                  {
                    "text": "TEG can be used to determine level of coagulation activity, platelet function (qualitative/quantitative), fibrinogen activity, fibrinolytic activity"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Vitamin K Deficiency": {
            "name": "Vitamin K Deficiency",
            "url": "https://app.pathprimer.com/document/3da982e9-2201-4257-b9fa-b26a53084f05/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Vitamin K is a critical to having normal hemostasisFactors II, VII, IX, X, and protein C and protein S require vitamin K to have coagulation activity",
                    "sub_points": [
                      "Factors II, VII, IX, X, and protein C and protein S require vitamin K to have coagulation activity"
                    ]
                  },
                  {
                    "text": "Vitamin K is a fat soluble vitamin that is found in leafy vegetablesDietary deficiencies can be seen in severe malnutrition, alcoholism, & total parenteral nutrition without vitamin K supplementation",
                    "sub_points": [
                      "Dietary deficiencies can be seen in severe malnutrition, alcoholism, & total parenteral nutrition without vitamin K supplementation"
                    ]
                  },
                  {
                    "text": "Vitamin K is also produced by normal gut flora; absorbed in the terminal ileum"
                  },
                  {
                    "text": "Vitamin K deficiency most often occurs in infancy, but can occur at any age"
                  },
                  {
                    "text": "Hemorrhagic disease of the newborn occurs when Vitamin K does not cross the placenta, low level of vitamin K in the breast milk and low synthesis by gut flora"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "In vitamin K deficiency, the PT is prolonged, and the aPTT is normal-to-prolongedThe aPTT is not as sensitive as the PT is to coagulation abnormalities caused by vitamin K deficiency",
                    "sub_points": [
                      "The aPTT is not as sensitive as the PT is to coagulation abnormalities caused by vitamin K deficiency"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Overview": [
                  {
                    "text": "Vitamin K is a critical to having normal hemostasisFactors II, VII, IX, and X require vitamin K to have coagulation activityProtein C and its cofactor protein S require vitamin K to have anticoagulant activity",
                    "sub_points": [
                      "Factors II, VII, IX, and X require vitamin K to have coagulation activity",
                      "Protein C and its cofactor protein S require vitamin K to have anticoagulant activity"
                    ]
                  },
                  {
                    "text": "Vitamin K is a fat soluble vitamin that is found in leafy vegetablesDietary deficiencies can be seen in severe malnutrition, alcoholism, & total parenteral nutrition without vitamin K supplementation",
                    "sub_points": [
                      "Dietary deficiencies can be seen in severe malnutrition, alcoholism, & total parenteral nutrition without vitamin K supplementation"
                    ]
                  },
                  {
                    "text": "Vitamin K is produced by normal gut floraChanges in the gut flora can be caused by antibiotics leading to decreased vitamin K available from bacterial synthesis",
                    "sub_points": [
                      "Changes in the gut flora can be caused by antibiotics leading to decreased vitamin K available from bacterial synthesis"
                    ]
                  },
                  {
                    "text": "The types of vitamin K are K-1 (phytonadione; plant-derived), K-2 (menaquinone; gut flora), and K-3 (menadione, synthetic water soluble form)"
                  },
                  {
                    "text": "Vitamin K deficiency most often occurs in infancy, but can occur at any age"
                  },
                  {
                    "text": "It is absorbed in the terminal ileumMalabsorption can be a cause of vitamin K deficiencye.g. Biliary diseases, Crohns Disease, pancreatitis, short bowel syndrome",
                    "sub_points": [
                      "Malabsorption can be a cause of vitamin K deficiencye.g. Biliary diseases, Crohns Disease, pancreatitis, short bowel syndrome",
                      "e.g. Biliary diseases, Crohns Disease, pancreatitis, short bowel syndrome"
                    ]
                  }
                ],
                "Vitamin K recycling (see figure)": [
                  {
                    "text": "Vitamin K is a cofactor needed to convert glutamic acid residues in the vitamin-K dependent coagulation factors II, VII, IX, and X, and proteins C and S"
                  },
                  {
                    "text": "Warfarin inhibits the recycling of vitamin KWithout the recycling, vitamin K is not available for carboxylationWithout carboxylation, the vitamin K dependent coagulation factors do not have coagulation activity",
                    "sub_points": [
                      "Without the recycling, vitamin K is not available for carboxylation",
                      "Without carboxylation, the vitamin K dependent coagulation factors do not have coagulation activity"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "InfantsHemorrhagic disease of the newbornHemorrhagic disease of the newborn occurs when one or more of the follow occur:Vitamin K does not cross the placentaThere is a low level of vitamin K in the breast milkLow synthesis of vitamin K by gut floraIntracranial and retroperitoneal bleeding can occur",
                    "sub_points": [
                      "Hemorrhagic disease of the newbornHemorrhagic disease of the newborn occurs when one or more of the follow occur:Vitamin K does not cross the placentaThere is a low level of vitamin K in the breast milkLow synthesis of vitamin K by gut floraIntracranial and retroperitoneal bleeding can occur",
                      "Hemorrhagic disease of the newborn occurs when one or more of the follow occur:Vitamin K does not cross the placentaThere is a low level of vitamin K in the breast milkLow synthesis of vitamin K by gut flora",
                      "Vitamin K does not cross the placenta",
                      "There is a low level of vitamin K in the breast milk",
                      "Low synthesis of vitamin K by gut flora",
                      "Intracranial and retroperitoneal bleeding can occur"
                    ]
                  },
                  {
                    "text": "AdultsLess common; does not occur in adults with normal diet and adequate gut floraDietary deficiencies can be seen in severe malnutrition, alcoholism, & total parenteral nutrition without vitamin K supplementationPatients taking antibiotics that decrease the normal gut flora can become vitamin K deficientBleeding can be mucocutaneous: epistaxis, gum bleeding, gastrointestinal bleeding, menorrhagia, and hematuria",
                    "sub_points": [
                      "Less common; does not occur in adults with normal diet and adequate gut floraDietary deficiencies can be seen in severe malnutrition, alcoholism, & total parenteral nutrition without vitamin K supplementationPatients taking antibiotics that decrease the normal gut flora can become vitamin K deficient",
                      "Dietary deficiencies can be seen in severe malnutrition, alcoholism, & total parenteral nutrition without vitamin K supplementation",
                      "Patients taking antibiotics that decrease the normal gut flora can become vitamin K deficient",
                      "Bleeding can be mucocutaneous: epistaxis, gum bleeding, gastrointestinal bleeding, menorrhagia, and hematuria"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Patients are treated with oral, subcutaneous or intravenous Vitamin K"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Decreased vitamin K dependent coagulation factors": [
                  {
                    "text": "Prothrombin Time (PT) and activated partial thromboplastin time (aPTT)In vitamin K deficiency, the PT is prolonged, and the aPTT is normal-to-prolongedThe aPTT is not as sensitive as the PT is to coagulation abnormalities caused by vitamin K deficiency",
                    "sub_points": [
                      "In vitamin K deficiency, the PT is prolonged, and the aPTT is normal-to-prolongedThe aPTT is not as sensitive as the PT is to coagulation abnormalities caused by vitamin K deficiency",
                      "The aPTT is not as sensitive as the PT is to coagulation abnormalities caused by vitamin K deficiency"
                    ]
                  },
                  {
                    "text": "Vitamin K dependent coagulation factor activities can be measuredFactor II, VII, IX, X, protein C and protein S show decreased activity",
                    "sub_points": [
                      "Factor II, VII, IX, X, protein C and protein S show decreased activity"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Dysfibrinogenemia": {
            "name": "Dysfibrinogenemia",
            "url": "https://app.pathprimer.com/document/726719e2-7fac-4987-9cb1-0210e3c881a9/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Typically, dysfibrinogenemias are functional defects of fibrinogen with normal fibrinogen antigen levels"
                  },
                  {
                    "text": "Acquired dysfibrinogenemiaSeen in patients with severe liver disease or (rarely) renal cell carcinomaPatients usually present with bleeding disorders characterized by epistaxis, postoperative bleeding, easy bruising, or poor wound healing",
                    "sub_points": [
                      "Seen in patients with severe liver disease or (rarely) renal cell carcinoma",
                      "Patients usually present with bleeding disorders characterized by epistaxis, postoperative bleeding, easy bruising, or poor wound healing"
                    ]
                  },
                  {
                    "text": "Congenital fibrinogen disordersType I: Afibrinogenemia or hypofibrinogenemia are due to quantitative abnormality (decreased antigen) and resulting decreased activityType II: Dysfibrinogenemia is due to functional defects of fibrinogen (fibrinogen antigen level is normal)Patients may present with bleeding disorder (most common), thrombosis, or combination of bleeding and thrombosis, but most are asymptomatic",
                    "sub_points": [
                      "Type I: Afibrinogenemia or hypofibrinogenemia are due to quantitative abnormality (decreased antigen) and resulting decreased activity",
                      "Type II: Dysfibrinogenemia is due to functional defects of fibrinogen (fibrinogen antigen level is normal)",
                      "Patients may present with bleeding disorder (most common), thrombosis, or combination of bleeding and thrombosis, but most are asymptomatic"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Thrombin time (TT) is best screening test; time will be prolonged"
                  },
                  {
                    "text": "Reptilase time is used to evaluate prolonged TTProlonged in hypofibrinogenemia and dysfibrinogenemiaNot prolonged in presence of heparin",
                    "sub_points": [
                      "Prolonged in hypofibrinogenemia and dysfibrinogenemia",
                      "Not prolonged in presence of heparin"
                    ]
                  },
                  {
                    "text": "Confirmatory test is ratio of fibrinogen activity to antigen; decreased (ratio < 0.7) in dysfibrinogenemia (acquired and congenital)Liver function tests should be performed to differentiate inherited dysfibrinogenemia from acquired dysfibrinogenemia",
                    "sub_points": [
                      "Liver function tests should be performed to differentiate inherited dysfibrinogenemia from acquired dysfibrinogenemia"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Typically, dysfibrinogenemias are functional defects of fibrinogenFibrinogen activity is low, but fibrinogen antigen level is normal",
                    "sub_points": [
                      "Fibrinogen activity is low, but fibrinogen antigen level is normal"
                    ]
                  },
                  {
                    "text": "Acquired dysfibrinogenemiaTypically due to structural defect in fibrinogenSeen in patients with severe liver disease or (rarely) renal cell carcinoma",
                    "sub_points": [
                      "Typically due to structural defect in fibrinogen",
                      "Seen in patients with severe liver disease or (rarely) renal cell carcinoma"
                    ]
                  },
                  {
                    "text": "Congenital fibrinogen disordersType I: Afibrinogenemia or hypofibrinogenemiaQuantitative abnormality (decreased antigen) and resulting decreased activityType II: DysfibrinogenemiaDue to functional defects of fibrinogen (fibrinogen antigen level is normal)Missense mutations (most common), insertions, or deletions in Aα, Bβ, or γ genes of fibrinogen lead to functionally defective fibrinogen moleculeFew genotypes can clearly predict clinical phenotypeMost frequent mutations are in N-terminus of Aα chain or in C-terminus of γ chainAutosomal dominant inheritance",
                    "sub_points": [
                      "Type I: Afibrinogenemia or hypofibrinogenemiaQuantitative abnormality (decreased antigen) and resulting decreased activity",
                      "Quantitative abnormality (decreased antigen) and resulting decreased activity",
                      "Type II: DysfibrinogenemiaDue to functional defects of fibrinogen (fibrinogen antigen level is normal)Missense mutations (most common), insertions, or deletions in Aα, Bβ, or γ genes of fibrinogen lead to functionally defective fibrinogen moleculeFew genotypes can clearly predict clinical phenotypeMost frequent mutations are in N-terminus of Aα chain or in C-terminus of γ chainAutosomal dominant inheritance",
                      "Due to functional defects of fibrinogen (fibrinogen antigen level is normal)",
                      "Missense mutations (most common), insertions, or deletions in Aα, Bβ, or γ genes of fibrinogen lead to functionally defective fibrinogen moleculeFew genotypes can clearly predict clinical phenotypeMost frequent mutations are in N-terminus of Aα chain or in C-terminus of γ chain",
                      "Few genotypes can clearly predict clinical phenotype",
                      "Most frequent mutations are in N-terminus of Aα chain or in C-terminus of γ chain",
                      "Autosomal dominant inheritance"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "No racial or gender predilections"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Patients with congenital dysfibrinogenemia may present with bleeding disorder (most common), thrombosis, or combination of bleeding and thrombosis, but most are asymptomaticMore than 200 different mutations have been identifiedSome mutations lead to fibrin clot that cannot be stabilized, which results in bleeding episodesOther mutations lead to fibrinogen molecule that is resistant to fibrinolysis, leading to thrombotic eventsSpontaneous abortions and postpartum hemorrhage have been reportedMost thrombotic events are venous thromboemboliOne variant of dysfibrinogenemia is caused by mutation in Aα-chain and is associated with amyloidosis",
                    "sub_points": [
                      "More than 200 different mutations have been identifiedSome mutations lead to fibrin clot that cannot be stabilized, which results in bleeding episodesOther mutations lead to fibrinogen molecule that is resistant to fibrinolysis, leading to thrombotic events",
                      "Some mutations lead to fibrin clot that cannot be stabilized, which results in bleeding episodes",
                      "Other mutations lead to fibrinogen molecule that is resistant to fibrinolysis, leading to thrombotic events",
                      "Spontaneous abortions and postpartum hemorrhage have been reported",
                      "Most thrombotic events are venous thromboemboli",
                      "One variant of dysfibrinogenemia is caused by mutation in Aα-chain and is associated with amyloidosis"
                    ]
                  },
                  {
                    "text": "Patients with acquired dysfibrinogenemia usually present with bleeding characterized by epistaxis, postoperative bleeding, easy bruising, or poor wound healing"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Very few evidence-based guidelines exist due to rarity of disorder and lack of studies"
                  },
                  {
                    "text": "Patient should be treated with fresh frozen plasma, cryoprecipitate, or fibrinogen concentrates to control bleeding; or, if patient is known to bleed, may be treated prophylactically, prior to surgeryFibrinogen concentrates are preferred because of viral inactivation, standardization of dose, and lower risk of transfusion reactions (including volume overload)Maintain fibrinogen activity > 1 mg/dLRisk of thrombosis increases with fibrinogen concentrates, so patient should be closely monitored",
                    "sub_points": [
                      "Fibrinogen concentrates are preferred because of viral inactivation, standardization of dose, and lower risk of transfusion reactions (including volume overload)",
                      "Maintain fibrinogen activity > 1 mg/dL",
                      "Risk of thrombosis increases with fibrinogen concentrates, so patient should be closely monitored"
                    ]
                  },
                  {
                    "text": "Low molecular weight heparin (LMWH) is used to treat thrombosisWarfarin should be avoided because these patients have baseline elevated prothrombin time (PT)",
                    "sub_points": [
                      "Warfarin should be avoided because these patients have baseline elevated prothrombin time (PT)"
                    ]
                  },
                  {
                    "text": "Obstetric patientsHemorrhage due to placental abruption is commonPostpartum thrombosis is common complicationCaesarean delivery with fibrinogen concentrates should be performedFibrinogen concentrates with LMWH prophylaxis should be considered for obstetric patients with recurrent miscarriages",
                    "sub_points": [
                      "Hemorrhage due to placental abruption is common",
                      "Postpartum thrombosis is common complication",
                      "Caesarean delivery with fibrinogen concentrates should be performed",
                      "Fibrinogen concentrates with LMWH prophylaxis should be considered for obstetric patients with recurrent miscarriages"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Prothrombin Time and Activated Partial Thromboplastin Time": [
                  {
                    "text": "Patients present with abnormal PT and activated partial thromboplastin time (aPTT) coagulation results"
                  }
                ],
                "Thrombin Time": [
                  {
                    "text": "Thrombin time (TT) is best screening testTime will be prolongedPatient's citrated plasma is mixed with standard amount of thrombinRate of clot formation is then calculatedPatients with dysfibrinogenemia have prolonged TT because dysfunctional fibrinogen cannot be converted to fibrin by exogenous thrombin; therefore, clotting time is prolonged",
                    "sub_points": [
                      "Time will be prolonged",
                      "Patient's citrated plasma is mixed with standard amount of thrombin",
                      "Rate of clot formation is then calculated",
                      "Patients with dysfibrinogenemia have prolonged TT because dysfunctional fibrinogen cannot be converted to fibrin by exogenous thrombin; therefore, clotting time is prolonged"
                    ]
                  },
                  {
                    "text": "Only 1 variant of inherited dysfibrinogenemia that causes shortened TT has been documented"
                  }
                ],
                "Reptilase Time": [
                  {
                    "text": "Used to evaluate prolonged TT"
                  },
                  {
                    "text": "Same principle as TT, except reptilase (snake venom) is added to patient plasma instead of thrombinProlonged in hypofibrinogenemia and dysfibrinogenemiaNot prolonged in presence of heparin",
                    "sub_points": [
                      "Prolonged in hypofibrinogenemia and dysfibrinogenemia",
                      "Not prolonged in presence of heparin"
                    ]
                  }
                ],
                "Fibrinogen Activity-to-Antigen Ratio": [
                  {
                    "text": "Confirmatory test1) Determine fibrinogen activityHigh concentration of thrombin is added to patient platelet-poor plasmaRate of clot formation (Clauss method) is measuredActivity is determined by reading off standardized curve of fibrinogen activity vs. clot time2) Calculate fibrinogen antigen concentration using immunoassays or precipitation-based methodsNumerous preanalytical variables can influence fibrinogen antigen concentration, such as acute illness (acute phase reactant), nephrotic syndrome, pregnancy, liver disease, and estrogen replacement therapy",
                    "sub_points": [
                      "1) Determine fibrinogen activityHigh concentration of thrombin is added to patient platelet-poor plasmaRate of clot formation (Clauss method) is measuredActivity is determined by reading off standardized curve of fibrinogen activity vs. clot time",
                      "High concentration of thrombin is added to patient platelet-poor plasma",
                      "Rate of clot formation (Clauss method) is measured",
                      "Activity is determined by reading off standardized curve of fibrinogen activity vs. clot time",
                      "2) Calculate fibrinogen antigen concentration using immunoassays or precipitation-based methodsNumerous preanalytical variables can influence fibrinogen antigen concentration, such as acute illness (acute phase reactant), nephrotic syndrome, pregnancy, liver disease, and estrogen replacement therapy",
                      "Numerous preanalytical variables can influence fibrinogen antigen concentration, such as acute illness (acute phase reactant), nephrotic syndrome, pregnancy, liver disease, and estrogen replacement therapy"
                    ]
                  },
                  {
                    "text": "Ratio of fibrinogen activity to antigen is decreased (ratio < 0.7) in dysfibrinogenemia (acquired and congenital)Liver function tests should be performed to differentiate inherited dysfibrinogenemia from acquired dysfibrinogenemia",
                    "sub_points": [
                      "Liver function tests should be performed to differentiate inherited dysfibrinogenemia from acquired dysfibrinogenemia"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Disseminated Intravascular Coagulation (DIC)": {
            "name": "Disseminated Intravascular Coagulation (DIC)",
            "url": "https://app.pathprimer.com/document/7f2eb0a5-0636-48a8-97d3-320797618701/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "DIC is a systemic disease caused by a serious underlying disease with potential for both hemorrhage and thrombosisSimultaneous formation of thrombin and plasminBalance between thrombin and plasmin formation determines the prothrombotic versus hemorrhagic state, respectively",
                    "sub_points": [
                      "Simultaneous formation of thrombin and plasminBalance between thrombin and plasmin formation determines the prothrombotic versus hemorrhagic state, respectively",
                      "Balance between thrombin and plasmin formation determines the prothrombotic versus hemorrhagic state, respectively"
                    ]
                  },
                  {
                    "text": "DIC is a clinical diagnosis"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Common laboratory abnormalities in DICProlonged PT and APTT (can be normal in prothrombotic state)Decreased fibrinogen (can be normal-elevated in prothrombotic state)ThrombocytopeniaElevated plasma D-dimer test results",
                    "sub_points": [
                      "Prolonged PT and APTT (can be normal in prothrombotic state)",
                      "Decreased fibrinogen (can be normal-elevated in prothrombotic state)",
                      "Thrombocytopenia",
                      "Elevated plasma D-dimer test results"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Classic Clinical Findings": [
                  {
                    "text": "DIC is a clinical diagnosis"
                  },
                  {
                    "text": "Most common manifestationsBleedingOozing from incisions, mucosal membranes, IV sites, hematuriaThrombosisPurpura fulminans (subdermal microthrombosis with skin necrosis)Limb ischemia and gangreneLoss of visionAcute neurologic thrombotic eventsConcomitant bleeding and thrombosisSingle or multiorgan dysfunctionAcute kidney injuryAdrenal insufficiencyAcute respiratory distress syndromeCardiac ischemia, arrhythmiaCNS abnormalitiesGastrointestinal bleedingLiver dysfunction",
                    "sub_points": [
                      "BleedingOozing from incisions, mucosal membranes, IV sites, hematuria",
                      "Oozing from incisions, mucosal membranes, IV sites, hematuria",
                      "ThrombosisPurpura fulminans (subdermal microthrombosis with skin necrosis)Limb ischemia and gangreneLoss of visionAcute neurologic thrombotic events",
                      "Purpura fulminans (subdermal microthrombosis with skin necrosis)",
                      "Limb ischemia and gangrene",
                      "Loss of vision",
                      "Acute neurologic thrombotic events",
                      "Concomitant bleeding and thrombosis",
                      "Single or multiorgan dysfunctionAcute kidney injuryAdrenal insufficiencyAcute respiratory distress syndromeCardiac ischemia, arrhythmiaCNS abnormalitiesGastrointestinal bleedingLiver dysfunction",
                      "Acute kidney injury",
                      "Adrenal insufficiency",
                      "Acute respiratory distress syndrome",
                      "Cardiac ischemia, arrhythmia",
                      "CNS abnormalities",
                      "Gastrointestinal bleeding",
                      "Liver dysfunction"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "DIC is a systemic disease caused by a serious underlying condition with potential for both hemorrhage and thrombosisActivation of coagulation that is sustained and excessiveLeads to consumption of coagulation factorsConsumption of inhibitory factorsSimultaneous formation of thrombin and plasminBalance between thrombin and plasmin formation determines the prothrombotic vs. hemorrhagic state, respectively",
                    "sub_points": [
                      "Activation of coagulation that is sustained and excessiveLeads to consumption of coagulation factors",
                      "Leads to consumption of coagulation factors",
                      "Consumption of inhibitory factors",
                      "Simultaneous formation of thrombin and plasminBalance between thrombin and plasmin formation determines the prothrombotic vs. hemorrhagic state, respectively",
                      "Balance between thrombin and plasmin formation determines the prothrombotic vs. hemorrhagic state, respectively"
                    ]
                  },
                  {
                    "text": "Examples of common underlying disorders that lead to DICSepsisGram-negative infection (most common)Gram-positive infection (less common)Immunocompromised patients with fungemiaMalignancyAcute promyelocytic leukemiaCarcinomatosisTumor lysis syndromeTrousseau syndromeA sign of malignancy -- thrombophlebitis migrans: recurrent thrombophlebitis that appears in different locationsObstetric complicationsAbruptio placentae and placenta previaRetained dead fetusMassive tissue injuryDuring surgery: Release of thromboplastic material within the tissueBurns",
                    "sub_points": [
                      "SepsisGram-negative infection (most common)Gram-positive infection (less common)Immunocompromised patients with fungemia",
                      "Gram-negative infection (most common)",
                      "Gram-positive infection (less common)",
                      "Immunocompromised patients with fungemia",
                      "MalignancyAcute promyelocytic leukemiaCarcinomatosisTumor lysis syndromeTrousseau syndromeA sign of malignancy -- thrombophlebitis migrans: recurrent thrombophlebitis that appears in different locations",
                      "Acute promyelocytic leukemia",
                      "Carcinomatosis",
                      "Tumor lysis syndrome",
                      "Trousseau syndromeA sign of malignancy -- thrombophlebitis migrans: recurrent thrombophlebitis that appears in different locations",
                      "A sign of malignancy -- thrombophlebitis migrans: recurrent thrombophlebitis that appears in different locations",
                      "Obstetric complicationsAbruptio placentae and placenta previaRetained dead fetus",
                      "Abruptio placentae and placenta previa",
                      "Retained dead fetus",
                      "Massive tissue injuryDuring surgery: Release of thromboplastic material within the tissueBurns",
                      "During surgery: Release of thromboplastic material within the tissue",
                      "Burns"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Primary treatment should be controlling the underlying illness"
                  },
                  {
                    "text": "Platelet transfusion for thrombocytopenia < 50,000/µL"
                  },
                  {
                    "text": "Plasma or cryoprecipitate to replace fibrinogen (< 60 mg/dL)"
                  },
                  {
                    "text": "Plasma to replace coagulation factors (< 25% normal activity)"
                  },
                  {
                    "text": "Heparin therapy remains extremely controversialIn some studies, infusion of heparin has seemed to increase mortality (hemorrhagic)Decrease thrombotic events if thrombotic risk is greater than bleedingShould be used if Trousseau syndrome is underlying illnessMay also be useful in purpura fulminans and acute promyelocytic leukemia, each of which represents a subacute thrombotic form of DIC",
                    "sub_points": [
                      "In some studies, infusion of heparin has seemed to increase mortality (hemorrhagic)",
                      "Decrease thrombotic events if thrombotic risk is greater than bleeding",
                      "Should be used if Trousseau syndrome is underlying illness",
                      "May also be useful in purpura fulminans and acute promyelocytic leukemia, each of which represents a subacute thrombotic form of DIC"
                    ]
                  },
                  {
                    "text": "Antifibrinolytic inhibitors (e.g., e-aminocaproic acid) occasionally advocated when hemorrhagic risk is greater than thrombotic riskIf bleeding does not decrease within 24 hours, it is unlikely to do so later",
                    "sub_points": [
                      "If bleeding does not decrease within 24 hours, it is unlikely to do so later"
                    ]
                  },
                  {
                    "text": "Recombinant factor VIIaEfficacy of factor VIIa in reported cases seems impressiveRisk of thrombotic complications is a major concern",
                    "sub_points": [
                      "Efficacy of factor VIIa in reported cases seems impressive",
                      "Risk of thrombotic complications is a major concern"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Depends on underlying cause and approach to treatment"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Severe hepatic cirrhosis: Similar laboratory profile"
                  },
                  {
                    "text": "Dilutional coagulopathy"
                  },
                  {
                    "text": "HELLP (hemolysis, elevated liver function tests, and low platelets) syndrome"
                  },
                  {
                    "text": "Preeclampsia/eclampsia"
                  },
                  {
                    "text": "Massive thrombosis"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP)"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "DIC is a clinical diagnosis and treatment should not be based exclusively on laboratory results"
                  },
                  {
                    "text": "Common laboratory abnormalities in DICProlonged prothrombin time (PT) and activated partial thromboplastin time (APTT) (both can be normal in prothrombotic state)Decreased fibrinogen (can be normal-elevated in prothrombotic state)ThrombocytopeniaElevated plasma D-dimer test results",
                    "sub_points": [
                      "Prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT) (both can be normal in prothrombotic state)",
                      "Decreased fibrinogen (can be normal-elevated in prothrombotic state)",
                      "Thrombocytopenia",
                      "Elevated plasma D-dimer test results"
                    ]
                  },
                  {
                    "text": "Coagulation factor levels reduced"
                  },
                  {
                    "text": "Reduced levels of natural anticoagulants ATIII, plasminogen, and α2-PI"
                  },
                  {
                    "text": "Circulating levels of plasminogen activator inhibitor-1 (PAI-1) paradoxically elevatedAcute-phase reactantInhibits the fibrinolytic system, which leads to massive thrombosis, organ dysfunction, and death",
                    "sub_points": [
                      "Acute-phase reactant",
                      "Inhibits the fibrinolytic system, which leads to massive thrombosis, organ dysfunction, and death"
                    ]
                  }
                ],
                "Analytic Techniques": [
                  {
                    "text": "D-dimer testImmunonephelometric assayLatex agglutination assayMeasures insoluble cross-linked fibrin degradation products that arose from plasmin cleavage of cross-linked fibrinD-dimer is sensitive, but not specific for DIC (elevated in wide variety of thrombotic conditions)With careful establishment of a cut-off value, the D-dimer test may be used in concert with clinical findings to rule out deep vein thrombosis or pulmonary embolism",
                    "sub_points": [
                      "Immunonephelometric assay",
                      "Latex agglutination assay",
                      "Measures insoluble cross-linked fibrin degradation products that arose from plasmin cleavage of cross-linked fibrin",
                      "D-dimer is sensitive, but not specific for DIC (elevated in wide variety of thrombotic conditions)",
                      "With careful establishment of a cut-off value, the D-dimer test may be used in concert with clinical findings to rule out deep vein thrombosis or pulmonary embolism"
                    ]
                  },
                  {
                    "text": "Fibrin degradation products (FDPs)FDPs can be produced from plasmin-cleaved fibrinogen, soluble fibrin, or insoluble fibrinIncrease in FDPs is not specifically a measure of plasmin-cleaved, insoluble, cross-linked fibrin equivalent to that obtained with the D-dimer assay",
                    "sub_points": [
                      "FDPs can be produced from plasmin-cleaved fibrinogen, soluble fibrin, or insoluble fibrin",
                      "Increase in FDPs is not specifically a measure of plasmin-cleaved, insoluble, cross-linked fibrin equivalent to that obtained with the D-dimer assay"
                    ]
                  },
                  {
                    "text": "Fibrin monomerLarge molecular mass protein of fibrinogen that remains after fibrinopeptides A and B are liberatedCan be elevated in DIC, but if DIC is severe, it may be absentUnreliable assay for use in recognizing DIC",
                    "sub_points": [
                      "Large molecular mass protein of fibrinogen that remains after fibrinopeptides A and B are liberated",
                      "Can be elevated in DIC, but if DIC is severe, it may be absent",
                      "Unreliable assay for use in recognizing DIC"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Factor XIII Deficiency": {
            "name": "Factor XIII Deficiency",
            "url": "https://app.pathprimer.com/document/27098af9-0316-45e2-85ae-a001d873c3cd/lesson/59c68187-e049-4053-ae9f-4fba2bbc1724",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Factor XIII stabilizes fibrin by cross-linking fibrin fibers"
                  },
                  {
                    "text": "Forms peptide bonds on specific amino acid residues of alpha and gamma chains"
                  },
                  {
                    "text": "Clot characteristics in patients with factor XIII deficiencyUnstable because fibrin is only held together with hydrogen bonds and electrostatic forcesExtremely sensitive to fibrinolysis",
                    "sub_points": [
                      "Unstable because fibrin is only held together with hydrogen bonds and electrostatic forces",
                      "Extremely sensitive to fibrinolysis"
                    ]
                  },
                  {
                    "text": "Autosomal recessive inheritance"
                  },
                  {
                    "text": "Bleeding manifestations present in early lifeUmbilical stump bleeding in ~ 80% of patientsSevere bleeding after circumcisionRecurrent gum bleeding with teething",
                    "sub_points": [
                      "Umbilical stump bleeding in ~ 80% of patients",
                      "Severe bleeding after circumcision",
                      "Recurrent gum bleeding with teething"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Normal PT and aPTT, platelet count, thrombin time, and bleeding time"
                  },
                  {
                    "text": "Clot stability testAbnormal clot solubility in 5 M/L urea or 1% monochloroacetic acid; clot dissolves more quickly than control",
                    "sub_points": [
                      "Abnormal clot solubility in 5 M/L urea or 1% monochloroacetic acid; clot dissolves more quickly than control"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Factor XIII stabilizes fibrin by cross-linking fibrin fibers"
                  },
                  {
                    "text": "Forms peptide bonds on specific amino acid residues of alpha and gamma chains"
                  },
                  {
                    "text": "Clot characteristics in patients with factor XIII deficiencyUnstable because fibrin is only held together with hydrogen bonds and electrostatic forcesExtremely sensitive to fibrinolysis",
                    "sub_points": [
                      "Unstable because fibrin is only held together with hydrogen bonds and electrostatic forces",
                      "Extremely sensitive to fibrinolysis"
                    ]
                  },
                  {
                    "text": "Factor XIII is found in plasma and in plateletsCirculates in plasma as tetramer with 2 catalytic A subunits and 2 B subunits that function as carriers for A subunitsPlatelet factor XIII is dimer of 2 A subunitsPlatelet factor XIII accounts for 50% of total factor XIII activity",
                    "sub_points": [
                      "Circulates in plasma as tetramer with 2 catalytic A subunits and 2 B subunits that function as carriers for A subunits",
                      "Platelet factor XIII is dimer of 2 A subunitsPlatelet factor XIII accounts for 50% of total factor XIII activity",
                      "Platelet factor XIII accounts for 50% of total factor XIII activity"
                    ]
                  },
                  {
                    "text": "Factor XIII deficiency classified into factor XIII-A and factor XIII-B deficienciesMost cases are due to lack of A subunitsFXIII-A type I and type II are quantitative and qualitative defects, respectively",
                    "sub_points": [
                      "Most cases are due to lack of A subunitsFXIII-A type I and type II are quantitative and qualitative defects, respectively",
                      "FXIII-A type I and type II are quantitative and qualitative defects, respectively"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Autosomal recessive inheritance"
                  },
                  {
                    "text": "Incidence is < 1 per 1 million people"
                  },
                  {
                    "text": "Consanguinity is frequently found in affected individuals"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Symptomatic individuals have < 1% normal factor XIII activity"
                  },
                  {
                    "text": "Bleeding manifestations present in early lifeUmbilical stump bleeding in ~ 80% patientsSevere bleeding after circumcisionRecurrent gum bleeding with teething",
                    "sub_points": [
                      "Umbilical stump bleeding in ~ 80% patients",
                      "Severe bleeding after circumcision",
                      "Recurrent gum bleeding with teething"
                    ]
                  },
                  {
                    "text": "Bleeding manifestationsHematomaSoft tissue hemorrhagePseudotumor formation with poor wound healingIntracranial hemorrhage (30% of patients), which can be spontaneous",
                    "sub_points": [
                      "Hematoma",
                      "Soft tissue hemorrhage",
                      "Pseudotumor formation with poor wound healing",
                      "Intracranial hemorrhage (30% of patients), which can be spontaneous"
                    ]
                  },
                  {
                    "text": "Men: Oligospermia and infertility"
                  },
                  {
                    "text": "Women: Recurrent pregnancy loss"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Minimal factor XIII activity is necessary (~ 5%) to prevent bleeding"
                  },
                  {
                    "text": "Factor XIII half-life is long (9-10 days)"
                  },
                  {
                    "text": "Prophylactic therapy is feasible and indicated, especially if treating intracranial bleeding2-3 mL plasma per kg of body weight every 3-4 weeksCryoprecipitate 1 unit per 10-20 kg of body weight every 3-4 weeksPlasma-derived pasteurized factor XIII every 4-6 weeks",
                    "sub_points": [
                      "2-3 mL plasma per kg of body weight every 3-4 weeks",
                      "Cryoprecipitate 1 unit per 10-20 kg of body weight every 3-4 weeks",
                      "Plasma-derived pasteurized factor XIII every 4-6 weeks"
                    ]
                  },
                  {
                    "text": "Pregnancy and factor XIII-A deficiencyReplacement therapy early in pregnancy with concentrate and target level higher than 10% factor XIII",
                    "sub_points": [
                      "Replacement therapy early in pregnancy with concentrate and target level higher than 10% factor XIII"
                    ]
                  },
                  {
                    "text": "Complications of component therapyTransfusion transmitted infectionTransfusion reactionsAllergicFebrile nonhemolyticCirculatory overloadTransfusion-related acute lung injuryDevelopment of antibodies against factor XIIIFactor XIII antibodies can be difficult to treatAdministration of plasma, cryoprecipitate, factor XIII concentratesExchange transfusion may be necessaryImmunosuppression with intravenous immune globulin, cyclophosphamide, steroid, rituximab",
                    "sub_points": [
                      "Transfusion transmitted infection",
                      "Transfusion reactionsAllergicFebrile nonhemolyticCirculatory overloadTransfusion-related acute lung injury",
                      "Allergic",
                      "Febrile nonhemolytic",
                      "Circulatory overload",
                      "Transfusion-related acute lung injury",
                      "Development of antibodies against factor XIIIFactor XIII antibodies can be difficult to treatAdministration of plasma, cryoprecipitate, factor XIII concentratesExchange transfusion may be necessaryImmunosuppression with intravenous immune globulin, cyclophosphamide, steroid, rituximab",
                      "Factor XIII antibodies can be difficult to treatAdministration of plasma, cryoprecipitate, factor XIII concentratesExchange transfusion may be necessaryImmunosuppression with intravenous immune globulin, cyclophosphamide, steroid, rituximab",
                      "Administration of plasma, cryoprecipitate, factor XIII concentrates",
                      "Exchange transfusion may be necessary",
                      "Immunosuppression with intravenous immune globulin, cyclophosphamide, steroid, rituximab"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Acquired factor XIII deficiencyDecreased factor XIII reported in Henoch-Schönlein purpura, Crohn disease, ulcerative colitis",
                    "sub_points": [
                      "Decreased factor XIII reported in Henoch-Schönlein purpura, Crohn disease, ulcerative colitis"
                    ]
                  },
                  {
                    "text": "Anti-factor XIII autoantibodies (e.g., SLE)"
                  },
                  {
                    "text": "Autoantibodies associated with isoniazid, penicillin, phenytoin"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Routine Coagulation Testing": [
                  {
                    "text": "Normal prothrombin time (PT) and activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Normal platelet count"
                  },
                  {
                    "text": "Normal thrombin time"
                  },
                  {
                    "text": "Normal bleeding time"
                  }
                ],
                "Specialty Coagulation Testing": [
                  {
                    "text": "Clot stability testAbnormal clot solubility in 5 M/L urea or 1% monochloroacetic acidTest methodClot removed from thrombin-treated plasma samplesClots from affected patient dissolve rapidly (within a few minutes) in 5M/L urea or 1% monochloroacetic acidClots from normal plasma remain insoluble for 24 hoursTest is qualitative and detects only severe factor XIII deficiencyDeficiency should be confirmed with quantitative test",
                    "sub_points": [
                      "Abnormal clot solubility in 5 M/L urea or 1% monochloroacetic acid",
                      "Test methodClot removed from thrombin-treated plasma samplesClots from affected patient dissolve rapidly (within a few minutes) in 5M/L urea or 1% monochloroacetic acidClots from normal plasma remain insoluble for 24 hoursTest is qualitative and detects only severe factor XIII deficiency",
                      "Clot removed from thrombin-treated plasma samples",
                      "Clots from affected patient dissolve rapidly (within a few minutes) in 5M/L urea or 1% monochloroacetic acid",
                      "Clots from normal plasma remain insoluble for 24 hours",
                      "Test is qualitative and detects only severe factor XIII deficiency",
                      "Deficiency should be confirmed with quantitative test"
                    ]
                  },
                  {
                    "text": "Mixing studyMixture of patient plasma and normal plasma can be used to rule out a factor XIII inhibitor",
                    "sub_points": [
                      "Mixture of patient plasma and normal plasma can be used to rule out a factor XIII inhibitor"
                    ]
                  },
                  {
                    "text": "Quantitative assayDetermines factor XIII levelAmine-casein incorporation assay or ammonia production through transamidase activity",
                    "sub_points": [
                      "Determines factor XIII level",
                      "Amine-casein incorporation assay or ammonia production through transamidase activity"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Thrombotic Disorders": {
        "name": "Thrombotic Disorders",
        "url": "https://app.pathprimer.com/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
        "topics": {
          "Evaluation of Thrombosis in a Patient": {
            "name": "Evaluation of Thrombosis in a Patient",
            "url": "https://app.pathprimer.com/document/99b80a8f-04dd-4c0a-96a5-76c28c7ceef6/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Thrombophilia is acquired or inherited predisposition to thrombosis"
                  },
                  {
                    "text": "VTE is major health problem with incidence of 300,000 new cases/yrIn 25% of patients, first symptom of pulmonary embolism is sudden deathOf patients with idiopathic VTE, 50% have underlying hereditary thrombophilia",
                    "sub_points": [
                      "In 25% of patients, first symptom of pulmonary embolism is sudden death",
                      "Of patients with idiopathic VTE, 50% have underlying hereditary thrombophilia"
                    ]
                  },
                  {
                    "text": "Thrombophilia risk factors include acquired and inherited factorsPatients hospitalized for medical and surgical disordersActive malignancy accounts for 20% of VTE in communityMyeloproliferative syndromesOral contraceptives, estrogen replacement therapy, estrogen receptor modulators in treatment of breast cancerHereditary thrombophilias (e.g., activated protein C resistance, protein C or S deficiency, antithrombin deficiency, prothrombin mutations, dysfibrinogenemia, hyperhomocysteinemia, elevated factor VIII activity)",
                    "sub_points": [
                      "Patients hospitalized for medical and surgical disorders",
                      "Active malignancy accounts for 20% of VTE in community",
                      "Myeloproliferative syndromes",
                      "Oral contraceptives, estrogen replacement therapy, estrogen receptor modulators in treatment of breast cancer",
                      "Hereditary thrombophilias (e.g., activated protein C resistance, protein C or S deficiency, antithrombin deficiency, prothrombin mutations, dysfibrinogenemia, hyperhomocysteinemia, elevated factor VIII activity)"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "No single laboratory test can screen or diagnose all thrombophilias"
                  },
                  {
                    "text": "Testing may give erroneous results after acute thrombosis"
                  }
                ]
              },
              "OVERVIEW": {
                "General Overview": [
                  {
                    "text": "Thrombophilia is acquired or inherited predisposition to thrombosis"
                  },
                  {
                    "text": "Most common presentation of thrombophilia is venous thromboembolism (VTE)"
                  },
                  {
                    "text": "Most individuals with thrombophilia do not have thrombotic event\"Second hit\" triggers thrombotic eventFor example, inherited thrombophilia plus acute malignancy",
                    "sub_points": [
                      "\"Second hit\" triggers thrombotic eventFor example, inherited thrombophilia plus acute malignancy",
                      "For example, inherited thrombophilia plus acute malignancy"
                    ]
                  },
                  {
                    "text": "VTE is major health problem with incidence of 300,000 new cases/yr"
                  },
                  {
                    "text": "In 25% of patients, first symptom of pulmonary embolism is sudden death"
                  },
                  {
                    "text": "Of patients with idiopathic VTE, 50% have underlying hereditary thrombophilia"
                  },
                  {
                    "text": "Thrombophilia risk factors include acquired and inherited factorsPatients hospitalized for medical and surgical disordersOlder age, high body mass index, neurologic disease, immobility, fracture, intensive care admissionActive malignancy accounts for 20% of VTE in communityMyeloproliferative syndromesOral contraceptives, estrogen replacement therapy, estrogen receptor modulators in treatment of breast cancerHereditary thrombophiliasActivated protein C resistance, protein C or S deficiency, antithrombin deficiency, prothrombin mutations, dysfibrinogenemia, hyperhomocysteinemia, elevated factor VIII activityAntiphospholipid antibody syndromeHeparin-induced thrombocytopeniaCentral venous catheter or transvenous pacemakerAtherosclerosis",
                    "sub_points": [
                      "Patients hospitalized for medical and surgical disordersOlder age, high body mass index, neurologic disease, immobility, fracture, intensive care admission",
                      "Older age, high body mass index, neurologic disease, immobility, fracture, intensive care admission",
                      "Active malignancy accounts for 20% of VTE in community",
                      "Myeloproliferative syndromes",
                      "Oral contraceptives, estrogen replacement therapy, estrogen receptor modulators in treatment of breast cancer",
                      "Hereditary thrombophiliasActivated protein C resistance, protein C or S deficiency, antithrombin deficiency, prothrombin mutations, dysfibrinogenemia, hyperhomocysteinemia, elevated factor VIII activity",
                      "Activated protein C resistance, protein C or S deficiency, antithrombin deficiency, prothrombin mutations, dysfibrinogenemia, hyperhomocysteinemia, elevated factor VIII activity",
                      "Antiphospholipid antibody syndrome",
                      "Heparin-induced thrombocytopenia",
                      "Central venous catheter or transvenous pacemaker",
                      "Atherosclerosis"
                    ]
                  }
                ],
                "Indications for Thrombophilia Testing": [
                  {
                    "text": "No absolute indications to initiate thrombophilia work-up"
                  },
                  {
                    "text": "Common practicesTesting after idiopathic thrombotic eventIdiopathic thrombosis in young patient (< 50 yr old)Thrombosis at an unusual siteSagittal sinus, portal vein, mesenteric vessels, renal vesselsRecurrent fetal lossNeonatal purpura fulminansFirst-degree family members of patient with diagnosis of inherited thrombophiliaSelected screening of at-risk populationsWomen before starting oral contraceptive therapy or estrogen replacement therapy",
                    "sub_points": [
                      "Testing after idiopathic thrombotic event",
                      "Idiopathic thrombosis in young patient (< 50 yr old)",
                      "Thrombosis at an unusual siteSagittal sinus, portal vein, mesenteric vessels, renal vessels",
                      "Sagittal sinus, portal vein, mesenteric vessels, renal vessels",
                      "Recurrent fetal loss",
                      "Neonatal purpura fulminans",
                      "First-degree family members of patient with diagnosis of inherited thrombophilia",
                      "Selected screening of at-risk populationsWomen before starting oral contraceptive therapy or estrogen replacement therapy",
                      "Women before starting oral contraceptive therapy or estrogen replacement therapy"
                    ]
                  }
                ],
                "Screening Family Members": [
                  {
                    "text": "Reasons for testing family membersRisk factor modification or prophylaxisResult of genetic testing does not justify starting thromboprophylaxis",
                    "sub_points": [
                      "Risk factor modification or prophylaxis",
                      "Result of genetic testing does not justify starting thromboprophylaxis"
                    ]
                  },
                  {
                    "text": "Genetic counseling should be provided before testingInformed consent required because genetic testing may affect ability to obtain life or disability insurance or employmentNonpaternity can be identified on testing",
                    "sub_points": [
                      "Informed consent required because genetic testing may affect ability to obtain life or disability insurance or employment",
                      "Nonpaternity can be identified on testing"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Testing Depends on Clinical Situation": [
                  {
                    "text": "Thrombophilia testing is complex and depends on whether thrombophilia is weak or strong predictor of thrombosis"
                  },
                  {
                    "text": "Thrombophilia testing requires clinical history to direct work-up toward inherited or acquired disorders"
                  },
                  {
                    "text": "No single laboratory test can screen or diagnose all thrombophilias"
                  },
                  {
                    "text": "Testing may give erroneous results after acute thrombosisProtein C, protein S, and antithrombin may be low after acute thrombosisTesting should be performed, or repeated, after resolution of acute eventPatients should be tested off anticoagulantsWarfarin decreases protein C and protein SHeparin decreases antithrombinDecreased coagulation factor activity due to anticoagulation interferes with functional coagulation assays such as lupus anticoagulants and natural anticoagulantsAcute inflammation can result in nonpathologic antiphospholipid antibodies and elevation of acute phase reactants (factor VIII and fibrinogen)",
                    "sub_points": [
                      "Protein C, protein S, and antithrombin may be low after acute thrombosis",
                      "Testing should be performed, or repeated, after resolution of acute event",
                      "Patients should be tested off anticoagulantsWarfarin decreases protein C and protein SHeparin decreases antithrombinDecreased coagulation factor activity due to anticoagulation interferes with functional coagulation assays such as lupus anticoagulants and natural anticoagulants",
                      "Warfarin decreases protein C and protein S",
                      "Heparin decreases antithrombin",
                      "Decreased coagulation factor activity due to anticoagulation interferes with functional coagulation assays such as lupus anticoagulants and natural anticoagulants",
                      "Acute inflammation can result in nonpathologic antiphospholipid antibodies and elevation of acute phase reactants (factor VIII and fibrinogen)"
                    ]
                  },
                  {
                    "text": "Screening testsComplete blood count with platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, thrombin time (TT)",
                    "sub_points": [
                      "Complete blood count with platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, thrombin time (TT)"
                    ]
                  },
                  {
                    "text": "Specific testsAntiphospholipid antibodiesEnzyme-linked immunosorbent assays (ELISAs) for anticardiolipin antibodies and β-2-glycoprotein-1 antibodiesLupus anticoagulantAt least 2 should be performed: lupus-sensitive PTT, dilute PT, dilute Russell viper venom timeConfirmatory assays: hexagonal phospholipid neutralization, phospholipid neutralizationMixing studyHeparin-induced thrombocytopeniaHeparin-PF4 antibody testingSerotonin release assayHereditary thrombophiliasActivated protein C resistance and factor V Leiden molecular testingProthrombin G20210A polymorphism molecular testingProtein C, protein S, antithrombin antigen and activityFactor VIII activity &/orFVIIIgene polymorphism molecular testingParoxysmal nocturnal hemoglobinuria testingCD55 and CD59 by flow cytometryJAK2mutation for underlying myeloproliferative neoplasmPlasminogen",
                    "sub_points": [
                      "Antiphospholipid antibodiesEnzyme-linked immunosorbent assays (ELISAs) for anticardiolipin antibodies and β-2-glycoprotein-1 antibodiesLupus anticoagulantAt least 2 should be performed: lupus-sensitive PTT, dilute PT, dilute Russell viper venom timeConfirmatory assays: hexagonal phospholipid neutralization, phospholipid neutralizationMixing study",
                      "Enzyme-linked immunosorbent assays (ELISAs) for anticardiolipin antibodies and β-2-glycoprotein-1 antibodies",
                      "Lupus anticoagulantAt least 2 should be performed: lupus-sensitive PTT, dilute PT, dilute Russell viper venom timeConfirmatory assays: hexagonal phospholipid neutralization, phospholipid neutralizationMixing study",
                      "At least 2 should be performed: lupus-sensitive PTT, dilute PT, dilute Russell viper venom time",
                      "Confirmatory assays: hexagonal phospholipid neutralization, phospholipid neutralization",
                      "Mixing study",
                      "Heparin-induced thrombocytopeniaHeparin-PF4 antibody testingSerotonin release assay",
                      "Heparin-PF4 antibody testing",
                      "Serotonin release assay",
                      "Hereditary thrombophiliasActivated protein C resistance and factor V Leiden molecular testingProthrombin G20210A polymorphism molecular testingProtein C, protein S, antithrombin antigen and activityFactor VIII activity &/orFVIIIgene polymorphism molecular testing",
                      "Activated protein C resistance and factor V Leiden molecular testing",
                      "Prothrombin G20210A polymorphism molecular testing",
                      "Protein C, protein S, antithrombin antigen and activity",
                      "Factor VIII activity &/orFVIIIgene polymorphism molecular testing",
                      "Paroxysmal nocturnal hemoglobinuria testingCD55 and CD59 by flow cytometry",
                      "CD55 and CD59 by flow cytometry",
                      "JAK2mutation for underlying myeloproliferative neoplasm",
                      "Plasminogen"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Antithrombin Deficiency": {
            "name": "Antithrombin Deficiency",
            "url": "https://app.pathprimer.com/document/618e8bde-ec8b-4f8d-8740-ff77e682c4c3/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "AT acts as pseudosubstrate by binding to active site of thrombin and factor Xa, as well as factors IXa, XIa, XIIa, high molecular weight kininogen, and prekallikrein, which are then cleared by the liver"
                  },
                  {
                    "text": "Heparin binds to AT, which exposes active site and potentiates activity of AT by approximately 1,000-fold"
                  },
                  {
                    "text": "Thrombotic events (venous more than arterial) starting in 2nd decade of life"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Antithrombin (AT)Serine protease inhibitorActs as pseudosubstrate by binding to active site of thrombin and factor Xa, as well as factors IXa, XIa, XIIa, high molecular weight kininogen and prekallikrein, which are then cleared by the liverHeparin binds to AT, which exposes active site and potentiates AT activity by approximately 1,000-fold",
                    "sub_points": [
                      "Serine protease inhibitor",
                      "Acts as pseudosubstrate by binding to active site of thrombin and factor Xa, as well as factors IXa, XIa, XIIa, high molecular weight kininogen and prekallikrein, which are then cleared by the liver",
                      "Heparin binds to AT, which exposes active site and potentiates AT activity by approximately 1,000-fold"
                    ]
                  },
                  {
                    "text": "Gene for AT isSERPINC1,located on long arm of chromosome 1"
                  },
                  {
                    "text": "Decreased AT activityIncreased risk of venous thromboembolismRecurrent pregnancy loss",
                    "sub_points": [
                      "Increased risk of venous thromboembolism",
                      "Recurrent pregnancy loss"
                    ]
                  },
                  {
                    "text": "AT deficiency can be inherited (as type I or type II) or acquired"
                  },
                  {
                    "text": "Hereditary causesType I: Autosomal dominant; gene deletions or point mutations lead to decreased AT protein and activityType II: Autosomal dominant; functionally abnormal AT molecule; normal AT protein but decreased activityType IIa: Mutations that affect the AT binding siteType IIb: Mutations that affect the heparin binding siteType IIc: Mutations that are near the AT “reactive loop”",
                    "sub_points": [
                      "Type I: Autosomal dominant; gene deletions or point mutations lead to decreased AT protein and activity",
                      "Type II: Autosomal dominant; functionally abnormal AT molecule; normal AT protein but decreased activityType IIa: Mutations that affect the AT binding siteType IIb: Mutations that affect the heparin binding siteType IIc: Mutations that are near the AT “reactive loop”",
                      "Type IIa: Mutations that affect the AT binding site",
                      "Type IIb: Mutations that affect the heparin binding site",
                      "Type IIc: Mutations that are near the AT “reactive loop”"
                    ]
                  },
                  {
                    "text": "Physiologic changesNewbornsAT activity remains unchanged during pregnancyHealthy neonates are born with < 50% of normal adult AT levels, although they are not predisposed to the same thrombotic complications as adults",
                    "sub_points": [
                      "Newborns",
                      "AT activity remains unchanged during pregnancyHealthy neonates are born with < 50% of normal adult AT levels, although they are not predisposed to the same thrombotic complications as adults",
                      "Healthy neonates are born with < 50% of normal adult AT levels, although they are not predisposed to the same thrombotic complications as adults"
                    ]
                  },
                  {
                    "text": "Acquired causesDecreased synthesis: Liver diseaseIncreased consumption: SepsisIncreased clearance: Kidney disease (e.g., nephrotic syndrome); medications (e.g., heparin)",
                    "sub_points": [
                      "Decreased synthesis: Liver disease",
                      "Increased consumption: Sepsis",
                      "Increased clearance: Kidney disease (e.g., nephrotic syndrome); medications (e.g., heparin)"
                    ]
                  },
                  {
                    "text": "Patients with AT deficiency at greater risk for thrombosis than those with protein C or protein S deficiency"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Incidence: Inherited AT deficiency occurs in approximately 1 in 10,000 people"
                  },
                  {
                    "text": "Ethnicity: No racial predilection"
                  },
                  {
                    "text": "Sex: Occurs equally in males and females"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Thrombotic events (venous more than arterial) starting in 2nd decade of life"
                  },
                  {
                    "text": "Thrombosis most often occurs in lower extremities or as pulmonary embolism"
                  },
                  {
                    "text": "Severity of thrombosis varies depending on which mutation is inherited (> 100 different mutations causing AT deficiency have been identified)"
                  },
                  {
                    "text": "Pregnancy complications including fetal loss, preeclampsia, and hypertension"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Prophylactic anticoagulation treatment remains controversial"
                  },
                  {
                    "text": "Heparin may be used during acute thrombotic event"
                  },
                  {
                    "text": "AT concentrate can be used prior to high-risk situations (e.g., major surgery)"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Dysfibrinogenemia"
                  },
                  {
                    "text": "Protein C deficiency"
                  },
                  {
                    "text": "Protein S deficiency"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Antithrombin Activity Assays": [
                  {
                    "text": "Use mostly chromogenic methodsSynthetic thrombin attached to chromogenic peptide substratePatient plasma incubated with synthetic thrombinPatient's AT forms thrombin-antithrombin complex and cleaves synthetic thrombin from chromogenic peptide in 1:1 ratioUnbound chromogenic peptide then emits color, which is detected via spectrophotometryAmount of chromogenic peptide substrate detected is inversely proportional to amount of AT presentSome assays use factor Xa instead of thrombin to avoid interference with heparin cofactor II, which is a naturally occurring substance that inhibits thrombin but not factor XaHeparin cofactor II can cause overestimation of AT levels in thrombin-based assaysOther assays use bovine thrombin, which is not inhibited by heparin cofactor II",
                    "sub_points": [
                      "Synthetic thrombin attached to chromogenic peptide substrate",
                      "Patient plasma incubated with synthetic thrombin",
                      "Patient's AT forms thrombin-antithrombin complex and cleaves synthetic thrombin from chromogenic peptide in 1:1 ratio",
                      "Unbound chromogenic peptide then emits color, which is detected via spectrophotometry",
                      "Amount of chromogenic peptide substrate detected is inversely proportional to amount of AT present",
                      "Some assays use factor Xa instead of thrombin to avoid interference with heparin cofactor II, which is a naturally occurring substance that inhibits thrombin but not factor XaHeparin cofactor II can cause overestimation of AT levels in thrombin-based assays",
                      "Heparin cofactor II can cause overestimation of AT levels in thrombin-based assays",
                      "Other assays use bovine thrombin, which is not inhibited by heparin cofactor II"
                    ]
                  }
                ],
                "Antithrombin Antigen Measurement": [
                  {
                    "text": "Enzyme-linked immunoassay (ELISA)"
                  },
                  {
                    "text": "Latex immunoassay"
                  },
                  {
                    "text": "As with other immunoassays, interferences with hemolysis, lipemia, hyperbilirubinemia, rheumatoid factor, heterophilic antibodies"
                  },
                  {
                    "text": "Type 1: Decreased AT antigen and activity"
                  },
                  {
                    "text": "Type 2: Normal AT antigen but decreased activity"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Protein S Deficiency": {
            "name": "Protein S Deficiency",
            "url": "https://app.pathprimer.com/document/b40457d3-0d17-4cc4-90dc-4d0e5ad8b683/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Protein S acts as cofactor for activated protein C, which then﻿ inactivates factor Va and VIIIa"
                  },
                  {
                    "text": "Vitamin K-dependent; mainly produced in liver, but also endothelium and megakaryocytes"
                  },
                  {
                    "text": "Deficiency can be inherited (autosomal dominant) or acquired (more common)"
                  },
                  {
                    "text": "Patients at increased risk for venous thromboembolism (VTE), particularly in lower extremities, at young age (< 45 years)"
                  },
                  {
                    "text": "Recurrent fetal loss"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Antigen (quantitative) and activity (function) tests can be performed for protein S"
                  },
                  {
                    "text": "Tests for protein S deficiency should not be ordered during acute thrombotic episode or while patient is on warfarin"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Protein SActs as cofactor for activated protein C, which then﻿ inactivates factor Va and VIIIaMay also directly inhibit factors Va and Xa in prothrombinase complex, and factor VIIIa in tenase complexProthrombinase complex converts the inactive prothrombin to active thrombinFactors VIIIa and IXa combine to form the tenase complex which then go on to activate factor XVitamin K–dependent; mainly produced in liver, but also endothelium and megakaryocytesApproximately 60% is bound to C4b-binding protein; remaining 40% of free protein S is functionally active",
                    "sub_points": [
                      "Acts as cofactor for activated protein C, which then﻿ inactivates factor Va and VIIIa",
                      "May also directly inhibit factors Va and Xa in prothrombinase complex, and factor VIIIa in tenase complexProthrombinase complex converts the inactive prothrombin to active thrombinFactors VIIIa and IXa combine to form the tenase complex which then go on to activate factor X",
                      "Prothrombinase complex converts the inactive prothrombin to active thrombin",
                      "Factors VIIIa and IXa combine to form the tenase complex which then go on to activate factor X",
                      "Vitamin K–dependent; mainly produced in liver, but also endothelium and megakaryocytes",
                      "Approximately 60% is bound to C4b-binding protein; remaining 40% of free protein S is functionally active"
                    ]
                  },
                  {
                    "text": "Protein S deficiency can be inherited (autosomal dominant) or acquired (more common)AcquiredDecreased synthesis: Liver diseaseIncreased consumption: Disseminated intravascular coagulationIncrease in binding protein (C4b) leads to more bound protein S and less free protein S, which decreases activityCan be seen in nephrotic syndrome and pregnancyAlthough protein S is decreased in neonatal period, C4b-binding protein is also decreased, leading to increase in free protein SFunctional levels only slightly decreased compared to normal adultCertain medications may lower protein S (e.g., heparin, warfarin, hormone replacement therapy, and oral contraceptives)",
                    "sub_points": [
                      "AcquiredDecreased synthesis: Liver diseaseIncreased consumption: Disseminated intravascular coagulationIncrease in binding protein (C4b) leads to more bound protein S and less free protein S, which decreases activityCan be seen in nephrotic syndrome and pregnancyAlthough protein S is decreased in neonatal period, C4b-binding protein is also decreased, leading to increase in free protein SFunctional levels only slightly decreased compared to normal adultCertain medications may lower protein S (e.g., heparin, warfarin, hormone replacement therapy, and oral contraceptives)",
                      "Decreased synthesis: Liver disease",
                      "Increased consumption: Disseminated intravascular coagulation",
                      "Increase in binding protein (C4b) leads to more bound protein S and less free protein S, which decreases activityCan be seen in nephrotic syndrome and pregnancy",
                      "Can be seen in nephrotic syndrome and pregnancy",
                      "Although protein S is decreased in neonatal period, C4b-binding protein is also decreased, leading to increase in free protein SFunctional levels only slightly decreased compared to normal adult",
                      "Functional levels only slightly decreased compared to normal adult",
                      "Certain medications may lower protein S (e.g., heparin, warfarin, hormone replacement therapy, and oral contraceptives)"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Occurs in ~ 1 in 500 individuals"
                  },
                  {
                    "text": "3x more common in Japanese population than in white population"
                  },
                  {
                    "text": "No gender differences"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Patients at increased risk for venous thromboembolism (VTE), particularly in lower extremities, at young age (< 45 years)"
                  },
                  {
                    "text": "Does not appear to be risk factor for arterial thrombosis"
                  },
                  {
                    "text": "Recurrent fetal loss"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Prophylactic treatment with anticoagulation therapy; however, anticoagulation is not indicated in asymptomatic patients or in absence of history of VTE"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Antithrombin deficiency"
                  },
                  {
                    "text": "Protein C deficiency"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Antigenic Assays": [
                  {
                    "text": "Measure free and bound protein S by mixing patient plasma with monoclonal antibody that binds to protein S and causes agglutinationAgglutination causes change in absorption of lightIncrease in light absorption is directly proportional to concentration of protein S presentFree protein S can be measured directly by antigenic assays using antibodies specific for free protein S antigen",
                    "sub_points": [
                      "Agglutination causes change in absorption of lightIncrease in light absorption is directly proportional to concentration of protein S presentFree protein S can be measured directly by antigenic assays using antibodies specific for free protein S antigen",
                      "Increase in light absorption is directly proportional to concentration of protein S present",
                      "Free protein S can be measured directly by antigenic assays using antibodies specific for free protein S antigen"
                    ]
                  }
                ],
                "Clot-Based Functional Assays": [
                  {
                    "text": "Activity assay"
                  },
                  {
                    "text": "Patient plasma is mixed with protein S-deficient plasma, activated protein C, and factor Va"
                  },
                  {
                    "text": "Calcium is added to initiate clotting"
                  },
                  {
                    "text": "Clotting time is measured using assay based on activated partial thromboplastin time (aPTT) or prothrombin time (PT)"
                  },
                  {
                    "text": "Clotting time is compared to reference curve to determine protein S activity"
                  },
                  {
                    "text": "Assay is subject to variety of preanalytical variablesHeparin and lupus anticoagulant may cause falsely high result when using aPTT assaysActivated protein C resistance, factor V Leiden mutation, or high levels of factor VIII (acute phase reactant) can yield spuriously low resultLow protein S activity should be confirmed with free protein S antigen",
                    "sub_points": [
                      "Heparin and lupus anticoagulant may cause falsely high result when using aPTT assays",
                      "Activated protein C resistance, factor V Leiden mutation, or high levels of factor VIII (acute phase reactant) can yield spuriously low result",
                      "Low protein S activity should be confirmed with free protein S antigen"
                    ]
                  },
                  {
                    "text": "Tests for protein S deficiency should not be ordered during acute thrombotic episode or while patient is on warfarin"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Protein C Deficiency": {
            "name": "Protein C Deficiency",
            "url": "https://app.pathprimer.com/document/1183dfaf-39ee-4764-a2c0-716473735af3/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Activated protein C (APC) is released from receptor, binds with its cofactor (protein S), and cleaves factor Va and VIIIa to its inactive forms, Vi and VIIIi, respectively"
                  },
                  {
                    "text": "> 7x increase in risk of venous thromboembolism (VTE), particularly in deep veins of lower extremities"
                  },
                  {
                    "text": "﻿Recurrent fetal loss"
                  },
                  {
                    "text": "Warfarin-induced skin necrosisOccurs shortly after initiation of warfarin therapyCondition manifests as rapid skin necrosis, mostly on extremities, breasts, trunk, and penis",
                    "sub_points": [
                      "Occurs shortly after initiation of warfarin therapy",
                      "Condition manifests as rapid skin necrosis, mostly on extremities, breasts, trunk, and penis"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Functional assays should be performed firstIf low functional activity detected, antigen assay should be performed to detect type 2 protein C deficiencyTests for protein C deficiency should not be ordered during acute thrombotic episode or while patient is on warfarin",
                    "sub_points": [
                      "If low functional activity detected, antigen assay should be performed to detect type 2 protein C deficiency",
                      "Tests for protein C deficiency should not be ordered during acute thrombotic episode or while patient is on warfarin"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Protein C is vitamin K-dependent zymogen protease synthesized by liverShort half-life (6-8 hours)",
                    "sub_points": [
                      "Short half-life (6-8 hours)"
                    ]
                  },
                  {
                    "text": "Under normal physiological conditionsThrombin (IIa) binds to thrombomodulin complex located on endothelial cell surfaceProtein C is bound to endothelial surface protein C receptor and is cleaved by thrombin-thrombomodulin complexCleavage of protein C at a specific site leads to activation of protein CActivated protein C (APC) is released from receptor, binds with its cofactor (protein S), and cleaves factors Va and VIIIa to inactive forms, Vi and VIIIi, respectively",
                    "sub_points": [
                      "Thrombin (IIa) binds to thrombomodulin complex located on endothelial cell surface",
                      "Protein C is bound to endothelial surface protein C receptor and is cleaved by thrombin-thrombomodulin complexCleavage of protein C at a specific site leads to activation of protein CActivated protein C (APC) is released from receptor, binds with its cofactor (protein S), and cleaves factors Va and VIIIa to inactive forms, Vi and VIIIi, respectively",
                      "Cleavage of protein C at a specific site leads to activation of protein C",
                      "Activated protein C (APC) is released from receptor, binds with its cofactor (protein S), and cleaves factors Va and VIIIa to inactive forms, Vi and VIIIi, respectively"
                    ]
                  },
                  {
                    "text": "Deficiency can be inherited or acquiredInheritedAutosomal dominantCan occur as homozygous or heterozygous deficiencyHomozygotes are at risk for neonatal purpura fulminans: Combination of disseminated intravascular coagulation and skin necrosisType 1Most commonQuantitative decrease in normally functioning protein C due to missense or nonsense mutations (most common), promoter mutations, or frameshift deletions or insertionsType 2Point mutation causes qualitative decrease in protein C activityAcquiredDue to decreased synthesis: Liver disease, warfarin treatmentDue to increased consumption: Sepsis, disseminated intravascular coagulation, major surgerySevere form of protein C deficiency can be seen in patients with meningococcemia",
                    "sub_points": [
                      "InheritedAutosomal dominantCan occur as homozygous or heterozygous deficiencyHomozygotes are at risk for neonatal purpura fulminans: Combination of disseminated intravascular coagulation and skin necrosisType 1Most commonQuantitative decrease in normally functioning protein C due to missense or nonsense mutations (most common), promoter mutations, or frameshift deletions or insertionsType 2Point mutation causes qualitative decrease in protein C activity",
                      "Autosomal dominant",
                      "Can occur as homozygous or heterozygous deficiencyHomozygotes are at risk for neonatal purpura fulminans: Combination of disseminated intravascular coagulation and skin necrosis",
                      "Homozygotes are at risk for neonatal purpura fulminans: Combination of disseminated intravascular coagulation and skin necrosis",
                      "Type 1Most commonQuantitative decrease in normally functioning protein C due to missense or nonsense mutations (most common), promoter mutations, or frameshift deletions or insertions",
                      "Most common",
                      "Quantitative decrease in normally functioning protein C due to missense or nonsense mutations (most common), promoter mutations, or frameshift deletions or insertions",
                      "Type 2Point mutation causes qualitative decrease in protein C activity",
                      "Point mutation causes qualitative decrease in protein C activity",
                      "AcquiredDue to decreased synthesis: Liver disease, warfarin treatmentDue to increased consumption: Sepsis, disseminated intravascular coagulation, major surgerySevere form of protein C deficiency can be seen in patients with meningococcemia",
                      "Due to decreased synthesis: Liver disease, warfarin treatment",
                      "Due to increased consumption: Sepsis, disseminated intravascular coagulation, major surgery",
                      "Severe form of protein C deficiency can be seen in patients with meningococcemia"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Heterozygous deficiency found in 1 in 200-500 people"
                  },
                  {
                    "text": "Homozygous deficiency found in 1 in 160,000-360,000 people"
                  },
                  {
                    "text": "Males and females affected equally"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "> 7x increase in risk of venous thromboembolism (VTE), particularly in deep veins of lower extremitiesVTE typically occurs in 2nd decade of life",
                    "sub_points": [
                      "VTE typically occurs in 2nd decade of life"
                    ]
                  },
                  {
                    "text": "Some studies indicate protein C deficiency may be risk factor for arterial thrombosis (e.g., ischemic stroke)"
                  },
                  {
                    "text": "﻿Recurrent fetal loss"
                  },
                  {
                    "text": "Warfarin-induced skin necrosisCondition seen primarily in patients with protein C deficiencyAlso documented in patients with protein S deficiency and factor V LeidenOccurs shortly after initiation of warfarin therapyWarfarin administration leads to decrease in vitamin K-dependent pro-coagulant proteins and protein CEffect on protein C is more rapid (due to shorter half-life) than those of other vitamin K-dependent proteinsLeads to transient hypercoagulable stateManifests as rapid skin necrosis, mostly on extremities, breasts, trunk, and penisLesions start as erythematous macules and progress to edematous, purpuric, and necrotic lesions if protein C is not administeredHistology of skin lesions shows fibrin thrombi throughout dermis and subcutis, and red blood cell extravasation",
                    "sub_points": [
                      "Condition seen primarily in patients with protein C deficiencyAlso documented in patients with protein S deficiency and factor V Leiden",
                      "Also documented in patients with protein S deficiency and factor V Leiden",
                      "Occurs shortly after initiation of warfarin therapyWarfarin administration leads to decrease in vitamin K-dependent pro-coagulant proteins and protein CEffect on protein C is more rapid (due to shorter half-life) than those of other vitamin K-dependent proteinsLeads to transient hypercoagulable state",
                      "Warfarin administration leads to decrease in vitamin K-dependent pro-coagulant proteins and protein CEffect on protein C is more rapid (due to shorter half-life) than those of other vitamin K-dependent proteinsLeads to transient hypercoagulable state",
                      "Effect on protein C is more rapid (due to shorter half-life) than those of other vitamin K-dependent proteins",
                      "Leads to transient hypercoagulable state",
                      "Manifests as rapid skin necrosis, mostly on extremities, breasts, trunk, and penisLesions start as erythematous macules and progress to edematous, purpuric, and necrotic lesions if protein C is not administeredHistology of skin lesions shows fibrin thrombi throughout dermis and subcutis, and red blood cell extravasation",
                      "Lesions start as erythematous macules and progress to edematous, purpuric, and necrotic lesions if protein C is not administered",
                      "Histology of skin lesions shows fibrin thrombi throughout dermis and subcutis, and red blood cell extravasation"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Protein S deficiency"
                  },
                  {
                    "text": "Antithrombin deficiency"
                  },
                  {
                    "text": "Dysfibrinogenemia"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Protein C Assays": [
                  {
                    "text": "2 types of protein C assays available: Functional (activity) and antigen (quantitative)"
                  },
                  {
                    "text": "Functional assays should be performed firstIf low functional activity detected, antigen assay should be performed to assess for type 2 protein C deficiencyTests for protein C deficiency should not be ordered during acute thrombotic episode or while patient is on warfarin",
                    "sub_points": [
                      "If low functional activity detected, antigen assay should be performed to assess for type 2 protein C deficiency",
                      "Tests for protein C deficiency should not be ordered during acute thrombotic episode or while patient is on warfarin"
                    ]
                  },
                  {
                    "text": "Functional assaysClot-based assayPatient plasma mixed with venom from southern copperhead snake (Protac), which activates protein CActivity of activated protein C is measured by prolongation of clotting time in activated partial thromboplastin time (aPTT)Variety of preanalytical variables can affect resultsSubstances that interfere with clotting time may give false-normal result (e.g., direct thrombin inhibitors, heparin, lupus anticoagulant)High levels of factor VIII &/or factor V Leiden mutation may result in falsely low levels of protein C activityChromogenic assayPatient plasma mixed with synthetic substrate that resembles normal activated protein C substrateActivity is measured by ability of activated protein C to cleave synthetic substrate, which releases a chromogenic substrate, which is then detected via spectrophotometryMost laboratories use chromogenic assays due to fewer preanalytical interferencesHeterozygote protein C activity: 35-65%",
                    "sub_points": [
                      "Clot-based assayPatient plasma mixed with venom from southern copperhead snake (Protac), which activates protein CActivity of activated protein C is measured by prolongation of clotting time in activated partial thromboplastin time (aPTT)Variety of preanalytical variables can affect resultsSubstances that interfere with clotting time may give false-normal result (e.g., direct thrombin inhibitors, heparin, lupus anticoagulant)High levels of factor VIII &/or factor V Leiden mutation may result in falsely low levels of protein C activity",
                      "Patient plasma mixed with venom from southern copperhead snake (Protac), which activates protein C",
                      "Activity of activated protein C is measured by prolongation of clotting time in activated partial thromboplastin time (aPTT)",
                      "Variety of preanalytical variables can affect resultsSubstances that interfere with clotting time may give false-normal result (e.g., direct thrombin inhibitors, heparin, lupus anticoagulant)High levels of factor VIII &/or factor V Leiden mutation may result in falsely low levels of protein C activity",
                      "Substances that interfere with clotting time may give false-normal result (e.g., direct thrombin inhibitors, heparin, lupus anticoagulant)",
                      "High levels of factor VIII &/or factor V Leiden mutation may result in falsely low levels of protein C activity",
                      "Chromogenic assayPatient plasma mixed with synthetic substrate that resembles normal activated protein C substrateActivity is measured by ability of activated protein C to cleave synthetic substrate, which releases a chromogenic substrate, which is then detected via spectrophotometryMost laboratories use chromogenic assays due to fewer preanalytical interferences",
                      "Patient plasma mixed with synthetic substrate that resembles normal activated protein C substrate",
                      "Activity is measured by ability of activated protein C to cleave synthetic substrate, which releases a chromogenic substrate, which is then detected via spectrophotometry",
                      "Most laboratories use chromogenic assays due to fewer preanalytical interferences",
                      "Heterozygote protein C activity: 35-65%"
                    ]
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Protein C: 70-130%"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Activated Protein C Resistance": {
            "name": "Activated Protein C Resistance",
            "url": "https://app.pathprimer.com/document/76362a0e-f1c9-4810-8da2-cda54a915541/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Activated protein C (APC) is released from receptor, binds with its cofactor (protein S), and cleaves factor Va and VIIIa to its inactive forms (Vi and VIIIi, respectively)"
                  },
                  {
                    "text": "Factor V Leiden (FVL)﻿Most common cause of APC resistance﻿﻿Autosomal dominant inheritance﻿In FVL, mutation (substitution of glutamine for arginine at position 506) on factor V gene generates factor V that is resistant to APCFactor V that is resistant to degradation by APC leads to prothrombotic state﻿",
                    "sub_points": [
                      "﻿Most common cause of APC resistance﻿",
                      "﻿Autosomal dominant inheritance﻿",
                      "In FVL, mutation (substitution of glutamine for arginine at position 506) on factor V gene generates factor V that is resistant to APC",
                      "Factor V that is resistant to degradation by APC leads to prothrombotic state﻿"
                    ]
                  },
                  {
                    "text": "Increased risk of VTE and recurrent pregnancy loss﻿"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Protein C function under normal physiological conditionsThrombin (IIa) binds to thrombomodulin located on endothelial cell surface﻿Causes activation of protein C, which is bound to endothelial surface protein C receptor﻿APC is released from receptor, binds with its cofactor (protein S), and cleaves factor Va and VIIIa to inactive forms (Vi and VIIIi, respectively)Factors Va and VIIIa are important cofactors in conversion of prothrombin to thrombin",
                    "sub_points": [
                      "Thrombin (IIa) binds to thrombomodulin located on endothelial cell surface﻿",
                      "Causes activation of protein C, which is bound to endothelial surface protein C receptor﻿",
                      "APC is released from receptor, binds with its cofactor (protein S), and cleaves factor Va and VIIIa to inactive forms (Vi and VIIIi, respectively)Factors Va and VIIIa are important cofactors in conversion of prothrombin to thrombin",
                      "Factors Va and VIIIa are important cofactors in conversion of prothrombin to thrombin"
                    ]
                  },
                  {
                    "text": "Inherited causes of APC resistanceFactor V Leiden (FVL)Most common cause﻿Autosomal dominant inheritance﻿Mutation (substitution of glutamine for arginine at position 506) on factor V gene generates factor V that is resistant to APCFactor V that is resistant to degradation by APC leads to prothrombotic state﻿Other mutations can cause APC resistanceFactor V Cambridge (substitution of arginine with threonine at position 306)Factor V Nara (substitution of tryptophan with arginine at position 1920)Factor V Liverpool (substitution of isoleucine with threonine at position 359)",
                    "sub_points": [
                      "Factor V Leiden (FVL)Most common cause﻿Autosomal dominant inheritance﻿Mutation (substitution of glutamine for arginine at position 506) on factor V gene generates factor V that is resistant to APCFactor V that is resistant to degradation by APC leads to prothrombotic state﻿",
                      "Most common cause",
                      "﻿Autosomal dominant inheritance﻿",
                      "Mutation (substitution of glutamine for arginine at position 506) on factor V gene generates factor V that is resistant to APC",
                      "Factor V that is resistant to degradation by APC leads to prothrombotic state﻿",
                      "Other mutations can cause APC resistanceFactor V Cambridge (substitution of arginine with threonine at position 306)Factor V Nara (substitution of tryptophan with arginine at position 1920)Factor V Liverpool (substitution of isoleucine with threonine at position 359)",
                      "Factor V Cambridge (substitution of arginine with threonine at position 306)",
                      "Factor V Nara (substitution of tryptophan with arginine at position 1920)",
                      "Factor V Liverpool (substitution of isoleucine with threonine at position 359)"
                    ]
                  },
                  {
                    "text": "Acquired causesIncreased levels of estrogen (as seen in patients taking oral contraceptives &/or hormone replacement therapy, or who are pregnant) can also cause APC resistance",
                    "sub_points": [
                      "Increased levels of estrogen (as seen in patients taking oral contraceptives &/or hormone replacement therapy, or who are pregnant) can also cause APC resistance"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Most common in white people of Northern European descentExtremely rare in those of Asian or African descent",
                    "sub_points": [
                      "Extremely rare in those of Asian or African descent"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "﻿Increased risk of venous thromboembolism (VTE)﻿Heterozygous carriers have 1.96- to 4.2x increased riskHomozygous carriers have 8x increased riskMost common in deep veins of legs, but can also occur in cerebral, mesenteric, or portal venous systemsPatients with cerebral venous thromboembolism are frequently on oral contraceptivesRisk increases with ageRisk significantly increased if multiple genetic abnormalities are present",
                    "sub_points": [
                      "Heterozygous carriers have 1.96- to 4.2x increased risk",
                      "Homozygous carriers have 8x increased risk",
                      "Most common in deep veins of legs, but can also occur in cerebral, mesenteric, or portal venous systemsPatients with cerebral venous thromboembolism are frequently on oral contraceptives",
                      "Patients with cerebral venous thromboembolism are frequently on oral contraceptives",
                      "Risk increases with age",
                      "Risk significantly increased if multiple genetic abnormalities are present"
                    ]
                  },
                  {
                    "text": "﻿Associated with recurrent pregnancy loss﻿"
                  },
                  {
                    "text": "Does not increase risk of arterial thrombosis"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Prophylactic treatment for patients with no history of VTE is not indicated"
                  },
                  {
                    "text": "Anticoagulation prior to major surgery may be indicated, depending on type and severity of surgery and if patient has history of VTE"
                  },
                  {
                    "text": "American College of Obstetrics and Gynecology recommends treatment for pregnant women with FVL, as followsPatients with heterozygous FVL mutation, but no personal or family history of VTEAntepartum: Close clinical follow-up without anticoagulation therapyPostpartum: Anticoagulation therapy if patient has additional risk factors for VTE (e.g., obesity, immobility)Patients with heterozygous FVL mutation with either personal history of VTE or 1st-degree relative with history of VTEAntepartum: Anticoagulation therapy with low molecular weight heparin or close clinical follow-upPostpartum: Anticoagulation therapyPatients with heterozygous FVL mutation and prothrombin G20210A mutation, or homozygous FVL mutation with either personal history of VTE or 1st-degree relative with history of VTEAntepartum: Anticoagulation therapy with low molecular weight heparinPostpartum: Anticoagulation therapy",
                    "sub_points": [
                      "Patients with heterozygous FVL mutation, but no personal or family history of VTEAntepartum: Close clinical follow-up without anticoagulation therapyPostpartum: Anticoagulation therapy if patient has additional risk factors for VTE (e.g., obesity, immobility)",
                      "Antepartum: Close clinical follow-up without anticoagulation therapy",
                      "Postpartum: Anticoagulation therapy if patient has additional risk factors for VTE (e.g., obesity, immobility)",
                      "Patients with heterozygous FVL mutation with either personal history of VTE or 1st-degree relative with history of VTEAntepartum: Anticoagulation therapy with low molecular weight heparin or close clinical follow-upPostpartum: Anticoagulation therapy",
                      "Antepartum: Anticoagulation therapy with low molecular weight heparin or close clinical follow-up",
                      "Postpartum: Anticoagulation therapy",
                      "Patients with heterozygous FVL mutation and prothrombin G20210A mutation, or homozygous FVL mutation with either personal history of VTE or 1st-degree relative with history of VTEAntepartum: Anticoagulation therapy with low molecular weight heparinPostpartum: Anticoagulation therapy",
                      "Antepartum: Anticoagulation therapy with low molecular weight heparin",
                      "Postpartum: Anticoagulation therapy"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Activated Protein C Resistance Assay": [
                  {
                    "text": "Activated partial thromboplastin time (APTT) is determined on patient plasma"
                  },
                  {
                    "text": "Standard amount of APC is added to patient plasma, and APTT is performed again"
                  },
                  {
                    "text": "In normal patients, excess of APC favors degradation of factors Va and VIIIa and, therefore, prolongs APTT"
                  },
                  {
                    "text": "Patients with APC resistance have little to no change when standard amount of APC is added"
                  },
                  {
                    "text": "APC resistance ratio = ratio of APTT preaddition APC to APTT postaddition APC"
                  },
                  {
                    "text": "Assays that use APTT are subject to various preanalytic variables (e.g., lupus anticoagulant, heparin, &/or oral anticoagulant therapy)In 2nd-generation assays using APTT, reagent predilutes patient plasma with factor V-deficient plasma to reduce potential interference from heparin and lupus anticoagulants",
                    "sub_points": [
                      "In 2nd-generation assays using APTT, reagent predilutes patient plasma with factor V-deficient plasma to reduce potential interference from heparin and lupus anticoagulants"
                    ]
                  }
                ],
                "Other Assays": [
                  {
                    "text": "Other methods use PT, factor Xa clotting time, or Russell viper venom time (RVVT) instead of APTT"
                  },
                  {
                    "text": "Patients with low APC resistance assay ratios should undergo FVL mutation testing"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Plasminogen Activator Inhibitor-1": {
            "name": "Plasminogen Activator Inhibitor-1",
            "url": "https://app.pathprimer.com/document/b3e2ac76-7002-4f92-a065-4fb31e99181f/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "PAI-1 is serine protease inhibitor synthesized by endothelial cells and hepatocytes and stored within alpha granules of platelets"
                  },
                  {
                    "text": "In PAI-1 deficiency, fibrinolysis is increased and may result in bleeding diathesis;﻿PAI-1 deficiency is associated with mild to moderate bleeding"
                  },
                  {
                    "text": "Elevated PAI-1 is associated with increased risk for venous thrombosis, including VOD after bone marrow transplantation; elevated PAI-1 has also been seen in patients with liver disease, obesity, malignancy, and sepsis"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Plasminogen Activator Inhibitor-1": [
                  {
                    "text": "Plasminogen activator inihibitor-1 (PAI-1) is serine protease inhibitorSynthesized by endothelial cells and hepatocytesStored within alpha granules of platelets",
                    "sub_points": [
                      "Synthesized by endothelial cells and hepatocytes",
                      "Stored within alpha granules of platelets"
                    ]
                  },
                  {
                    "text": "PAI-1 is potent inhibitor of plasminogen activators urokinase plasminogen activator and tissue plasminogen activator (t-PA)﻿Plasminogen activators convert plasminogen to plasmin to promote fibrinolysis by lysing fibrin into fibrin degradation productsPAI-1 inhibits formation of plasminDownregulates fibrinolysis",
                    "sub_points": [
                      "Plasminogen activators convert plasminogen to plasmin to promote fibrinolysis by lysing fibrin into fibrin degradation products",
                      "PAI-1 inhibits formation of plasminDownregulates fibrinolysis",
                      "Downregulates fibrinolysis"
                    ]
                  },
                  {
                    "text": "Pathologic conditions due to deficiencies and elevations in PAI-1 occur"
                  }
                ],
                "Plasminogen Activator Inhibitor-1 Deficiency": [
                  {
                    "text": "In PAI-1 deficiency, fibrinolysis is increasedMay result in bleeding diathesis﻿Quantitative deficiencies and qualitative defects have been described",
                    "sub_points": [
                      "May result in bleeding diathesis﻿",
                      "Quantitative deficiencies and qualitative defects have been described"
                    ]
                  },
                  {
                    "text": "Genetics and epidemiologyAutosomal inheritance12.2-kb gene located on chromosome 7 at q21.3-q22Very rareIncidence unknown due to rarity and lack of laboratory assays available to establish diagnosisNo apparent gender or racial predilections",
                    "sub_points": [
                      "Autosomal inheritance",
                      "12.2-kb gene located on chromosome 7 at q21.3-q22",
                      "Very rareIncidence unknown due to rarity and lack of laboratory assays available to establish diagnosis",
                      "Incidence unknown due to rarity and lack of laboratory assays available to establish diagnosis",
                      "No apparent gender or racial predilections"
                    ]
                  },
                  {
                    "text": "Clinical findingsAssociated with mild to moderate bleedingMenorrhagia in womenDelayed bleedingInjuryTraumaSurgeryDental procedures",
                    "sub_points": [
                      "Associated with mild to moderate bleeding",
                      "Menorrhagia in women",
                      "Delayed bleedingInjuryTraumaSurgeryDental procedures",
                      "Injury",
                      "Trauma",
                      "Surgery",
                      "Dental procedures"
                    ]
                  },
                  {
                    "text": "TreatmentAntifibrinolytic agentsEpsilon-aminocaproic acid (EACA)Tranexamic acid",
                    "sub_points": [
                      "Antifibrinolytic agentsEpsilon-aminocaproic acid (EACA)Tranexamic acid",
                      "Epsilon-aminocaproic acid (EACA)",
                      "Tranexamic acid"
                    ]
                  }
                ],
                "Elevated Plasminogen Activator Inhibitor-1": [
                  {
                    "text": "Excess PAI-1 leads to deficient levels of plasminFibrinolysis downregulated",
                    "sub_points": [
                      "Fibrinolysis downregulated"
                    ]
                  },
                  {
                    "text": "Association between elevated PAI-1 and increased risk for venous thrombosisIncluding veno-occlusive disease (VOD) after bone marrow transplantation",
                    "sub_points": [
                      "Including veno-occlusive disease (VOD) after bone marrow transplantation"
                    ]
                  },
                  {
                    "text": "Elevated levels of PAI-1 also seen in patients with liver disease, obesity, malignancy, sepsis"
                  },
                  {
                    "text": "PAI-1 is acute phase reactantExpression of PAI-1 increased in response to inflammationElevated PAI-1 associated with increased body mass index (BMI) and insulin resistance",
                    "sub_points": [
                      "Expression of PAI-1 increased in response to inflammation",
                      "Elevated PAI-1 associated with increased body mass index (BMI) and insulin resistance"
                    ]
                  },
                  {
                    "text": "No apparent gender or racial predilections"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Testing should evaluate PAI-1 antigen, activity, and t-PA activity"
                  },
                  {
                    "text": "PAI-1 functional assayMeasures ability of PAI-1 to inactivate exogenous t-PA",
                    "sub_points": [
                      "Measures ability of PAI-1 to inactivate exogenous t-PA"
                    ]
                  },
                  {
                    "text": "Enzyme-linked immunosorbent assay (ELISA) can be used to measure PAI-1 antigen"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Prothrombin Mutation": {
            "name": "Prothrombin Mutation",
            "url": "https://app.pathprimer.com/document/8c8c6c5b-7962-4ebe-9625-d7f37bf577e7/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Prothrombin is vitamin K-dependent protein that is converted to thrombin by factor Xa; thrombin goes on to convert fibrinogen to fibrin to form cross-linked, stable clot"
                  },
                  {
                    "text": "Patients with mutation have 2- to 4-fold increase in risk for VTE"
                  },
                  {
                    "text": "Single point mutation at 3’ untranslated region (substitution of adenine for guanine in position 20210) on prothrombin gene is associated with increased risk of thrombosisMutation is known as G20210A and leads to gain of function and increased levels of prothrombin",
                    "sub_points": [
                      "Mutation is known as G20210A and leads to gain of function and increased levels of prothrombin"
                    ]
                  },
                  {
                    "text": "Risk increases almost 20-fold if patient has concomitant factor V Leiden mutation"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Molecular testing (PCR-based) for detection of 20210A mutation"
                  },
                  {
                    "text": "Genetic testing is unaffected by concurrent illness/event and unaffected by anticoagulation"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Prothrombin (factor IIa) is a vitamin K-dependent protein that is converted to thrombin by factor Xa"
                  },
                  {
                    "text": "Synthesized by liver"
                  },
                  {
                    "text": "Thrombin goes on to convert fibrinogen to fibrin to form cross-linked, stable clot"
                  },
                  {
                    "text": "Single point mutation at 3’ untranslated region (substitution of adenine for guanine in position 20210) on prothrombin gene is associated with increased risk of thrombosisMutation known as G20210AMutation leads to gain of function and increased levels of prothrombin",
                    "sub_points": [
                      "Mutation known as G20210A",
                      "Mutation leads to gain of function and increased levels of prothrombin"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Prothrombin mutation is more common in Caucasians from southern EuropePrevalence in Caucasians is approximately 2%",
                    "sub_points": [
                      "Prevalence in Caucasians is approximately 2%"
                    ]
                  },
                  {
                    "text": "Mutation is extremely rare in Asians and African Americans"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Patients with mutation have 2- to 4-fold increase in risk for venous thromboembolism (VTE)Risk increases almost 20-fold if patient has concomitant factor V Leiden mutationVTE more common in veins of lower extremities",
                    "sub_points": [
                      "Risk increases almost 20-fold if patient has concomitant factor V Leiden mutation",
                      "VTE more common in veins of lower extremities"
                    ]
                  },
                  {
                    "text": "Recurrent pregnancy loss has been described"
                  },
                  {
                    "text": "According to some studies, there may be slight (1.32-fold) increased risk of arterial thrombosis including myocardial infarction and stroke"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Individuals with mutation but with no history of thromboembolic events are not routinely treated with prophylactic anticoagulationWomen with mutation are advised to avoid oral contraceptives",
                    "sub_points": [
                      "Women with mutation are advised to avoid oral contraceptives"
                    ]
                  },
                  {
                    "text": "Individuals with G20210A mutation and history of unprovoked VTE are treated with antiplatelet therapyPatients with provoked VTE may or may not receive long-term anticoagulation, depending on multiple factorsFamily historyRecurrent VTELife-threatening VTEOther risk factors",
                    "sub_points": [
                      "Patients with provoked VTE may or may not receive long-term anticoagulation, depending on multiple factorsFamily historyRecurrent VTELife-threatening VTEOther risk factors",
                      "Family history",
                      "Recurrent VTE",
                      "Life-threatening VTE",
                      "Other risk factors"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Diagnostic Methods": [
                  {
                    "text": "Molecular testing (PCR-based) for detection of 20210 mutationGenetic testing unaffected by concurrent illness/event and unaffected by anticoagulation",
                    "sub_points": [
                      "Genetic testing unaffected by concurrent illness/event and unaffected by anticoagulation"
                    ]
                  },
                  {
                    "text": "Normal prothrombin time (PT) and activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Increased prothrombin levels cannot be used to determine risk of thrombosisTesting is not recommendedOverlap in prothrombin levels in patients with mutation and normal rangeTesting is subject to wide variety of preanalytic variables",
                    "sub_points": [
                      "Testing is not recommended",
                      "Overlap in prothrombin levels in patients with mutation and normal range",
                      "Testing is subject to wide variety of preanalytic variables"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hyperhomocysteinemia": {
            "name": "Hyperhomocysteinemia",
            "url": "https://app.pathprimer.com/document/6e46010c-d12c-4489-8052-661f3fc00111/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Homocysteine is metabolized from methionine, an essential amino acid found in meat, fish, fruits, and nuts"
                  },
                  {
                    "text": "Hyperhomocysteinemia can be due to genetic or dietary causes or medicationsMost common cause for severe hyperhomocysteinemia is cystathionine β-synthase deficiencyCertain medications can increase homocysteine levels, including methotrexate, nitrous oxide, phenytoin, carbamazepine, oral contraceptives",
                    "sub_points": [
                      "Most common cause for severe hyperhomocysteinemia is cystathionine β-synthase deficiency",
                      "Certain medications can increase homocysteine levels, including methotrexate, nitrous oxide, phenytoin, carbamazepine, oral contraceptives"
                    ]
                  },
                  {
                    "text": "MTHFRmutations are common in Caucasians and very rare in African Americans, but they do not always lead to hyperhomocysteinemia"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Homocysteine levels vary with diet, so patients must be fasting at time of blood draw for accurate results"
                  },
                  {
                    "text": "Specimen must be kept on ice because homocysteine is unstable at room temperature; prolonged storage at room temperature causes falsely elevated results"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Homocysteine is metabolized from methionine, an essential amino acid found in meat, fish, fruits, and nuts"
                  },
                  {
                    "text": "Homocysteine is metabolized via remethylation pathway or transsulfuration pathway"
                  },
                  {
                    "text": "Remethylation pathway is responsible for regulating homocysteine levels during fasting state when there is methionine deficiencyDependent on enzymes methylenetetrahydrofolate reductase (MTHFR) and methionine synthase and cofactor vitamin B12",
                    "sub_points": [
                      "Dependent on enzymes methylenetetrahydrofolate reductase (MTHFR) and methionine synthase and cofactor vitamin B12"
                    ]
                  },
                  {
                    "text": "Transsulfuration pathway is responsible for postprandial state when methionine is in excessDependent on enzyme cystathionine β-synthase and cofactor vitamin B6",
                    "sub_points": [
                      "Dependent on enzyme cystathionine β-synthase and cofactor vitamin B6"
                    ]
                  },
                  {
                    "text": "Hyperhomocysteinemia can be due to genetic or dietary causesGeneticMost common cause for severe hyperhomocysteinemia is cystathionine β-synthase deficiencyOther causes include mutations inMTHFR﻿gene﻿Most common cause of genetic hyperhomocysteinemiaNot all dietaryVitamin B12, vitamin B6, and folate deficiencies can cause elevated levels of homocysteineCertain medications can increase homocysteine levelsMethotrexateNitrous oxidePhenytoinCarbamazepineOral contraceptives",
                    "sub_points": [
                      "GeneticMost common cause for severe hyperhomocysteinemia is cystathionine β-synthase deficiencyOther causes include mutations inMTHFR﻿gene﻿Most common cause of genetic hyperhomocysteinemia",
                      "Most common cause for severe hyperhomocysteinemia is cystathionine β-synthase deficiency",
                      "Other causes include mutations inMTHFR﻿gene﻿Most common cause of genetic hyperhomocysteinemia",
                      "Most common cause of genetic hyperhomocysteinemia",
                      "Not all dietaryVitamin B12, vitamin B6, and folate deficiencies can cause elevated levels of homocysteine",
                      "Vitamin B12, vitamin B6, and folate deficiencies can cause elevated levels of homocysteine",
                      "Certain medications can increase homocysteine levelsMethotrexateNitrous oxidePhenytoinCarbamazepineOral contraceptives",
                      "Methotrexate",
                      "Nitrous oxide",
                      "Phenytoin",
                      "Carbamazepine",
                      "Oral contraceptives"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "MTHFRmutations are common in CaucasiansVery rare in African AmericansDo not always lead to hyperhomocysteinemia",
                    "sub_points": [
                      "Very rare in African Americans",
                      "Do not always lead to hyperhomocysteinemia"
                    ]
                  },
                  {
                    "text": "Cystathionine β-synthase deficiencyHomozygous deficiency occurs in approximately 1 in 200,000 peopleHeterozygous deficiency occurs in approximately 1 in 300 people",
                    "sub_points": [
                      "Homozygous deficiency occurs in approximately 1 in 200,000 people",
                      "Heterozygous deficiency occurs in approximately 1 in 300 people"
                    ]
                  },
                  {
                    "text": "No sexual predilection"
                  },
                  {
                    "text": "Dietary causes are rare in Western cultures"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Mental retardation, ectopia lentis, marfanoid body habitus, venous and arterial thrombosis"
                  },
                  {
                    "text": "Premature atherosclerosisMyocardial infarction, coronary artery disease, carotid artery stenosis, cerebrovascular infarctionHomocysteine contributes to thrombosis byIncreasing platelets adhesion moleculesIncreasing platelet synthesis of thromboxane A₂Promoting endothelial cell injury",
                    "sub_points": [
                      "Myocardial infarction, coronary artery disease, carotid artery stenosis, cerebrovascular infarction",
                      "Homocysteine contributes to thrombosis byIncreasing platelets adhesion moleculesIncreasing platelet synthesis of thromboxane A₂Promoting endothelial cell injury",
                      "Increasing platelets adhesion molecules",
                      "Increasing platelet synthesis of thromboxane A₂",
                      "Promoting endothelial cell injury"
                    ]
                  },
                  {
                    "text": "Decreased bone mineral density leading to increased risk of fracturesHomocysteine interferes with cross-linking of collagen, which subsequently interferes with bone formation",
                    "sub_points": [
                      "Homocysteine interferes with cross-linking of collagen, which subsequently interferes with bone formation"
                    ]
                  },
                  {
                    "text": "Hyperhomocysteinemia and concomitant homozygousMTHFRmutations associated withEarly cardiovascular diseaseThrombosisRecurrent fetal lossIntrauterine growth restrictionStillbirth",
                    "sub_points": [
                      "Early cardiovascular disease",
                      "Thrombosis",
                      "Recurrent fetal loss",
                      "Intrauterine growth restriction",
                      "Stillbirth"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Well-designed studies with clinical follow-up are lacking"
                  },
                  {
                    "text": "Current evidence suggests treatment with vitamin B6, vitamin B12, and folic acid supplementation may benefit patients with severe hyperhomocysteinemia"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Homocysteine Levels": [
                  {
                    "text": "Homocysteine levels are measured by using immunoassay or high-performance liquid chromatography (HPLC)"
                  },
                  {
                    "text": "Homocysteine levels vary with dietPatients must be fasting at time of blood draw for accurate results",
                    "sub_points": [
                      "Patients must be fasting at time of blood draw for accurate results"
                    ]
                  },
                  {
                    "text": "Preanalytic variablesSpecimen must be kept on iceHomocysteine is unstable at room temperatureProlonged storage at room temperature causes falsely elevated results",
                    "sub_points": [
                      "Specimen must be kept on iceHomocysteine is unstable at room temperatureProlonged storage at room temperature causes falsely elevated results",
                      "Homocysteine is unstable at room temperature",
                      "Prolonged storage at room temperature causes falsely elevated results"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Diagnosis of Lupus Anticoagulant": {
            "name": "Diagnosis of Lupus Anticoagulant",
            "url": "https://app.pathprimer.com/document/08b41ebd-3b19-4d9b-aebb-93d5b35ffcde/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Lupus anticoagulants are class of immunoglobulins that interfere with phospholipid-dependent clotting assays"
                  },
                  {
                    "text": "Presence of LA is typically associated with APS but can also be due to autoimmune disease (i.e., SLE), chronic inflammatory conditions, or medications (i.e., hydralazine)"
                  },
                  {
                    "text": "Lupus anticoagulantis misnomerMost patients with LA do not have SLELA is procoagulant in vivo and anticoagulant in vitro",
                    "sub_points": [
                      "Most patients with LA do not have SLE",
                      "LA is procoagulant in vivo and anticoagulant in vitro"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Patients who test positive for LA must have testing repeated at least 12 weeks after initial testing but within 5 years of initial testing to be considered positive for LA"
                  },
                  {
                    "text": "Testing must include screening test, mixing study, and confirmatory test"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Lupus anticoagulants (LA) are class of immunoglobulins that interfere with phospholipid-dependent clotting assaysLupus anticoagulantis misnomerMost patients with LA do not have systemic lupus erythematosus (SLE)LA is procoagulant in vivo and anticoagulant in vitroPatients with LA have antibody that binds phospholipid and causes prolongation of clotting time",
                    "sub_points": [
                      "Lupus anticoagulantis misnomerMost patients with LA do not have systemic lupus erythematosus (SLE)LA is procoagulant in vivo and anticoagulant in vitroPatients with LA have antibody that binds phospholipid and causes prolongation of clotting time",
                      "Most patients with LA do not have systemic lupus erythematosus (SLE)",
                      "LA is procoagulant in vivo and anticoagulant in vitroPatients with LA have antibody that binds phospholipid and causes prolongation of clotting time",
                      "Patients with LA have antibody that binds phospholipid and causes prolongation of clotting time"
                    ]
                  },
                  {
                    "text": "Presence of LA is typically associated with antiphospholipid syndrome (APS) but can also be due to autoimmune disease (e.g., SLE), chronic inflammatory conditions, or medications (e.g., hydralazine)"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Significantly more common in female than male patients"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Patients are at increased risk for venous thromboembolism (VTE) and recurrent fetal loss &/or obstetric complications"
                  },
                  {
                    "text": "Please see section titled \"Antiphospholipid Antibody Syndrome\" for additional details"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Antithrombin deficiency"
                  },
                  {
                    "text": "Protein C deficiency"
                  },
                  {
                    "text": "Coagulation factor deficiencies"
                  },
                  {
                    "text": "Warfarin or heparin use"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Specimen Collection": [
                  {
                    "text": "Collect specimen in 3.2% sodium citrate tube with 1:9 anticoagulant:whole blood ratio"
                  },
                  {
                    "text": "Sample must be sent to laboratory and centrifuged within 4 hours to prevent loss of coagulation factors"
                  }
                ],
                "Patient Testing": [
                  {
                    "text": "Testing should be limited to high-risk groupsPatients with unexplained prolonged activated partial thromboplastin time (aPTT), arterial thrombosis in patient < 50 yearsPatients with recurrent pregnancy losses or unexplained obstetrical complications",
                    "sub_points": [
                      "Patients with unexplained prolonged activated partial thromboplastin time (aPTT), arterial thrombosis in patient < 50 years",
                      "Patients with recurrent pregnancy losses or unexplained obstetrical complications"
                    ]
                  }
                ],
                "Diagnostic Criteria": [
                  {
                    "text": "Patients who test positive for LA must have testing repeated at least 12 weeks after initial testing but within 5 years of initial testing to be considered positive for LA"
                  },
                  {
                    "text": "Number of different groups have published recommendations for testing of LA as well as guidelines for diagnostic criteriaHowever, there are no generally accepted requirements",
                    "sub_points": [
                      "However, there are no generally accepted requirements"
                    ]
                  },
                  {
                    "text": "Most organizations agree following tests must be performedScreening test: Prolongation of 2 phospholipid-dependent clotting time (screening tests)Mixing study: Prolongation will not correct with normal plasmaConfirmatory test: Confirmatory test must be performed to demonstrate phospholipid dependence of prolongationFactor deficiencies, warfarin, heparin, and other anticoagulant use must be ruled out",
                    "sub_points": [
                      "Screening test: Prolongation of 2 phospholipid-dependent clotting time (screening tests)",
                      "Mixing study: Prolongation will not correct with normal plasma",
                      "Confirmatory test: Confirmatory test must be performed to demonstrate phospholipid dependence of prolongation",
                      "Factor deficiencies, warfarin, heparin, and other anticoagulant use must be ruled out"
                    ]
                  }
                ],
                "Screening Tests": [
                  {
                    "text": "Dilute Russell viper venom time (DRVVT)Russell viper venom is potent activator of factor XWhen combined with phospholipid, calcium, and prothrombin, will cause clotting",
                    "sub_points": [
                      "Russell viper venom is potent activator of factor X",
                      "When combined with phospholipid, calcium, and prothrombin, will cause clotting"
                    ]
                  },
                  {
                    "text": "Kaolin clotting time (KCT)Patient plasma and normal plasma are mixedKaolin and calcium are added to initiate coagulationKCT is time it takes for clot formation once calcium is addedFactor deficiency is excluded by adding high concentration of normal plasma that will correct factor deficiency and subsequently correct KCTInterpretationKCT ratio is calculated using different dilutions of patient plasmaKCT (80:20% normal:patient plasma) / KCT (100% normal plasma)Ratio of > 1.2 is considered positive in most laboratoriesInterferencesSince there is no added phospholipid, this assay is particularly sensitive to platelet contamination",
                    "sub_points": [
                      "Patient plasma and normal plasma are mixed",
                      "Kaolin and calcium are added to initiate coagulation",
                      "KCT is time it takes for clot formation once calcium is added",
                      "Factor deficiency is excluded by adding high concentration of normal plasma that will correct factor deficiency and subsequently correct KCT",
                      "InterpretationKCT ratio is calculated using different dilutions of patient plasmaKCT (80:20% normal:patient plasma) / KCT (100% normal plasma)Ratio of > 1.2 is considered positive in most laboratories",
                      "KCT ratio is calculated using different dilutions of patient plasma",
                      "KCT (80:20% normal:patient plasma) / KCT (100% normal plasma)",
                      "Ratio of > 1.2 is considered positive in most laboratories",
                      "InterferencesSince there is no added phospholipid, this assay is particularly sensitive to platelet contamination",
                      "Since there is no added phospholipid, this assay is particularly sensitive to platelet contamination"
                    ]
                  },
                  {
                    "text": "aPTTSome manufacturers offer aPTT tests designed for detecting LA due to their low phospholipid contentaPTT is rarely accepted by itself as adequate screening test, as it could also be elevated for multiple reasons, including factor inhibitors",
                    "sub_points": [
                      "Some manufacturers offer aPTT tests designed for detecting LA due to their low phospholipid content",
                      "aPTT is rarely accepted by itself as adequate screening test, as it could also be elevated for multiple reasons, including factor inhibitors"
                    ]
                  }
                ],
                "Mixing Studies": [
                  {
                    "text": "Patient plasma is mixed with equal amount of plasma from normal control (1:1 mix)"
                  },
                  {
                    "text": "If aPTT corrects, prolonged aPTT is likely due to factor deficiency"
                  },
                  {
                    "text": "If aPTT fails to correct, suspect LA or specific factor inhibitor (e.g., factor VIII inhibitor)"
                  },
                  {
                    "text": "Mixing studies can also be performed with other clotting assay, such as DRVVT"
                  }
                ],
                "Confirmatory Tests": [
                  {
                    "text": "DRVVT confirmatoryIf DRVVT is prolonged, neutralization step is performed (confirmatory test)Patient's plasma is mixed with high concentration of phospholipidHigh concentration of phospholipid bypasses LA by absorbing LA, which corrects clotting timeIf clotting time does not correct, suspect factor deficiency",
                    "sub_points": [
                      "If DRVVT is prolonged, neutralization step is performed (confirmatory test)",
                      "Patient's plasma is mixed with high concentration of phospholipid",
                      "High concentration of phospholipid bypasses LA by absorbing LA, which corrects clotting time",
                      "If clotting time does not correct, suspect factor deficiency"
                    ]
                  },
                  {
                    "text": "Platelet neutralization procedure (PNP)Platelets neutralize LAPatient's plasma is mixed with platelet suspensionIf aPTT is shortened = LA; aPTT is unchanged = inhibitorCannot differentiate between LA and factor VIII inhibitors",
                    "sub_points": [
                      "Platelets neutralize LA",
                      "Patient's plasma is mixed with platelet suspension",
                      "If aPTT is shortened = LA; aPTT is unchanged = inhibitor",
                      "Cannot differentiate between LA and factor VIII inhibitors"
                    ]
                  },
                  {
                    "text": "Hexagonal phospholipid neutralizationSame principle as PNP, except excess phospholipid is in hexagonal conformationaPTT is shortened = LA (usually by ~ 8 seconds); aPTT is unchanged = inhibitorMore sensitive than PNP",
                    "sub_points": [
                      "Same principle as PNP, except excess phospholipid is in hexagonal conformation",
                      "aPTT is shortened = LA (usually by ~ 8 seconds); aPTT is unchanged = inhibitor",
                      "More sensitive than PNP"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Antiphospholipid Antibody Syndrome": {
            "name": "Antiphospholipid Antibody Syndrome",
            "url": "https://app.pathprimer.com/document/eeba64f8-05bb-41d5-8995-d05b3fae9ebd/lesson/68cf65c1-88bd-496e-ab9e-6186ce674456",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "APS is acquired prothrombotic disorder that requires both clinical and laboratory criteria for diagnosisClinical criteria: Vascular thrombosis or recurrent pregnancy morbidityLaboratory criteria: Evidence of antiphospholipid antibodies by ELISA or clot-based assayCardiolipin antibodies (IgG, IgM, and sometimes IgA)Lupus anticoagulant assay (RVVT &/or HEXA if aPTT prolonged)Anti-β₂GPI",
                    "sub_points": [
                      "Clinical criteria: Vascular thrombosis or recurrent pregnancy morbidity",
                      "Laboratory criteria: Evidence of antiphospholipid antibodies by ELISA or clot-based assayCardiolipin antibodies (IgG, IgM, and sometimes IgA)Lupus anticoagulant assay (RVVT &/or HEXA if aPTT prolonged)Anti-β₂GPI",
                      "Cardiolipin antibodies (IgG, IgM, and sometimes IgA)",
                      "Lupus anticoagulant assay (RVVT &/or HEXA if aPTT prolonged)",
                      "Anti-β₂GPI"
                    ]
                  },
                  {
                    "text": "Catastrophic antiphospholipid syndromeSystemic vascular occlusion involving 3 or more organ systems either simultaneously or within 1 week, and histological confirmation of small-vessel thrombosis, and laboratory confirmation of APAs",
                    "sub_points": [
                      "Systemic vascular occlusion involving 3 or more organ systems either simultaneously or within 1 week, and histological confirmation of small-vessel thrombosis, and laboratory confirmation of APAs"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Reagents used to test for syphilis contain phospholipids and can result in false-positive testing in patients with APAs"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Overview": [
                  {
                    "text": "Antiphospholipid antibody syndrome (APS): Acquired prothrombotic disorder that requires both clinical and laboratory criteria for diagnosisClinical criteria: Vascular thrombosis or recurrent pregnancy morbidityLaboratory criteria: Evidence of antiphospholipid antibodies by ELISA or clot-based assay",
                    "sub_points": [
                      "Clinical criteria: Vascular thrombosis or recurrent pregnancy morbidity",
                      "Laboratory criteria: Evidence of antiphospholipid antibodies by ELISA or clot-based assay"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Autoimmune syndrome in which antibodies against phospholipids or phospholipid-protein complexes are produced"
                  },
                  {
                    "text": "One major target of antiphospholipid antibodies (APA) is β₂-glycoprotein I (β₂GPI)Directly injures endothelial cellsIncreases expression of tissue factor",
                    "sub_points": [
                      "Directly injures endothelial cells",
                      "Increases expression of tissue factor"
                    ]
                  },
                  {
                    "text": "APAs interfere with protein C pathwayReducing activation of protein CInhibiting protein C complexBinding and protecting factor Va and factor VIIIa from degradation",
                    "sub_points": [
                      "Reducing activation of protein C",
                      "Inhibiting protein C complex",
                      "Binding and protecting factor Va and factor VIIIa from degradation"
                    ]
                  },
                  {
                    "text": "Other effects of antiphospholipid antibodiesInduce platelet activation and aggregationInterfere with complement activation",
                    "sub_points": [
                      "Induce platelet activation and aggregation",
                      "Interfere with complement activation"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "More common in women than men"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Sydney criteria for diagnosisTo fulfill diagnostic criteria, patient must meet at least 1 clinical and 1 laboratory criteriaClinical criteriaOne or more episodes of venous, arterial, or small vessel thrombosis in any tissue or organ, with unequivocal imaging or histologic evidence of thrombosisSuperficial venous thrombosis does not satisfy this criteriaObstetric complicationsOne or more unexplained deaths of morphologically normal fetus at ≥ 10 weeks' gestation orOne or more premature births of morphologically normal neonate before 34 weeks' gestation because of eclampsia, preeclampsia, or placental insufficiencyThree or more consecutive pregnancy losses at < 10 weeks gestation, unexplained by other causesLaboratory criteriaMedium or high titers of IgG or IgM anticardiolipin or anti-β₂GPI on 2 separate occasions, measured at least 12 weeks apartLupus anticoagulant detected on 2 separate occasions, measured at least 12 weeks apart",
                    "sub_points": [
                      "To fulfill diagnostic criteria, patient must meet at least 1 clinical and 1 laboratory criteria",
                      "Clinical criteriaOne or more episodes of venous, arterial, or small vessel thrombosis in any tissue or organ, with unequivocal imaging or histologic evidence of thrombosisSuperficial venous thrombosis does not satisfy this criteriaObstetric complicationsOne or more unexplained deaths of morphologically normal fetus at ≥ 10 weeks' gestation orOne or more premature births of morphologically normal neonate before 34 weeks' gestation because of eclampsia, preeclampsia, or placental insufficiencyThree or more consecutive pregnancy losses at < 10 weeks gestation, unexplained by other causes",
                      "One or more episodes of venous, arterial, or small vessel thrombosis in any tissue or organ, with unequivocal imaging or histologic evidence of thrombosisSuperficial venous thrombosis does not satisfy this criteria",
                      "Superficial venous thrombosis does not satisfy this criteria",
                      "Obstetric complicationsOne or more unexplained deaths of morphologically normal fetus at ≥ 10 weeks' gestation orOne or more premature births of morphologically normal neonate before 34 weeks' gestation because of eclampsia, preeclampsia, or placental insufficiencyThree or more consecutive pregnancy losses at < 10 weeks gestation, unexplained by other causes",
                      "One or more unexplained deaths of morphologically normal fetus at ≥ 10 weeks' gestation or",
                      "One or more premature births of morphologically normal neonate before 34 weeks' gestation because of eclampsia, preeclampsia, or placental insufficiency",
                      "Three or more consecutive pregnancy losses at < 10 weeks gestation, unexplained by other causes",
                      "Laboratory criteriaMedium or high titers of IgG or IgM anticardiolipin or anti-β₂GPI on 2 separate occasions, measured at least 12 weeks apartLupus anticoagulant detected on 2 separate occasions, measured at least 12 weeks apart",
                      "Medium or high titers of IgG or IgM anticardiolipin or anti-β₂GPI on 2 separate occasions, measured at least 12 weeks apart",
                      "Lupus anticoagulant detected on 2 separate occasions, measured at least 12 weeks apart"
                    ]
                  },
                  {
                    "text": "Catastrophic antiphospholipid syndromeSystemic vascular occlusion involving 3 or more organ systems either simultaneously or within 1 week, and histological confirmation of small vessel thrombosis, and laboratory confirmation of APAsHigh mortality",
                    "sub_points": [
                      "Systemic vascular occlusion involving 3 or more organ systems either simultaneously or within 1 week, and histological confirmation of small vessel thrombosis, and laboratory confirmation of APAs",
                      "High mortality"
                    ]
                  },
                  {
                    "text": "Variety of clinical manifestations associated with APS not considered criteria for diagnosisCardiac valve abnormalities (mitral valve and aortic valve are most frequently affected)Premature coronary atherosclerosisPeripheral arterial diseaseMigraines, seizures, optic neuritis, cognitive impairment, multiple sclerosisDiffuse alveolar hemorrhageGlomerulonephritisLivedo reticularisThrombocytopenia",
                    "sub_points": [
                      "Cardiac valve abnormalities (mitral valve and aortic valve are most frequently affected)",
                      "Premature coronary atherosclerosis",
                      "Peripheral arterial disease",
                      "Migraines, seizures, optic neuritis, cognitive impairment, multiple sclerosis",
                      "Diffuse alveolar hemorrhage",
                      "Glomerulonephritis",
                      "Livedo reticularis",
                      "Thrombocytopenia"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment for patients with APS remains controversialPatient with thrombosis: Warfarin, with or without aspirinStroke: Warfarin, with or without aspirinObstetric complications: Unfractionated heparin or low-molecular-weight heparin with aspirinCorticosteroids can be added for patients not responsive to anticoagulation therapyCatastrophic antiphospholipid syndrome: Anticoagulation, corticosteroids, plasma exchange, &/or intravenous immunoglobulin",
                    "sub_points": [
                      "Patient with thrombosis: Warfarin, with or without aspirin",
                      "Stroke: Warfarin, with or without aspirin",
                      "Obstetric complications: Unfractionated heparin or low-molecular-weight heparin with aspirinCorticosteroids can be added for patients not responsive to anticoagulation therapy",
                      "Corticosteroids can be added for patients not responsive to anticoagulation therapy",
                      "Catastrophic antiphospholipid syndrome: Anticoagulation, corticosteroids, plasma exchange, &/or intravenous immunoglobulin"
                    ]
                  },
                  {
                    "text": "Asymptomatic patients: Treatment with aspirin should be reserved for those at high risk of developing thrombosis (i.e., multiple laboratory abnormalities, cardiac valve disease, systemic lupus erythematosus)"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Overview": [
                  {
                    "text": "See PATHPrimer topic “Diagnosis of Lupus Anticoagulant” for complete laboratory diagnosis discussion"
                  },
                  {
                    "text": "TestingComplete blood countProthrombin time, activated partial thromboplastin time (aPTT)APA may cause prolongation of aPTT, despite association with thrombosis, rather than bleedingCardiolipin antibodiesIgGIgMSometimes IgALupus anticoagulant assay (RVVT [Russel viper venom time] &/or HEXA [hexagonal phase phospholipid neutralization assay] if aPTT prolonged)Anti-β₂GPI",
                    "sub_points": [
                      "Complete blood count",
                      "Prothrombin time, activated partial thromboplastin time (aPTT)APA may cause prolongation of aPTT, despite association with thrombosis, rather than bleeding",
                      "APA may cause prolongation of aPTT, despite association with thrombosis, rather than bleeding",
                      "Cardiolipin antibodiesIgGIgMSometimes IgA",
                      "IgG",
                      "IgM",
                      "Sometimes IgA",
                      "Lupus anticoagulant assay (RVVT [Russel viper venom time] &/or HEXA [hexagonal phase phospholipid neutralization assay] if aPTT prolonged)",
                      "Anti-β₂GPI"
                    ]
                  },
                  {
                    "text": "Reagents used to test for syphilis contain phospholipids and can result in false-positive testing in patients with APAs"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Platelet Disorders": {
        "name": "Platelet Disorders",
        "url": "https://app.pathprimer.com/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
        "topics": {
          "Wiskott-Aldrich Syndrome (Microthrombocytopenia)": {
            "name": "Wiskott-Aldrich Syndrome (Microthrombocytopenia)",
            "url": "https://app.pathprimer.com/document/2be786f6-0fea-4cbb-ad58-659880c02e3f/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Patients with Wiscott-Aldrich syndrome (WAS) have decreased or absent production of Wiscott-Aldrich syndrome protein (WASp)"
                  },
                  {
                    "text": "X-linked inheritance"
                  },
                  {
                    "text": "Immunodeficiency"
                  },
                  {
                    "text": "Eczema"
                  },
                  {
                    "text": "MicrothrombocytopeniaPresence of small platelets suggestive of WAS",
                    "sub_points": [
                      "Presence of small platelets suggestive of WAS"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Patients with Wiscott-Aldrich syndrome (WAS) have decreased or absent production of Wiscott-Aldrich syndrome protein (WASp)WASp is an intracellular protein important in regulation of actin polymerization and cellular signalingLinks cytoskeleton and signaling pathways and is key regulator of cytoskeletal assemblyBinds other signaling proteins, including Cdc42 (a GTPase) and p47nck (SH3-containing adapter protein)",
                    "sub_points": [
                      "WASp is an intracellular protein important in regulation of actin polymerization and cellular signalingLinks cytoskeleton and signaling pathways and is key regulator of cytoskeletal assemblyBinds other signaling proteins, including Cdc42 (a GTPase) and p47nck (SH3-containing adapter protein)",
                      "Links cytoskeleton and signaling pathways and is key regulator of cytoskeletal assembly",
                      "Binds other signaling proteins, including Cdc42 (a GTPase) and p47nck (SH3-containing adapter protein)"
                    ]
                  },
                  {
                    "text": "Phenotype correlates with degree of WASp expression in patient lymphocytesMilder phenotype associated with presence of intact protein in reduced amountsMore severe phenotype associated with absent WASp or expression of truncated form",
                    "sub_points": [
                      "Milder phenotype associated with presence of intact protein in reduced amounts",
                      "More severe phenotype associated with absent WASp or expression of truncated form"
                    ]
                  },
                  {
                    "text": "WAS gene located on X chromosome at Xp11.22-23"
                  },
                  {
                    "text": "Genotype-phenotype correlationsMissense mutations associated with milder diseaseNonsense mutations and larger deletions associated with severe disease",
                    "sub_points": [
                      "Missense mutations associated with milder disease",
                      "Nonsense mutations and larger deletions associated with severe disease"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "X-linked inheritance, a.k.a. X-linked thrombocytopenia (XLT)Presents almost exclusively in males",
                    "sub_points": [
                      "Presents almost exclusively in males"
                    ]
                  },
                  {
                    "text": "Incidence: 4 cases per 1 million births"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Presents with variable bleeding manifestations"
                  },
                  {
                    "text": "Immunodeficiency: Results in increased infections"
                  },
                  {
                    "text": "Eczema"
                  },
                  {
                    "text": "Thrombocytopenia and microthrombocytopenia"
                  },
                  {
                    "text": "Severe disease presentation may also includeAutoimmune diseases (e.g., autoimmune hemolytic anemia)Increased risk of lymphoma (particularly in adulthood)",
                    "sub_points": [
                      "Autoimmune diseases (e.g., autoimmune hemolytic anemia)",
                      "Increased risk of lymphoma (particularly in adulthood)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Platelet transfusion for bleeding episodes"
                  },
                  {
                    "text": "Allogeneic bone marrow transplantation can be curative"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Other inherited or acquired causes of thrombocytopenia (idiopathic thrombocytopenic purpura [ITP], thrombotic thrombocytopenic purpura [TTP])Presence of immune deficiency and eczema suggestive of WASX-linked inheritance pattern in setting of accompanying manifestations suggestive of WASPresence of small platelets suggestive of WAS",
                    "sub_points": [
                      "Presence of immune deficiency and eczema suggestive of WAS",
                      "X-linked inheritance pattern in setting of accompanying manifestations suggestive of WAS",
                      "Presence of small platelets suggestive of WAS"
                    ]
                  },
                  {
                    "text": "Hypogammaglobulinemia"
                  },
                  {
                    "text": "Severe combined immunodeficiency"
                  },
                  {
                    "text": "X-linked lymphoproliferative syndrome"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "MicrothrombocytopeniaDecreased mean platelet volume (MPV): 3.5-5 fL",
                    "sub_points": [
                      "Decreased mean platelet volume (MPV): 3.5-5 fL"
                    ]
                  },
                  {
                    "text": "Thrombocytopenia"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Normal platelet count: 150,000-450,000/µL"
                  },
                  {
                    "text": "Normal MPV: 7-11 fL"
                  }
                ],
                "Molecular": [
                  {
                    "text": "If WAS suspected, analysis ofWASgene may help"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "MYH9 Mutations (Macrothrombocytopenia)": {
            "name": "MYH9 Mutations (Macrothrombocytopenia)",
            "url": "https://app.pathprimer.com/document/63753735-cdbb-421f-b020-457411c67617/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Nonmuscle myosin heavy-chain IIA (NMMHC-IIA) is protein product ofMYH9gene and is component of nonmuscle myosin IIA (NMM-IIA)"
                  },
                  {
                    "text": "NMM-IIA is expressed in various tissues; therefore, patients withMYH9-related diseases can present with multiple manifestations"
                  },
                  {
                    "text": "MYH9-related diseases are divided into 4 syndromes depending on presence or absence of macrothrombocytopenia, neutrophil inclusion bodies, hearing loss, nephritis, and cataractsMay-Hegglin anomaly (MHA)Epstein syndrome (EPS)Fechtner syndrome (FS)Sebastian platelet syndrome (SPS)",
                    "sub_points": [
                      "May-Hegglin anomaly (MHA)",
                      "Epstein syndrome (EPS)",
                      "Fechtner syndrome (FS)",
                      "Sebastian platelet syndrome (SPS)"
                    ]
                  },
                  {
                    "text": "Autosomal dominant inheritance"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Nonmuscle myosin heavy-chain IIA (NMMHC-IIA) is protein product ofMYH9gene and is component of nonmuscle myosin IIA (NMM-IIA)Precise biological function of NMM-IIA unknownHas been suggested to act as molecular motor that facilitates changes in cell shape",
                    "sub_points": [
                      "Precise biological function of NMM-IIA unknown",
                      "Has been suggested to act as molecular motor that facilitates changes in cell shape"
                    ]
                  },
                  {
                    "text": "Abnormal localization of myosin, tubulin, and various intracellular signaling molecules is noted before and after platelet activation in patients with MYH9-related diseasesConsistent with NMM-IIA playing role in platelet cytoskeletal organization",
                    "sub_points": [
                      "Consistent with NMM-IIA playing role in platelet cytoskeletal organization"
                    ]
                  },
                  {
                    "text": "NMM-IIA expressed in various tissues; therefore, patients withMYH9-related diseases can present with multiple abnormalitiesPlatelet: Thrombocytopenia and macroplatelets (platelets as big as or larger than red blood cells)Neutrophil: Döhle-like body inclusionsAuditory: High-frequency hearing lossRenal: NephritisOcular: Cataracts",
                    "sub_points": [
                      "Platelet: Thrombocytopenia and macroplatelets (platelets as big as or larger than red blood cells)",
                      "Neutrophil: Döhle-like body inclusions",
                      "Auditory: High-frequency hearing loss",
                      "Renal: Nephritis",
                      "Ocular: Cataracts"
                    ]
                  },
                  {
                    "text": "MYH9gene is located on chromosome 22"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Autosomal dominant inheritance"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Presents with mild bleeding manifestationsMacroplateletsThrombocytopenia",
                    "sub_points": [
                      "Macroplatelets",
                      "Thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Other presenting signs and symptomsHearing lossNephritisCataracts",
                    "sub_points": [
                      "Hearing loss",
                      "Nephritis",
                      "Cataracts"
                    ]
                  },
                  {
                    "text": "MYH9-related diseases divided into 4 syndromes, depending on presence or absence of macrothrombocytopenia, neutrophil inclusion bodies, hearing loss, nephritis, and cataractsMay-Hegglin anomaly (MHA)Epstein syndrome (EPS)Fechtner syndrome (FS)Sebastian platelet syndrome (SPS)",
                    "sub_points": [
                      "May-Hegglin anomaly (MHA)",
                      "Epstein syndrome (EPS)",
                      "Fechtner syndrome (FS)",
                      "Sebastian platelet syndrome (SPS)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Platelet transfusion for bleeding episodes"
                  },
                  {
                    "text": "Other general measures may help support hemostasis in patients with congenital platelet disordersDDAVP (1-desamino-8D-arginine vasopressin)Antifibrinolytic agents",
                    "sub_points": [
                      "DDAVP (1-desamino-8D-arginine vasopressin)",
                      "Antifibrinolytic agents"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "OtherMYH9-related diseases"
                  },
                  {
                    "text": "Other disorders that may present with macrothrombocytopeniaChronic idiopathic thrombocytopenic purpura (ITP)Only 10% of platelets in chronic ITP may be macroplatelets (whereas these account for virtually all platelets inMYH9-related disease)Bernard-Soulier syndrome (BSS)Platelet aggregation studies show defective agglutination in response to ristocetin, while platelet agglutination inMYH9-related disease is normalParis-Trousseau syndrome and Jacobsen syndromeParis-Trousseau syndrome and Jacobsen syndrome are accompanied by clinical features not typically found inMYH9-related diseasesMental retardationFacial/cardiac abnormalitiesX-linked macrothrombocytopeniaX-linked macrothrombocytopenia is accompanied by other features not typically found inMYH9-related diseasesSplenomegalyRed blood cell abnormalities (anemia and reticulocytosis)Gray platelet syndrome (GPS)Associated with presence of pale, gray platelets on peripheral blood smearPlatelet granulation inMYH9-related diseases is normal",
                    "sub_points": [
                      "Chronic idiopathic thrombocytopenic purpura (ITP)Only 10% of platelets in chronic ITP may be macroplatelets (whereas these account for virtually all platelets inMYH9-related disease)",
                      "Only 10% of platelets in chronic ITP may be macroplatelets (whereas these account for virtually all platelets inMYH9-related disease)",
                      "Bernard-Soulier syndrome (BSS)Platelet aggregation studies show defective agglutination in response to ristocetin, while platelet agglutination inMYH9-related disease is normal",
                      "Platelet aggregation studies show defective agglutination in response to ristocetin, while platelet agglutination inMYH9-related disease is normal",
                      "Paris-Trousseau syndrome and Jacobsen syndromeParis-Trousseau syndrome and Jacobsen syndrome are accompanied by clinical features not typically found inMYH9-related diseasesMental retardationFacial/cardiac abnormalities",
                      "Paris-Trousseau syndrome and Jacobsen syndrome are accompanied by clinical features not typically found inMYH9-related diseasesMental retardationFacial/cardiac abnormalities",
                      "Mental retardation",
                      "Facial/cardiac abnormalities",
                      "X-linked macrothrombocytopeniaX-linked macrothrombocytopenia is accompanied by other features not typically found inMYH9-related diseasesSplenomegalyRed blood cell abnormalities (anemia and reticulocytosis)",
                      "X-linked macrothrombocytopenia is accompanied by other features not typically found inMYH9-related diseasesSplenomegalyRed blood cell abnormalities (anemia and reticulocytosis)",
                      "Splenomegaly",
                      "Red blood cell abnormalities (anemia and reticulocytosis)",
                      "Gray platelet syndrome (GPS)Associated with presence of pale, gray platelets on peripheral blood smearPlatelet granulation inMYH9-related diseases is normal",
                      "Associated with presence of pale, gray platelets on peripheral blood smear",
                      "Platelet granulation inMYH9-related diseases is normal"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Platelet count: Decreased"
                  },
                  {
                    "text": "Mean platelet volume (MPV): Increased"
                  },
                  {
                    "text": "Peripheral blood smearPresence of macroplatelets+/- Dohle-like inclusions in neutrophils",
                    "sub_points": [
                      "Presence of macroplatelets",
                      "+/- Dohle-like inclusions in neutrophils"
                    ]
                  },
                  {
                    "text": "Platelet aggregation pattern: Normal"
                  }
                ],
                "Molecular": [
                  {
                    "text": "MYH9gene80% of identified mutations are localized to 5 amino acid residuesEvaluation of patients with these common mutations may allow for some genotype-phenotype associationsArg702 closely related to hearing loss and nephritisGlu1841 associated with absence of kidney or hearing manifestations",
                    "sub_points": [
                      "80% of identified mutations are localized to 5 amino acid residues",
                      "Evaluation of patients with these common mutations may allow for some genotype-phenotype associationsArg702 closely related to hearing loss and nephritisGlu1841 associated with absence of kidney or hearing manifestations",
                      "Arg702 closely related to hearing loss and nephritis",
                      "Glu1841 associated with absence of kidney or hearing manifestations"
                    ]
                  },
                  {
                    "text": "Analysis ofMYH9gene may be useful in confirming diagnosis of anMYH9-related disease"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Thrombotic Thrombocytopenic Purpura": {
            "name": "Thrombotic Thrombocytopenic Purpura",
            "url": "https://app.pathprimer.com/document/cb38dccc-818f-4c5b-9031-be8e00a872ae/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "ADAMTS13 deficiency due to gene mutation or production of autoantibodies results in persistence of ULvWFMs that are able to bind platelets spontaneously leading to widespread formation of platelet-rich thrombi in microvasculature"
                  },
                  {
                    "text": "﻿Accumulation of platelets in clots leads to thrombocytopenia, mechanical red blood cell destruction (schistocytes), end-organ damage due to ischemia"
                  },
                  {
                    "text": "90% mortality rate without treatment"
                  },
                  {
                    "text": "20% mortality rate with treatment"
                  },
                  {
                    "text": "﻿Classical pentad of findings in TTPThrombocytopeniaMicroangiopathic hemolytic anemiaNeurologic signsRenal dysfunctionFever",
                    "sub_points": [
                      "Thrombocytopenia",
                      "Microangiopathic hemolytic anemia",
                      "Neurologic signs",
                      "Renal dysfunction",
                      "Fever"
                    ]
                  },
                  {
                    "text": "Current criteria have been narrowed to thrombocytopenia and microangiopathic hemolytic anemia with no other obvious cause for these findings"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "ADAMTS13 is zinc-containing metalloprotease enzyme responsible for cleaving von Willebrand factor (vWF) into smaller multimers"
                  },
                  {
                    "text": "ADAMTS13 deficiency due to gene mutation or production of autoantibodies results in persistence of ultra-large vWF multimers (ULvWFM) that are able to bind platelets spontaneously leading to widespread formation of platelet-rich thrombi in microvasculature"
                  },
                  {
                    "text": "﻿Accumulation of platelets in clots leads to thrombocytopenia, mechanical red blood cell destruction (schistocytes), end-organ damage due to ischemia"
                  },
                  {
                    "text": "Resulting syndrome is thrombotic thrombocytopenic purpura (TTP)"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "90% mortality rate without treatment"
                  },
                  {
                    "text": "20% mortality rate with treatment"
                  },
                  {
                    "text": "Congenital TTP (inherited ADAMTS13 deficiency)Autosomal recessive inheritanceHomozygous or compound heterozygous mutations",
                    "sub_points": [
                      "Autosomal recessive inheritance",
                      "Homozygous or compound heterozygous mutations"
                    ]
                  },
                  {
                    "text": "Idiopathic/acquired TTPAcquired ADAMTS13 deficiencyCaused by inhibition or clearance of ADAMTS13 by autoantibodiesOccurs more often in women than men~ 1/3 of patients will have relapseRecurrence is more common in patients with ADAMTS13 levels below 5% and high-titer antibodiesMay be precipitated by various clinical conditionsHIV infectionMedicationsQuinineClopidogrel and ticlopidinePregnancyCancerBone marrow transplantation",
                    "sub_points": [
                      "Acquired ADAMTS13 deficiencyCaused by inhibition or clearance of ADAMTS13 by autoantibodiesOccurs more often in women than men~ 1/3 of patients will have relapseRecurrence is more common in patients with ADAMTS13 levels below 5% and high-titer antibodies",
                      "Caused by inhibition or clearance of ADAMTS13 by autoantibodies",
                      "Occurs more often in women than men",
                      "~ 1/3 of patients will have relapse",
                      "Recurrence is more common in patients with ADAMTS13 levels below 5% and high-titer antibodies",
                      "May be precipitated by various clinical conditionsHIV infectionMedicationsQuinineClopidogrel and ticlopidinePregnancyCancerBone marrow transplantation",
                      "HIV infection",
                      "MedicationsQuinineClopidogrel and ticlopidine",
                      "Quinine",
                      "Clopidogrel and ticlopidine",
                      "Pregnancy",
                      "Cancer",
                      "Bone marrow transplantation"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "﻿Classical pentad of findings in TTPThrombocytopeniaMicroangiopathic hemolytic anemiaNeurologic signsRenal dysfunctionFever",
                    "sub_points": [
                      "Thrombocytopenia",
                      "Microangiopathic hemolytic anemia",
                      "Neurologic signs",
                      "Renal dysfunction",
                      "Fever"
                    ]
                  },
                  {
                    "text": "Current criteria have been narrowed to thrombocytopenia and microangiopathic hemolytic anemia with no other obvious cause for these findings"
                  },
                  {
                    "text": "Congenital TTPWith severe deficiency, initial presentation is usually in infancy or childhoodLess severe deficiency may present later in life",
                    "sub_points": [
                      "With severe deficiency, initial presentation is usually in infancy or childhood",
                      "Less severe deficiency may present later in life"
                    ]
                  },
                  {
                    "text": "Idiopathic TTP due to ADAMTS13 deficiencyTends to present later on in life (i.e., age 20-60 years)",
                    "sub_points": [
                      "Tends to present later on in life (i.e., age 20-60 years)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Congenital TTPPlasma infusion",
                    "sub_points": [
                      "Plasma infusion"
                    ]
                  },
                  {
                    "text": "Acquired TTPTreatment goal is to replace ADAMTS13 activity and remove/decrease autoantibodies if presentImmediate infusion of plasma (30 mL/kg/day) until plasma exchange can be initiatedDaily plasma exchange with plasma replacementGlucocorticoids (e.g., IV prednisolone)Red blood cells as needed to treat anemiaSuccessful treatment is indicated by normalization of platelet count and lactate dehydrogenase (LDH)Platelet transfusion is generally avoided in TTP patients and is reserved only for life-threatening bleeding events, including intracerebral or gastrointestinal bleedingTreatment options for patients who are refractory to treatmentContinue daily plasma exchange and consider cryoprecipitate-poor plasmaRituximab (in combination with plasma exchange)Rule out concomitant heparin-induced thrombocytopeniaSearch for and eliminate infection (e.g., catheter infection)VincristineSplenectomyAzathioprine or cyclophosphamide",
                    "sub_points": [
                      "Treatment goal is to replace ADAMTS13 activity and remove/decrease autoantibodies if presentImmediate infusion of plasma (30 mL/kg/day) until plasma exchange can be initiatedDaily plasma exchange with plasma replacementGlucocorticoids (e.g., IV prednisolone)Red blood cells as needed to treat anemia",
                      "Immediate infusion of plasma (30 mL/kg/day) until plasma exchange can be initiated",
                      "Daily plasma exchange with plasma replacement",
                      "Glucocorticoids (e.g., IV prednisolone)",
                      "Red blood cells as needed to treat anemia",
                      "Successful treatment is indicated by normalization of platelet count and lactate dehydrogenase (LDH)",
                      "Platelet transfusion is generally avoided in TTP patients and is reserved only for life-threatening bleeding events, including intracerebral or gastrointestinal bleeding",
                      "Treatment options for patients who are refractory to treatmentContinue daily plasma exchange and consider cryoprecipitate-poor plasmaRituximab (in combination with plasma exchange)Rule out concomitant heparin-induced thrombocytopeniaSearch for and eliminate infection (e.g., catheter infection)VincristineSplenectomyAzathioprine or cyclophosphamide",
                      "Continue daily plasma exchange and consider cryoprecipitate-poor plasma",
                      "Rituximab (in combination with plasma exchange)",
                      "Rule out concomitant heparin-induced thrombocytopenia",
                      "Search for and eliminate infection (e.g., catheter infection)",
                      "Vincristine",
                      "Splenectomy",
                      "Azathioprine or cyclophosphamide"
                    ]
                  },
                  {
                    "text": "Drug-induced TTPDiscontinue offending medication",
                    "sub_points": [
                      "Discontinue offending medication"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Several other conditions can present with thrombocytopenia and hemolytic anemia﻿Hemolytic uremic syndrome (HUS)Thrombocytopenia, LDH elevation, schistocytosis usually more severe in TTPRenal injury usually more severe in HUSPlasma ADAMTS13 activity usually severely reduced in TTP, while in normal range in HUSDisseminated intravascular coagulationWill have abnormal coagulation studiesEvans syndromeWill have positive direct antiglobulin test (DAT) and lack schistocytesMalignant hypertensionMalfunctioning prosthetic cardiac valvesSevere vasculitisPreeclampsia/eclampsiaHemolysis, elevated liver enzymes, low platelet count (HELLP syndrome)Medication effect",
                    "sub_points": [
                      "﻿Hemolytic uremic syndrome (HUS)Thrombocytopenia, LDH elevation, schistocytosis usually more severe in TTPRenal injury usually more severe in HUSPlasma ADAMTS13 activity usually severely reduced in TTP, while in normal range in HUS",
                      "Thrombocytopenia, LDH elevation, schistocytosis usually more severe in TTP",
                      "Renal injury usually more severe in HUS",
                      "Plasma ADAMTS13 activity usually severely reduced in TTP, while in normal range in HUS",
                      "Disseminated intravascular coagulationWill have abnormal coagulation studies",
                      "Will have abnormal coagulation studies",
                      "Evans syndromeWill have positive direct antiglobulin test (DAT) and lack schistocytes",
                      "Will have positive direct antiglobulin test (DAT) and lack schistocytes",
                      "Malignant hypertension",
                      "Malfunctioning prosthetic cardiac valves",
                      "Severe vasculitis",
                      "Preeclampsia/eclampsia",
                      "Hemolysis, elevated liver enzymes, low platelet count (HELLP syndrome)",
                      "Medication effect"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "﻿Decreased platelet count (often less than 20,000/uL)"
                  },
                  {
                    "text": "﻿Presence of schistocytes on peripheral blood smear"
                  },
                  {
                    "text": "Elevated LDH"
                  },
                  {
                    "text": "Normal prothrombin time and activated partial thromboplastin time"
                  },
                  {
                    "text": "Normal fibrinogen and D dimer"
                  },
                  {
                    "text": "Negative DAT"
                  },
                  {
                    "text": "Decreased ADAMTS13 activityUsually < 5% in congenital TTPUsually < 5% in acquired TTPIf acquired TTP due to autoantibodies against ADAMTS13, then antibodies are also detectedNormal ADAMTS13 activity is not sufficient to rule out TTP",
                    "sub_points": [
                      "Usually < 5% in congenital TTP",
                      "Usually < 5% in acquired TTPIf acquired TTP due to autoantibodies against ADAMTS13, then antibodies are also detected",
                      "If acquired TTP due to autoantibodies against ADAMTS13, then antibodies are also detected",
                      "Normal ADAMTS13 activity is not sufficient to rule out TTP"
                    ]
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Normal ADAMTS13 activity > 60%"
                  }
                ],
                "Molecular": [
                  {
                    "text": "ADAMTS13geneLocated on chromosome 9Mutations have been foundDeletionSplice siteFrame-shiftMissenseIf familial mutation is known, genotyping may be useful",
                    "sub_points": [
                      "Located on chromosome 9",
                      "Mutations have been foundDeletionSplice siteFrame-shiftMissense",
                      "Deletion",
                      "Splice site",
                      "Frame-shift",
                      "Missense",
                      "If familial mutation is known, genotyping may be useful"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Idiopathic Thrombocytopenic Purpura": {
            "name": "Idiopathic Thrombocytopenic Purpura",
            "url": "https://app.pathprimer.com/document/ecefa988-42c4-4a75-843f-e9bdbc231024/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Antiplatelet antibodies result in increased platelet destruction or inhibited release of platelets"
                  },
                  {
                    "text": "Thrombocytopenia (increased destruction and decreased production) and decreased platelet function contribute to risk of bleeding in ITP"
                  },
                  {
                    "text": "Goal of treatment is to prevent major bleeding"
                  },
                  {
                    "text": "Children tend to have acute ITP with spontaneous remission within weeks to months"
                  },
                  {
                    "text": "Adults tend to have chronic ITP and may require multiple therapeutic attempts"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Immune-mediated destruction or inhibited release of plateletsCross-reactivity suspected in cases preceded by infection or potential drug reactionInfective agents may share epitopes with plateletsAntiplatelet antibodiesMost often directed against platelet membrane glycoproteins GPIIb/IIIa and GPIb-IX",
                    "sub_points": [
                      "Cross-reactivity suspected in cases preceded by infection or potential drug reactionInfective agents may share epitopes with platelets",
                      "Infective agents may share epitopes with platelets",
                      "Antiplatelet antibodiesMost often directed against platelet membrane glycoproteins GPIIb/IIIa and GPIb-IX",
                      "Most often directed against platelet membrane glycoproteins GPIIb/IIIa and GPIb-IX"
                    ]
                  },
                  {
                    "text": "Decreased platelet production also present"
                  },
                  {
                    "text": "Thrombocytopenia (increased destruction and decreased production) and decreased platelet function contribute to risk of bleeding in idiopathic thrombocytopenic purpura (ITP)"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Incidence is 3.3 per 100,000 adults/year"
                  },
                  {
                    "text": "Incidence is 1.9-6.4 per 100,000 children/year"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Bleeding symptomsMost patients with ITP donothave clinically important bleedingMucocutaneous bleedingPurpuraPetechiaeMenorrhagiaEpistaxis and gingival bleeding less commonGastrointestinal bleeding rare but can be severe",
                    "sub_points": [
                      "Most patients with ITP donothave clinically important bleeding",
                      "Mucocutaneous bleedingPurpuraPetechiaeMenorrhagiaEpistaxis and gingival bleeding less commonGastrointestinal bleeding rare but can be severe",
                      "Purpura",
                      "Petechiae",
                      "Menorrhagia",
                      "Epistaxis and gingival bleeding less common",
                      "Gastrointestinal bleeding rare but can be severe"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Goal of treatment is to prevent major bleeding"
                  },
                  {
                    "text": "ChildrenChildren tend to have acute ITP with spontaneous remission within weeks to monthsTreatment recommended for mild cutaneous bleeding (bruising and petechiae)Common initial treatmentsIntravenous immune globulin (IVIG)Anti-Rh(D) (anti-D)Corticosteroids",
                    "sub_points": [
                      "Children tend to have acute ITP with spontaneous remission within weeks to months",
                      "Treatment recommended for mild cutaneous bleeding (bruising and petechiae)",
                      "Common initial treatmentsIntravenous immune globulin (IVIG)Anti-Rh(D) (anti-D)Corticosteroids",
                      "Intravenous immune globulin (IVIG)",
                      "Anti-Rh(D) (anti-D)",
                      "Corticosteroids"
                    ]
                  },
                  {
                    "text": "AdultsAdults tend to have chronic ITP and may require multiple therapeutic attemptsTreatment decisions guided more by platelet count than bleeding symptomsInitial managementPlatelet count > 30,000/μL with no or cutaneous bleedingObservationPlatelet count < 30,000/μL or symptomatic bleedingCorticosteroidsIVIG or anti-D may be used as additional treatment in patients with overt bleedingSecond-line treatment for patients not responding to corticosteroids with platelet count < 20,000/μL or symptomatic bleedingRituximabThrombopoietin receptor antagonists (romiplostim or eltrombopag)Splenectomy (most effective treatment for ITP)Treatment of patients refractory to above-listed treatmentsSearch for and remove accessory spleensCyclophosphamideVinca alkaloidsAzathioprineTreatment of bleeding emergencyPlatelet transfusionHigh-dose intravenous (IV) glucocorticoids or IVIG",
                    "sub_points": [
                      "Adults tend to have chronic ITP and may require multiple therapeutic attempts",
                      "Treatment decisions guided more by platelet count than bleeding symptoms",
                      "Initial managementPlatelet count > 30,000/μL with no or cutaneous bleedingObservationPlatelet count < 30,000/μL or symptomatic bleedingCorticosteroidsIVIG or anti-D may be used as additional treatment in patients with overt bleeding",
                      "Platelet count > 30,000/μL with no or cutaneous bleedingObservation",
                      "Observation",
                      "Platelet count < 30,000/μL or symptomatic bleedingCorticosteroidsIVIG or anti-D may be used as additional treatment in patients with overt bleeding",
                      "Corticosteroids",
                      "IVIG or anti-D may be used as additional treatment in patients with overt bleeding",
                      "Second-line treatment for patients not responding to corticosteroids with platelet count < 20,000/μL or symptomatic bleedingRituximabThrombopoietin receptor antagonists (romiplostim or eltrombopag)Splenectomy (most effective treatment for ITP)",
                      "Rituximab",
                      "Thrombopoietin receptor antagonists (romiplostim or eltrombopag)",
                      "Splenectomy (most effective treatment for ITP)",
                      "Treatment of patients refractory to above-listed treatmentsSearch for and remove accessory spleensCyclophosphamideVinca alkaloidsAzathioprine",
                      "Search for and remove accessory spleens",
                      "Cyclophosphamide",
                      "Vinca alkaloids",
                      "Azathioprine",
                      "Treatment of bleeding emergencyPlatelet transfusionHigh-dose intravenous (IV) glucocorticoids or IVIG",
                      "Platelet transfusion",
                      "High-dose intravenous (IV) glucocorticoids or IVIG"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Other possible causes of thrombocytopenia should be excludedPseudothrombocytopenia—examine peripheral smearEthylenediamine tetraacetic acid (EDTA)-dependent platelet clumpingPlatelet satellitism",
                    "sub_points": [
                      "Pseudothrombocytopenia—examine peripheral smearEthylenediamine tetraacetic acid (EDTA)-dependent platelet clumpingPlatelet satellitism",
                      "Ethylenediamine tetraacetic acid (EDTA)-dependent platelet clumping",
                      "Platelet satellitism"
                    ]
                  },
                  {
                    "text": "Drug-induced thrombocytopeniaEspecially heparin-induced thrombocytopenia (HIT)",
                    "sub_points": [
                      "Especially heparin-induced thrombocytopenia (HIT)"
                    ]
                  },
                  {
                    "text": "Hypersplenism"
                  },
                  {
                    "text": "InfectionsHuman immunodeficiency virus (HIV)Hepatitis CCytomegalovirus",
                    "sub_points": [
                      "Human immunodeficiency virus (HIV)",
                      "Hepatitis C",
                      "Cytomegalovirus"
                    ]
                  },
                  {
                    "text": "Congenital thrombocytopenias—family history of thrombocytopenia, peripheral smearBernard-Soulier syndromeMYH9-related thrombocytopeniaFanconi syndromeWiskott-Aldrich syndromeThrombocytopenia with absent radius",
                    "sub_points": [
                      "Bernard-Soulier syndrome",
                      "MYH9-related thrombocytopenia",
                      "Fanconi syndrome",
                      "Wiskott-Aldrich syndrome",
                      "Thrombocytopenia with absent radius"
                    ]
                  },
                  {
                    "text": "Type 2B von Willebrand disease—check von Willebrand factor activity and antigen"
                  },
                  {
                    "text": "Myelodysplasia—bone marrow biopsy may be helpful in older patients"
                  },
                  {
                    "text": "Chronic disseminated intravascular coagulation—check D-dimer levels"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura—check peripheral smear for schistocytes"
                  },
                  {
                    "text": "Acquired pure megakaryocytic aplasia—marrow aspirate showing no megakaryocytes prompted by poor response to treatment"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Platelet count < 100,000/μL"
                  }
                ],
                "Specimen Collection": [
                  {
                    "text": "Complete blood count specimen collected in EDTA anticoagulantIf pseudothrombocytopenia is observed, collect in citrate anticoagulant",
                    "sub_points": [
                      "If pseudothrombocytopenia is observed, collect in citrate anticoagulant"
                    ]
                  }
                ],
                "Microscopy": [
                  {
                    "text": "Peripheral blood smear shows isolated thrombocytopenia"
                  },
                  {
                    "text": "Bone marrow has normal to increased megakaryocytes"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Reactive Thrombocytosis": {
            "name": "Reactive Thrombocytosis",
            "url": "https://app.pathprimer.com/document/8e36d0c5-be35-442b-9eef-efbf4a289bbf/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "RT develops secondary to another disorder"
                  },
                  {
                    "text": "Mainstay of treatment for RT is to treat the underlying condition"
                  },
                  {
                    "text": "Important to distinguish RT from malignancy, especially with ET, because the only presenting finding of ET may be thrombocytosis"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Thrombocytosis is defined as platelet count above 450,000/uL (upper limit of normal for lab reference range)"
                  },
                  {
                    "text": "Reactive thrombocytosis (RT) caused by increased megakaryocyte production of platelets"
                  },
                  {
                    "text": "Platelets are acute-phase reactantsPhysiologically normal megakaryocyte response to increased thrombopoietic and inflammatory cytokinesInflammatory cytokines involved include interleukin (IL)-1, IL-6, and IL-11Patients with RT have elevated thrombopoietin levels",
                    "sub_points": [
                      "Physiologically normal megakaryocyte response to increased thrombopoietic and inflammatory cytokines",
                      "Inflammatory cytokines involved include interleukin (IL)-1, IL-6, and IL-11",
                      "Patients with RT have elevated thrombopoietin levels"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "RT accounts for 88-97% of thrombocytosis"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "RT develops secondary to another disorder"
                  },
                  {
                    "text": "Most common causesIron deficiencyBacterial infections and tuberculosisInflammatory diseasesAdvanced malignanciesAcute blood lossHemolysisSplenectomy (post-splenectomy) or aspleniaRebound after chemotherapy-induced thrombocytopenia",
                    "sub_points": [
                      "Iron deficiency",
                      "Bacterial infections and tuberculosis",
                      "Inflammatory diseases",
                      "Advanced malignancies",
                      "Acute blood loss",
                      "Hemolysis",
                      "Splenectomy (post-splenectomy) or asplenia",
                      "Rebound after chemotherapy-induced thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Thrombotic and hemorrhagic events very rare in patients with RT"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Mainstay of treatment for RT is to treat the underlying condition"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Spurious or pseudothrombocytosisLaboratory artifact caused by impedance-type automated hematology analyzers that erroneously count precipitates, cells, or cell fragments as platelets (similar size)SchistocytesCytoplasmic fragments of neoplastic cellsCryoglobulinemia with circulating crystalsBacteria, microorganisms, or fungiParasites or malarial trophozoites",
                    "sub_points": [
                      "Laboratory artifact caused by impedance-type automated hematology analyzers that erroneously count precipitates, cells, or cell fragments as platelets (similar size)SchistocytesCytoplasmic fragments of neoplastic cellsCryoglobulinemia with circulating crystalsBacteria, microorganisms, or fungiParasites or malarial trophozoites",
                      "Schistocytes",
                      "Cytoplasmic fragments of neoplastic cells",
                      "Cryoglobulinemia with circulating crystals",
                      "Bacteria, microorganisms, or fungi",
                      "Parasites or malarial trophozoites"
                    ]
                  },
                  {
                    "text": "Primary thrombocytosisMalignanciesEssential thrombocythemia (ET)Polycythemia veraPrimary myelofibrosisChronic myeloid leukemiaRefractory anemia with ringed sideroblasts and thrombocytosisChronic myelomonocytic leukemiaMyelodysplastic syndrome/myeloproliferative neoplasm overlapImportant to distinguish RT from malignancy, especially with ET, because the only presenting finding of ET may be thrombocytosisHereditary/familial thrombocytosisAutosomal dominant inheritanceMediated by heterogeneous gene mutations resulting in gain of function mutations in genes for thrombopoietin (TPO) or its receptor (c-MPL)",
                    "sub_points": [
                      "MalignanciesEssential thrombocythemia (ET)Polycythemia veraPrimary myelofibrosisChronic myeloid leukemiaRefractory anemia with ringed sideroblasts and thrombocytosisChronic myelomonocytic leukemiaMyelodysplastic syndrome/myeloproliferative neoplasm overlapImportant to distinguish RT from malignancy, especially with ET, because the only presenting finding of ET may be thrombocytosis",
                      "Essential thrombocythemia (ET)",
                      "Polycythemia vera",
                      "Primary myelofibrosis",
                      "Chronic myeloid leukemia",
                      "Refractory anemia with ringed sideroblasts and thrombocytosis",
                      "Chronic myelomonocytic leukemia",
                      "Myelodysplastic syndrome/myeloproliferative neoplasm overlap",
                      "Important to distinguish RT from malignancy, especially with ET, because the only presenting finding of ET may be thrombocytosis",
                      "Hereditary/familial thrombocytosisAutosomal dominant inheritanceMediated by heterogeneous gene mutations resulting in gain of function mutations in genes for thrombopoietin (TPO) or its receptor (c-MPL)",
                      "Autosomal dominant inheritance",
                      "Mediated by heterogeneous gene mutations resulting in gain of function mutations in genes for thrombopoietin (TPO) or its receptor (c-MPL)"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Other Laboratory Analytes Helpful in Diagnosis": [
                  {
                    "text": "Other increased acute phase reactants in RTElevated C-reactive protein (CRP)Increased erythrocyte sedimentation rate (ESR)Elevated fibrinogen levels",
                    "sub_points": [
                      "Elevated C-reactive protein (CRP)",
                      "Increased erythrocyte sedimentation rate (ESR)",
                      "Elevated fibrinogen levels"
                    ]
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Platelet count reference range 150,000-450,000/uL"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Bernard-Soulier Syndrome": {
            "name": "Bernard-Soulier Syndrome",
            "url": "https://app.pathprimer.com/document/1ee8258b-bc1e-4589-acf4-cc0cc10573c7/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "GPIb/V/IX complex on platelet surface binds to von Willebrand factor (vWF) during platelet adhesion"
                  },
                  {
                    "text": "Bernard-Soulier syndrome (BSS), caused by abnormalities in GPIb/V/IX complex, results inThrombocytopeniaMacroplatelets (platelets as large as or larger than red blood cell)Defective platelet adhesion/binding to vWF",
                    "sub_points": [
                      "Thrombocytopenia",
                      "Macroplatelets (platelets as large as or larger than red blood cell)",
                      "Defective platelet adhesion/binding to vWF"
                    ]
                  },
                  {
                    "text": "Autosomal recessive inheritance"
                  },
                  {
                    "text": "Presents with moderate to severe bleeding manifestations"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Decreased platelet count (ranging from 20,000/mL to normal reference range)"
                  },
                  {
                    "text": "Abnormal platelet aggregation patternAbsent or extremely diminished platelet agglutination in response to ristocetinNormal aggregation in response to ADP, epinephrine, and collagen agonists",
                    "sub_points": [
                      "Absent or extremely diminished platelet agglutination in response to ristocetin",
                      "Normal aggregation in response to ADP, epinephrine, and collagen agonists"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "GPIb/V/IX complex on platelet surface binds to von Willebrand factor (vWF) during platelet adhesion"
                  },
                  {
                    "text": "4 separate genes encode 4 polypeptides that make up this complexGPIbαGPIbβGPVGPIX",
                    "sub_points": [
                      "GPIbα",
                      "GPIbβ",
                      "GPV",
                      "GPIX"
                    ]
                  },
                  {
                    "text": "Normal platelets have ~ 25,000 GPIb/V/IX complexes on their surface"
                  },
                  {
                    "text": "Bernard-Soulier syndrome (BSS), caused by abnormalities in GPIb/V/IX complex, results inThrombocytopeniaMacroplatelets (platelets as large as or larger than red blood cell)Defective platelet adhesion/binding to vWF",
                    "sub_points": [
                      "Thrombocytopenia",
                      "Macroplatelets (platelets as large as or larger than red blood cell)",
                      "Defective platelet adhesion/binding to vWF"
                    ]
                  },
                  {
                    "text": "Mutations inGPIbα,GPIbβ, andGPIXgenes have all been identified in BSS patientsMutations inGPIbα are most common",
                    "sub_points": [
                      "Mutations inGPIbα are most common"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Autosomal recessive inheritance"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Presents with moderate to severe bleeding manifestations"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Platelet transfusion for bleeding episodesAlloimmunization (development of antibodies against GPIb/V/IX) with refractoriness to platelet transfusion has occurred",
                    "sub_points": [
                      "Alloimmunization (development of antibodies against GPIb/V/IX) with refractoriness to platelet transfusion has occurred"
                    ]
                  },
                  {
                    "text": "DDAVP (1-desamino-8D-arginine vasopressin)"
                  },
                  {
                    "text": "Recombinant factor VIIa (rVIIa)"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Other disorders that may present with macrothrombocytopeniaAutosomal dominant Mediterranean macrothrombocytopeniaHeterozygous mutation inGPIbαVelocardiofacial syndromeHeterozygous absence of GPIb/V/IX complexAssociated with other manifestations of microdeletion of chromosome 22q11 (Di George syndrome) not typically found in BSS, includingCleft palateDelayed developmentImmune dysfunctionCardiac defectsChronic idiopathic thrombocytopenic purpura (ITP)Acquired; likely that relatives are not affectedPatients with BSS may have relatives who also have macrothrombocytopenia (inherited)Only 10% of platelets in chronic ITP may be \"macroplatelets\" (whereas these account for virtually all platelets in BSS-related disease)MYH9-related diseaseIn BSS platelet aggregation studies show defective agglutination in response to ristocetin, while normal ristocetin-induced platelet agglutination should occur in MYH9-related diseaseParis-Trousseau syndrome and Jacobsen syndromeAccompanied by clinical features not typically found in BSSMental retardationFacial/cardiac abnormalitiesX-linked macrothrombocytopeniaAccompanied by other features not typically found in BSSSplenomegalyRed blood cell abnormalities (anemia and reticulocytosis)Gray platelet syndrome (GPS)Associated with presence of pale, gray platelets on peripheral blood smearNot seen in BSS",
                    "sub_points": [
                      "Autosomal dominant Mediterranean macrothrombocytopeniaHeterozygous mutation inGPIbα",
                      "Heterozygous mutation inGPIbα",
                      "Velocardiofacial syndromeHeterozygous absence of GPIb/V/IX complexAssociated with other manifestations of microdeletion of chromosome 22q11 (Di George syndrome) not typically found in BSS, includingCleft palateDelayed developmentImmune dysfunctionCardiac defects",
                      "Heterozygous absence of GPIb/V/IX complex",
                      "Associated with other manifestations of microdeletion of chromosome 22q11 (Di George syndrome) not typically found in BSS, includingCleft palateDelayed developmentImmune dysfunctionCardiac defects",
                      "Cleft palate",
                      "Delayed development",
                      "Immune dysfunction",
                      "Cardiac defects",
                      "Chronic idiopathic thrombocytopenic purpura (ITP)Acquired; likely that relatives are not affectedPatients with BSS may have relatives who also have macrothrombocytopenia (inherited)Only 10% of platelets in chronic ITP may be \"macroplatelets\" (whereas these account for virtually all platelets in BSS-related disease)",
                      "Acquired; likely that relatives are not affected",
                      "Patients with BSS may have relatives who also have macrothrombocytopenia (inherited)",
                      "Only 10% of platelets in chronic ITP may be \"macroplatelets\" (whereas these account for virtually all platelets in BSS-related disease)",
                      "MYH9-related diseaseIn BSS platelet aggregation studies show defective agglutination in response to ristocetin, while normal ristocetin-induced platelet agglutination should occur in MYH9-related disease",
                      "In BSS platelet aggregation studies show defective agglutination in response to ristocetin, while normal ristocetin-induced platelet agglutination should occur in MYH9-related disease",
                      "Paris-Trousseau syndrome and Jacobsen syndromeAccompanied by clinical features not typically found in BSSMental retardationFacial/cardiac abnormalities",
                      "Accompanied by clinical features not typically found in BSSMental retardationFacial/cardiac abnormalities",
                      "Mental retardation",
                      "Facial/cardiac abnormalities",
                      "X-linked macrothrombocytopeniaAccompanied by other features not typically found in BSSSplenomegalyRed blood cell abnormalities (anemia and reticulocytosis)",
                      "Accompanied by other features not typically found in BSSSplenomegalyRed blood cell abnormalities (anemia and reticulocytosis)",
                      "Splenomegaly",
                      "Red blood cell abnormalities (anemia and reticulocytosis)",
                      "Gray platelet syndrome (GPS)Associated with presence of pale, gray platelets on peripheral blood smearNot seen in BSS",
                      "Associated with presence of pale, gray platelets on peripheral blood smearNot seen in BSS",
                      "Not seen in BSS"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Variably decreased platelet count (ranging from 20,000/mL to normal reference range)"
                  },
                  {
                    "text": "Increased mean platelet volume (MPV)"
                  },
                  {
                    "text": "Presence of macroplatelets on peripheral blood smear"
                  },
                  {
                    "text": "Abnormal platelet aggregation patternAbsent or extremely diminished platelet agglutination in response to ristocetinNormal aggregation in response to ADP, epinephrine, and collagen agonists",
                    "sub_points": [
                      "Absent or extremely diminished platelet agglutination in response to ristocetin",
                      "Normal aggregation in response to ADP, epinephrine, and collagen agonists"
                    ]
                  }
                ],
                "Specimen Collection": [
                  {
                    "text": "3.2% sodium citrate; citrate to whole blood ratio of 1:9 for platelet aggregation studies"
                  },
                  {
                    "text": "EDTA sample for complete blood count"
                  }
                ],
                "Specialized Assays": [
                  {
                    "text": "Diagnostic work-up of BSS can include flow cytometry using fluorescently labeled monoclonal antibodies directed against GPIb/V/IXDemonstrates decreased surface expression of GPIb/V/IX compared to control platelets",
                    "sub_points": [
                      "Demonstrates decreased surface expression of GPIb/V/IX compared to control platelets"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "Analysis ofGPIbα,GPIbβ, andGPIXcan help distinguish between homozygosity and compound heterozygosity in particular patient"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Scott Syndrome": {
            "name": "Scott Syndrome",
            "url": "https://app.pathprimer.com/document/eef44997-f996-442b-aa15-4e309fb205d7/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "In resting platelets, outer leaflet of membrane is rich in choline phospholipids (phosphatidylcholine and sphingosine), and inner leaflet is rich in aminophospholipids (phosphatidylserine and phosphatidylethanolamine) resulting in negatively charged phospholipids being concentrated on inner leaflet"
                  },
                  {
                    "text": "Assembly of coagulation factors on surface of platelets for secondary hemostasis requires exposure of negatively charged phospholipids (e.g., phosphatidylserine) on platelet surface"
                  },
                  {
                    "text": "In Scott syndrome, external exposure of negatively charged phospholipids in response to physiologic agonists or calcium ionophore is impaired"
                  },
                  {
                    "text": "Defects in scramblase enzyme geneANO6(anoctamin 6) encoding TMEM16F have been associated with Scott syndrome"
                  },
                  {
                    "text": "Manifests with mild to moderately severe bleeding"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Most traditional laboratory tests are normal"
                  },
                  {
                    "text": "If Scott syndrome is suspected, analysis ofANO6gene may be helpful"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Transport enzymes control exchange of phospholipids between outer and inner leaflets of platelet cell membrane"
                  },
                  {
                    "text": "In resting platelets, outer leaflet of membrane is rich in choline phospholipids (phosphatidylcholine and sphingosine), and inner leaflet is rich in aminophospholipids (phosphatidylserine and phosphatidylethanolamine) resulting in negatively charged phospholipids being concentrated on inner leafletFlippase moves negatively charged phospholipids (phosphatidylserine and phosphatidylethanolamine) from outer to inner leaflet (adenosine triphosphate [ATP] dependent)Floppase (ABCC1) moves phosphatidylcholine and sphingosine from inner leaflet to outer leaflet (ATP dependent)Scramblase catalyzes bidirectional movement of phospholipids in response to calcium influx",
                    "sub_points": [
                      "Flippase moves negatively charged phospholipids (phosphatidylserine and phosphatidylethanolamine) from outer to inner leaflet (adenosine triphosphate [ATP] dependent)",
                      "Floppase (ABCC1) moves phosphatidylcholine and sphingosine from inner leaflet to outer leaflet (ATP dependent)",
                      "Scramblase catalyzes bidirectional movement of phospholipids in response to calcium influx"
                    ]
                  },
                  {
                    "text": "Assembly of coagulation factors on surface of platelets for secondary hemostasis requires exposure of negatively charged phospholipids (e.g., phosphatidylserine) on platelet surface"
                  },
                  {
                    "text": "Phosphatidylserine exposure usually occurs after platelet activation"
                  },
                  {
                    "text": "Prothrombinase and tenase complexes localize to exposed phosphatidylserine to generate thrombin and promote coagulation"
                  },
                  {
                    "text": "In Scott syndrome, external exposure of negatively charged phospholipids in response to physiologic agonists or calcium ionophore is impaired"
                  },
                  {
                    "text": "Defects in scramblase enzyme geneANO6(anoctamin 6) encoding transmembrane protein 16F (TMEM16F) have been associated with Scott syndromeANO6is located on chromosome 12TMEM16F promotes calcium-dependent scrambling of membrane proteins",
                    "sub_points": [
                      "ANO6is located on chromosome 12",
                      "TMEM16F promotes calcium-dependent scrambling of membrane proteins"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Very rare"
                  },
                  {
                    "text": "Autosomal recessive inheritance"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Manifests with mild to moderately severe bleeding"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Platelet transfusion for bleeding episodes"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Disorders of secondary hemostasisNormal platelet count and platelet function in setting of bleeding may suggest deficient coagulation factor activityMeasurement of activated partial thromboplastin time (aPTT) and prothrombin time (PT) should give normal results, ruling this out",
                    "sub_points": [
                      "Normal platelet count and platelet function in setting of bleeding may suggest deficient coagulation factor activity",
                      "Measurement of activated partial thromboplastin time (aPTT) and prothrombin time (PT) should give normal results, ruling this out"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Most traditional laboratory tests are normalNormal platelet countNormal platelet aggregationNormal aPTTNormal PT",
                    "sub_points": [
                      "Normal platelet count",
                      "Normal platelet aggregation",
                      "Normal aPTT",
                      "Normal PT"
                    ]
                  }
                ],
                "Specialized Assays": [
                  {
                    "text": "Evaluation of phosphatidylserine exposureFlow cytometry to detect fluorescently labeled annexin V binding after platelet activationAnnexin V is a plasma protein with high affinity for phosphatidylserineNormal platelets should have annexin V staining after activationAnnexin V staining absent in Scott syndrome",
                    "sub_points": [
                      "Flow cytometry to detect fluorescently labeled annexin V binding after platelet activationAnnexin V is a plasma protein with high affinity for phosphatidylserineNormal platelets should have annexin V staining after activation",
                      "Annexin V is a plasma protein with high affinity for phosphatidylserine",
                      "Normal platelets should have annexin V staining after activation",
                      "Annexin V staining absent in Scott syndrome"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "If Scott syndrome is suspected, analysis ofANO6gene may be helpful"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hermansky-Pudlak Syndrome": {
            "name": "Hermansky-Pudlak Syndrome",
            "url": "https://app.pathprimer.com/document/ec37c4fc-1f8d-422d-bcde-04f91238e1bb/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "HPS is caused by mutations in genes responsible for assembling and packaging specialized lysosomes such as platelet dense granules and melanosomes"
                  },
                  {
                    "text": "Mutations in 9 different genes result in HPS phenotype"
                  },
                  {
                    "text": "HPS results in disease phenotype with platelet SPD and OCA"
                  },
                  {
                    "text": "Most patients are ﻿subtype HPS-1 and are from Puerto Rico"
                  },
                  {
                    "text": "Large population of patients in Northwest Puerto Rico where it occurs in 1:1800 individuals"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Abnormal platelet aggregation pattern"
                  },
                  {
                    "text": "Platelet electron microscopy shows no or extreme ﻿lack of dense granules"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Hermansky-Pudlak syndrome (HPS) is caused by mutations in genes responsible for assembling and packaging specialized lysosomes such as platelet dense granules and melanosomes"
                  },
                  {
                    "text": "HPS results in disease phenotype with platelet storage pool deficiency (SPD) and oculocutaneous albinism (OCA)"
                  },
                  {
                    "text": "SPD refers to deficiency in contents of platelet dense granules &/or alpha granules"
                  },
                  {
                    "text": "Release of platelet granules is important for platelet aggregation at sites of vascular damage by releasing both signaling and procoagulant molecules"
                  },
                  {
                    "text": "HPS is characterized by absence of or severe decrease in dense granules that contain key platelet signaling moleculesCalciumAdenosine diphosphate (ADP)Adenosine triphosphate (ATP)5-Hydroxytryptamine",
                    "sub_points": [
                      "Calcium",
                      "Adenosine diphosphate (ADP)",
                      "Adenosine triphosphate (ATP)",
                      "5-Hydroxytryptamine"
                    ]
                  },
                  {
                    "text": "Mutations in 9 different genes result in HPS phenotype"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Autosomal recessive inheritance"
                  },
                  {
                    "text": "Heterozygotes have no clinical findings"
                  },
                  {
                    "text": "Most patients are ﻿subtype HPS-1 and are from Puerto Rico"
                  },
                  {
                    "text": "Large population of patients in Northwest Puerto Rico where it occurs in 1:1800 individuals"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Manifests with mild to moderate bleeding"
                  },
                  {
                    "text": "Other signs and symptomsOCACongenital nystagmusDecreased visual acuityPulmonary fibrosis (PF; 60% of patients with HPS-1)Granulomatous colitis (GC; 15% of patients with HPS-1)",
                    "sub_points": [
                      "OCA",
                      "Congenital nystagmus",
                      "Decreased visual acuity",
                      "Pulmonary fibrosis (PF; 60% of patients with HPS-1)",
                      "Granulomatous colitis (GC; 15% of patients with HPS-1)"
                    ]
                  },
                  {
                    "text": "9 HPS subtypes—associated with presence and absence of common signs and symptomsAll subtypes associated with OCA and SPDHPS-1May also have PF (nearly all affected individuals) and GCHPS-2May also have PF and neutropeniaHPS-4May also have PF and GCHPS-6May also have GCHPS-3, HPS-5, HPS-8, HPS-9 have different genetic abnormalities but similar clinical presentations",
                    "sub_points": [
                      "All subtypes associated with OCA and SPD",
                      "HPS-1May also have PF (nearly all affected individuals) and GC",
                      "May also have PF (nearly all affected individuals) and GC",
                      "HPS-2May also have PF and neutropenia",
                      "May also have PF and neutropenia",
                      "HPS-4May also have PF and GC",
                      "May also have PF and GC",
                      "HPS-6May also have GC",
                      "May also have GC",
                      "HPS-3, HPS-5, HPS-8, HPS-9 have different genetic abnormalities but similar clinical presentations"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Platelet transfusion for bleeding episodes"
                  },
                  {
                    "text": "Other general measures may help support hemostasis in patients with congenital platelet disordersDesmopressin acetate (1-desamino-8D-arginine vasopressin [DDAVP])Antifibrinolytic agentsRecombinant factor VIIa",
                    "sub_points": [
                      "Desmopressin acetate (1-desamino-8D-arginine vasopressin [DDAVP])",
                      "Antifibrinolytic agents",
                      "Recombinant factor VIIa"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Chédiak-Higashi syndromeRare autosomal recessive disorderCharacterized by SPD, OCA, immune deficiency, neurologic dysfunction, presence of giant cytoplasmic inclusions in neutrophilsImmune deficiency due to defective cytotoxic T-cell and natural killer cell functionPresence of immune deficiency, neurologic manifestations, and neutrophil inclusions help distinguish from HPS",
                    "sub_points": [
                      "Rare autosomal recessive disorder",
                      "Characterized by SPD, OCA, immune deficiency, neurologic dysfunction, presence of giant cytoplasmic inclusions in neutrophils",
                      "Immune deficiency due to defective cytotoxic T-cell and natural killer cell function",
                      "Presence of immune deficiency, neurologic manifestations, and neutrophil inclusions help distinguish from HPS"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Normal platelet count"
                  },
                  {
                    "text": "Abnormal platelet aggregation patternLack or blunting of secondary wave of aggregation in response to ADP and epinephrine agonists.Markedly impaired response to collagen agonist may also be present.",
                    "sub_points": [
                      "Lack or blunting of secondary wave of aggregation in response to ADP and epinephrine agonists.",
                      "Markedly impaired response to collagen agonist may also be present."
                    ]
                  }
                ],
                "Specialized Assays": [
                  {
                    "text": "Platelet electron microscopy shows no or extreme ﻿lack of dense granules"
                  },
                  {
                    "text": "Platelet luminometry (measures dense granule release by detecting ATP) shows no granule release"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Genes associated with HPSHPS1HPS3HPS4HPS5HPS6AP3B1BLOC1S3BLOC1S6DTNBP1",
                    "sub_points": [
                      "HPS1",
                      "HPS3",
                      "HPS4",
                      "HPS5",
                      "HPS6",
                      "AP3B1",
                      "BLOC1S3",
                      "BLOC1S6",
                      "DTNBP1"
                    ]
                  },
                  {
                    "text": "Analysis of 9 genes associated with HPS can be useful in confirming diagnosis"
                  },
                  {
                    "text": "Mutations of certain genes associated with different clinical manifestationsHPS without pulmonary fibrosisBLOC1S3BLOC1S6DTNBP1HPS3HPS5HPS6HPS with pulmonary fibrosisAP3B1HPS1HPS4",
                    "sub_points": [
                      "HPS without pulmonary fibrosisBLOC1S3BLOC1S6DTNBP1HPS3HPS5HPS6",
                      "BLOC1S3",
                      "BLOC1S6",
                      "DTNBP1",
                      "HPS3",
                      "HPS5",
                      "HPS6",
                      "HPS with pulmonary fibrosisAP3B1HPS1HPS4",
                      "AP3B1",
                      "HPS1",
                      "HPS4"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Glanzmann Thrombasthenia": {
            "name": "Glanzmann Thrombasthenia",
            "url": "https://app.pathprimer.com/document/ea87a1ae-732d-48bc-972e-ca0327699f5c/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "GT results from quantitative or qualitative defect in the GPIIb/IIIa complex"
                  },
                  {
                    "text": "GPIIb/IIIa platelet receptor binds to fibrinogen and von Willebrand factor during platelet adhesion and aggregation"
                  },
                  {
                    "text": "Autosomal recessive inheritance"
                  },
                  {
                    "text": "Presents with moderate to severe bleeding manifestations"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Platelet aggregation pattern: AbnormalAbsence of primary and secondary waves of aggregation in response to ADP, epinephrine, and collagen agonistsNormal platelet agglutination in response to ristocetin",
                    "sub_points": [
                      "Absence of primary and secondary waves of aggregation in response to ADP, epinephrine, and collagen agonists",
                      "Normal platelet agglutination in response to ristocetin"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "GPIIb/IIIa platelet receptor binds to fibrinogen and von Willebrand factor during platelet adhesion and aggregationTwo distinct genes located on chromosome 17 encode for GPIIb and GPIIIa",
                    "sub_points": [
                      "Two distinct genes located on chromosome 17 encode for GPIIb and GPIIIa"
                    ]
                  },
                  {
                    "text": "Normal resting platelets have 50,000-80,000 GPIIb/IIIa complexes on their surface"
                  },
                  {
                    "text": "Glanzmann thrombasthenia (GT)Result of quantitative or qualitative defect in GPIIb/IIIa complexPossibly caused by mutation in genes for either GPIIb or GPIIIa",
                    "sub_points": [
                      "Result of quantitative or qualitative defect in GPIIb/IIIa complex",
                      "Possibly caused by mutation in genes for either GPIIb or GPIIIa"
                    ]
                  },
                  {
                    "text": "Type 1 GTCharacterized by severe quantitative deficiency of GPIIb/IIIa (< 5% of normal)",
                    "sub_points": [
                      "Characterized by severe quantitative deficiency of GPIIb/IIIa (< 5% of normal)"
                    ]
                  },
                  {
                    "text": "Type 2 GTCharacterized by moderate decrease in surface expression of GPIIb/IIIa (10-20% of normal)",
                    "sub_points": [
                      "Characterized by moderate decrease in surface expression of GPIIb/IIIa (10-20% of normal)"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Autosomal recessive inheritance"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Presents with moderate to severe bleeding manifestations"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Platelet transfusion for bleeding episodesComplicationsAlloimmunization (development of antibodies against GPIIb/IIIa) with refractoriness to platelet transfusion has occurred",
                    "sub_points": [
                      "ComplicationsAlloimmunization (development of antibodies against GPIIb/IIIa) with refractoriness to platelet transfusion has occurred",
                      "Alloimmunization (development of antibodies against GPIIb/IIIa) with refractoriness to platelet transfusion has occurred"
                    ]
                  },
                  {
                    "text": "Recombinant factor VIIa (rVIIa) has been used successfully"
                  },
                  {
                    "text": "Allogeneic bone marrow transplantation can be curativeDevelopment of antibodies against GPIIb/IIIa still a potential problem following transplant",
                    "sub_points": [
                      "Development of antibodies against GPIIb/IIIa still a potential problem following transplant"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "AfibrinogenemiaDistinguished from GT by measuring plasma fibrinogen",
                    "sub_points": [
                      "Distinguished from GT by measuring plasma fibrinogen"
                    ]
                  },
                  {
                    "text": "Treatment with medications that inhibit GPIIb/IIIa (e.g., abciximab, tirofiban, eptifibatide)Investigate using medication history",
                    "sub_points": [
                      "Investigate using medication history"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Analytes": [
                  {
                    "text": "Platelet count: Normal"
                  },
                  {
                    "text": "Platelet morphology: Normal"
                  },
                  {
                    "text": "Platelet aggregation pattern: AbnormalAbsence of primary and secondary waves of aggregation in response to ADP, epinephrine, and collagen agonistsNormal platelet agglutination in response to ristocetin",
                    "sub_points": [
                      "Absence of primary and secondary waves of aggregation in response to ADP, epinephrine, and collagen agonists",
                      "Normal platelet agglutination in response to ristocetin"
                    ]
                  }
                ],
                "Specimen Collection": [
                  {
                    "text": "3.2% sodium citrate; citrate to whole blood ratio of 1:9 for platelet aggregation studies"
                  },
                  {
                    "text": "EDTA sample for complete blood count"
                  }
                ],
                "Specialized Assays": [
                  {
                    "text": "Diagnostic work-up of GT can include flow cytometry using fluorescently labeled monoclonal antibodies directed against GPIIb/IIIaDemonstrates decreased surface expression of GPIIb/IIIa compared to control platelets",
                    "sub_points": [
                      "Demonstrates decreased surface expression of GPIIb/IIIa compared to control platelets"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "Analysis ofGPIIBandGPIIIAgenes can help distinguish between homozygosity and compound heterozygosity in a particular patient"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Uremia": {
            "name": "Uremia",
            "url": "https://app.pathprimer.com/document/b37139b5-686f-4082-a790-5bdaf74a5500/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Platelet dysfunction believed to be primary hemostatic abnormality in uremia"
                  },
                  {
                    "text": "Important to exclude other causes of bleeding"
                  },
                  {
                    "text": "Management of bleeding in uremic patients can be challengingDialysisDesmopressin (DDAVP)Increasing hematocritTransfusion of RBCs",
                    "sub_points": [
                      "Dialysis",
                      "Desmopressin (DDAVP)",
                      "Increasing hematocritTransfusion of RBCs",
                      "Transfusion of RBCs"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Abnormal platelet aggregation studies and prolonged bleeding times are common findings in uremic patients but do not correlate well with bleeding risk"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Platelet dysfunction believed to be primary hemostatic abnormality in uremia"
                  },
                  {
                    "text": "Increased risk of bleeding in patients with chronic renal failure and uremia is multifactorialAnemiaRed blood cells (RBCs) normally displace platelets to periphery of blood vesselsThis action may be decreased in anemiaPlatelet function defectsAdhesionDecreased glycoprotein Ib receptor complexes on platelets of uremic patientsDecreased high-molecular-weight multimers of von Willebrand factor (vWF) in plasma of uremic patientsAggregationReduced binding of fibrinogen to platelets of uremic patientsDecreased synthesis of thromboxane A₂ (TXA₂) leading to decreased dense granule and α granule releaseAccumulation of platelet-inhibitory substances in plasma of uremic patientsGuanidinosuccinic acid is nitric oxide (NO) precursor that is present in increased amounts in plasma of uremic patientsNO is known to inhibit platelet functionHemodialysis-induced platelet function abnormalitiesContinued platelet activation associated with dialysis procedureActin polymerization and depolymerizationRelease of granule contents and binding of proteins to platelet surfaceMembrane protein sheddingVascular abnormalities",
                    "sub_points": [
                      "AnemiaRed blood cells (RBCs) normally displace platelets to periphery of blood vesselsThis action may be decreased in anemia",
                      "Red blood cells (RBCs) normally displace platelets to periphery of blood vesselsThis action may be decreased in anemia",
                      "This action may be decreased in anemia",
                      "Platelet function defectsAdhesionDecreased glycoprotein Ib receptor complexes on platelets of uremic patientsDecreased high-molecular-weight multimers of von Willebrand factor (vWF) in plasma of uremic patientsAggregationReduced binding of fibrinogen to platelets of uremic patientsDecreased synthesis of thromboxane A₂ (TXA₂) leading to decreased dense granule and α granule releaseAccumulation of platelet-inhibitory substances in plasma of uremic patientsGuanidinosuccinic acid is nitric oxide (NO) precursor that is present in increased amounts in plasma of uremic patientsNO is known to inhibit platelet functionHemodialysis-induced platelet function abnormalitiesContinued platelet activation associated with dialysis procedureActin polymerization and depolymerizationRelease of granule contents and binding of proteins to platelet surfaceMembrane protein shedding",
                      "AdhesionDecreased glycoprotein Ib receptor complexes on platelets of uremic patientsDecreased high-molecular-weight multimers of von Willebrand factor (vWF) in plasma of uremic patients",
                      "Decreased glycoprotein Ib receptor complexes on platelets of uremic patients",
                      "Decreased high-molecular-weight multimers of von Willebrand factor (vWF) in plasma of uremic patients",
                      "AggregationReduced binding of fibrinogen to platelets of uremic patientsDecreased synthesis of thromboxane A₂ (TXA₂) leading to decreased dense granule and α granule release",
                      "Reduced binding of fibrinogen to platelets of uremic patients",
                      "Decreased synthesis of thromboxane A₂ (TXA₂) leading to decreased dense granule and α granule release",
                      "Accumulation of platelet-inhibitory substances in plasma of uremic patientsGuanidinosuccinic acid is nitric oxide (NO) precursor that is present in increased amounts in plasma of uremic patientsNO is known to inhibit platelet function",
                      "Guanidinosuccinic acid is nitric oxide (NO) precursor that is present in increased amounts in plasma of uremic patients",
                      "NO is known to inhibit platelet function",
                      "Hemodialysis-induced platelet function abnormalitiesContinued platelet activation associated with dialysis procedureActin polymerization and depolymerizationRelease of granule contents and binding of proteins to platelet surfaceMembrane protein shedding",
                      "Continued platelet activation associated with dialysis procedure",
                      "Actin polymerization and depolymerization",
                      "Release of granule contents and binding of proteins to platelet surface",
                      "Membrane protein shedding",
                      "Vascular abnormalities"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Common bleeding presentation in uremiaGastrointestinal tract bleedingEasy bruisingEpistaxisGingival bleedingProlonged bleeding after venipuncture or trauma",
                    "sub_points": [
                      "Gastrointestinal tract bleeding",
                      "Easy bruising",
                      "Epistaxis",
                      "Gingival bleeding",
                      "Prolonged bleeding after venipuncture or trauma"
                    ]
                  },
                  {
                    "text": "Important to exclude other causes of bleeding"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Management of bleeding in uremic patients can be challenging"
                  },
                  {
                    "text": "DialysisBest treatment for improving hemostasisRemoves some platelet-inhibitory substancesImproves platelet functionNormalizes prolonged bleeding timesPeritoneal and hemodialysis equally effectiveEvidence of platelet activation in hemodialysisPotential bleeding risk due to anticoagulation",
                    "sub_points": [
                      "Best treatment for improving hemostasis",
                      "Removes some platelet-inhibitory substances",
                      "Improves platelet function",
                      "Normalizes prolonged bleeding times",
                      "Peritoneal and hemodialysis equally effectiveEvidence of platelet activation in hemodialysis",
                      "Evidence of platelet activation in hemodialysis",
                      "Potential bleeding risk due to anticoagulation"
                    ]
                  },
                  {
                    "text": "Desmopressin (1-desamino-8-D-arginine vasopressin [DDAVP])Demonstrated to shorten bleeding time within 30-60 minutesEffect lasts up to 4 hoursCauses release of vWF from endothelial cellsUsed to prevent surgical bleeding in uremic patientsAdverse effectsFacial flushingMild tachycardiaWater retentionHyponatremiaArterial thrombosisMemory loss",
                    "sub_points": [
                      "Demonstrated to shorten bleeding time within 30-60 minutes",
                      "Effect lasts up to 4 hours",
                      "Causes release of vWF from endothelial cells",
                      "Used to prevent surgical bleeding in uremic patients",
                      "Adverse effectsFacial flushingMild tachycardiaWater retentionHyponatremiaArterial thrombosisMemory loss",
                      "Facial flushing",
                      "Mild tachycardia",
                      "Water retention",
                      "Hyponatremia",
                      "Arterial thrombosis",
                      "Memory loss"
                    ]
                  },
                  {
                    "text": "Increasing hematocritTransfusion of RBCsTreatment with erythropoietinBoth treatments associated with normalization of bleeding time and reduced bleeding tendency",
                    "sub_points": [
                      "Transfusion of RBCs",
                      "Treatment with erythropoietin",
                      "Both treatments associated with normalization of bleeding time and reduced bleeding tendency"
                    ]
                  },
                  {
                    "text": "Conjugated estrogens (i.e., Premarin)Normalize bleeding time and help control bleedingMay have effect through mediating changes in NO synthesis",
                    "sub_points": [
                      "Normalize bleeding time and help control bleeding",
                      "May have effect through mediating changes in NO synthesis"
                    ]
                  },
                  {
                    "text": "Cryoprecipitate transfusion"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Platelet Function": [
                  {
                    "text": "Abnormal platelet aggregation studies and prolonged bleeding times are common findings in uremic patients but do not correlate well with bleeding risk"
                  },
                  {
                    "text": "Noted platelet function defectsReduced adenosine diphosphate (ADP)-induced platelet aggregationProlonged bleeding time (even after increasing hematocrit)Prolonged platelet function analysis (PFA-100) closure times",
                    "sub_points": [
                      "Reduced adenosine diphosphate (ADP)-induced platelet aggregation",
                      "Prolonged bleeding time (even after increasing hematocrit)",
                      "Prolonged platelet function analysis (PFA-100) closure times"
                    ]
                  }
                ],
                "Mild Thrombocytopenia": [
                  {
                    "text": "Shortened platelet survival"
                  },
                  {
                    "text": "Decreased marrow production of platelets"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "von Willebrand Disease Type I": {
            "name": "von Willebrand Disease Type I",
            "url": "https://app.pathprimer.com/document/e833928e-532d-41c0-a3b2-2b1b16aee793/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "vWD is most common inherited bleeding disorder, affecting 0.1-1.0% of population"
                  },
                  {
                    "text": "Type I vWD represents 70% of vWD cases"
                  },
                  {
                    "text": "Bleeding is typically mucocutaneousBruising without recognized traumaProlonged, recurrent nosebleedsMenorrhagia",
                    "sub_points": [
                      "Bruising without recognized trauma",
                      "Prolonged, recurrent nosebleeds",
                      "Menorrhagia"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "﻿Decreased vWF activity"
                  },
                  {
                    "text": "Decreased vWF antigen in proportion to decrease in vWF activity"
                  },
                  {
                    "text": "vWF:RCo/vWF:Ag ratio is > 0.5-0.7"
                  },
                  {
                    "text": "﻿Normal multimeric distribution on vWF multimer analysis"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "von Willebrand factor (vWF) plays important roles in platelet adhesion/aggregation and acts as carrier for factor VIII (FVIII)"
                  },
                  {
                    "text": "Bleeding in von Willebrand Disease (vWD) can be due to defects in primary and/or secondary hemostasis"
                  },
                  {
                    "text": "3 classification subtypesType I vWD: Partial quantitative deficiency of essentially normal vWFType II vWD: Qualitative defects in vWFType III vWD: Virtually complete quantitative deficiency of vWF",
                    "sub_points": [
                      "Type I vWD: Partial quantitative deficiency of essentially normal vWF",
                      "Type II vWD: Qualitative defects in vWF",
                      "Type III vWD: Virtually complete quantitative deficiency of vWF"
                    ]
                  },
                  {
                    "text": "Type I vWD mutations affect vWF levels by 3 main mechanismsIntracellular retention/reduced secretion of vWFIncreased vWF clearanceDecreased production of vWF",
                    "sub_points": [
                      "Intracellular retention/reduced secretion of vWF",
                      "Increased vWF clearance",
                      "Decreased production of vWF"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "vWD is most common inherited bleeding disorder, affecting 0.1-1.0% of population"
                  },
                  {
                    "text": "Autosomal inheritance"
                  },
                  {
                    "text": "Type I vWDRepresents 70% of vWD casesAutosomal dominant inheritance",
                    "sub_points": [
                      "Represents 70% of vWD cases",
                      "Autosomal dominant inheritance"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Bleeding is typically mucocutaneousBruising without recognized traumaProlonged, recurrent nosebleedsMenorrhagiaOral cavity bleedingGum bleeding after tooth-brushing or flossingBleeding after dental cleanings or tooth extractionExcessive postpartum bleedingMusculoskeletal bleeding is unusual",
                    "sub_points": [
                      "Bruising without recognized trauma",
                      "Prolonged, recurrent nosebleeds",
                      "Menorrhagia",
                      "Oral cavity bleedingGum bleeding after tooth-brushing or flossingBleeding after dental cleanings or tooth extraction",
                      "Gum bleeding after tooth-brushing or flossing",
                      "Bleeding after dental cleanings or tooth extraction",
                      "Excessive postpartum bleeding",
                      "Musculoskeletal bleeding is unusual"
                    ]
                  },
                  {
                    "text": "Type I vWD predominantly presents with mild mucocutaneous bleedingEpistaxis and bruising are common symptoms in childrenMenorrhagia is most common finding in women of childbearing age",
                    "sub_points": [
                      "Epistaxis and bruising are common symptoms in children",
                      "Menorrhagia is most common finding in women of childbearing age"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment of bleeding in Type I vWD is divided into 3 categories﻿Localized control of bleedingApplication of direct pressureTopical hemostatic agentsGelatin/foam matrixTopical thrombinFibrin sealants﻿AntifibrinolyticsTranexamic acidε-aminocaproic acidUseful at time of minor surgical and dental procedures to prevent or treat bleedingShould not be used in patients with hematuria, to avoid urinary obstructionTreatments that directly increase plasma vWF and FVIII levelsDesmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)Useful in most type I vWD patientsConsidered adequate for dental procedures, minor surgery, or treating epistaxis or menorrhagiaCan be administered as intranasal, intravenous, or subcutaneousPromotes release of stored vWF, with peak effects within 30-60 minutesDesmopressin challenge: Test patient’s response prior to therapeutic useAdverse effects include facial flushing, mild tachycardia, water retention, hyponatremia, and arterial thrombosisEstrogen may increase synthesis of vWFWomen with mild to moderate vWD may benefit from therapy with estrogen to decrease menorrhagiavWF/FVIII concentratesRequired for patients who do not have adequate response to DDAVP, who experience adverse effects to DDAVP, and for whom DDAVP is contraindicatedUsually required in patients undergoing major or repeated surgeryTreatment goal is to maintain peak vWF:RCo and FVIII activity levels at more than 100% and trough more than 50% until hemostasis is achievedDosing is weight-based; infusions can be given every 12-24 hours",
                    "sub_points": [
                      "﻿Localized control of bleedingApplication of direct pressureTopical hemostatic agentsGelatin/foam matrixTopical thrombinFibrin sealants",
                      "Application of direct pressure",
                      "Topical hemostatic agentsGelatin/foam matrixTopical thrombinFibrin sealants",
                      "Gelatin/foam matrix",
                      "Topical thrombin",
                      "Fibrin sealants",
                      "﻿AntifibrinolyticsTranexamic acidε-aminocaproic acidUseful at time of minor surgical and dental procedures to prevent or treat bleedingShould not be used in patients with hematuria, to avoid urinary obstruction",
                      "Tranexamic acid",
                      "ε-aminocaproic acid",
                      "Useful at time of minor surgical and dental procedures to prevent or treat bleeding",
                      "Should not be used in patients with hematuria, to avoid urinary obstruction",
                      "Treatments that directly increase plasma vWF and FVIII levelsDesmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)Useful in most type I vWD patientsConsidered adequate for dental procedures, minor surgery, or treating epistaxis or menorrhagiaCan be administered as intranasal, intravenous, or subcutaneousPromotes release of stored vWF, with peak effects within 30-60 minutesDesmopressin challenge: Test patient’s response prior to therapeutic useAdverse effects include facial flushing, mild tachycardia, water retention, hyponatremia, and arterial thrombosisEstrogen may increase synthesis of vWFWomen with mild to moderate vWD may benefit from therapy with estrogen to decrease menorrhagiavWF/FVIII concentratesRequired for patients who do not have adequate response to DDAVP, who experience adverse effects to DDAVP, and for whom DDAVP is contraindicatedUsually required in patients undergoing major or repeated surgeryTreatment goal is to maintain peak vWF:RCo and FVIII activity levels at more than 100% and trough more than 50% until hemostasis is achievedDosing is weight-based; infusions can be given every 12-24 hours",
                      "Desmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)Useful in most type I vWD patientsConsidered adequate for dental procedures, minor surgery, or treating epistaxis or menorrhagiaCan be administered as intranasal, intravenous, or subcutaneousPromotes release of stored vWF, with peak effects within 30-60 minutesDesmopressin challenge: Test patient’s response prior to therapeutic useAdverse effects include facial flushing, mild tachycardia, water retention, hyponatremia, and arterial thrombosis",
                      "Useful in most type I vWD patients",
                      "Considered adequate for dental procedures, minor surgery, or treating epistaxis or menorrhagia",
                      "Can be administered as intranasal, intravenous, or subcutaneous",
                      "Promotes release of stored vWF, with peak effects within 30-60 minutes",
                      "Desmopressin challenge: Test patient’s response prior to therapeutic use",
                      "Adverse effects include facial flushing, mild tachycardia, water retention, hyponatremia, and arterial thrombosis",
                      "Estrogen may increase synthesis of vWFWomen with mild to moderate vWD may benefit from therapy with estrogen to decrease menorrhagia",
                      "Women with mild to moderate vWD may benefit from therapy with estrogen to decrease menorrhagia",
                      "vWF/FVIII concentratesRequired for patients who do not have adequate response to DDAVP, who experience adverse effects to DDAVP, and for whom DDAVP is contraindicatedUsually required in patients undergoing major or repeated surgeryTreatment goal is to maintain peak vWF:RCo and FVIII activity levels at more than 100% and trough more than 50% until hemostasis is achieved",
                      "Required for patients who do not have adequate response to DDAVP, who experience adverse effects to DDAVP, and for whom DDAVP is contraindicated",
                      "Usually required in patients undergoing major or repeated surgery",
                      "Treatment goal is to maintain peak vWF:RCo and FVIII activity levels at more than 100% and trough more than 50% until hemostasis is achieved",
                      "Dosing is weight-based; infusions can be given every 12-24 hours"
                    ]
                  },
                  {
                    "text": "Short-term prophylaxis in preparation for known bleeding event is standard of care in vWDAntifibrinolyticsDesmopressinvWF/FVIII concentrates",
                    "sub_points": [
                      "Antifibrinolytics",
                      "Desmopressin",
                      "vWF/FVIII concentrates"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Acquired von Willebrand Disease (AvWD) should be ruled outCheck for clinical conditions associated with AvWDBleeding history of patient and other family members may be helpful",
                    "sub_points": [
                      "Check for clinical conditions associated with AvWD",
                      "Bleeding history of patient and other family members may be helpful"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Screening Assays": [
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "Fibrinogen"
                  },
                  {
                    "text": "PFA-100"
                  }
                ],
                "Diagnostic Assays for vWD": [
                  {
                    "text": "vWF antigen (vWF:Ag)Determines quantity of vWF protein< 30% or < 30 IU/dL is considered vWD30-50% or 30-50 IU/dL is considered “low” vWFMeasured using 2 types of assaysEnzyme linked immunosorbance (ELISA)Latex immunoassay (LIA)",
                    "sub_points": [
                      "Determines quantity of vWF protein",
                      "< 30% or < 30 IU/dL is considered vWD",
                      "30-50% or 30-50 IU/dL is considered “low” vWF",
                      "Measured using 2 types of assaysEnzyme linked immunosorbance (ELISA)Latex immunoassay (LIA)",
                      "Enzyme linked immunosorbance (ELISA)",
                      "Latex immunoassay (LIA)"
                    ]
                  },
                  {
                    "text": "vWF activity< 30% or < 30 IU/dL is considered vWD30-50% or 30-50 IU/dL is considered “low” vWFMeasured using 2 types of assaysRistocetin cofactor activity assay (vWF:RCo)Gold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinCollagen-binding activity assay (vWF:CB)Measures ability of vWF to bind collagen-coated plates",
                    "sub_points": [
                      "< 30% or < 30 IU/dL is considered vWD",
                      "30-50% or 30-50 IU/dL is considered “low” vWF",
                      "Measured using 2 types of assaysRistocetin cofactor activity assay (vWF:RCo)Gold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinCollagen-binding activity assay (vWF:CB)Measures ability of vWF to bind collagen-coated plates",
                      "Ristocetin cofactor activity assay (vWF:RCo)Gold standardMeasures ability of vWF to agglutinate platelets in response to ristocetin",
                      "Gold standard",
                      "Measures ability of vWF to agglutinate platelets in response to ristocetin",
                      "Collagen-binding activity assay (vWF:CB)Measures ability of vWF to bind collagen-coated plates",
                      "Measures ability of vWF to bind collagen-coated plates"
                    ]
                  },
                  {
                    "text": "FVIII activityMeasured using 2 types of assaysaPTT-based one-stage clotting assayChromogenic factor activity assay",
                    "sub_points": [
                      "Measured using 2 types of assaysaPTT-based one-stage clotting assayChromogenic factor activity assay",
                      "aPTT-based one-stage clotting assay",
                      "Chromogenic factor activity assay"
                    ]
                  }
                ],
                "Assays for vWD Subtyping": [
                  {
                    "text": "vWF multimer analysisSodium dodecyl sulfate-agarose electrophoresis used to assess vWF multimers in plasmaClassification of multimersHigh molecular weight (HMW)Intermediate molecular weight (IMW)Low molecular weight (LMW)",
                    "sub_points": [
                      "Sodium dodecyl sulfate-agarose electrophoresis used to assess vWF multimers in plasma",
                      "Classification of multimersHigh molecular weight (HMW)Intermediate molecular weight (IMW)Low molecular weight (LMW)",
                      "High molecular weight (HMW)",
                      "Intermediate molecular weight (IMW)",
                      "Low molecular weight (LMW)"
                    ]
                  },
                  {
                    "text": "Ristocetin-induced platelet aggregation (RIPA)Measures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin",
                    "sub_points": [
                      "Measures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin"
                    ]
                  },
                  {
                    "text": "GenotypingIdentification of mutation is not necessary for making diagnosisMay be useful for discriminating between various types of vWD",
                    "sub_points": [
                      "Identification of mutation is not necessary for making diagnosis",
                      "May be useful for discriminating between various types of vWD"
                    ]
                  }
                ],
                "Assay Results in Type I vWD": [
                  {
                    "text": "Normal platelet count"
                  },
                  {
                    "text": "Normal or prolonged PT and aPTT"
                  },
                  {
                    "text": "﻿Decreased vWF activity"
                  },
                  {
                    "text": "Decreased vWF antigen in proportion to decrease in vWF activity"
                  },
                  {
                    "text": "vWF:RCo/vWF:Ag ratio is > 0.5-0.7"
                  },
                  {
                    "text": "Normal or decreased FVIII activity"
                  },
                  {
                    "text": "﻿Normal multimeric distribution on vWF multimer analysis"
                  },
                  {
                    "text": "Usually normal RIPA"
                  }
                ],
                "Sample Processing and Storage": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature to prevent cryoprecipitation of vWF and other proteins"
                  },
                  {
                    "text": "Separate plasma from red blood cells promptly with centrifugation at room temperature to remove platelets"
                  },
                  {
                    "text": "If samples are assayed within 2 hours, keep plasma at room temperature"
                  },
                  {
                    "text": "If samples will not be assayed within 2 hours, they should be frozen and stored at or below -40°C"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Normal vWF antigen 50-150%"
                  },
                  {
                    "text": "Normal vWF:RCo 50-150%"
                  },
                  {
                    "text": "Normal vWF:CB 50-150%"
                  },
                  {
                    "text": "Normal vWF multimeric analysis: “Normal multimeric distribution”"
                  },
                  {
                    "text": "Normal FVIII activity 50-150%"
                  }
                ],
                "Factors Affecting vWF Levels": [
                  {
                    "text": "ABO blood groupIndividuals with O blood type have ~ 30% lower levels of vWF than those with A, B, or AB blood typeDifference is due to shortened survival of vWF in circulation of blood type O individuals",
                    "sub_points": [
                      "Individuals with O blood type have ~ 30% lower levels of vWF than those with A, B, or AB blood type",
                      "Difference is due to shortened survival of vWF in circulation of blood type O individuals"
                    ]
                  },
                  {
                    "text": "Hormone levelsHypothyroidism is associated with decreased levels of vWFEstrogenvWF levels at baseline in women during follicular phase of menstrual cyclevWF levels are higher in women during late luteal phase of menstrual cycleOral contraceptive pills can increase vWF levelsvWF levels increase 2-3 fold during 2nd and 3rd trimesters of pregnancyAdrenalineβ-adrenergic stimulation as occurs during physical stress, such as illness and recent exercise, and emotional stress causes increase in vWF levels",
                    "sub_points": [
                      "Hypothyroidism is associated with decreased levels of vWF",
                      "EstrogenvWF levels at baseline in women during follicular phase of menstrual cyclevWF levels are higher in women during late luteal phase of menstrual cycleOral contraceptive pills can increase vWF levelsvWF levels increase 2-3 fold during 2nd and 3rd trimesters of pregnancy",
                      "vWF levels at baseline in women during follicular phase of menstrual cycle",
                      "vWF levels are higher in women during late luteal phase of menstrual cycle",
                      "Oral contraceptive pills can increase vWF levels",
                      "vWF levels increase 2-3 fold during 2nd and 3rd trimesters of pregnancy",
                      "Adrenalineβ-adrenergic stimulation as occurs during physical stress, such as illness and recent exercise, and emotional stress causes increase in vWF levels",
                      "β-adrenergic stimulation as occurs during physical stress, such as illness and recent exercise, and emotional stress causes increase in vWF levels"
                    ]
                  },
                  {
                    "text": "InflammationvWF is acute phase reactant and is increased with inflammation",
                    "sub_points": [
                      "vWF is acute phase reactant and is increased with inflammation"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "vWF geneLocated on chromosome 12178 kb long52 exons",
                    "sub_points": [
                      "Located on chromosome 12",
                      "178 kb long",
                      "52 exons"
                    ]
                  },
                  {
                    "text": "vWF pseudogenePartial duplication of vWF geneLocated on chromosome 22Must be taken into account when designing primers for amplification of vWF gene on chromosome 22Need to avoid amplifying pseudogene",
                    "sub_points": [
                      "Partial duplication of vWF gene",
                      "Located on chromosome 22",
                      "Must be taken into account when designing primers for amplification of vWF gene on chromosome 22Need to avoid amplifying pseudogene",
                      "Need to avoid amplifying pseudogene"
                    ]
                  },
                  {
                    "text": "GenotypingPoint mutations, usually missense mutations, identified in 65% of type I vWDMutations in type I vWD occur throughout vWF geneNot useful in type I vWDMutations are not localized to particular domain or exon, making likelihood of finding mutation low",
                    "sub_points": [
                      "Point mutations, usually missense mutations, identified in 65% of type I vWD",
                      "Mutations in type I vWD occur throughout vWF gene",
                      "Not useful in type I vWDMutations are not localized to particular domain or exon, making likelihood of finding mutation low",
                      "Mutations are not localized to particular domain or exon, making likelihood of finding mutation low"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "von Willebrand Disease Type II": {
            "name": "von Willebrand Disease Type II",
            "url": "https://app.pathprimer.com/document/19c0642d-cdd8-4da3-9c0f-74990a292758/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Type II vWD: Qualitative defects of vWF"
                  },
                  {
                    "text": "Type 2A vWDMost common type II variant﻿Decreased-normal levels of vWF; however, vWF functions abnormallyMutation affects platelet to platelet adhesionImpaired vWF multimer assembly; results in decreased HMWMs and IMWMs",
                    "sub_points": [
                      "Most common type II variant",
                      "﻿Decreased-normal levels of vWF; however, vWF functions abnormally",
                      "Mutation affects platelet to platelet adhesion",
                      "Impaired vWF multimer assembly; results in decreased HMWMs and IMWMs"
                    ]
                  },
                  {
                    "text": "Type 2B vWDIncreased affinity for platelet GpIb﻿Spontaneous binding of vWF to platelets leads to depletion of HMWMs and formation of platelet aggregatesPlatelet aggregates are removed from circulation, leading to thrombocytopenia",
                    "sub_points": [
                      "Increased affinity for platelet GpIb",
                      "﻿Spontaneous binding of vWF to platelets leads to depletion of HMWMs and formation of platelet aggregates",
                      "Platelet aggregates are removed from circulation, leading to thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Type 2M vWDNo deficiency of HMWMs and IMWMs",
                    "sub_points": [
                      "No deficiency of HMWMs and IMWMs"
                    ]
                  },
                  {
                    "text": "Type 2N vWDMarkedly decreased binding affinity for FVIIIResults in enhanced clearance and low circulating levels of FVIIIvWD is most common inherited bleeding disorder, affecting 0.1-1.0% of population",
                    "sub_points": [
                      "Markedly decreased binding affinity for FVIII",
                      "Results in enhanced clearance and low circulating levels of FVIII",
                      "vWD is most common inherited bleeding disorder, affecting 0.1-1.0% of population"
                    ]
                  },
                  {
                    "text": "Bleeding is typically mucocutaneous"
                  },
                  {
                    "text": "Musculoskeletal bleeding may be present in type 2N vWD due to low levels of FVIII"
                  },
                  {
                    "text": "DesmopressinDDAVP challenge: Test patient’s response prior to therapeutic useGenerally contraindicated in type 2B vWD",
                    "sub_points": [
                      "DDAVP challenge: Test patient’s response prior to therapeutic use",
                      "Generally contraindicated in type 2B vWD"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Type II vWD is suspected when vWF activity is decreased out of proportion to decrease in vWF:AgTypes 2A, 2B, and 2M have vWF:RCo/vWF:Ag ratio < 0.5-0.7",
                    "sub_points": [
                      "Types 2A, 2B, and 2M have vWF:RCo/vWF:Ag ratio < 0.5-0.7"
                    ]
                  },
                  {
                    "text": "Type 2N vWD: Decreased FVIII activity (5-15%)"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Bleeding in von Willebrand Disease (vWD) can be due to defects in primary &/or secondary hemostasisvon Willebrand factor (vWF) plays important role in platelet adhesion/aggregationvWF acts as carrier for factor VIII (FVIII)",
                    "sub_points": [
                      "von Willebrand factor (vWF) plays important role in platelet adhesion/aggregation",
                      "vWF acts as carrier for factor VIII (FVIII)"
                    ]
                  },
                  {
                    "text": "3 classification subtypesType I vWD: Partial quantitative deficiency of essentially normal vWFType II vWD: Qualitative defects of vWFType III vWD: Virtually complete quantitative deficiency of vWF",
                    "sub_points": [
                      "Type I vWD: Partial quantitative deficiency of essentially normal vWF",
                      "Type II vWD: Qualitative defects of vWF",
                      "Type III vWD: Virtually complete quantitative deficiency of vWF"
                    ]
                  },
                  {
                    "text": "Type II vWD is further subclassified based on type of qualitative defectType 2A vWD﻿Decreased-normal levels of vWF; however, vWF functions abnormallyMutation affects platelet to platelet adhesionMutations causing type 2A vWD have multiple effectsImpaired vWF dimer assembly﻿Impaired vWF multimer assembly; results in decreased high molecular weight multimers (HMWMs) and intermediate molecular weight multimers (IMWMs)Increased susceptibility to ADAMTS13-mediated proteolysisType 2B vWDIncreased affinity for platelet GpIbMajor platelet vWF receptor responsible for initial platelet adhesionMutations causing type 2B vWD lead to gain-of-function mutations in GpIba binding site on vWF, leading to ﻿spontaneous binding of vWF to plateletsSpontaneous binding of vWF to platelets leads to depletion of HMWMs and formation of platelet aggregatesPlatelet aggregates are removed from circulation, leading to thrombocytopeniaType 2M vWDDecreased vWF-dependent platelet adhesionNo deficiency of HMWMs and IMWMsMutations causing type 2M vWD lead to loss-of-function mutations in GpIba binding site on vWFMutations that impair interaction of vWF with collagen are also classified as causing type 2M vWDType 2N vWDMarkedly decreased binding affinity for FVIIIMutations causing type 2N vWDMutation located in FVIII binding site of vWFMutation causes conformation change in vWFLeads to impaired interaction between vWF and FVIIIResults in enhanced clearance and low circulating levels of FVIII",
                    "sub_points": [
                      "Type 2A vWD﻿Decreased-normal levels of vWF; however, vWF functions abnormallyMutation affects platelet to platelet adhesionMutations causing type 2A vWD have multiple effectsImpaired vWF dimer assembly﻿Impaired vWF multimer assembly; results in decreased high molecular weight multimers (HMWMs) and intermediate molecular weight multimers (IMWMs)Increased susceptibility to ADAMTS13-mediated proteolysis",
                      "﻿Decreased-normal levels of vWF; however, vWF functions abnormally",
                      "Mutation affects platelet to platelet adhesion",
                      "Mutations causing type 2A vWD have multiple effectsImpaired vWF dimer assembly﻿Impaired vWF multimer assembly; results in decreased high molecular weight multimers (HMWMs) and intermediate molecular weight multimers (IMWMs)Increased susceptibility to ADAMTS13-mediated proteolysis",
                      "Impaired vWF dimer assembly",
                      "﻿Impaired vWF multimer assembly; results in decreased high molecular weight multimers (HMWMs) and intermediate molecular weight multimers (IMWMs)",
                      "Increased susceptibility to ADAMTS13-mediated proteolysis",
                      "Type 2B vWDIncreased affinity for platelet GpIbMajor platelet vWF receptor responsible for initial platelet adhesionMutations causing type 2B vWD lead to gain-of-function mutations in GpIba binding site on vWF, leading to ﻿spontaneous binding of vWF to plateletsSpontaneous binding of vWF to platelets leads to depletion of HMWMs and formation of platelet aggregatesPlatelet aggregates are removed from circulation, leading to thrombocytopenia",
                      "Increased affinity for platelet GpIbMajor platelet vWF receptor responsible for initial platelet adhesion",
                      "Major platelet vWF receptor responsible for initial platelet adhesion",
                      "Mutations causing type 2B vWD lead to gain-of-function mutations in GpIba binding site on vWF, leading to ﻿spontaneous binding of vWF to plateletsSpontaneous binding of vWF to platelets leads to depletion of HMWMs and formation of platelet aggregatesPlatelet aggregates are removed from circulation, leading to thrombocytopenia",
                      "Spontaneous binding of vWF to platelets leads to depletion of HMWMs and formation of platelet aggregates",
                      "Platelet aggregates are removed from circulation, leading to thrombocytopenia",
                      "Type 2M vWDDecreased vWF-dependent platelet adhesionNo deficiency of HMWMs and IMWMsMutations causing type 2M vWD lead to loss-of-function mutations in GpIba binding site on vWFMutations that impair interaction of vWF with collagen are also classified as causing type 2M vWD",
                      "Decreased vWF-dependent platelet adhesion",
                      "No deficiency of HMWMs and IMWMs",
                      "Mutations causing type 2M vWD lead to loss-of-function mutations in GpIba binding site on vWF",
                      "Mutations that impair interaction of vWF with collagen are also classified as causing type 2M vWD",
                      "Type 2N vWDMarkedly decreased binding affinity for FVIIIMutations causing type 2N vWDMutation located in FVIII binding site of vWFMutation causes conformation change in vWFLeads to impaired interaction between vWF and FVIIIResults in enhanced clearance and low circulating levels of FVIII",
                      "Markedly decreased binding affinity for FVIII",
                      "Mutations causing type 2N vWDMutation located in FVIII binding site of vWFMutation causes conformation change in vWFLeads to impaired interaction between vWF and FVIIIResults in enhanced clearance and low circulating levels of FVIII",
                      "Mutation located in FVIII binding site of vWF",
                      "Mutation causes conformation change in vWF",
                      "Leads to impaired interaction between vWF and FVIII",
                      "Results in enhanced clearance and low circulating levels of FVIII"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "vWD is most common inherited bleeding disorder, affecting 0.1-1.0% of population"
                  },
                  {
                    "text": "Autosomal inheritance"
                  },
                  {
                    "text": "Type II vWD accounts for ~ 25% of all vWDType 2A vWD~ 10-15% of all vWD casesMost common type II variantUsually autosomal dominant inheritance (some variants are recessive)Type 2B vWD~ 5% of all vWD casesAutosomal dominant inheritanceType 2M vWD< 5% of all vWD casesUsually autosomal dominant inheritance (some variants are recessive)Type 2N vWDAutosomal recessive inheritance~ 5-10% of all vWD cases",
                    "sub_points": [
                      "Type 2A vWD~ 10-15% of all vWD casesMost common type II variantUsually autosomal dominant inheritance (some variants are recessive)",
                      "~ 10-15% of all vWD cases",
                      "Most common type II variant",
                      "Usually autosomal dominant inheritance (some variants are recessive)",
                      "Type 2B vWD~ 5% of all vWD casesAutosomal dominant inheritance",
                      "~ 5% of all vWD cases",
                      "Autosomal dominant inheritance",
                      "Type 2M vWD< 5% of all vWD casesUsually autosomal dominant inheritance (some variants are recessive)",
                      "< 5% of all vWD cases",
                      "Usually autosomal dominant inheritance (some variants are recessive)",
                      "Type 2N vWDAutosomal recessive inheritance~ 5-10% of all vWD cases",
                      "Autosomal recessive inheritance",
                      "~ 5-10% of all vWD cases"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Bleeding is typically mucocutaneousBruising without recognized traumaProlonged, recurrent nosebleedsMenorrhagiaOral cavity bleedingGum bleeding after tooth-brushing or flossingBleeding after dental cleanings or tooth extractionExcessive postpartum bleeding",
                    "sub_points": [
                      "Bruising without recognized trauma",
                      "Prolonged, recurrent nosebleeds",
                      "Menorrhagia",
                      "Oral cavity bleedingGum bleeding after tooth-brushing or flossingBleeding after dental cleanings or tooth extraction",
                      "Gum bleeding after tooth-brushing or flossing",
                      "Bleeding after dental cleanings or tooth extraction",
                      "Excessive postpartum bleeding"
                    ]
                  },
                  {
                    "text": "Musculoskeletal bleeding is unusual"
                  },
                  {
                    "text": "Type II vWD bleeding manifestations are usually mild to moderate, but bleeding episodes can also be severeMusculoskeletal bleeding may be present in type 2N vWD, due to low levels of FVIII",
                    "sub_points": [
                      "Musculoskeletal bleeding may be present in type 2N vWD, due to low levels of FVIII"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment of bleeding in vWD is divided into 3 categories"
                  },
                  {
                    "text": "First category: Localized control of bleedingApplication of direct pressureTopical hemostatic agentsGelatin/foam matrixTopical thrombinFibrin sealants",
                    "sub_points": [
                      "Application of direct pressure",
                      "Topical hemostatic agentsGelatin/foam matrixTopical thrombinFibrin sealants",
                      "Gelatin/foam matrix",
                      "Topical thrombin",
                      "Fibrin sealants"
                    ]
                  },
                  {
                    "text": "Second category: AntifibrinolyticsTranexamic acidε-aminocaproic acidUseful at time of minor surgical and dental procedures to prevent or treat bleedingShould not be used in patients with hematuria to avoid urinary obstruction",
                    "sub_points": [
                      "Tranexamic acid",
                      "ε-aminocaproic acid",
                      "Useful at time of minor surgical and dental procedures to prevent or treat bleeding",
                      "Should not be used in patients with hematuria to avoid urinary obstruction"
                    ]
                  },
                  {
                    "text": "Third category: Treatments that directly increase plasma vWF and FVIII levelsDesmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)DDAVP challenge: Test patient’s response prior to therapeutic useResponse of type II vWD patients to DDAVP is variableType 2A vWD: Patients often show adequate responseType 2M vWD: Patients typically do not respond wellGenerally contraindicated in type 2B vWD: Can lead to profound thrombocytopenia and bleeding with exposure to DDVAP when abnormal vWF is releasedType 2N vWD: 2-9 fold increase in vWF and FVIII following desmopressin; increase in FVIII only lasts for ~ 3 hoursAdverse effects include facial flushing, mild tachycardia, water retention, hyponatremia, arterial thrombosisWhen appropriate, can be used for dental procedures, minor surgery, or treating epistaxis or menorrhagia in type 2 vWD patientsPromotes release of stored vWF, with peak effects within 30-60 minutesEstrogen may increase synthesis of vWFWomen with mild to moderate vWD may benefit from therapy with estrogen to decrease menorrhagiavWF/FVIII concentratesRequired for patientsWho do not have adequate response to desmopressinWho experience adverse effects from DDAVPFor whom DDAVP is contraindicatedUsually required in patients undergoing major surgeryDosing is weight-basedInfusions can be given every 12-24 hoursShort-term prophylaxis in preparation for possible bleeding event is standard of care in vWDAntifibrinolyticsDDAVP (when appropriate)vWF/FVIII concentrates",
                    "sub_points": [
                      "Desmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)DDAVP challenge: Test patient’s response prior to therapeutic useResponse of type II vWD patients to DDAVP is variableType 2A vWD: Patients often show adequate responseType 2M vWD: Patients typically do not respond wellGenerally contraindicated in type 2B vWD: Can lead to profound thrombocytopenia and bleeding with exposure to DDVAP when abnormal vWF is releasedType 2N vWD: 2-9 fold increase in vWF and FVIII following desmopressin; increase in FVIII only lasts for ~ 3 hoursAdverse effects include facial flushing, mild tachycardia, water retention, hyponatremia, arterial thrombosisWhen appropriate, can be used for dental procedures, minor surgery, or treating epistaxis or menorrhagia in type 2 vWD patientsPromotes release of stored vWF, with peak effects within 30-60 minutes",
                      "DDAVP challenge: Test patient’s response prior to therapeutic use",
                      "Response of type II vWD patients to DDAVP is variableType 2A vWD: Patients often show adequate responseType 2M vWD: Patients typically do not respond wellGenerally contraindicated in type 2B vWD: Can lead to profound thrombocytopenia and bleeding with exposure to DDVAP when abnormal vWF is releasedType 2N vWD: 2-9 fold increase in vWF and FVIII following desmopressin; increase in FVIII only lasts for ~ 3 hoursAdverse effects include facial flushing, mild tachycardia, water retention, hyponatremia, arterial thrombosis",
                      "Type 2A vWD: Patients often show adequate response",
                      "Type 2M vWD: Patients typically do not respond well",
                      "Generally contraindicated in type 2B vWD: Can lead to profound thrombocytopenia and bleeding with exposure to DDVAP when abnormal vWF is released",
                      "Type 2N vWD: 2-9 fold increase in vWF and FVIII following desmopressin; increase in FVIII only lasts for ~ 3 hours",
                      "Adverse effects include facial flushing, mild tachycardia, water retention, hyponatremia, arterial thrombosis",
                      "When appropriate, can be used for dental procedures, minor surgery, or treating epistaxis or menorrhagia in type 2 vWD patients",
                      "Promotes release of stored vWF, with peak effects within 30-60 minutes",
                      "Estrogen may increase synthesis of vWFWomen with mild to moderate vWD may benefit from therapy with estrogen to decrease menorrhagia",
                      "Women with mild to moderate vWD may benefit from therapy with estrogen to decrease menorrhagia",
                      "vWF/FVIII concentratesRequired for patientsWho do not have adequate response to desmopressinWho experience adverse effects from DDAVPFor whom DDAVP is contraindicatedUsually required in patients undergoing major surgeryDosing is weight-basedInfusions can be given every 12-24 hours",
                      "Required for patientsWho do not have adequate response to desmopressinWho experience adverse effects from DDAVPFor whom DDAVP is contraindicated",
                      "Who do not have adequate response to desmopressin",
                      "Who experience adverse effects from DDAVP",
                      "For whom DDAVP is contraindicated",
                      "Usually required in patients undergoing major surgery",
                      "Dosing is weight-based",
                      "Infusions can be given every 12-24 hours",
                      "Short-term prophylaxis in preparation for possible bleeding event is standard of care in vWDAntifibrinolyticsDDAVP (when appropriate)vWF/FVIII concentrates",
                      "Antifibrinolytics",
                      "DDAVP (when appropriate)",
                      "vWF/FVIII concentrates"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Acquired von Willebrand Disease (AvWD) should be ruled outAvWD can have similar presentation and laboratory findings to those of type 2A and 2B vWDCheck for clinical conditions associated with AvWDBleeding history of patient and other family members may be helpful",
                    "sub_points": [
                      "AvWD can have similar presentation and laboratory findings to those of type 2A and 2B vWD",
                      "Check for clinical conditions associated with AvWD",
                      "Bleeding history of patient and other family members may be helpful"
                    ]
                  },
                  {
                    "text": "Platelet-type or pseudo-vWDPlatelet defect that has similar phenotype as type 2B vWDDecreased platelet countDecreased vWF activity out of proportion to decrease in vWF:AgDecreased vWF antigenvWF:RCo/vWF:Ag ratio < 0.5-0.7Normal or decreased FVIII activityAbsence of HMWM on vWF multimer analysisIncreased response to low-dose ristocetin-induced platelet aggregation (RIPA)Caused by mutations in GpIba gene (vWF receptor on platelets) resulting in abnormal GPIb receptor with increased binding (gain-of-function) affinity for normal vWFDistinguished from type 2B vWD using modification of RIPA test with patient platelets mixed with normal plasma and, separately, patient plasma mixed with normal platelets﻿Increased low-dose RIPA with patient platelets mixed with normal plasma is consistent with platelet-type vWD﻿Increased low-dose RIPA with patient plasma mixed with normal platelets is consistent with type 2B vWDGenetic studies can also be used to distinguish type 2B vWD from platelet-type vWD",
                    "sub_points": [
                      "Platelet defect that has similar phenotype as type 2B vWDDecreased platelet countDecreased vWF activity out of proportion to decrease in vWF:AgDecreased vWF antigenvWF:RCo/vWF:Ag ratio < 0.5-0.7Normal or decreased FVIII activityAbsence of HMWM on vWF multimer analysisIncreased response to low-dose ristocetin-induced platelet aggregation (RIPA)",
                      "Decreased platelet count",
                      "Decreased vWF activity out of proportion to decrease in vWF:Ag",
                      "Decreased vWF antigen",
                      "vWF:RCo/vWF:Ag ratio < 0.5-0.7",
                      "Normal or decreased FVIII activity",
                      "Absence of HMWM on vWF multimer analysis",
                      "Increased response to low-dose ristocetin-induced platelet aggregation (RIPA)",
                      "Caused by mutations in GpIba gene (vWF receptor on platelets) resulting in abnormal GPIb receptor with increased binding (gain-of-function) affinity for normal vWF",
                      "Distinguished from type 2B vWD using modification of RIPA test with patient platelets mixed with normal plasma and, separately, patient plasma mixed with normal platelets﻿Increased low-dose RIPA with patient platelets mixed with normal plasma is consistent with platelet-type vWD﻿Increased low-dose RIPA with patient plasma mixed with normal platelets is consistent with type 2B vWD",
                      "﻿Increased low-dose RIPA with patient platelets mixed with normal plasma is consistent with platelet-type vWD",
                      "﻿Increased low-dose RIPA with patient plasma mixed with normal platelets is consistent with type 2B vWD",
                      "Genetic studies can also be used to distinguish type 2B vWD from platelet-type vWD"
                    ]
                  },
                  {
                    "text": "Mild hemophilia ABoth mild hemophilia A and type 2N vWD can have FVIII activity in 5-15% rangePresence of autosomal inheritance pattern suggests type 2N vWDBleeding or history of bleeding in female patients suggests type 2N vWDIn type 2N vWD, vWF:FVIII binding (vWF:FVIIIB) assay will show decreased affinity of vWF for FVIIIGenetic studies can also be used to distinguish type 2N vWD from mild hemophilia A",
                    "sub_points": [
                      "Both mild hemophilia A and type 2N vWD can have FVIII activity in 5-15% range",
                      "Presence of autosomal inheritance pattern suggests type 2N vWD",
                      "Bleeding or history of bleeding in female patients suggests type 2N vWDIn type 2N vWD, vWF:FVIII binding (vWF:FVIIIB) assay will show decreased affinity of vWF for FVIII",
                      "In type 2N vWD, vWF:FVIII binding (vWF:FVIIIB) assay will show decreased affinity of vWF for FVIII",
                      "Genetic studies can also be used to distinguish type 2N vWD from mild hemophilia A"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Screening Assays": [
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "PFA-100"
                  }
                ],
                "Diagnostic Assays for vWD": [
                  {
                    "text": "vWF antigen (vWF:Ag)< 30% or < 30 IU/dL is considered vWD30-50% or 30-50 IU/dL is considered “low” vWFDetermines quantity of vWF proteinMeasured using 2 types of assaysEnzyme linked immunosorbance (ELISA)Latex immunoassay (LIA)",
                    "sub_points": [
                      "< 30% or < 30 IU/dL is considered vWD",
                      "30-50% or 30-50 IU/dL is considered “low” vWF",
                      "Determines quantity of vWF protein",
                      "Measured using 2 types of assaysEnzyme linked immunosorbance (ELISA)Latex immunoassay (LIA)",
                      "Enzyme linked immunosorbance (ELISA)",
                      "Latex immunoassay (LIA)"
                    ]
                  },
                  {
                    "text": "vWF activity< 30% or <30 IU/dL is considered vWD30-50% or 30-50 IU/dL is considered “low” vWFMeasured using 2 types of assaysRistocetin cofactor activity assay (vWF:RCo)Gold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinCollagen-binding activity assay (vWF:CB)Measures ability of vWF to bind collagen-coated plates",
                    "sub_points": [
                      "< 30% or <30 IU/dL is considered vWD",
                      "30-50% or 30-50 IU/dL is considered “low” vWF",
                      "Measured using 2 types of assaysRistocetin cofactor activity assay (vWF:RCo)Gold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinCollagen-binding activity assay (vWF:CB)Measures ability of vWF to bind collagen-coated plates",
                      "Ristocetin cofactor activity assay (vWF:RCo)Gold standardMeasures ability of vWF to agglutinate platelets in response to ristocetin",
                      "Gold standard",
                      "Measures ability of vWF to agglutinate platelets in response to ristocetin",
                      "Collagen-binding activity assay (vWF:CB)Measures ability of vWF to bind collagen-coated plates",
                      "Measures ability of vWF to bind collagen-coated plates"
                    ]
                  },
                  {
                    "text": "FVIII activityMeasured using 2 types of assaysaPTT-based one-stage clotting assayChromogenic factor activity assay",
                    "sub_points": [
                      "Measured using 2 types of assaysaPTT-based one-stage clotting assayChromogenic factor activity assay",
                      "aPTT-based one-stage clotting assay",
                      "Chromogenic factor activity assay"
                    ]
                  }
                ],
                "Assays for vWD Subtyping": [
                  {
                    "text": "vWF multimer analysisSodium dodecyl sulfate-agarose electrophoresis used to assess vWF multimers in plasmaClassification of multimersHigh molecular weight (HMW)Intermediate molecular weight (IMW)Low molecular weight (LMW)",
                    "sub_points": [
                      "Sodium dodecyl sulfate-agarose electrophoresis used to assess vWF multimers in plasma",
                      "Classification of multimersHigh molecular weight (HMW)Intermediate molecular weight (IMW)Low molecular weight (LMW)",
                      "High molecular weight (HMW)",
                      "Intermediate molecular weight (IMW)",
                      "Low molecular weight (LMW)"
                    ]
                  },
                  {
                    "text": "RIPAMeasures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin",
                    "sub_points": [
                      "Measures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin"
                    ]
                  },
                  {
                    "text": "GenotypingIdentification of mutation is not necessary for making diagnosisMay be useful for discriminating between various types of vWD",
                    "sub_points": [
                      "Identification of mutation is not necessary for making diagnosis",
                      "May be useful for discriminating between various types of vWD"
                    ]
                  }
                ],
                "Assay Results in Type II vWD": [
                  {
                    "text": "Type II vWD is suspected when vWF activity is decreased out of proportion to decrease in vWF:Ag"
                  },
                  {
                    "text": "Type 2A vWDNormal platelet countNormal or prolonged aPTTNormal PTDecreased vWF activity out of proportion to decrease in vWF:AgDecreased vWF antigenvWF:RCo/vWF:Ag ratio < 0.5-0.7Normal or decreased FVIII activity﻿Absence of HMWM and IMWM on vWF multimer analysis﻿Decreased RIPA",
                    "sub_points": [
                      "Normal platelet count",
                      "Normal or prolonged aPTT",
                      "Normal PT",
                      "Decreased vWF activity out of proportion to decrease in vWF:Ag",
                      "Decreased vWF antigen",
                      "vWF:RCo/vWF:Ag ratio < 0.5-0.7",
                      "Normal or decreased FVIII activity",
                      "﻿Absence of HMWM and IMWM on vWF multimer analysis",
                      "﻿Decreased RIPA"
                    ]
                  },
                  {
                    "text": "Type 2B vWDLow or normal platelet countNormal or prolonged aPTTNormal PTDecreased vWF activity out of proportion to decrease in vWF:Ag﻿Decreased vWF antigenvWF:RCo/vWF:Ag ratio < 0.5-0.7Normal or decreased FVIII activity﻿Absence of HMWM on vWF multimer analysis﻿Normal RIPA with increased low-dose RIPA",
                    "sub_points": [
                      "Low or normal platelet count",
                      "Normal or prolonged aPTT",
                      "Normal PT",
                      "Decreased vWF activity out of proportion to decrease in vWF:Ag",
                      "﻿Decreased vWF antigen",
                      "vWF:RCo/vWF:Ag ratio < 0.5-0.7",
                      "Normal or decreased FVIII activity",
                      "﻿Absence of HMWM on vWF multimer analysis",
                      "﻿Normal RIPA with increased low-dose RIPA"
                    ]
                  },
                  {
                    "text": "Type 2M vWDNormal platelet countNormal or prolonged aPTTNormal PTDecreased vWF activity (vWFR:Co) out of proportion to decrease in vWF:Ag﻿Decreased vWF antigenvWF:RCo/vWF:Ag ratio < 0.5-0.7Normal or decreased FVIII activity﻿Normal multimeric distribution on vWF multimer analysisDecreased RIPA",
                    "sub_points": [
                      "Normal platelet count",
                      "Normal or prolonged aPTT",
                      "Normal PT",
                      "Decreased vWF activity (vWFR:Co) out of proportion to decrease in vWF:Ag",
                      "﻿Decreased vWF antigen",
                      "vWF:RCo/vWF:Ag ratio < 0.5-0.7",
                      "Normal or decreased FVIII activity",
                      "﻿Normal multimeric distribution on vWF multimer analysis",
                      "Decreased RIPA"
                    ]
                  },
                  {
                    "text": "Type 2N vWDNormal platelet countProlonged aPTTNormal PTNormal or decreased vWF activityNormal or decreased vWF antigenvWF:RCo/vWF:Ag ratio > 0.5-0.7Decreased FVIII activity (5-15%)﻿Normal multimeric distribution on vWF multimer analysisNormal RIPA",
                    "sub_points": [
                      "Normal platelet count",
                      "Prolonged aPTT",
                      "Normal PT",
                      "Normal or decreased vWF activity",
                      "Normal or decreased vWF antigen",
                      "vWF:RCo/vWF:Ag ratio > 0.5-0.7",
                      "Decreased FVIII activity (5-15%)",
                      "﻿Normal multimeric distribution on vWF multimer analysis",
                      "Normal RIPA"
                    ]
                  }
                ],
                "Sample Processing and Storage": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature to prevent cryoprecipitation of vWF and other proteins"
                  },
                  {
                    "text": "Separate plasma from red blood cells promptly with centrifugation at room temperature to remove platelets"
                  },
                  {
                    "text": "If samples are assayed within 2 hours, keep plasma at room temperature"
                  },
                  {
                    "text": "If samples will not be assayed within 2 hours, they should be frozen and stored at or below -40°C"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Normal vWF antigen 50-150%"
                  },
                  {
                    "text": "Normal vWF:RCo 50-150%"
                  },
                  {
                    "text": "Normal vWF:CB 50-150%"
                  },
                  {
                    "text": "Normal vWF multimeric analysis: “Normal multimeric distribution”"
                  },
                  {
                    "text": "Normal FVIII activity 50-150%"
                  }
                ],
                "Factors Affecting vWF Levels": [
                  {
                    "text": "ABO blood groupIndividuals with O blood type have ~ 30% lower levels of vWF than those with A, B, or AB blood typeDifference is due to shortened survival of vWF in circulation of blood type O individuals",
                    "sub_points": [
                      "Individuals with O blood type have ~ 30% lower levels of vWF than those with A, B, or AB blood type",
                      "Difference is due to shortened survival of vWF in circulation of blood type O individuals"
                    ]
                  },
                  {
                    "text": "Hormone levelsHypothyroidism is associated with decreased levels of vWFEstrogenvWF levels at baseline in women during follicular phase of menstrual cyclevWF levels are higher in women during late luteal phase of menstrual cycleOral contraceptive pills can increase vWF levelsvWF levels increase 2-3 fold during 2nd and 3rd trimesters of pregnancyAdrenalineβ-adrenergic stimulation as occurs during physical stress, such as illness and recent exercise, and emotional stress causes increase in vWF levels",
                    "sub_points": [
                      "Hypothyroidism is associated with decreased levels of vWF",
                      "EstrogenvWF levels at baseline in women during follicular phase of menstrual cyclevWF levels are higher in women during late luteal phase of menstrual cycleOral contraceptive pills can increase vWF levelsvWF levels increase 2-3 fold during 2nd and 3rd trimesters of pregnancy",
                      "vWF levels at baseline in women during follicular phase of menstrual cycle",
                      "vWF levels are higher in women during late luteal phase of menstrual cycle",
                      "Oral contraceptive pills can increase vWF levels",
                      "vWF levels increase 2-3 fold during 2nd and 3rd trimesters of pregnancy",
                      "Adrenalineβ-adrenergic stimulation as occurs during physical stress, such as illness and recent exercise, and emotional stress causes increase in vWF levels",
                      "β-adrenergic stimulation as occurs during physical stress, such as illness and recent exercise, and emotional stress causes increase in vWF levels"
                    ]
                  },
                  {
                    "text": "InflammationvWF is acute phase reactant and is increased with inflammation",
                    "sub_points": [
                      "vWF is acute phase reactant and is increased with inflammation"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "vWF geneLocated on chromosome 12178 kb long52 exons",
                    "sub_points": [
                      "Located on chromosome 12",
                      "178 kb long",
                      "52 exons"
                    ]
                  },
                  {
                    "text": "vWF pseudogenePartial duplication of vWF geneLocated on chromosome 22Must be taken into account when designing primers for amplification of vWF gene on chromosome 22Need to avoid amplifying pseudogene",
                    "sub_points": [
                      "Partial duplication of vWF gene",
                      "Located on chromosome 22",
                      "Must be taken into account when designing primers for amplification of vWF gene on chromosome 22Need to avoid amplifying pseudogene",
                      "Need to avoid amplifying pseudogene"
                    ]
                  },
                  {
                    "text": "GenotypingMay be useful if type 2N is suspectedUseful in discriminating between type 2B vWD and platelet-type vWD",
                    "sub_points": [
                      "May be useful if type 2N is suspected",
                      "Useful in discriminating between type 2B vWD and platelet-type vWD"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "von Willebrand Disease Type III": {
            "name": "von Willebrand Disease Type III",
            "url": "https://app.pathprimer.com/document/ed41f7cc-3111-4c56-b880-a572c7eb8390/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Type III vWD includes virtually ﻿complete quantitative deficiency of vWF"
                  },
                  {
                    "text": "Type III vWD can present with severe mucocutaneous bleeding or musculoskeletal bleeding"
                  },
                  {
                    "text": "Differential includes hemophilia A (FVIII deficiency)Hemophilia follows x-linked inheritancevWD follows autosomal recessive inheritance",
                    "sub_points": [
                      "Hemophilia follows x-linked inheritance",
                      "vWD follows autosomal recessive inheritance"
                    ]
                  },
                  {
                    "text": "Primary therapy for patients with Type III vWD is vWF/FVIII concentratesType III vWD patients typically do not respond to desmopressin",
                    "sub_points": [
                      "Type III vWD patients typically do not respond to desmopressin"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Severely decreased FVIII activity (~ 2-10%)"
                  },
                  {
                    "text": "﻿Absence of all multimers on vWF multimer analysis"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "von Willebrand factor (vWF) plays important roles in platelet adhesion/aggregation and acts as carrier for factor VIII (FVIII)"
                  },
                  {
                    "text": "Bleeding in von Willebrand disease (vWD) can be due to defects in primary &/or secondary hemostasis"
                  },
                  {
                    "text": "3 classification subtypesType I vWD: Partial quantitative deficiency of essentially normal vWFType II vWD: Qualitative defects of vWFType III vWD: Virtually complete quantitative deficiency of vWF",
                    "sub_points": [
                      "Type I vWD: Partial quantitative deficiency of essentially normal vWF",
                      "Type II vWD: Qualitative defects of vWF",
                      "Type III vWD: Virtually complete quantitative deficiency of vWF"
                    ]
                  },
                  {
                    "text": "Mutations found in type III vWD lead to virtually complete deficiency of vWF through various mechanismsFormation of null alleles that produce little or no vWFImpaired dimer or multimer formation, leading to intracellular retention or decreased secretion of vWF",
                    "sub_points": [
                      "Formation of null alleles that produce little or no vWF",
                      "Impaired dimer or multimer formation, leading to intracellular retention or decreased secretion of vWF"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "vWD is most common inherited bleeding disorder, affecting 0.1-1.0% of population"
                  },
                  {
                    "text": "Autosomal inheritance"
                  },
                  {
                    "text": "Type III vWD< 5% of all vWD casesAutosomal recessive inheritanceHeterozygous carriers may have more mucocutaneous bleeding symptoms than normal individuals",
                    "sub_points": [
                      "< 5% of all vWD cases",
                      "Autosomal recessive inheritance",
                      "Heterozygous carriers may have more mucocutaneous bleeding symptoms than normal individuals"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Type III vWD can present with severe mucocutaneous bleeding or musculoskeletal bleedingMucocutaneous bleedingBruising without recognized traumaProlonged, recurrent nosebleedsMenorrhagiaExcessive postpartum bleedingBleeding after dental cleanings or tooth extractionMusculoskeletal bleeding",
                    "sub_points": [
                      "Mucocutaneous bleedingBruising without recognized traumaProlonged, recurrent nosebleedsMenorrhagiaExcessive postpartum bleedingBleeding after dental cleanings or tooth extraction",
                      "Bruising without recognized trauma",
                      "Prolonged, recurrent nosebleeds",
                      "Menorrhagia",
                      "Excessive postpartum bleeding",
                      "Bleeding after dental cleanings or tooth extraction",
                      "Musculoskeletal bleeding"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment of bleeding in vWD is divided into 3 categoriesLocalized control of bleedingApplication of direct pressureTopical hemostatic agentsGelatin/foam matrixTopical thrombinFibrin sealantsAntifibrinolyticsTranexamic acidε-aminocaproic acidAid in clot stabilizationUseful at time of minor surgical and dental procedures to prevent or treat bleedingShould not be used in patients with hematuria, to avoid urinary obstructionAntifibrinolytic agents that are excreted in the urine can inhibit urinary fibrinolysisTherefore, if patient is bleeding into urinary tract and has hematuria, antibrinolytic agent may block breakdown of clots that form, leading to obstruction of ureters by clotTreatments that directly increase plasma vWF and FVIII levelsvWF/FVIII concentratesPrimary therapy for patients with type III vWDDosing is weight basedInfusions can be given every 12-24 hoursDesmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)Type III vWD patients typically do not respond to desmopressin",
                    "sub_points": [
                      "Localized control of bleedingApplication of direct pressureTopical hemostatic agentsGelatin/foam matrixTopical thrombinFibrin sealants",
                      "Application of direct pressure",
                      "Topical hemostatic agentsGelatin/foam matrixTopical thrombinFibrin sealants",
                      "Gelatin/foam matrix",
                      "Topical thrombin",
                      "Fibrin sealants",
                      "AntifibrinolyticsTranexamic acidε-aminocaproic acidAid in clot stabilizationUseful at time of minor surgical and dental procedures to prevent or treat bleedingShould not be used in patients with hematuria, to avoid urinary obstructionAntifibrinolytic agents that are excreted in the urine can inhibit urinary fibrinolysisTherefore, if patient is bleeding into urinary tract and has hematuria, antibrinolytic agent may block breakdown of clots that form, leading to obstruction of ureters by clot",
                      "Tranexamic acid",
                      "ε-aminocaproic acid",
                      "Aid in clot stabilization",
                      "Useful at time of minor surgical and dental procedures to prevent or treat bleeding",
                      "Should not be used in patients with hematuria, to avoid urinary obstructionAntifibrinolytic agents that are excreted in the urine can inhibit urinary fibrinolysisTherefore, if patient is bleeding into urinary tract and has hematuria, antibrinolytic agent may block breakdown of clots that form, leading to obstruction of ureters by clot",
                      "Antifibrinolytic agents that are excreted in the urine can inhibit urinary fibrinolysis",
                      "Therefore, if patient is bleeding into urinary tract and has hematuria, antibrinolytic agent may block breakdown of clots that form, leading to obstruction of ureters by clot",
                      "Treatments that directly increase plasma vWF and FVIII levelsvWF/FVIII concentratesPrimary therapy for patients with type III vWDDosing is weight basedInfusions can be given every 12-24 hoursDesmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)Type III vWD patients typically do not respond to desmopressin",
                      "vWF/FVIII concentratesPrimary therapy for patients with type III vWDDosing is weight basedInfusions can be given every 12-24 hours",
                      "Primary therapy for patients with type III vWD",
                      "Dosing is weight based",
                      "Infusions can be given every 12-24 hours",
                      "Desmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)Type III vWD patients typically do not respond to desmopressin",
                      "Type III vWD patients typically do not respond to desmopressin"
                    ]
                  },
                  {
                    "text": "Short-term prophylaxis with agents, such as antifibrinolytics and vWF/FVIII concentrates, in preparation for known bleeding event, is standard of care in vWD"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Acquired von Willebrand Disease (AvWD) should be ruled outCheck for clinical conditions associated with AvWDBleeding history of patient and other family members may be helpful",
                    "sub_points": [
                      "Check for clinical conditions associated with AvWD",
                      "Bleeding history of patient and other family members may be helpful"
                    ]
                  },
                  {
                    "text": "Hemophilia A (FVIII deficiency)Hemophilia follows x-linked inheritancevWD follows autosomal recessive inheritance",
                    "sub_points": [
                      "Hemophilia follows x-linked inheritance",
                      "vWD follows autosomal recessive inheritance"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Screening Assays": [
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "PFA-100"
                  }
                ],
                "Diagnostic Assays for vWD": [
                  {
                    "text": "vWF antigen (vWF:Ag)Determines quantity of vWF proteinMeasured using 2 types of assaysEnzyme linked immunosorbance (ELISA)Latex immunoassay (LIA)",
                    "sub_points": [
                      "Determines quantity of vWF protein",
                      "Measured using 2 types of assaysEnzyme linked immunosorbance (ELISA)Latex immunoassay (LIA)",
                      "Enzyme linked immunosorbance (ELISA)",
                      "Latex immunoassay (LIA)"
                    ]
                  },
                  {
                    "text": "vWF activityMeasured using 2 types of assaysRistocetin cofactor activity assay (vWF:RCo)Gold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinCollagen-binding activity assay (vWF:CB)Measures ability of vWF to bind collagen-coated plates",
                    "sub_points": [
                      "Measured using 2 types of assaysRistocetin cofactor activity assay (vWF:RCo)Gold standardMeasures ability of vWF to agglutinate platelets in response to ristocetinCollagen-binding activity assay (vWF:CB)Measures ability of vWF to bind collagen-coated plates",
                      "Ristocetin cofactor activity assay (vWF:RCo)Gold standardMeasures ability of vWF to agglutinate platelets in response to ristocetin",
                      "Gold standard",
                      "Measures ability of vWF to agglutinate platelets in response to ristocetin",
                      "Collagen-binding activity assay (vWF:CB)Measures ability of vWF to bind collagen-coated plates",
                      "Measures ability of vWF to bind collagen-coated plates"
                    ]
                  },
                  {
                    "text": "FVIII activityMeasured using 2 types of assaysaPTT-based 1-stage clotting assayChromogenic factor activity assay",
                    "sub_points": [
                      "Measured using 2 types of assaysaPTT-based 1-stage clotting assayChromogenic factor activity assay",
                      "aPTT-based 1-stage clotting assay",
                      "Chromogenic factor activity assay"
                    ]
                  }
                ],
                "Assays for vWD Subtyping": [
                  {
                    "text": "vWF multimer analysisSodium dodecyl sulfate-agarose electrophoresis used to assess vWF multimers in plasmaClassification of multimersHigh molecular weight (HMW)Intermediate molecular weight (IMW)Low molecular weight (LMW)",
                    "sub_points": [
                      "Sodium dodecyl sulfate-agarose electrophoresis used to assess vWF multimers in plasma",
                      "Classification of multimersHigh molecular weight (HMW)Intermediate molecular weight (IMW)Low molecular weight (LMW)",
                      "High molecular weight (HMW)",
                      "Intermediate molecular weight (IMW)",
                      "Low molecular weight (LMW)"
                    ]
                  },
                  {
                    "text": "Ristocetin-induced platelet aggregation (RIPA)Measures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin",
                    "sub_points": [
                      "Measures capacity of vWF to agglutinate platelets at varying low concentrations of ristocetin"
                    ]
                  },
                  {
                    "text": "GenotypingIdentification of mutation is not necessary for making diagnosisMay be useful for discriminating between various types of vWD",
                    "sub_points": [
                      "Identification of mutation is not necessary for making diagnosis",
                      "May be useful for discriminating between various types of vWD"
                    ]
                  }
                ],
                "Assay Results in Type III vWD": [
                  {
                    "text": "Normal platelet count"
                  },
                  {
                    "text": "Prolonged aPTT"
                  },
                  {
                    "text": "Normal PT"
                  },
                  {
                    "text": "Severely decreased (or below limit of detection) vWF activity"
                  },
                  {
                    "text": "Severely decreased (or below limit of detection) vWF antigen"
                  },
                  {
                    "text": "Severely decreased FVIII activity (~ 2-10%)"
                  },
                  {
                    "text": "﻿Absence of all multimers on vWF multimer analysis"
                  },
                  {
                    "text": "Absent RIPA"
                  }
                ],
                "Sample Processing and Storage": [
                  {
                    "text": "After collection, samples should be transported to laboratory at room temperature to prevent cryoprecipitation of vWF and other proteins"
                  },
                  {
                    "text": "Separate plasma from red blood cells promptly with centrifugation at room temperature to remove platelets"
                  },
                  {
                    "text": "If samples are assayed within 2 hours, keep plasma at room temperature"
                  },
                  {
                    "text": "If samples will not be assayed within 2 hours, they should be frozen and stored at or below -40°C"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Normal vWF antigen 50-150%"
                  },
                  {
                    "text": "Normal vWF:RCo 50-150%"
                  },
                  {
                    "text": "Normal vWF:CB 50-150%"
                  },
                  {
                    "text": "Normal vWF multimeric analysis: \"Normal multimeric distribution\""
                  },
                  {
                    "text": "Normal FVIII activity 50-150%"
                  }
                ],
                "Factors Affecting vWF Levels": [
                  {
                    "text": "ABO blood groupIndividuals with O blood type have ~ 30% lower levels of vWF than those with A, B, or AB blood typeDifference is due to shortened survival of vWF in circulation of blood type O individuals",
                    "sub_points": [
                      "Individuals with O blood type have ~ 30% lower levels of vWF than those with A, B, or AB blood type",
                      "Difference is due to shortened survival of vWF in circulation of blood type O individuals"
                    ]
                  },
                  {
                    "text": "Hormone levelsHypothyroidism is associated with decreased levels of vWFEstrogenvWF levels at baseline in women during follicular phase of menstrual cyclevWF levels are higher in women during late luteal phase of menstrual cycleOral contraceptive pills can increase vWF levelsvWF levels increase 2-3x during 2nd and 3rd trimesters of pregnancyInflammationvWF is acute phase reactant and is increased with inflammationAdrenalineβ-adrenergic stimulation causes increase in vWF levelsPhysical stress such as illness and recent exerciseEmotional stress",
                    "sub_points": [
                      "Hypothyroidism is associated with decreased levels of vWF",
                      "EstrogenvWF levels at baseline in women during follicular phase of menstrual cyclevWF levels are higher in women during late luteal phase of menstrual cycleOral contraceptive pills can increase vWF levelsvWF levels increase 2-3x during 2nd and 3rd trimesters of pregnancy",
                      "vWF levels at baseline in women during follicular phase of menstrual cycle",
                      "vWF levels are higher in women during late luteal phase of menstrual cycle",
                      "Oral contraceptive pills can increase vWF levels",
                      "vWF levels increase 2-3x during 2nd and 3rd trimesters of pregnancy",
                      "InflammationvWF is acute phase reactant and is increased with inflammation",
                      "vWF is acute phase reactant and is increased with inflammation",
                      "Adrenalineβ-adrenergic stimulation causes increase in vWF levelsPhysical stress such as illness and recent exerciseEmotional stress",
                      "β-adrenergic stimulation causes increase in vWF levelsPhysical stress such as illness and recent exerciseEmotional stress",
                      "Physical stress such as illness and recent exercise",
                      "Emotional stress"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "vWF geneLocated on chromosome 12178 kb long52 exons",
                    "sub_points": [
                      "Located on chromosome 12",
                      "178 kb long",
                      "52 exons"
                    ]
                  },
                  {
                    "text": "vWF pseudogenePartial duplication of vWF geneLocated on chromosome 22Must be taken into account when designing primers for amplification of vWF gene on chromosome 22Need to avoid amplifying pseudogene",
                    "sub_points": [
                      "Partial duplication of vWF gene",
                      "Located on chromosome 22",
                      "Must be taken into account when designing primers for amplification of vWF gene on chromosome 22Need to avoid amplifying pseudogene",
                      "Need to avoid amplifying pseudogene"
                    ]
                  },
                  {
                    "text": "GenotypingMutations associated with type III vWD are found throughout coding region of vWF geneUp to 80% of type III vWD patients have 2 null alleles~ 1/3 of null mutations result from nonsense mutations~ 20% of type III vWD mutations are missense mutations located predominantly in exons 3-11 or exons 37-52, leading to impaired dimer and multimer formation, or intracellular vWF retention and decreased secretion~ 12% of type III vWD mutations are due to large deletions, predominantly causing frame-shift mutationsGenotyping may be useful in some scenarios in type III vWDPrenatal assessment if known risk of inheriting type III vWD (e.g., both parents known to be heterozygous for mutations)Assessing risk of alloantibody formation following treatment with vWF concentrates",
                    "sub_points": [
                      "Mutations associated with type III vWD are found throughout coding region of vWF gene",
                      "Up to 80% of type III vWD patients have 2 null alleles",
                      "~ 1/3 of null mutations result from nonsense mutations",
                      "~ 20% of type III vWD mutations are missense mutations located predominantly in exons 3-11 or exons 37-52, leading to impaired dimer and multimer formation, or intracellular vWF retention and decreased secretion",
                      "~ 12% of type III vWD mutations are due to large deletions, predominantly causing frame-shift mutations",
                      "Genotyping may be useful in some scenarios in type III vWDPrenatal assessment if known risk of inheriting type III vWD (e.g., both parents known to be heterozygous for mutations)Assessing risk of alloantibody formation following treatment with vWF concentrates",
                      "Prenatal assessment if known risk of inheriting type III vWD (e.g., both parents known to be heterozygous for mutations)",
                      "Assessing risk of alloantibody formation following treatment with vWF concentrates"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acquired von Willebrand Disease": {
            "name": "Acquired von Willebrand Disease",
            "url": "https://app.pathprimer.com/document/6f7680f8-25cd-4f9e-8945-f18ea2a0d1bb/lesson/c58a9f5a-1fc1-4b6b-a346-bcaa01063a25",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "AvWD is usually associated with underlying illness﻿Lymphoproliferative disorders﻿Myeloproliferative disorders﻿Autoimmune disorders﻿Hypothyroidism﻿MedicationsValproic acidCiprofloxacin",
                    "sub_points": [
                      "﻿Lymphoproliferative disorders",
                      "﻿Myeloproliferative disorders",
                      "﻿Autoimmune disorders",
                      "﻿Hypothyroidism",
                      "﻿MedicationsValproic acidCiprofloxacin",
                      "Valproic acid",
                      "Ciprofloxacin"
                    ]
                  },
                  {
                    "text": "Pathophysiology of AvWD varies based on associated illnessBleeding is typically mucocutaneous",
                    "sub_points": [
                      "Bleeding is typically mucocutaneous"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Pattern of vWF assays may be similar to congenital types 1, 2A, or 2B vWD"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Acquired von Willebrand disease (AvWD): Rare acquired bleeding disorderUsually associated with underlying illness",
                    "sub_points": [
                      "Usually associated with underlying illness"
                    ]
                  },
                  {
                    "text": "von Willebrand factor (vWF): Plays important roles in platelet adhesion/aggregation and acts as carrier for factor VIIIBleeding in AvWD can be due to defects in primary and secondary hemostasis",
                    "sub_points": [
                      "Bleeding in AvWD can be due to defects in primary and secondary hemostasis"
                    ]
                  },
                  {
                    "text": "Pathophysiology of AvWD varies based on associated illnessAutoantibodies to vWF﻿Primary mechanism in AvWD associated with lymphoproliferative and autoimmune conditionsNonspecific or specific antibodiesMay bind to functional domains of vWF, inhibiting activityMay bind to nonfunctional domains of vWF, leading to enhanced clearance through reticuloendothelial systemAdsorption of vWFHigh molecular weight multimers (HMWMs) adsorb to platelets or tumor cellsLeads to loss of HMWMsAdsorption to platelets seen in myeloproliferative disordersAdsorption to tumor cells seen in Wilms tumorIncreased shear-induced destruction of vWFLeads to loss of HMWMsSeen in aortic stenosis and use of ventricular assist devices (VADs)﻿Increased proteolysis of vWFCardiac valve diseaseUremia﻿Treatment with ciprofloxacin﻿Defective synthesis of vWF﻿Hypothyroidism﻿Valproic acid treatment",
                    "sub_points": [
                      "Autoantibodies to vWF﻿Primary mechanism in AvWD associated with lymphoproliferative and autoimmune conditionsNonspecific or specific antibodiesMay bind to functional domains of vWF, inhibiting activityMay bind to nonfunctional domains of vWF, leading to enhanced clearance through reticuloendothelial system",
                      "﻿Primary mechanism in AvWD associated with lymphoproliferative and autoimmune conditions",
                      "Nonspecific or specific antibodiesMay bind to functional domains of vWF, inhibiting activityMay bind to nonfunctional domains of vWF, leading to enhanced clearance through reticuloendothelial system",
                      "May bind to functional domains of vWF, inhibiting activity",
                      "May bind to nonfunctional domains of vWF, leading to enhanced clearance through reticuloendothelial system",
                      "Adsorption of vWFHigh molecular weight multimers (HMWMs) adsorb to platelets or tumor cellsLeads to loss of HMWMsAdsorption to platelets seen in myeloproliferative disordersAdsorption to tumor cells seen in Wilms tumor",
                      "High molecular weight multimers (HMWMs) adsorb to platelets or tumor cells",
                      "Leads to loss of HMWMs",
                      "Adsorption to platelets seen in myeloproliferative disorders",
                      "Adsorption to tumor cells seen in Wilms tumor",
                      "Increased shear-induced destruction of vWFLeads to loss of HMWMsSeen in aortic stenosis and use of ventricular assist devices (VADs)",
                      "Leads to loss of HMWMs",
                      "Seen in aortic stenosis and use of ventricular assist devices (VADs)",
                      "﻿Increased proteolysis of vWFCardiac valve diseaseUremia﻿Treatment with ciprofloxacin",
                      "Cardiac valve disease",
                      "Uremia",
                      "﻿Treatment with ciprofloxacin",
                      "﻿Defective synthesis of vWF﻿Hypothyroidism﻿Valproic acid treatment",
                      "﻿Hypothyroidism",
                      "﻿Valproic acid treatment"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Overall prevalence of AvWD is unknown but may be underestimated"
                  },
                  {
                    "text": "Prevalence among selected patient populations10% among patients with hematological disorders79% among patients with aortic stenosisUp to 100% in patients with left VADs",
                    "sub_points": [
                      "10% among patients with hematological disorders",
                      "79% among patients with aortic stenosis",
                      "Up to 100% in patients with left VADs"
                    ]
                  },
                  {
                    "text": "Median age of diagnosis is 62 years (range: 2 to 96 years)"
                  },
                  {
                    "text": "No gender predilection"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Typical presentationAdult patient with no prior history of bleeding disorder or family history of bleeding, and new onset bleeding",
                    "sub_points": [
                      "Adult patient with no prior history of bleeding disorder or family history of bleeding, and new onset bleeding"
                    ]
                  },
                  {
                    "text": "Majority of patients (72%) have bleeding symptoms, while some patients are diagnosed after incidental finding of abnormal laboratory results"
                  },
                  {
                    "text": "Bleeding is typically mucocutaneous"
                  },
                  {
                    "text": "Generally occurs in context of associated clinical condition﻿Lymphoproliferative disordersMonoclonal gammopathy of undetermined significance (MGUS)Multiple myelomaWaldenström macroglobulinemiaNon-Hodgkin lymphomaChronic lymphocytic leukemiaHairy cell leukemiaAcute lymphocytic leukemia﻿Myeloproliferative disordersEssential thrombocythemiaPolycythemia vera﻿Autoimmune disordersSystemic lupus erythematosus (SLE)SclerodermaMixed connective tissue diseaseAntiphospholipid antibody syndrome﻿Solid tumorsWilms tumorAdrenocortical carcinomaLung carcinomaGastric carcinoma﻿Cardiovascular disorders (congenital or acquired)Septal or valvular defectsAortic stenosisVADs﻿Hypothyroidism﻿MedicationsValproic acidCiprofloxacinGriseofulvinHydroxyethyl starch",
                    "sub_points": [
                      "﻿Lymphoproliferative disordersMonoclonal gammopathy of undetermined significance (MGUS)Multiple myelomaWaldenström macroglobulinemiaNon-Hodgkin lymphomaChronic lymphocytic leukemiaHairy cell leukemiaAcute lymphocytic leukemia",
                      "Monoclonal gammopathy of undetermined significance (MGUS)",
                      "Multiple myeloma",
                      "Waldenström macroglobulinemia",
                      "Non-Hodgkin lymphoma",
                      "Chronic lymphocytic leukemia",
                      "Hairy cell leukemia",
                      "Acute lymphocytic leukemia",
                      "﻿Myeloproliferative disordersEssential thrombocythemiaPolycythemia vera",
                      "Essential thrombocythemia",
                      "Polycythemia vera",
                      "﻿Autoimmune disordersSystemic lupus erythematosus (SLE)SclerodermaMixed connective tissue diseaseAntiphospholipid antibody syndrome",
                      "Systemic lupus erythematosus (SLE)",
                      "Scleroderma",
                      "Mixed connective tissue disease",
                      "Antiphospholipid antibody syndrome",
                      "﻿Solid tumorsWilms tumorAdrenocortical carcinomaLung carcinomaGastric carcinoma",
                      "Wilms tumor",
                      "Adrenocortical carcinoma",
                      "Lung carcinoma",
                      "Gastric carcinoma",
                      "﻿Cardiovascular disorders (congenital or acquired)Septal or valvular defectsAortic stenosisVADs",
                      "Septal or valvular defects",
                      "Aortic stenosis",
                      "VADs",
                      "﻿Hypothyroidism",
                      "﻿MedicationsValproic acidCiprofloxacinGriseofulvinHydroxyethyl starch",
                      "Valproic acid",
                      "Ciprofloxacin",
                      "Griseofulvin",
                      "Hydroxyethyl starch"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Two major components to treatment of bleeding due to AvWD﻿Treatment of acute bleedingDesmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)Increases vWF and factor VIIIShort-lived response if underlying cause still presentvWF/factor VIII concentratesIncreases vWF and factor VIIIShort-lived response if underlying cause still presentHigh-dose intravenous immunoglobulin (IVIG)Decreases antibody response, leading to decreased clearance or decreased inhibition of activity of vWFAntifibrinolytics (tranexamic acid or epsilon-aminocaproic acid)Aids in clot stabilizationCan be used alone or in combination with other agentsShould not be used in patients with hematuria (may cause urinary obstruction)PlasmapheresisDecreases antibody titer, leading to decreased clearance or decreased inhibition of activity of vWFRecombinant activated factor VII (rFVIIa)Must use with caution due to risk of thrombosisTreatment of underlying cause of AvWD (depends on pathophysiology of associated condition)AntibodiesTreat with high-dose IVIG, steroids, immunosuppressive medications, plasmapheresisMyeloproliferative disordersTreat with cytoreductive therapyCardiovascular abnormalitiesRepair congenital defectValve replacementDiscontinuation of VAD with transplant",
                    "sub_points": [
                      "﻿Treatment of acute bleedingDesmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)Increases vWF and factor VIIIShort-lived response if underlying cause still presentvWF/factor VIII concentratesIncreases vWF and factor VIIIShort-lived response if underlying cause still presentHigh-dose intravenous immunoglobulin (IVIG)Decreases antibody response, leading to decreased clearance or decreased inhibition of activity of vWFAntifibrinolytics (tranexamic acid or epsilon-aminocaproic acid)Aids in clot stabilizationCan be used alone or in combination with other agentsShould not be used in patients with hematuria (may cause urinary obstruction)PlasmapheresisDecreases antibody titer, leading to decreased clearance or decreased inhibition of activity of vWFRecombinant activated factor VII (rFVIIa)Must use with caution due to risk of thrombosis",
                      "Desmopressin (1-desamino-8-D-arginine vasopressin, or DDAVP)Increases vWF and factor VIIIShort-lived response if underlying cause still present",
                      "Increases vWF and factor VIII",
                      "Short-lived response if underlying cause still present",
                      "vWF/factor VIII concentratesIncreases vWF and factor VIIIShort-lived response if underlying cause still present",
                      "Increases vWF and factor VIII",
                      "Short-lived response if underlying cause still present",
                      "High-dose intravenous immunoglobulin (IVIG)Decreases antibody response, leading to decreased clearance or decreased inhibition of activity of vWF",
                      "Decreases antibody response, leading to decreased clearance or decreased inhibition of activity of vWF",
                      "Antifibrinolytics (tranexamic acid or epsilon-aminocaproic acid)Aids in clot stabilizationCan be used alone or in combination with other agentsShould not be used in patients with hematuria (may cause urinary obstruction)",
                      "Aids in clot stabilization",
                      "Can be used alone or in combination with other agents",
                      "Should not be used in patients with hematuria (may cause urinary obstruction)",
                      "PlasmapheresisDecreases antibody titer, leading to decreased clearance or decreased inhibition of activity of vWF",
                      "Decreases antibody titer, leading to decreased clearance or decreased inhibition of activity of vWF",
                      "Recombinant activated factor VII (rFVIIa)Must use with caution due to risk of thrombosis",
                      "Must use with caution due to risk of thrombosis",
                      "Treatment of underlying cause of AvWD (depends on pathophysiology of associated condition)AntibodiesTreat with high-dose IVIG, steroids, immunosuppressive medications, plasmapheresisMyeloproliferative disordersTreat with cytoreductive therapyCardiovascular abnormalitiesRepair congenital defectValve replacementDiscontinuation of VAD with transplant",
                      "AntibodiesTreat with high-dose IVIG, steroids, immunosuppressive medications, plasmapheresis",
                      "Treat with high-dose IVIG, steroids, immunosuppressive medications, plasmapheresis",
                      "Myeloproliferative disordersTreat with cytoreductive therapy",
                      "Treat with cytoreductive therapy",
                      "Cardiovascular abnormalitiesRepair congenital defectValve replacementDiscontinuation of VAD with transplant",
                      "Repair congenital defect",
                      "Valve replacement",
                      "Discontinuation of VAD with transplant"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Important to distinguish AvWD from congenital von Willebrand disease (vWD) because laboratory results can be similar in both conditionsAvWD usually has later onset of diseaseAvWD not usually accompanied by family history of bleeding",
                    "sub_points": [
                      "AvWD usually has later onset of disease",
                      "AvWD not usually accompanied by family history of bleeding"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "﻿vWF Assays": [
                  {
                    "text": "Pattern of results may be similar to congenital types 1, 2A, or 2B vWD"
                  },
                  {
                    "text": "Decreased vWF activity as measured by ristocetin cofactor activity assay (vWF:RCo) or collagen-binding activity assay (vWF:CB)"
                  },
                  {
                    "text": "May have absence of HMWMs on vWF multimeric analysis, depending on mechanism"
                  },
                  {
                    "text": "vWF antigen may be normal or decreased, depending on mechanismDecreased vWF antigen if due toAntibodies that enhance clearanceAdsorption to cellsDecreased productionMay have normal vWF antigen if due toIncreased shear-induced destructionAntibodies that do not lead to enhanced clearance",
                    "sub_points": [
                      "Decreased vWF antigen if due toAntibodies that enhance clearanceAdsorption to cellsDecreased production",
                      "Antibodies that enhance clearance",
                      "Adsorption to cells",
                      "Decreased production",
                      "May have normal vWF antigen if due toIncreased shear-induced destructionAntibodies that do not lead to enhanced clearance",
                      "Increased shear-induced destruction",
                      "Antibodies that do not lead to enhanced clearance"
                    ]
                  }
                ],
                "﻿Factor VIII Assay": [
                  {
                    "text": "Factor VIII activity levels may be normal or decreased"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Normal vWF antigen = 50-150%"
                  },
                  {
                    "text": "Normal vWF:RCo = 50-150%"
                  },
                  {
                    "text": "Normal vWF multimeric analysis = “normal multimeric distribution”"
                  },
                  {
                    "text": "Normal factor VIII activity = 50-150%"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Anticoagulation Therapy": {
        "name": "Anticoagulation Therapy",
        "url": "https://app.pathprimer.com/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
        "topics": {
          "Unfractionated Heparin Anticoagulation and Reversal": {
            "name": "Unfractionated Heparin Anticoagulation and Reversal",
            "url": "https://app.pathprimer.com/document/51ecf8a5-7c93-4ef6-abfc-fbe7e99c9ee2/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "When rapid anticoagulation is required, UFH is drug of choiceLimited to hospital/inpatient setting; because of short half-life, heparin must be administered as constant intravenous infusionOral anticoagulants preferred for long-term anticoagulation (e.g., LMWH, warfarin, direct thrombin, factor Xa inhibitors)",
                    "sub_points": [
                      "Limited to hospital/inpatient setting; because of short half-life, heparin must be administered as constant intravenous infusion",
                      "Oral anticoagulants preferred for long-term anticoagulation (e.g., LMWH, warfarin, direct thrombin, factor Xa inhibitors)"
                    ]
                  },
                  {
                    "text": "Heparin has following effectsActs as cofactor that accelerates natural anticoagulant AT; AT inhibits thrombin (IIa) and factors Xa, IXa, XIa, XIIaMobilizes calcium from boneInhibits vWF-dependent platelet function",
                    "sub_points": [
                      "Acts as cofactor that accelerates natural anticoagulant AT; AT inhibits thrombin (IIa) and factors Xa, IXa, XIa, XIIa",
                      "Mobilizes calcium from bone",
                      "Inhibits vWF-dependent platelet function"
                    ]
                  },
                  {
                    "text": "Adverse effects include bleeding, heparin-induced thrombocytopenia, osteopenia"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "aPTT is used to monitor heparin therapy and to adjust heparin dose to maintain therapeutic level; ACT is used to monitor heparin when high doses are used (e.g., mechanical circulatory support)"
                  },
                  {
                    "text": "ACT and aPTT are not interchangeable"
                  },
                  {
                    "text": "Anti-Xa activity can be used to monitor UFH or LMWH therapy"
                  }
                ]
              },
              "OVERVIEW": {
                "Background": [
                  {
                    "text": "When rapid anticoagulation is required, UFH is drug of choice"
                  },
                  {
                    "text": "Indications for UFHTreatment and prevention of venous thromboembolismUnstable anginaAcute myocardial infarctionAngioplastyCoronary artery bypass surgeryMechanical circulatory supportECMOCardiac bypass",
                    "sub_points": [
                      "Treatment and prevention of venous thromboembolism",
                      "Unstable angina",
                      "Acute myocardial infarction",
                      "Angioplasty",
                      "Coronary artery bypass surgery",
                      "Mechanical circulatory supportECMOCardiac bypass",
                      "ECMO",
                      "Cardiac bypass"
                    ]
                  },
                  {
                    "text": "Limited to hospital/inpatient setting"
                  },
                  {
                    "text": "Oral anticoagulants preferred for long-term anticoagulationLMWHWarfarinDirect thrombin inhibitorsFactor Xa inhibitors",
                    "sub_points": [
                      "LMWH",
                      "Warfarin",
                      "Direct thrombin inhibitors",
                      "Factor Xa inhibitors"
                    ]
                  }
                ],
                "History": [
                  {
                    "text": "Controversial assignment of credit to Howell and McLean for the discovery of heparin"
                  },
                  {
                    "text": "Heparin was initially isolated as fat-soluble anticoagulant from liver (heparphosphatide)Water-soluble heparin was identified later",
                    "sub_points": [
                      "Water-soluble heparin was identified later"
                    ]
                  }
                ],
                "Structure": [
                  {
                    "text": "Sulfated long chain acidic glycosaminoglycans"
                  },
                  {
                    "text": "Extracted from porcine intestine and beef lung"
                  },
                  {
                    "text": "UFH size ranges from 3,000 to 30,000 Da with a mean of 15 KDa and mean of 45 monosaccharides3000-30,000 DaMean 15 KDaMean 45 monosaccharides",
                    "sub_points": [
                      "3000-30,000 Da",
                      "Mean 15 KDa",
                      "Mean 45 monosaccharides"
                    ]
                  }
                ],
                "Biologic Effects": [
                  {
                    "text": "Heparin has following effectsActs as cofactor that accelerates natural anticoagulant ATAT inhibits thrombin (IIa) and factors Xa, IXa, XIa, XIIaAccelerates natural anticoagulant heparin cofactor IIMobilizes calcium from boneSuppresses osteoblast activityActivates osteoclastsCan result in osteopeniaInhibits smooth muscle proliferationReduces TF:VIIa complexes through endothelial TFPIInhibits vWF-dependent platelet functionDecreases factor Va and VIIIa",
                    "sub_points": [
                      "Acts as cofactor that accelerates natural anticoagulant ATAT inhibits thrombin (IIa) and factors Xa, IXa, XIa, XIIa",
                      "AT inhibits thrombin (IIa) and factors Xa, IXa, XIa, XIIa",
                      "Accelerates natural anticoagulant heparin cofactor II",
                      "Mobilizes calcium from boneSuppresses osteoblast activityActivates osteoclastsCan result in osteopenia",
                      "Suppresses osteoblast activity",
                      "Activates osteoclasts",
                      "Can result in osteopenia",
                      "Inhibits smooth muscle proliferation",
                      "Reduces TF:VIIa complexes through endothelial TFPI",
                      "Inhibits vWF-dependent platelet function",
                      "Decreases factor Va and VIIIa"
                    ]
                  }
                ],
                "Anticoagulant Effect Mechanism of Action": [
                  {
                    "text": "Pentasaccharide sequence in heparin is essential for anticoagulant function of heparin"
                  },
                  {
                    "text": "Heparin binds to AT and to thrombin (IIa) resulting in inhibition of thrombin"
                  },
                  {
                    "text": "Heparin needs to bind only to AT to inhibit factor XaSmaller fragments (< 18 saccharides) are unable to bind thrombin and ATHave anti-Xa activity only",
                    "sub_points": [
                      "Smaller fragments (< 18 saccharides) are unable to bind thrombin and ATHave anti-Xa activity only",
                      "Have anti-Xa activity only"
                    ]
                  }
                ],
                "Pharmacokinetics": [
                  {
                    "text": "UFH is administered as intravenous or subcutaneous injectionLower bioavailability with subcutaneous injection",
                    "sub_points": [
                      "Lower bioavailability with subcutaneous injection"
                    ]
                  },
                  {
                    "text": "One-third of heparin polysaccharides possess necessary pentasaccharide sequence for anticoagulant activity"
                  },
                  {
                    "text": "High-molecular-weight fractions are cleared faster than low-molecular-weight fractions"
                  },
                  {
                    "text": "Half-life of heparin varies depending on concentrationLow concentration: 30 minHigh concentration: up to 150 minOn average half-time is about 1 hr",
                    "sub_points": [
                      "Low concentration: 30 min",
                      "High concentration: up to 150 min",
                      "On average half-time is about 1 hr"
                    ]
                  },
                  {
                    "text": "Kinetics of clearance is initial rapid clearance, followed by slower clearance"
                  },
                  {
                    "text": "Heparin is bound to endothelium, monocytes, and macrophages"
                  }
                ],
                "Anticoagulation": [
                  {
                    "text": "Parenteral or subcutaneous administration"
                  },
                  {
                    "text": "Subcutaneous administration usually used for deep venous thrombosis prophylaxis in hospitalized patients"
                  },
                  {
                    "text": "Because of short half-life, heparin must be administered as constant intravenous infusionTypically loading dose is followed by constant infusionPTT, ACT, or anti-Xa activity is measuredInfusion is adjusted so that laboratory value is within therapeutic rangeNomograms often used to efficiently obtain therapeutic range and to prevent excursions from this range",
                    "sub_points": [
                      "Typically loading dose is followed by constant infusion",
                      "PTT, ACT, or anti-Xa activity is measuredInfusion is adjusted so that laboratory value is within therapeutic range",
                      "Infusion is adjusted so that laboratory value is within therapeutic range",
                      "Nomograms often used to efficiently obtain therapeutic range and to prevent excursions from this range"
                    ]
                  }
                ],
                "Adverse Effects": [
                  {
                    "text": "BleedingDose-dependent increased risk of bleedingApproximately 5% risk of bleedingRisk varies depending on presence of risk factorsRisk factorsConcomitant administration of antiplatelet medications (e.g., aspirin)Older age (> 60 yr)Concomitant liver disease or underlying illnessSurgery, trauma, or other invasive procedureOther hemostatic defectsRisk lower if used for prophylaxisProtamine sulfate should be administered to reverse effect (1 mg per 100 U)",
                    "sub_points": [
                      "Dose-dependent increased risk of bleedingApproximately 5% risk of bleedingRisk varies depending on presence of risk factors",
                      "Approximately 5% risk of bleeding",
                      "Risk varies depending on presence of risk factors",
                      "Risk factorsConcomitant administration of antiplatelet medications (e.g., aspirin)Older age (> 60 yr)Concomitant liver disease or underlying illnessSurgery, trauma, or other invasive procedureOther hemostatic defects",
                      "Concomitant administration of antiplatelet medications (e.g., aspirin)",
                      "Older age (> 60 yr)",
                      "Concomitant liver disease or underlying illness",
                      "Surgery, trauma, or other invasive procedure",
                      "Other hemostatic defects",
                      "Risk lower if used for prophylaxis",
                      "Protamine sulfate should be administered to reverse effect (1 mg per 100 U)"
                    ]
                  },
                  {
                    "text": "Heparin-induced thrombocytopeniaComplication of heparin therapy due to heparin-platelet factor 4 antibodiesCharacterized by thrombocytopenia and thrombosis that occurs 3-10 days after initiation of heparin therapyThrombocytopenia usually nadirs around 150 x 10⁶/mL or 50% of baselineThrombosis can be venous or arterial",
                    "sub_points": [
                      "Complication of heparin therapy due to heparin-platelet factor 4 antibodies",
                      "Characterized by thrombocytopenia and thrombosis that occurs 3-10 days after initiation of heparin therapy",
                      "Thrombocytopenia usually nadirs around 150 x 10⁶/mL or 50% of baseline",
                      "Thrombosis can be venous or arterial"
                    ]
                  },
                  {
                    "text": "OsteopeniaHeparin activates osteoclastsUp to 30% of patients may experience osteopeniaVertebral fractures can be seen in 2%-3% of patientsRisk of osteopenia increased with long-term therapyMore of a problem with LMWH",
                    "sub_points": [
                      "Heparin activates osteoclasts",
                      "Up to 30% of patients may experience osteopenia",
                      "Vertebral fractures can be seen in 2%-3% of patients",
                      "Risk of osteopenia increased with long-term therapyMore of a problem with LMWH",
                      "More of a problem with LMWH"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Unfractionated heparin (UFH)"
                  },
                  {
                    "text": "Extracorporeal membrane oxygenation (ECMO)"
                  },
                  {
                    "text": "Low-molecular-weight heparin (LMWH)"
                  },
                  {
                    "text": "Antithrombin (AT)"
                  },
                  {
                    "text": "Tissue factor (TF)"
                  },
                  {
                    "text": "Tissue factor pathway inhibitor (TFPI)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Partial thromboplastin time (PTT)"
                  },
                  {
                    "text": "Activated clotting time (ACT)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Activated Partial Thromboplastin Time": [
                  {
                    "text": "Used to monitor heparin therapy and to adjust heparin dose to maintain therapeutic level"
                  },
                  {
                    "text": "Performed on PPP prepared from 3.2% sodium citrate anticoagulated whole blood1:9 anticoagulant:whole blood ratio",
                    "sub_points": [
                      "1:9 anticoagulant:whole blood ratio"
                    ]
                  },
                  {
                    "text": "PPP is incubated in tube of cuvette at 37°C"
                  },
                  {
                    "text": "Partial thromboplastin reagent and calcium are added to sample and time to clot formation is measured"
                  },
                  {
                    "text": "Clot formation detected by mechanical, electrical impedance, spectrophotometric, or visual method"
                  },
                  {
                    "text": "Heparin therapeutic range is determined for each laboratory's own PTT testing system"
                  }
                ],
                "Activated Clotting Time": [
                  {
                    "text": "Whole blood assay that uses activator (e.g., kaolin) to initiate clot formation"
                  },
                  {
                    "text": "Used to monitor heparin when high doses are usedSuch as for mechanical circulatory supportMeasured in seconds",
                    "sub_points": [
                      "Such as for mechanical circulatory support",
                      "Measured in seconds"
                    ]
                  },
                  {
                    "text": "Can be measured in operating room or at patient's bedside"
                  },
                  {
                    "text": "ACT and aPTT are not interchangeable"
                  }
                ],
                "Anti-Xa Activity": [
                  {
                    "text": "Anti-Xa activity can be used to monitor UFH or LMWH therapy"
                  },
                  {
                    "text": "UFH heparin anti-Xa activity is measured in PPP"
                  },
                  {
                    "text": "PPP contains antithrombin:heparin complexes that depend on heparin content of PPP"
                  },
                  {
                    "text": "Antithrombin:heparin complexes inhibit standard amount of factor Xa added to sample"
                  },
                  {
                    "text": "Some factor Xa not inhibited by AT:heparin complexes—Xa(free)"
                  },
                  {
                    "text": "Substrate with reporting structure is addedReporting structure emits fluorescence based on enzymatic activity of Xa(free)",
                    "sub_points": [
                      "Reporting structure emits fluorescence based on enzymatic activity of Xa(free)"
                    ]
                  },
                  {
                    "text": "Signal is inversely proportional to heparin activityMore heparin → greater AT:heparin complexes → more inhibition of Xa → less Xa(free) → less reporter signal released by Xa activity",
                    "sub_points": [
                      "More heparin → greater AT:heparin complexes → more inhibition of Xa → less Xa(free) → less reporter signal released by Xa activity"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Heparin Therapeutic Range Determination": {
            "name": "Heparin Therapeutic Range Determination",
            "url": "https://app.pathprimer.com/document/e98b9605-1485-49c1-8419-b64906a49aa3/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Heparin is cofactor that accelerates activity of natural anticoagulant ATIII"
                  },
                  {
                    "text": "ATIII inhibits thrombin, factor Xa, factor IXa, factor XIa, and factor XIIa"
                  },
                  {
                    "text": "Treatment is most commonly monitored using aPTTRange falls between 1.5-2.5 times normal reference value (mean of normal donors)",
                    "sub_points": [
                      "Range falls between 1.5-2.5 times normal reference value (mean of normal donors)"
                    ]
                  },
                  {
                    "text": "Anti-Xa activity is chromogenic assay used to measure heparin levels"
                  },
                  {
                    "text": "aPTT is typically used to monitor heparin, but anti-Xa activity may be necessary in some situationsElevated aPTT prior to initiation of therapyIncreased bleeding risk requiring tighter controlHeparin resistance",
                    "sub_points": [
                      "Elevated aPTT prior to initiation of therapy",
                      "Increased bleeding risk requiring tighter control",
                      "Heparin resistance"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "aPTT measures factors of intrinsic and common pathways (factor XII, factor XI, factor IX, factor V, factor VIII, factor X, factor II)"
                  },
                  {
                    "text": "Each laboratory should establish its own heparin therapeutic range for each lot of reagent"
                  }
                ]
              },
              "OVERVIEW": {
                "Heparin Administration": [
                  {
                    "text": "Heparin is cofactor that accelerates activity of natural anticoagulant ATIII"
                  },
                  {
                    "text": "ATIII inhibits thrombin, factor Xa, factor IXa, factor XIa, and factor XIIa"
                  },
                  {
                    "text": "Heparin fractions of at least 18 saccharides in length, including critical pentasaccharide sequence, are required to inhibit thrombin"
                  },
                  {
                    "text": "Only pentasaccharide sequence is necessary to inhibit factor Xa"
                  },
                  {
                    "text": "Heparin is most commonly administered parenterally for therapeutic anticoagulationBolus followed by continuous infusionAfter 4-6 hours, aPTT is measured and heparin infusion adjusted according to established nomograms",
                    "sub_points": [
                      "Bolus followed by continuous infusion",
                      "After 4-6 hours, aPTT is measured and heparin infusion adjusted according to established nomograms"
                    ]
                  }
                ],
                "Heparin Monitoring": [
                  {
                    "text": "Treatment is most commonly monitored using aPTTRange falls between 1.5-2.5 times normal reference value (mean of normal donors)aPTT reagent preparations have different sensitivities to heparinEach laboratory therefore must establish its own heparin therapeutic ranges for each reagent lotFor some reagents, 1.5 times reference value falls below 0.2 units/mL by protamine titrationaPTT therapeutic range should be established for each reagent lotCorresponds to heparin level of 0.2-0.4 units/mL using protamine titrationCorresponds to 0.3-0.7 units/mL using anti-Xa assay",
                    "sub_points": [
                      "Range falls between 1.5-2.5 times normal reference value (mean of normal donors)",
                      "aPTT reagent preparations have different sensitivities to heparinEach laboratory therefore must establish its own heparin therapeutic ranges for each reagent lot",
                      "Each laboratory therefore must establish its own heparin therapeutic ranges for each reagent lot",
                      "For some reagents, 1.5 times reference value falls below 0.2 units/mL by protamine titration",
                      "aPTT therapeutic range should be established for each reagent lotCorresponds to heparin level of 0.2-0.4 units/mL using protamine titrationCorresponds to 0.3-0.7 units/mL using anti-Xa assay",
                      "Corresponds to heparin level of 0.2-0.4 units/mL using protamine titration",
                      "Corresponds to 0.3-0.7 units/mL using anti-Xa assay"
                    ]
                  },
                  {
                    "text": "Anti-Xa activity is chromogenic assay used to measure heparin levelsaPTT is typically used to monitor heparin, but anti-Xa activity may be necessary in some situationsElevated aPTT prior to initiation of therapyLupus anticoagulantFactor deficiencyHepatic insufficiencyIncreased bleeding risk requiring tighter controlRecent surgeryStrokeSevere thrombocytopeniaExtremes of ageExtremes of weightRenal insufficiencyHeparin resistance",
                    "sub_points": [
                      "aPTT is typically used to monitor heparin, but anti-Xa activity may be necessary in some situationsElevated aPTT prior to initiation of therapyLupus anticoagulantFactor deficiencyHepatic insufficiencyIncreased bleeding risk requiring tighter controlRecent surgeryStrokeSevere thrombocytopeniaExtremes of ageExtremes of weightRenal insufficiencyHeparin resistance",
                      "Elevated aPTT prior to initiation of therapyLupus anticoagulantFactor deficiencyHepatic insufficiency",
                      "Lupus anticoagulant",
                      "Factor deficiency",
                      "Hepatic insufficiency",
                      "Increased bleeding risk requiring tighter controlRecent surgeryStrokeSevere thrombocytopeniaExtremes of ageExtremes of weightRenal insufficiency",
                      "Recent surgery",
                      "Stroke",
                      "Severe thrombocytopenia",
                      "Extremes of age",
                      "Extremes of weight",
                      "Renal insufficiency",
                      "Heparin resistance"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Antithrombin III (ATIII)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  },
                  {
                    "text": "Thrombin-antithrombin (TAT)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Performing aPTT": [
                  {
                    "text": "aPTT measures factors of intrinsic and common pathways (factor XII, factor XI, factor IX, factor V, factor VIII, factor X, factor II)"
                  },
                  {
                    "text": "Test is performed on PPP prepared from citrated whole blood"
                  },
                  {
                    "text": "Sample volume of PPP is aliquoted into test tube and incubated at 37°C"
                  },
                  {
                    "text": "Prewarmed reagent containing standardized amount of phospholipid (e.g., cephalin) and activator (e.g., silica) are added to sample"
                  },
                  {
                    "text": "Calcium is then added to activate coagulation"
                  },
                  {
                    "text": "Time to detect clot is measured and reportedClot detection can be visual (e.g., tilt-tube), mechanical, optical",
                    "sub_points": [
                      "Clot detection can be visual (e.g., tilt-tube), mechanical, optical"
                    ]
                  }
                ],
                "Performing Anti-Xa assay": [
                  {
                    "text": "Patient PPP is prepared from 3.2% sodium citrate anticoagulated sample of whole blood"
                  },
                  {
                    "text": "Plasma contains heparin:antithrombin complexes that inhibit factor Xa added to sample"
                  },
                  {
                    "text": "A residual amount of free factor Xa remains, depending on activity of TAT complexes"
                  },
                  {
                    "text": "A reagent substrate for factor Xa is added, and factor Xa will cleave chromogenic signal from substrate"
                  },
                  {
                    "text": "Measurement of signal is inversely proportional to heparin activity"
                  }
                ],
                "Establishing Heparin Therapeutic Range": [
                  {
                    "text": "Each laboratory should establish its own heparin therapeutic range for each lot of reagent"
                  },
                  {
                    "text": "Therapeutic range establishes balance in risk of bleeding and risk of thrombosis"
                  },
                  {
                    "text": "Brill-Edwards methodPerform anti-Xa activity (or protamine titration) and aPTT on minimum of 40 subjects on heparin therapyPlot anti-Xa activity on x-axis and aPTT on y-axisPerform linear regression and plot with data pointsAt 0.3 and 0.7 units/mL anti-Xa activity (or 0.2-0.4 units/mL by protamine titration), read corresponding aPTT off linear regression lineCorresponding aPTTs establish therapeutic range",
                    "sub_points": [
                      "Perform anti-Xa activity (or protamine titration) and aPTT on minimum of 40 subjects on heparin therapy",
                      "Plot anti-Xa activity on x-axis and aPTT on y-axis",
                      "Perform linear regression and plot with data points",
                      "At 0.3 and 0.7 units/mL anti-Xa activity (or 0.2-0.4 units/mL by protamine titration), read corresponding aPTT off linear regression line",
                      "Corresponding aPTTs establish therapeutic range"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Additives": [
                  {
                    "text": "3.2% sodium citrate in 1:9 anticoagulant:whole blood ratio"
                  },
                  {
                    "text": "Waste tube should be drawn and discarded first"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Low Molecular Weight Heparin Therapy": {
            "name": "Low Molecular Weight Heparin Therapy",
            "url": "https://app.pathprimer.com/document/5c913a78-a1c6-426a-b714-6a62a0b8810d/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "LMWH consists of smaller fractions of heparin separated from UFHBinding to both coagulation factor and AT is required to inhibit thrombin, and LMWH is too short to mediate inhibition of thrombin",
                    "sub_points": [
                      "Binding to both coagulation factor and AT is required to inhibit thrombin, and LMWH is too short to mediate inhibition of thrombin"
                    ]
                  },
                  {
                    "text": "LMWH has advantages over UFHMore predictable absorptionMore predictable anticoagulant effectMonitoring is not necessary, except under certain conditionsRenal insufficiencyPregnancyExtremes of age (i.e., pediatrics and elderly)Extremes of weight (e.g., obesity)",
                    "sub_points": [
                      "More predictable absorption",
                      "More predictable anticoagulant effect",
                      "Monitoring is not necessary, except under certain conditionsRenal insufficiencyPregnancyExtremes of age (i.e., pediatrics and elderly)Extremes of weight (e.g., obesity)",
                      "Renal insufficiency",
                      "Pregnancy",
                      "Extremes of age (i.e., pediatrics and elderly)",
                      "Extremes of weight (e.g., obesity)"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Background": [
                  {
                    "text": "LMWH consists of smaller fractions of heparin separated from UFH"
                  },
                  {
                    "text": "LMWHs range from 2-10 KDa in weight, compared with 5-30 KDa range for UFH"
                  },
                  {
                    "text": "LMWH Inhibits factor Xa similarly to UFH, but LMWH is much less efficient at inhibiting thrombinPentasaccharide sequence is required for inhibition of thrombin and factor XaBinding to both coagulation factor and AT is required to inhibit thrombin, and LMWH is too short to mediate inhibition of thrombin",
                    "sub_points": [
                      "Pentasaccharide sequence is required for inhibition of thrombin and factor Xa",
                      "Binding to both coagulation factor and AT is required to inhibit thrombin, and LMWH is too short to mediate inhibition of thrombin"
                    ]
                  },
                  {
                    "text": "LMWH has advantages over UFHMore predictable absorptionMore predictable bioavailabilityMore predictable anticoagulant effectMonitoring is rarely necessary; only required for small number of indications",
                    "sub_points": [
                      "More predictable absorption",
                      "More predictable bioavailability",
                      "More predictable anticoagulant effect",
                      "Monitoring is rarely necessary; only required for small number of indications"
                    ]
                  },
                  {
                    "text": "Administered subcutaneously"
                  }
                ],
                "Mechanism of Action": [
                  {
                    "text": "Heparin accelerates activity of AT"
                  },
                  {
                    "text": "Pentasaccharide sequence is essential for UFH and LMWH activity"
                  },
                  {
                    "text": "Longer length of UFH allows binding to both AT and factor Xa or thrombin"
                  },
                  {
                    "text": "LMWH can only bind to AT, due to its shorter length reducing it's ability to inhibit factor Xa and thrombinInhibition of factor Xa is much greater than inhibition of thrombin",
                    "sub_points": [
                      "Inhibition of factor Xa is much greater than inhibition of thrombin"
                    ]
                  }
                ],
                "Pharmacokinetics": [
                  {
                    "text": "Elimination half-life is dose dependent"
                  },
                  {
                    "text": "Half-life ranges from 3-6 hours"
                  },
                  {
                    "text": "Peak anti-Xa activity is reached at 5 hours after dose"
                  },
                  {
                    "text": "Longer half-life of LMWH, compared with UFH, allows for once or twice daily dosing"
                  },
                  {
                    "text": "LMWH is hepatically and renally clearedDose should be modified in patients with renal impairmentDecreased creatinine clearance",
                    "sub_points": [
                      "Dose should be modified in patients with renal impairmentDecreased creatinine clearance",
                      "Decreased creatinine clearance"
                    ]
                  }
                ],
                "LMWH Therapy": [
                  {
                    "text": "IndicationsProphylaxis or treatment for venous thromboembolismProphylaxis or treatment of acute coronary syndromes",
                    "sub_points": [
                      "Prophylaxis or treatment for venous thromboembolism",
                      "Prophylaxis or treatment of acute coronary syndromes"
                    ]
                  },
                  {
                    "text": "Monitoring is not necessary, except under certain conditionsRenal insufficiencyPregnancyExtremes of age (i.e., pediatrics and elderly)Extremes of weight (e.g., obesity)",
                    "sub_points": [
                      "Renal insufficiency",
                      "Pregnancy",
                      "Extremes of age (i.e., pediatrics and elderly)",
                      "Extremes of weight (e.g., obesity)"
                    ]
                  },
                  {
                    "text": "Target anti-Xa activity depends on preparation and once or twice daily dosing; measured at 4 hours after injectione.g., target anti-Xa activity for twice daily enoxaparin is 0.6-1.0 U/mLe.g., target anti-Xa activity for once daily enoxaparin is 1.0 U/mL",
                    "sub_points": [
                      "e.g., target anti-Xa activity for twice daily enoxaparin is 0.6-1.0 U/mL",
                      "e.g., target anti-Xa activity for once daily enoxaparin is 1.0 U/mL"
                    ]
                  }
                ],
                "Adverse Effects": [
                  {
                    "text": "BleedingInjection siteNeuraxial blocks (e.g., epidural) can result in hematoma and paralysisHigher risk of bleeding with higher doses (i.e., treatment dose > prophylaxis)Concern in patients with renal impairment",
                    "sub_points": [
                      "Injection siteNeuraxial blocks (e.g., epidural) can result in hematoma and paralysis",
                      "Neuraxial blocks (e.g., epidural) can result in hematoma and paralysis",
                      "Higher risk of bleeding with higher doses (i.e., treatment dose > prophylaxis)",
                      "Concern in patients with renal impairment"
                    ]
                  },
                  {
                    "text": "HITPlatelet activating antibodies are formed against heparin-platelet factor 4 and can lead to thrombocytopenia and thrombosisMuch less common with LMWH compared with UFH",
                    "sub_points": [
                      "Platelet activating antibodies are formed against heparin-platelet factor 4 and can lead to thrombocytopenia and thrombosis",
                      "Much less common with LMWH compared with UFH"
                    ]
                  },
                  {
                    "text": "OsteopeniaLower risk with LMWH compared with UFHOverall risk related to dose and duration of treatment",
                    "sub_points": [
                      "Lower risk with LMWH compared with UFH",
                      "Overall risk related to dose and duration of treatment"
                    ]
                  },
                  {
                    "text": "Drug-drug interactionsOther anticoagulants (e.g., warfarin, direct thrombin inhibitors)Antiplatelet agents (e.g., aspirin, clopidogrel, dipyridamole, NSAIDs)",
                    "sub_points": [
                      "Other anticoagulants (e.g., warfarin, direct thrombin inhibitors)",
                      "Antiplatelet agents (e.g., aspirin, clopidogrel, dipyridamole, NSAIDs)"
                    ]
                  }
                ],
                "Reversal": [
                  {
                    "text": "Protamine is used to reverse UFH but is less effective in reversing LMWH"
                  },
                  {
                    "text": "Protamine neutralizes antithrombin (anti-IIa) effect of heparin"
                  },
                  {
                    "text": "1 mg per 100 U heparin is usually administered"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Antithrombin (AT)"
                  },
                  {
                    "text": "Heparin-induced thrombocytopenia (HIT)"
                  },
                  {
                    "text": "Low molecular weight heparin (LMWH)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  },
                  {
                    "text": "Unfractionated heparin (UFH)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Chromogenic Anti-Xa Activity": [
                  {
                    "text": "Fixed amount of factor Xa is added to sample of PPP"
                  },
                  {
                    "text": "PPP sample contains heparin:antithrombin complexes that inhibit factor Xa"
                  },
                  {
                    "text": "Residual activity of factor Xa is measured by adding reporting substrate that releases chromogenic signal when acted upon by factor Xa"
                  },
                  {
                    "text": "Chromogenic signal is inversely proportional to heparin activity in sample"
                  }
                ],
                "aPTT and PT": [
                  {
                    "text": "Insensitive to LMWH therapy"
                  },
                  {
                    "text": "Unsuitable for monitoring of LMWH"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Heparin-Induced Thrombocytopenia": {
            "name": "Heparin-Induced Thrombocytopenia",
            "url": "https://app.pathprimer.com/document/c075091f-9d38-4199-8b40-955dd256c6ca/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "HIT is heparin-induced, antibody-mediated thrombotic disorder paradoxically associated with thrombocytopeniaDue to heparin-dependent, platelet-activating IgG antibodies against heparin-PF4Antibodies are commonly transient and may not be detected several weeks to months after they developTarget antigen is PF4 and heparinAntibodies form due to UFH > LMWH (8 x)",
                    "sub_points": [
                      "Due to heparin-dependent, platelet-activating IgG antibodies against heparin-PF4",
                      "Antibodies are commonly transient and may not be detected several weeks to months after they develop",
                      "Target antigen is PF4 and heparin",
                      "Antibodies form due to UFH > LMWH (8 x)"
                    ]
                  },
                  {
                    "text": "Thrombocytopenia starts 5-10 days after exposure (heparin start date is day 0)"
                  },
                  {
                    "text": "Platelet count nadirs range 15,000-150,000 in 90% of patients"
                  },
                  {
                    "text": "> 50% patients develop new thrombosisDeep vein thrombosis most common venous thrombosisLimb ischemia is most common arterial thrombosis",
                    "sub_points": [
                      "Deep vein thrombosis most common venous thrombosis",
                      "Limb ischemia is most common arterial thrombosis"
                    ]
                  },
                  {
                    "text": "TreatmentStop heparinCessation alone is not sufficient for patients with HITAlternate, rapid-acting anticoagulant should be startedStill risk of thrombosis with cessation alone, even after 30 days",
                    "sub_points": [
                      "Stop heparin",
                      "Cessation alone is not sufficient for patients with HITAlternate, rapid-acting anticoagulant should be startedStill risk of thrombosis with cessation alone, even after 30 days",
                      "Alternate, rapid-acting anticoagulant should be started",
                      "Still risk of thrombosis with cessation alone, even after 30 days"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Serotonin release assayHigh-sensitivity assay for clinically significant antibodies",
                    "sub_points": [
                      "High-sensitivity assay for clinically significant antibodies"
                    ]
                  },
                  {
                    "text": "Solid phase ELISA assays (PF4)Only minority of patients with anti-heparin:PF4 antibodies develop clinical HITNegative test strongly argues against HIT (high negative predictive value)",
                    "sub_points": [
                      "Only minority of patients with anti-heparin:PF4 antibodies develop clinical HIT",
                      "Negative test strongly argues against HIT (high negative predictive value)"
                    ]
                  },
                  {
                    "text": "HIT antibody testing should be performed only on patients with clinical suspicion of HITScoring system (e.g., 4 T's) is useful to determine pre-test probability",
                    "sub_points": [
                      "Scoring system (e.g., 4 T's) is useful to determine pre-test probability"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "HIT Nomenclature": [
                  {
                    "text": "HIT is heparin-induced, antibody-mediated thrombotic disorder paradoxically associated with thrombocytopeniaDue to heparin-dependent, platelet-activating IgG antibodies against heparin-PF4Parallel activation of coagulationAssociated with venous and arterial thrombosisIncidence is ~ 3%50-67% of HIT patients have thrombotic event within 30 days",
                    "sub_points": [
                      "Due to heparin-dependent, platelet-activating IgG antibodies against heparin-PF4",
                      "Parallel activation of coagulation",
                      "Associated with venous and arterial thrombosis",
                      "Incidence is ~ 3%",
                      "50-67% of HIT patients have thrombotic event within 30 days"
                    ]
                  },
                  {
                    "text": "Pseudo-HITNonimmune heparin-associated thrombocytopeniaPlatelet proaggregating effect of heparinMild thrombocytopenia, no thrombotic risk",
                    "sub_points": [
                      "Nonimmune heparin-associated thrombocytopenia",
                      "Platelet proaggregating effect of heparin",
                      "Mild thrombocytopenia, no thrombotic risk"
                    ]
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Formation of heparin-dependent IgG antibodies that activate platelets via platelet Fc receptor"
                  },
                  {
                    "text": "Target antigen is PF4 and heparinConformational change in PF4 after heparin binding",
                    "sub_points": [
                      "Conformational change in PF4 after heparin binding"
                    ]
                  },
                  {
                    "text": "High frequency of antibody formationUp to 75% of patients undergoing cardiac surgery develop antibodies within 1-2 weeksVariables on which it dependsHeparin preparationUFH > LMWH (8 x)Duration of treatmentLimiting heparin treatment to fewer than 5 days decreases riskPatient populationSurgical > medical > obstetricCardiac > orthopedic",
                    "sub_points": [
                      "Up to 75% of patients undergoing cardiac surgery develop antibodies within 1-2 weeks",
                      "Variables on which it dependsHeparin preparationUFH > LMWH (8 x)Duration of treatmentLimiting heparin treatment to fewer than 5 days decreases riskPatient populationSurgical > medical > obstetricCardiac > orthopedic",
                      "Heparin preparationUFH > LMWH (8 x)",
                      "UFH > LMWH (8 x)",
                      "Duration of treatmentLimiting heparin treatment to fewer than 5 days decreases risk",
                      "Limiting heparin treatment to fewer than 5 days decreases risk",
                      "Patient populationSurgical > medical > obstetricCardiac > orthopedic",
                      "Surgical > medical > obstetric",
                      "Cardiac > orthopedic"
                    ]
                  },
                  {
                    "text": "Antibodies are commonly transient and may not be detected several weeks to months after they develop"
                  },
                  {
                    "text": "Only few patients with anti-heparin/PF4 antibodies will develop thrombocytopeniaHigh titer IgG antibodies are most likely to cause HIT",
                    "sub_points": [
                      "High titer IgG antibodies are most likely to cause HIT"
                    ]
                  },
                  {
                    "text": "Thrombin generationIncreased TAT complexesPlatelet activation releases microparticles that accelerate coagulation reactionsPF4 neutralizes anticoagulant effects of heparinProcoagulant changes to endothelium, monocytes, and neutrophils",
                    "sub_points": [
                      "Increased TAT complexes",
                      "Platelet activation releases microparticles that accelerate coagulation reactions",
                      "PF4 neutralizes anticoagulant effects of heparin",
                      "Procoagulant changes to endothelium, monocytes, and neutrophils"
                    ]
                  }
                ],
                "Clinical Features (4 T's)": [
                  {
                    "text": "Scoring systems based on following criteria are available≤ 3 points = low probability of HIT4-5 points = intermediate probability of HIT6-8 points = high probability of HIT",
                    "sub_points": [
                      "≤ 3 points = low probability of HIT",
                      "4-5 points = intermediate probability of HIT",
                      "6-8 points = high probability of HIT"
                    ]
                  },
                  {
                    "text": "Timing of thrombocytopeniaThrombocytopenia starts 5-10 days after exposure (heparin start date is day 0)70% of patients have this \"typical\" onsetGradually declines to thrombocytopenic levelsRapid-onset HIT (before 5 days) if patient was recently exposed to heparin and has residual heparin-associated antibodiesDue to acute platelet activation in presence of preformed HIT antibodiesDelayed-onset HITThrombocytopenia starts after heparin is stopped",
                    "sub_points": [
                      "Thrombocytopenia starts 5-10 days after exposure (heparin start date is day 0)70% of patients have this \"typical\" onset",
                      "70% of patients have this \"typical\" onset",
                      "Gradually declines to thrombocytopenic levels",
                      "Rapid-onset HIT (before 5 days) if patient was recently exposed to heparin and has residual heparin-associated antibodiesDue to acute platelet activation in presence of preformed HIT antibodies",
                      "Due to acute platelet activation in presence of preformed HIT antibodies",
                      "Delayed-onset HITThrombocytopenia starts after heparin is stopped",
                      "Thrombocytopenia starts after heparin is stopped"
                    ]
                  },
                  {
                    "text": "ThrombocytopeniaSeverityPlatelet count nadirs range 15,000-150,000 in 90% of patientsIn mild to moderately severe HIT, mean nadir is 60,000 plateletsSome patients may fall by 50%, but platelets still remain in reference rangePetechiae are absent even with platelets < 15,000ResolutionPersists until heparin is withdrawn5-7 days to return to normal after heparin withdrawal (up to 30 days)",
                    "sub_points": [
                      "SeverityPlatelet count nadirs range 15,000-150,000 in 90% of patientsIn mild to moderately severe HIT, mean nadir is 60,000 plateletsSome patients may fall by 50%, but platelets still remain in reference rangePetechiae are absent even with platelets < 15,000",
                      "Platelet count nadirs range 15,000-150,000 in 90% of patients",
                      "In mild to moderately severe HIT, mean nadir is 60,000 platelets",
                      "Some patients may fall by 50%, but platelets still remain in reference range",
                      "Petechiae are absent even with platelets < 15,000",
                      "ResolutionPersists until heparin is withdrawn5-7 days to return to normal after heparin withdrawal (up to 30 days)",
                      "Persists until heparin is withdrawn",
                      "5-7 days to return to normal after heparin withdrawal (up to 30 days)"
                    ]
                  },
                  {
                    "text": "ThrombosisMay be initial presentation for HIT> 50% of patients develop new thrombosisTypes of thrombosisVenous thrombosis is more common than arterial thrombosisDeep vein thrombosis is most common venous thrombosisLimb ischemia is most common arterial thrombosisPulmonary embolismCerebral vein thrombosisStrokeMyocardial infarction",
                    "sub_points": [
                      "May be initial presentation for HIT",
                      "> 50% of patients develop new thrombosis",
                      "Types of thrombosisVenous thrombosis is more common than arterial thrombosisDeep vein thrombosis is most common venous thrombosisLimb ischemia is most common arterial thrombosisPulmonary embolismCerebral vein thrombosisStrokeMyocardial infarction",
                      "Venous thrombosis is more common than arterial thrombosis",
                      "Deep vein thrombosis is most common venous thrombosis",
                      "Limb ischemia is most common arterial thrombosis",
                      "Pulmonary embolism",
                      "Cerebral vein thrombosis",
                      "Stroke",
                      "Myocardial infarction"
                    ]
                  },
                  {
                    "text": "Other explanations (4th T does not start with T)Presence of other explanations for thrombocytopenia decreases pre-test probability for HIT",
                    "sub_points": [
                      "Presence of other explanations for thrombocytopenia decreases pre-test probability for HIT"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Dilutional (e.g., post cardiac bypass)"
                  },
                  {
                    "text": "Production abnormalities (e.g., hematologic malignancy)"
                  },
                  {
                    "text": "Consumption (e.g., sepsis, disseminated intravascular coagulation)"
                  }
                ],
                "Treatment of Thrombosis": [
                  {
                    "text": "Stop heparin"
                  },
                  {
                    "text": "Alternate, rapid-acting anticoagulant should be startedLepirudinDanaparoidArgatrobanFondaparinux",
                    "sub_points": [
                      "Lepirudin",
                      "Danaparoid",
                      "Argatroban",
                      "Fondaparinux"
                    ]
                  },
                  {
                    "text": "Warfarin is contraindicated"
                  },
                  {
                    "text": "Avoid prophylactic platelet transfusions"
                  }
                ],
                "Treatment of Isolated HIT": [
                  {
                    "text": "Stop heparinCessation alone is not sufficient for patient with HITStill risk of thrombosis with cessation alone even after 30 days",
                    "sub_points": [
                      "Cessation alone is not sufficient for patient with HIT",
                      "Still risk of thrombosis with cessation alone even after 30 days"
                    ]
                  },
                  {
                    "text": "Alternative anticoagulation should be started at therapeutic dosesDanaparoidLepirudinFondaparinuxArgatrobanBivalirudin",
                    "sub_points": [
                      "Danaparoid",
                      "Lepirudin",
                      "Fondaparinux",
                      "Argatroban",
                      "Bivalirudin"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Enzyme immunoassay (EIA)"
                  },
                  {
                    "text": "Heparin-induced thrombocytopenia (HIT)"
                  },
                  {
                    "text": "Low-molecular-weight heparin (LMWH)"
                  },
                  {
                    "text": "Platelet factor 4 (PF4)"
                  },
                  {
                    "text": "Serotonin release assay (SRA)"
                  },
                  {
                    "text": "Thrombin-antithrombin (TAT)"
                  },
                  {
                    "text": "Unfractionated heparin (UFH)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Monitoring": [
                  {
                    "text": "Patients started on heparin should have baseline platelet count prior to initiating heparin"
                  },
                  {
                    "text": "Platelet count should be monitored at least every 2 days from day 4 to day 10 or later"
                  },
                  {
                    "text": "For lower risk procedures and LMWH, less frequent monitoring may be performed"
                  },
                  {
                    "text": "For someone with prior history of heparin exposure in past 100 days, platelet count on day 1 should be obtained"
                  }
                ],
                "Platelet Activation Assays": [
                  {
                    "text": "Detects HIT IgG antibodies by detecting ability of antibody to activate platelets in presence of heparin"
                  },
                  {
                    "text": "Platelet activation is nonspecific; results should be interpreted with caution"
                  },
                  {
                    "text": "Serotonin release assayMethod14C labeled serotonin released from platelets is measuredFresh functional platelets from normal donor (known reactive)Platelets are usually washed plateletsNormal, positive HIT, and low positive HIT plasma control samples are also runIncubate labeled platelets with patient serum + heparinPositive SRA strongly associated with thrombocytopenia, with odds ratio of 80High sensitivity assay for clinically significant antibodiesInsensitivity to clinically insignificant antibodiesTechnically demanding; requires validated controls and donor platelets",
                    "sub_points": [
                      "Method14C labeled serotonin released from platelets is measuredFresh functional platelets from normal donor (known reactive)Platelets are usually washed plateletsNormal, positive HIT, and low positive HIT plasma control samples are also runIncubate labeled platelets with patient serum + heparin",
                      "14C labeled serotonin released from platelets is measuredFresh functional platelets from normal donor (known reactive)Platelets are usually washed platelets",
                      "Fresh functional platelets from normal donor (known reactive)",
                      "Platelets are usually washed platelets",
                      "Normal, positive HIT, and low positive HIT plasma control samples are also run",
                      "Incubate labeled platelets with patient serum + heparin",
                      "Positive SRA strongly associated with thrombocytopenia, with odds ratio of 80",
                      "High sensitivity assay for clinically significant antibodies",
                      "Insensitivity to clinically insignificant antibodies",
                      "Technically demanding; requires validated controls and donor platelets"
                    ]
                  }
                ],
                "Immunoassays": [
                  {
                    "text": "Solid phase ELISA assaysAntigens immobilized to solid phasePolyvinylsulfate:human platelet-derived PF4 orHeparin:human platelet-derived PF4 orHeparin:PF4 containing platelet lysateMeasures IgG only or IgG, IgA, IgM depending on assay specificationsIgG-specific assays have superior diagnostic specificityExpressed as optical densityConfirmatory EIA testing using heparin neutralization test (add excess heparin to sample and neutralize positive EIA test)",
                    "sub_points": [
                      "Antigens immobilized to solid phasePolyvinylsulfate:human platelet-derived PF4 orHeparin:human platelet-derived PF4 orHeparin:PF4 containing platelet lysate",
                      "Polyvinylsulfate:human platelet-derived PF4 or",
                      "Heparin:human platelet-derived PF4 or",
                      "Heparin:PF4 containing platelet lysate",
                      "Measures IgG only or IgG, IgA, IgM depending on assay specificationsIgG-specific assays have superior diagnostic specificity",
                      "IgG-specific assays have superior diagnostic specificity",
                      "Expressed as optical density",
                      "Confirmatory EIA testing using heparin neutralization test (add excess heparin to sample and neutralize positive EIA test)"
                    ]
                  },
                  {
                    "text": "Fluid phase immunoassaysPatient serum reacts with biotin labeled heparin:PF4 complexesIgG antibodies are captured with staphylococcal protein AAmount of heparin:PF4:IgG complexes is quantifiedLower false-positive rate",
                    "sub_points": [
                      "Patient serum reacts with biotin labeled heparin:PF4 complexes",
                      "IgG antibodies are captured with staphylococcal protein A",
                      "Amount of heparin:PF4:IgG complexes is quantified",
                      "Lower false-positive rate"
                    ]
                  },
                  {
                    "text": "Particle gel immunoassayHeparin:PF4 binds to polystyrene beadsSerum or plasma is added, and anti-PF4/heparin antibodies bind to beadsAntihuman globulin is addedAgglutination is observed, intermediate sensitivity and specificity",
                    "sub_points": [
                      "Heparin:PF4 binds to polystyrene beads",
                      "Serum or plasma is added, and anti-PF4/heparin antibodies bind to beads",
                      "Antihuman globulin is added",
                      "Agglutination is observed, intermediate sensitivity and specificity"
                    ]
                  }
                ],
                "Immunoassay Interpretation": [
                  {
                    "text": "Only minority of patients with anti-heparin:PF4 antibodies develop clinical HIT"
                  },
                  {
                    "text": "Positive EIA HIT test result may not actually indicate HIT (high false-positive rate)"
                  },
                  {
                    "text": "Greater strength of result (higher optical density), higher likelihood of HIT"
                  },
                  {
                    "text": "Negative test strongly argues against HIT (high negative predictive value)"
                  }
                ],
                "Testing Recommendations": [
                  {
                    "text": "HIT antibody testing should be performed only on patients with clinical suspicion of HITPre-test probability should be determinedScoring system (e.g., 4 T's) is useful to determine pre-test probability",
                    "sub_points": [
                      "Pre-test probability should be determined",
                      "Scoring system (e.g., 4 T's) is useful to determine pre-test probability"
                    ]
                  },
                  {
                    "text": "Usual algorithm is to perform HIT immunoassay as 1st screenIf test is negative, strong evidence against HITIf test is positive, platelet activation assay (e.g., SRA) should be performed",
                    "sub_points": [
                      "If test is negative, strong evidence against HIT",
                      "If test is positive, platelet activation assay (e.g., SRA) should be performed"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Warfarin Therapy": {
            "name": "Warfarin Therapy",
            "url": "https://app.pathprimer.com/document/86eb98a7-6d27-4d13-bcec-23f17d462322/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Mechanism of action: Inhibits vitamin K reductase and vitamin K epoxide reductaseDecreased vitamin K activity results in decreased vitamin K-dependent carboxylase-mediated γ-carboxylation of coagulation factors II, VII, IX, and X and protein C and protein S",
                    "sub_points": [
                      "Decreased vitamin K activity results in decreased vitamin K-dependent carboxylase-mediated γ-carboxylation of coagulation factors II, VII, IX, and X and protein C and protein S"
                    ]
                  },
                  {
                    "text": "Metabolized by the liver: S-warfarin—CYP2C9 enzymeHepatic enzyme p450CYP2C92C9*1 80%-90% of population﻿2C9*3 less common; less efficient at metabolism",
                    "sub_points": [
                      "Hepatic enzyme p450CYP2C9",
                      "2C9*1 80%-90% of population",
                      "﻿2C9*3 less common; less efficient at metabolism"
                    ]
                  },
                  {
                    "text": "Half-life of protein C and protein S is shorter than time to antithrombotic effectWarfarin initiation requires heparin overlap so that thrombotic effects of decreased protein C and protein S are counteracted until antithrombotic effect of decreased factors II and X activity starts",
                    "sub_points": [
                      "Warfarin initiation requires heparin overlap so that thrombotic effects of decreased protein C and protein S are counteracted until antithrombotic effect of decreased factors II and X activity starts"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Monitoring is performed using PT/INR"
                  },
                  {
                    "text": "INR was created to standardize PT when different thromboplastins are used from laboratory to laboratory"
                  },
                  {
                    "text": "INR = (PT/PTmean)ISI"
                  },
                  {
                    "text": "Short draws or overfilling can change anticoagulant-to-whole blood ratio"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "History": [
                  {
                    "text": "Discovered during investigation of \"sweet clover disease\" in 1924 by Schofield"
                  },
                  {
                    "text": "Dicumarol isolated by Link"
                  },
                  {
                    "text": "Warfarin synthesized by Wisconsin Alumni Research Foundation (WARF) for use as rat poison in 1948"
                  },
                  {
                    "text": "Warfarin was approved for clinical use as anticoagulant in 1954"
                  }
                ],
                "Background": [
                  {
                    "text": "Mainstay of oral anticoagulant therapy for last 60 yr"
                  },
                  {
                    "text": "Most commonly prescribed oral anticoagulant"
                  },
                  {
                    "text": "Indications for oral anticoagulationPrimary and secondary prevention of venous thromboembolismPrevention of system embolism in patients with atrial fibrillation, myocardial infarction, heart valve replacement",
                    "sub_points": [
                      "Primary and secondary prevention of venous thromboembolism",
                      "Prevention of system embolism in patients with atrial fibrillation, myocardial infarction, heart valve replacement"
                    ]
                  }
                ],
                "Mechanism of Action": [
                  {
                    "text": "Inhibits vitamin K reductase and vitamin K epoxide reductase"
                  },
                  {
                    "text": "Prevents recycling of vitamin K 2,3-epoxide"
                  },
                  {
                    "text": "Decreased vitamin K activity results in decreased vitamin K-dependent carboxylase-mediated γ-carboxylation of coagulation factors II, VII, IX, and X and protein C and protein S"
                  }
                ],
                "Pharmacokinetics": [
                  {
                    "text": "Absorbed in gastrointestinal (GI) tract"
                  },
                  {
                    "text": "Half-life 36-42 hr"
                  },
                  {
                    "text": "Anticoagulant effect on prothrombin time (PT)Peak 72-96 hr",
                    "sub_points": [
                      "Peak 72-96 hr"
                    ]
                  },
                  {
                    "text": "Antithrombotic effectPeak 6 daysFactor II and factor X activity related to antithrombotic effect",
                    "sub_points": [
                      "Peak 6 days",
                      "Factor II and factor X activity related to antithrombotic effect"
                    ]
                  },
                  {
                    "text": "Metabolized by liverS-warfarin—CYP2C9 enzymeInactive metabolites excreted by kidney and liver",
                    "sub_points": [
                      "S-warfarin—CYP2C9 enzyme",
                      "Inactive metabolites excreted by kidney and liver"
                    ]
                  }
                ],
                "Pharmacogenomics": [
                  {
                    "text": "Hepatic enzyme p450CYP2C9S-warfarin metabolism2C9*1 80%-90% of population2C9*3 less commonLess efficient at metabolism",
                    "sub_points": [
                      "S-warfarin metabolism",
                      "2C9*1 80%-90% of population",
                      "2C9*3 less commonLess efficient at metabolism",
                      "Less efficient at metabolism"
                    ]
                  },
                  {
                    "text": "Vitamin K 2,3-epoxide reductase (VKORC1)Haplotypes A and B have higher expression of messenger RNA (mRNA)Explains 25% of variation in warfarin responseHaplotype B requires higher warfarin dose",
                    "sub_points": [
                      "Haplotypes A and B have higher expression of messenger RNA (mRNA)",
                      "Explains 25% of variation in warfarin response",
                      "Haplotype B requires higher warfarin dose"
                    ]
                  }
                ],
                "Acquired Variation in Warfarin Response": [
                  {
                    "text": "Compliance"
                  },
                  {
                    "text": "GI absorption"
                  },
                  {
                    "text": "Hepatic impairment"
                  },
                  {
                    "text": "﻿Diet (green leafy vegetables with vitamin K)"
                  },
                  {
                    "text": "Alcohol (increased clearance)"
                  },
                  {
                    "text": "Numerous drug-drug interactionsTrimethoprim-sulfamethoxazole (TMP-SMZ) inhibits S-warfarinCimetidine and omeprazole inhibit clearance of R isomerAmiodarone potentiates anticoagulant effectAcetaminophen can increase international normalized ratio (INR) 10-foldRifampicin, barbiturates, and carbamazepine inhibit warfarin clearance",
                    "sub_points": [
                      "Trimethoprim-sulfamethoxazole (TMP-SMZ) inhibits S-warfarin",
                      "Cimetidine and omeprazole inhibit clearance of R isomer",
                      "Amiodarone potentiates anticoagulant effect",
                      "Acetaminophen can increase international normalized ratio (INR) 10-fold",
                      "Rifampicin, barbiturates, and carbamazepine inhibit warfarin clearance"
                    ]
                  },
                  {
                    "text": "Hypermetabolic statesFeverHyperthyroidismThyroxine treatment",
                    "sub_points": [
                      "Fever",
                      "Hyperthyroidism",
                      "Thyroxine treatment"
                    ]
                  }
                ],
                "Initiation and Maintenance of Therapy": [
                  {
                    "text": "Half-life of protein C and protein S is shorter than time to antithrombotic effectWarfarin initiation requires heparin overlapSo that thrombotic effects of decreased protein C and protein S are counteracted until antithrombotic effect of decreased factor II and factor X activity startsFailure to use heparin overlap can result in warfarin-induced skin necrosis",
                    "sub_points": [
                      "Warfarin initiation requires heparin overlapSo that thrombotic effects of decreased protein C and protein S are counteracted until antithrombotic effect of decreased factor II and factor X activity starts",
                      "So that thrombotic effects of decreased protein C and protein S are counteracted until antithrombotic effect of decreased factor II and factor X activity starts",
                      "Failure to use heparin overlap can result in warfarin-induced skin necrosis"
                    ]
                  },
                  {
                    "text": "Warfarin initiation nomograms for thrombosis treatment are publishedRequires daily PT/INR for initiationWarfarin dose adjusted based on INRWarfarin initiation may also change based on molecular testing ofCYP2C9andVKORC1haplotypes",
                    "sub_points": [
                      "Requires daily PT/INR for initiation",
                      "Warfarin dose adjusted based on INR",
                      "Warfarin initiation may also change based on molecular testing ofCYP2C9andVKORC1haplotypes"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Monitoring performed using PT/INR"
                  },
                  {
                    "text": "PT3.2% sodium citrate whole-blood sample is centrifuged using a \"hard spin\" to make platelet-poor plasma (PPP)Plasma is aliquoted into cuvette or tube and incubated at 37°CThromboplastin is added along with calciumThromboplastin contains source of phospholipid and tissue factorThromboplastins are most commonly made from recombinant tissue factor or rabbit brainTime to clot is measured and reported as thrombin time",
                    "sub_points": [
                      "3.2% sodium citrate whole-blood sample is centrifuged using a \"hard spin\" to make platelet-poor plasma (PPP)",
                      "Plasma is aliquoted into cuvette or tube and incubated at 37°C",
                      "Thromboplastin is added along with calciumThromboplastin contains source of phospholipid and tissue factorThromboplastins are most commonly made from recombinant tissue factor or rabbit brain",
                      "Thromboplastin contains source of phospholipid and tissue factor",
                      "Thromboplastins are most commonly made from recombinant tissue factor or rabbit brain",
                      "Time to clot is measured and reported as thrombin time"
                    ]
                  },
                  {
                    "text": "INRINR was created to standardize PT when different thromboplastins are used from laboratory to laboratoryINR = (PT/PTmean)ISIPT = PT of patientPTmean = geometric mean of 120 normal donors from patient population of laboratoryISI = international sensitivity indexlog(INR) = ISI x bWhere b is the slope of the linear regression comparing PT measured by international reference preparation (IRP) prepared by the World Health OrganizationISI = normalization factor between thromboplastins and IRP",
                    "sub_points": [
                      "INR was created to standardize PT when different thromboplastins are used from laboratory to laboratoryINR = (PT/PTmean)ISIPT = PT of patientPTmean = geometric mean of 120 normal donors from patient population of laboratoryISI = international sensitivity index",
                      "INR = (PT/PTmean)ISIPT = PT of patientPTmean = geometric mean of 120 normal donors from patient population of laboratoryISI = international sensitivity index",
                      "PT = PT of patient",
                      "PTmean = geometric mean of 120 normal donors from patient population of laboratory",
                      "ISI = international sensitivity index",
                      "log(INR) = ISI x bWhere b is the slope of the linear regression comparing PT measured by international reference preparation (IRP) prepared by the World Health OrganizationISI = normalization factor between thromboplastins and IRP",
                      "Where b is the slope of the linear regression comparing PT measured by international reference preparation (IRP) prepared by the World Health Organization",
                      "ISI = normalization factor between thromboplastins and IRP"
                    ]
                  }
                ],
                "Specimen Collection": [
                  {
                    "text": "PT3.2% sodium citrate1:9 ratio of citrate anticoagulant to whole bloodDraw waste tube firstTransport and test within 4 hr or centrifuge and freeze plasma",
                    "sub_points": [
                      "3.2% sodium citrate",
                      "1:9 ratio of citrate anticoagulant to whole blood",
                      "Draw waste tube first",
                      "Transport and test within 4 hr or centrifuge and freeze plasma"
                    ]
                  }
                ],
                "Interfering Substances": [
                  {
                    "text": "HematocritIf hematocrit is too high (> 55%), there is too much anticoagulant for decreased plasma volumeIf hematocrit is too low (< 25%), then there is too little anticoagulant for the increased plasma volume",
                    "sub_points": [
                      "If hematocrit is too high (> 55%), there is too much anticoagulant for decreased plasma volume",
                      "If hematocrit is too low (< 25%), then there is too little anticoagulant for the increased plasma volume"
                    ]
                  },
                  {
                    "text": "PPPPlatelet count of PPP should be measured at least every 6 months to ensure residual platelets have been removedPlatelets contain phospholipid and change standardized amount of phospholipid in test system",
                    "sub_points": [
                      "Platelet count of PPP should be measured at least every 6 months to ensure residual platelets have been removed",
                      "Platelets contain phospholipid and change standardized amount of phospholipid in test system"
                    ]
                  },
                  {
                    "text": "Waste tubeWaste tube should always be drawnSkin plug can activate coagulationIndwelling lines can dilute sampleHeparin contamination can anticoagulate sample",
                    "sub_points": [
                      "Waste tube should always be drawnSkin plug can activate coagulationIndwelling lines can dilute sampleHeparin contamination can anticoagulate sample",
                      "Skin plug can activate coagulation",
                      "Indwelling lines can dilute sample",
                      "Heparin contamination can anticoagulate sample"
                    ]
                  },
                  {
                    "text": "Anticoagulation ratioShort draws or overfilling can change anticoagulant-to-whole blood ratioAfter centrifugation, too much or too little anticoagulant for plasma volume can alter results",
                    "sub_points": [
                      "Short draws or overfilling can change anticoagulant-to-whole blood ratio",
                      "After centrifugation, too much or too little anticoagulant for plasma volume can alter results"
                    ]
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "PT reference range varies with institution and prothrombin test system"
                  },
                  {
                    "text": "Each laboratory should establish own reference range"
                  },
                  {
                    "text": "International sensitivity index is determined by manufacturer and provided in reagent package insert"
                  }
                ],
                "Molecular and Cytogenetic Tests": [
                  {
                    "text": "Molecular typing forCYP2C9andVKORC1haplotypes can be performed by polymerase chain reaction (PCR)"
                  },
                  {
                    "text": "Haplotype results can be used to change initial warfarin dose"
                  }
                ],
                "Therapeutic Range": [
                  {
                    "text": "Examples of INR therapeutic targetsVenous thromboembolism prophylaxis: 1.5-2.0Venous thromboembolism (deep vein thrombosis, pulmonary embolism) treatment: 2.0-3.0Systemic embolism (tissue valves, atrial fibrillation, acute myocardial infarction) prophylaxis: 2.0-3.0Mechanical valve: 2.5-3.5Lupus anticoagulant: 2.0-3.0",
                    "sub_points": [
                      "Venous thromboembolism prophylaxis: 1.5-2.0",
                      "Venous thromboembolism (deep vein thrombosis, pulmonary embolism) treatment: 2.0-3.0",
                      "Systemic embolism (tissue valves, atrial fibrillation, acute myocardial infarction) prophylaxis: 2.0-3.0",
                      "Mechanical valve: 2.5-3.5",
                      "Lupus anticoagulant: 2.0-3.0"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Direct Thrombin Inhibitors": {
            "name": "Direct Thrombin Inhibitors",
            "url": "https://app.pathprimer.com/document/cb1a9f16-d13e-4dca-9e63-9b00c447c24d/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Utilization of these antithrombotic agents requires careful risk-benefit analysis of thrombotic risk and bleeding risk"
                  },
                  {
                    "text": "ChallengesAccepted methods for measurement/monitoring may not be availableReversal agents for all antithrombic agents are not available",
                    "sub_points": [
                      "Accepted methods for measurement/monitoring may not be available",
                      "Reversal agents for all antithrombic agents are not available"
                    ]
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "DabigatranRenal function should be assessed prior to initiation (80% renally cleared)Elevated thrombin time (TT) in absence of fibrin degradation products, heparin, or other direct thrombin inhibitors is consistent with dabigatran effect",
                    "sub_points": [
                      "Renal function should be assessed prior to initiation (80% renally cleared)",
                      "Elevated thrombin time (TT) in absence of fibrin degradation products, heparin, or other direct thrombin inhibitors is consistent with dabigatran effect"
                    ]
                  },
                  {
                    "text": "ArgatrobanNo structural homology to heparin; therefore, no risk of heparin-induced thrombocytopenia (HIT)Hepatically cleared; adjust dose for hepatic failure",
                    "sub_points": [
                      "No structural homology to heparin; therefore, no risk of heparin-induced thrombocytopenia (HIT)",
                      "Hepatically cleared; adjust dose for hepatic failure"
                    ]
                  },
                  {
                    "text": "LepirudinDiffers from hirudin by 1 amino acid and absence of sulfate on tyrosine at position 63Hirudin originally derived from medicinal leechesAnticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic diseaseAntihirudin antibodies; paradoxically increase drug potency and increase risk of bleeding",
                    "sub_points": [
                      "Differs from hirudin by 1 amino acid and absence of sulfate on tyrosine at position 63",
                      "Hirudin originally derived from medicinal leeches",
                      "Anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease",
                      "Antihirudin antibodies; paradoxically increase drug potency and increase risk of bleeding"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Direct Thrombin Inhibitors": [
                  {
                    "text": "Used for prophylaxis and treatmentVenous thromboembolism (e.g., deep venous thrombosis, pulmonary embolism)Atrial fibrillationAcute coronary syndromesMechanical heart valves",
                    "sub_points": [
                      "Venous thromboembolism (e.g., deep venous thrombosis, pulmonary embolism)",
                      "Atrial fibrillation",
                      "Acute coronary syndromes",
                      "Mechanical heart valves"
                    ]
                  },
                  {
                    "text": "Utilization of these antithrombotic agents requires careful risk-benefit analysis of thrombotic risk and bleeding risk"
                  },
                  {
                    "text": "ChallengesAccepted methods for measurement/monitoring may not be availableReversal agents for all antithrombic agents are not availableTreatment of bleeding episodes is not well established for all agents",
                    "sub_points": [
                      "Accepted methods for measurement/monitoring may not be available",
                      "Reversal agents for all antithrombic agents are not available",
                      "Treatment of bleeding episodes is not well established for all agents"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Oral Direct Thrombin Inhibitors": [
                  {
                    "text": "DabigatranMechanism of actionSmall molecule is direct thrombin inhibitorInhibits both free and bound thrombinAffects both platelet activation and coagulation cascadePharmacologyPeak levels at 2-3 hours after administrationRenal function should be assessed prior to initiation (80% renally cleared)Dosage should be adjusted according to creatinine clearanceMonitoringIn most patients monitoring is not necessaryWhen switching from warfarin to dabigatran, INR will not reflect dabigatran for a couple of days and vice-versa; switching from dabigatran to warfarin, INR will not reflect warfarin until a couple of days after discontinuing dabigatranElevated thrombin time (TT) in absence of fibrin degradation products, heparin, and other direct thrombin inhibitors is consistent with dabigatran effectIndications and usagePrevention of stroke and systemic thromboembolism in patients with nonvalvular atrial fibrillationProphylaxis against deep venous thrombosis and pulmonary embolism after hip replacement surgeryTreatment of deep venous thrombosis and pulmonary embolism in patients treated with parenteral anticoagulants for > 5 daysAdverse effectsHemorrhageCan be life threateningIncreased risk if other anticoagulants/antiplatelet agents are administered (e.g., antiplatelet agents, heparin)Should be discontinued for 2-4 days prior to surgery to decrease bleeding riskIncreased risk of thromboembolism and bleeding in patient with bileaflet prosthetic valvesReversalHemodialysis can remove dabigatranIdarucizumab is specific reversal agent for dabigatran; used for uncontrolled bleeding or imminent surgical procedureIn oral overdose, activated charcoal can be administered",
                    "sub_points": [
                      "Mechanism of actionSmall molecule is direct thrombin inhibitorInhibits both free and bound thrombinAffects both platelet activation and coagulation cascade",
                      "Small molecule is direct thrombin inhibitor",
                      "Inhibits both free and bound thrombin",
                      "Affects both platelet activation and coagulation cascade",
                      "PharmacologyPeak levels at 2-3 hours after administrationRenal function should be assessed prior to initiation (80% renally cleared)Dosage should be adjusted according to creatinine clearance",
                      "Peak levels at 2-3 hours after administration",
                      "Renal function should be assessed prior to initiation (80% renally cleared)",
                      "Dosage should be adjusted according to creatinine clearance",
                      "MonitoringIn most patients monitoring is not necessaryWhen switching from warfarin to dabigatran, INR will not reflect dabigatran for a couple of days and vice-versa; switching from dabigatran to warfarin, INR will not reflect warfarin until a couple of days after discontinuing dabigatranElevated thrombin time (TT) in absence of fibrin degradation products, heparin, and other direct thrombin inhibitors is consistent with dabigatran effect",
                      "In most patients monitoring is not necessary",
                      "When switching from warfarin to dabigatran, INR will not reflect dabigatran for a couple of days and vice-versa; switching from dabigatran to warfarin, INR will not reflect warfarin until a couple of days after discontinuing dabigatran",
                      "Elevated thrombin time (TT) in absence of fibrin degradation products, heparin, and other direct thrombin inhibitors is consistent with dabigatran effect",
                      "Indications and usagePrevention of stroke and systemic thromboembolism in patients with nonvalvular atrial fibrillationProphylaxis against deep venous thrombosis and pulmonary embolism after hip replacement surgeryTreatment of deep venous thrombosis and pulmonary embolism in patients treated with parenteral anticoagulants for > 5 days",
                      "Prevention of stroke and systemic thromboembolism in patients with nonvalvular atrial fibrillation",
                      "Prophylaxis against deep venous thrombosis and pulmonary embolism after hip replacement surgery",
                      "Treatment of deep venous thrombosis and pulmonary embolism in patients treated with parenteral anticoagulants for > 5 days",
                      "Adverse effectsHemorrhageCan be life threateningIncreased risk if other anticoagulants/antiplatelet agents are administered (e.g., antiplatelet agents, heparin)Should be discontinued for 2-4 days prior to surgery to decrease bleeding riskIncreased risk of thromboembolism and bleeding in patient with bileaflet prosthetic valvesReversalHemodialysis can remove dabigatranIdarucizumab is specific reversal agent for dabigatran; used for uncontrolled bleeding or imminent surgical procedureIn oral overdose, activated charcoal can be administered",
                      "HemorrhageCan be life threateningIncreased risk if other anticoagulants/antiplatelet agents are administered (e.g., antiplatelet agents, heparin)Should be discontinued for 2-4 days prior to surgery to decrease bleeding risk",
                      "Can be life threatening",
                      "Increased risk if other anticoagulants/antiplatelet agents are administered (e.g., antiplatelet agents, heparin)",
                      "Should be discontinued for 2-4 days prior to surgery to decrease bleeding risk",
                      "Increased risk of thromboembolism and bleeding in patient with bileaflet prosthetic valves",
                      "ReversalHemodialysis can remove dabigatranIdarucizumab is specific reversal agent for dabigatran; used for uncontrolled bleeding or imminent surgical procedureIn oral overdose, activated charcoal can be administered",
                      "Hemodialysis can remove dabigatran",
                      "Idarucizumab is specific reversal agent for dabigatran; used for uncontrolled bleeding or imminent surgical procedure",
                      "In oral overdose, activated charcoal can be administered"
                    ]
                  }
                ],
                "Parenteral Direct Thrombin Inhibitors": [
                  {
                    "text": "ArgatrobanMechanism of actionCompetitive, reversible, thrombin inhibitorBinds to active site of thrombinNo structural homology to heparin; therefore, no risk of heparin-induced thrombocytopenia (HIT)PharmacologyHepatically cleared; adjust dose for hepatic failureAdministered as continuous IV infusionSteady state reached in 1-3 hoursMonitoringAdjust infusion to aPTT ratio of 1.5-3.0 compared with baselineIndications and usageProphylaxis or treatment of thrombosis in patients with HITAdverse effectsHemorrhageGastrointestinal bleeding is most commonDependent on intensity and duration of treatmentWarfarin/argatroban drug-drug interactionReversalNo specific reversal agentIf bleeding occurs, infusion should be stopped and aPTT should return to baseline in 2-4 hours",
                    "sub_points": [
                      "Mechanism of actionCompetitive, reversible, thrombin inhibitorBinds to active site of thrombinNo structural homology to heparin; therefore, no risk of heparin-induced thrombocytopenia (HIT)",
                      "Competitive, reversible, thrombin inhibitor",
                      "Binds to active site of thrombin",
                      "No structural homology to heparin; therefore, no risk of heparin-induced thrombocytopenia (HIT)",
                      "PharmacologyHepatically cleared; adjust dose for hepatic failureAdministered as continuous IV infusionSteady state reached in 1-3 hours",
                      "Hepatically cleared; adjust dose for hepatic failure",
                      "Administered as continuous IV infusion",
                      "Steady state reached in 1-3 hours",
                      "MonitoringAdjust infusion to aPTT ratio of 1.5-3.0 compared with baseline",
                      "Adjust infusion to aPTT ratio of 1.5-3.0 compared with baseline",
                      "Indications and usageProphylaxis or treatment of thrombosis in patients with HIT",
                      "Prophylaxis or treatment of thrombosis in patients with HIT",
                      "Adverse effectsHemorrhageGastrointestinal bleeding is most commonDependent on intensity and duration of treatmentWarfarin/argatroban drug-drug interactionReversalNo specific reversal agentIf bleeding occurs, infusion should be stopped and aPTT should return to baseline in 2-4 hours",
                      "HemorrhageGastrointestinal bleeding is most commonDependent on intensity and duration of treatmentWarfarin/argatroban drug-drug interaction",
                      "Gastrointestinal bleeding is most common",
                      "Dependent on intensity and duration of treatment",
                      "Warfarin/argatroban drug-drug interaction",
                      "ReversalNo specific reversal agentIf bleeding occurs, infusion should be stopped and aPTT should return to baseline in 2-4 hours",
                      "No specific reversal agent",
                      "If bleeding occurs, infusion should be stopped and aPTT should return to baseline in 2-4 hours"
                    ]
                  },
                  {
                    "text": "LepirudinMechanism of action65 amino acid polypeptide direct thrombin inhibitor; hirudin analogueHirudin originally derived from medicinal leechesDiffers from hirudin by 1 amino acid and absence of sulfate on tyrosine at position 63Binds to active site of thrombin and inhibits activity in a 1:1 stoichiometryPharmacologyPlasma half-life = 1 hourSystemic clearance is proportional to creatinine clearance; dose adjustment in renal insufficiency is recommendedAdministered as continuous IV infusionMeasurement and monitoringChromogenic assayActivity of lepirudin is measured using chromogenic assayMeasured in antithrombin units (ATU): One unit is amount of lepirudin that neutralizes 1 unit of WHO reference thrombinaPTT monitoring shows dose-dependent prolongationTarget should be 1.5-2.5Higher targets increase bleeding riskMonitoring begins 4 hours after start of administrationIndications and usageAnticoagulation in patients with HIT and associated thromboembolic diseaseAdverse effectsHemorrhage is most common side effect; increased risk with renal failureAntihirudin antibodies; paradoxically increase drug potency and increase risk of bleedingAnaphylaxis can occur in patients with antibodies who are re-exposed to lepirudinNo specific reversal agent is available",
                    "sub_points": [
                      "Mechanism of action65 amino acid polypeptide direct thrombin inhibitor; hirudin analogueHirudin originally derived from medicinal leechesDiffers from hirudin by 1 amino acid and absence of sulfate on tyrosine at position 63Binds to active site of thrombin and inhibits activity in a 1:1 stoichiometry",
                      "65 amino acid polypeptide direct thrombin inhibitor; hirudin analogue",
                      "Hirudin originally derived from medicinal leeches",
                      "Differs from hirudin by 1 amino acid and absence of sulfate on tyrosine at position 63",
                      "Binds to active site of thrombin and inhibits activity in a 1:1 stoichiometry",
                      "PharmacologyPlasma half-life = 1 hourSystemic clearance is proportional to creatinine clearance; dose adjustment in renal insufficiency is recommendedAdministered as continuous IV infusion",
                      "Plasma half-life = 1 hour",
                      "Systemic clearance is proportional to creatinine clearance; dose adjustment in renal insufficiency is recommended",
                      "Administered as continuous IV infusion",
                      "Measurement and monitoringChromogenic assayActivity of lepirudin is measured using chromogenic assayMeasured in antithrombin units (ATU): One unit is amount of lepirudin that neutralizes 1 unit of WHO reference thrombinaPTT monitoring shows dose-dependent prolongationTarget should be 1.5-2.5Higher targets increase bleeding riskMonitoring begins 4 hours after start of administration",
                      "Chromogenic assayActivity of lepirudin is measured using chromogenic assayMeasured in antithrombin units (ATU): One unit is amount of lepirudin that neutralizes 1 unit of WHO reference thrombin",
                      "Activity of lepirudin is measured using chromogenic assay",
                      "Measured in antithrombin units (ATU): One unit is amount of lepirudin that neutralizes 1 unit of WHO reference thrombin",
                      "aPTT monitoring shows dose-dependent prolongationTarget should be 1.5-2.5Higher targets increase bleeding riskMonitoring begins 4 hours after start of administration",
                      "Target should be 1.5-2.5",
                      "Higher targets increase bleeding risk",
                      "Monitoring begins 4 hours after start of administration",
                      "Indications and usageAnticoagulation in patients with HIT and associated thromboembolic disease",
                      "Anticoagulation in patients with HIT and associated thromboembolic disease",
                      "Adverse effectsHemorrhage is most common side effect; increased risk with renal failureAntihirudin antibodies; paradoxically increase drug potency and increase risk of bleedingAnaphylaxis can occur in patients with antibodies who are re-exposed to lepirudinNo specific reversal agent is available",
                      "Hemorrhage is most common side effect; increased risk with renal failure",
                      "Antihirudin antibodies; paradoxically increase drug potency and increase risk of bleedingAnaphylaxis can occur in patients with antibodies who are re-exposed to lepirudin",
                      "Anaphylaxis can occur in patients with antibodies who are re-exposed to lepirudin",
                      "No specific reversal agent is available"
                    ]
                  },
                  {
                    "text": "BivalirudinMechanism of action20 amino acid direct thrombin inhibitorAnalogue of hirudinDirect inhibitor of circulating and clot-bound thrombinPharmacologyPlasma half-life = 25 minutes20% renally cleared; rest hydrolyzed in nonorgan pathwayBolus and then continuous IV infusionMonitoringaPTT; dose dependent, linear increase in aPTTIndications and usageUnstable angina undergoing percutaneous transluminal coronary angioplastyPercutaneous coronary intervention with use of GPIIb/IIIa inhibitorWith, or at risk of, HIT +/- thrombosisAdverse effectsHemorrhage is most common side effectNot immunogenic, like lepirudinNo specific reversal agent is available",
                    "sub_points": [
                      "Mechanism of action20 amino acid direct thrombin inhibitorAnalogue of hirudinDirect inhibitor of circulating and clot-bound thrombin",
                      "20 amino acid direct thrombin inhibitor",
                      "Analogue of hirudin",
                      "Direct inhibitor of circulating and clot-bound thrombin",
                      "PharmacologyPlasma half-life = 25 minutes20% renally cleared; rest hydrolyzed in nonorgan pathwayBolus and then continuous IV infusion",
                      "Plasma half-life = 25 minutes",
                      "20% renally cleared; rest hydrolyzed in nonorgan pathway",
                      "Bolus and then continuous IV infusion",
                      "MonitoringaPTT; dose dependent, linear increase in aPTT",
                      "aPTT; dose dependent, linear increase in aPTT",
                      "Indications and usageUnstable angina undergoing percutaneous transluminal coronary angioplastyPercutaneous coronary intervention with use of GPIIb/IIIa inhibitorWith, or at risk of, HIT +/- thrombosis",
                      "Unstable angina undergoing percutaneous transluminal coronary angioplasty",
                      "Percutaneous coronary intervention with use of GPIIb/IIIa inhibitor",
                      "With, or at risk of, HIT +/- thrombosis",
                      "Adverse effectsHemorrhage is most common side effectNot immunogenic, like lepirudinNo specific reversal agent is available",
                      "Hemorrhage is most common side effect",
                      "Not immunogenic, like lepirudin",
                      "No specific reversal agent is available"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Factor Xa Inhibitors and Monitoring": {
            "name": "Factor Xa Inhibitors and Monitoring",
            "url": "https://app.pathprimer.com/document/adbb8027-7280-4fe4-a55a-160a3d8f39da/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Rivaroxaban and apixaban"
                  },
                  {
                    "text": "IndicationsReduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillationProphylaxis against and treatment of DVT and PE",
                    "sub_points": [
                      "Reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation",
                      "Prophylaxis against and treatment of DVT and PE"
                    ]
                  },
                  {
                    "text": "Additive anticoagulation effect (anti-Xa and PT) when given at same time as low-molecular-weight heparin or warfarin"
                  },
                  {
                    "text": "Routine monitoring is not intended for dose adjustment"
                  },
                  {
                    "text": "PT and aPTT are not increased in dose-dependent fashion and, thus, should not be used for monitoring"
                  },
                  {
                    "text": "Adverse reactionsBleeding is most commonHematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)",
                    "sub_points": [
                      "Bleeding is most common",
                      "Hematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)"
                    ]
                  },
                  {
                    "text": "No specific antidote is available"
                  }
                ]
              },
              "OVERVIEW": {
                "Oral Factor Xa Inhibitors": [
                  {
                    "text": "RivaroxabanIndicationsReduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillationProphylaxis against and treatment of DVT and PEMechanism of action and pharmacologyDirect factor Xa inhibitor (free and bound)Reversible inhibitionUnlike heparin, antithrombin III is not required60-80% bioavailability, depending on dose administeredPeak concentration at 3 hours; 5-10-hour half-lifeHepatic and renal impairment increases rivaroxaban exposureAdministrationAdditive anticoagulation effect [anti-Xa and prothrombin time (PT)] when given at same time as low-molecular-weight heparin or warfarinWhen switching to or from rivaroxaban, laboratory tests may not immediately reflect effect of rivaroxabanMonitoringRoutine monitoring is not intended for dose adjustmentPT and activated partial thromboplastin time (aPTT) can be measured to determine if there is rivaroxaban effectPT and aPTT are not increased in dose-dependent fashion and, thus, should not be used for monitoringAdverse reactionsBleeding is most commonHematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)Increased risk if administered with other anticoagulants or antiplatelet agentsNo specific antidote is availableNot able to remove via dialysisActivated charcoal if recently ingestedProthrombin complex concentrates and recombinant activated factor VII have been used",
                    "sub_points": [
                      "IndicationsReduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillationProphylaxis against and treatment of DVT and PE",
                      "Reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation",
                      "Prophylaxis against and treatment of DVT and PE",
                      "Mechanism of action and pharmacologyDirect factor Xa inhibitor (free and bound)Reversible inhibitionUnlike heparin, antithrombin III is not required60-80% bioavailability, depending on dose administeredPeak concentration at 3 hours; 5-10-hour half-lifeHepatic and renal impairment increases rivaroxaban exposure",
                      "Direct factor Xa inhibitor (free and bound)",
                      "Reversible inhibition",
                      "Unlike heparin, antithrombin III is not required",
                      "60-80% bioavailability, depending on dose administered",
                      "Peak concentration at 3 hours; 5-10-hour half-life",
                      "Hepatic and renal impairment increases rivaroxaban exposure",
                      "AdministrationAdditive anticoagulation effect [anti-Xa and prothrombin time (PT)] when given at same time as low-molecular-weight heparin or warfarinWhen switching to or from rivaroxaban, laboratory tests may not immediately reflect effect of rivaroxaban",
                      "Additive anticoagulation effect [anti-Xa and prothrombin time (PT)] when given at same time as low-molecular-weight heparin or warfarin",
                      "When switching to or from rivaroxaban, laboratory tests may not immediately reflect effect of rivaroxaban",
                      "MonitoringRoutine monitoring is not intended for dose adjustmentPT and activated partial thromboplastin time (aPTT) can be measured to determine if there is rivaroxaban effectPT and aPTT are not increased in dose-dependent fashion and, thus, should not be used for monitoring",
                      "Routine monitoring is not intended for dose adjustment",
                      "PT and activated partial thromboplastin time (aPTT) can be measured to determine if there is rivaroxaban effect",
                      "PT and aPTT are not increased in dose-dependent fashion and, thus, should not be used for monitoring",
                      "Adverse reactionsBleeding is most commonHematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)Increased risk if administered with other anticoagulants or antiplatelet agentsNo specific antidote is availableNot able to remove via dialysisActivated charcoal if recently ingestedProthrombin complex concentrates and recombinant activated factor VII have been used",
                      "Bleeding is most common",
                      "Hematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)",
                      "Increased risk if administered with other anticoagulants or antiplatelet agents",
                      "No specific antidote is availableNot able to remove via dialysisActivated charcoal if recently ingestedProthrombin complex concentrates and recombinant activated factor VII have been used",
                      "Not able to remove via dialysis",
                      "Activated charcoal if recently ingested",
                      "Prothrombin complex concentrates and recombinant activated factor VII have been used"
                    ]
                  },
                  {
                    "text": "ApixabanIndicationsReduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillationTreatment of DVT and PESecondary prophylaxis against DVT and PEPrimary prophylaxis against DVT in patients undergoing knee or hip replacement surgeryMechanism of action and pharmacologyReversible direct factor Xa inhibitor50% oral bioavailability, peak concentration at 3 hours; half-life of 9-14 hoursRenally and hepatically clearedAdministrationAdditive anticoagulation effect when given at same time as low-molecular-weight heparin or warfarinWhen switching to or from apixaban, laboratory tests may not immediately reflect effect of apixabanMonitoringRoutine monitoring is not intended for dose adjustmentPT and aPTT can be measured to determine if there is apixaban effectPT and aPTT are not increased in dose-dependent fashion and, thus, should not be used for monitoringAnti-factor Xa activity measurement using chromogenic assays has been done but is not recommended for monitoringAdverse reactionsBleeding is most commonHematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)Increased risk if administered with other anticoagulants or antiplatelet agentsNo specific antidote is availableNot dialyzableActivated charcoal if recently ingestedProthrombin complex concentrates and recombinant activated factor VII have been used",
                    "sub_points": [
                      "IndicationsReduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillationTreatment of DVT and PESecondary prophylaxis against DVT and PEPrimary prophylaxis against DVT in patients undergoing knee or hip replacement surgery",
                      "Reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation",
                      "Treatment of DVT and PE",
                      "Secondary prophylaxis against DVT and PE",
                      "Primary prophylaxis against DVT in patients undergoing knee or hip replacement surgery",
                      "Mechanism of action and pharmacologyReversible direct factor Xa inhibitor50% oral bioavailability, peak concentration at 3 hours; half-life of 9-14 hoursRenally and hepatically cleared",
                      "Reversible direct factor Xa inhibitor",
                      "50% oral bioavailability, peak concentration at 3 hours; half-life of 9-14 hours",
                      "Renally and hepatically cleared",
                      "AdministrationAdditive anticoagulation effect when given at same time as low-molecular-weight heparin or warfarinWhen switching to or from apixaban, laboratory tests may not immediately reflect effect of apixaban",
                      "Additive anticoagulation effect when given at same time as low-molecular-weight heparin or warfarin",
                      "When switching to or from apixaban, laboratory tests may not immediately reflect effect of apixaban",
                      "MonitoringRoutine monitoring is not intended for dose adjustmentPT and aPTT can be measured to determine if there is apixaban effectPT and aPTT are not increased in dose-dependent fashion and, thus, should not be used for monitoringAnti-factor Xa activity measurement using chromogenic assays has been done but is not recommended for monitoring",
                      "Routine monitoring is not intended for dose adjustment",
                      "PT and aPTT can be measured to determine if there is apixaban effect",
                      "PT and aPTT are not increased in dose-dependent fashion and, thus, should not be used for monitoring",
                      "Anti-factor Xa activity measurement using chromogenic assays has been done but is not recommended for monitoring",
                      "Adverse reactionsBleeding is most commonHematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)Increased risk if administered with other anticoagulants or antiplatelet agentsNo specific antidote is availableNot dialyzableActivated charcoal if recently ingestedProthrombin complex concentrates and recombinant activated factor VII have been used",
                      "Bleeding is most common",
                      "Hematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)",
                      "Increased risk if administered with other anticoagulants or antiplatelet agents",
                      "No specific antidote is availableNot dialyzableActivated charcoal if recently ingestedProthrombin complex concentrates and recombinant activated factor VII have been used",
                      "Not dialyzable",
                      "Activated charcoal if recently ingested",
                      "Prothrombin complex concentrates and recombinant activated factor VII have been used"
                    ]
                  }
                ],
                "Parenteral Factor Xa Inhibitors": [
                  {
                    "text": "PentasaccharidesIndicationsReduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillationTreatment of DVT and PESecondary prophylaxis against DVT and PEPrimary prophylaxis against DVT in patients undergoing knee or hip replacement surgeryMechanism of action and pharmacologyReversible direct factor Xa inhibitor50% oral bioavailabilityPeak concentration at 3 hours; half-life of 9-14 hoursRenally and hepatically clearedAdministrationAdditive anticoagulation effect when given at same time as low-molecular-weight heparin or warfarinMonitoringRoutine monitoring is not intended for dose adjustmentPT and aPTT can be measured to determine if there is drug effectPT and aPTT are not increased in dose-dependent fashion and should not be used for monitoringAnti-factor Xa activity measurement using chromogenic assays has been done but is not recommended for monitoringAdverse reactionsBleeding is most commonHematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)Increased risk if administered with other anticoagulants or antiplatelet agentsNo specific antidote is availableNot dialyzableActivated charcoal if recently ingestedProthrombin complex concentrates and recombinant activated factor VII have been used",
                    "sub_points": [
                      "IndicationsReduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillationTreatment of DVT and PESecondary prophylaxis against DVT and PEPrimary prophylaxis against DVT in patients undergoing knee or hip replacement surgery",
                      "Reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation",
                      "Treatment of DVT and PE",
                      "Secondary prophylaxis against DVT and PE",
                      "Primary prophylaxis against DVT in patients undergoing knee or hip replacement surgery",
                      "Mechanism of action and pharmacologyReversible direct factor Xa inhibitor50% oral bioavailabilityPeak concentration at 3 hours; half-life of 9-14 hoursRenally and hepatically cleared",
                      "Reversible direct factor Xa inhibitor",
                      "50% oral bioavailability",
                      "Peak concentration at 3 hours; half-life of 9-14 hours",
                      "Renally and hepatically cleared",
                      "AdministrationAdditive anticoagulation effect when given at same time as low-molecular-weight heparin or warfarin",
                      "Additive anticoagulation effect when given at same time as low-molecular-weight heparin or warfarin",
                      "MonitoringRoutine monitoring is not intended for dose adjustmentPT and aPTT can be measured to determine if there is drug effectPT and aPTT are not increased in dose-dependent fashion and should not be used for monitoringAnti-factor Xa activity measurement using chromogenic assays has been done but is not recommended for monitoring",
                      "Routine monitoring is not intended for dose adjustment",
                      "PT and aPTT can be measured to determine if there is drug effect",
                      "PT and aPTT are not increased in dose-dependent fashion and should not be used for monitoring",
                      "Anti-factor Xa activity measurement using chromogenic assays has been done but is not recommended for monitoring",
                      "Adverse reactionsBleeding is most commonHematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)Increased risk if administered with other anticoagulants or antiplatelet agentsNo specific antidote is availableNot dialyzableActivated charcoal if recently ingestedProthrombin complex concentrates and recombinant activated factor VII have been used",
                      "Bleeding is most common",
                      "Hematomas after neuraxial blocks (i.e., epidural or spinal anesthesia)",
                      "Increased risk if administered with other anticoagulants or antiplatelet agents",
                      "No specific antidote is availableNot dialyzableActivated charcoal if recently ingestedProthrombin complex concentrates and recombinant activated factor VII have been used",
                      "Not dialyzable",
                      "Activated charcoal if recently ingested",
                      "Prothrombin complex concentrates and recombinant activated factor VII have been used"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Activated partial thromboplastin time (aPTT)"
                  },
                  {
                    "text": "Deep venous thrombosis (DVT)"
                  },
                  {
                    "text": "Prothrombin time (PT)"
                  },
                  {
                    "text": "Pulmonary embolism (PE)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "COX Inhibitors and Monitoring": {
            "name": "COX Inhibitors and Monitoring",
            "url": "https://app.pathprimer.com/document/f1f756d5-851f-4000-b23f-60e0eb080f82/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Aspirin irreversibly acetylates COX-1, leading to impaired prostaglandin synthesis and TXA₂ production"
                  },
                  {
                    "text": "Decreased TXA₂ production results in impaired platelet aggregation in response to collagen, ADP, AA, and low-dose thrombin"
                  },
                  {
                    "text": "Platelet inhibition is irreversible and lasts life span of platelet (7-10 days)"
                  },
                  {
                    "text": "Bleeding is most common adverse effect associated with aspirin"
                  },
                  {
                    "text": "Aspirin inhibits COX-1 (predominantly present in platelets) more selectively than COX-2 (expressed in tissues in response to inflammation)"
                  }
                ]
              },
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "Exposure of blood to dysfunctional or damaged endothelial surfaces leads to thrombus formation with deposition of platelets, fibrin, RBCs, and WBCs"
                  },
                  {
                    "text": "Thrombi forming in arterial circulation are tightly packed and platelet-rich with smaller amounts of fibrin"
                  },
                  {
                    "text": "Thrombi forming in venous circulation comprise more loosely packed mixture of fibrin, RBCs, and WBCs"
                  },
                  {
                    "text": "Important role of platelets in atherothrombotic vascular disease makes antiplatelet medications mainstay of therapy"
                  }
                ],
                "Antiplatelet Therapy": [
                  {
                    "text": "Antiplatelet therapy can be oral or intravenous"
                  },
                  {
                    "text": "Various aspects of platelet function have been targeted for antiplatelet therapyCOX pathway (secretion/granule release)ADP receptor signaling (secretion/granule release)GPIIb/IIIa (aggregation)",
                    "sub_points": [
                      "COX pathway (secretion/granule release)",
                      "ADP receptor signaling (secretion/granule release)",
                      "GPIIb/IIIa (aggregation)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cells (RBCs)"
                  },
                  {
                    "text": "White blood cells (WBCs)"
                  },
                  {
                    "text": "Cyclooxygenase (COX)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Glycoprotein IIb-IIIa (GPIIb/IIIa)"
                  },
                  {
                    "text": "Thromboxane A₂ (TXA₂)"
                  },
                  {
                    "text": "Arachidonic acid (AA)"
                  },
                  {
                    "text": "Gastrointestinal (GI)"
                  },
                  {
                    "text": "Light transmission aggregometry (LTA)"
                  },
                  {
                    "text": "Platelet-rich plasma (PRP)"
                  },
                  {
                    "text": "Platelet function analyzer (PFA-100)"
                  },
                  {
                    "text": "Infrared (IR)"
                  },
                  {
                    "text": "Aspirin reaction units (ARUs)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Aspirin": [
                  {
                    "text": "Aspirin irreversibly acetylates COX-1, leading to impaired prostaglandin synthesis and TXA₂ productionDecreased TXA₂ production results in impaired platelet aggregation in response to collagen, ADP, AA, and low-dose thrombinAspirin inhibits COX-1 more selectively than COX-2COX-1 predominantly present in plateletsCOX-2 expressed in tissues in response to inflammation",
                    "sub_points": [
                      "Decreased TXA₂ production results in impaired platelet aggregation in response to collagen, ADP, AA, and low-dose thrombin",
                      "Aspirin inhibits COX-1 more selectively than COX-2COX-1 predominantly present in plateletsCOX-2 expressed in tissues in response to inflammation",
                      "COX-1 predominantly present in platelets",
                      "COX-2 expressed in tissues in response to inflammation"
                    ]
                  },
                  {
                    "text": "Aspirin therapyOralDosingInitial dose of 142-325 mg (nonenteric)75-325 mg/day of enteric formulation",
                    "sub_points": [
                      "Oral",
                      "DosingInitial dose of 142-325 mg (nonenteric)75-325 mg/day of enteric formulation",
                      "Initial dose of 142-325 mg (nonenteric)",
                      "75-325 mg/day of enteric formulation"
                    ]
                  },
                  {
                    "text": "Aspirin rapidly absorbed in proximal GI tractPeak serum levels reached in 15-20 minPlatelet inhibition detected within 40-60 minEnteric-coated aspirin reaches peak serum levels in ~ 60 minPlatelet inhibition detected at ~ 90 min",
                    "sub_points": [
                      "Peak serum levels reached in 15-20 min",
                      "Platelet inhibition detected within 40-60 min",
                      "Enteric-coated aspirin reaches peak serum levels in ~ 60 minPlatelet inhibition detected at ~ 90 min",
                      "Platelet inhibition detected at ~ 90 min"
                    ]
                  },
                  {
                    "text": "Plasma concentration of aspirin decreases rapidly with circulating half life of ~ 20 min"
                  },
                  {
                    "text": "Platelet inhibition is irreversible and lasts life span of platelet (7-10 days)"
                  },
                  {
                    "text": "Platelet activity returns to > 50% within 5-6 days of last aspirin doseEvery 24 hr 10% of circulating platelets are replaced",
                    "sub_points": [
                      "Every 24 hr 10% of circulating platelets are replaced"
                    ]
                  },
                  {
                    "text": "Bleeding is most common adverse effect associated with aspirinRisk of major bleeding with aspirin therapy related to several factorsDosageDuration of administrationAssociated structural defectsPeptic ulcer diseaseHelicobacter pyloriinfectionUnderlying hemostatic abnormalitiesSimultaneous use of other antithrombotic agents",
                    "sub_points": [
                      "Risk of major bleeding with aspirin therapy related to several factorsDosageDuration of administrationAssociated structural defectsPeptic ulcer diseaseHelicobacter pyloriinfectionUnderlying hemostatic abnormalitiesSimultaneous use of other antithrombotic agents",
                      "Dosage",
                      "Duration of administration",
                      "Associated structural defectsPeptic ulcer diseaseHelicobacter pyloriinfection",
                      "Peptic ulcer disease",
                      "Helicobacter pyloriinfection",
                      "Underlying hemostatic abnormalities",
                      "Simultaneous use of other antithrombotic agents"
                    ]
                  },
                  {
                    "text": "Ability of aspirin to inhibit platelet aggregation may vary among individualsResistance to aspirin therapyClinical resistance refers to patients who experience new thrombotic event while receiving regular and effective-dose therapyLaboratory resistance refers to patients in whom therapy does not produce expected effects on platelet function as measured by ≥ 1 screening laboratory testsPrevalence of resistance to aspirin therapy reported as 5-60%Depending on population studied and method used to assess resistanceAcquired causes of aspirin resistanceNoncomplianceConcomitant administration of ibuprofen (reversibly inhibits COX-1)Acute illness",
                    "sub_points": [
                      "Resistance to aspirin therapyClinical resistance refers to patients who experience new thrombotic event while receiving regular and effective-dose therapyLaboratory resistance refers to patients in whom therapy does not produce expected effects on platelet function as measured by ≥ 1 screening laboratory tests",
                      "Clinical resistance refers to patients who experience new thrombotic event while receiving regular and effective-dose therapy",
                      "Laboratory resistance refers to patients in whom therapy does not produce expected effects on platelet function as measured by ≥ 1 screening laboratory tests",
                      "Prevalence of resistance to aspirin therapy reported as 5-60%Depending on population studied and method used to assess resistance",
                      "Depending on population studied and method used to assess resistance",
                      "Acquired causes of aspirin resistanceNoncomplianceConcomitant administration of ibuprofen (reversibly inhibits COX-1)Acute illness",
                      "Noncompliance",
                      "Concomitant administration of ibuprofen (reversibly inhibits COX-1)",
                      "Acute illness"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Rationale for Laboratory Testing for Antiplatelet Therapy": [
                  {
                    "text": "Laboratory monitoring of effect of antiplatelet agents is useful in certain settingsDetermining if patient’s platelets are resistant to inhibition by a particular agentDetermining what dose of antiplatelet agent produced desired level of inhibition of functionDetermining when platelet function has returned to adequate level to support hemostasis after cessation of antiplatelet therapy",
                    "sub_points": [
                      "Determining if patient’s platelets are resistant to inhibition by a particular agent",
                      "Determining what dose of antiplatelet agent produced desired level of inhibition of function",
                      "Determining when platelet function has returned to adequate level to support hemostasis after cessation of antiplatelet therapy"
                    ]
                  }
                ],
                "Light Transmission Aggregometry": [
                  {
                    "text": "LTA can be used to study platelet aggregation in response to AA"
                  },
                  {
                    "text": "Sample collected in 3.2% sodium citrate"
                  },
                  {
                    "text": "LTA uses PRP obtained by gentle centrifugation of whole-blood sample"
                  },
                  {
                    "text": "Aspirin therapy should cause decreased aggregation in response to AA"
                  },
                  {
                    "text": "Clinical utility of LTA limitedCostTime needed to perform assayNeed for expert interpretation of results",
                    "sub_points": [
                      "Cost",
                      "Time needed to perform assay",
                      "Need for expert interpretation of results"
                    ]
                  }
                ],
                "Platelet Function Analyzer": [
                  {
                    "text": "PFA-100 uses whole blood to measure platelet function under high shear flow conditions"
                  },
                  {
                    "text": "Sample collected in 3.2% sodium citrate"
                  },
                  {
                    "text": "Whole blood passes through opening cut into membrane coated with 1 of 2 agonist combinationsCollagen and epinephrineCollagen and ADP",
                    "sub_points": [
                      "Collagen and epinephrine",
                      "Collagen and ADP"
                    ]
                  },
                  {
                    "text": "Time to occlusion of opening by platelet plug is measuredProlonged occlusion or “closure” times suggestive of impaired platelet function",
                    "sub_points": [
                      "Prolonged occlusion or “closure” times suggestive of impaired platelet function"
                    ]
                  },
                  {
                    "text": "Results reported as closure times"
                  },
                  {
                    "text": "Although PFA-100 has been used to monitor effects of aspirin, it has produced variable results in most studies"
                  }
                ],
                "VerifyNow Assay": [
                  {
                    "text": "Uses whole blood to study optical platelet aggregation"
                  },
                  {
                    "text": "Samples collected into special Greiner VACUETTE tube with 3.2% sodium citrate"
                  },
                  {
                    "text": "Test system includes fibrinogen-coated beads impregnated with IR dye"
                  },
                  {
                    "text": "After addition of AA as agonist, platelets become activatedGPIIb-IIIa receptors are able to bind to fibrinogen-coated beads, leading to aggregation of beads with platelets",
                    "sub_points": [
                      "GPIIb-IIIa receptors are able to bind to fibrinogen-coated beads, leading to aggregation of beads with platelets"
                    ]
                  },
                  {
                    "text": "Extent of aggregation detected as increase in IR light transmittance after addition of AA"
                  },
                  {
                    "text": "Testing takes ~ 10 min and is believed to reliably assess response of patient's platelets to aspirin therapy"
                  },
                  {
                    "text": "Platelet aggregation reported as ARUsLower ARUs indicate greater inhibition by aspirin",
                    "sub_points": [
                      "Lower ARUs indicate greater inhibition by aspirin"
                    ]
                  }
                ],
                "Additional Assays": [
                  {
                    "text": "Flow cytometryExpression of P-selectin (activation marker) on platelet surface after treatment with AA can be used to detect effects of aspirin therapy",
                    "sub_points": [
                      "Expression of P-selectin (activation marker) on platelet surface after treatment with AA can be used to detect effects of aspirin therapy"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "P2Y₁₂ Inhibitors and Monitoring": {
            "name": "P2Y₁₂ Inhibitors and Monitoring",
            "url": "https://app.pathprimer.com/document/f77bf166-2911-430e-aa69-8d9bc956fcb9/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "ADP activates platelets, increases cytoplasmic Ca²⁺ through influx from extracellular fluid and mobilization from internal stores, and decreases intracellular cAMP"
                  },
                  {
                    "text": "Two main types of ADP receptors (G-protein coupled P2Y receptors) are P2Y₁ receptor, which is coupled to Gq, and P2Y₁₂ receptor, which is coupled to Gi2"
                  },
                  {
                    "text": "Antiplatelet medications that disrupt ADP-mediated platelet activation target P2Y₁₂ receptor﻿"
                  },
                  {
                    "text": "Clopidogrel is thienopyridine derivative and irreversibly inhibits ADP binding to P2Y₁₂ receptorProdrug extensively metabolized in liver by CYP2C19 to active compound with plasma elimination half-life of approximately 8 hrVariability in ability of clopidogrel to inhibit platelet aggregation among individuals documented",
                    "sub_points": [
                      "Prodrug extensively metabolized in liver by CYP2C19 to active compound with plasma elimination half-life of approximately 8 hr",
                      "Variability in ability of clopidogrel to inhibit platelet aggregation among individuals documented"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "LTA can be used to study platelet aggregation in response to ADP"
                  },
                  {
                    "text": "﻿P2Y₁₂ inhibitor therapy should cause decreased aggregation in response to ADP﻿"
                  }
                ]
              },
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "Exposure of blood to dysfunctional or damaged endothelial surfaces leads to thrombus formation with deposition of platelets, fibrin, RBCs, and WBCs"
                  },
                  {
                    "text": "Thrombi forming in arterial circulation are tightly packed and platelet-rich with smaller amounts of fibrin"
                  },
                  {
                    "text": "Thrombi forming in venous circulation contain more loosely packed mixture of fibrin, RBCs, and WBCs"
                  },
                  {
                    "text": "Important role of platelets in atherothrombotic vascular disease makes antiplatelet medications mainstay of therapy"
                  }
                ],
                "Antiplatelet Therapy": [
                  {
                    "text": "Antiplatelet therapy can be oral or intravenous"
                  },
                  {
                    "text": "Various aspects of platelet function targeted for antiplatelet therapyCOX pathwaySecretion/granule releaseADP receptor signalingSecretion/granule releaseGPIIb-IIIa (aggregation)",
                    "sub_points": [
                      "COX pathwaySecretion/granule release",
                      "Secretion/granule release",
                      "ADP receptor signalingSecretion/granule release",
                      "Secretion/granule release",
                      "GPIIb-IIIa (aggregation)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  },
                  {
                    "text": "Cyclooxygenase (COX)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Glycoprotein (GP)"
                  },
                  {
                    "text": "Cyclic adenosine monophosphate (cAMP)"
                  },
                  {
                    "text": "High on-treatment platelet reactivity (HOPR)"
                  },
                  {
                    "text": "Light transmission aggregometry (LTA)"
                  },
                  {
                    "text": "Platelet-rich plasma (PRP)"
                  },
                  {
                    "text": "Infrared (IR)"
                  },
                  {
                    "text": "Platelet response unit (PRU)"
                  },
                  {
                    "text": "Vasodilator-stimulated phosphoprotein (VASP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Adenosine Diphosphate-Mediated Platelet Activation": [
                  {
                    "text": "ADP activates plateletsIncreases cytoplasmic Ca²⁺ through influx from extracellular fluid and mobilization from internal storesDecreases intracellular cAMP",
                    "sub_points": [
                      "Increases cytoplasmic Ca²⁺ through influx from extracellular fluid and mobilization from internal stores",
                      "Decreases intracellular cAMP"
                    ]
                  },
                  {
                    "text": "Two main types of ADP receptorsG-protein coupled P2Y receptorsP2Y₁ receptor is coupled to GqResponsible for ADP-induced shape change and triggers transient aggregatory responseP2Y₁₂ receptor is coupled to Gi2Mediates amplification of aggregation response and increases clot stabilityAntiplatelet medications that disrupt ADP-mediated platelet activation target P2Y₁₂ receptor﻿Ionotropic P2X receptor",
                    "sub_points": [
                      "G-protein coupled P2Y receptorsP2Y₁ receptor is coupled to GqResponsible for ADP-induced shape change and triggers transient aggregatory responseP2Y₁₂ receptor is coupled to Gi2Mediates amplification of aggregation response and increases clot stabilityAntiplatelet medications that disrupt ADP-mediated platelet activation target P2Y₁₂ receptor﻿",
                      "P2Y₁ receptor is coupled to GqResponsible for ADP-induced shape change and triggers transient aggregatory response",
                      "Responsible for ADP-induced shape change and triggers transient aggregatory response",
                      "P2Y₁₂ receptor is coupled to Gi2Mediates amplification of aggregation response and increases clot stabilityAntiplatelet medications that disrupt ADP-mediated platelet activation target P2Y₁₂ receptor﻿",
                      "Mediates amplification of aggregation response and increases clot stability",
                      "Antiplatelet medications that disrupt ADP-mediated platelet activation target P2Y₁₂ receptor﻿",
                      "Ionotropic P2X receptor"
                    ]
                  }
                ],
                "Clopidogrel": [
                  {
                    "text": "Clopidogrel is thienopyridine derivative"
                  },
                  {
                    "text": "Irreversibly inhibits ADP binding to P2Y₁₂ receptor﻿At steady state, average inhibition of ADP binding is 40%-60%",
                    "sub_points": [
                      "At steady state, average inhibition of ADP binding is 40%-60%"
                    ]
                  },
                  {
                    "text": "Clopidogrel therapyOralDosing75 mg/dayLoading dose of 300-600 mg may be given to quickly initiate therapy",
                    "sub_points": [
                      "Oral",
                      "Dosing75 mg/dayLoading dose of 300-600 mg may be given to quickly initiate therapy",
                      "75 mg/day",
                      "Loading dose of 300-600 mg may be given to quickly initiate therapy"
                    ]
                  },
                  {
                    "text": "Clopidogrel rapidly absorbed with peak plasma levels of predominant circulating metabolite achieved at approximately 60 minProdrug extensively metabolized in liver by CYP2C19 to active compound with plasma elimination half-life of approximately 8 hr",
                    "sub_points": [
                      "Prodrug extensively metabolized in liver by CYP2C19 to active compound with plasma elimination half-life of approximately 8 hr"
                    ]
                  },
                  {
                    "text": "Variability in ability of clopidogrel to inhibit platelet aggregation among individuals documentedResistance to clopidogrel therapy can be defined in terms of clinical resistance or laboratory resistanceClinical resistance refers to patients who experience new thrombotic event while receiving regular and effective-dose therapyHOPR refers to patients in whom therapy does not produce expected effects on platelet function as measured by ≥ 1 screening laboratory testsPossible causes of clopidogrel resistanceNoncomplianceDrug interactionsProton pump inhibitors may affect clopidogrel metabolismGenetic polymorphisms that affect clopidogrel absorption, metabolic activation, biologic activityLoss-of-function CYP2C19 allelesProduce less of active clopidogrel metabolite in healthy individuals and patientsCommon throughout various populationsApproximately 30% EuropeansApproximately 40% AfricansApproximately 50% AsiansIncreasing clopidogrel doses in patients with these alleles produces better antiplatelet responsesDue to high prevalence of these alleles, monitoring antiplatelet response to clopidogrel may be usefulAlternatives for patients who do not have adequate response to clopidogrelPrasugrelTicagrelor",
                    "sub_points": [
                      "Resistance to clopidogrel therapy can be defined in terms of clinical resistance or laboratory resistanceClinical resistance refers to patients who experience new thrombotic event while receiving regular and effective-dose therapyHOPR refers to patients in whom therapy does not produce expected effects on platelet function as measured by ≥ 1 screening laboratory tests",
                      "Clinical resistance refers to patients who experience new thrombotic event while receiving regular and effective-dose therapy",
                      "HOPR refers to patients in whom therapy does not produce expected effects on platelet function as measured by ≥ 1 screening laboratory tests",
                      "Possible causes of clopidogrel resistanceNoncomplianceDrug interactionsProton pump inhibitors may affect clopidogrel metabolismGenetic polymorphisms that affect clopidogrel absorption, metabolic activation, biologic activity",
                      "Noncompliance",
                      "Drug interactionsProton pump inhibitors may affect clopidogrel metabolism",
                      "Proton pump inhibitors may affect clopidogrel metabolism",
                      "Genetic polymorphisms that affect clopidogrel absorption, metabolic activation, biologic activity",
                      "Loss-of-function CYP2C19 allelesProduce less of active clopidogrel metabolite in healthy individuals and patientsCommon throughout various populationsApproximately 30% EuropeansApproximately 40% AfricansApproximately 50% AsiansIncreasing clopidogrel doses in patients with these alleles produces better antiplatelet responsesDue to high prevalence of these alleles, monitoring antiplatelet response to clopidogrel may be usefulAlternatives for patients who do not have adequate response to clopidogrelPrasugrelTicagrelor",
                      "Produce less of active clopidogrel metabolite in healthy individuals and patients",
                      "Common throughout various populationsApproximately 30% EuropeansApproximately 40% AfricansApproximately 50% Asians",
                      "Approximately 30% Europeans",
                      "Approximately 40% Africans",
                      "Approximately 50% Asians",
                      "Increasing clopidogrel doses in patients with these alleles produces better antiplatelet responses",
                      "Due to high prevalence of these alleles, monitoring antiplatelet response to clopidogrel may be useful",
                      "Alternatives for patients who do not have adequate response to clopidogrelPrasugrelTicagrelor",
                      "Prasugrel",
                      "Ticagrelor"
                    ]
                  }
                ],
                "Prasugrel": [
                  {
                    "text": "Third-generation thienopyridine"
                  },
                  {
                    "text": "Irreversibly inhibits binding of ADP to P2Y﻿₁₂﻿receptor"
                  },
                  {
                    "text": "Prasugrel therapyOralDosing10 mg/dayLoading dose of 60 mg may be given to quickly initiate therapy",
                    "sub_points": [
                      "Oral",
                      "Dosing10 mg/dayLoading dose of 60 mg may be given to quickly initiate therapy",
                      "10 mg/day",
                      "Loading dose of 60 mg may be given to quickly initiate therapy"
                    ]
                  },
                  {
                    "text": "Prasugrel is prodrug that undergoes rapid de-esterification to intermediate, thiolactoneThiolactone converted to active metabolite by single cytochrome P-450-dependent step",
                    "sub_points": [
                      "Thiolactone converted to active metabolite by single cytochrome P-450-dependent step"
                    ]
                  },
                  {
                    "text": "Maximum plasma concentration of active metabolite occurs within 30 minPlatelet inhibition begins 15-30 min after administration of 60-mg loading doseReaches 60%-70% platelet inhibition at 2-4 hrDuring maintenance therapy of 10 mg/day there is steady state 50% platelet inhibitionPlatelet aggregation returns to pretreatment levels within 7-10 days after discontinuation of prasugrel",
                    "sub_points": [
                      "Platelet inhibition begins 15-30 min after administration of 60-mg loading doseReaches 60%-70% platelet inhibition at 2-4 hr",
                      "Reaches 60%-70% platelet inhibition at 2-4 hr",
                      "During maintenance therapy of 10 mg/day there is steady state 50% platelet inhibition",
                      "Platelet aggregation returns to pretreatment levels within 7-10 days after discontinuation of prasugrel"
                    ]
                  },
                  {
                    "text": "Compared with clopidogrel, prasugrel induces platelet inhibition with more rapid onset, is more consistent, and reaches higher level"
                  },
                  {
                    "text": "Prasugrel may have increased risk of bleeding compared with clopidogrel in certain patient populationsPatients ≥ 75 yr oldUse only after careful considerationPatients with history of transient ischemic attackContraindicatedPatients weighing < 60 kgDose at 5 mg/day if must use",
                    "sub_points": [
                      "Patients ≥ 75 yr oldUse only after careful consideration",
                      "Use only after careful consideration",
                      "Patients with history of transient ischemic attackContraindicated",
                      "Contraindicated",
                      "Patients weighing < 60 kgDose at 5 mg/day if must use",
                      "Dose at 5 mg/day if must use"
                    ]
                  }
                ],
                "Ticagrelor": [
                  {
                    "text": "High-affinity ADP analogue"
                  },
                  {
                    "text": "Causes reversible inhibition of P2Y₁₂ receptor by binding to it and changing its conformation"
                  },
                  {
                    "text": "Ticagrelor therapyOralDosing90 mg twice dailyLoading dose of 180 mg may be given to quickly initiate therapy",
                    "sub_points": [
                      "Oral",
                      "Dosing90 mg twice dailyLoading dose of 180 mg may be given to quickly initiate therapy",
                      "90 mg twice daily",
                      "Loading dose of 180 mg may be given to quickly initiate therapy"
                    ]
                  },
                  {
                    "text": "Ticagrelor is rapidly absorbed and undergoes enzymatic degradation to active metabolitePeak plasma concentrations reached within 1-3 hr after administration50%-60% platelet inhibition within 2-4 hr after 180-mg loading dosePlasma half-life 6-13 hr",
                    "sub_points": [
                      "Peak plasma concentrations reached within 1-3 hr after administration",
                      "50%-60% platelet inhibition within 2-4 hr after 180-mg loading dose",
                      "Plasma half-life 6-13 hr"
                    ]
                  },
                  {
                    "text": "Compared with clopidogrel, ticagrelor results in earlier, more consistent, more pronounced platelet inhibition"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Rationale for Laboratory Testing for Antiplatelet Therapy": [
                  {
                    "text": "Laboratory monitoring of effect of antiplatelet agents is useful in certain settingsDetermining if patient’s platelets are resistant to inhibition by a particular agentDetermining what dose of an antiplatelet agent will produce desired level of inhibition of functionDetermining when, after cessation of antiplatelet therapy, platelet function has returned to adequate level to support hemostasis",
                    "sub_points": [
                      "Determining if patient’s platelets are resistant to inhibition by a particular agent",
                      "Determining what dose of an antiplatelet agent will produce desired level of inhibition of function",
                      "Determining when, after cessation of antiplatelet therapy, platelet function has returned to adequate level to support hemostasis"
                    ]
                  }
                ],
                "Light Transmission Aggregometry": [
                  {
                    "text": "LTA can be used to study platelet aggregation in response to ADP"
                  },
                  {
                    "text": "Sample collected in 3.2% sodium citrate"
                  },
                  {
                    "text": "LTA uses PRP obtained by gentle centrifugation of whole-blood sample"
                  },
                  {
                    "text": "﻿P2Y₁₂ inhibitor therapy should cause decreased aggregation in response to ADP﻿"
                  }
                ],
                "VerifyNow Assay": [
                  {
                    "text": "VerifyNow Assay uses whole blood to study optical platelet aggregation"
                  },
                  {
                    "text": "Samples collected into special Greiner Vacuette tube with 3.2% sodium citrate"
                  },
                  {
                    "text": "Test system includes fibrinogen-coated beads impregnated with IR dye"
                  },
                  {
                    "text": "After addition of ADP and prostaglandin E₁ as agonist, platelets become activatedGPIIb-IIIa receptors are able to bind to fibrinogen-coated beads, leading to aggregation of beads with the platelets",
                    "sub_points": [
                      "GPIIb-IIIa receptors are able to bind to fibrinogen-coated beads, leading to aggregation of beads with the platelets"
                    ]
                  },
                  {
                    "text": "Extent of aggregation is detected as increase in IR light transmittance after addition of agonists"
                  },
                  {
                    "text": "Testing takes approximately 10 min to perform"
                  },
                  {
                    "text": "Platelet aggregation reported as PRUsLower PRUs indicate greater P2Y₁₂ inhibition",
                    "sub_points": [
                      "Lower PRUs indicate greater P2Y₁₂ inhibition"
                    ]
                  }
                ],
                "Additional Assays": [
                  {
                    "text": "Flow cytometryPhosphorylation state of VASP, a specific intracellular marker of residual P2Y₁₂ receptor reactivity, can be measured",
                    "sub_points": [
                      "Phosphorylation state of VASP, a specific intracellular marker of residual P2Y₁₂ receptor reactivity, can be measured"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "GPIIb/IIIa Inhibitors and Monitoring": {
            "name": "GPIIb/IIIa Inhibitors and Monitoring",
            "url": "https://app.pathprimer.com/document/1df0e4a2-bd06-4157-be95-44294b16f857/lesson/bbefe37e-8841-4e01-b888-e8011cae88c9",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "GPIIb-IIIa receptor on platelets binds to fibrinogen and von Willebrand factor (vWF) to mediate platelet-platelet interactions"
                  },
                  {
                    "text": "Absence or lack of activity of GPIIb-IIIa receptors leads to lack of platelet aggregation"
                  },
                  {
                    "text": "Three intravenous (IV) GPIIb-IIIa receptor antagonists are availableAbciximab: Fab fragment of chimeric human-murine monoclonal antibodyEptifibatide: Nonimmunogenic cyclic heptapeptide with active pharmacophore that is derived from structure of barourin, a platelet GPIIb-IIIa inhibitor from snake venom (southeastern pigmy rattlesnake)Tirofiban: Tyrosine derivative, nonpeptide inhibitor of GPIIb-IIIa receptor",
                    "sub_points": [
                      "Abciximab: Fab fragment of chimeric human-murine monoclonal antibody",
                      "Eptifibatide: Nonimmunogenic cyclic heptapeptide with active pharmacophore that is derived from structure of barourin, a platelet GPIIb-IIIa inhibitor from snake venom (southeastern pigmy rattlesnake)",
                      "Tirofiban: Tyrosine derivative, nonpeptide inhibitor of GPIIb-IIIa receptor"
                    ]
                  },
                  {
                    "text": "Major adverse effect of GPIIb-IIIa receptor antagonists is thrombocytopenia"
                  }
                ]
              },
              "OVERVIEW": {
                "Pathophysiology": [
                  {
                    "text": "Exposure of blood to dysfunctional or damaged endothelial surfaces leads to thrombus formation with deposition of platelets, fibrin, red blood cells (RBCs), and white blood cells (WBCs)Thrombi forming in arterial circulation are tightly packed and platelet-rich with smaller amounts of fibrinThrombi forming in venous circulation contain more loosely packed mixture of fibrin, RBCs, and WBCs",
                    "sub_points": [
                      "Thrombi forming in arterial circulation are tightly packed and platelet-rich with smaller amounts of fibrin",
                      "Thrombi forming in venous circulation contain more loosely packed mixture of fibrin, RBCs, and WBCs"
                    ]
                  },
                  {
                    "text": "Important role of platelets in atherothrombotic vascular disease makes antiplatelet medications a mainstay of therapy"
                  }
                ],
                "Antiplatelet Therapy": [
                  {
                    "text": "Antiplatelet therapy can be oral or intravenous"
                  },
                  {
                    "text": "Various aspects of platelet function have been targeted for antiplatelet therapyCyclooxygenase (COX) pathway (secretion/granule release)Adenosine diphosphate (ADP) receptor signaling (secretion/granule release)GPIIb-IIIa (aggregation)",
                    "sub_points": [
                      "Cyclooxygenase (COX) pathway (secretion/granule release)",
                      "Adenosine diphosphate (ADP) receptor signaling (secretion/granule release)",
                      "GPIIb-IIIa (aggregation)"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "GPIIb-IIIa Receptor and Platelet Aggregation": [
                  {
                    "text": "GPIIb-IIIa receptor on platelets binds to fibrinogen and von Willebrand factor (vWF) to mediate platelet-platelet interactions"
                  },
                  {
                    "text": "Absence or lack of activity of the GPIIb-IIIa receptors leads to lack of platelet aggregation"
                  },
                  {
                    "text": "Three intravenous (IV) GPIIb-IIIa receptor antagonists are available"
                  },
                  {
                    "text": "Major adverse effect of GPIIb-IIIa receptor antagonists is thrombocytopenia"
                  }
                ],
                "Abciximab": [
                  {
                    "text": "Abciximab: Fab fragment of chimeric human-murine monoclonal antibody"
                  },
                  {
                    "text": "IV administration of abciximab in doses from 0.15 mg/kg to 0.3 mg/kg boluses causes rapid dose-dependent inhibition of platelet aggregation in response to ADPAt highest dose, 80% of GPIIb-IIIa receptors are occupied within 2 hoursLow-level receptor blockade is present for up to 10 days following cessation of infusionPlatelet aggregation in response to low-dose ADP is restored to 50% of baseline or more within 24 hours of discontinuing infusion",
                    "sub_points": [
                      "At highest dose, 80% of GPIIb-IIIa receptors are occupied within 2 hours",
                      "Low-level receptor blockade is present for up to 10 days following cessation of infusion",
                      "Platelet aggregation in response to low-dose ADP is restored to 50% of baseline or more within 24 hours of discontinuing infusion"
                    ]
                  },
                  {
                    "text": "Free plasma concentrations of abciximab rapidly decreased after bolus administration with initial half-life of < 10 minutes and second-phase half-life of 30 minutes"
                  },
                  {
                    "text": "Abciximab remains in circulation for 10 days or longer in platelet-bound state, and it is known that it can release and bind again to other GPIIb-IIIa receptors"
                  },
                  {
                    "text": "Plasma levels of unbound drug are low (ratio of drug to GPIIb-IIIa receptor = 1.5-2.0)Inhibitory effect of abciximab can be rapidly reversed with platelet transfusion",
                    "sub_points": [
                      "Inhibitory effect of abciximab can be rapidly reversed with platelet transfusion"
                    ]
                  }
                ],
                "Eptifibatide": [
                  {
                    "text": "Eptifibatide: Nonimmunogenic cyclic heptapeptide with an active pharmacophore that is derived from structure of barourin, a platelet GPIIb-IIIa inhibitor from snake venom (southeastern pigmy rattlesnake)"
                  },
                  {
                    "text": "Eptifibatide therapyDosing: 180 µg/kg bolus x 2, followed by infusion of 2 µg/kg for 18 hours",
                    "sub_points": [
                      "Dosing: 180 µg/kg bolus x 2, followed by infusion of 2 µg/kg for 18 hours"
                    ]
                  },
                  {
                    "text": "Plasma half-life = 10-15 minutes"
                  },
                  {
                    "text": "Antiplatelet effect has rapid onset"
                  },
                  {
                    "text": "Plasma levels of unbound drug are high (ratio of drug to GPIIb-IIIa receptor = 250-2000)Platelet transfusions are often not effective in reversing inhibitory effect of eptifibatide",
                    "sub_points": [
                      "Platelet transfusions are often not effective in reversing inhibitory effect of eptifibatide"
                    ]
                  }
                ],
                "Tirofiban": [
                  {
                    "text": "Tirofiban: Tyrosine derivative, nonpeptide inhibitor of GPIIb-IIIa receptorStructure mimics RGD sequence of fibrinogen that binds GPIIb-IIIa",
                    "sub_points": [
                      "Structure mimics RGD sequence of fibrinogen that binds GPIIb-IIIa"
                    ]
                  },
                  {
                    "text": "Tirofiban therapyDosing: 0.4 µg/kg per min x 30 minutes, followed by infusion of 0.1 µg/kg per minute for 12-24 hours",
                    "sub_points": [
                      "Dosing: 0.4 µg/kg per min x 30 minutes, followed by infusion of 0.1 µg/kg per minute for 12-24 hours"
                    ]
                  },
                  {
                    "text": "Plasma levels of unbound drug are high (ratio of drug to GPIIb-IIIa receptor = greater than 250)Platelet transfusions are often not effective in reversing inhibitory effect of tirofiban",
                    "sub_points": [
                      "Platelet transfusions are often not effective in reversing inhibitory effect of tirofiban"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Rationale for Laboratory Testing for Antiplatelet Therapy": [
                  {
                    "text": "Laboratory monitoring of effect of antiplatelet agents is useful in certain settingsDetermine if patient’s platelets are resistant to inhibition by particular agentDetermine what dose of antiplatelet agent will produce desired level of inhibition of functionDetermine when, after cessation of antiplatelet therapy, platelet function has returned to adequate level to support hemostasis",
                    "sub_points": [
                      "Determine if patient’s platelets are resistant to inhibition by particular agent",
                      "Determine what dose of antiplatelet agent will produce desired level of inhibition of function",
                      "Determine when, after cessation of antiplatelet therapy, platelet function has returned to adequate level to support hemostasis"
                    ]
                  }
                ],
                "Whole Blood Aggregometry": [
                  {
                    "text": "Whole blood aggregometry (WBA) can be used to study platelet aggregation in response to collagen or ADP agonists"
                  },
                  {
                    "text": "Sample collected in 3.2% sodium citrate"
                  },
                  {
                    "text": "GPIIb-IIIa inhibitor therapy should cause decreased aggregation in response to collagen and ADP"
                  }
                ],
                "VerifyNow Assay": [
                  {
                    "text": "VerifyNow assay uses whole blood to study optical platelet aggregationSamples are collected into special Greiner Vacuette tube with 3.2% lithium heparinTest system includes fibrinogen-coated beads that are impregnated with infrared (IR) dyeAfter addition of thrombin-receptor-activating peptide (TRAP) as agonist, platelets become activated and GPIIb-IIIa receptors are able to bind to fibrinogen-coated beads, leading to aggregation of beads with platelets",
                    "sub_points": [
                      "Samples are collected into special Greiner Vacuette tube with 3.2% lithium heparin",
                      "Test system includes fibrinogen-coated beads that are impregnated with infrared (IR) dye",
                      "After addition of thrombin-receptor-activating peptide (TRAP) as agonist, platelets become activated and GPIIb-IIIa receptors are able to bind to fibrinogen-coated beads, leading to aggregation of beads with platelets"
                    ]
                  },
                  {
                    "text": "Extent of aggregation is detected as increase in IR light transmittance following addition of agonists"
                  },
                  {
                    "text": "Testing takes ~ 10 minutes"
                  },
                  {
                    "text": "Decreased aggregation is expected in presence of GPIIb-IIIa inhibitors"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      }
    }
  }
}